<SEC-DOCUMENT>0001401914-19-000048.txt : 20190514
<SEC-HEADER>0001401914-19-000048.hdr.sgml : 20190514
<ACCEPTANCE-DATETIME>20190514161147
ACCESSION NUMBER:		0001401914-19-000048
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		57
CONFORMED PERIOD OF REPORT:	20190331
FILED AS OF DATE:		20190514
DATE AS OF CHANGE:		20190514

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Dare Bioscience, Inc.
		CENTRAL INDEX KEY:			0001401914
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				204139823
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36395
		FILM NUMBER:		19822822

	BUSINESS ADDRESS:	
		STREET 1:		3655 NOBEL DRIVE
		STREET 2:		SUITE 260
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122
		BUSINESS PHONE:		858-926-7655

	MAIL ADDRESS:	
		STREET 1:		3655 NOBEL DRIVE
		STREET 2:		SUITE 260
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cerulean Pharma Inc.
		DATE OF NAME CHANGE:	20090714

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tempo Pharmaceuticals Inc
		DATE OF NAME CHANGE:	20070604
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>dare-03312019x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s5733184822235948AF4A02CE39E58730"></a></div><div style="line-height:120%;padding-top:2px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:16pt;"><font style="font-family:Arial;font-size:16pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:Arial;font-size:16pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">WASHINGTON, DC 20549</font></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:16pt;"><font style="font-family:Arial;font-size:16pt;font-weight:bold;">FORM 10-Q</font></div><div style="line-height:120%;padding-top:2px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(Mark One)</font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:7%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">x</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">For the quarterly period ended </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:2px;text-align:center;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">OR</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:7%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#9744;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">For the transition period from </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;to </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;"><img src="darecovera03.jpg" alt="darecovera03.jpg" style="height:90px;width:266px;"></div><div style="line-height:120%;padding-top:10px;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:27%;"></td><td style="width:46%;"></td><td style="width:27%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:18pt;"><font style="font-family:Arial;font-size:18pt;font-weight:bold;">DAR&#201; BIOSCIENCE, INC.</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(Exact Name of Registrant as Specified in its Charter)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Delaware</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(State or Other Jurisdiction</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">of Incorporation)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Commission File No. 001-36395</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">20-4139823</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(IRS Employer</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Identification No.)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3655 Nobel Drive, Suite 260</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">San Diego, CA</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(Address of Principal Executive Offices)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(858) 926-7655</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(Registrant&#8217;s telephone number, including area code)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">92122</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(Zip Code)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(Former name, former address and former fiscal year, if changed since last report)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">x</font><font style="font-family:Arial;font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">o</font></div><div style="line-height:120%;padding-top:5px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:9pt;">Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">x</font><font style="font-family:Arial;font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">o</font></div><div style="line-height:120%;padding-top:5px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</font></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:24%;"></td><td style="width:3%;"></td><td style="width:4%;"></td><td style="width:40%;"></td><td style="width:25%;"></td><td style="width:4%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Large Accelerated Filer</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Accelerated filer</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">o</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Non-accelerated filer</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">x</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Smaller reporting company</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">x</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Emerging growth company</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">x</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;text-indent:24px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">x </font></div><div style="line-height:120%;padding-top:5px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">o</font><font style="font-family:Arial;font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">x </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Securities registered pursuant to Section 12(b) of the Act:</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:37%;"></td><td style="width:25%;"></td><td style="width:38%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Title of each class</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Trading Symbol(s)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Name of each exchange on which registered</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">DARE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Nasdaq Capital Market</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:5px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">As of </font><font style="font-family:Arial;font-size:9pt;">May&#160;13, 2019</font><font style="font-family:Arial;font-size:9pt;">, 16,683,411 shares of the Registrant&#8217;s Common Stock, par value $0.0001, were issued and outstanding.</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><a name="sCFC1EA362BD556D6887FB8A652AD93E5"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">This Quarterly Report on Form 10-Q, in particular &#8220;Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations,&#8221; of Part I. Financial Information, and the information incorporated by reference herein contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this report, including statements regarding our strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;design,&#8221; &#8220;intend,&#8221; &#8220;expect,&#8221; &#8220;could,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;contemplate,&#8221; project,&#8221; &#8220;target,&#8221; &#8220;tend to,&#8221; or the negative version of these words and similar expressions.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including those factors described in Part II, Item 1A, &#8220;Risk Factors,&#8221; in this report, and elsewhere in this report. Given these uncertainties, you should not place undue reliance on any forward-looking statement. The following factors are among those that may cause such differences:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Inability to continue as a going concern;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Inability to raise additional capital, under favorable terms or at all;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Inability to successfully attract partners and enter into collaborations on acceptable terms;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Failure to select or capitalize on the most scientifically, clinically or commercially promising or profitable indications or therapeutic areas for our product candidates due to limited financial resources;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Inability to develop and commercialize our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Failure or delay in starting, conducting and completing clinical trials or obtaining United States Food and Drug Administration, or FDA, or foreign regulatory approval for our product candidates in a timely manner;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">A change in the FDA&#8217;s primary oversight responsibility;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">A change in regulatory requirements for our product candidates, including the development pathway pursuant to Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, or the FDA's 505(b)(2) pathway;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Unsuccessful clinical trial outcomes stemming from clinical trial designs, failure to enroll a sufficient number of patients, higher than anticipated patient dropout rates, failure to meet established clinical endpoints, undesirable side effects and other safety concerns;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Negative publicity concerning the safety and efficacy of our product candidates, or of product candidates being developed by others that share characteristics similar to our candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Inability to demonstrate sufficient efficacy of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Loss of our licensed rights to develop and commercialize a product candidate as a result of the termination of the underlying licensing agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Monetary obligations and other requirements in connection with our exclusive, in-license agreements covering the patents and related intellectual property related to our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Developments by our competitors that make our product candidates less competitive or obsolete;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Dependence on third parties to conduct clinical trials and to manufacture product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Dependence on third parties to supply clinical supplies and raw materials, drugs and other materials required to produce a finished product and to produce the quantities needed;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Failure of our product candidates, if approved, to gain market acceptance or obtain adequate coverage for third party reimbursement;</font></div></td></tr></table><div><br></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">A reduction in demand for contraceptives caused by an elimination of current requirements that health insurance plans cover and reimburse FDA-cleared or approved contraceptive products without cost sharing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Lack of precedent to help assess whether health insurance plans will cover our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">The reimbursement environment relating to our product candidates at the time we obtain regulatory approval, if ever;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Difficulty in introducing branded products in a market made up of generic products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Inability to adequately protect or enforce our, or our licensor&#8217;s, intellectual property rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Lack of patent protection for the active ingredients in certain of our product candidates which could expose those product candidates to competition from other formulations using the same active ingredients;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Higher risk of failure associated with product candidates in pre-clinical stages of development that may lead investors to assign them little to no value and make these assets difficult to fund;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Disputes or other developments concerning our intellectual property rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Actual and anticipated fluctuations in our quarterly or annual operating results;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Price and volume fluctuations in the stock market, and in our stock in particular, which could subject us to securities class-action litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Litigation or public concern about the safety of our potential products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Strict government regulations on our business, including various fraud and abuse laws, including, without limitation, the U.S. federal Anti-Kickback Statute, the U.S. federal False Claims Act and the U.S. Foreign Corrupt Practices Act;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Regulations governing the production or marketing of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Loss of, or inability to attract, key personnel; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Increased costs as a result of operating as a public company, and substantial time devoted by our management to compliance initiatives and corporate governance practices.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">All forward-looking statements in this report are current only as of the date of this report. We do not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any statement is made or to reflect the occurrence of unanticipated events, except as required by law.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><hr style="page-break-after:always"><div><a name="sF61CCC4E73C659ABB260E0FED424DBEC"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:86%;"></td><td style="width:6%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">Page</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;font-weight:bold;" href="#s506AE2657451514ABA61138E5ABAE367"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PART I. FINANCIAL INFORMATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Item 1.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sDF818C6DC012526D98ED48C6BD8EBC03"><font style="font-family:Arial;font-size:10pt;">Consolidated Financial Statements (Unaudited)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s506AE2657451514ABA61138E5ABAE367">1</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Item 2.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA78090057A1B52EDBB8B97A1D6F1A675"><font style="font-family:Arial;font-size:10pt;">Management's Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sA78090057A1B52EDBB8B97A1D6F1A675">21</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Item 3.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s8F10712F2D1457769C8F11203F7499C1"><font style="font-family:Arial;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s8F10712F2D1457769C8F11203F7499C1">29</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Item 4.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s88A30F014AA951A7B920A599A338495E"><font style="font-family:Arial;font-size:10pt;">Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s88A30F014AA951A7B920A599A338495E">29</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;font-weight:bold;" href="#s71237209CB2752AFBC7E986A60DC9546"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PART II. OTHER INFORMATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Item 1.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s27542F97B5D2521C9325CC462D04B324"><font style="font-family:Arial;font-size:10pt;">Legal Proceedings</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s27542F97B5D2521C9325CC462D04B324">30</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Item 1A.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s48E768CE7D035EE5889E8CC52402AA84"><font style="font-family:Arial;font-size:10pt;">Risk Factors</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s48E768CE7D035EE5889E8CC52402AA84">30</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Item 2.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s393E305420A354EDAD8198359136A089"><font style="font-family:Arial;font-size:10pt;">Unregistered Sales of Equity Securities and Use of Proceeds</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s393E305420A354EDAD8198359136A089">30</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Item 3.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s212E6BC650505D939FC5D56B815F89AF"><font style="font-family:Arial;font-size:10pt;">Defaults Upon Senior Securities</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s212E6BC650505D939FC5D56B815F89AF">30</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Item 4.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s6100D1F504555C37AF3B66BC60E7A30D"><font style="font-family:Arial;font-size:10pt;">Mine Safety Disclosures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s6100D1F504555C37AF3B66BC60E7A30D">30</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Item 5.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sAEE5E415E8AE5624AE3EAEE8EEB6FFE5"><font style="font-family:Arial;font-size:10pt;">Other Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#sAEE5E415E8AE5624AE3EAEE8EEB6FFE5">30</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Item 6.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s0999079D2BF053E0B46B966F219D76F3"><font style="font-family:Arial;font-size:10pt;">Exhibits</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s0999079D2BF053E0B46B966F219D76F3">31</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s901C819646A653A1ACDBFABAA3C7B9FC"><font style="font-family:Arial;font-size:10pt;">SIGNATURES</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Arial;font-size:10pt;" href="#s901C819646A653A1ACDBFABAA3C7B9FC">32</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="s506AE2657451514ABA61138E5ABAE367"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PART I.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">FINANCIAL INFORMATION</font></div></td></tr></table><div><a name="sDF818C6DC012526D98ED48C6BD8EBC03"></a></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Item 1. Consolidated Financial Statements (Unaudited)</font></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="s47F8AF23406251BBBA00C9E9BF6366D6"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Dar&#233; Bioscience, Inc. and Subsidiaries</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Consolidated Balance Sheets</font></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">March&#160;31, <br>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, <br>2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Current assets</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,505,026</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6,805,889</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">166,713</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">31,037</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prepaid expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">588,524</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">403,097</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,260,263</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,240,023</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Property and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8,245</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,396</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other non-current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">751,347</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">577,968</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,019,855</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,827,387</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Liabilities and stockholders&#8217; equity</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Current liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">325,618</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">459,705</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">690,829</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">631,351</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,016,447</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,091,056</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">223,039</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,711</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,239,486</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,100,767</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Commitments and contingencies (Note 8)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Stockholders' equity</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Preferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Common stock, $0.0001 par value; 120,000,000 shares authorized; 11,422,161 shares issued and outstanding each period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,143</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,143</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(89,107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(96,728</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">35,889,940</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">35,791,972</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(32,021,607</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(28,969,767</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total stockholders' equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,780,369</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6,726,620</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total liabilities and stockholders' equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,019,855</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,827,387</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">See accompanying notes to interim consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><a name="s8979C36F2DAD507E9064CAD0E6B1974E"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Dar&#233; Bioscience</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Inc</font><font style="font-family:inherit;font-size:10pt;">. </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">and</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Subsidiaries</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Consolidated</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Statements</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">of</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Operations</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">and</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Comprehensive</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Loss</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Unaudited</font><font style="font-family:inherit;font-size:10pt;">)</font></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three months ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Operating expenses</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">General and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,277,180</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,303,189</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Research and development expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,693,391</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,086,653</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">License expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">112,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">100,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Impairment of goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,187,519</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,083,071</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,677,361</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,083,071</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(7,677,361</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other income</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">31,231</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,744</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,051,840</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(7,665,617</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Foreign currency translation adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,621</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(13,746</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,044,219</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(7,679,363</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Loss per common share - basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.27</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(0.88</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Weighted average number of common shares outstanding:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,422,161</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8,684,550</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">See accompanying notes to interim consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="s19498413373144f19ad4a60ce348453d"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Dar&#233; Bioscience, Inc. and Subsidiaries</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Consolidated Statements of Stockholders&#8217; Equity</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:25%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Additional</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Accumulated<br>other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">paid-in</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">comprehensive</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Accumulated</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">stockholders'</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Balance at December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">11,422,161</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,143</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">35,791,972</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(96,728</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(28,969,767</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6,726,620</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">97,968</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">97,968</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,051,840</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,051,840</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Foreign currency translation adjustments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,621</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,621</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Balance at March 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">11,422,161</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,143</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">35,889,940</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(89,107</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(32,021,607</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3,780,369</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Three Months Ended March 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Additional</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Accumulated<br>other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">paid-in</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">comprehensive</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Accumulated</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">stockholders'</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6,047,161</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">605</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">25,541,210</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(18,080</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(12,230,952</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">13,292,783</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,124</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,124</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net proceeds from issuance of common stock and warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">375,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,037,727</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,037,764</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Issuance of common stock via public offering, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,000,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,159,548</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,160,048</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(7,665,617</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(7,665,617</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Foreign currency translation adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(13,746</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(13,746</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Balance at March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">11,422,161</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1,142</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">35,747,609</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(31,826</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(19,896,569</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">15,820,356</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">See accompanying notes to interim consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><a name="s51478E71C6CC59ABB690BF769F59E420"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Dar&#233; Bioscience, Inc. and Subsidiaries</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Consolidated Statements of Cash Flows</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">(Unaudited)</font><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three months ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,051,840</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(7,665,617</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Non-cash adjustments reconciling net loss to operating cash flows:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,150</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">97,968</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Non-cash lease expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10,130</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Impairment of goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,187,519</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Changes in operating assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(135,676</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">255,318</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prepaid expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(201,129</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">20,694</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">193,495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other non-current assets and deferred charges</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">55,233</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">37,131</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(134,087</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(40,340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">59,478</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(118,707</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(9,711</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,496</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,308,484</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2,118,887</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net proceeds from issuance of common stock and warrants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10,197,813</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10,197,813</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Effect of exchange rate changes on cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,621</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(13,746</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Net change in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,300,863</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8,065,180</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash and cash equivalents, beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6,805,889</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,559,846</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Cash and cash equivalents, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,505,026</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15,625,026</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Supplemental disclosure of non-cash operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Operating right-of-use assets obtained in exchange for new operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">231,698</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">See accompanying notes to interim consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="s5EB53D07C69154F788B063E280D809A7"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Dar&#233; Bioscience, Inc. and Subsidiaries</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements (Unaudited)</font></div><div><a name="s8F0AB7F34D0A5A6AADB8E9F76F135CFB"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ORGANIZATION AND DESCRIPTION OF THE BUSINESS</font></div></td></tr></table><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dar&#233; Bioscience, Inc. is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women&#8217;s health. Dar&#233; Bioscience, Inc. and its wholly owned subsidiaries operate in </font><font style="font-family:Arial;font-size:10pt;">one</font><font style="font-family:Arial;font-size:10pt;">&#32;segment. In this report, the &#8220;Company&#8221; refers collectively to Dar&#233; Bioscience, Inc. and its wholly owned subsidiaries, unless otherwise stated or the context otherwise requires.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company is driven by a mission to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health and fertility. The Company's business strategy is to license or otherwise acquire the rights to differentiated product candidates in women's health, some of which have existing clinical proof-of-concept data, and to advance those candidates through clinical development and regulatory approval alone or in collaboration with strategic partners.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has assembled a portfolio of clinical-stage and pre-clinical-stage candidates addressing unmet needs in women&#8217;s health. The Company&#8217;s portfolio includes these four clinical-stage candidates:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis, or BV; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ovaprene, a non-hormonal monthly contraceptive intravaginal ring; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder, or FSAD; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy following menopause. </font></div></td></tr></table><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company's portfolio also includes these pre-clinical stage product candidates:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy, or VVA, in patients with hormone-receptor positive breast cancer;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-RH1, a novel approach to non-hormonal contraception for both men and women by targeting the CatSper ion channel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ORB-204 and ORB-214, 6-month and 12-month formulations of injectable etonogestrel for contraception;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and for fertility support as part of an </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">in vitro</font><font style="font-family:Arial;font-size:10pt;">&#32;fertilization, or IVF, treatment plan;  and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-OAB1, an intravaginal ring containing oxybutynin for the treatment of overactive bladder.</font></div></td></tr></table><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s primary operations have consisted of, and are expected to continue to consist of, product research and development and advancing its portfolio of product candidates through clinical development and regulatory approval.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">To date, the Company has not obtained any regulatory approvals for any of its product candidates, commercialized any of its product candidates or generated any product revenue. The Company is subject to several risks common to clinical-stage biopharmaceutical companies, including dependence on key individuals, competition from other companies, the need to develop commercially viable products in a timely and cost-effective manner, and the need to obtain adequate additional capital to fund the development of product candidates. The Company is also subject to several risks common to other companies in the industry, including rapid technology change, regulatory approval of products, uncertainty of market acceptance of products, competition from substitute products and larger </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">companies, compliance with government regulations, protection of proprietary technology, dependence on third parties, and product liability.</font></div><div><a name="sA8C2863FD67A527FB5999D425E6EAEE7"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">GOING CONCERN</font></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, as of </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">, the Company had an accumulated deficit of approximately </font><font style="font-family:Arial;font-size:10pt;">$32.0 million</font><font style="font-family:Arial;font-size:10pt;">&#32;and had cash and cash equivalents of approximately </font><font style="font-family:Arial;font-size:10pt;">$3.5 million</font><font style="font-family:Arial;font-size:10pt;">. The Company also had negative cash flow from operations of approximately </font><font style="font-family:Arial;font-size:10pt;">$3.3 million</font><font style="font-family:Arial;font-size:10pt;">&#32;during the three months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#32;In March of 2019, the Company announced that it received a Notice of Award for an additional </font><font style="font-family:Arial;font-size:10pt;">$982,851</font><font style="font-family:Arial;font-size:10pt;">&#32;of the anticipated </font><font style="font-family:Arial;font-size:10pt;">$1.9 million</font><font style="font-family:Arial;font-size:10pt;">&#32;from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, or the NIH Grant, which will be applied to the clinical development efforts supporting Ovaprene. As of March 31, 2019, the Company recorded a receivable in the amount of </font><font style="font-family:Arial;font-size:10pt;">$161,007</font><font style="font-family:Arial;font-size:10pt;">&#32;for expenses eligible for reimbursement under the NIH Grant that were incurred through March 31, 2019. See Note 9, "Grant Award," herein. In April of 2019, the Company completed a sale of common stock raising net proceeds of approximately </font><font style="font-family:Arial;font-size:10pt;">$5.2 million</font><font style="font-family:Arial;font-size:10pt;">. See Note 11, "Subsequent Events," herein. The Company still needs to raise additional capital to continue to fund its operations and to successfully execute its current operating plan, including the development of its current product candidates. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has a history of losses from operations, expects negative cash flows from its operations will continue for the foreseeable future, and expects that its net losses will continue for at least the next several years as it develops its existing product candidates and seeks to acquire, license or develop additional product candidates. These circumstances raise substantial doubt about the Company's ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty of the Company's ability to continue as a going concern.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company is focused primarily on the development and commercialization of innovative products in women&#8217;s health. The Company will continue to incur significant research and development and other expenses related to these activities. If the clinical trials for any of the Company&#8217;s product candidates fail to produce successful results such that those product candidates do not advance in clinical development, then the Company&#8217;s business and prospects may suffer. Even if the product candidates advance in clinical development, they may fail to gain regulatory approval. Even if the product candidates are approved, they may fail to achieve market acceptance, and the Company may never become profitable. Even if the Company becomes profitable, it may not sustain profitability.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company believes that its current available current cash resources will be sufficient to fund planned operations into the first quarter of 2020. For the foreseeable future, the Company's ability to continue its operations will depend on its ability to obtain additional capital.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company is currently evaluating a variety of capital raising options, including financings, government or other grant funding, collaborations and strategic alliances or other similar types of arrangements to cover its operating expenses, including the development of its product candidates and any future product candidates it may license or otherwise acquire. The amount and timing of the Company's capital needs have been and will continue to depend highly on many factors, including the product development programs the Company chooses to pursue and the pace and results of its clinical development efforts. If the Company raises capital through collaborations, strategic alliances or other similar types of arrangements, it may have to relinquish, on terms that are not favorable to the Company, rights to some of its technologies or product candidates it would otherwise seek to develop or commercialize. There can be no assurance that capital will be available when needed or that, if available, it will be obtained on terms favorable to the Company and its stockholders. Additionally, equity or debt financings may have a dilutive effect on the holdings of the Company's existing stockholders. If the Company cannot raise capital when needed, on favorable terms or at all, the Company will not be able to continue development of its product candidates, will need to reevaluate its planned operations and may need to delay, scale back or eliminate some or all of its development programs, reduce expenses, file for bankruptcy, reorganize, merge with another entity, or cease operations. If the Company becomes unable to continue as a going concern, the Company may have to liquidate its assets, and might realize significantly less than the values at which they are carried on its consolidated financial statements, and stockholders may lose all or part of their investment in the Company's common stock. The interim consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><a name="sDFD2063DF287588CB2415100D93377B2"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s significant accounting policies are described in Note 1 to the interim consolidated financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, filed with the Securities and Exchange Commission, or SEC on April 1, 2019. Since the date of those consolidated financial statements, there have been no material changes to the Company&#8217;s significant accounting policies, except as described below.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The accompanying interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as defined by the Financial Accounting Standards Board, or FASB, for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X.&#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management&#8217;s opinion, the accompanying interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results of the interim periods presented.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Interim financial results are not necessarily indicative of results anticipated for any other interim period or for the full year. The accompanying interim consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use, or ROU, lease assets, current portion of lease obligations, and long-term lease obligations on the Company's balance sheets.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ROU lease assets represent the Company's right to use an underlying asset for the lease term and lease obligations represent the Company's obligation to make lease payments arising from the lease. Operating ROU lease assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term. If the lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The ROU lease asset also includes any lease payments made and excludes lease incentives. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. (See Note 7, Leased Properties.)</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The three-level hierarchy of valuation techniques established to measure fair value is defined as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level 1: inputs are unadjusted quoted prices in active markets for identical assets or liabilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level 2: inputs other than level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of assets or liabilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash and cash equivalents of </font><font style="font-family:Arial;font-size:10pt;">$3.5 million</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">$6.8 million</font><font style="font-family:Arial;font-size:10pt;">&#32;measured at fair value as of </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, respectively, are classified within Level 1 of the fair value hierarchy. Other receivables are financial assets with carrying values that approximate fair value due to the short-term nature of these assets. Accounts payable and accrued expenses and other liabilities are financial liabilities with carrying values that approximate fair value due to the short-term nature of these liabilities.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Standards</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In May 2014, FASB issued Accounting Standards Update, or ASU, 2014-09, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Arial;font-size:10pt;">, which impacts the way in which some entities recognize revenue for certain types of transactions. The new standard became effective beginning in 2018 for public companies. Because the Company does not currently have any contracts with customers, the Company&#8217;s adoption of this accounting standard did not impact the Company&#8217;s interim consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In February 2016, FASB issued ASU 2016-02, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:Arial;font-size:10pt;">, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. The new standard is effective for public companies for fiscal years beginning after December&#160;15, 2018, with early adoption permitted. ASU 2016-02 became effective for the Company on January 1, 2019 and was adopted using a modified retrospective approach and the effective date is as of the initial application. Consequently, financial information was not updated, and the disclosures required under ASU 2016-02 are not provided for dates and periods prior to January 1, 2019. ASU 2016-02 provides a number of optional practical expedients and accounting policy elections. The Company elected the package of practical expedients requiring no reassessment of whether any expired or existing contracts are or contain leases, the lease classification of any expired or existing leases, or initial direct costs for any existing leases. The Company recorded approximately </font><font style="font-family:Arial;font-size:10pt;">$232,000</font><font style="font-family:Arial;font-size:10pt;">&#32;right-of-use assets and </font><font style="font-family:Arial;font-size:10pt;">$241,000</font><font style="font-family:Arial;font-size:10pt;">&#32;lease liabilities related to its lease of office space as of the adoption date in the consolidated balance sheets. There are no changes to the statement of operations or cash flows as a result of the adoption.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In January 2017, FASB issued ASU 2017-01, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Business Combinations (Topic 805): Clarifying the Definition of a Business</font><font style="font-family:Arial;font-size:10pt;">, which intended to clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The standard became effective for the Company on January 1, 2018. The Company&#8217;s early adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In July 2017, FASB issued ASU 2017-11, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815): (I) Accounting for Certain Financial Instruments with Down Round Features, (II) Replacement for the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception.</font><font style="font-family:Arial;font-size:10pt;">&#32;This update was issued to provide additional clarity related to accounting for certain financial instruments that have characteristics of both liabilities and equity. In particular, this update addresses freestanding and embedded financial instruments with down round features and whether they should be treated as a liability or equity instrument. Part II simply replaces the indefinite deferral for certain mandatorily redeemable non-controlling interests and mandatorily redeemable financial instruments of nonpublic entities contained within the Accounting Standards Committee Topic 480 with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. For public business entities, the amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company has early adopted ASU 2017-11. As a result, the Company has not recognized the fair value of the warrants containing down round features that were issued in the underwritten offering in February 2018 (see Note 6) as liabilities.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Disclosure Update and Simplification,</font><font style="font-family:Arial;font-size:10pt;">&#32;amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements relating to the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of income is required to be filed. This final rule was effective November 5, 2018. In accordance with the new rule, the Company added a Consolidated Statement of Stockholders' Equity in this report and elected to present a reconciliation in a single statement that shows the changes in stockholders' equity for each interim period, as well as each comparable period.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><a name="s6426BA8B60EA5580B97DDE094D7E74A8"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ACQUISITIONS</font></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Cerulean/Private Dar&#233; Stock Purchase Transaction</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On </font><font style="font-family:Arial;font-size:10pt;">July&#160;19, 2017</font><font style="font-family:Arial;font-size:10pt;">, the Company completed its business combination with Dar&#233; Bioscience Operations, Inc., a privately held Delaware corporation, or Private Dar&#233;, in accordance with the terms of the Stock Purchase Agreement dated as of </font><font style="font-family:Arial;font-size:10pt;">March&#160;19, 2017</font><font style="font-family:Arial;font-size:10pt;">, or the Dar&#233; Stock Purchase Agreement, by and among the Company, Private Dar&#233; and the holders of capital stock and securities convertible into capital stock of Private Dar&#233; named therein, or the Private Dar&#233; Stockholders. Pursuant to the Dar&#233; Stock Purchase Agreement, each Private Dar&#233; Stockholder sold their shares of capital stock in Private Dar&#233; to the Company in exchange for newly issued shares of the Company&#8217;s common stock, and as a result, Private Dar&#233; became a wholly owned subsidiary of the Company and the Private Dar&#233; Stockholders became majority stockholders of the Company. In connection with the closing of that transaction, the Company changed its name from &#8220;Cerulean Pharma Inc.&#8221; to &#8220;Dar&#233; Bioscience, Inc.&#8221; In this report, that transaction is referred to as the Cerulean/Private Dar&#233; stock purchase transaction and &#8220;Cerulean&#8221; refers to Cerulean Pharma Inc. before that transaction closed. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Cerulean/Private Dar&#233; stock purchase transaction was accounted for as a reverse merger under the acquisition method of accounting whereby Private Dar&#233; was considered to have acquired Cerulean for financial reporting purposes because immediately upon completion of the transaction, Private Dar&#233; stockholders held a majority of the voting interest of the combined company. Pursuant to business combination accounting, the Company applied the acquisition method, which requires the assets acquired and liabilities assumed be recorded at fair value with limited exceptions. The excess of the purchase price over the assets acquired and liabilities assumed represents goodwill. The goodwill is primarily attributable to the cash and cash equivalents at closing of the transaction of approximately </font><font style="font-family:Arial;font-size:10pt;">$9.9 million</font><font style="font-family:Arial;font-size:10pt;">&#32;and the impact of the unamortized fair value of stock options granted by Cerulean that were outstanding immediately before the transaction closed of approximately </font><font style="font-family:Arial;font-size:10pt;">$3.7 million</font><font style="font-family:Arial;font-size:10pt;">. The unamortized fair value of such stock options relates to an option modification approved on </font><font style="font-family:Arial;font-size:10pt;">March&#160;19, 2017</font><font style="font-family:Arial;font-size:10pt;">&#32;that provided for an acceleration of vesting of such options upon a change in control event. Such modification became effective upon the closing of the Cerulean/Private Dar&#233; stock purchase transaction. Hence, the unamortized fair value of such stock options is deemed to be part of total purchase consideration and goodwill. Transaction costs associated with the Cerulean/Private Dar&#233; stock purchase transaction of </font><font style="font-family:Arial;font-size:10pt;">$0.96 million</font><font style="font-family:Arial;font-size:10pt;">&#32;are included in general and administrative expense. The total purchase price consideration of approximately </font><font style="font-family:Arial;font-size:10pt;">$24.3 million</font><font style="font-family:Arial;font-size:10pt;">&#32;represents the fair value of the shares of Cerulean stock issued in connection with the Cerulean/Private Dar&#233; stock purchase transaction and the unamortized fair value of the stock options described above, which was allocated as follows:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Purchase Consideration</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fair value of shares issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">20,625</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unamortized fair value of Cerulean options</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,654</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Fair value of total consideration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">24,279</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Assets acquired and liabilities assumed</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,918</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prepaid expense and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,915</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(233</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total assets acquired and liabilities assumed</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,600</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Goodwill</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12,679</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The final allocation of the purchase price depended on finalizing the valuation of the fair value of assets acquired and liabilities assumed. The Company retrospectively recorded purchase price adjustments at the acquisition date to increase current liabilities and current assets by </font><font style="font-family:Arial;font-size:10pt;">$23,609</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">$225,778</font><font style="font-family:Arial;font-size:10pt;">, respectively, which reduced the original goodwill amount of </font><font style="font-family:Arial;font-size:10pt;">$12.9 million</font><font style="font-family:Arial;font-size:10pt;">&#32;by </font><font style="font-family:Arial;font-size:10pt;">$202,169</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company tests its goodwill for impairment at least annually as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31</font><font style="font-family:Arial;font-size:10pt;">&#32;and between annual tests if it becomes aware of an event or change in circumstance that would indicate the carrying value may be impaired. The Company tests goodwill for impairment at the entity level because it operates on the basis of a single reporting unit. A goodwill impairment is the amount by which a reporting unit&#8217;s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. When impaired, the carrying value of goodwill is written down to fair value. Any excess of the reporting unit goodwill carrying value over the fair value is recognized as impairment loss.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company assessed goodwill at December&#160;31, 2017. The Company determined there was an impairment and recognized an impairment charge of approximately </font><font style="font-family:Arial;font-size:10pt;">$7.5 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in the consolidated statement of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">operations and comprehensive loss for the year ended December&#160;31, 2017 and reduced the goodwill carrying value from approximately </font><font style="font-family:Arial;font-size:10pt;">$12.7 million</font><font style="font-family:Arial;font-size:10pt;">&#32;to </font><font style="font-family:Arial;font-size:10pt;">$5.2 million</font><font style="font-family:Arial;font-size:10pt;">&#32;on its consolidated balance sheet as of December&#160;31, 2017. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company assessed goodwill at March 31, 2018, determined there was an impairment and recognized an impairment charge of approximately </font><font style="font-family:Arial;font-size:10pt;">$5.2 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in the interim consolidated statement of operations and comprehensive loss for the three months ended March 31, 2018. As of March 31, 2018, the goodwill carrying value on the Company&#8217;s consolidated balance sheet was written off in its entirety.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Pear Tree Merger</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On </font><font style="font-family:Arial;font-size:10pt;">April&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">, the Company entered into an Agreement and Plan of Merger, the Merger Agreement, with Pear Tree Pharmaceuticals, Inc., or Pear Tree, Dar&#233; Merger Sub, Inc., a wholly-owned subsidiary of the Company, or Merger Sub, and two individuals in their respective capacities as Pear Tree stockholders&#8217; representatives. The transactions contemplated by the Merger Agreement closed on </font><font style="font-family:Arial;font-size:10pt;">May&#160;16, 2018</font><font style="font-family:Arial;font-size:10pt;">, and as a result, Pear Tree became the Company&#8217;s wholly owned subsidiary. The Company acquired Pear Tree to secure the rights to develop DARE-VVA1, a proprietary vaginal formulation of tamoxifen, as a potential treatment for vulvar and vaginal atrophy.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company determined that the acquisition of Pear Tree should be accounted for as an asset acquisition instead of a business combination because substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, and therefore, the asset is not considered a business. Transaction costs of approximately </font><font style="font-family:Arial;font-size:10pt;">$452,000</font><font style="font-family:Arial;font-size:10pt;">&#32;associated with the merger are included in the Company&#8217;s research and development expense.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In accordance with the terms of the Merger Agreement, because the Negative Consideration Amount (as defined below) exceeded the Positive Consideration Amount (as defined below), at the time of the closing of the merger, the excess amount (approximately </font><font style="font-family:Arial;font-size:10pt;">$132,000</font><font style="font-family:Arial;font-size:10pt;">) will be offset against future payments otherwise due under the Merger Agreement to certain former and continuing Pear Tree service providers and former holders of Pear Tree&#8217;s capital stock, or the Holders, including the potential </font><font style="font-family:Arial;font-size:10pt;">$75,000</font><font style="font-family:Arial;font-size:10pt;">&#32;payment due on the </font><font style="font-family:Arial;font-size:10pt;">one</font><font style="font-family:Arial;font-size:10pt;">-year anniversary of the closing of the merger. Positive Consideration Amount means the sum of </font><font style="font-family:Arial;font-size:10pt;">$75,000</font><font style="font-family:Arial;font-size:10pt;">, and the cash and cash equivalents held by Pear Tree at closing, and Negative Consideration Amount means the sum of (i) certain Pear Tree indebtedness and transaction expenses, (ii) transaction expenses of the stockholders&#8217; representatives, and (iii) amounts payable under Pear Tree&#8217;s management incentive plan. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Under the Merger Agreement, the Holders will be eligible to receive, subject to certain offsets, tiered royalties, including customary provisions permitting royalty reductions and offset, based on percentages of annual net sales of certain products subject to license agreements the Company assumed and a percentage of sublicense revenue. The Company must also make contingent payments to the Holders that are based on achieving certain clinical, regulatory and commercial milestones, which may be paid, in the Company&#8217;s sole discretion, in cash or shares of the Company&#8217;s common stock.</font></div><div><a name="sF65DAEA676F9561EA3CC5C7E56E56806"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">STOCK-BASED COMPENSATION</font></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">The 2015 Employee, Director and Consultant Equity Incentive Plan</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prior to the Cerulean/Private Dar&#233; stock purchase transaction, the 2015 Employee, Director and Consultant Equity Incentive Plan of Private Dar&#233;, or the 2015 Private Dar&#233; Plan, governed the issuance of equity awards to Private Dar&#233; employees, officers, non-employee directors and consultants. Options granted under the 2015 Private Dar&#233; Plan have terms of </font><font style="font-family:Arial;font-size:10pt;">ten years</font><font style="font-family:Arial;font-size:10pt;">&#32;from the date of grant unless earlier terminated and generally vest over a </font><font style="font-family:Arial;font-size:10pt;">three</font><font style="font-family:Arial;font-size:10pt;">-year period. Upon closing of the Cerulean/Private Dar&#233; stock purchase transaction, the Company assumed the 2015 Private Dar&#233; Plan and each outstanding option to acquire Private Dar&#233; stock that was not exercised prior to the closing. Options to purchase </font><font style="font-family:Arial;font-size:10pt;">50,000</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of Private Dar&#233; stock were assumed. Such options were assumed on the same terms as were applicable to them under the 2015 Private Dar&#233; Plan and became an option to purchase such number of shares of the Company&#8217;s common stock equal to the number of Private Dar&#233; shares subject to such option multiplied by the exchange ratio specified in the Dar&#233; Stock Purchase Agreement, at a correspondingly adjusted exercise price. Based on the exchange ratio and after giving effect to the reverse stock split effected in connection with the closing of the Cerulean/Private Dar&#233; stock purchase transaction, such options were replaced with options to purchase </font><font style="font-family:Arial;font-size:10pt;">10,149</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of the Company&#8217;s common stock, all of which were outstanding as of </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Private Dar&#233; issued </font><font style="font-family:Arial;font-size:10pt;">900,000</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">200,000</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of fully vested restricted stock to non-employees under the 2015 Private Dar&#233; Plan during 2015 and 2016, respectively. In connection with the closing of the Cerulean/Private Dar&#233; stock purchase transaction, the Company assumed these shares and replaced them with </font><font style="font-family:Arial;font-size:10pt;">223,295</font><font style="font-family:Arial;font-size:10pt;">&#32;restricted shares of the Company&#8217;s common stock (after giving effect to the reverse stock split effected in connection with the closing of the Cerulean/Private Dar&#233; stock purchase transaction).</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">No further awards may be granted under the 2015 Private Dar&#233; Plan following the closing of the Cerulean/Private Dar&#233; stock purchase transaction.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">2014 Employee Stock Purchase Plan</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In March 2014, the Company&#8217;s board of directors adopted, and its stockholders approved the 2014 Employee Stock Purchase Plan, or the ESPP, which became effective in April 2014. The ESPP permits eligible employees to enroll in a </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;">-month offering period whereby participants may purchase shares of the Company&#8217;s common stock, through payroll deductions, at a price equal to </font><font style="font-family:Arial;font-size:10pt;">85%</font><font style="font-family:Arial;font-size:10pt;">&#32;of the closing price of the common stock on the first day of the offering period or on the last day of the offering period, whichever is lower. Purchase dates under the ESPP occur on or about June 30 and December 31 each year. The Company&#8217;s board of directors decided not to initiate a new offering period beginning January 1, 2017 and no offering period has been initiated since then. There was </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;">&#32;stock-based compensation related to the ESPP for the </font><font style="font-family:Arial;font-size:10pt;">three</font><font style="font-family:Arial;font-size:10pt;">&#32;months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;or </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Amended and Restated 2014 Stock Incentive Plan</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company maintains the Amended and Restated 2014 Plan, or the Amended 2014 Plan, which was approved by the Company&#8217;s stockholders on July 10, 2018. The Amended 2014 Plan was an amendment and restatement of the Company&#8217;s 2014 Stock Incentive Plan, or the 2014 Plan.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">When adopted, there were </font><font style="font-family:Arial;font-size:10pt;">2,046,885</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of common stock authorized for issuance under the Amended 2014 Plan. The number of authorized shares increases annually on the first day of each fiscal year until, and including, the fiscal year ending December 31, 2024 by the least of (i) </font><font style="font-family:Arial;font-size:10pt;">2,000,000</font><font style="font-family:Arial;font-size:10pt;">, (ii) </font><font style="font-family:Arial;font-size:10pt;">4%</font><font style="font-family:Arial;font-size:10pt;">&#32;of the number of outstanding shares of common stock on such date, or (iii) an amount determined by the Company&#8217;s board of directors. On January 1, 2019, the number of authorized shares increased by </font><font style="font-family:Arial;font-size:10pt;">456,886</font><font style="font-family:Arial;font-size:10pt;">&#32;to </font><font style="font-family:Arial;font-size:10pt;">2,503,771</font><font style="font-family:Arial;font-size:10pt;">, which increase represented </font><font style="font-family:Arial;font-size:10pt;">4%</font><font style="font-family:Arial;font-size:10pt;">&#32;of the number of outstanding shares of common stock on such date.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In March 2017, the Company&#8217;s board of directors approved two modifications to outstanding stock options granted under the 2014 Plan to participants providing services to the Company as of that date. One modification extended the exercise period of such stock options to </font><font style="font-family:Arial;font-size:10pt;">two years</font><font style="font-family:Arial;font-size:10pt;">&#32;after such participant&#8217;s termination date, unless the exercise period absent such modification would be longer. The other modification provided for accelerated vesting of such stock options upon a change in control event. These modifications resulted in unamortized fair value expense of approximately </font><font style="font-family:Arial;font-size:10pt;">$3.7 million</font><font style="font-family:Arial;font-size:10pt;">&#32;and was recorded as part of the total consideration in the Cerulean/Private Dar&#233; stock purchase transaction (see Note 4). The two modifications resulted in certain options remaining outstanding that would have otherwise expired.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">At </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">323,560</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of common stock were reserved for future issuance under the Amended 2014 Plan, and options to purchase </font><font style="font-family:Arial;font-size:10pt;">2,190,360</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of the Company&#8217;s common stock granted under the Amended 2014 Plan were outstanding.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Summary of Stock Option Activity</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The table below summarizes stock option activity under the Amended 2014 Plan, and related information for the </font><font style="font-family:Arial;font-size:10pt;">three</font><font style="font-family:Arial;font-size:10pt;">&#32;months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">. The exercise price of all options granted during the </font><font style="font-family:Arial;font-size:10pt;">three</font><font style="font-family:Arial;font-size:10pt;">&#32;months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;was equal to the market value of the Company&#8217;s common stock on the date of the grant. As of </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">, unamortized stock-based compensation expense of </font><font style="font-family:Arial;font-size:10pt;">$1,343,624</font><font style="font-family:Arial;font-size:10pt;">&#32;will be amortized over a weighted average period of </font><font style="font-family:Arial;font-size:10pt;">3.3 years</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:73%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Number of Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Outstanding at December 31, 2018 (1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,635,790</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">563,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.76</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Canceled/forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(8,360</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17.81</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(70</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">59.48</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Outstanding at March 31, 2019 (unaudited) (1)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,190,360</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8.40</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Exercisable at March&#160;31, 2019 (unaudited)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">650,151</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">25.97</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:0px;padding-top:8px;text-indent:0px;"><font style="padding-top:8px;font-family:Arial;font-size:10pt;padding-right:48px;">(1)</font><font style="font-family:Arial;font-size:10pt;">Includes </font><font style="font-family:Arial;font-size:10pt;">10,149</font><font style="font-family:Arial;font-size:10pt;">&#32;shares subject to options granted under the 2015 Private Dar&#233; Plan assumed in connection with the Cerulean/Private Dar&#233; stock purchase transaction.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Compensation Expense</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total stock-based compensation expense related to stock options granted to employees and directors recognized in the consolidated statement of operations is as follows:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">24,703</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">73,265</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,124</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">97,968</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,124</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The assumptions used in the Black-Scholes option-pricing model for stock options granted to employees and to directors in respect of board services during the </font><font style="font-family:Arial;font-size:10pt;">three</font><font style="font-family:Arial;font-size:10pt;">&#32;months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;are as follows:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:86%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br>March 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Expected life in years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10.0</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.70%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">120%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Forfeiture rate</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.0%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.0%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Weighted-average fair value of options granted</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$0.72</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock After the Cerulean/Private Dar&#233; Stock Purchase Transaction</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The </font><font style="font-family:Arial;font-size:10pt;">3.14 million</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of common stock issued in connection with the Cerulean/Private Dar&#233; stock purchase transaction to the Private Dar&#233; stockholders were not registered with the SEC and may only be sold if registered under the Securities Act of 1933, as amended, or pursuant to an exemption from the registration requirements thereunder. The shares held by non-affiliates became eligible for sale </font><font style="font-family:Arial;font-size:10pt;color:#222222;">under&#160;Rule 144 beginning</font><font style="font-family:Arial;font-size:10pt;">&#32;six months after the closing of the Cerulean/Private Dar&#233; stock purchase transaction</font><font style="font-family:Arial;font-size:10pt;color:#222222;">.</font></div><div><a name="sD6DF70E880195ABDBB3242CA71573B61"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">STOCKHOLDERS&#8217; EQUITY</font></div></td></tr></table><div style="line-height:120%;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">ATM Sales Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In January 2018, the Company entered into a common stock sales agreement under which the Company may sell up to an aggregate of </font><font style="font-family:Arial;font-size:10pt;">$10 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in gross proceeds through the sale of shares of common stock from time to time in &#8220;at-the-market&#8221; equity offerings (as defined in Rule 415 promulgated under the Securities Act of 1933, as amended), including in sales made directly on the Nasdaq Capital Market, or Nasdaq, to or through a market maker or, subject to the Company's prior approval, in negotiated transactions. The Company agreed to pay a commission of up to </font><font style="font-family:Arial;font-size:10pt;">3%</font><font style="font-family:Arial;font-size:10pt;">&#32;of the gross proceeds of any common stock sold under this agreement plus certain legal expenses. The common stock sales agreement was amended in August 2018 to refer to the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-227019) that was filed to replace the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-206396) that expired on August 28, 2018.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During the three months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">, the Company issued and sold </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;">&#32;shares under the common stock sales agreement. During the three months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, the Company generated gross proceeds of approximately </font><font style="font-family:Arial;font-size:10pt;">$1.1 million</font><font style="font-family:Arial;font-size:10pt;">&#32;and incurred issuance costs of </font><font style="font-family:Arial;font-size:10pt;">$237,403</font><font style="font-family:Arial;font-size:10pt;">&#32;under this agreement on sales of an aggregate of </font><font style="font-family:Arial;font-size:10pt;">375,000</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of the Company's common stock.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Underwritten Public Offering</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In February 2018, the Company closed an underwritten public offering of </font><font style="font-family:Arial;font-size:10pt;">5.0 million</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of its common stock and warrants to purchase up to </font><font style="font-family:Arial;font-size:10pt;">3.5 million</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of its common stock. Each share of common stock was sold with a warrant to purchase up to </font><font style="font-family:Arial;font-size:10pt;">0.70</font><font style="font-family:Arial;font-size:10pt;">&#32;of a share of the Company&#8217;s common stock. The Company granted the underwriter a </font><font style="font-family:Arial;font-size:10pt;">30</font><font style="font-family:Arial;font-size:10pt;">-day over-allotment option to purchase up to an additional </font><font style="font-family:Arial;font-size:10pt;">750,000</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of common stock and/or warrants to purchase up to </font><font style="font-family:Arial;font-size:10pt;">525,000</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of common stock.&#160; The underwriter exercised the option with respect </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to warrants to purchase </font><font style="font-family:Arial;font-size:10pt;">220,500</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of common stock. The Company received gross proceeds of </font><font style="font-family:Arial;font-size:10pt;">$10.3 million</font><font style="font-family:Arial;font-size:10pt;">, including the proceeds from the sale of the warrants upon exercise of the underwriter&#8217;s over-allotment option, and net proceeds of approximately </font><font style="font-family:Arial;font-size:10pt;">$9.4 million</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock Warrants</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The warrants issued in the February 2018 underwritten offering have an exercise price of </font><font style="font-family:Arial;font-size:10pt;">$3.00</font><font style="font-family:Arial;font-size:10pt;">&#32;per share and</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:10pt;">are exercisable immediately and for </font><font style="font-family:Arial;font-size:10pt;">five</font><font style="font-family:Arial;font-size:10pt;">&#32;years from issuance.</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:10pt;">The warrants include a price-based anti-dilution provision, which provides that, subject to certain limited exceptions, the exercise price of the warrants will be adjusted downward if the Company issues or sells (or is deemed to issue or sell) securities at a price that is less than the exercise price in effect immediately prior to such issuance or sale (or deemed issuance or sale). In that case, the exercise price of the warrants will be adjusted to equal the price at which the new securities are issued or sold (or are deemed to have been issued or sold). In addition, subject to certain exceptions, if the Company issues, sells or enters into any agreement to issue or sell securities at a price which varies or may vary with the market price of the shares of the Company&#8217;s common stock, the warrant holders have the right to substitute such variable price for the exercise price of the warrant then in effect. The warrants are exercisable only for cash, unless a registration statement covering the shares issued upon exercise of the warrants is not effective, in which case the warrants may be exercised on a cashless basis. A registration statement covering the shares issued upon exercise of the warrants is currently effective.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The exercise price of these warrants was automatically reduced to </font><font style="font-family:Arial;font-size:10pt;">$0.98</font><font style="font-family:Arial;font-size:10pt;">&#32;per share in connection with the initial closing of the Company's underwritten public offering in April 2019. See Note 11, "Subsequent Events," herein.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company estimated the fair value of the warrants as of February 15, 2018 to be approximately </font><font style="font-family:Arial;font-size:10pt;">$3.0 million</font><font style="font-family:Arial;font-size:10pt;">&#32;which has been recorded in equity as of the grant date. The Company early adopted ASU 2017-11 and as a result has recorded the fair value of the warrants as equity (see Note 3).</font></div><div style="line-height:120%;padding-top:8px;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">No</font><font style="font-family:Arial;font-size:10pt;">&#32;warrants were exercised during the three months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;or </font><font style="font-family:Arial;font-size:10pt;">2018</font><font style="font-family:Arial;font-size:10pt;">. As of </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">, the Company had these warrants outstanding:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:32%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Shares Underlying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Outstanding Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Expiration Date</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,906</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">120.40</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December&#160;1, 2021</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,737</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">120.40</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December&#160;6, 2021</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17,190</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">60.50</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">January&#160;8, 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6,500</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">April&#160;4, 2026</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,720,500</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3.00</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">February&#160;15, 2023</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,750,833</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><a name="se94900a093bb40238a48dc72f194bf1e"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">7. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">LEASED PROPERTIES</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Effective January 1, 2019, the Company adopted ASC 842, which requires recognition of a right-of-use asset and lease liability for all leases at the commencement date based on the present value of lease payments over the lease term. Additional qualitative and quantitative disclosures regarding the Company's leasing arrangements are also required. The Company adopted ASC 842 prospectively and elected the package of transition practical expedients that does not require reassessment of: (1) whether any existing or expired contracts are or contain leases, (2) lease classification and (3) initial direct costs. In addition, the Company has elected other available practical expedients to not separate lease and nonlease components, which consist principally of common area maintenance charges, for all classes of underlying assets and to exclude leases with an initial term of 12 months or less.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has one lease for its corporate headquarters that commenced on July 1, 2018 for </font><font style="font-family:Arial;font-size:10pt;">3,169</font><font style="font-family:Arial;font-size:10pt;">&#32;square feet of office space. The term of the lease is </font><font style="font-family:Arial;font-size:10pt;">37 months</font><font style="font-family:Arial;font-size:10pt;">&#32;and terminates on July 31, 2021. The Company has the option to extend the term of the lease for </font><font style="font-family:Arial;font-size:10pt;">one year</font><font style="font-family:Arial;font-size:10pt;">&#32;at the Company's discretion. The gross monthly base rent is </font><font style="font-family:Arial;font-size:10pt;">$8,873</font><font style="font-family:Arial;font-size:10pt;">, which will increase approximately </font><font style="font-family:Arial;font-size:10pt;">4%</font><font style="font-family:Arial;font-size:10pt;">&#32;per year, subject to certain future adjustments. The base rent was abated during the second month of the lease. The Company evaluates renewal options at lease inception and on an ongoing basis, and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. The lease does not require material variable lease payments, a residual value guarantee or restrictive covenants.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The lease does not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment. The Company used an incremental borrowing rate of 7% as of January 1, 2019 for the operating lease that commenced prior to that date. The depreciable lives of operating lease assets and leasehold improvements are limited by the expected lease term.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of March 31, 2019, the Company recorded a right of use asset of </font><font style="font-family:Arial;font-size:10pt;">$212,909</font><font style="font-family:Arial;font-size:10pt;">&#32;within its other non-current  assets and </font><font style="font-family:Arial;font-size:10pt;">$83,751</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">$139,288</font><font style="font-family:Arial;font-size:10pt;">, respectively within current and non-current other liabilities on its consolidated balance sheet.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of March 31, 2019, future minimum lease payments for the Company's corporate headquarters are:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:83%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Years ending December 31:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Remainder of 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">81,950</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">112,943</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">67,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total future minimum lease payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">262,488</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Less: Difference between future minimum lease payments and discounted operating lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">39,449</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total operating lease liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">223,039</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Operating lease costs were&#160;</font><font style="font-family:Arial;font-size:10pt;">$27,038</font><font style="font-family:Arial;font-size:10pt;">&#160;for the three months ended&#160;March&#160;31, 2019. Operating lease costs are included in general and administrative expenses in the condensed consolidated statement of operations. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash paid for amounts included in the measurement of operating lease liabilities were&#160;</font><font style="font-family:Arial;font-size:10pt;">$26,620</font><font style="font-family:Arial;font-size:10pt;">&#160;for the three months ended&#160;March&#160;31, 2019, and this amount is included in operating activities in the condensed consolidated statements of cash flows. </font></div><div><a name="sB6DCF3174C085D7FAE1A2077C1059387"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">COMMITMENTS AND CONTINGENCIES</font></div></td></tr></table><div style="line-height:120%;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">License and Research Agreements</font></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">ADVA-Tec License Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In March 2017, the Company entered into a license agreement, or the ADVA-Tec License Agreement, with ADVA-Tec, Inc., or ADVA-Tec, under which the Company was granted the exclusive right to develop and commercialize Ovaprene for human contraceptive use worldwide. ADVA-Tec and its affiliates own issued patents or patent applications covering Ovaprene and control proprietary trade secrets covering the manufacture of Ovaprene. As of the date of this report, this patent portfolio includes </font><font style="font-family:Arial;font-size:10pt;">nine</font><font style="font-family:Arial;font-size:10pt;">&#32;issued U.S. patents and </font><font style="font-family:Arial;font-size:10pt;">one</font><font style="font-family:Arial;font-size:10pt;">&#32;pending U.S. patent application, and </font><font style="font-family:Arial;font-size:10pt;">59</font><font style="font-family:Arial;font-size:10pt;">&#32;granted patents and </font><font style="font-family:Arial;font-size:10pt;">four</font><font style="font-family:Arial;font-size:10pt;">&#32;pending patent applications in other major markets, all of which are exclusively licensed to the Company for the human contraceptive use of Ovaprene as a human contraceptive device. The license continues on a country-by-country basis until the later of the life of the licensed patents or the Company&#8217;s last commercial sale of Ovaprene. Under the terms of the ADVA-Tec Agreement, the Company has a right of first refusal to license these patents and patent applications for additional indications.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following is a summary of other terms of the ADVA-Tec License Agreement:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Research and Development.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">ADVA-Tec will conduct certain research and development work as necessary to allow the Company to seek a Premarket Approval, or PMA, from the United States Food and Drug Administration, or the FDA, and will supply the Company with its requirements of Ovaprene for clinical and commercial use on commercially reasonable terms. The Company must use commercially reasonable efforts to develop and commercialize Ovaprene, and must meet certain minimum spending amounts per year, such amounts totaling </font><font style="font-family:Arial;font-size:10pt;">$5.0 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in the aggregate over the first </font><font style="font-family:Arial;font-size:10pt;">three years</font><font style="font-family:Arial;font-size:10pt;">, to cover such activities until a final PMA is filed, or until the first commercial sale of Ovaprene, whichever occurs first.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Milestone Payments.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">The Company will pay ADVA-Tec: (1) up to </font><font style="font-family:Arial;font-size:10pt;">$14.6 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in the aggregate based on the achievement of specified development and regulatory milestones; and (2) up to </font><font style="font-family:Arial;font-size:10pt;">$20 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in the aggregate based on the achievement of certain worldwide net sales milestones. The development and regulatory milestones  include: the completion of a successful postcoital clinical study, which is required before the Company can commence a Phase 3 pivotal human clinical trial; approval by the FDA to commence such Phase 3 pivotal human clinical trial; successful completion of such Phase 3 pivotal human clinical trial; the FDA&#8217;s acceptance of a PMA filing for Ovaprene; </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the FDA&#8217;s approval of the PMA for Ovaprene; obtaining Conformit&#233; Europ&#233;enne Marking of Ovaprene in at least </font><font style="font-family:Arial;font-size:10pt;">three</font><font style="font-family:Arial;font-size:10pt;">&#32;designated European countries; obtaining regulatory approval in at least three designated European countries; and obtaining regulatory approval in Japan. Because these milestone payments depend upon the successful progress of the Company&#8217;s product development programs, the Company cannot estimate with certainty when these payments will occur, if ever.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Royalty Payments.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">After the commercial launch of Ovaprene, the Company will pay to ADVA-Tec royalties based on aggregate annual net sales of Ovaprene in specified regions, at a royalty rate that will vary between </font><font style="font-family:Arial;font-size:10pt;">1%</font><font style="font-family:Arial;font-size:10pt;">&#32;and </font><font style="font-family:Arial;font-size:10pt;">10%</font><font style="font-family:Arial;font-size:10pt;">&#32;and will increase based on various net sales thresholds.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Termination Rights.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">Unless earlier terminated, the license the Company received under the ADVA-Tec License Agreement continues on a country-by-country basis until the later of the life of the licensed patents or the Company's last commercial sale of Ovaprene. In addition to customary termination rights for both parties: (A) the Company may terminate the agreement with or without cause in whole or on a country-by-country basis upon </font><font style="font-family:Arial;font-size:10pt;">60</font><font style="font-family:Arial;font-size:10pt;">&#32;days prior written notice; and (B) ADVA-Tec may terminate the agreement if the Company develops or commercializes any non-hormonal ring-based vaginal contraceptive device competitive to Ovaprene or if the Company fails to: (1) in certain limited circumstances, commercialize Ovaprene in certain designated countries within three years of the first commercial sale of Ovaprene, (2) satisfy the annual spending obligation described above, (3) use commercially reasonable efforts to complete all necessary pre-clinical and clinical studies required to support and submit a PMA, (4) conduct clinical trials as set forth in the development plan that is agreed by the Company and ADVA-Tec, and as may be modified by a joint research committee, unless such failure is caused by events outside of the Company&#8217;s reasonable control, or (5) enroll a patient in the first non-significant risk medical device study or clinical trial as allowed by an institutional review board within </font><font style="font-family:Arial;font-size:10pt;">six months</font><font style="font-family:Arial;font-size:10pt;">&#32;of the production and release of Ovaprene, unless such failure is caused by events outside of its reasonable control.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For products currently in development, future potential milestone payments based on product development are approximately </font><font style="font-family:Arial;font-size:10pt;">$14.6 million</font><font style="font-family:Arial;font-size:10pt;">&#32;as of </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">. Future potential milestone payments related to commercialization totaled </font><font style="font-family:Arial;font-size:10pt;">$20 million</font><font style="font-family:Arial;font-size:10pt;">&#32;at </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">. There are </font><font style="font-family:Arial;font-size:10pt;">1</font><font style="font-family:Arial;font-size:10pt;">-</font><font style="font-family:Arial;font-size:10pt;">10%</font><font style="font-family:Arial;font-size:10pt;">&#32;royalties required under the license agreement. The Company is unable to estimate with certainty the timing on when these milestone payments will occur as these payments are dependent upon the Company's product development programs.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">SST License and Collaboration Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In February 2018, the Company entered into a license and collaboration agreement, or the SST License Agreement, with Strategic Science &amp;&#160;Technologies-D,&#160;LLC and Strategic Science &amp; Technologies, LLC, referred to collectively as SST. The SST License Agreement provides the Company with an exclusive, royalty-bearing, sublicensable license to develop and commercialize, in all countries and geographic territories of the world, for all indications for women related to female sexual dysfunction and/or female reproductive health, including treatment of female sexual arousal disorder, or the Field of Use, SST&#8217;s topical formulation of Sildenafil Cream, 3.6% as it exists as of the effective date of the SST License Agreement, or any other topically applied pharmaceutical product containing sildenafil or a salt thereof as a pharmaceutically active ingredient, alone or with other active ingredients, but specifically excluding any product containing ibuprofen or any salt derivative of ibuprofen, or the Licensed Products.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following is a summary of other terms of the SST License Agreement:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Invention </font><font style="font-family:Arial;font-size:10pt;">Ownership</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">The Company retains rights to inventions made by its employees, SST retains rights to inventions made by its employees, and each party shall own a </font><font style="font-family:Arial;font-size:10pt;">50%</font><font style="font-family:Arial;font-size:10pt;">&#32;undivided interest in all joint inventions.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Joint </font><font style="font-family:Arial;font-size:10pt;">Development</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#32;Committee</font><font style="font-family:Arial;font-size:10pt;">. The parties will collaborate through a joint development committee that will determine the strategic objectives for, and generally oversee, the development efforts of both parties under the SST License Agreement.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Development</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">The Company must use commercially reasonable efforts to develop the Licensed Products in the Field of Use in accordance with a development plan in the SST License Agreement, and to commercialize the Licensed Products in the Field of Use. The Company is responsible for all reasonable internal and external costs and expenses incurred by SST in its performance of the development activities it must perform under the SST License Agreement.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Royalty </font><font style="font-family:Arial;font-size:10pt;">Payments.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">SST will be eligible to receive tiered royalties based on percentages of annual net sales of Licensed Products in the single digits to the mid double digits, subject to customary royalty reductions and offsets, and a percentage of sublicense revenue.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Milestone Payments.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">SST will be eligible to receive payments (1) ranging from </font><font style="font-family:Arial;font-size:10pt;">$0.5 million</font><font style="font-family:Arial;font-size:10pt;">&#32;to </font><font style="font-family:Arial;font-size:10pt;">$18.0 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in the aggregate on achieving certain clinical and regulatory milestones in the U.S. and worldwide, and (2) </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">between </font><font style="font-family:Arial;font-size:10pt;">$10.0 million</font><font style="font-family:Arial;font-size:10pt;">&#32;to </font><font style="font-family:Arial;font-size:10pt;">$100 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in the aggregate upon achieving certain commercial sales milestones. If the Company enters into strategic development or distribution partnerships related to the Licensed Products, additional milestone payments would be due to SST.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">License Term.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s license received under the SST License Agreement continues on a country-by-country basis until the later of </font><font style="font-family:Arial;font-size:10pt;">10 years</font><font style="font-family:Arial;font-size:10pt;">&#32;from the date of the first commercial sale of such Licensed Product or the expiration of the last valid claim of patent rights covering the Licensed Product in the Field of Use. Upon expiration (but not termination) of the SST License Agreement in a particular country, the Company will have a fully paid-up license under the licensed intellectual property to develop and commercialize the applicable Licensed Products in the applicable country on a non-exclusive basis.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Termination.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">In addition to customary termination rights for both parties: (1) prior to receipt of approval by a regulatory authority necessary for commercialization of a Licensed Product in the corresponding jurisdiction, including New Drug Application Approval, or NDA Approval, the Company may terminate the SST License Agreement without cause upon </font><font style="font-family:Arial;font-size:10pt;">90</font><font style="font-family:Arial;font-size:10pt;">&#32;days prior written notice to SST; (2)&#160;following receipt of approval by a regulatory authority necessary for commercialization of a Licensed Product in the corresponding jurisdiction, including NDA Approval, the Company may terminate the SST License Agreement without cause upon </font><font style="font-family:Arial;font-size:10pt;">180</font><font style="font-family:Arial;font-size:10pt;">&#160;days prior written notice; and (3) SST may terminate the SST License Agreement with respect to the applicable Licensed Product(s) in the applicable country(ies) upon </font><font style="font-family:Arial;font-size:10pt;">30</font><font style="font-family:Arial;font-size:10pt;">&#160;days&#8217; notice to the Company if the Company fails to use commercially reasonable efforts to perform development activities in substantial accordance with the development plan and does not cure such failure within </font><font style="font-family:Arial;font-size:10pt;">60</font><font style="font-family:Arial;font-size:10pt;">&#160;days of receipt of SST&#8217;s notice thereof.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Orbis Development and Option Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In March 2018, the Company entered into an exclusive development and option agreement, or the Orbis Agreement, with Orbis Biosciences, or Orbis, for the development of long-acting injectable etonogestrel contraceptive with 6- and 12-month durations (ORB-204 and ORB-214, respectively). Under the Orbis Agreement, the  Company paid Orbis </font><font style="font-family:Arial;font-size:10pt;">$300,000</font><font style="font-family:Arial;font-size:10pt;">&#32;to conduct the first stage of development work, Stage 1, as follows: </font><font style="font-family:Arial;font-size:10pt;">$150,000</font><font style="font-family:Arial;font-size:10pt;">&#32;upon signing the Orbis Agreement, </font><font style="font-family:Arial;font-size:10pt;">$75,000</font><font style="font-family:Arial;font-size:10pt;">&#32;at the </font><font style="font-family:Arial;font-size:10pt;">50%</font><font style="font-family:Arial;font-size:10pt;">&#32;completion point, not later than 6 months following the date the Orbis Agreement was signed (which the Company paid in September 2018), and </font><font style="font-family:Arial;font-size:10pt;">$75,000</font><font style="font-family:Arial;font-size:10pt;">&#32;upon delivery by Orbis of the 6-month batch, not later than 11 months following the date the Orbis Agreement was signed (which the Company paid in January 2019). Upon Orbis successfully completing Stage 1 of the development program and achieving the predetermined target milestones for Stage 1, the Company will have </font><font style="font-family:Arial;font-size:10pt;">90</font><font style="font-family:Arial;font-size:10pt;">&#32;days to instruct Orbis whether to commence the second stage of development work, Stage 2. Should the Company execute its option to proceed to Stage 2, it will have to provide additional funding to Orbis for such activities. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pre-clinical studies for the 6- and 12-month formulations have been completed, including establishing pharmacokinetics and pharmacodynamics profiles. The collaboration with Orbis will continue to advance the program through formulation optimization with the goal of achieving sustained release over the target time period.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Orbis Agreement provides the Company with an option to enter into a license agreement for ORB-204 and ORB-214 should development efforts be successful.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Juniper Pharmaceuticals - License Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In April 2018,&#160;the Company entered into an Exclusive License Agreement, or the Juniper License Agreement, with Juniper Pharmaceuticals, Inc., or Juniper, under which Juniper granted the Company (a) an exclusive, royalty-bearing worldwide license under certain patent rights, either owned by or exclusively licensed to Juniper, to make, have made, use, have used, sell, have sold, import and have imported products and processes; and (b) a non-exclusive, royalty-bearing worldwide license to use certain technological information owned by Juniper to make, have made, use, have used, sell, have sold, import and have imported products and processes. The Company is entitled to sublicense the rights granted to it under the Juniper License Agreement.</font></div><div style="line-height:120%;padding-top:8px;text-indent:94px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following is a summary of certain terms of the Juniper License Agreement:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Upfront Fee.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">The Company paid a </font><font style="font-family:Arial;font-size:10pt;">$250,000</font><font style="font-family:Arial;font-size:10pt;">&#32;non-creditable upfront license fee to Juniper in connection with the execution of the Juniper License Agreement.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Annual Maintenance Fee</font><font style="font-family:Arial;font-size:10pt;">. The Company will pay an annual license maintenance fee to Juniper on each anniversary of the date of the Juniper License Agreement, the amount of which will be </font><font style="font-family:Arial;font-size:10pt;">$50,000</font><font style="font-family:Arial;font-size:10pt;">&#32;for the first two years and </font><font style="font-family:Arial;font-size:10pt;">$100,000</font><font style="font-family:Arial;font-size:10pt;">&#32;thereafter, and which will be creditable against royalties and other payments due to Juniper in the same calendar year but may not be carried forward to any other year.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Milestone </font><font style="font-family:Arial;font-size:10pt;">Payments.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">The Company must make potential future development and sales milestone payments of (1) up to </font><font style="font-family:Arial;font-size:10pt;">$13.5 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in the aggregate upon achieving certain clinical and regulatory milestones, and (2) </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">up to </font><font style="font-family:Arial;font-size:10pt;">$30.3 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in the aggregate upon achieving certain commercial sales milestones for each product or process covered by the licenses granted under the Juniper License Agreement.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Royalty Payments</font><font style="font-family:Arial;font-size:10pt;">. During the royalty term, the Company will pay Juniper mid-single-digit to low double-digit royalties based on worldwide net sales of products and processes covered by the licenses granted under the Juniper</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">License</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">Agreement. In lieu of such royalty payments, the Company will pay Juniper a low double-digit percentage of all sublicense income the Company receives for the sublicense of rights under the Juniper License Agreement to a third party. The royalty term, which is determined on a country-by-country basis and product-by-product basis (or process-by-process basis), begins with the first commercial sale of a product or process in a country and terminates on the latest of (1) the expiration date of the last valid claim within the licensed patent rights with respect to such product or process in such country, (2) </font><font style="font-family:Arial;font-size:10pt;">10 years</font><font style="font-family:Arial;font-size:10pt;">&#32;following the first commercial sale of such product or process in such country, and (3) when one or more generic products for such product or process are commercially available in such country, except that if there is no such generic product by the 10th year following the first commercial sale in such country, then the royalty term will terminate on the 10-year anniversary of the first commercial sale in such country.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Efforts</font><font style="font-family:Arial;font-size:10pt;">. The Company must use commercially reasonable efforts to develop and make at least one product or process available to the public, which efforts include achieving specific diligence requirements by specific dates specified in the Juniper License Agreement.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">T</font><font style="font-family:Arial;font-size:10pt;">erm. Unless earlier terminated, the term of the Juniper License Agreement will continue on a country-by-country basis until the later of (1) the expiration date of the last valid claim within such country, or (2) 10 years from the date of first commercial sale of a product or process in such country. Upon expiration (but not early termination) of the Juniper License Agreement, the licenses granted thereunder will convert automatically to fully-paid irrevocable licenses. Juniper may terminate the Juniper License Agreement (1) upon </font><font style="font-family:Arial;font-size:10pt;">30</font><font style="font-family:Arial;font-size:10pt;">&#32;days&#8217; notice for the Company&#8217;s uncured breach of any payment obligation under the Juniper License Agreement, (2) if the Company fails to maintain required insurance, (3) immediately upon the Company&#8217;s insolvency or the making of an assignment for the benefit of the Company&#8217;s creditors or if a bankruptcy petition is filed for or against the Company, which petition is not dismissed within </font><font style="font-family:Arial;font-size:10pt;">90 days</font><font style="font-family:Arial;font-size:10pt;">, or (4) upon </font><font style="font-family:Arial;font-size:10pt;">60</font><font style="font-family:Arial;font-size:10pt;">&#32;days&#8217; notice for any uncured material breach by the Company of any of its other obligations under the Juniper License Agreement. The Company may terminate the Juniper License Agreement on a country-by-country basis for any reason by giving </font><font style="font-family:Arial;font-size:10pt;">180</font><font style="font-family:Arial;font-size:10pt;">&#32;days&#8217; notice (or </font><font style="font-family:Arial;font-size:10pt;">90 days</font><font style="font-family:Arial;font-size:10pt;">&#8217; notice if such termination occurs prior to receipt of marketing approval in the United States). If Juniper terminates the Juniper License Agreement for the reason described in clause (4) above or if the Company terminates the Juniper License Agreement, Juniper will have full access including the right to use and reference all product data generated during the term of the Juniper License Agreement that is owned by the Company.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Pear Tree Acquisition</font></div><div style="line-height:120%;padding-top:8px;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company may be required to make certain royalty and milestone payments under the Merger Agreement (see Note 4).</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Hammock/MilanaPharm Assignment and License Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On December 5, 2018, the Company entered into (a) an Assignment Agreement with Hammock Pharmaceuticals, Inc., or the Assignment Agreement, and (b) a First Amendment to License Agreement with TriLogic Pharma, LLC and MilanaPharm LLC, or the License Amendment. Both agreements relate to the Exclusive License Agreement among Hammock, TriLogic and MilanaPharm dated as of January 9, 2017, or the MilanaPharm License Agreement. Under the Assignment Agreement and the MilanaPharm License Agreement, as amended by the License Amendment, the Company acquired an exclusive, worldwide license under certain intellectual property to, among other things, develop and commercialize products for the diagnosis, treatment and prevention of human diseases or conditions in or through any intravaginal or urological applications. The licensed intellectual property relates to the hydrogel drug delivery platform of TriLogic and MilanaPharm known as TRI-726. In DARE-BV1, this proprietary technology is formulated with clindamycin, an antibiotic used to treat certain bacterial infections, including BV, and has been engineered to produce a dual release pattern after vaginal application, providing maximum duration of exposure to clindamycin at the site of infection.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following is a summary of other terms of the License Amendment:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">License Fees.</font><font style="font-family:Arial;font-size:10pt;">&#32;The Company paid </font><font style="font-family:Arial;font-size:10pt;">$25,000</font><font style="font-family:Arial;font-size:10pt;">&#32;to MilanaPharm in connection with the execution of the License Amendment and must pay </font><font style="font-family:Arial;font-size:10pt;">$200,000</font><font style="font-family:Arial;font-size:10pt;">&#32;to MilanaPharm (in the Company's discretion, either in cash or with shares of the Company's common stock) within 15 days of the first to occur of December 5, 2019 or the closing of an equity financing in which the Company raises aggregate proceeds of at least </font><font style="font-family:Arial;font-size:10pt;">$10.0 million</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Milestone Payments.</font><font style="font-family:Arial;font-size:10pt;">&#32;The Company will pay to MilanaPharm (1) up to </font><font style="font-family:Arial;font-size:10pt;">$300,000</font><font style="font-family:Arial;font-size:10pt;">&#32;in the aggregate upon achievement of certain development milestones; and (2) up to </font><font style="font-family:Arial;font-size:10pt;">$1.75 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in the aggregate upon achieving certain commercial sales milestones. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Foreign Sublicense Income.</font><font style="font-family:Arial;font-size:10pt;">&#32;The Company will pay MilanaPharm a low double-digit percentage of all income received by the Company or its affiliates in connection with any sublicense granted to a third party for use outside of the United States, subject to certain exclusions.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Royalty Payments.</font><font style="font-family:Arial;font-size:10pt;">&#32;During the royalty term, the Company will pay MilanaPharm high single-digit to low double-digit royalties based on annual worldwide net sales of licensed products and processes. The royalty term, which is determined on a country-by-country basis and licensed product-by-product basis (or process-by-process basis), begins with the first commercial sale of a licensed product or process in a country and terminates on the latest of (a) the expiration date of the last valid claim of the licensed patent rights that cover the method of use of such product or process in such country, or (b) 10 years following the first commercial sale of such product or process in such country. Royalty payments are subject to reduction in certain circumstances, including as a result of generic competition, patent prosecution expenses incurred by the Company, or payments to third parties for rights or know-how that are required for the Company to exercise the licenses granted to it under the MilanaPharm License Agreement or that are strategically important or could add value to a licensed product or process in a manner expected to materially generate or increase sales.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Efforts</font><font style="font-family:Arial;font-size:10pt;">. The Company must use commercially reasonable efforts and resources to (1) develop and commercialize at least one licensed product or process in the United States and at least one licensed product or process in at least one of Canada, the United Kingdom, France, Germany, Italy or Spain, and (2) continue to commercialize that product or process following the first commercial sale of a licensed product or process in the applicable jurisdiction.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Term</font><font style="font-family:Arial;font-size:10pt;">. Unless earlier terminated, the term of the MilanaPharm License Agreement will continue until (1) on a licensed product-by-product (or process-by-process basis) and country-by-country basis, the date of expiration of the royalty term with respect to such licensed product in such country, and (2) the expiration of all applicable royalty terms under the MilanaPharm License Agreement with respect to all licensed products and processes in all countries. Upon expiration of the term with respect to any licensed product or process in a country (but not upon earlier termination of the MilanaPharm License Agreement), the licenses granted to the Company under the MilanaPharm License Agreement will convert automatically to an exclusive, fully paid-up, royalty-free, perpetual, non-terminable and irrevocable right and license under the licensed intellectual property. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition to customary termination rights for all parties, MilanaPharm may terminate the license granted to the Company solely with respect to a licensed product or process in a country if, after having launched such product or process in such country, (1) the Company, or its affiliates or sublicensees, discontinue the sale of such product or process in such country and MilanaPharm notifies the Company of such termination within 60 days of having first been notified by the Company of such discontinuation, or (2) the Company, or its affiliates or sublicensees, (A) discontinues all commercially reasonable marketing efforts to sell, and discontinues all sales of, such product or process in such country for nine months or more, (B) fails to resume such commercially reasonable marketing efforts within 120 days of having been notified of such failure by MilanaPharm, (C) fails to reasonably demonstrate a strategic justification for the discontinuation and failure to resume to MilanaPharm, and (D) MilanaPharm gives 90 days&#8217; notice to the Company.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following is a summary of other terms of the Assignment Agreement with Hammock:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Assignment; Technology Transfer</font><font style="font-family:Arial;font-size:10pt;">. Hammock assigned and transferred to the Company all of its right, title and interest in and to the MilanaPharm License Agreement and agreed to cooperate to transfer to the Company all of the data, materials and the licensed technology in its possession pursuant to a technology transfer plan to be agreed upon by the parties, with a goal for the Company to independently practice the licensed intellectual property as soon as commercially practical in order to develop and commercialize the licensed products and processes. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Fees</font><font style="font-family:Arial;font-size:10pt;">. The Company paid </font><font style="font-family:Arial;font-size:10pt;">$250,000</font><font style="font-family:Arial;font-size:10pt;">&#32;to Hammock in connection with the execution of the Assignment Agreement and must pay </font><font style="font-family:Arial;font-size:10pt;">$250,000</font><font style="font-family:Arial;font-size:10pt;">&#32;to Hammock (in the Company's discretion either in cash or with shares of the Company's common stock) within 15 days of the first to occur of December 5, 2019 or the closing of an equity financing in which the Company raises aggregate proceeds of at least </font><font style="font-family:Arial;font-size:10pt;">$10.0 million</font><font style="font-family:Arial;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Milestone Payments</font><font style="font-family:Arial;font-size:10pt;">. The Company will pay Hammock up to </font><font style="font-family:Arial;font-size:10pt;">$1.1 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in the aggregate upon achievement of certain clinical and regulatory development milestones.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Term</font><font style="font-family:Arial;font-size:10pt;">. The Assignment Agreement will terminate upon the later of (1) completion of the parties&#8217; technology transfer plan, and (2) payment to Hammock of the last of the payments described above, including the milestone payments.</font></div><div><a name="s949C66C1D9C6506DA9B7E6E9EBCB9B8B"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">GRANT AWARD</font></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In April 2018, the Company received a Notice of Award for the first </font><font style="font-family:Arial;font-size:10pt;">$224,665</font><font style="font-family:Arial;font-size:10pt;">&#32;of the anticipated </font><font style="font-family:Arial;font-size:10pt;">$1.9 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in grant funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, a division of the National Institutes of Health, or the NIH.&#160;The Company must incur and track expenses eligible for reimbursement under the award and submit a detailed accounting of such expenses to receive payment. The Company subsequently received award payments totaling </font><font style="font-family:Arial;font-size:10pt;">$224,665</font><font style="font-family:Arial;font-size:10pt;">. The award payments were applied to clinical development efforts supporting Ovaprene and were recognized in the statement of operations as a reduction to research and development activities as the related costs were incurred to meet those obligations over the period. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On March 11, 2019, the Company received a Notice of Award for an additional </font><font style="font-family:Arial;font-size:10pt;">$982,851</font><font style="font-family:Arial;font-size:10pt;">&#32;of the anticipated </font><font style="font-family:Arial;font-size:10pt;">$1.9 million</font><font style="font-family:Arial;font-size:10pt;">&#32;in grant funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The second award followed the NIH's review of an interim data analysis and other results of the first phase of the research supporting Ovaprene. The award will be applied to clinical development efforts supporting Ovaprene. The remaining portion of the award under the grant, </font><font style="font-family:Arial;font-size:10pt;">$730,722</font><font style="font-family:Arial;font-size:10pt;">, is contingent upon, among other matters, assessment that the results of the ongoing Ovaprene study satisfy specified requirements set out in the award notice, and the availability of funds. At </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">, the Company recorded a receivable of approximately </font><font style="font-family:Arial;font-size:10pt;">$161,007</font><font style="font-family:Arial;font-size:10pt;">&#32;for expenses eligible for reimbursement incurred through </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div><a name="sD136B591EE025819A52E01B320950EA7"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">NET LOSS PER SHARE</font></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company computes basic net loss per share using the weighted average number of common shares outstanding during the period. Diluted net income per share is based upon the weighted average number of common shares and potentially dilutive securities (common share equivalents) outstanding during the period. Common share equivalents outstanding, determined using the treasury stock method, are comprised of shares that may be issued under outstanding options and warrants to purchase shares of the Company&#8217;s common stock. Common share equivalents are excluded from the diluted net loss per share calculation if their effect is anti-dilutive.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following potentially dilutive outstanding securities were excluded from diluted net loss per common share for the period indicated because of their anti-dilutive effect:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Potentially dilutive securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Three months ended<br>March&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,190,360</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">543,396</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,750,833</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,751,002</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,941,193</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,294,398</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="sfd5a8eca52aa4ed3ac68909735e95d15"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">11. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">SUBSEQUENT EVENTS</font></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Capital Raising</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On April 11, 2019, the Company closed an underwritten public offering of </font><font style="font-family:Arial;font-size:10pt;">4,575,000</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of its common stock at a public offering price of </font><font style="font-family:Arial;font-size:10pt;">$1.10</font><font style="font-family:Arial;font-size:10pt;">&#32;per share. The Company granted the underwriters a 30-day over-allotment option to purchase up to an additional </font><font style="font-family:Arial;font-size:10pt;">686,250</font><font style="font-family:Arial;font-size:10pt;">&#32;shares which was exercised in full on April 12, 2019. Including the over-allotment shares, the Company issued a total of </font><font style="font-family:Arial;font-size:10pt;">5,261,250</font><font style="font-family:Arial;font-size:10pt;">&#32;shares in the underwritten public offering, and received gross proceeds of approximately </font><font style="font-family:Arial;font-size:10pt;">$5.8 million</font><font style="font-family:Arial;font-size:10pt;">&#32;and net proceeds of approximately </font><font style="font-family:Arial;font-size:10pt;">$5.2 million</font><font style="font-family:Arial;font-size:10pt;">&#32;after deducting underwriting discounts and offering expenses.</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">February 2018 Warrant Exercise Price Reduced </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As discussed in Note 6 above, the outstanding warrants to purchase up to an aggregate of </font><font style="font-family:Arial;font-size:10pt;">3,720,500</font><font style="font-family:Arial;font-size:10pt;">&#32;shares of the Company's common that were issued and sold in February 2018 include price-based anti-dilution provisions. Under the terms of those warrants, subject to certain limited exceptions, their exercise price will be reduced each time the Company issues or sells any securities for a consideration per share less than a price equal to the exercise price of those warrants in effect immediately prior to such issuance or sale. If the Company issues shares of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">common stock for cash, the consideration received therefor will be deemed to be the net amount of consideration the Company received therefor. As of immediately prior to the initial closing of the April 2019 underwritten public offering, the exercise price of the warrants was </font><font style="font-family:Arial;font-size:10pt;">$3.00</font><font style="font-family:Arial;font-size:10pt;">&#32;per share. The net amount of consideration the Company received for shares issued and sold at the initial closing was </font><font style="font-family:Arial;font-size:10pt;">$0.98</font><font style="font-family:Arial;font-size:10pt;">&#32;per share. On April 11, 2019, in accordance with the anti-dilution provision of the warrants and as a result of the sale of such shares, the exercise price of the warrants was automatically reduced to </font><font style="font-family:Arial;font-size:10pt;">$0.98</font><font style="font-family:Arial;font-size:10pt;">&#32;per share. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><a name="sA78090057A1B52EDBB8B97A1D6F1A675"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">The following discussion and analysis of financial condition and results of operations should be read in conjunction with our interim consolidated financial statements and notes thereto included in this Quarterly Report on Form 10-Q and our audited financial statements and notes thereto for the year ended December 31, 2018 included in our Annual Report on Form 10-K for the year ended December 31, 2018, or our 2018 10-K, filed with the Securities and Exchange Commission, or SEC, on April 1, 2019. Past operating results are not necessarily indicative of results that may occur in future periods.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#32;The following discussion includes forward-looking statements.&#160;See &#8220;CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS,&#8221; above. Forward-looking statements are not guarantees of future performance and our actual results may differ materially from those currently anticipated and from historical results depending upon a variety of factors, including, but not limited to, those discussed in Part I, Item 1A. Risk Factors in our 2018 10-K and in our subsequent filings with the SEC, including any discussed in Part II, Item 1A of this report under the heading &#8220;Risk Factors,&#8221; which are incorporated herein by reference.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In this report: (a) &#8220;Cerulean&#8221; refers to Cerulean Pharma, Inc. before the Cerulean/Private Dar&#233; stock purchase transaction closed (as described in the &#8220;2017 Business Combination and Related Transactions&#8221; section below); and (b) &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Dar&#233;&#8221; or the &#8220;Company&#8221; refer collectively to Dar&#233; Bioscience, Inc. and its wholly owned subsidiaries, unless otherwise stated or the context otherwise requires. All information presented in this report is based on our fiscal year. Unless otherwise stated, references to particular years, quarters, months or periods refer to our fiscal years ending December 31 and the associated quarters, months and periods of those fiscal years.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dar&#233; Bioscience</font><font style="font-family:Arial;font-size:9pt;">&#174;</font><font style="font-family:Arial;font-size:10pt;">&#32;is a registered trademark of Dar&#233; Bioscience, Inc. Ovaprene</font><font style="font-family:Arial;font-size:9pt;">&#174;</font><font style="font-family:Arial;font-size:10pt;">&#32;is a registered trademark licensed to Dar&#233; Bioscience, Inc. All other trademarks, service marks or trade names appearing in this report are the property of their respective owners. Use or display by us of other parties&#8217; trademarks, service marks or trade names is not intended to and does not imply a relationship with, or endorsements or sponsorship of, us by the trademark, service mark or trade name owners.</font></div><div><a name="s32BB4162BCC75498AAE53B50B57D0801"></a></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Business Overview</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women&#8217;s health. We are driven by a mission to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health and fertility. Our business strategy is to license or otherwise acquire the rights to differentiated product candidates in our areas of focus, some of which have existing clinical proof-of-concept data, and to take those candidates through advanced stages of clinical development. We and our wholly owned subsidiaries operate in one business segment.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Since July 2017, we have assembled a portfolio of clinical-stage and pre-clinical stage candidates addressing unmet needs in women's health. Our portfolio includes these four clinical-stage product candidates:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2% for bacterial vaginosis, or BV;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ovaprene&#174;, a non-hormonal monthly contraceptive intravaginal ring;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil for female sexual arousal disorder, or FSAD; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy, or HRT, following menopause.</font></div></td></tr></table><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our portfolio also includes these pre-clinical stage product candidates:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy, or VVA, in patients with hormone-receptor positive breast cancer;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-RH1, a novel approach to non-hormonal contraception for both men and women by targeting the CatSper ion channel;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ORB-204 and ORB-214, 6-month and 12-month formulations of injectable etonogestrel for contraception;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and for fertility support as part of an IVF treatment plan; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-OAB1, an intravaginal ring containing oxybutynin for the treatment of overactive bladder.</font></div></td></tr></table><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#32;We expect that the bulk of our development expenses over the next two years will support the advancement of our four clinical-stage product candidates. In addition, we intend to fund a portion of the development expenses of our pre-clinical stage product candidates, particularly those like DARE-FRT1 and DARE-VVA1 that have the opportunity to advance into clinical studies more quickly. We expect that DARE-FRT1 will advance into a clinical study in approximately 12 to 18 months. Any additional product candidates we may obtain in the future will also require cash to fund their development.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">DARE-BV1</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-BV1 is a proprietary solution-to-gel formulation containing clindamycin, an antibiotic used to treat certain bacterial infections, including BV. DARE-BV1 is designed to be administered in a convenient, single vaginal dose with a dual release pattern to prolong the duration of exposure to clindamycin at the site of infection and to potentially improve the rate of effectiveness compared to existing FDA-approved therapies. Current FDA-approved therapies for BV have clinical cure rates of less than 70 percent. In an investigator initiated pilot study that enrolled 30 women, DARE-BV1 demonstrated an 88 percent clinical cure rate in evaluable subjects (n=26) at the test-of-cure visit (Day 7-14) after one administration. We plan to utilize the FDA's 505(b)(2) pathway to obtain marketing approval of DARE-BV1 for BV in the U.S. We expect to commence a Phase 3 clinical study of DARE-BV1 in approximately 250 women in the fourth quarter of 2019 and, if the study is successful, to be in a position to file a new drug application, or NDA, with the FDA in 2020. We anticipate that the cost of the Phase 3 clinical study, including manufacturing activities, and the NDA filing thereafter to be less than $10.0 million.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Ovaprene</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ovaprene is an intravaginal ring that, if approved, would represent a new category of birth control. Ovaprene is designed to be worn conveniently over multiple weeks, require no intervention at the time of intercourse, and it does not contain hormones. Ovaprene is a silicone-reinforced ring with a soft, absorbable scaffolding that encircles a fluid-permeable barrier. A non-braided, multi-filament mesh in the center of the ring functions as a physical barrier to sperm. The silicone ring also releases ferrous gluconate to create a spermiostatic environment within the vagina. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ovaprene is a combination product and, following a request for designation process, the FDA designated Center for Devices and Radiological Health, or CDRH, as the lead agency FDA program center for premarket review and product regulation. CDRH has determined that a PMA will be required to market Ovaprene in the U.S. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In May 2018, we announced initiation of a postcoital test, or PCT, clinical trial of Ovaprene. This ongoing clinical trial is designed to assess general safety, acceptability, and effectiveness in preventing progressively motile sperm, or PMS, from reaching the cervical canal following intercourse. The study will enroll approximately 50 couples, with the woman to be evaluated over the course of five menstrual cycles, with a target of having approximately 25 women complete a total of 21 visits. Each woman&#8217;s cervical mucus will be measured at several points during the study, including a baseline measurement at menstrual cycle 1 that excludes the use of any product. Subsequent cycles and visits will include the use of a diaphragm (menstrual cycle 2) and Ovaprene (menstrual cycles 3, 4 and 5). Data from the PCT clinical trial are expected to be available in the second half of 2019. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PCT clinical trials have been used as a surrogate marker for contraceptive effectiveness. Infertility research suggests that higher rates of pregnancy are associated with PMS per high power field, or HPF, of from greater than one to greater than 20 sperm, and less than 5 PMS per HPF is considered reflective of contraceptive effectiveness.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">If the PCT clinical trial demonstrates that less than 5 PMS per HPF progressed into the cervical canal in most women and can be safely worn over multiple weeks, we intend to prepare and file an Investigational Device Exemption, or IDE, with the FDA to commence a pivotal clinical trial to support marketing approvals of Ovaprene in the United States, Europe and other countries worldwide.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Sildenafil Cream, 3.6%</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sildenafil Cream, 3.6%, which incorporates sildenafil, the same active ingredient in the male erectile dysfunction drug Viagra&#174;, if approved, could be the first FDA-approved FSAD treatment option for women. FSAD is characterized primarily by a persistent or recurrent inability to attain or maintain sufficient physical sexual arousal, frequently resulting in distress or interpersonal difficulty. Sildenafil Cream, 3.6% is formulated to increase blood flow locally to the vulvar-vaginal tissue, leading to a potential improvement in genital arousal response. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We plan to leverage the existing data and established safety profile of sildenafil and the Viagra&#174; brand to utilize the FDA&#8217;s 505(b)(2) pathway to obtain marketing approval of Sildenafil Cream, 3.6% in the U.S. During the third quarter of 2018, we had a Type C meeting with the FDA regarding the design of our Phase 2b clinical trial for Sildenafil Cream, 3.6% and the overall development program for this product candidate. Based on the FDA guidance we received from that meeting, we commenced Phase 2b related activities during the fourth quarter of 2018 with the initiation of a non-interventional study intended to support the validity of specific patient reported outcome, or PRO, measures. This content validity PRO study seeks to identify and document the genital arousal symptoms that will be assessed in our planned at-home Phase 2b trial, as well as our pivotal studies, and to demonstrate that these symptoms are the most important and relevant to our target population and are also acceptable endpoints for the FDA. In parallel, we will continue to explore additional clinical and non-clinical work that might be valuable or required to support the overall program and the anticipated design of the Phase 2b trial. Because our plan is for the co-primary endpoints used in the Phase 2b trial to reflect the endpoints used in the Phase 3 trials, after the ongoing qualitative study is completed and before the Phase 2b at-home trial is initiated, we plan to request another Type C meeting to obtain the FDA&#8217;s guidance on the endpoints for our Phase 2b and Phase 3 clinical trials, including whether the FDA agrees that the PRO instruments are content valid for the target population. The timing of when we initiate the Phase 2b at-home trial will be influenced by such guidance.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">DARE-HRT1</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-HRT1 is an intravaginal ring, or IVR, containing bio-identical estradiol and bio-identical progesterone to treat the vasomotor symptoms (VMS) associated with menopause as part of a hormone replacement therapy regimen. There are currently no FDA-approved IVRs that deliver bio-identical progesterone in combination with bio-identical estradiol. The IVR technology used in DARE-HRT1 was developed by Dr. Robert Langer from the Massachusetts Institute of Technology and Dr. William Crowley from Massachusetts General Hospital and Harvard Medical School. We plan to utilize the FDA's 505(b)(2) pathway to obtain marketing approval of DARE-HRT1 in the U.S. We intend to initiate a Phase 1 clinical study for DARE-HRT1 during 2019 and to report topline results in 2020. DARE-HRT1 has the potential to be a first-in-class product. </font></div><div><a name="s134B57D7CFBD5DA78ADBBC5BD5E8464D"></a></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Financial Overview</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We incurred a loss of approximately </font><font style="font-family:Arial;font-size:10pt;">$3.1 million</font><font style="font-family:Arial;font-size:10pt;">&#32;for the quarter ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">. As of March 31, 2019, we had (a) an accumulated deficit of approximately </font><font style="font-family:Arial;font-size:10pt;">$32.0 million</font><font style="font-family:Arial;font-size:10pt;">&#32;and (b) cash and cash equivalents of approximately </font><font style="font-family:Arial;font-size:10pt;">$3.5 million</font><font style="font-family:Arial;font-size:10pt;">. We also had negative cash flow from operations of approximately </font><font style="font-family:Arial;font-size:10pt;">$3.3 million</font><font style="font-family:Arial;font-size:10pt;">&#32;during the three months ended March 31, 2019. As further discussed below, in an underwritten public offering we closed in April 2019, we received aggregate net proceeds of approximately $5.2 million. We will need to raise substantial additional capital to continue to fund our operations and to successfully execute our current operating plan, including the development of our current product candidates. The amount and timing of future funding will depend on many factors, including the pace and results of our clinical development efforts. If we do not raise capital as and when needed, we will not be able to continue development of our product candidates or we will be required to delay, scale back or eliminate some or all of our development programs or cease operations.</font></div><div><a name="s761DB3F9EB895689969D7C1909742AD7"></a></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2017 Business Combination and Related Transactions</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Until July 20, 2017, our corporate name was Cerulean Pharma Inc., or Cerulean. Cerulean was incorporated in Delaware in December 2005. On July 19, 2017, Cerulean and Dar&#233; Bioscience Operations, Inc., a privately held Delaware corporation, or Private Dar&#233;, completed a transaction in which the holders of capital stock and securities convertible into capital stock of Private Dar&#233;, which holders are collectively referred to as the Private Dar&#233; Stockholders, sold their shares of capital stock of Private Dar&#233; to Cerulean in exchange for newly issued shares of Cerulean common stock. As a result of that transaction, Private Dar&#233; became a wholly owned subsidiary of Cerulean. As of immediately following the closing of that transaction: (i) the Private Dar&#233; Stockholders owned approximately 51% of the outstanding common stock of Cerulean, and (ii) the equity holders of Cerulean immediately prior to the closing, collectively, owned approximately 49% of the outstanding common stock of Cerulean. In connection with the transaction, Cerulean changed </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">its name from &#8220;Cerulean Pharma, Inc.&#8221; to &#8220;Dar&#233; Bioscience, Inc.&#8221; We refer to the transaction described above as the Cerulean/Private Dar&#233; stock purchase transaction.</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="se3e99177402945d7a1574dedc6b22a9b"></a></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Recent Events</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Capital Raising</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On April 11, 2019, we closed an underwritten public offering of 4,575,000 shares of our common stock at a public offering price of $1.10 per share. We granted the underwriters a 30-day over-allotment option to purchase up to an additional 686,250 shares, which was exercised in full on April 12, 2019. Including the over-allotment shares, we issued a total of 5,261,250 shares in the underwritten public offering, and received gross proceeds of approximately $5.8 million and net proceeds of approximately $5.2 million after deducting underwriting discounts and offering expenses.</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">February 2018 Warrant Exercise Price Reduced </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As discussed in Note 6 of the accompanying Notes to Consolidated Financial Statements, the outstanding warrants to purchase up to an aggregate of 3,720,500 shares of our common stock we issued and sold in February 2018 include price-based anti-dilution provisions. Under the terms of those warrants, subject to certain limited exceptions, their exercise price will be reduced each time we issue or sell any securities for a consideration per share less than a price equal to the exercise price of those warrants in effect immediately prior to such issuance or sale. If we issue shares of our common stock for cash, the consideration received therefor will be deemed to be the net amount of consideration we received therefor. As of immediately prior to the initial closing of the April 2019 underwritten public offering, the exercise price of the warrants was $3.00 per share. The net amount of consideration we received for shares issued and sold at the initial closing was $0.98 per share. On April 11, 2019, in accordance with the anti-dilution provision of the warrants and as a result of the sale of such shares, the exercise price of the warrants was automatically reduced to $0.98 per share. </font></div><div><a name="s56934C205F28504E819381C2EA597E4B"></a></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Financial Operations Overview</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Revenue</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">To date we have not generated any revenue and do not expect to generate any revenue for the foreseeable future. In the future, we may generate revenue from product sales, license fees, milestone and research and development payments in connection with strategic partnerships, and royalties resulting from the sales of products developed under licenses of intellectual property. Any revenue generated is expected to fluctuate from quarter to quarter as a result of the timing and amounts of any such payments. Our ability to generate product revenue will depend on the successful clinical development of our product candidates, receiving regulatory approvals to market such products and the eventual successful commercialization of product candidates. If we fail to complete the development of products candidates in a timely manner, or to receive regulatory approval for such product candidates, our ability to generate future revenue and our results of operations would be materially adversely affected.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Research and development expenses include research and development costs for our product candidates and transaction costs related to our acquisitions. We recognize all research and development expenses as they are incurred. Research and development expenses consist primarily of:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:78px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">expenses incurred under agreements with consultants and clinical trial sites that conduct research and development activities on our behalf;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:78px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">laboratory and vendor expenses related to the execution of clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:78px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">contract manufacturing expenses, primarily for the production of clinical supplies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:78px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">transaction costs related to the acquisition of technologies and related intellectual property; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:78px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">internal costs that are associated with activities performed by our research and development organization and generally benefit multiple programs.</font></div></td></tr></table><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We expect research and development expenses to increase in the future as we invest in the development of our clinical-stage product candidates and as any other potential product candidates we may develop are advanced </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">into and through clinical trials in the pursuit of regulatory approvals. Such activities will require a significant increase in investment in regulatory support, clinical supplies, inventory build-up related costs, and the payment of success-based milestones. In addition, we continue to evaluate opportunities to acquire or in-license other product candidates and technologies, which may result in higher research and development expenses due to, among other factors, license fee and/or milestone payments.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. We may not obtain regulatory approval for any product candidate on a timely and cost-effective basis or at all. The probability of success of our product candidates may be affected by numerous factors, including clinical results and data, competition, intellectual property rights, manufacturing capability and commercial viability. As a result, we cannot accurately determine the duration and completion costs of development projects or when and to what extent we will generate revenue from the commercialization of any of our product candidates.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">General and Administrative Expense</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">General and administrative expenses consist of personnel costs, facility expenses, expenses for outside professional services, including legal, audit and accounting services. Personnel costs consist of salaries, benefits and stock-based compensation. Facility expenses consist of rent and other related costs. We expect to incur additional expenses because of additional costs associated with being a public company, including expenses related to compliance with SEC and Nasdaq rules and regulations, additional insurance, investor relations, and other administrative expenses and professional services.</font></div><div><a name="s85560330ACFA521D97D776494FAA9B0D"></a></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Critical Accounting Policies and Significant Judgments and Estimates</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Management&#8217;s discussion and analysis of financial condition and results of operations is based on our interim consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Preparing these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses. On an ongoing basis, we evaluate these estimates and judgments. We base our estimates on historical experience and on various assumptions we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. For a description of critical accounting policies that affect our significant judgments and estimates used in the preparation of our unaudited consolidated interim financial statements, refer to Item 7 in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations and Note 1 to our financial statements contained in our 2018 10-K and Note 3 to our unaudited interim consolidated financial statements contained in this report.</font></div><div><a name="sA04E241D12AB51E1BD78CA686BC71243"></a></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Results of Operations</font></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Comparison of Three Months Ended </font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#32;and </font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">2018</font><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#32;(Unaudited)</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes our results for the periods indicated, together with the changes in those items in dollars:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three months ended March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Dollar</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">General and administrative expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,277,180</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,303,189</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(26,009</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Research and development expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,693,391</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,086,653</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">606,738</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">License expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">112,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">100,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Impairment of goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,187,519</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(5,187,519</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,083,071</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,677,361</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(4,594,290</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,083,071</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(7,677,361</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,594,290</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other income</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">31,231</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,744</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">19,487</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,051,840</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(7,665,617</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,613,777</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other comprehensive loss:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Foreign currency translation adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,621</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(13,746</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">21,367</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,044,219</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(7,679,363</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,635,144</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Revenues</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We did not recognize any revenues for either of the three months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;or </font><font style="font-family:Arial;font-size:10pt;">2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">General and administrative expenses</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The decrease of </font><font style="font-family:Arial;font-size:10pt;">$26,009</font><font style="font-family:Arial;font-size:10pt;">&#32;in general and administrative expenses&#160;for the three months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;as compared to the three months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;was primarily attributable to (i) a decrease of approximately $311,800 in legal and professional services as the result of no fundraising activities in the current period as compared to the same period of the prior year, (ii) an increase in personnel costs of approximately $239,800 reflecting the hiring of additional employees which resulted in higher salary, benefit and bonus expenses in the current period, and (iii) an increase in stock-based compensation expense of $64,141 due to stock options granted in the current period compared to the same period of the prior year.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Research and development expenses</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The increase of </font><font style="font-family:Arial;font-size:10pt;">$606,738</font><font style="font-family:Arial;font-size:10pt;">&#32;in research and development expenses for the three months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;as compared to the three months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;was primarily attributable to (i) an increase in costs related to development activities of approximately $389,000 for Ovaprene and Sildenafil Cream, 3.6%, and to a lesser extent, DARE-BV1 and DARE-HRT1, offset by grant funding recorded as a reduction to research and development expense related to Ovaprene of approximately </font><font style="font-family:Arial;font-size:10pt;">$161,007</font><font style="font-family:Arial;font-size:10pt;">, (ii) an increase in personnel costs of approximately $346,000 due to increased salary, benefit and bonus expenses due to staff additions, and (iii) an increase in stock-based compensation expense of $21,628 due to stock options granted in the current period and none being granted during the same period of the prior year.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">License expenses</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The license expense of $112,500 for the three months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;related to the accrual of deferred license fees due under the Assignment Agreement with Hammock Pharmaceuticals, Inc. and the First Amendment to License Agreement with TriLogic Pharma, LLC and MilanaPharm LLC. We accrued $62,500 and $50,000 during the quarter with respect to, respectively, the $250,000 of license fees payable under the Assignment Agreement and the $200,000 of license fees payable under the First Amendment to License Agreement, both of which are payable, at the latest, in December 2019. In our discretion, we may both of these license fees either in cash or with shares of our common stock. The license expense of $100,000 for the three months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;was entirely related to fees paid to Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC. For further discussion, see Note 8, "Commitments and Contingencies" of the Notes to the Interim Consolidated Financial Statements (Unaudited).</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill impairment expense</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We incurred an impairment loss of $5,187,519 for the three months ended March 31, 2018 due to our determination that the carrying amount of our goodwill exceeded its estimated fair value at March 31, 2018. For a discussion of our goodwill analysis, see Note 4, "Acquisitions," of the Notes to the Interim Consolidated Financial Statements (Unaudited).</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Other income</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The increase of </font><font style="font-family:Arial;font-size:10pt;">$19,487</font><font style="font-family:Arial;font-size:10pt;">&#32;in other income for the three months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;as compared to the three months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;was primarily due to interest earned on cash balances in the current period.</font></div><div><a name="sF96B201F0E475C338BC9078097E0F86C"></a></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources and Financial Condition</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We prepared the accompanying consolidated financial statements on a going concern basis, which assumes that we will realize our assets and satisfy our liabilities in the normal course of business. For the three months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">, we incurred a net loss from operations of </font><font style="font-family:Arial;font-size:10pt;">$3.1 million</font><font style="font-family:Arial;font-size:10pt;">. In addition, we have a history of losses from operations, we expect negative cash flows from our operations to continue for the foreseeable future, and we expect that our net losses will continue for at least the next several years as we develop our existing product candidates and seek to acquire, license or develop additional product candidates.</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">At </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">, our accumulated deficit was approximately </font><font style="font-family:Arial;font-size:10pt;">$32.0 million</font><font style="font-family:Arial;font-size:10pt;">, our cash and cash equivalents were approximately </font><font style="font-family:Arial;font-size:10pt;">$3.5 million</font><font style="font-family:Arial;font-size:10pt;">&#32;and working capital was approximately </font><font style="font-family:Arial;font-size:10pt;">$3.2 million</font><font style="font-family:Arial;font-size:10pt;">. We also had negative cash flow from operations of approximately </font><font style="font-family:Arial;font-size:10pt;">$3.3 million</font><font style="font-family:Arial;font-size:10pt;">&#32;during the three months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">. From our underwritten public offering that closed in April 2019, we received gross proceeds of approximately $5.8 million and net proceeds of approximately $5.2 million after deducting underwriting discounts and offering expenses. Considering our current cash resources, we believe our existing resources will be sufficient to fund planned operations into the first quarter of 2020. For the foreseeable future, our ability to continue our operations will depend upon our ability to obtain additional capital.</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">These circumstances raise substantial doubt about our ability to continue as a going concern. The accompanying interim consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and reclassification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty of our ability to remain a going concern.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Plan of Operations and Future Funding Requirements</font></div><div style="line-height:120%;padding-top:13px;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our primary uses of capital are, and we expect will continue to be, staff-related expenses, the cost of clinical trials and regulatory activities related to our product candidates, costs associated with contract manufacturing services and third-party clinical research and development services, payments due under license agreements upon the successful achievement of milestones of our product candidates, legal expenses, other regulatory expenses and general overhead costs.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We expect our expenses to increase in 2019 primarily in connection with the continuation of the Ovaprene PCT clinical trial and study readout by year end 2019, the initiation of a Phase 3 clinical trial of DARE-BV1, the continuation of Phase 2b-related activities and potential commencement of the at-home Phase 2b clinical study of Sildenafil Cream, 3.6%, the initiation of a Phase 1 clinical study of DARE-HRT1, and to a lesser extent, efforts to advance our pre-clinical portfolio candidates.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">To date, we have not obtained any regulatory approvals for any of our product candidates, commercialized any of our product candidates or generated any product revenue, and we cannot anticipate if, and when we will generate any revenue. We have devoted significant resources to acquiring our portfolio of product candidates and to research and development activities for our product candidates. We must obtain regulatory approvals to sell any of our products in the future. We will need to generate sufficient safety and efficacy data on our product candidates for them to be attractive assets for potential strategic partners to license or for pharmaceutical companies to acquire, and for us to generate cash and other license fees related to such product candidates.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Based on our current operating plan estimates, we do not have sufficient cash to satisfy our working capital needs and other liquidity requirements over at least the next 12 months from the date of issuance of the accompanying interim consolidated financial statements. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We will need to raise substantial additional capital to continue to fund our operations and to successfully execute our current operating plan, including the development of our current product candidates. We are currently evaluating a variety of capital raising options, including financings, government or other grant funding, collaborations and strategic alliances or other similar types of arrangements to cover our operating expenses, including the development of our product candidates and any future product candidates we may license or otherwise acquire. The amount and timing of our capital needs have been and will continue to depend highly on many factors, including the product development programs we choose to pursue and the pace and results of our clinical development efforts. If we raise capital through collaborations, strategic alliances or other similar types of arrangements, we may have to relinquish, on </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">terms that are not favorable to us, rights to some of our technologies or product candidates we would otherwise seek to develop or commercialize. There can be no assurance that capital will be available when needed or that, if available, it will be obtained on terms favorable to us and our stockholders. In addition, equity or debt financings may have a dilutive effect on the holdings of our existing stockholders. If we cannot raise capital when needed, on favorable terms or at all, we will not be able to continue development of our product candidates, will need to reevaluate our planned operations and may need to delay, scale back or eliminate some or all of our development programs, reduce expenses, file for bankruptcy, reorganize, merge with another entity, or cease operations. If we become unable to continue as a going concern, we may have to liquidate our assets, and might realize significantly less than the values at which they are carried on our financial statements, and stockholders may lose all or part of their investment in our common stock. See &#8220;ITEM 1A. RISK FACTORS&#8212;Risks Related to Our Business&#8212;</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">We will need to raise additional capital to continue our operations</font><font style="font-family:Arial;font-size:10pt;">,&#8221; in our 2018 10-K.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Cash Flows</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table shows a summary of our cash flows for the periods indicated:</font></div><div style="line-height:120%;padding-top:8px;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three months ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,308,484</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2,118,887</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10,197,813</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Effect of exchange rate changes on cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,621</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(13,746</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:76px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net increase (decrease) in cash</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,300,863</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8,065,180</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Net cash used in operating activities</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash used in operating activities for the three months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;included the net loss of </font><font style="font-family:Arial;font-size:10pt;">$3,051,840</font><font style="font-family:Arial;font-size:10pt;">, decreased by non-cash stock-based compensation expense of </font><font style="font-family:Arial;font-size:10pt;">$97,968</font><font style="font-family:Arial;font-size:10pt;">. Major components reducing operating cash in this period were a </font><font style="font-family:Arial;font-size:10pt;">$201,129</font><font style="font-family:Arial;font-size:10pt;">&#32;increase in prepaid expenses, a </font><font style="font-family:Arial;font-size:10pt;">$135,676</font><font style="font-family:Arial;font-size:10pt;">&#32;increase in other receivables, and a </font><font style="font-family:Arial;font-size:10pt;">$134,087</font><font style="font-family:Arial;font-size:10pt;">&#32;decrease of accounts payable. Components providing operating cash in this period were a </font><font style="font-family:Arial;font-size:10pt;">$59,478</font><font style="font-family:Arial;font-size:10pt;">&#32;increase of accrued expenses and a </font><font style="font-family:Arial;font-size:10pt;">$55,233</font><font style="font-family:Arial;font-size:10pt;">&#32;increase in other non-current assets and deferred charges.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash used in operating activities for the three months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;included the net loss of $7,665,617, decreased by non-cash impairment of goodwill of $5,187,519, and non-cash stock-based compensation expense of $9,124. Major components reducing operating cash in this period were a $40,340 decrease of accounts payable and a $118,707 decrease in accrued expenses. Major components providing operating cash were a $255,318 decrease in other receivables and $193,495 decrease in other current assets.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Net cash provided by financing activities</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">No cash was provided by financing activities for the three months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash provided by financing activities for the three months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">&#32;consisted of proceeds from the underwritten public offering completed in February 2018 and sales under the at-the-market offering agreement completed in January and February 2018.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">License and Royalty Agreements</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have to make various royalty and milestone payments under the product license and development agreements related to our three clinical-stage assets, DARE-BV1, Ovaprene, and Sildenafil Cream, 3.6%, and under the other agreements related to our preclinical candidates.&#160;For further discussion of these potential payments, see Note 8, &#8220;Commitments and Contingencies,&#8221; of the Notes to the Interim Consolidated Financial Statements (Unaudited).</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Other Contracts</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We enter into contracts in the normal course of business with various third parties for research studies, clinical trials, testing and other services. These contracts generally provide for termination upon notice, and we do not believe that our non-cancelable obligations under these agreements are material.</font></div><div><a name="s5B987CB92FFA524B8B418CEB98D689C8"></a></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable SEC rules.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><a name="s8F10712F2D1457769C8F11203F7499C1"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Item 3. Quantitative and Qualitative Disclosures About Market Risk</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Under SEC rules and regulations, as a smaller reporting company we are not required to provide the information required by this item.</font></div><div><a name="s88A30F014AA951A7B920A599A338495E"></a></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Item 4. Controls and Procedures</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Based on an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) were effective as of </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;at the reasonable assurance level.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the fiscal quarter to which this report relates that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><a name="s71237209CB2752AFBC7E986A60DC9546"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PART II. OTHER INFORMATION</font></div><div><a name="s27542F97B5D2521C9325CC462D04B324"></a></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Item 1. Legal Proceedings</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">From time to time, we may become involved in various claims and legal proceedings. Regardless of outcome, litigation and other legal and administrative proceedings can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. There are no material pending legal proceedings, other than ordinary routine litigation incidental to our business, to which we are a party or of which any of our property is in the subject.</font></div><div><a name="s48E768CE7D035EE5889E8CC52402AA84"></a></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Item 1A. Risk Factors</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:62px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">An investment in shares of our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described in our 2018 10-K, in addition to other information in this report, before investing in our common stock. The occurrence of any of these risks could have a material adverse effect on our business, financial condition, results of operations and growth prospects. In these circumstances, the market price of our common stock could decline, and you may lose all or part of your investment. There have been no material changes from the risk factors disclosed in Part I, Item 1A. Risk Factors in our 2018 10-K.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><a name="s393E305420A354EDAD8198359136A089"></a></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</font></div><div style="line-height:120%;padding-left:0px;padding-top:10px;text-align:justify;text-indent:96px;"><font style="padding-top:10px;text-align:justify;font-family:Arial;font-size:10pt;padding-right:48px;">(a)</font><font style="font-family:Arial;font-size:10pt;">None.</font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:96px;"><font style="text-align:justify;font-family:Arial;font-size:10pt;padding-right:48px;">(b)</font><font style="font-family:Arial;font-size:10pt;">None.</font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:96px;"><font style="text-align:justify;font-family:Arial;font-size:10pt;padding-right:48px;">(c)</font><font style="font-family:Arial;font-size:10pt;">None.</font></div><div><a name="s212E6BC650505D939FC5D56B815F89AF"></a></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Item 3. Defaults Upon Senior Securities</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">None.</font></div><div><a name="s6100D1F504555C37AF3B66BC60E7A30D"></a></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Item 4. Mine Safety Disclosures</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Not applicable.</font></div><div><a name="sAEE5E415E8AE5624AE3EAEE8EEB6FFE5"></a></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Item 5. Other Information</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a) None.</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b) None.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><a name="s0999079D2BF053E0B46B966F219D76F3"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:justify;-sec-extract:summary;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Item 6. Exhibits</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Incorporated by Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Exhibit</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Description of Exhibit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:0px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Form</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">File No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Filing Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Filed Herewith</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">31.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit311.htm"><font style="font-family:Arial;font-size:10pt;">Certification of principal executive officer pursuant to Rule&#160;13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">31.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit312.htm"><font style="font-family:Arial;font-size:10pt;">Certification of principal financial officer pursuant to Rule&#160;13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">32.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit321.htm"><font style="font-family:Arial;font-size:10pt;">Certification of principal executive officer pursuant to 18&#160;U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">#</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">32.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit322.htm"><font style="font-family:Arial;font-size:10pt;">Certification of principal financial officer pursuant to 18&#160;U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">#</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">101.INS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">XBRL Instance Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">101.SCH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">XBRL Taxonomy Extension Schema Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">101.CAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">101.DEF</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">101.LAB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">XBRL Taxonomy Extension Label Linkbase Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">101.PRE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">XBRL Taxonomy Extension Presentation Linkbase Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">X</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"># Furnished herewith. This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated herein by reference into any filing of the registrant whether made before or after the date hereof, regardless of any general incorporation in such filing.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><a name="s901C819646A653A1ACDBFABAA3C7B9FC"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Signatures</font></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:46%;"></td><td style="width:7%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dar&#233; Bioscience, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Date: May&#160;14, 2019</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">By:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Sabrina Martucci Johnson</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sabrina Martucci Johnson</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Date: May&#160;14, 2019</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">By:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Lisa Walters-Hoffert</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Lisa Walters-Hoffert</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">32</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sA3B5213351DC1901F775983BD46249FC"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Exhibit 31.1 </font></div><div style="line-height:120%;padding-top:32px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">CERTIFICATIONS</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">I, Sabrina Martucci Johnson, certify that: </font></div><div style="line-height:120%;text-align:justify;font-size:6pt;"><font style="font-family:Arial;font-size:6pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.32285115303984%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">I have reviewed this Quarterly Report on Form 10-Q of Dar&#233; Bioscience, Inc.;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.32285115303984%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.32285115303984%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.32285115303984%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.9035639412998%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:5%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.9035639412998%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:5%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.9035639412998%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:5%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">c.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.9035639412998%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:5%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">d.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.32285115303984%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.9035639412998%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:5%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.9035639412998%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:5%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Date:  </font><font style="font-family:Arial;font-size:10pt;">May&#160;14, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:39.20335429769392%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Sabrina Martucci Johnson</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sabrina Martucci Johnson</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(principal executive officer)</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sD3215A7142FEB101DD1E983DA9EBC893"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Exhibit 31.2 </font></div><div style="line-height:120%;padding-top:32px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">CERTIFICATIONS </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">I, Lisa Walters-Hoffert, certify that: </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.32285115303984%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">I have reviewed this Quarterly Report on Form 10-Q of Dar&#233; Bioscience, Inc.;</font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.32285115303984%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.32285115303984%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.32285115303984%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.9035639412998%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:5%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.9035639412998%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:5%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.9035639412998%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:5%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">c.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.9035639412998%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:5%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">d.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.32285115303984%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.9035639412998%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:5%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.9035639412998%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:5%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Date: </font><font style="font-family:Arial;font-size:10pt;">May&#160;14, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:39.20335429769392%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Lisa Walters-Hoffert</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Lisa Walters-Hoffert</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(principal financial officer)</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s4C125F2CD760DA4E5EE09843A1756B7E"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Exhibit 32.1 </font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In connection with the Quarterly Report on Form 10-Q of Dar&#233; Bioscience, Inc. (the &#8220;Company&#8221;) for the fiscal quarter ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Sabrina Martucci Johnson, President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that, to her knowledge on the date hereof: </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Date: </font><font style="font-family:Arial;font-size:10pt;">May&#160;14, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:39.95726495726496%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Sabrina Martucci Johnson</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sabrina Martucci Johnson</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(principal executive officer)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>exhibit322.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sF42D9B13BB63D53B7C86984660D70B15"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Exhibit 32.2 </font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In connection with the Quarterly Report on Form 10-Q of Dar&#233; Bioscience, Inc. (the &#8220;Company&#8221;) for the fiscal quarter ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Lisa Walters-Hoffert, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that, to her knowledge on the date hereof: </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Date: </font><font style="font-family:Arial;font-size:10pt;">May&#160;14, 2019</font><font style="font-family:Arial;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:39.95726495726496%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Lisa Walters-Hoffert</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Lisa Walters-Hoffert</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(principal financial officer)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>dare-20190331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:DC7027140D4B5437A6036A4958565E21,x:94347a69b7f545a8848bfec705ecf200-->
<xbrli:xbrl xmlns:acec="http://fasb.org/dis/acec/2018-01-31" xmlns:ap="http://fasb.org/dis/ap/2018-01-31" xmlns:aro="http://fasb.org/dis/aro/2018-01-31" xmlns:bc="http://fasb.org/dis/bc/2018-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2018-01-31" xmlns:cc="http://fasb.org/dis/cc/2018-01-31" xmlns:cce="http://fasb.org/dis/cce/2018-01-31" xmlns:codification-part="http://fasb.org/codification-part/2018-01-31" xmlns:com="http://fasb.org/stm/com/2018-01-31" xmlns:con="http://fasb.org/dis/con/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2018-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2018-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2018-01-31" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2018-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2018-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2017-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2017-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2017-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2017-01-31" xmlns:dare="http://darebioscience.com/20190331" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2018-01-31" xmlns:debt="http://fasb.org/dis/debt/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2018-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2018-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2018-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:diha="http://fasb.org/dis/diha/2018-01-31" xmlns:disops="http://fasb.org/dis/disops/2018-01-31" xmlns:dr="http://fasb.org/dis/dr/2018-01-31" xmlns:edco="http://fasb.org/dis/edco/2018-01-31" xmlns:ei="http://fasb.org/dis/ei/2018-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2018-01-31" xmlns:eps="http://fasb.org/dis/eps/2018-01-31" xmlns:equity="http://fasb.org/dis/equity/2018-01-31" xmlns:ero="http://fasb.org/dis/ero/2018-01-31" xmlns:eui="http://fasb.org/dis/eui/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2018-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2018-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2018-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2018-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2018-01-31" xmlns:foct="http://fasb.org/dis/foct/2018-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2018-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2018-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2018-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2018-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2018-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2018-01-31" xmlns:guar="http://fasb.org/dis/guar/2018-01-31" xmlns:hco="http://fasb.org/dis/hco/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2018-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2018-01-31" xmlns:ides="http://fasb.org/dis/ides/2018-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2018-01-31" xmlns:inv="http://fasb.org/dis/inv/2018-01-31" xmlns:invco="http://fasb.org/dis/invco/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2018-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:lea="http://fasb.org/dis/lea/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2018-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:ni="http://fasb.org/dis/ni/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:nt="http://fasb.org/dis/nt/2018-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2018-01-31" xmlns:oi="http://fasb.org/dis/oi/2018-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2018-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2018-01-31" xmlns:pay="http://fasb.org/dis/pay/2018-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2018-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2018-01-31" xmlns:rd="http://fasb.org/dis/rd/2018-01-31" xmlns:re="http://fasb.org/dis/re/2018-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:regop="http://fasb.org/dis/regop/2018-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2018-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2018-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2018-01-31" xmlns:ru="http://fasb.org/dis/ru/2018-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2018-01-31" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2018-01-31" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2018-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2018-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2018-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2018-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2018-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2018-01-31" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2018-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2018-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2018-01-31" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2018-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2018-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2018-01-31" xmlns:se="http://fasb.org/dis/se/2018-01-31" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2018-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2018-01-31" xmlns:sec-re="http://fasb.org/dis/sec-re/2018-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2018-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2018-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2018-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2018-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2018-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2018-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2018-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2018-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2018-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2018-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2018-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:soc="http://fasb.org/stm/soc/2018-01-31" xmlns:soi="http://fasb.org/stm/soi/2018-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2018-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2018-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2018-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2018-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2018-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2018-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2018-01-31" xmlns:spc="http://fasb.org/stm/spc/2018-01-31" xmlns:sr="http://fasb.org/dis/sr/2018-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:srt-all="http://fasb.org/srt-all/2018-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2018-01-31" xmlns:srt-std="http://fasb.org/srt-std/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:te="http://fasb.org/dis/te/2018-01-31" xmlns:tin-part="http://fasb.org/tin-part/2018-01-31" xmlns:ts="http://fasb.org/dis/ts/2018-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2018-01-31" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2018-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2018-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2018-01-31" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="dare-20190331.xsd" xlink:type="simple" />
	<xbrli:context id="FD2019Q1YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q2May13">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-05-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Apr">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q2Apr_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Mar_srt_ProductOrServiceAxis_us-gaap_GrantMember_us-gaap_HealthCareTrustFundAxis_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_NationalInstitutesOfHealthMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HealthCareTrustFundAxis">dare:EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:SecondPhaseOfResearchAndAvailabilityOfFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1Jan1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_dei_LegalEntityAxis_dare_PrivateDareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">dare:PrivateDareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3Jul19">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-07-19</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2May15-May16_us-gaap_BusinessAcquisitionAxis_dare_PearTreePharmaceuticalsIncMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:PearTreePharmaceuticalsIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-15</xbrli:startDate>
			<xbrli:endDate>2018-05-16</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Jul18-Jul19">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-18</xbrli:startDate>
			<xbrli:endDate>2017-07-19</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2May15-May16_us-gaap_BusinessAcquisitionAxis_dare_PearTreePharmaceuticalsIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:PearTreePharmaceuticalsIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-15</xbrli:startDate>
			<xbrli:endDate>2018-05-16</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Apr29-Apr30_us-gaap_BusinessAcquisitionAxis_dare_PearTreePharmaceuticalsIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:PearTreePharmaceuticalsIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-29</xbrli:startDate>
			<xbrli:endDate>2018-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2May16_us-gaap_BusinessAcquisitionAxis_dare_PearTreePharmaceuticalsIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dare:PearTreePharmaceuticalsIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-05-16</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Jul18-Jul19_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-18</xbrli:startDate>
			<xbrli:endDate>2017-07-19</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q3Jul10-Jul10_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-10</xbrli:startDate>
			<xbrli:endDate>2018-07-10</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Jan1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q3Jul10_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-07-10</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_dei_LegalEntityAxis_dare_PrivateDareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">dare:PrivateDareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar01-Mar31_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1Jan1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_dei_LegalEntityAxis_dare_PrivateDareMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_dare_TwoThousandAndFifteenStockIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">dare:PrivateDareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_dare_TwoThousandAndFifteenStockIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_dei_LegalEntityAxis_dare_PrivateDareMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_dare_TwoThousandAndFifteenStockIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">dare:PrivateDareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q1Mar01-Mar31_us-gaap_PlanNameAxis_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-03-01</xbrli:startDate>
			<xbrli:endDate>2014-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_dei_LegalEntityAxis_dare_PrivateDareMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_dare_TwoThousandAndFifteenStockIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">dare:PrivateDareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_PlanNameAxis_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_dei_LegalEntityAxis_dare_PrivateDareMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_dare_TwoThousandAndFifteenStockIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">dare:PrivateDareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_dei_LegalEntityAxis_dare_PrivateDareMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_dare_TwoThousandAndFifteenStockIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">dare:PrivateDareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_dei_LegalEntityAxis_dare_PrivateDareMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_dare_TwoThousandAndFifteenStockIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">dare:PrivateDareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_PlanNameAxis_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dare:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb01-Feb28_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-01</xbrli:startDate>
			<xbrli:endDate>2018-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Jan01-Jan31_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb01-Feb28">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-01</xbrli:startDate>
			<xbrli:endDate>2018-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q2Apr11_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-04-11</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb01-Feb28_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-01</xbrli:startDate>
			<xbrli:endDate>2018-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb15_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201711Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201711Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnAprilFourTwoThousandTwentySixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dare:WarrantsExpiringOnAprilFourTwoThousandTwentySixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q3Jul1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-07-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q3Jul1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-07-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Mar_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_OrbisMember_us-gaap_TypeOfArrangementAxis_dare_DevelopmentAndOptionAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:OrbisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:DevelopmentAndOptionAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar01-Mar31_srt_ProductOrServiceAxis_dare_OvapreneMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:OvapreneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Apr_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_SalesMilestonesMember_us-gaap_TypeOfArrangementAxis_dare_JuniperPharmaceuticalsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:SalesMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:JuniperPharmaceuticalsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar01-Mar31_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Dec5_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_dare_UponAchievingCertainDevelopmentMilestonesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_MilanaPharmMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainDevelopmentMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-05</xbrli:startDate>
			<xbrli:endDate>2018-12-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Mar_us-gaap_RelatedPartyTransactionAxis_dare_UponSigningOfDevelopmentAndOptionAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_OrbisMember_us-gaap_TypeOfArrangementAxis_dare_DevelopmentAndOptionAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponSigningOfDevelopmentAndOptionAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:OrbisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:DevelopmentAndOptionAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Mar01-Mar31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb01-Feb28_srt_RangeAxis_srt_MinimumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-01</xbrli:startDate>
			<xbrli:endDate>2018-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Apr_us-gaap_TypeOfArrangementAxis_dare_JuniperPharmaceuticalsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:JuniperPharmaceuticalsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1_us-gaap_TypeOfArrangementAxis_dare_JuniperPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:JuniperPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb01-Feb28_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_dare_UponAchievingCertainCommercialMilestonesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_us-gaap_TypeOfArrangementAxis_dare_LicenseAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainCommercialMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-01</xbrli:startDate>
			<xbrli:endDate>2018-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Apr_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ClinicalAndRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_dare_JuniperPharmaceuticalsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:JuniperPharmaceuticalsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_srt_ProductOrServiceAxis_dare_OvapreneMember_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:OvapreneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb01-Feb28_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-01</xbrli:startDate>
			<xbrli:endDate>2018-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb01-Feb28_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-01</xbrli:startDate>
			<xbrli:endDate>2018-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar01-Mar31_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_dare_UponAchievementOfSpecifiedCommercializationMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dare:UponAchievementOfSpecifiedCommercializationMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Mar_us-gaap_RelatedPartyTransactionAxis_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_OrbisMember_us-gaap_TypeOfArrangementAxis_dare_DevelopmentAndOptionAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:OrbisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:DevelopmentAndOptionAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Dec5_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_MilanaPharmMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-05</xbrli:startDate>
			<xbrli:endDate>2018-12-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar01-Mar31_srt_RangeAxis_srt_MaximumMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Dec5_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_HammockPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_dare_AssignmentAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:HammockPharmaceuticalsInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:AssignmentAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-05</xbrli:startDate>
			<xbrli:endDate>2018-12-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar01-Mar31_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dare:UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb01-Feb28_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_us-gaap_TypeOfArrangementAxis_dare_LicenseAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-01</xbrli:startDate>
			<xbrli:endDate>2018-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb01-Feb28_srt_ProductOrServiceAxis_dare_OvapreneMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dare:OvapreneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-01</xbrli:startDate>
			<xbrli:endDate>2018-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Dec5_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_dare_UponAchievingCertainCommercialMilestonesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_MilanaPharmMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainCommercialMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:MilanaPharmMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-05</xbrli:startDate>
			<xbrli:endDate>2018-12-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb_srt_RangeAxis_srt_MinimumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar01-Mar31_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">dare:UponReachingCertainWorldwideNetSalesMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:ADVATecAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Dec5_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_HammockPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_dare_AssignmentAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dare:UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:HammockPharmaceuticalsInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dare:AssignmentAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-05</xbrli:startDate>
			<xbrli:endDate>2018-12-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Mar11_srt_ProductOrServiceAxis_us-gaap_GrantMember_us-gaap_HealthCareTrustFundAxis_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_NationalInstitutesOfHealthMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HealthCareTrustFundAxis">dare:EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:RemainingPortionOfResearchAndAvailabilityOfFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-11</xbrli:startDate>
			<xbrli:endDate>2019-03-11</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Mar11_srt_ProductOrServiceAxis_us-gaap_GrantMember_us-gaap_HealthCareTrustFundAxis_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_NationalInstitutesOfHealthMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HealthCareTrustFundAxis">dare:EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dare:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">dare:SecondPhaseOfResearchAndAvailabilityOfFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-11</xbrli:startDate>
			<xbrli:endDate>2019-03-11</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1_srt_ProductOrServiceAxis_us-gaap_GrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q2Apr11_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_dare_PublicStockOfferingIncludingOverAllotmentOfSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PublicStockOfferingIncludingOverAllotmentOfSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-11</xbrli:startDate>
			<xbrli:endDate>2019-04-11</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q2Apr11_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-04-11</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q2Apr11_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-11</xbrli:startDate>
			<xbrli:endDate>2019-04-11</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q2Apr11_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_dare_PublicStockOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001401914</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dare:PublicStockOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-11</xbrli:startDate>
			<xbrli:endDate>2019-04-11</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="U_dareCountry">
		<xbrli:measure>dare:Country</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="sqft">
		<xbrli:measure>utreg:sqft</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="U_darePatent">
		<xbrli:measure>dare:Patent</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="U_dareSegment">
		<xbrli:measure>dare:Segment</xbrli:measure>
	</xbrli:unit>
	<dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued contextRef="FD2018Q1QTD" decimals="0" id="Fact-F4542F76CBC63F414BBA9A5A0495D34A" unitRef="usd">1037764</dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued>
	<dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-75F15FEC50A994FCFD019A5A04B16B7C" unitRef="usd">1037727</dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued>
	<dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-CD31175EE304334E555C9A5A04A104F1" unitRef="usd">37</dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued>
	<dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-0635D6FC0E0434EDEE3B9A5A97AD8523" unitRef="shares">375000</dare:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares>
	<dare:AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease contextRef="D2017Q1Mar01-Mar31_srt_ProductOrServiceAxis_dare_OvapreneMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" id="Fact-4825D4EEF16C5FD2875B378631330ED2">P6M</dare:AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease>
	<dare:AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries contextRef="D2017Q1Mar01-Mar31_srt_ProductOrServiceAxis_dare_OvapreneMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" id="Fact-4F8AF49B41355C788595F20062377432">P3Y</dare:AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries>
	<dare:BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentAssets contextRef="I2017Q3Jul19" decimals="0" id="Fact-864AA063C4945C8684C61BA08B82E731" unitRef="usd">225778</dare:BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentAssets>
	<dare:BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentLiabilities contextRef="I2017Q3Jul19" decimals="0" id="Fact-857CFCC426965B2892B7DBDD7C538FA6" unitRef="usd">23609</dare:BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentLiabilities>
	<dare:BusinessCombinationReverseMergerConsiderationTransferred contextRef="D2017Q3Jul18-Jul19" decimals="-5" id="Fact-E2B34F37DF22068E81FB4CA6F015786D" unitRef="usd">24300000</dare:BusinessCombinationReverseMergerConsiderationTransferred>
	<dare:BusinessCombinationReverseMergerConsiderationTransferred contextRef="D2017Q3Jul18-Jul19" decimals="-3" id="Fact-118CDD2B082E580A957E4006B41002E0" unitRef="usd">24279000</dare:BusinessCombinationReverseMergerConsiderationTransferred>
	<dare:BusinessCombinationReverseMergerConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="D2017Q3Jul18-Jul19" decimals="-3" id="Fact-517AA63280CD550F937ACED2A56FCC8D" unitRef="usd">20625000</dare:BusinessCombinationReverseMergerConsiderationTransferredEquityInterestsIssuedAndIssuable>
	<dare:BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="I2017Q3Jul19" decimals="-3" id="Fact-21DF1E5090875F97BB5D58EB3FA47EDB" unitRef="usd">9918000</dare:BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
	<dare:BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="I2017Q3Jul19" decimals="-5" id="Fact-AB64BC8DA6F0528EAFB005202B678C72" unitRef="usd">9900000</dare:BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
	<dare:BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherCurrentAssets contextRef="I2017Q3Jul19" decimals="-3" id="Fact-E7F78FF6B4385BA19A953B7AE598152B" unitRef="usd">1915000</dare:BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherCurrentAssets>
	<dare:BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable contextRef="I2017Q3Jul19" decimals="-3" id="Fact-593B3CDECB7556B2A71E0AE13D7ED1C3" unitRef="usd">233000</dare:BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
	<dare:BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="I2017Q3Jul19" decimals="-3" id="Fact-7673C5B760FE548B819C3FE8CE0FC462" unitRef="usd">11600000</dare:BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
	<dare:BusinessCombinationReverseMergerStockPurchaseTransactionCost contextRef="D2017Q3Jul18-Jul19_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-4" id="Fact-5867A8F005AE5BD2A5C9F86AF0D7EFF3" unitRef="usd">960000</dare:BusinessCombinationReverseMergerStockPurchaseTransactionCost>
	<dare:BusinessCombinationReverseMergerStockPurchaseTransactionCost contextRef="D2018Q2May15-May16_us-gaap_BusinessAcquisitionAxis_dare_PearTreePharmaceuticalsIncMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-90EF2141208C53F18D26D6F55DFD9469" unitRef="usd">452000</dare:BusinessCombinationReverseMergerStockPurchaseTransactionCost>
	<dare:BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions contextRef="D2017Q3Jul18-Jul19" decimals="-3" id="Fact-7E64D2BC41E959709CAB4E75D453AD1F" unitRef="usd">3654000</dare:BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions>
	<dare:BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions contextRef="D2017Q3Jul18-Jul19" decimals="-5" id="Fact-2F615DB40A4955A6ACF2493BEB2CD519" unitRef="usd">3700000</dare:BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions>
	<dare:ClassOfWarrantOrRightsWarrantsExpirationDate contextRef="FD2019Q1YTD_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" id="Fact-81C3635963515585BF5ACCDA9DDFB2F1">2026-04-04</dare:ClassOfWarrantOrRightsWarrantsExpirationDate>
	<dare:ClassOfWarrantOrRightsWarrantsExpirationDate contextRef="FD2019Q1YTD_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember" id="Fact-F12B66FE861859808B8D92223E5B3B6A">2021-12-01</dare:ClassOfWarrantOrRightsWarrantsExpirationDate>
	<dare:ClassOfWarrantOrRightsWarrantsExpirationDate contextRef="FD2019Q1YTD_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember" id="Fact-FE6F20039B1C5635BE242BBE9800713A">2021-12-06</dare:ClassOfWarrantOrRightsWarrantsExpirationDate>
	<dare:ClassOfWarrantOrRightsWarrantsExpirationDate contextRef="FD2019Q1YTD_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" id="Fact-CF7FA7D10FBC5E3885D2FB365CD88DD5">2023-02-15</dare:ClassOfWarrantOrRightsWarrantsExpirationDate>
	<dare:ClassOfWarrantOrRightsWarrantsExpirationDate contextRef="FD2019Q1YTD_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember" id="Fact-8643CE48D2B351AD8A865677D139A6BB">2020-01-08</dare:ClassOfWarrantOrRightsWarrantsExpirationDate>
	<dare:CommencementPeriodForStageTwoUponAchievementOfStageOne contextRef="D2018Q1Mar_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_OrbisMember_us-gaap_TypeOfArrangementAxis_dare_DevelopmentAndOptionAgreementMember" id="Fact-5BEF7E1BB9168B78F9E3551F7B889A9E">P90D</dare:CommencementPeriodForStageTwoUponAchievementOfStageOne>
	<dare:EstimatedFairValueOfWarrantsRecordedInEquity contextRef="I2018Q1Feb15_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201711Member" decimals="-5" id="Fact-F82DD97E4CAC51D293D16025C95B04C4" unitRef="usd">3000000</dare:EstimatedFairValueOfWarrantsRecordedInEquity>
	<dare:GrossProceedsFromIssuanceOfCommonStock contextRef="D2018Q1Jan01-Jan31_srt_RangeAxis_srt_MaximumMember" decimals="INF" id="Fact-EAD99546157B5F8596C094B29AD06F89" unitRef="usd">10000000</dare:GrossProceedsFromIssuanceOfCommonStock>
	<dare:GrossProceedsFromIssuanceOfCommonStock contextRef="FD2018Q1QTD" decimals="-5" id="Fact-B959B3C6BC2064E893D39A7862D9A923" unitRef="usd">1100000</dare:GrossProceedsFromIssuanceOfCommonStock>
	<dare:GrossProceedsFromOfferingOfCommonStockAndWarrants contextRef="D2018Q1Feb01-Feb28_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="-5" id="Fact-13139C41F7E657B89E4853B7DF32837F" unitRef="usd">10300000</dare:GrossProceedsFromOfferingOfCommonStockAndWarrants>
	<dare:IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges contextRef="FD2018Q1QTD" decimals="0" id="Fact-8275F074882A5A95A86B0870A1788FD8" unitRef="usd">-37131</dare:IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges>
	<dare:IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges contextRef="FD2019Q1YTD" decimals="0" id="Fact-CF63D03FA6EF5DF9A0F47D4DD0563E69" unitRef="usd">-55233</dare:IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges>
	<dare:LicenseAgreementExpirationPeriod contextRef="D2018Q1Feb01-Feb28_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" id="Fact-0F8EB30107ED59D79A7BD83E82C98C38">P10Y</dare:LicenseAgreementExpirationPeriod>
	<dare:LicenseAgreementNoticePeriodOfTermination contextRef="D2018Q2Apr_us-gaap_TypeOfArrangementAxis_dare_JuniperPharmaceuticalsInc.Member" id="Fact-111BD75503FF78137119552240899561">P180D</dare:LicenseAgreementNoticePeriodOfTermination>
	<dare:LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation contextRef="D2018Q2Apr_us-gaap_TypeOfArrangementAxis_dare_JuniperPharmaceuticalsInc.Member" id="Fact-14076B49800ED7985C6E552219429447">P60D</dare:LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation>
	<dare:LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation contextRef="D2018Q2Apr_us-gaap_TypeOfArrangementAxis_dare_JuniperPharmaceuticalsInc.Member" id="Fact-4E3C286DB3212239D8F35521D4FF0675">P30D</dare:LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation>
	<dare:LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess contextRef="D2018Q2Apr_us-gaap_TypeOfArrangementAxis_dare_JuniperPharmaceuticalsInc.Member" id="Fact-5DD455B49F21DCF965FC5521B714842D">P10Y</dare:LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess>
	<dare:LicenseAgreementTerminationPeriodAfterReceiptOfApproval contextRef="D2018Q1Feb01-Feb28_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" id="Fact-97AFB0E00B3650A19956A9D4E430D3C6">P180D</dare:LicenseAgreementTerminationPeriodAfterReceiptOfApproval>
	<dare:LicenseAgreementTerminationPeriodDueToPerformanceFailure contextRef="D2017Q1Mar01-Mar31_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" id="Fact-6669C2DE51D75775BF57BEB4FD692D28">P60D</dare:LicenseAgreementTerminationPeriodDueToPerformanceFailure>
	<dare:LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries contextRef="D2018Q1Feb01-Feb28_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" id="Fact-92609D15295F58B883A2E43C26EE7D41">P30D</dare:LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries>
	<dare:LicenseAgreementTerminationPeriodPriorToReceiptOfApproval contextRef="D2018Q1Feb01-Feb28_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" id="Fact-A1F03C4B37D756A7A4DCAEE080AF2906">P90D</dare:LicenseAgreementTerminationPeriodPriorToReceiptOfApproval>
	<dare:LicenseAgreementTerminationPeriodPriorToReceiptOfApproval contextRef="D2018Q1_us-gaap_TypeOfArrangementAxis_dare_JuniperPharmaceuticalsMember" id="Fact-D40C3DE5B4D95766839414588CA63FFD">P90D</dare:LicenseAgreementTerminationPeriodPriorToReceiptOfApproval>
	<dare:LicenseFee contextRef="D2018Q4Dec5_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_HammockPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_dare_AssignmentAgreementMember" decimals="-3" id="Fact-0AA6A3A04C93E77CDD09975BBB794FDE" unitRef="usd">250000</dare:LicenseFee>
	<dare:LicenseFee contextRef="D2018Q4Dec5_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_MilanaPharmMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" decimals="-3" id="Fact-2F2D22C6DCAEAEC81B1597381F32D46B" unitRef="usd">25000</dare:LicenseFee>
	<dare:LicenseFee contextRef="FD2018Q1QTD" decimals="0" id="Fact-84648F805C207D092BC34B154196DCD1" unitRef="usd">100000</dare:LicenseFee>
	<dare:LicenseFee contextRef="FD2019Q1YTD" decimals="0" id="Fact-CAD87E18862E3C8F1E404B15418A6D55" unitRef="usd">112500</dare:LicenseFee>
	<dare:LicenseFeeToBePaidUponContingency contextRef="D2018Q4Dec5_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_HammockPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_dare_AssignmentAgreementMember" decimals="-3" id="Fact-AD75EFA930D710E677D5975BDEC26251" unitRef="usd">250000</dare:LicenseFeeToBePaidUponContingency>
	<dare:LicenseFeeToBePaidUponContingency contextRef="D2018Q4Dec5_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_MilanaPharmMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" decimals="-3" id="Fact-FC2853C732096EED2CD59758D19D32D3" unitRef="usd">200000</dare:LicenseFeeToBePaidUponContingency>
	<dare:MaximumPotentialMilestonePayments contextRef="D2018Q2Apr_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ClinicalAndRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_dare_JuniperPharmaceuticalsInc.Member" decimals="-5" id="Fact-E3B10DDADBD6ECFD0040552164A82379" unitRef="usd">13500000</dare:MaximumPotentialMilestonePayments>
	<dare:MaximumPotentialMilestonePayments contextRef="D2018Q2Apr_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_SalesMilestonesMember_us-gaap_TypeOfArrangementAxis_dare_JuniperPharmaceuticalsInc.Member" decimals="-5" id="Fact-24FA63DB8FED9569633855218294F2F9" unitRef="usd">30300000</dare:MaximumPotentialMilestonePayments>
	<dare:MilestonePaymentsContingentAmount contextRef="D2018Q1Feb01-Feb28_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_dare_UponAchievingCertainCommercialMilestonesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_us-gaap_TypeOfArrangementAxis_dare_LicenseAndCollaborationAgreementMember" decimals="-6" id="Fact-DCA6773A8DD211BD31BF551E1B6086B4" unitRef="usd">100000000</dare:MilestonePaymentsContingentAmount>
	<dare:MilestonePaymentsContingentAmount contextRef="D2018Q1Feb01-Feb28_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" decimals="INF" id="Fact-D5F681F57B6659198ECA7EB004E17EBF" unitRef="usd">18000000</dare:MilestonePaymentsContingentAmount>
	<dare:MilestonePaymentsContingentAmount contextRef="D2018Q1Feb01-Feb28_srt_RangeAxis_srt_MinimumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" decimals="INF" id="Fact-4D974239391B5A0C8D2B99BC8A2C64A7" unitRef="usd">500000.0</dare:MilestonePaymentsContingentAmount>
	<dare:MilestonePaymentsContingentAmount contextRef="D2018Q4Dec5_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_HammockPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_dare_AssignmentAgreementMember" decimals="-5" id="Fact-F3575B0BA75491BEA886970AF882CBC9" unitRef="usd">1100000</dare:MilestonePaymentsContingentAmount>
	<dare:MilestonePaymentsContingentAmount contextRef="D2018Q4Dec5_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_dare_UponAchievingCertainCommercialMilestonesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_MilanaPharmMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" decimals="-4" id="Fact-B87A03DC37352FB9384996FC5C3BD288" unitRef="usd">1750000</dare:MilestonePaymentsContingentAmount>
	<dare:MilestonePaymentsContingentAmount contextRef="D2018Q4Dec5_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_dare_UponAchievingCertainDevelopmentMilestonesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_MilanaPharmMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" decimals="-3" id="Fact-FD26D678ECAE5AEB8D04970418AD49A4" unitRef="usd">300000</dare:MilestonePaymentsContingentAmount>
	<dare:NetProceedsFromIssuanceOfCommonStockAndWarrants contextRef="FD2018Q1QTD" decimals="0" id="Fact-CC55D8A9923093990A094B1FF1295430" unitRef="usd">10197813</dare:NetProceedsFromIssuanceOfCommonStockAndWarrants>
	<dare:NetProceedsFromIssuanceOfCommonStockAndWarrants contextRef="FD2019Q1YTD" decimals="0" id="Fact-5C47EE9E39125C0A8AFA519BAB5BB516" unitRef="usd">0</dare:NetProceedsFromIssuanceOfCommonStockAndWarrants>
	<dare:NonCashLeaseExpense contextRef="FD2019Q1YTD" decimals="0" id="Fact-397B0E36CAB4901857269A55942203D1" unitRef="usd">10130</dare:NonCashLeaseExpense>
	<dare:NoticePeriodForTerminationOfAgreementForBothParties contextRef="D2018Q1Feb01-Feb28_srt_ProductOrServiceAxis_dare_OvapreneMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" id="Fact-4E31AACADFB5511AA95EDBAFACBEF44B">P60D</dare:NoticePeriodForTerminationOfAgreementForBothParties>
	<dare:NumberOfCommonStockWarrantsExercised contextRef="FD2018Q1QTD" decimals="INF" id="Fact-A5E790D1B5B1517CAFD21442034652C5" unitRef="shares">0</dare:NumberOfCommonStockWarrantsExercised>
	<dare:NumberOfCommonStockWarrantsExercised contextRef="FD2019Q1YTD" decimals="INF" id="Fact-42D3F6EA77D85314BCE76E87B2E6011F" unitRef="shares">0</dare:NumberOfCommonStockWarrantsExercised>
	<dare:NumberOfDesignatedCountries contextRef="D2017Q1Mar01-Mar31_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" decimals="INF" id="Fact-786CE649C7FB54119763F4EE46D97F05" unitRef="U_dareCountry">3</dare:NumberOfDesignatedCountries>
	<dare:NumberOfPatentApplications contextRef="FI2019Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember" decimals="INF" id="Fact-2552B034441467FEE9FC552837908C19" unitRef="U_darePatent">4</dare:NumberOfPatentApplications>
	<dare:NumberOfPatentsGranted contextRef="FI2019Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember" decimals="INF" id="Fact-E3C7C1920D802A43A8FF5527F68B0B67" unitRef="U_darePatent">59</dare:NumberOfPatentsGranted>
	<dare:NumberOfPatentsIssued contextRef="FI2019Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember" decimals="INF" id="Fact-DE26CC7C820CB2B550B55527B093C6E6" unitRef="U_darePatent">9</dare:NumberOfPatentsIssued>
	<dare:NumberOfPendingPatents contextRef="FI2019Q1_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember" decimals="INF" id="Fact-EE826A76C6A189AB274D5527CE6994A9" unitRef="U_darePatent">1</dare:NumberOfPendingPatents>
	<dare:OfferingPeriod contextRef="D2014Q1Mar01-Mar31_us-gaap_PlanNameAxis_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" id="Fact-C464AC0AF7F65F9898B71C5806BD5521">P6M</dare:OfferingPeriod>
	<dare:PercentageOfAggregateCommission contextRef="D2018Q1Jan01-Jan31_srt_RangeAxis_srt_MaximumMember" decimals="INF" id="Fact-AC0B85925D3858689BCA12C6D49B88F0" unitRef="number">0.03</dare:PercentageOfAggregateCommission>
	<dare:PercentageOfIncreaseInAnnualBaseRent contextRef="D2018Q3Jul1" decimals="2" id="Fact-850DD09EFDB3724C064B9C968F286A38" unitRef="number">0.04</dare:PercentageOfIncreaseInAnnualBaseRent>
	<dare:PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement contextRef="D2018Q1Feb01-Feb28_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" decimals="INF" id="Fact-CA3C440C44E659DC93633B4813980514" unitRef="number">0.50</dare:PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement>
	<dare:PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement contextRef="D2018Q1Feb01-Feb28_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_us-gaap_TypeOfArrangementAxis_dare_LicenseAndCollaborationAgreementMember" decimals="INF" id="Fact-AEADEE45B256D57814A7551DC2C87D09" unitRef="number">0.5</dare:PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement>
	<dare:PercentageOfRoyaltyRate contextRef="D2017Q1Mar01-Mar31_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" decimals="2" id="Fact-987674B828B658D1BE6D87E54F931709" unitRef="number">0.10</dare:PercentageOfRoyaltyRate>
	<dare:PercentageOfRoyaltyRate contextRef="D2017Q1Mar01-Mar31_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" decimals="2" id="Fact-BE7022CC4838E59958099A7CFC5BE8E4" unitRef="number">0.01</dare:PercentageOfRoyaltyRate>
	<dare:PeriodOfDismissalOfBankruptcyPetition contextRef="D2018Q2Apr_us-gaap_TypeOfArrangementAxis_dare_JuniperPharmaceuticalsInc.Member" id="Fact-B0B453D9952900A5CB835521FB34E8EA">P90D</dare:PeriodOfDismissalOfBankruptcyPetition>
	<dare:PeriodOfTerminationOfStockOptionsVestedAfterTerminationDate contextRef="D2017Q1Mar01-Mar31_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-5658166195DB507B84356AE9CC7FBDEF">P2Y</dare:PeriodOfTerminationOfStockOptionsVestedAfterTerminationDate>
	<dare:PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne contextRef="D2018Q2Apr_us-gaap_TypeOfArrangementAxis_dare_JuniperPharmaceuticalsInc.Member" decimals="-3" id="Fact-E1EC2B2FA1532C0AFD44551FB0CA361C" unitRef="usd">50000</dare:PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne>
	<dare:PotentialAnnualLicenseMaintenanceFeePaymentsThereafter contextRef="D2018Q2Apr_us-gaap_TypeOfArrangementAxis_dare_JuniperPharmaceuticalsInc.Member" decimals="-3" id="Fact-F651EFB310EF76D44950551FD640330C" unitRef="usd">100000</dare:PotentialAnnualLicenseMaintenanceFeePaymentsThereafter>
	<dare:PotentialCashPaymentsToAcquireBusiness contextRef="I2018Q2May16_us-gaap_BusinessAcquisitionAxis_dare_PearTreePharmaceuticalsIncMember" decimals="-3" id="Fact-2DCC4C9654CC5C909FFC98D832357990" unitRef="usd">75000</dare:PotentialCashPaymentsToAcquireBusiness>
	<dare:ProceedsFromIssuanceOfCommonStockAndWarrants contextRef="D2018Q1Feb01-Feb28_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="-5" id="Fact-1560339A742B5217BC0DDCBC98FC8392" unitRef="usd">9400000</dare:ProceedsFromIssuanceOfCommonStockAndWarrants>
	<dare:ProceedsRaisedFromEquityFinancing contextRef="D2018Q4Dec5_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_HammockPharmaceuticalsInc.Member_us-gaap_TypeOfArrangementAxis_dare_AssignmentAgreementMember" decimals="-5" id="Fact-E9A82497672439CB474F975BF4937C42" unitRef="usd">10000000</dare:ProceedsRaisedFromEquityFinancing>
	<dare:ProceedsRaisedFromEquityFinancing contextRef="D2018Q4Dec5_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_MilanaPharmMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" decimals="-5" id="Fact-ED4ED9FE16B10F364810975A551F295C" unitRef="usd">10000000</dare:ProceedsRaisedFromEquityFinancing>
	<dare:ReimbursementOfGrantExpensesReceivable contextRef="FI2019Q1" decimals="0" id="Fact-403979B98F2BFA7DEE389A6949CA5AD9" unitRef="usd">161007</dare:ReimbursementOfGrantExpensesReceivable>
	<dare:ResearchAndDevelopmentMilestonePayment contextRef="D2017Q1Mar01-Mar31_srt_RangeAxis_srt_MaximumMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" decimals="-5" id="Fact-AF63E39180995FF7845F84924D9831A0" unitRef="usd">14600000</dare:ResearchAndDevelopmentMilestonePayment>
	<dare:ResearchAndDevelopmentMilestonePayment contextRef="D2017Q1Mar01-Mar31_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" decimals="-6" id="Fact-0FFA3C6AAE629D17C033551BB7BFD795" unitRef="usd">20000000</dare:ResearchAndDevelopmentMilestonePayment>
	<dare:ResearchAndDevelopmentMilestonePayment contextRef="D2018Q1Mar01-Mar31" decimals="-3" id="Fact-ED208A3E7B345D15A928D8EA188F1BBA" unitRef="usd">75000</dare:ResearchAndDevelopmentMilestonePayment>
	<dare:ResearchAndDevelopmentMilestonePayment contextRef="D2018Q1Mar_us-gaap_RelatedPartyTransactionAxis_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_OrbisMember_us-gaap_TypeOfArrangementAxis_dare_DevelopmentAndOptionAgreementMember" decimals="-3" id="Fact-1345B4014BFEAA00F467551F508B5AB0" unitRef="usd">75000</dare:ResearchAndDevelopmentMilestonePayment>
	<dare:ResearchAndDevelopmentMilestonePayment contextRef="D2018Q1Mar_us-gaap_RelatedPartyTransactionAxis_dare_UponSigningOfDevelopmentAndOptionAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_OrbisMember_us-gaap_TypeOfArrangementAxis_dare_DevelopmentAndOptionAgreementMember" decimals="-3" id="Fact-5B84EE24F0805DBB639E551F2B388BDC" unitRef="usd">150000</dare:ResearchAndDevelopmentMilestonePayment>
	<dare:ResearchAndDevelopmentMilestonePayment contextRef="D2018Q1Mar_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_OrbisMember_us-gaap_TypeOfArrangementAxis_dare_DevelopmentAndOptionAgreementMember" decimals="-3" id="Fact-49436AA892DF2D29475E551EF8005172" unitRef="usd">300000</dare:ResearchAndDevelopmentMilestonePayment>
	<dare:ResearchAndDevelopmentMilestonePayment contextRef="FD2019Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_dare_UponAchievementOfSpecifiedCommercializationMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember" decimals="-6" id="Fact-B728219CBAD5DE5D3FEF9A7C9553D8EE" unitRef="usd">20000000</dare:ResearchAndDevelopmentMilestonePayment>
	<dare:ResearchAndDevelopmentMilestonePayment contextRef="FD2019Q1YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember" decimals="-5" id="Fact-C36389694C184EEF4310551D600F3B6E" unitRef="usd">14600000</dare:ResearchAndDevelopmentMilestonePayment>
	<dare:SecuredInvestmentRequiredForLicenseAgreement contextRef="I2018Q1Feb_srt_RangeAxis_srt_MinimumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" decimals="-5" id="Fact-E77E7EFDBA975878BA40C59CDBE7BCDE" unitRef="usd">10000000</dare:SecuredInvestmentRequiredForLicenseAgreement>
	<dare:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate contextRef="FD2019Q1YTD" decimals="3" id="Fact-0B75C2BF1B67537BA9183DF71A3A1A22" unitRef="number">0.000</dare:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate>
	<dare:StockOptionModificationApprovalDate contextRef="FD2019Q1YTD" id="Fact-21A01049F0FC5BBBA375FD82C1AB3B29">2017-03-19</dare:StockOptionModificationApprovalDate>
	<dare:StockPurchaseAgreementDate contextRef="FD2019Q1YTD_dei_LegalEntityAxis_dare_PrivateDareMember" id="Fact-1F77EDDFB046555692477CAA669FBA64">2017-03-19</dare:StockPurchaseAgreementDate>
	<dare:StockPurchaseAndOtherTransactionsCompletionDate contextRef="FD2019Q1YTD_dei_LegalEntityAxis_dare_PrivateDareMember" id="Fact-7EF54042ADD1534AB85B7A8BED89172E">2017-07-19</dare:StockPurchaseAndOtherTransactionsCompletionDate>
	<dare:UnamortizedFairValueExpenseInStockPurchaseTransaction contextRef="D2017Q1Mar01-Mar31_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-7937DDEF73445325B878C3DC7F880027" unitRef="usd">3700000</dare:UnamortizedFairValueExpenseInStockPurchaseTransaction>
	<dare:UnderwritersOptionToPurchaseAdditionalShares contextRef="D2018Q1Feb01-Feb28_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="INF" id="Fact-9B8606758EE55350A3FA98873D314326" unitRef="shares">750000</dare:UnderwritersOptionToPurchaseAdditionalShares>
	<dare:UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod contextRef="D2018Q1Feb01-Feb28_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" id="Fact-CF40BF37A940507E8C26388C52939523">P30D</dare:UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod>
	<dare:UpfrontLicenseFeePaid contextRef="D2018Q1_us-gaap_TypeOfArrangementAxis_dare_JuniperPharmaceuticalsMember" decimals="-3" id="Fact-A46FE91ABEDC5302B4857DE94F29992E" unitRef="usd">250000</dare:UpfrontLicenseFeePaid>
	<dare:WeightedAverageAmortizationPeriod contextRef="FD2019Q1YTD" id="Fact-2372A4B440875FDC9E243B33A23C5F7E">P3Y3M18D</dare:WeightedAverageAmortizationPeriod>
	<dei:AmendmentFlag contextRef="FD2019Q1YTD" id="Fact-CC4E6BD7E79256B9B2F38EB9D7D00C4B">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2019Q1YTD" id="Fact-AE1B8C7E3B5A5F378D153238A40F6FC8">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2019Q1YTD" id="Fact-3431FFAF4F1C5A0DBA052776CE5F1C54">Q1</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2019Q1YTD" id="Fact-8EAFDF1AA9CD50F1B26FBCBB011B036B">2019</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2019Q1YTD" id="Fact-39F3820D1D46558AB41D61A2CD6A6D3D">2019-03-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2019Q1YTD" id="Fact-31639433BE99573C8F4601B3193733D6">10-Q</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2019Q1YTD" id="Fact-F7888C4D3C815FF182283D2340838B31">0001401914</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2019Q2May13" decimals="INF" id="Fact-B5E418C6DFB75B5E889C1AE3E5B570BC" unitRef="shares">16683411</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityEmergingGrowthCompany contextRef="FD2019Q1YTD" id="Fact-71BE313037A85AB390AEE664485FDA52">true</dei:EntityEmergingGrowthCompany>
	<dei:EntityExTransitionPeriod contextRef="FD2019Q1YTD" id="Fact-155410B775395701917E4672F718B173">true</dei:EntityExTransitionPeriod>
	<dei:EntityFilerCategory contextRef="FD2019Q1YTD" id="Fact-EDD7A9DD1B1F57F18F968693F1BF950A">Non-accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="FD2019Q1YTD" id="Fact-E6C2738626B157F0A1BC4D08A9B62F7A">Dare Bioscience, Inc.</dei:EntityRegistrantName>
	<dei:EntitySmallBusiness contextRef="FD2019Q1YTD" id="Fact-00EF6B2B2E305528B2F91464C6715843">true</dei:EntitySmallBusiness>
	<dei:TradingSymbol contextRef="FD2019Q1YTD" id="Fact-0C39205C6CEA5D1190A9E6D1DA89941E">DARE</dei:TradingSymbol>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="FI2018Q4" decimals="0" id="Fact-B71CDFA651595B14A0FB597EEF3969EC" unitRef="usd">459705</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="FI2019Q1" decimals="0" id="Fact-AB66AED6E43F5B368FD470957754810E" unitRef="usd">325618</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2018Q4" decimals="0" id="Fact-F22598806806A3D5D9E34B04F1CA276F" unitRef="usd">631351</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2019Q1" decimals="0" id="Fact-6B9F0D02DEBED25BC1644B04F1C6E11D" unitRef="usd">690829</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q4" decimals="0" id="Fact-9959537477C75E19905F381224AEEFF7" unitRef="usd">-96728</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2019Q1" decimals="0" id="Fact-35F43AA7B7585A6EB58E142435AD8E61" unitRef="usd">-89107</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2018Q4" decimals="0" id="Fact-A2F66CFE650D5967AA448802A7AC9BDA" unitRef="usd">35791972</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2019Q1" decimals="0" id="Fact-488E65D2E46B57908DAC56A42A53DF81" unitRef="usd">35889940</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q1QTD" decimals="0" id="Fact-0B9994D9C98B27CDCF796BDD12049F42" unitRef="usd">9124</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-DB41F21CA45E448DF8C76BDD0DFD5F86" unitRef="usd">9124</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2019Q1YTD" decimals="0" id="Fact-8E02CC5521E76FC0F9D3515F464EF8B6" unitRef="usd">97968</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-FB8B004796D87263023F515F42F3B77E" unitRef="usd">97968</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-90D844CC8BEE59DFBEE1D1134382EDA2" unitRef="usd">9124</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="0" id="Fact-12E200D1BB9B54F988C279D4E7A2C5D9" unitRef="usd">9124</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="0" id="Fact-90D2825055EEEAC526F84B35893B7A22" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1YTD_us-gaap_PlanNameAxis_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" decimals="0" id="Fact-0C77B7DB2DCC549393E339DFDCE4F51A" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-61F389937E0A5512ABDA34D153FE335F" unitRef="usd">97968</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="0" id="Fact-F65D05E5A2B953FF9F054451E566D5EE" unitRef="usd">73265</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="0" id="Fact-AD670FF4CD755F1D88561FC1FCC8A2DB" unitRef="usd">24703</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q1YTD_us-gaap_PlanNameAxis_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" decimals="0" id="Fact-5BA2FFAFA27957C6834C115D9E3BDFF5" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q1QTD" decimals="0" id="Fact-30D73D631CAE53678D8B262BA61C51F1" unitRef="shares">4294398</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-6BDBB3B6419254AEB6D330EB7C85EC1E" unitRef="shares">543396</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="0" id="Fact-AAB21F7E5BB45BD7B88FA3CC4A1CC75B" unitRef="shares">3751002</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-9723EC508857599DB4B1E34C5E9FD924" unitRef="shares">2190360</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="0" id="Fact-AFF6E1F9FC125C0CB5E380E602EA1C9A" unitRef="shares">3750833</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q1YTD" decimals="0" id="Fact-B61BA8116B345FD486C8662FC8BC4763" unitRef="shares">5941193</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:Assets contextRef="FI2018Q4" decimals="0" id="Fact-215C2D5A54985C20AB01C7A6C56DEA3B" unitRef="usd">7827387</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2019Q1" decimals="0" id="Fact-17CAFBD3C9085763BD6F1BA14BE3ED97" unitRef="usd">5019855</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2018Q4" decimals="0" id="Fact-381F16B7655550AA86499649B0FAFDE0" unitRef="usd">7240023</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2019Q1" decimals="0" id="Fact-43FEC24A19DE5B6391BF7F87D4A60B0F" unitRef="usd">4260263</us-gaap:AssetsCurrent>
	<us-gaap:BusinessAcquisitionDateOfAcquisitionAgreement1 contextRef="D2018Q2Apr29-Apr30_us-gaap_BusinessAcquisitionAxis_dare_PearTreePharmaceuticalsIncMember" id="Fact-E4271377290E5C3C9EBFD33D2A2BD08A">2018-04-30</us-gaap:BusinessAcquisitionDateOfAcquisitionAgreement1>
	<us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1 contextRef="D2018Q2May15-May16_us-gaap_BusinessAcquisitionAxis_dare_PearTreePharmaceuticalsIncMember" id="Fact-DC9411AD55AB5DF68854645C428CB509">2018-05-16</us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1>
	<us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1 contextRef="FD2019Q1YTD_dei_LegalEntityAxis_dare_PrivateDareMember" id="Fact-37A2C0B3E6375B8897E7BD5A2E7B647C">2017-07-19</us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1>
	<us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="D2018Q2May15-May16_us-gaap_BusinessAcquisitionAxis_dare_PearTreePharmaceuticalsIncMember" decimals="-3" id="Fact-222CBEDCBAD25F1AB1797AD67F761434" unitRef="usd">132000</us-gaap:BusinessCombinationConsiderationTransferred1>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q4" decimals="0" id="Fact-104D3370F7035BA09AC7C2B779DDBD80" unitRef="usd">6805889</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2019Q1" decimals="-5" id="Fact-327CDF0CD8475EC691309847DA35AA53" unitRef="usd">3500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2019Q1" decimals="0" id="Fact-F013C2E6DCAB56F098FACED86006774B" unitRef="usd">3505026</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-288DFCA2C92556B2ACB2762CB3E4D8ED" unitRef="usd">6800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2019Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-48F4D6C5420258ACBC3CBFBA6C67A6D4" unitRef="usd">3500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2017Q4" decimals="0" id="Fact-8E7E58F9C8CD5D11BF1CD7526541E015" unitRef="usd">7559846</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2018Q1" decimals="0" id="Fact-26ECC8B55F86573C91DF8683CEE77DF5" unitRef="usd">15625026</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2018Q4" decimals="0" id="Fact-0C284F1908615C46A245B4A2D59DC9BC" unitRef="usd">6805889</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2019Q1" decimals="0" id="Fact-8C29998E6DAE57EBAA6D343CC95D5881" unitRef="usd">3505026</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="FD2018Q1QTD" decimals="0" id="Fact-FCA88970F3DF5A22A3452FABC2E03DAE" unitRef="usd">8065180</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="FD2019Q1YTD" decimals="0" id="Fact-CDA9D3F28CA25E5D8F0ECA5B5EF8BA65" unitRef="usd">-3300863</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2019Q1_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" decimals="2" id="Fact-CED999582ECE5BA881B9C738E0FAFE7D" unitRef="usdPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2019Q1_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember" decimals="2" id="Fact-030B3E4C8D8B5AAE999BDE12A3BF5A6D" unitRef="usdPerShare">120.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2019Q1_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember" decimals="2" id="Fact-2B08EF1FAE065077BF7BECFB23026F2B" unitRef="usdPerShare">120.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2019Q1_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" decimals="2" id="Fact-6378A20943535E028635392CDFDC5146" unitRef="usdPerShare">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2019Q1_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember" decimals="2" id="Fact-1A2ADB16A87C5B978A72D1398C5A6F93" unitRef="usdPerShare">60.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2018Q1Feb_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="2" id="Fact-832A5C6105375CA4BC4B914ECA408946" unitRef="usdPerShare">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2019Q2Apr11_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="2" id="Fact-6439F84889EB47E127B6556E9C34FDED" unitRef="usdPerShare">0.98</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2018Q1Feb_srt_RangeAxis_srt_MaximumMember" decimals="INF" id="Fact-02FB483592A85B2CBD9C7D5E1AB08E30" unitRef="shares">3500000.0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2018Q1Feb_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="INF" id="Fact-FD4B757D4C085961A62AD6B757825897" unitRef="shares">525000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2019Q1" decimals="INF" id="Fact-CC8A0A32B13559B08C99922F30998064" unitRef="shares">3750833</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2019Q1_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" decimals="INF" id="Fact-3D540475D42D5BDB8480A11A8E9B2952" unitRef="shares">6500</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2019Q1_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember" decimals="INF" id="Fact-5CEB18C8F253542293E190205ED2E215" unitRef="shares">2906</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2019Q1_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember" decimals="INF" id="Fact-EA1C15032CD7564089101A5258F2785A" unitRef="shares">3737</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2019Q1_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" decimals="INF" id="Fact-167A365641C25CD5A18B76C62E78B0D8" unitRef="shares">3720500</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2019Q1_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember" decimals="INF" id="Fact-3FCE2BA0716059829F577677F5803DFD" unitRef="shares">17190</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2018Q4" id="Fact-87415F8B5E075B078F3B1D9C983057DA" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2019Q1" id="Fact-E45FCF54B0815523A42495F85B44306B" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2019Q1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-6380EBB0A15A5CFF92A6B6D1AD181DBF" unitRef="shares">323560</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2018Q4" decimals="INF" id="Fact-B400B2763EF25731B289C26F69A4A07D" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2019Q1" decimals="INF" id="Fact-C31BE695B6AE5D5F84D768591AC8B8D0" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2018Q4" decimals="INF" id="Fact-69AE1E8A7E0D5C44912AB9EA14427C4E" unitRef="shares">120000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2019Q1" decimals="INF" id="Fact-3BEDE5C54C9857D4BD77DC888C8A2EB3" unitRef="shares">120000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2018Q4" decimals="INF" id="Fact-1EA2F43674865E4CB3D288361E7F59AD" unitRef="shares">11422161</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2019Q1" decimals="INF" id="Fact-BBEEADBDE84054A8878D4AA72D220171" unitRef="shares">11422161</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2019Q1_dei_LegalEntityAxis_dare_PrivateDareMember" decimals="-4" id="Fact-6129279E85B4540AA308596DFC15F41C" unitRef="shares">3140000</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2018Q4" decimals="INF" id="Fact-D92C8C7AA863526AAD15D0770EBA351B" unitRef="shares">11422161</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2019Q1" decimals="INF" id="Fact-B8C9B4D4C4E95DB49EFDEBA0CC3777FB" unitRef="shares">11422161</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2019Q1_dei_LegalEntityAxis_dare_PrivateDareMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_dare_TwoThousandAndFifteenStockIncentivePlanMember" decimals="INF" id="Fact-B954BDD06FE75D31B977897C0464A64C" unitRef="shares">223295</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2018Q4" decimals="0" id="Fact-F6C5D9E6DA7454C8B4C55D8DE0D76700" unitRef="usd">1143</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2019Q1" decimals="0" id="Fact-AAB4563F0BCF5E11BEEBE82B110DA9BA" unitRef="usd">1143</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2018Q1QTD" decimals="0" id="Fact-C81BF78823CD57C1B4F3604EB9AB9B0E" unitRef="usd">-7679363</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2019Q1YTD" decimals="0" id="Fact-5A009655145D5A00AC7AFBF5D73E3536" unitRef="usd">-3044219</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ContractualObligation contextRef="FI2017Q1_srt_ProductOrServiceAxis_dare_OvapreneMember_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_ADVATecAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" decimals="INF" id="Fact-1DB6D9DD8EA55BF6B94C9E15898ADDEF" unitRef="usd">5000000</us-gaap:ContractualObligation>
	<us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent contextRef="FI2019Q1" decimals="0" id="Fact-6A04B9D8634750DCA29A1A0282EF25FB" unitRef="usd">1343624</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
	<us-gaap:Depreciation contextRef="FD2018Q1QTD" decimals="0" id="Fact-3D719D970115EAC7FA974B1D853E262A" unitRef="usd">0</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2019Q1YTD" decimals="0" id="Fact-E14E5101A8AE57C099EEAB8EAABB3D53" unitRef="usd">1150</us-gaap:Depreciation>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2018Q1QTD" decimals="2" id="Fact-3F601BA5E64A58D98ED9200FFE26EF24" unitRef="usdPerShare">-0.88</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2019Q1YTD" decimals="2" id="Fact-1E9C4D6EBBC352C480895CBC268A8FC6" unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2018Q1QTD" decimals="0" id="Fact-3B56E4B0389958358915BFA81EB281B4" unitRef="usd">-13746</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2019Q1YTD" decimals="0" id="Fact-31B0369D3FDA555C9288B06A9C61E633" unitRef="usd">7621</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2018Q1QTD" decimals="0" id="Fact-C325FDFB6B1B56C8855A357EC4FAF075" unitRef="usd">1303189</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2019Q1YTD" decimals="0" id="Fact-DB8A2E36ED1B5AEF89A6FDC772E13B1E" unitRef="usd">1277180</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:Goodwill contextRef="FI2017Q4" decimals="-5" id="Fact-1EAF9947303659B2BE58E8EBEDC0454F" unitRef="usd">5200000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="I2017Q3Jul19" decimals="-5" id="Fact-2339D38A98A25574A932B689BAC355F8" unitRef="usd">12700000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="I2017Q3Jul19" decimals="-3" id="Fact-6347455244325CCB955708DB4611CE17" unitRef="usd">12679000</us-gaap:Goodwill>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="D2017Q3Jul18-Jul19" decimals="-5" id="Fact-8C4159AD1EBF51E59A463CEF099D35B7" unitRef="usd">12900000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillImpairmentLoss contextRef="FD2017Q4YTD" decimals="-5" id="Fact-8AC3ACB0AD195E639706837EAB536A39" unitRef="usd">7500000</us-gaap:GoodwillImpairmentLoss>
	<us-gaap:GoodwillImpairmentLoss contextRef="FD2018Q1QTD" decimals="0" id="Fact-FDC2D3033C9AE6B499614B1553AA3DA8" unitRef="usd">5187519</us-gaap:GoodwillImpairmentLoss>
	<us-gaap:GoodwillImpairmentLoss contextRef="FD2018Q1QTD" decimals="-5" id="Fact-406E0A3633575F4E892CA41F657A5F2C" unitRef="usd">5200000</us-gaap:GoodwillImpairmentLoss>
	<us-gaap:GoodwillImpairmentLoss contextRef="FD2019Q1YTD" decimals="0" id="Fact-FF660AE07F3A05AA377F4B15539B3757" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
	<us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="D2017Q3Jul18-Jul19" decimals="0" id="Fact-BE49EDB0A3195B73BF9A9264374CBEFE" unitRef="usd">-202169</us-gaap:GoodwillPurchaseAccountingAdjustments>
	<us-gaap:GrantsReceivable contextRef="I2018Q2Apr" decimals="-5" id="Fact-220ACD394DAFD3F28DE69A649228D927" unitRef="usd">1900000</us-gaap:GrantsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2018Q1QTD" decimals="0" id="Fact-7F70D896B5D45144A3ADE367C89F55A8" unitRef="usd">-40340</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2019Q1YTD" decimals="0" id="Fact-A1DDBCA679AE54CB8F617B45F966A4E1" unitRef="usd">-134087</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2018Q1QTD" decimals="0" id="Fact-C2DBC1197E1A1030D7EB9A5E08A8948B" unitRef="usd">-118707</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2019Q1YTD" decimals="0" id="Fact-320A77C146F1AF578EE59A5E08796928" unitRef="usd">59478</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="FD2018Q1QTD" decimals="0" id="Fact-FED0EAEBBC7BB042934B4B1EE99D2C0B" unitRef="usd">-193495</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
	<us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="FD2019Q1YTD" decimals="0" id="Fact-F26A475576DE548089CDBD427BEDB22B" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2018Q1QTD" decimals="0" id="Fact-3FBBF55D097157EC9793132A0278FE03" unitRef="usd">2496</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2019Q1YTD" decimals="0" id="Fact-F672B00C58155A83842AD347F3E185B6" unitRef="usd">-9711</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInOtherReceivables contextRef="FD2018Q1QTD" decimals="0" id="Fact-DA7B3A94050D6CBF1C304B1EE7A1F995" unitRef="usd">-255318</us-gaap:IncreaseDecreaseInOtherReceivables>
	<us-gaap:IncreaseDecreaseInOtherReceivables contextRef="FD2019Q1YTD" decimals="0" id="Fact-F3B64C2F40F356858D344CA9D0954A46" unitRef="usd">135676</us-gaap:IncreaseDecreaseInOtherReceivables>
	<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="FD2018Q1QTD" decimals="0" id="Fact-B5A77721F98F52B5A7852D73DB816064" unitRef="usd">-20694</us-gaap:IncreaseDecreaseInPrepaidExpense>
	<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="FD2019Q1YTD" decimals="0" id="Fact-3D1DC833764A5C459145B81533569917" unitRef="usd">201129</us-gaap:IncreaseDecreaseInPrepaidExpense>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="FI2019Q1" decimals="0" id="Fact-EF47D5D7814FB0B9C92955A71E292101" unitRef="usd">262488</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="FI2019Q1" decimals="0" id="Fact-3E2231EAD21BA12048CBA2C9EC333374" unitRef="usd">81950</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="FI2019Q1" decimals="0" id="Fact-0BADDC62BF46D807B76155A70E1C4402" unitRef="usd">67595</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="FI2019Q1" decimals="0" id="Fact-68686178C48F06D7CFE155A7011DD868" unitRef="usd">112943</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
	<us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="FI2019Q1" decimals="0" id="Fact-8277ACD31660E0EC8A4B55A767EB05E9" unitRef="usd">39449</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
	<us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="I2018Q3Jul1" id="Fact-E8EA1037677BAD9F0ADD77B3D81ACA4E">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
	<us-gaap:LesseeOperatingLeaseTermOfContract contextRef="I2018Q3Jul1" id="Fact-AC09F453F075CC18877277B2AB6D51D8">P37M</us-gaap:LesseeOperatingLeaseTermOfContract>
	<us-gaap:Liabilities contextRef="FI2018Q4" decimals="0" id="Fact-208C497D9BA55519BB4F2AF05A28BC25" unitRef="usd">1100767</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2019Q1" decimals="0" id="Fact-2D196EA0F3A65B02B68075F18D2A55D8" unitRef="usd">1239486</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2018Q4" decimals="0" id="Fact-525C7843099A524BA69F919AFBC16459" unitRef="usd">7827387</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2019Q1" decimals="0" id="Fact-33AD8FBB004F5FD1B3C9E365057B465A" unitRef="usd">5019855</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2018Q4" decimals="0" id="Fact-AAA2914128305087B8347627DFC740B8" unitRef="usd">1091056</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2019Q1" decimals="0" id="Fact-A10FF1231BD859158FEC4F13CE9A8F3E" unitRef="usd">1016447</us-gaap:LiabilitiesCurrent>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2018Q1QTD" decimals="0" id="Fact-CBF85ABA68C05805AB34547B63EE46BC" unitRef="usd">10197813</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2019Q1YTD" decimals="0" id="Fact-F12A67909B48522183EE6D8A955462EA" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2018Q1QTD" decimals="0" id="Fact-2A1774E455C35C3C89053F90974413A0" unitRef="usd">-2118887</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2019Q1YTD" decimals="0" id="Fact-17166D54B12B5ACA9AA5D66203D7E7CC" unitRef="usd">-3308484</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2019Q1YTD" decimals="-5" id="Fact-F41A1E713B2E5647BC9F76D023F2E574" unitRef="usd">-3300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q1QTD" decimals="0" id="Fact-045D7623ED115FB3A90E51BA0A3233AA" unitRef="usd">-7665617</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-2ED91678FDDEC3FEE2396BDD4422A4E9" unitRef="usd">-7665617</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q1YTD" decimals="0" id="Fact-654FFBD4BED25A6487E3CC1A71BAE1DC" unitRef="usd">-3051840</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-6C627A33224AE088AC32515F75311551" unitRef="usd">-3051840</us-gaap:NetIncomeLoss>
	<us-gaap:NetRentableArea contextRef="I2018Q3Jul1" decimals="0" id="Fact-EA882D7586F1947DE81277B05F384A2D" unitRef="sqft">3169</us-gaap:NetRentableArea>
	<us-gaap:NumberOfOperatingSegments contextRef="FD2019Q1YTD" decimals="INF" id="Fact-39F558E19C8197AE80BB4B2929F0917F" unitRef="U_dareSegment">1</us-gaap:NumberOfOperatingSegments>
	<us-gaap:OperatingExpenses contextRef="FD2018Q1QTD" decimals="0" id="Fact-D6A46B095466586E9F378B3348ACFB16" unitRef="usd">7677361</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2019Q1YTD" decimals="0" id="Fact-6DD5D9981D265507BCE3E9CC8FB97739" unitRef="usd">3083071</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2018Q1QTD" decimals="0" id="Fact-777061D832645173927E51986C05245A" unitRef="usd">-7677361</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2019Q1YTD" decimals="0" id="Fact-2EA6ED070F165066941278620FC5B907" unitRef="usd">-3083071</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeaseCost contextRef="FD2019Q1YTD" decimals="0" id="Fact-9160BB7A9E3E5FBD39F4558F2284577C" unitRef="usd">27038</us-gaap:OperatingLeaseCost>
	<us-gaap:OperatingLeaseLiability contextRef="FI2019Q1" decimals="0" id="Fact-4AF0F2518D01D6F23C16A2CAE5122565" unitRef="usd">223039</us-gaap:OperatingLeaseLiability>
	<us-gaap:OperatingLeaseLiability contextRef="I2019Q1Jan1" decimals="-3" id="Fact-A99F5E57E8F358EE491E4B02267D7010" unitRef="usd">241000</us-gaap:OperatingLeaseLiability>
	<us-gaap:OperatingLeaseLiabilityCurrent contextRef="FI2019Q1" decimals="0" id="Fact-73074C40F4DB2D5995F9558D5ACDEB4C" unitRef="usd">83751</us-gaap:OperatingLeaseLiabilityCurrent>
	<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="FI2019Q1" decimals="0" id="Fact-53F7DABCFD5DE06F1D28558DB3FA0BA3" unitRef="usd">139288</us-gaap:OperatingLeaseLiabilityNoncurrent>
	<us-gaap:OperatingLeasePayments contextRef="FD2019Q1YTD" decimals="0" id="Fact-87E92EF39AFB151AA239558F87710BAE" unitRef="usd">26620</us-gaap:OperatingLeasePayments>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="FI2019Q1" decimals="0" id="Fact-C33971C671DAF5C53C689893B615B2DE" unitRef="usd">212909</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="I2019Q1Jan1" decimals="-3" id="Fact-FC73C2495D685334BD564B01CB6186DC" unitRef="usd">232000</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeasesRentExpenseMinimumRentals contextRef="D2018Q3Jul1" decimals="0" id="Fact-78824B7EE29D5B6C4DDD77B4550E4914" unitRef="usd">8873</us-gaap:OperatingLeasesRentExpenseMinimumRentals>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2018Q4" decimals="0" id="Fact-ADB3FCCF0D21561CA33DB6790CC8CE85" unitRef="usd">577968</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2019Q1" decimals="0" id="Fact-A49CED2FD5935E2AAF69F20417BD428E" unitRef="usd">751347</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2018Q1QTD" decimals="0" id="Fact-99A1944DB04F5F72A091A132381CA441" unitRef="usd">-13746</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-470D7BB1D08CE3FA425B6BDD6FC0BE1B" unitRef="usd">-13746</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2019Q1YTD" decimals="0" id="Fact-F61C7537829E5D1AA389A5E16AE6DD3A" unitRef="usd">7621</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-ADD8D25228F58CCDC9BC515FA5E8EAA4" unitRef="usd">7621</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2018Q4" decimals="0" id="Fact-78F3F39BEAA9594A85CBC7307170A96E" unitRef="usd">9711</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2019Q1" decimals="0" id="Fact-1F3B40E9649AD98313E26BDB51C54314" unitRef="usd">223039</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2018Q1QTD" decimals="0" id="Fact-05F722270D95544788803EF73820EE85" unitRef="usd">11744</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2019Q1YTD" decimals="0" id="Fact-73A9811BFC7B5109833129809E6CEA02" unitRef="usd">31231</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherReceivablesNetCurrent contextRef="FI2018Q4" decimals="0" id="Fact-B975F733E29F50B0AE71A68C9DEAB9FB" unitRef="usd">31037</us-gaap:OtherReceivablesNetCurrent>
	<us-gaap:OtherReceivablesNetCurrent contextRef="FI2019Q1" decimals="0" id="Fact-B8929CA8922052C683214D8D04E198B9" unitRef="usd">166713</us-gaap:OtherReceivablesNetCurrent>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2019Q1YTD" decimals="0" id="Fact-A38C280AACD5767151339A793632A9BB" unitRef="usd">237403</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2018Q4" decimals="INF" id="Fact-8E30170580E058E4A1C4C76540820A99" unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2019Q1" decimals="INF" id="Fact-507B1067837C597BACE1CB03BFF85706" unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2018Q4" decimals="INF" id="Fact-DA2A678776985FE1BD5369558007DC97" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2019Q1" decimals="INF" id="Fact-A5BFFBDB0BDF55F6A6DFAE372786DAB0" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2018Q4" decimals="INF" id="Fact-551E32E0B0BA5A73977CEDA424FD7192" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2019Q1" decimals="INF" id="Fact-7448CED78B0A50819AC83913E69C032C" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2018Q4" decimals="INF" id="Fact-5411B7BC03525B32A6D3B4240BC2DE38" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2019Q1" decimals="INF" id="Fact-789CFB804C6D570EBD2A1A0F340AA126" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockValue contextRef="FI2018Q4" decimals="0" id="Fact-896584D26C17537AA150D90B3FF900CB" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2019Q1" decimals="0" id="Fact-2AAFBD8BA1DC5709B795C7C9F6463CA6" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidExpenseCurrent contextRef="FI2018Q4" decimals="0" id="Fact-BEE3A4BB57B552A894088A993FDD6D9F" unitRef="usd">403097</us-gaap:PrepaidExpenseCurrent>
	<us-gaap:PrepaidExpenseCurrent contextRef="FI2019Q1" decimals="0" id="Fact-E5C590311BF85D38AD061F01F4D64BEA" unitRef="usd">588524</us-gaap:PrepaidExpenseCurrent>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="D2019Q2Apr11_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_dare_PublicStockOfferingIncludingOverAllotmentOfSharesMember" decimals="-5" id="Fact-9ED0E0CDDF0FF8B919AD5566BE7758C6" unitRef="usd">5800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="D2019Q2Apr_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-00E154C9939F8F80CFA69A6667DE2B86" unitRef="usd">5200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProfitLoss contextRef="FD2018Q1QTD" decimals="0" id="Fact-26946300AA4154329660A2F7EB170A06" unitRef="usd">-7665617</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2019Q1YTD" decimals="0" id="Fact-3C3EE3C3D9945D39A213FA096F616F97" unitRef="usd">-3051840</us-gaap:ProfitLoss>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2018Q4" decimals="0" id="Fact-B9F97589C9A7094F25BA4B0622FFF0AA" unitRef="usd">9396</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2019Q1" decimals="0" id="Fact-0C63F791D46654D087BCD44AF373C71C" unitRef="usd">8245</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred contextRef="FD2019Q1YTD" decimals="0" id="Fact-AD2CA8DF8E60585A94A7719E7C5980C7" unitRef="usd">224665</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q1QTD" decimals="0" id="Fact-0CA3A23AB2DC5106863C985861CC7E29" unitRef="usd">1086653</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2019Q1YTD" decimals="0" id="Fact-820FADA79026529E94B9CF904359A9B2" unitRef="usd">1693391</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2018Q4" decimals="0" id="Fact-9C15A1E09AE9561E89AC98BFDBE59711" unitRef="usd">-28969767</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2019Q1" decimals="-5" id="Fact-86CAC9BFD965528CA04BC7836F1BDAB7" unitRef="usd">-32000000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2019Q1" decimals="0" id="Fact-A6E17555283E58B98C23BE6426E69BF4" unitRef="usd">-32021607</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2018Q1_srt_ProductOrServiceAxis_us-gaap_GrantMember" decimals="0" id="Fact-0DCE20B9A58756C7A2B9AD59AEC05115" unitRef="usd">224665</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2019Q1Mar11_srt_ProductOrServiceAxis_us-gaap_GrantMember_us-gaap_HealthCareTrustFundAxis_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_NationalInstitutesOfHealthMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember" decimals="0" id="Fact-5126CBEC35125520D3CF919753180F05" unitRef="usd">730722</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2019Q1Mar11_srt_ProductOrServiceAxis_us-gaap_GrantMember_us-gaap_HealthCareTrustFundAxis_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_NationalInstitutesOfHealthMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember" decimals="0" id="Fact-545B1C1EC0D9CC13C051BA7C9FCAF797" unitRef="usd">982851</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D2019Q1Mar_srt_ProductOrServiceAxis_us-gaap_GrantMember_us-gaap_HealthCareTrustFundAxis_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dare_NationalInstitutesOfHealthMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember" decimals="0" id="Fact-0BA056769A90F42B9DA79A64624B6B63" unitRef="usd">982851</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="FD2019Q1YTD" decimals="0" id="Fact-FE67CC5DA9EDE0C921A89A606046A2A8" unitRef="usd">231698</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="D2019Q2Apr11_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_dare_PublicStockOfferingIncludingOverAllotmentOfSharesMember" decimals="-5" id="Fact-54165796363A8E48C30955671E0F2DE7" unitRef="usd">5200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2019Q2Apr11_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_dare_PublicStockOfferingIncludingOverAllotmentOfSharesMember" decimals="INF" id="Fact-3F1AA039D4393C3AC37155692056F8F5" unitRef="shares">5261250</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2019Q2Apr11_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_dare_PublicStockOfferingMember" decimals="INF" id="Fact-D2CD74965D6CED68621E5558D3CC728D" unitRef="shares">4575000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2019Q2Apr11_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="INF" id="Fact-284F6708EEDD2D47320E55648B95D576" unitRef="shares">686250</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2019Q2Apr11_us-gaap_ClassOfWarrantOrRightAxis_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="2" id="Fact-C566AB41648A73F47EA1557F4DF98DF5" unitRef="usdPerShare">0.98</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2019Q2Apr11_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="2" id="Fact-06D45597BAE7C05377B75558EA62F040" unitRef="usdPerShare">1.10</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:ShareBasedCompensation contextRef="FD2018Q1QTD" decimals="0" id="Fact-9FBDA4843783570F81DC2ABC318D8BBD" unitRef="usd">9124</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2019Q1YTD" decimals="0" id="Fact-E05A1C7A2DFF503DAF54878B8DEFB039" unitRef="usd">97968</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="FD2019Q1YTD_dei_LegalEntityAxis_dare_PrivateDareMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_dare_TwoThousandAndFifteenStockIncentivePlanMember" id="Fact-21559E1CF5F55D34848098F1DCADBAAC">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2019Q1YTD_dei_LegalEntityAxis_dare_PrivateDareMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_dare_TwoThousandAndFifteenStockIncentivePlanMember" id="Fact-03A804D962345438B81E8DE2C9295424">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate contextRef="D2014Q1Mar01-Mar31_us-gaap_PlanNameAxis_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" decimals="2" id="Fact-793FDE0520B251E69915CC9F68A324FA" unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2019Q1YTD" decimals="3" id="Fact-A7E8900D3C855CF69CE9530649219B4B" unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2019Q1YTD" decimals="2" id="Fact-CEFC068140D95800B3B1EFFA129D053E" unitRef="number">1.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2019Q1YTD" decimals="4" id="Fact-548020EFA3A653B2B1E8014FB3A8EEE8" unitRef="number">0.0270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="FI2019Q1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-1FC059281EA957828935726401EA7476" unitRef="shares">2190360</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="I2018Q3Jul10_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-073FBB5D0FCA5275A5775EBF4881355B" unitRef="shares">2046885</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="I2019Q1Jan1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-010931DCC0F87CAECACA9A6DADACEE36" unitRef="shares">2503771</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2019Q1" decimals="INF" id="Fact-57AA776C9C4D5B1BA68A4A7BF596730D" unitRef="shares">650151</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2019Q1" decimals="2" id="Fact-8D69423C953E5E9FA0A290BE63BCDCE5" unitRef="usdPerShare">25.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="FD2019Q1YTD" decimals="INF" id="Fact-CDDBFAF2836F5810BC5BDB8BCB512A19" unitRef="shares">70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2019Q1YTD" decimals="INF" id="Fact-A7848B9AAB5B1005DFAD9A721122A562" unitRef="shares">8360</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2019Q1YTD" decimals="INF" id="Fact-8BCC28510445584DA53E48D454BABF6B" unitRef="shares">563000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2019Q1YTD" decimals="2" id="Fact-C02862522C8C506FBC0DD7F731AB68D4" unitRef="usdPerShare">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2018Q4" decimals="INF" id="Fact-D60CBC0FFC2452E7891AB871D09D4060" unitRef="shares">1635790</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2018Q4_dei_LegalEntityAxis_dare_PrivateDareMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_dare_TwoThousandAndFifteenStockIncentivePlanMember" decimals="INF" id="Fact-CA6493FD916D516F994162A2484DB1E6" unitRef="shares">10149</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2019Q1" decimals="INF" id="Fact-EF3D7C59B5B15B95A222C9B3DE87E7CB" unitRef="shares">2190360</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2019Q1_dei_LegalEntityAxis_dare_PrivateDareMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_dare_TwoThousandAndFifteenStockIncentivePlanMember" decimals="INF" id="Fact-CB95B45AE8535937BD5E3803F7FD5682" unitRef="shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2019Q1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_dare_TwoThousandAndFifteenStockIncentivePlanMember" decimals="INF" id="Fact-5BAC156695E85786B068710EBFFB08CB" unitRef="shares">10149</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="I2018Q3Jul10_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-268B1B88BA9D5D2F99D744B9A74552DB" unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2018Q4" decimals="2" id="Fact-2C901524BDF35F48942AD4F6556882C2" unitRef="usdPerShare">11.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2019Q1" decimals="2" id="Fact-FB696491222F59B9AD3D88D61F3B2BCA" unitRef="usdPerShare">8.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum contextRef="D2018Q3Jul10-Jul10_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-7734089466405FE5B5DEA173018E19C8" unitRef="number">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum contextRef="D2019Q1Jan1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-C60BCE2984EDC89953EE9A6F62148402" unitRef="number">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2019Q1YTD" decimals="2" id="Fact-0B147CF745967BFEF6D3517F0C07C14B" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2019Q1YTD" decimals="2" id="Fact-A354A7FD556A5D8880F1415835C71047" unitRef="usdPerShare">59.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2019Q1YTD" decimals="2" id="Fact-646D3F8FA31989AF18E39A72139904B4" unitRef="usdPerShare">17.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2019Q1YTD" decimals="2" id="Fact-1EE6B72BF83D579F8497DDE916A7A2EF" unitRef="usdPerShare">0.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2019Q1YTD" id="Fact-A31A6EF15EA05BBFA81C5B55DD69F00A">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease contextRef="D2019Q1Jan1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-B6BEB122075C740390119A6EE92AFE7B" unitRef="shares">456886</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease>
	<us-gaap:SharesIssuedPricePerShare contextRef="I2018Q1Feb" decimals="2" id="Fact-B5CFB5319F885934A6329556FBBEE48F" unitRef="usdPerShare">0.70</us-gaap:SharesIssuedPricePerShare>
	<us-gaap:SharesOutstanding contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-49C4D069DFEE627105A36BDCCA89884E" unitRef="shares">6047161</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-55BE3E909633984FA45E98912DA1F1D6" unitRef="shares">11422161</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-F38C2D9A759EEF8010706BDC1FBE5E66" unitRef="shares">11422161</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-0FE9CED8E1A2E7992CD36BDC1F9E3D56" unitRef="shares">11422161</us-gaap:SharesOutstanding>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2018Q1Feb01-Feb28" decimals="-5" id="Fact-64F557104D855CA3904712EAC45194BD" unitRef="shares">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2018Q1Feb01-Feb28_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="INF" id="Fact-FFA100CC3BEE5F0998108AADF5FCA4CE" unitRef="shares">220500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2018Q1QTD" decimals="INF" id="Fact-031080319D83B1D08B8B9A77D1C002F5" unitRef="shares">375000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-EE9D42B9AAEADFE91B8E9A5BCDE179CD" unitRef="shares">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2019Q1YTD" decimals="INF" id="Fact-322F07049AC155A3BF92CEB5775D4CFB" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="FD2016Q4YTD_dei_LegalEntityAxis_dare_PrivateDareMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_dare_TwoThousandAndFifteenStockIncentivePlanMember" decimals="INF" id="Fact-D30752CF910F5682B91BB5F219060EDB" unitRef="shares">900000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
	<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="FD2017Q4YTD_dei_LegalEntityAxis_dare_PrivateDareMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_dare_TwoThousandAndFifteenStockIncentivePlanMember" decimals="INF" id="Fact-02010532AAAA50CCAA84D6FD432906F1" unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2019Q1YTD" decimals="INF" id="Fact-C04A5BCED67B52B73603517DA2789A45" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q1QTD" decimals="0" id="Fact-71B6365B45C02A9D64249A5B4020289F" unitRef="usd">9160048</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-422AE44EFC0AA91DE2BB9A5B3FF0DE0F" unitRef="usd">9159548</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-1677417F589649F574969A5B400F8B1E" unitRef="usd">500</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4" decimals="0" id="Fact-B46265F8F2A179BD0D766BDCD2FB34A7" unitRef="usd">13292783</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-057708DFC1E0731EC8316BDCD00D98E4" unitRef="usd">-18080</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-87991AD532399C85086E6BDCCE1CE252" unitRef="usd">25541210</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-BE7D7FEDD8FEEB5C3DA26BDCCCA8BA1A" unitRef="usd">605</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-023E95345F40E4E3A4996BDCD179A8E7" unitRef="usd">-12230952</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q1" decimals="0" id="Fact-9F178F457F1D5DCA5DDC98913692A950" unitRef="usd">15820356</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-19F59C05DF7E63060906989132F7DDA3" unitRef="usd">-31826</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-71DF07261FF2C9FEB7339891311E2E3D" unitRef="usd">35747609</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-F1BB8139A1861CE3B7C698912F92CDD5" unitRef="usd">1142</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-96708DE3B75CC78395669891351AEEDE" unitRef="usd">-19896569</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4" decimals="0" id="Fact-5471AE014C5B5C6390D8F6B502D2EC97" unitRef="usd">6726620</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-F930632C65C447CD9F0C6BDC1FBA3F88" unitRef="usd">-96728</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-D514F7CBF4E2C68C50516BDC1FA62EC9" unitRef="usd">35791972</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-1CA99CBE042EFE32F8F56BDC1FB2053A" unitRef="usd">1143</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-90D8F3576798D0D5FF2D6BDC1FAE8455" unitRef="usd">-28969767</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q1" decimals="0" id="Fact-F1AF467BB46A5A4FBB7CAA3668B2051B" unitRef="usd">3780369</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-2EACDECA626643C45DBF6BDC1FAA3F2B" unitRef="usd">-89107</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-CBAEF57355484C4542FC6BDC1FC50956" unitRef="usd">35889940</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-89F73803E33FA3E5C6036BDC1FC1AAD5" unitRef="usd">1143</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-1FB840553949FC2C14D66BDC1FA2C7A1" unitRef="usd">-32021607</us-gaap:StockholdersEquity>
	<us-gaap:WarrantsAndRightsOutstandingTerm contextRef="I2018Q1Feb" id="Fact-636866978A815117B8581062CBF7CD29">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2018Q1QTD" decimals="0" id="Fact-70AC91DFCB055E98AD14CA9E35ED1598" unitRef="shares">8684550</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2019Q1YTD" decimals="0" id="Fact-E7D30361C725595BAE005E1D408A443F" unitRef="shares">11422161</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<dare:GrantAwardTextBlock contextRef="FD2019Q1YTD" id="Fact-5691BDFF7261CA43AA464B43AF907010">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;GRANT AWARD&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In April 2018, the Company received a Notice of Award for the first &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$224,665&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the anticipated &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1.9 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in grant funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, a division of the National Institutes of Health, or the NIH.&amp;#160;The Company must incur and track expenses eligible for reimbursement under the award and submit a detailed accounting of such expenses to receive payment. The Company subsequently received award payments totaling &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$224,665&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The award payments were applied to clinical development efforts supporting Ovaprene and were recognized in the statement of operations as a reduction to research and development activities as the related costs were incurred to meet those obligations over the period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;On March 11, 2019, the Company received a Notice of Award for an additional &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$982,851&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the anticipated &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1.9 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in grant funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The second award followed the NIH's review of an interim data analysis and other results of the first phase of the research supporting Ovaprene. The award will be applied to clinical development efforts supporting Ovaprene. The remaining portion of the award under the grant, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$730,722&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, is contingent upon, among other matters, assessment that the results of the ongoing Ovaprene study satisfy specified requirements set out in the award notice, and the availability of funds. At &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company recorded a receivable of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$161,007&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; for expenses eligible for reimbursement incurred through &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</dare:GrantAwardTextBlock>
	<dare:ScheduleOfBusinessCombinationReverseMergerTextBlock contextRef="FD2019Q1YTD" id="Fact-7C64A89449CC524188B5751A3614155A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The total purchase price consideration of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$24.3 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; represents the fair value of the shares of Cerulean stock issued in connection with the Cerulean/Private Dar&amp;#233; stock purchase transaction and the unamortized fair value of the stock options described above, which was allocated as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Purchase Consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Fair value of shares issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;20,625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Unamortized fair value of Cerulean options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,654&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Fair value of total consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;24,279&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Assets acquired and liabilities assumed&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;9,918&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Prepaid expense and other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,915&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Accounts payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(233&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Total assets acquired and liabilities assumed&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;11,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12,679&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</dare:ScheduleOfBusinessCombinationReverseMergerTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2019Q1YTD" id="Fact-74451D0737245D3D81DE986EFA1570C2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The accompanying interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as defined by the Financial Accounting Standards Board, or FASB, for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X.&amp;#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management&amp;#8217;s opinion, the accompanying interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results of the interim periods presented.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Interim financial results are not necessarily indicative of results anticipated for any other interim period or for the full year. The accompanying interim consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company&amp;#8217;s Annual Report on Form 10-K for the year ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:BusinessCombinationDisclosureTextBlock contextRef="FD2019Q1YTD" id="Fact-B7B9B16C370A588BAB3A06F4ACC7BC79">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;ACQUISITIONS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cerulean/Private Dar&amp;#233; Stock Purchase Transaction&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;On &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;July&amp;#160;19, 2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company completed its business combination with Dar&amp;#233; Bioscience Operations, Inc., a privately held Delaware corporation, or Private Dar&amp;#233;, in accordance with the terms of the Stock Purchase Agreement dated as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;March&amp;#160;19, 2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, or the Dar&amp;#233; Stock Purchase Agreement, by and among the Company, Private Dar&amp;#233; and the holders of capital stock and securities convertible into capital stock of Private Dar&amp;#233; named therein, or the Private Dar&amp;#233; Stockholders. Pursuant to the Dar&amp;#233; Stock Purchase Agreement, each Private Dar&amp;#233; Stockholder sold their shares of capital stock in Private Dar&amp;#233; to the Company in exchange for newly issued shares of the Company&amp;#8217;s common stock, and as a result, Private Dar&amp;#233; became a wholly owned subsidiary of the Company and the Private Dar&amp;#233; Stockholders became majority stockholders of the Company. In connection with the closing of that transaction, the Company changed its name from &amp;#8220;Cerulean Pharma Inc.&amp;#8221; to &amp;#8220;Dar&amp;#233; Bioscience, Inc.&amp;#8221; In this report, that transaction is referred to as the Cerulean/Private Dar&amp;#233; stock purchase transaction and &amp;#8220;Cerulean&amp;#8221; refers to Cerulean Pharma Inc. before that transaction closed. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Cerulean/Private Dar&amp;#233; stock purchase transaction was accounted for as a reverse merger under the acquisition method of accounting whereby Private Dar&amp;#233; was considered to have acquired Cerulean for financial reporting purposes because immediately upon completion of the transaction, Private Dar&amp;#233; stockholders held a majority of the voting interest of the combined company. Pursuant to business combination accounting, the Company applied the acquisition method, which requires the assets acquired and liabilities assumed be recorded at fair value with limited exceptions. The excess of the purchase price over the assets acquired and liabilities assumed represents goodwill. The goodwill is primarily attributable to the cash and cash equivalents at closing of the transaction of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$9.9 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and the impact of the unamortized fair value of stock options granted by Cerulean that were outstanding immediately before the transaction closed of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$3.7 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The unamortized fair value of such stock options relates to an option modification approved on &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;March&amp;#160;19, 2017&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; that provided for an acceleration of vesting of such options upon a change in control event. Such modification became effective upon the closing of the Cerulean/Private Dar&amp;#233; stock purchase transaction. Hence, the unamortized fair value of such stock options is deemed to be part of total purchase consideration and goodwill. Transaction costs associated with the Cerulean/Private Dar&amp;#233; stock purchase transaction of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$0.96 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; are included in general and administrative expense. The total purchase price consideration of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$24.3 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; represents the fair value of the shares of Cerulean stock issued in connection with the Cerulean/Private Dar&amp;#233; stock purchase transaction and the unamortized fair value of the stock options described above, which was allocated as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Purchase Consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Fair value of shares issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;20,625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Unamortized fair value of Cerulean options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,654&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Fair value of total consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;24,279&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Assets acquired and liabilities assumed&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;9,918&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Prepaid expense and other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,915&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Accounts payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(233&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Total assets acquired and liabilities assumed&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;11,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;12,679&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The final allocation of the purchase price depended on finalizing the valuation of the fair value of assets acquired and liabilities assumed. The Company retrospectively recorded purchase price adjustments at the acquisition date to increase current liabilities and current assets by &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$23,609&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$225,778&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, respectively, which reduced the original goodwill amount of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$12.9 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; by &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$202,169&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company tests its goodwill for impairment at least annually as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and between annual tests if it becomes aware of an event or change in circumstance that would indicate the carrying value may be impaired. The Company tests goodwill for impairment at the entity level because it operates on the basis of a single reporting unit. A goodwill impairment is the amount by which a reporting unit&amp;#8217;s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. When impaired, the carrying value of goodwill is written down to fair value. Any excess of the reporting unit goodwill carrying value over the fair value is recognized as impairment loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company assessed goodwill at December&amp;#160;31, 2017. The Company determined there was an impairment and recognized an impairment charge of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$7.5 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in the consolidated statement of operations and comprehensive loss for the year ended December&amp;#160;31, 2017 and reduced the goodwill carrying value from approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$12.7 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$5.2 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; on its consolidated balance sheet as of December&amp;#160;31, 2017. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company assessed goodwill at March 31, 2018, determined there was an impairment and recognized an impairment charge of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$5.2 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in the interim consolidated statement of operations and comprehensive loss for the three months ended March 31, 2018. As of March 31, 2018, the goodwill carrying value on the Company&amp;#8217;s consolidated balance sheet was written off in its entirety.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Pear Tree Merger&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;On &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;April&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company entered into an Agreement and Plan of Merger, the Merger Agreement, with Pear Tree Pharmaceuticals, Inc., or Pear Tree, Dar&amp;#233; Merger Sub, Inc., a wholly-owned subsidiary of the Company, or Merger Sub, and two individuals in their respective capacities as Pear Tree stockholders&amp;#8217; representatives. The transactions contemplated by the Merger Agreement closed on &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;May&amp;#160;16, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, and as a result, Pear Tree became the Company&amp;#8217;s wholly owned subsidiary. The Company acquired Pear Tree to secure the rights to develop DARE-VVA1, a proprietary vaginal formulation of tamoxifen, as a potential treatment for vulvar and vaginal atrophy.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company determined that the acquisition of Pear Tree should be accounted for as an asset acquisition instead of a business combination because substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, and therefore, the asset is not considered a business. Transaction costs of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$452,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; associated with the merger are included in the Company&amp;#8217;s research and development expense.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In accordance with the terms of the Merger Agreement, because the Negative Consideration Amount (as defined below) exceeded the Positive Consideration Amount (as defined below), at the time of the closing of the merger, the excess amount (approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$132,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;) will be offset against future payments otherwise due under the Merger Agreement to certain former and continuing Pear Tree service providers and former holders of Pear Tree&amp;#8217;s capital stock, or the Holders, including the potential &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$75,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; payment due on the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;-year anniversary of the closing of the merger. Positive Consideration Amount means the sum of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$75,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, and the cash and cash equivalents held by Pear Tree at closing, and Negative Consideration Amount means the sum of (i) certain Pear Tree indebtedness and transaction expenses, (ii) transaction expenses of the stockholders&amp;#8217; representatives, and (iii) amounts payable under Pear Tree&amp;#8217;s management incentive plan. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Under the Merger Agreement, the Holders will be eligible to receive, subject to certain offsets, tiered royalties, including customary provisions permitting royalty reductions and offset, based on percentages of annual net sales of certain products subject to license agreements the Company assumed and a percentage of sublicense revenue. The Company must also make contingent payments to the Holders that are based on achieving certain clinical, regulatory and commercial milestones, which may be paid, in the Company&amp;#8217;s sole discretion, in cash or shares of the Company&amp;#8217;s common stock.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
	<us-gaap:CommitmentsDisclosureTextBlock contextRef="FD2019Q1YTD" id="Fact-43434D71D98E5D06B979127F6155A31C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;COMMITMENTS AND CONTINGENCIES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;License and Research Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;ADVA-Tec License Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In March 2017, the Company entered into a license agreement, or the ADVA-Tec License Agreement, with ADVA-Tec, Inc., or ADVA-Tec, under which the Company was granted the exclusive right to develop and commercialize Ovaprene for human contraceptive use worldwide. ADVA-Tec and its affiliates own issued patents or patent applications covering Ovaprene and control proprietary trade secrets covering the manufacture of Ovaprene. As of the date of this report, this patent portfolio includes &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; issued U.S. patents and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; pending U.S. patent application, and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;59&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; granted patents and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; pending patent applications in other major markets, all of which are exclusively licensed to the Company for the human contraceptive use of Ovaprene as a human contraceptive device. The license continues on a country-by-country basis until the later of the life of the licensed patents or the Company&amp;#8217;s last commercial sale of Ovaprene. Under the terms of the ADVA-Tec Agreement, the Company has a right of first refusal to license these patents and patent applications for additional indications.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The following is a summary of other terms of the ADVA-Tec License Agreement:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Research and Development.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;ADVA-Tec will conduct certain research and development work as necessary to allow the Company to seek a Premarket Approval, or PMA, from the United States Food and Drug Administration, or the FDA, and will supply the Company with its requirements of Ovaprene for clinical and commercial use on commercially reasonable terms. The Company must use commercially reasonable efforts to develop and commercialize Ovaprene, and must meet certain minimum spending amounts per year, such amounts totaling &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in the aggregate over the first &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;three years&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, to cover such activities until a final PMA is filed, or until the first commercial sale of Ovaprene, whichever occurs first.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Milestone Payments.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company will pay ADVA-Tec: (1) up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$14.6 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in the aggregate based on the achievement of specified development and regulatory milestones; and (2) up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$20 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in the aggregate based on the achievement of certain worldwide net sales milestones. The development and regulatory milestones  include: the completion of a successful postcoital clinical study, which is required before the Company can commence a Phase 3 pivotal human clinical trial; approval by the FDA to commence such Phase 3 pivotal human clinical trial; successful completion of such Phase 3 pivotal human clinical trial; the FDA&amp;#8217;s acceptance of a PMA filing for Ovaprene; the FDA&amp;#8217;s approval of the PMA for Ovaprene; obtaining Conformit&amp;#233; Europ&amp;#233;enne Marking of Ovaprene in at least &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; designated European countries; obtaining regulatory approval in at least three designated European countries; and obtaining regulatory approval in Japan. Because these milestone payments depend upon the successful progress of the Company&amp;#8217;s product development programs, the Company cannot estimate with certainty when these payments will occur, if ever.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Royalty Payments.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;After the commercial launch of Ovaprene, the Company will pay to ADVA-Tec royalties based on aggregate annual net sales of Ovaprene in specified regions, at a royalty rate that will vary between &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and will increase based on various net sales thresholds.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Termination Rights.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Unless earlier terminated, the license the Company received under the ADVA-Tec License Agreement continues on a country-by-country basis until the later of the life of the licensed patents or the Company's last commercial sale of Ovaprene. In addition to customary termination rights for both parties: (A) the Company may terminate the agreement with or without cause in whole or on a country-by-country basis upon &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;60&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; days prior written notice; and (B) ADVA-Tec may terminate the agreement if the Company develops or commercializes any non-hormonal ring-based vaginal contraceptive device competitive to Ovaprene or if the Company fails to: (1) in certain limited circumstances, commercialize Ovaprene in certain designated countries within three years of the first commercial sale of Ovaprene, (2) satisfy the annual spending obligation described above, (3) use commercially reasonable efforts to complete all necessary pre-clinical and clinical studies required to support and submit a PMA, (4) conduct clinical trials as set forth in the development plan that is agreed by the Company and ADVA-Tec, and as may be modified by a joint research committee, unless such failure is caused by events outside of the Company&amp;#8217;s reasonable control, or (5) enroll a patient in the first non-significant risk medical device study or clinical trial as allowed by an institutional review board within &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;six months&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the production and release of Ovaprene, unless such failure is caused by events outside of its reasonable control.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;For products currently in development, future potential milestone payments based on product development are approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$14.6 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. Future potential milestone payments related to commercialization totaled &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$20 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; at &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. There are &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;-&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; royalties required under the license agreement. The Company is unable to estimate with certainty the timing on when these milestone payments will occur as these payments are dependent upon the Company's product development programs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;SST License and Collaboration Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In February 2018, the Company entered into a license and collaboration agreement, or the SST License Agreement, with Strategic Science &amp;amp;&amp;#160;Technologies-D,&amp;#160;LLC and Strategic Science &amp;amp; Technologies, LLC, referred to collectively as SST. The SST License Agreement provides the Company with an exclusive, royalty-bearing, sublicensable license to develop and commercialize, in all countries and geographic territories of the world, for all indications for women related to female sexual dysfunction and/or female reproductive health, including treatment of female sexual arousal disorder, or the Field of Use, SST&amp;#8217;s topical formulation of Sildenafil Cream, 3.6% as it exists as of the effective date of the SST License Agreement, or any other topically applied pharmaceutical product containing sildenafil or a salt thereof as a pharmaceutically active ingredient, alone or with other active ingredients, but specifically excluding any product containing ibuprofen or any salt derivative of ibuprofen, or the Licensed Products.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The following is a summary of other terms of the SST License Agreement:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Invention &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Ownership&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company retains rights to inventions made by its employees, SST retains rights to inventions made by its employees, and each party shall own a &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; undivided interest in all joint inventions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Joint &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Development&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt; Committee&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The parties will collaborate through a joint development committee that will determine the strategic objectives for, and generally oversee, the development efforts of both parties under the SST License Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Development&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company must use commercially reasonable efforts to develop the Licensed Products in the Field of Use in accordance with a development plan in the SST License Agreement, and to commercialize the Licensed Products in the Field of Use. The Company is responsible for all reasonable internal and external costs and expenses incurred by SST in its performance of the development activities it must perform under the SST License Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Royalty &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Payments.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;SST will be eligible to receive tiered royalties based on percentages of annual net sales of Licensed Products in the single digits to the mid double digits, subject to customary royalty reductions and offsets, and a percentage of sublicense revenue.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Milestone Payments.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;SST will be eligible to receive payments (1) ranging from &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$18.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in the aggregate on achieving certain clinical and regulatory milestones in the U.S. and worldwide, and (2) between &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$100 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in the aggregate upon achieving certain commercial sales milestones. If the Company enters into strategic development or distribution partnerships related to the Licensed Products, additional milestone payments would be due to SST.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;License Term.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company&amp;#8217;s license received under the SST License Agreement continues on a country-by-country basis until the later of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10 years&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; from the date of the first commercial sale of such Licensed Product or the expiration of the last valid claim of patent rights covering the Licensed Product in the Field of Use. Upon expiration (but not termination) of the SST License Agreement in a particular country, the Company will have a fully paid-up license under the licensed intellectual property to develop and commercialize the applicable Licensed Products in the applicable country on a non-exclusive basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Termination.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In addition to customary termination rights for both parties: (1) prior to receipt of approval by a regulatory authority necessary for commercialization of a Licensed Product in the corresponding jurisdiction, including New Drug Application Approval, or NDA Approval, the Company may terminate the SST License Agreement without cause upon &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;90&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; days prior written notice to SST; (2)&amp;#160;following receipt of approval by a regulatory authority necessary for commercialization of a Licensed Product in the corresponding jurisdiction, including NDA Approval, the Company may terminate the SST License Agreement without cause upon &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;180&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;days prior written notice; and (3) SST may terminate the SST License Agreement with respect to the applicable Licensed Product(s) in the applicable country(ies) upon &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;days&amp;#8217; notice to the Company if the Company fails to use commercially reasonable efforts to perform development activities in substantial accordance with the development plan and does not cure such failure within &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;60&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;days of receipt of SST&amp;#8217;s notice thereof.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Orbis Development and Option Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In March 2018, the Company entered into an exclusive development and option agreement, or the Orbis Agreement, with Orbis Biosciences, or Orbis, for the development of long-acting injectable etonogestrel contraceptive with 6- and 12-month durations (ORB-204 and ORB-214, respectively). Under the Orbis Agreement, the  Company paid Orbis &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$300,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; to conduct the first stage of development work, Stage 1, as follows: &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$150,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; upon signing the Orbis Agreement, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$75,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; at the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; completion point, not later than 6 months following the date the Orbis Agreement was signed (which the Company paid in September 2018), and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$75,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; upon delivery by Orbis of the 6-month batch, not later than 11 months following the date the Orbis Agreement was signed (which the Company paid in January 2019). Upon Orbis successfully completing Stage 1 of the development program and achieving the predetermined target milestones for Stage 1, the Company will have &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;90&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; days to instruct Orbis whether to commence the second stage of development work, Stage 2. Should the Company execute its option to proceed to Stage 2, it will have to provide additional funding to Orbis for such activities. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Pre-clinical studies for the 6- and 12-month formulations have been completed, including establishing pharmacokinetics and pharmacodynamics profiles. The collaboration with Orbis will continue to advance the program through formulation optimization with the goal of achieving sustained release over the target time period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Orbis Agreement provides the Company with an option to enter into a license agreement for ORB-204 and ORB-214 should development efforts be successful.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Juniper Pharmaceuticals - License Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In April 2018,&amp;#160;the Company entered into an Exclusive License Agreement, or the Juniper License Agreement, with Juniper Pharmaceuticals, Inc., or Juniper, under which Juniper granted the Company (a) an exclusive, royalty-bearing worldwide license under certain patent rights, either owned by or exclusively licensed to Juniper, to make, have made, use, have used, sell, have sold, import and have imported products and processes; and (b) a non-exclusive, royalty-bearing worldwide license to use certain technological information owned by Juniper to make, have made, use, have used, sell, have sold, import and have imported products and processes. The Company is entitled to sublicense the rights granted to it under the Juniper License Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:94px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The following is a summary of certain terms of the Juniper License Agreement:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Upfront Fee.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company paid a &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$250,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; non-creditable upfront license fee to Juniper in connection with the execution of the Juniper License Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Annual Maintenance Fee&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The Company will pay an annual license maintenance fee to Juniper on each anniversary of the date of the Juniper License Agreement, the amount of which will be &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$50,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; for the first two years and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$100,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; thereafter, and which will be creditable against royalties and other payments due to Juniper in the same calendar year but may not be carried forward to any other year.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Milestone &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Payments.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company must make potential future development and sales milestone payments of (1) up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$13.5 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in the aggregate upon achieving certain clinical and regulatory milestones, and (2) up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$30.3 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in the aggregate upon achieving certain commercial sales milestones for each product or process covered by the licenses granted under the Juniper License Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Royalty Payments&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. During the royalty term, the Company will pay Juniper mid-single-digit to low double-digit royalties based on worldwide net sales of products and processes covered by the licenses granted under the Juniper&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;License&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Agreement. In lieu of such royalty payments, the Company will pay Juniper a low double-digit percentage of all sublicense income the Company receives for the sublicense of rights under the Juniper License Agreement to a third party. The royalty term, which is determined on a country-by-country basis and product-by-product basis (or process-by-process basis), begins with the first commercial sale of a product or process in a country and terminates on the latest of (1) the expiration date of the last valid claim within the licensed patent rights with respect to such product or process in such country, (2) &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10 years&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; following the first commercial sale of such product or process in such country, and (3) when one or more generic products for such product or process are commercially available in such country, except that if there is no such generic product by the 10th year following the first commercial sale in such country, then the royalty term will terminate on the 10-year anniversary of the first commercial sale in such country.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Efforts&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The Company must use commercially reasonable efforts to develop and make at least one product or process available to the public, which efforts include achieving specific diligence requirements by specific dates specified in the Juniper License Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;T&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;erm. Unless earlier terminated, the term of the Juniper License Agreement will continue on a country-by-country basis until the later of (1) the expiration date of the last valid claim within such country, or (2) 10 years from the date of first commercial sale of a product or process in such country. Upon expiration (but not early termination) of the Juniper License Agreement, the licenses granted thereunder will convert automatically to fully-paid irrevocable licenses. Juniper may terminate the Juniper License Agreement (1) upon &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; days&amp;#8217; notice for the Company&amp;#8217;s uncured breach of any payment obligation under the Juniper License Agreement, (2) if the Company fails to maintain required insurance, (3) immediately upon the Company&amp;#8217;s insolvency or the making of an assignment for the benefit of the Company&amp;#8217;s creditors or if a bankruptcy petition is filed for or against the Company, which petition is not dismissed within &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;90 days&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, or (4) upon &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;60&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; days&amp;#8217; notice for any uncured material breach by the Company of any of its other obligations under the Juniper License Agreement. The Company may terminate the Juniper License Agreement on a country-by-country basis for any reason by giving &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;180&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; days&amp;#8217; notice (or &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;90 days&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8217; notice if such termination occurs prior to receipt of marketing approval in the United States). If Juniper terminates the Juniper License Agreement for the reason described in clause (4) above or if the Company terminates the Juniper License Agreement, Juniper will have full access including the right to use and reference all product data generated during the term of the Juniper License Agreement that is owned by the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Pear Tree Acquisition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company may be required to make certain royalty and milestone payments under the Merger Agreement (see Note 4).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Hammock/MilanaPharm Assignment and License Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;On December 5, 2018, the Company entered into (a) an Assignment Agreement with Hammock Pharmaceuticals, Inc., or the Assignment Agreement, and (b) a First Amendment to License Agreement with TriLogic Pharma, LLC and MilanaPharm LLC, or the License Amendment. Both agreements relate to the Exclusive License Agreement among Hammock, TriLogic and MilanaPharm dated as of January 9, 2017, or the MilanaPharm License Agreement. Under the Assignment Agreement and the MilanaPharm License Agreement, as amended by the License Amendment, the Company acquired an exclusive, worldwide license under certain intellectual property to, among other things, develop and commercialize products for the diagnosis, treatment and prevention of human diseases or conditions in or through any intravaginal or urological applications. The licensed intellectual property relates to the hydrogel drug delivery platform of TriLogic and MilanaPharm known as TRI-726. In DARE-BV1, this proprietary technology is formulated with clindamycin, an antibiotic used to treat certain bacterial infections, including BV, and has been engineered to produce a dual release pattern after vaginal application, providing maximum duration of exposure to clindamycin at the site of infection.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The following is a summary of other terms of the License Amendment:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;License Fees.&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; The Company paid &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$25,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; to MilanaPharm in connection with the execution of the License Amendment and must pay &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$200,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; to MilanaPharm (in the Company's discretion, either in cash or with shares of the Company's common stock) within 15 days of the first to occur of December 5, 2019 or the closing of an equity financing in which the Company raises aggregate proceeds of at least &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Milestone Payments.&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; The Company will pay to MilanaPharm (1) up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$300,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in the aggregate upon achievement of certain development milestones; and (2) up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1.75 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in the aggregate upon achieving certain commercial sales milestones. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Foreign Sublicense Income.&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; The Company will pay MilanaPharm a low double-digit percentage of all income received by the Company or its affiliates in connection with any sublicense granted to a third party for use outside of the United States, subject to certain exclusions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Royalty Payments.&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; During the royalty term, the Company will pay MilanaPharm high single-digit to low double-digit royalties based on annual worldwide net sales of licensed products and processes. The royalty term, which is determined on a country-by-country basis and licensed product-by-product basis (or process-by-process basis), begins with the first commercial sale of a licensed product or process in a country and terminates on the latest of (a) the expiration date of the last valid claim of the licensed patent rights that cover the method of use of such product or process in such country, or (b) 10 years following the first commercial sale of such product or process in such country. Royalty payments are subject to reduction in certain circumstances, including as a result of generic competition, patent prosecution expenses incurred by the Company, or payments to third parties for rights or know-how that are required for the Company to exercise the licenses granted to it under the MilanaPharm License Agreement or that are strategically important or could add value to a licensed product or process in a manner expected to materially generate or increase sales.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Efforts&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The Company must use commercially reasonable efforts and resources to (1) develop and commercialize at least one licensed product or process in the United States and at least one licensed product or process in at least one of Canada, the United Kingdom, France, Germany, Italy or Spain, and (2) continue to commercialize that product or process following the first commercial sale of a licensed product or process in the applicable jurisdiction.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Term&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. Unless earlier terminated, the term of the MilanaPharm License Agreement will continue until (1) on a licensed product-by-product (or process-by-process basis) and country-by-country basis, the date of expiration of the royalty term with respect to such licensed product in such country, and (2) the expiration of all applicable royalty terms under the MilanaPharm License Agreement with respect to all licensed products and processes in all countries. Upon expiration of the term with respect to any licensed product or process in a country (but not upon earlier termination of the MilanaPharm License Agreement), the licenses granted to the Company under the MilanaPharm License Agreement will convert automatically to an exclusive, fully paid-up, royalty-free, perpetual, non-terminable and irrevocable right and license under the licensed intellectual property. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In addition to customary termination rights for all parties, MilanaPharm may terminate the license granted to the Company solely with respect to a licensed product or process in a country if, after having launched such product or process in such country, (1) the Company, or its affiliates or sublicensees, discontinue the sale of such product or process in such country and MilanaPharm notifies the Company of such termination within 60 days of having first been notified by the Company of such discontinuation, or (2) the Company, or its affiliates or sublicensees, (A) discontinues all commercially reasonable marketing efforts to sell, and discontinues all sales of, such product or process in such country for nine months or more, (B) fails to resume such commercially reasonable marketing efforts within 120 days of having been notified of such failure by MilanaPharm, (C) fails to reasonably demonstrate a strategic justification for the discontinuation and failure to resume to MilanaPharm, and (D) MilanaPharm gives 90 days&amp;#8217; notice to the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The following is a summary of other terms of the Assignment Agreement with Hammock:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Assignment; Technology Transfer&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. Hammock assigned and transferred to the Company all of its right, title and interest in and to the MilanaPharm License Agreement and agreed to cooperate to transfer to the Company all of the data, materials and the licensed technology in its possession pursuant to a technology transfer plan to be agreed upon by the parties, with a goal for the Company to independently practice the licensed intellectual property as soon as commercially practical in order to develop and commercialize the licensed products and processes. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Fees&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The Company paid &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$250,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; to Hammock in connection with the execution of the Assignment Agreement and must pay &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$250,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; to Hammock (in the Company's discretion either in cash or with shares of the Company's common stock) within 15 days of the first to occur of December 5, 2019 or the closing of an equity financing in which the Company raises aggregate proceeds of at least &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Milestone Payments&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The Company will pay Hammock up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1.1 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in the aggregate upon achievement of certain clinical and regulatory development milestones.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Term&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The Assignment Agreement will terminate upon the later of (1) completion of the parties&amp;#8217; technology transfer plan, and (2) payment to Hammock of the last of the payments described above, including the milestone payments.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsDisclosureTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2019Q1YTD" id="Fact-7B66A1711E6554EF94F21DC1968408A9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;STOCK-BASED COMPENSATION&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;The 2015 Employee, Director and Consultant Equity Incentive Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Prior to the Cerulean/Private Dar&amp;#233; stock purchase transaction, the 2015 Employee, Director and Consultant Equity Incentive Plan of Private Dar&amp;#233;, or the 2015 Private Dar&amp;#233; Plan, governed the issuance of equity awards to Private Dar&amp;#233; employees, officers, non-employee directors and consultants. Options granted under the 2015 Private Dar&amp;#233; Plan have terms of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;ten years&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; from the date of grant unless earlier terminated and generally vest over a &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;-year period. Upon closing of the Cerulean/Private Dar&amp;#233; stock purchase transaction, the Company assumed the 2015 Private Dar&amp;#233; Plan and each outstanding option to acquire Private Dar&amp;#233; stock that was not exercised prior to the closing. Options to purchase &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;50,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of Private Dar&amp;#233; stock were assumed. Such options were assumed on the same terms as were applicable to them under the 2015 Private Dar&amp;#233; Plan and became an option to purchase such number of shares of the Company&amp;#8217;s common stock equal to the number of Private Dar&amp;#233; shares subject to such option multiplied by the exchange ratio specified in the Dar&amp;#233; Stock Purchase Agreement, at a correspondingly adjusted exercise price. Based on the exchange ratio and after giving effect to the reverse stock split effected in connection with the closing of the Cerulean/Private Dar&amp;#233; stock purchase transaction, such options were replaced with options to purchase &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10,149&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of the Company&amp;#8217;s common stock, all of which were outstanding as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Private Dar&amp;#233; issued &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;900,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;200,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of fully vested restricted stock to non-employees under the 2015 Private Dar&amp;#233; Plan during 2015 and 2016, respectively. In connection with the closing of the Cerulean/Private Dar&amp;#233; stock purchase transaction, the Company assumed these shares and replaced them with &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;223,295&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; restricted shares of the Company&amp;#8217;s common stock (after giving effect to the reverse stock split effected in connection with the closing of the Cerulean/Private Dar&amp;#233; stock purchase transaction).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;No further awards may be granted under the 2015 Private Dar&amp;#233; Plan following the closing of the Cerulean/Private Dar&amp;#233; stock purchase transaction.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;2014 Employee Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In March 2014, the Company&amp;#8217;s board of directors adopted, and its stockholders approved the 2014 Employee Stock Purchase Plan, or the ESPP, which became effective in April 2014. The ESPP permits eligible employees to enroll in a &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;-month offering period whereby participants may purchase shares of the Company&amp;#8217;s common stock, through payroll deductions, at a price equal to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;85%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the closing price of the common stock on the first day of the offering period or on the last day of the offering period, whichever is lower. Purchase dates under the ESPP occur on or about June 30 and December 31 each year. The Company&amp;#8217;s board of directors decided not to initiate a new offering period beginning January 1, 2017 and no offering period has been initiated since then. There was &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; stock-based compensation related to the ESPP for the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Amended and Restated 2014 Stock Incentive Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company maintains the Amended and Restated 2014 Plan, or the Amended 2014 Plan, which was approved by the Company&amp;#8217;s stockholders on July 10, 2018. The Amended 2014 Plan was an amendment and restatement of the Company&amp;#8217;s 2014 Stock Incentive Plan, or the 2014 Plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;When adopted, there were &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,046,885&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of common stock authorized for issuance under the Amended 2014 Plan. The number of authorized shares increases annually on the first day of each fiscal year until, and including, the fiscal year ending December 31, 2024 by the least of (i) &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,000,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, (ii) &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;4%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the number of outstanding shares of common stock on such date, or (iii) an amount determined by the Company&amp;#8217;s board of directors. On January 1, 2019, the number of authorized shares increased by &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;456,886&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,503,771&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, which increase represented &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;4%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the number of outstanding shares of common stock on such date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In March 2017, the Company&amp;#8217;s board of directors approved two modifications to outstanding stock options granted under the 2014 Plan to participants providing services to the Company as of that date. One modification extended the exercise period of such stock options to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;two years&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; after such participant&amp;#8217;s termination date, unless the exercise period absent such modification would be longer. The other modification provided for accelerated vesting of such stock options upon a change in control event. These modifications resulted in unamortized fair value expense of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$3.7 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and was recorded as part of the total consideration in the Cerulean/Private Dar&amp;#233; stock purchase transaction (see Note 4). The two modifications resulted in certain options remaining outstanding that would have otherwise expired.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;At &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;323,560&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of common stock were reserved for future issuance under the Amended 2014 Plan, and options to purchase &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,190,360&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of the Company&amp;#8217;s common stock granted under the Amended 2014 Plan were outstanding.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Summary of Stock Option Activity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The table below summarizes stock option activity under the Amended 2014 Plan, and related information for the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The exercise price of all options granted during the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; was equal to the market value of the Company&amp;#8217;s common stock on the date of the grant. As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, unamortized stock-based compensation expense of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1,343,624&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; will be amortized over a weighted average period of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3.3 years&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Number of Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Weighted Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Outstanding at December 31, 2018 (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,635,790&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;11.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;563,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Canceled/forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(8,360&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;17.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;59.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Outstanding at March 31, 2019 (unaudited) (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,190,360&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;8.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Exercisable at March&amp;#160;31, 2019 (unaudited)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;650,151&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;25.97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:0px;padding-top:8px;text-indent:0px;"&gt;&lt;font style="padding-top:8px;font-family:Arial;font-size:10pt;padding-right:48px;"&gt;(1)&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Includes &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10,149&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares subject to options granted under the 2015 Private Dar&amp;#233; Plan assumed in connection with the Cerulean/Private Dar&amp;#233; stock purchase transaction.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Compensation Expense&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total stock-based compensation expense related to stock options granted to employees and directors recognized in the consolidated statement of operations is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br clear="none"/&gt;March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;24,703&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;73,265&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;9,124&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;97,968&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;9,124&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The assumptions used in the Black-Scholes option-pricing model for stock options granted to employees and to directors in respect of board services during the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br clear="none"/&gt;March 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Expected life in years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2.70%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;120%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Forfeiture rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0.0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0.0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Weighted-average fair value of options granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$0.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Restricted Stock After the Cerulean/Private Dar&amp;#233; Stock Purchase Transaction&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3.14 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of common stock issued in connection with the Cerulean/Private Dar&amp;#233; stock purchase transaction to the Private Dar&amp;#233; stockholders were not registered with the SEC and may only be sold if registered under the Securities Act of 1933, as amended, or pursuant to an exemption from the registration requirements thereunder. The shares held by non-affiliates became eligible for sale &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;color:#222222;"&gt;under&amp;#160;Rule 144 beginning&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; six months after the closing of the Cerulean/Private Dar&amp;#233; stock purchase transaction&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;color:#222222;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2019Q1YTD" id="Fact-144635EF5B7057D49DB17FA7E8425E05">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;NET LOSS PER SHARE&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company computes basic net loss per share using the weighted average number of common shares outstanding during the period. Diluted net income per share is based upon the weighted average number of common shares and potentially dilutive securities (common share equivalents) outstanding during the period. Common share equivalents outstanding, determined using the treasury stock method, are comprised of shares that may be issued under outstanding options and warrants to purchase shares of the Company&amp;#8217;s common stock. Common share equivalents are excluded from the diluted net loss per share calculation if their effect is anti-dilutive.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The following potentially dilutive outstanding securities were excluded from diluted net loss per common share for the period indicated because of their anti-dilutive effect:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Potentially dilutive securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Three months ended&lt;br clear="none"/&gt;March&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,190,360&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;543,396&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,750,833&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,751,002&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5,941,193&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;4,294,398&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="FD2019Q1YTD" id="Fact-0AF23657EC325C8A8A214B4264CE66D7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The three-level hierarchy of valuation techniques established to measure fair value is defined as follows:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Level 1: inputs are unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Level 2: inputs other than level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Cash and cash equivalents of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$3.5 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$6.8 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; measured at fair value as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, respectively, are classified within Level 1 of the fair value hierarchy. Other receivables are financial assets with carrying values that approximate fair value due to the short-term nature of these assets. Accounts payable and accrued expenses and other liabilities are financial liabilities with carrying values that approximate fair value due to the short-term nature of these liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
	<us-gaap:LesseeLeasesPolicyTextBlock contextRef="FD2019Q1YTD" id="Fact-3132EAD3E5EF49529B39515892615019">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use, or ROU, lease assets, current portion of lease obligations, and long-term lease obligations on the Company's balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;ROU lease assets represent the Company's right to use an underlying asset for the lease term and lease obligations represent the Company's obligation to make lease payments arising from the lease. Operating ROU lease assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term. If the lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The ROU lease asset also includes any lease payments made and excludes lease incentives. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
	<us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="FD2019Q1YTD" id="Fact-9E2770F1E91A3DD254DC55940C5A465E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Years ending December 31:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Remainder of 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;81,950&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;112,943&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;67,595&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Total future minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;262,488&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Less: Difference between future minimum lease payments and discounted operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;39,449&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Total operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;223,039&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
	<us-gaap:LesseeOperatingLeasesTextBlock contextRef="FD2019Q1YTD" id="Fact-9926D7DA904598A3BEB3558B493C3D9C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;LEASED PROPERTIES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Effective January 1, 2019, the Company adopted ASC 842, which requires recognition of a right-of-use asset and lease liability for all leases at the commencement date based on the present value of lease payments over the lease term. Additional qualitative and quantitative disclosures regarding the Company's leasing arrangements are also required. The Company adopted ASC 842 prospectively and elected the package of transition practical expedients that does not require reassessment of: (1) whether any existing or expired contracts are or contain leases, (2) lease classification and (3) initial direct costs. In addition, the Company has elected other available practical expedients to not separate lease and nonlease components, which consist principally of common area maintenance charges, for all classes of underlying assets and to exclude leases with an initial term of 12 months or less.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company has one lease for its corporate headquarters that commenced on July 1, 2018 for &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,169&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; square feet of office space. The term of the lease is &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;37 months&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and terminates on July 31, 2021. The Company has the option to extend the term of the lease for &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;one year&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; at the Company's discretion. The gross monthly base rent is &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$8,873&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, which will increase approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;4%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; per year, subject to certain future adjustments. The base rent was abated during the second month of the lease. The Company evaluates renewal options at lease inception and on an ongoing basis, and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. The lease does not require material variable lease payments, a residual value guarantee or restrictive covenants.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The lease does not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment. The Company used an incremental borrowing rate of 7% as of January 1, 2019 for the operating lease that commenced prior to that date. The depreciable lives of operating lease assets and leasehold improvements are limited by the expected lease term.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;As of March 31, 2019, the Company recorded a right of use asset of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$212,909&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; within its other non-current  assets and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$83,751&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$139,288&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, respectively within current and non-current other liabilities on its consolidated balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;As of March 31, 2019, future minimum lease payments for the Company's corporate headquarters are:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Years ending December 31:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Remainder of 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;81,950&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;112,943&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;67,595&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Total future minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;262,488&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Less: Difference between future minimum lease payments and discounted operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;39,449&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Total operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;223,039&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Operating lease costs were&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$27,038&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;for the three months ended&amp;#160;March&amp;#160;31, 2019. Operating lease costs are included in general and administrative expenses in the condensed consolidated statement of operations. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Cash paid for amounts included in the measurement of operating lease liabilities were&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$26,620&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;for the three months ended&amp;#160;March&amp;#160;31, 2019, and this amount is included in operating activities in the condensed consolidated statements of cash flows.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2019Q1YTD" id="Fact-70E8D026F76357DE963199486B62DB2A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recently Adopted Accounting Standards&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In May 2014, FASB issued Accounting Standards Update, or ASU, 2014-09, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, which impacts the way in which some entities recognize revenue for certain types of transactions. The new standard became effective beginning in 2018 for public companies. Because the Company does not currently have any contracts with customers, the Company&amp;#8217;s adoption of this accounting standard did not impact the Company&amp;#8217;s interim consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In February 2016, FASB issued ASU 2016-02, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. The new standard is effective for public companies for fiscal years beginning after December&amp;#160;15, 2018, with early adoption permitted. ASU 2016-02 became effective for the Company on January 1, 2019 and was adopted using a modified retrospective approach and the effective date is as of the initial application. Consequently, financial information was not updated, and the disclosures required under ASU 2016-02 are not provided for dates and periods prior to January 1, 2019. ASU 2016-02 provides a number of optional practical expedients and accounting policy elections. The Company elected the package of practical expedients requiring no reassessment of whether any expired or existing contracts are or contain leases, the lease classification of any expired or existing leases, or initial direct costs for any existing leases. The Company recorded approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$232,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; right-of-use assets and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$241,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; lease liabilities related to its lease of office space as of the adoption date in the consolidated balance sheets. There are no changes to the statement of operations or cash flows as a result of the adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In January 2017, FASB issued ASU 2017-01, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Business Combinations (Topic 805): Clarifying the Definition of a Business&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, which intended to clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The standard became effective for the Company on January 1, 2018. The Company&amp;#8217;s early adoption of this standard did not have a material impact on the Company&amp;#8217;s consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In July 2017, FASB issued ASU 2017-11, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815): (I) Accounting for Certain Financial Instruments with Down Round Features, (II) Replacement for the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception.&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; This update was issued to provide additional clarity related to accounting for certain financial instruments that have characteristics of both liabilities and equity. In particular, this update addresses freestanding and embedded financial instruments with down round features and whether they should be treated as a liability or equity instrument. Part II simply replaces the indefinite deferral for certain mandatorily redeemable non-controlling interests and mandatorily redeemable financial instruments of nonpublic entities contained within the Accounting Standards Committee Topic 480 with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. For public business entities, the amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company has early adopted ASU 2017-11. As a result, the Company has not recognized the fair value of the warrants containing down round features that were issued in the underwritten offering in February 2018 (see Note 6) as liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Disclosure Update and Simplification,&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements relating to the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of income is required to be filed. This final rule was effective November 5, 2018. In accordance with the new rule, the Company added a Consolidated Statement of Stockholders' Equity in this report and elected to present a reconciliation in a single statement that shows the changes in stockholders' equity for each interim period, as well as each comparable period.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="FD2019Q1YTD" id="Fact-22655D1A0D2C5361A1185E135C1A41D5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;ORGANIZATION AND DESCRIPTION OF THE BUSINESS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Dar&amp;#233; Bioscience, Inc. is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women&amp;#8217;s health. Dar&amp;#233; Bioscience, Inc. and its wholly owned subsidiaries operate in &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; segment. In this report, the &amp;#8220;Company&amp;#8221; refers collectively to Dar&amp;#233; Bioscience, Inc. and its wholly owned subsidiaries, unless otherwise stated or the context otherwise requires.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company is driven by a mission to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health and fertility. The Company's business strategy is to license or otherwise acquire the rights to differentiated product candidates in women's health, some of which have existing clinical proof-of-concept data, and to advance those candidates through clinical development and regulatory approval alone or in collaboration with strategic partners.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company has assembled a portfolio of clinical-stage and pre-clinical-stage candidates addressing unmet needs in women&amp;#8217;s health. The Company&amp;#8217;s portfolio includes these four clinical-stage candidates:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:144px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:120px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis, or BV; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:144px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:120px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Ovaprene, a non-hormonal monthly contraceptive intravaginal ring; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:144px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:120px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder, or FSAD; and &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:144px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:120px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy following menopause. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company's portfolio also includes these pre-clinical stage product candidates:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:144px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:120px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy, or VVA, in patients with hormone-receptor positive breast cancer;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:144px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:120px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;DARE-RH1, a novel approach to non-hormonal contraception for both men and women by targeting the CatSper ion channel;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:144px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:120px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;ORB-204 and ORB-214, 6-month and 12-month formulations of injectable etonogestrel for contraception;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:144px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:120px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and for fertility support as part of an &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;in vitro&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; fertilization, or IVF, treatment plan;  and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:144px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:120px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;DARE-OAB1, an intravaginal ring containing oxybutynin for the treatment of overactive bladder.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company&amp;#8217;s primary operations have consisted of, and are expected to continue to consist of, product research and development and advancing its portfolio of product candidates through clinical development and regulatory approval.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;To date, the Company has not obtained any regulatory approvals for any of its product candidates, commercialized any of its product candidates or generated any product revenue. The Company is subject to several risks common to clinical-stage biopharmaceutical companies, including dependence on key individuals, competition from other companies, the need to develop commercially viable products in a timely and cost-effective manner, and the need to obtain adequate additional capital to fund the development of product candidates. The Company is also subject to several risks common to other companies in the industry, including rapid technology change, regulatory approval of products, uncertainty of market acceptance of products, competition from substitute products and larger companies, compliance with government regulations, protection of proprietary technology, dependence on third parties, and product liability.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
	<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="FD2019Q1YTD" id="Fact-B1ECBE61751253798E29FD5ECD034E00">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The following potentially dilutive outstanding securities were excluded from diluted net loss per common share for the period indicated because of their anti-dilutive effect:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Potentially dilutive securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;Three months ended&lt;br clear="none"/&gt;March&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,190,360&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;543,396&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,750,833&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,751,002&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5,941,193&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;4,294,398&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2019Q1YTD" id="Fact-92918B8A38795353B6434F8F749E1E96">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total stock-based compensation expense related to stock options granted to employees and directors recognized in the consolidated statement of operations is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br clear="none"/&gt;March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;24,703&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;73,265&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;9,124&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;97,968&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;9,124&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2019Q1YTD" id="Fact-8EC8B23A8D2452B5BB69E5B731AC6A8F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The table below summarizes stock option activity under the Amended 2014 Plan, and related information for the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The exercise price of all options granted during the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; was equal to the market value of the Company&amp;#8217;s common stock on the date of the grant. As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, unamortized stock-based compensation expense of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1,343,624&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; will be amortized over a weighted average period of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3.3 years&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Number of Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Weighted Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Outstanding at December 31, 2018 (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;1,635,790&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;11.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;563,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Canceled/forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(8,360&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;17.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;(70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;59.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Outstanding at March 31, 2019 (unaudited) (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,190,360&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;8.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Exercisable at March&amp;#160;31, 2019 (unaudited)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;650,151&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;25.97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:0px;padding-top:8px;text-indent:0px;"&gt;&lt;font style="padding-top:8px;font-family:Arial;font-size:10pt;padding-right:48px;"&gt;(1)&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Includes &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10,149&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares subject to options granted under the 2015 Private Dar&amp;#233; Plan assumed in connection with the Cerulean/Private Dar&amp;#233; stock purchase transaction.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2019Q1YTD" id="Fact-7A72B0BDC3FE514CB1F5FFC86D165781">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The assumptions used in the Black-Scholes option-pricing model for stock options granted to employees and to directors in respect of board services during the &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br clear="none"/&gt;March 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Expected life in years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2.70%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;120%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Forfeiture rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0.0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0.0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Weighted-average fair value of options granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$0.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="FD2019Q1YTD" id="Fact-A0168E6705C75FB896F02FFB6EE8F846">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company had these warrants outstanding:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:24%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:32%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Shares Underlying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Outstanding Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Expiration Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,906&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;120.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;1, 2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,737&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;120.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;6, 2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;17,190&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;60.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;January&amp;#160;8, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;6,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;April&amp;#160;4, 2026&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,720,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;February&amp;#160;15, 2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,750,833&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2019Q1YTD" id="Fact-09590DA8902F530DAC778FCF96629480">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company&amp;#8217;s significant accounting policies are described in Note 1 to the interim consolidated financial statements included in the Company&amp;#8217;s Annual Report on Form 10-K for the year ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, filed with the Securities and Exchange Commission, or SEC on April 1, 2019. Since the date of those consolidated financial statements, there have been no material changes to the Company&amp;#8217;s significant accounting policies, except as described below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The accompanying interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as defined by the Financial Accounting Standards Board, or FASB, for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X.&amp;#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management&amp;#8217;s opinion, the accompanying interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results of the interim periods presented.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Interim financial results are not necessarily indicative of results anticipated for any other interim period or for the full year. The accompanying interim consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company&amp;#8217;s Annual Report on Form 10-K for the year ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use, or ROU, lease assets, current portion of lease obligations, and long-term lease obligations on the Company's balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;ROU lease assets represent the Company's right to use an underlying asset for the lease term and lease obligations represent the Company's obligation to make lease payments arising from the lease. Operating ROU lease assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term. If the lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The ROU lease asset also includes any lease payments made and excludes lease incentives. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. (See Note 7, Leased Properties.)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The three-level hierarchy of valuation techniques established to measure fair value is defined as follows:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Level 1: inputs are unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Level 2: inputs other than level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:96px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;Cash and cash equivalents of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$3.5 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$6.8 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; measured at fair value as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, respectively, are classified within Level 1 of the fair value hierarchy. Other receivables are financial assets with carrying values that approximate fair value due to the short-term nature of these assets. Accounts payable and accrued expenses and other liabilities are financial liabilities with carrying values that approximate fair value due to the short-term nature of these liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recently Adopted Accounting Standards&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In May 2014, FASB issued Accounting Standards Update, or ASU, 2014-09, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, which impacts the way in which some entities recognize revenue for certain types of transactions. The new standard became effective beginning in 2018 for public companies. Because the Company does not currently have any contracts with customers, the Company&amp;#8217;s adoption of this accounting standard did not impact the Company&amp;#8217;s interim consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In February 2016, FASB issued ASU 2016-02, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. The new standard is effective for public companies for fiscal years beginning after December&amp;#160;15, 2018, with early adoption permitted. ASU 2016-02 became effective for the Company on January 1, 2019 and was adopted using a modified retrospective approach and the effective date is as of the initial application. Consequently, financial information was not updated, and the disclosures required under ASU 2016-02 are not provided for dates and periods prior to January 1, 2019. ASU 2016-02 provides a number of optional practical expedients and accounting policy elections. The Company elected the package of practical expedients requiring no reassessment of whether any expired or existing contracts are or contain leases, the lease classification of any expired or existing leases, or initial direct costs for any existing leases. The Company recorded approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$232,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; right-of-use assets and &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$241,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; lease liabilities related to its lease of office space as of the adoption date in the consolidated balance sheets. There are no changes to the statement of operations or cash flows as a result of the adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In January 2017, FASB issued ASU 2017-01, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Business Combinations (Topic 805): Clarifying the Definition of a Business&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, which intended to clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The standard became effective for the Company on January 1, 2018. The Company&amp;#8217;s early adoption of this standard did not have a material impact on the Company&amp;#8217;s consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In July 2017, FASB issued ASU 2017-11, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815): (I) Accounting for Certain Financial Instruments with Down Round Features, (II) Replacement for the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception.&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; This update was issued to provide additional clarity related to accounting for certain financial instruments that have characteristics of both liabilities and equity. In particular, this update addresses freestanding and embedded financial instruments with down round features and whether they should be treated as a liability or equity instrument. Part II simply replaces the indefinite deferral for certain mandatorily redeemable non-controlling interests and mandatorily redeemable financial instruments of nonpublic entities contained within the Accounting Standards Committee Topic 480 with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. For public business entities, the amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company has early adopted ASU 2017-11. As a result, the Company has not recognized the fair value of the warrants containing down round features that were issued in the underwritten offering in February 2018 (see Note 6) as liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;"&gt;Disclosure Update and Simplification,&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements relating to the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of income is required to be filed. This final rule was effective November 5, 2018. In accordance with the new rule, the Company added a Consolidated Statement of Stockholders' Equity in this report and elected to present a reconciliation in a single statement that shows the changes in stockholders' equity for each interim period, as well as each comparable period.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2019Q1YTD" id="Fact-7FA76EAFE0C25E2D9980ED7BFCB3998B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;STOCKHOLDERS&amp;#8217; EQUITY&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;ATM Sales Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In January 2018, the Company entered into a common stock sales agreement under which the Company may sell up to an aggregate of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$10 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; in gross proceeds through the sale of shares of common stock from time to time in &amp;#8220;at-the-market&amp;#8221; equity offerings (as defined in Rule 415 promulgated under the Securities Act of 1933, as amended), including in sales made directly on the Nasdaq Capital Market, or Nasdaq, to or through a market maker or, subject to the Company's prior approval, in negotiated transactions. The Company agreed to pay a commission of up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the gross proceeds of any common stock sold under this agreement plus certain legal expenses. The common stock sales agreement was amended in August 2018 to refer to the Company&amp;#8217;s shelf registration statement on Form S-3 (File No. 333-227019) that was filed to replace the Company&amp;#8217;s shelf registration statement on Form S-3 (File No. 333-206396) that expired on August 28, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;During the three months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company issued and sold &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares under the common stock sales agreement. During the three months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company generated gross proceeds of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1.1 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and incurred issuance costs of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$237,403&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; under this agreement on sales of an aggregate of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;375,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of the Company's common stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Underwritten Public Offering&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;In February 2018, the Company closed an underwritten public offering of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of its common stock and warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3.5 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of its common stock. Each share of common stock was sold with a warrant to purchase up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;0.70&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of a share of the Company&amp;#8217;s common stock. The Company granted the underwriter a &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;-day over-allotment option to purchase up to an additional &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;750,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of common stock and/or warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;525,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of common stock.&amp;#160; The underwriter exercised the option with respect to warrants to purchase &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;220,500&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of common stock. The Company received gross proceeds of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$10.3 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, including the proceeds from the sale of the warrants upon exercise of the underwriter&amp;#8217;s over-allotment option, and net proceeds of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$9.4 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Common Stock Warrants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The warrants issued in the February 2018 underwritten offering have an exercise price of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$3.00&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; per share and&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;are exercisable immediately and for &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; years from issuance.&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The warrants include a price-based anti-dilution provision, which provides that, subject to certain limited exceptions, the exercise price of the warrants will be adjusted downward if the Company issues or sells (or is deemed to issue or sell) securities at a price that is less than the exercise price in effect immediately prior to such issuance or sale (or deemed issuance or sale). In that case, the exercise price of the warrants will be adjusted to equal the price at which the new securities are issued or sold (or are deemed to have been issued or sold). In addition, subject to certain exceptions, if the Company issues, sells or enters into any agreement to issue or sell securities at a price which varies or may vary with the market price of the shares of the Company&amp;#8217;s common stock, the warrant holders have the right to substitute such variable price for the exercise price of the warrant then in effect. The warrants are exercisable only for cash, unless a registration statement covering the shares issued upon exercise of the warrants is not effective, in which case the warrants may be exercised on a cashless basis. A registration statement covering the shares issued upon exercise of the warrants is currently effective.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The exercise price of these warrants was automatically reduced to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$0.98&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; per share in connection with the initial closing of the Company's underwritten public offering in April 2019. See Note 11, "Subsequent Events," herein.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company estimated the fair value of the warrants as of February 15, 2018 to be approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; which has been recorded in equity as of the grant date. The Company early adopted ASU 2017-11 and as a result has recorded the fair value of the warrants as equity (see Note 3).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; warrants were exercised during the three months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. As of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company had these warrants outstanding:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:24%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:32%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Shares Underlying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Outstanding Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Expiration Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;2,906&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;120.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;1, 2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,737&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;120.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;December&amp;#160;6, 2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;17,190&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;60.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;January&amp;#160;8, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;6,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;10.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;April&amp;#160;4, 2026&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,720,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;February&amp;#160;15, 2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,750,833&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2019Q1YTD" id="Fact-697BE7E2094B308B0A394CB55DAF05FE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;SUBSEQUENT EVENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Capital Raising&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;On April 11, 2019, the Company closed an underwritten public offering of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;4,575,000&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of its common stock at a public offering price of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1.10&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; per share. The Company granted the underwriters a 30-day over-allotment option to purchase up to an additional &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;686,250&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares which was exercised in full on April 12, 2019. Including the over-allotment shares, the Company issued a total of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;5,261,250&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares in the underwritten public offering, and received gross proceeds of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$5.8 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and net proceeds of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$5.2 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; after deducting underwriting discounts and offering expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;"&gt;February 2018 Warrant Exercise Price Reduced &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;As discussed in Note 6 above, the outstanding warrants to purchase up to an aggregate of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;3,720,500&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; shares of the Company's common that were issued and sold in February 2018 include price-based anti-dilution provisions. Under the terms of those warrants, subject to certain limited exceptions, their exercise price will be reduced each time the Company issues or sells any securities for a consideration per share less than a price equal to the exercise price of those warrants in effect immediately prior to such issuance or sale. If the Company issues shares of common stock for cash, the consideration received therefor will be deemed to be the net amount of consideration the Company received therefor. As of immediately prior to the initial closing of the April 2019 underwritten public offering, the exercise price of the warrants was &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$3.00&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; per share. The net amount of consideration the Company received for shares issued and sold at the initial closing was &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$0.98&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; per share. On April 11, 2019, in accordance with the anti-dilution provision of the warrants and as a result of the sale of such shares, the exercise price of the warrants was automatically reduced to &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$0.98&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; per share.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="FD2019Q1YTD" id="Fact-7EE82483339E573A81E9A4DF892FCC34">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;font-weight:bold;"&gt;GOING CONCERN&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company has prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, as of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;, the Company had an accumulated deficit of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$32.0 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; and had cash and cash equivalents of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$3.5 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. The Company also had negative cash flow from operations of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$3.3 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; during the three months ended &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;March&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; In March of 2019, the Company announced that it received a Notice of Award for an additional &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$982,851&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; of the anticipated &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$1.9 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, or the NIH Grant, which will be applied to the clinical development efforts supporting Ovaprene. As of March 31, 2019, the Company recorded a receivable in the amount of &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$161,007&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt; for expenses eligible for reimbursement under the NIH Grant that were incurred through March 31, 2019. See Note 9, "Grant Award," herein. In April of 2019, the Company completed a sale of common stock raising net proceeds of approximately &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;$5.2 million&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;. See Note 11, "Subsequent Events," herein. The Company still needs to raise additional capital to continue to fund its operations and to successfully execute its current operating plan, including the development of its current product candidates. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company has a history of losses from operations, expects negative cash flows from its operations will continue for the foreseeable future, and expects that its net losses will continue for at least the next several years as it develops its existing product candidates and seeks to acquire, license or develop additional product candidates. These circumstances raise substantial doubt about the Company's ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty of the Company's ability to continue as a going concern.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company is focused primarily on the development and commercialization of innovative products in women&amp;#8217;s health. The Company will continue to incur significant research and development and other expenses related to these activities. If the clinical trials for any of the Company&amp;#8217;s product candidates fail to produce successful results such that those product candidates do not advance in clinical development, then the Company&amp;#8217;s business and prospects may suffer. Even if the product candidates advance in clinical development, they may fail to gain regulatory approval. Even if the product candidates are approved, they may fail to achieve market acceptance, and the Company may never become profitable. Even if the Company becomes profitable, it may not sustain profitability.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company believes that its current available current cash resources will be sufficient to fund planned operations into the first quarter of 2020. For the foreseeable future, the Company's ability to continue its operations will depend on its ability to obtain additional capital.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Arial;font-size:10pt;"&gt;The Company is currently evaluating a variety of capital raising options, including financings, government or other grant funding, collaborations and strategic alliances or other similar types of arrangements to cover its operating expenses, including the development of its product candidates and any future product candidates it may license or otherwise acquire. The amount and timing of the Company's capital needs have been and will continue to depend highly on many factors, including the product development programs the Company chooses to pursue and the pace and results of its clinical development efforts. If the Company raises capital through collaborations, strategic alliances or other similar types of arrangements, it may have to relinquish, on terms that are not favorable to the Company, rights to some of its technologies or product candidates it would otherwise seek to develop or commercialize. There can be no assurance that capital will be available when needed or that, if available, it will be obtained on terms favorable to the Company and its stockholders. Additionally, equity or debt financings may have a dilutive effect on the holdings of the Company's existing stockholders. If the Company cannot raise capital when needed, on favorable terms or at all, the Company will not be able to continue development of its product candidates, will need to reevaluate its planned operations and may need to delay, scale back or eliminate some or all of its development programs, reduce expenses, file for bankruptcy, reorganize, merge with another entity, or cease operations. If the Company becomes unable to continue as a going concern, the Company may have to liquidate its assets, and might realize significantly less than the values at which they are carried on its consolidated financial statements, and stockholders may lose all or part of their investment in the Company's common stock. The interim consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>dare-20190331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://darebioscience.com/20190331" xmlns:dare="http://darebioscience.com/20190331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dare-20190331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dare-20190331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dare-20190331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dare-20190331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="Acquisitions" roleURI="http://darebioscience.com/role/Acquisitions">
        <link:definition>2104100 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAdditionalInformationDetail" roleURI="http://darebioscience.com/role/AcquisitionsAdditionalInformationDetail">
        <link:definition>2404402 - Disclosure - Acquisitions - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsScheduleOfPurchasePriceConsiderationAllocationDetail" roleURI="http://darebioscience.com/role/AcquisitionsScheduleOfPurchasePriceConsiderationAllocationDetail">
        <link:definition>2404403 - Disclosure - Acquisitions - Schedule of Purchase Price Consideration Allocation (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTables" roleURI="http://darebioscience.com/role/AcquisitionsTables">
        <link:definition>2304301 - Disclosure - Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://darebioscience.com/role/CommitmentsAndContingencies">
        <link:definition>2109100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://darebioscience.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>2409401 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://darebioscience.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://darebioscience.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://darebioscience.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>1002000 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfStockholdersEquity" roleURI="http://darebioscience.com/role/ConsolidatedStatementsOfStockholdersEquity">
        <link:definition>1003000 - Statement - Consolidated Statements of Stockholders Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://darebioscience.com/role/DocumentAndEntityInformation">
        <link:definition>0002000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoingConcern" roleURI="http://darebioscience.com/role/GoingConcern">
        <link:definition>2102100 - Disclosure - Going Concern</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoingConcernAdditionalInformationDetail" roleURI="http://darebioscience.com/role/GoingConcernAdditionalInformationDetail">
        <link:definition>2402401 - Disclosure - Going Concern - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GrantAward" roleURI="http://darebioscience.com/role/GrantAward">
        <link:definition>2110100 - Disclosure - Grant Award</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GrantAwardAdditionalInformationDetail" roleURI="http://darebioscience.com/role/GrantAwardAdditionalInformationDetail">
        <link:definition>2410401 - Disclosure - Grant Award - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasedProperties" roleURI="http://darebioscience.com/role/LeasedProperties">
        <link:definition>2108100 - Disclosure - Leased Properties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasedPropertiesDetails" roleURI="http://darebioscience.com/role/LeasedPropertiesDetails">
        <link:definition>2408402 - Disclosure - Leased Properties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetails" roleURI="http://darebioscience.com/role/LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetails">
        <link:definition>2408403 - Disclosure - Leased Properties Leased Properties - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetailsCalc2" roleURI="http://darebioscience.com/role/LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetailsCalc2">
        <link:definition>2408403 - Disclosure - Leased Properties Leased Properties - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasedPropertiesTables" roleURI="http://darebioscience.com/role/LeasedPropertiesTables">
        <link:definition>2308301 - Disclosure - Leased Properties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://darebioscience.com/role/NetLossPerShare">
        <link:definition>2111100 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetail" roleURI="http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetail">
        <link:definition>2411402 - Disclosure - Net Loss Per Share - Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://darebioscience.com/role/NetLossPerShareTables">
        <link:definition>2311301 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndDescriptionOfBusiness" roleURI="http://darebioscience.com/role/OrganizationAndDescriptionOfBusiness">
        <link:definition>2101100 - Disclosure - Organization and Description of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndDescriptionOfBusinessAdditionalInformationDetail" roleURI="http://darebioscience.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail">
        <link:definition>2401401 - Disclosure - Organization and Description of the Business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://darebioscience.com/role/StockBasedCompensation">
        <link:definition>2106100 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetail" roleURI="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetail">
        <link:definition>2406402 - Disclosure - Stock Based compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedToEmployeesAndDirectorsDetail" roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedToEmployeesAndDirectorsDetail">
        <link:definition>2406405 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToStockOptionsGrantedToEmployeesAndDirectorsDetails" roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToStockOptionsGrantedToEmployeesAndDirectorsDetails">
        <link:definition>2406404 - Disclosure - Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryOfStockOptionActivityForAmended2014PlanAndRelatedInformationDetail" roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryOfStockOptionActivityForAmended2014PlanAndRelatedInformationDetail">
        <link:definition>2406403 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity for Amended 2014 Plan and Related Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://darebioscience.com/role/StockBasedCompensationTables">
        <link:definition>2306301 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://darebioscience.com/role/StockholdersEquity">
        <link:definition>2107100 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAdditionalInformationDetail" roleURI="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetail">
        <link:definition>2407402 - Disclosure - Stockholders' Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleOfCommonStockWarrantsOutstandingDetails" roleURI="http://darebioscience.com/role/StockholdersEquityScheduleOfCommonStockWarrantsOutstandingDetails">
        <link:definition>2407403 - Disclosure - Stockholders' Equity - Schedule of Common Stock Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://darebioscience.com/role/StockholdersEquityTables">
        <link:definition>2307301 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://darebioscience.com/role/SubsequentEvents">
        <link:definition>2112100 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://darebioscience.com/role/SubsequentEventsDetails">
        <link:definition>2412401 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://darebioscience.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2103100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>2403402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="dare_ADVATecAgreementMember" name="ADVATecAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued" name="AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" name="AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease" name="AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries" name="AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_AssignmentAgreementMember" name="AssignmentAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentAssets" name="BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentLiabilities" name="BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="dare_BusinessCombinationReverseMergerConsiderationTransferred" name="BusinessCombinationReverseMergerConsiderationTransferred" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="dare_BusinessCombinationReverseMergerConsiderationTransferredEquityInterestsIssuedAndIssuable" name="BusinessCombinationReverseMergerConsiderationTransferredEquityInterestsIssuedAndIssuable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_BusinessCombinationReverseMergerLineItems" name="BusinessCombinationReverseMergerLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" name="BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherCurrentAssets" name="BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherCurrentAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" name="BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" name="BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" name="BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost" name="BusinessCombinationReverseMergerStockPurchaseTransactionCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions" name="BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="dare_ClassOfWarrantOrRightsWarrantsExpirationDate" name="ClassOfWarrantOrRightsWarrantsExpirationDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:dateItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_ClinicalAndRegulatoryMilestonesMember" name="ClinicalAndRegulatoryMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_CommencementPeriodForStageTwoUponAchievementOfStageOne" name="CommencementPeriodForStageTwoUponAchievementOfStageOne" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_DevelopmentAndOptionAgreementMember" name="DevelopmentAndOptionAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_EstimatedFairValueOfWarrantsRecordedInEquity" name="EstimatedFairValueOfWarrantsRecordedInEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember" name="EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_GrantAwardTextBlock" name="GrantAwardTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_GrossProceedsFromIssuanceOfCommonStock" name="GrossProceedsFromIssuanceOfCommonStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="dare_GrossProceedsFromOfferingOfCommonStockAndWarrants" name="GrossProceedsFromOfferingOfCommonStockAndWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_HammockPharmaceuticalsInc.Member" name="HammockPharmaceuticalsInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges" name="IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_JuniperPharmaceuticalsInc.Member" name="JuniperPharmaceuticalsInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_JuniperPharmaceuticalsMember" name="JuniperPharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_LicenseAgreementExpirationPeriod" name="LicenseAgreementExpirationPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_LicenseAgreementNoticePeriodOfTermination" name="LicenseAgreementNoticePeriodOfTermination" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation" name="LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation" name="LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess" name="LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval" name="LicenseAgreementTerminationPeriodAfterReceiptOfApproval" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure" name="LicenseAgreementTerminationPeriodDueToPerformanceFailure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries" name="LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval" name="LicenseAgreementTerminationPeriodPriorToReceiptOfApproval" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_LicenseAndCollaborationAgreementMember" name="LicenseAndCollaborationAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_LicenseFee" name="LicenseFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="dare_LicenseFeeToBePaidUponContingency" name="LicenseFeeToBePaidUponContingency" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="dare_MaximumPotentialMilestonePayments" name="MaximumPotentialMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_MilanaPharmMember" name="MilanaPharmMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_MilestonePaymentsContingentAmount" name="MilestonePaymentsContingentAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_NationalInstitutesOfHealthMember" name="NationalInstitutesOfHealthMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_NetProceedsFromIssuanceOfCommonStockAndWarrants" name="NetProceedsFromIssuanceOfCommonStockAndWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="dare_NonCashLeaseExpense" name="NonCashLeaseExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="dare_NoticePeriodForTerminationOfAgreementForBothParties" name="NoticePeriodForTerminationOfAgreementForBothParties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_NumberOfCommonStockWarrantsExercised" name="NumberOfCommonStockWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_NumberOfDesignatedCountries" name="NumberOfDesignatedCountries" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_NumberOfPatentApplications" name="NumberOfPatentApplications" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="dare_NumberOfPatentsGranted" name="NumberOfPatentsGranted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="dare_NumberOfPatentsIssued" name="NumberOfPatentsIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="dare_NumberOfPendingPatents" name="NumberOfPendingPatents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="dare_OfferingPeriod" name="OfferingPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_OrbisMember" name="OrbisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_OvapreneMember" name="OvapreneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_PearTreePharmaceuticalsIncMember" name="PearTreePharmaceuticalsIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_PercentageOfAggregateCommission" name="PercentageOfAggregateCommission" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_PercentageOfIncreaseInAnnualBaseRent" name="PercentageOfIncreaseInAnnualBaseRent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement" name="PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_PercentageOfRoyaltyRate" name="PercentageOfRoyaltyRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_PeriodOfDismissalOfBankruptcyPetition" name="PeriodOfDismissalOfBankruptcyPetition" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_PeriodOfTerminationOfStockOptionsVestedAfterTerminationDate" name="PeriodOfTerminationOfStockOptionsVestedAfterTerminationDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne" name="PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" name="PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="dare_PotentialCashPaymentsToAcquireBusiness" name="PotentialCashPaymentsToAcquireBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="dare_PrivateDareMember" name="PrivateDareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_ProceedsFromIssuanceOfCommonStockAndWarrants" name="ProceedsFromIssuanceOfCommonStockAndWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="dare_ProceedsRaisedFromEquityFinancing" name="ProceedsRaisedFromEquityFinancing" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_PublicStockOfferingIncludingOverAllotmentOfSharesMember" name="PublicStockOfferingIncludingOverAllotmentOfSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_PublicStockOfferingMember" name="PublicStockOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_ReimbursementOfGrantExpensesReceivable" name="ReimbursementOfGrantExpensesReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember" name="RemainingPortionOfResearchAndAvailabilityOfFundsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_ResearchAndDevelopmentMilestonePayment" name="ResearchAndDevelopmentMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_SalesMilestonesMember" name="SalesMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_ScheduleOfBusinessCombinationReverseMergerTable" name="ScheduleOfBusinessCombinationReverseMergerTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_ScheduleOfBusinessCombinationReverseMergerTextBlock" name="ScheduleOfBusinessCombinationReverseMergerTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember" name="SecondPhaseOfResearchAndAvailabilityOfFundsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_SecuredInvestmentRequiredForLicenseAgreement" name="SecuredInvestmentRequiredForLicenseAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_SignificantAccountingPoliciesLineItems" name="SignificantAccountingPoliciesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_SignificantAccountingPoliciesTable" name="SignificantAccountingPoliciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_StockOptionModificationApprovalDate" name="StockOptionModificationApprovalDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:dateItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_StockPurchaseAgreementDate" name="StockPurchaseAgreementDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:dateItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_StockPurchaseAndOtherTransactionsCompletionDate" name="StockPurchaseAndOtherTransactionsCompletionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:dateItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_StockholdersEquityLineItems" name="StockholdersEquityLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_StockholdersEquityTable" name="StockholdersEquityTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" name="StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_TwoThousandAndFifteenStockIncentivePlanMember" name="TwoThousandAndFifteenStockIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" name="TwoThousandAndFourteenEmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_UnamortizedFairValueExpenseInStockPurchaseTransaction" name="UnamortizedFairValueExpenseInStockPurchaseTransaction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="dare_UnderwritersOptionToPurchaseAdditionalShares" name="UnderwritersOptionToPurchaseAdditionalShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod" name="UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_UpfrontLicenseFeePaid" name="UpfrontLicenseFeePaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_UponAchievementOfSpecifiedCommercializationMilestonesMember" name="UponAchievementOfSpecifiedCommercializationMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" name="UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" name="UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_UponAchievingCertainCommercialMilestonesMember" name="UponAchievingCertainCommercialMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_UponAchievingCertainDevelopmentMilestonesMember" name="UponAchievingCertainDevelopmentMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember" name="UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_UponReachingCertainWorldwideNetSalesMilestonesMember" name="UponReachingCertainWorldwideNetSalesMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_UponSigningOfDevelopmentAndOptionAgreementMember" name="UponSigningOfDevelopmentAndOptionAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" name="WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember" name="WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember" name="WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" name="WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember" name="WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="dare_WeightedAverageAmortizationPeriod" name="WeightedAverageAmortizationPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>dare-20190331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://darebioscience.com/role/Acquisitions" xlink:href="dare-20190331.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/AcquisitionsAdditionalInformationDetail" xlink:href="dare-20190331.xsd#AcquisitionsAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/AcquisitionsScheduleOfPurchasePriceConsiderationAllocationDetail" xlink:href="dare-20190331.xsd#AcquisitionsScheduleOfPurchasePriceConsiderationAllocationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/AcquisitionsTables" xlink:href="dare-20190331.xsd#AcquisitionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/CommitmentsAndContingencies" xlink:href="dare-20190331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="dare-20190331.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedBalanceSheets" xlink:href="dare-20190331.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="dare-20190331.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="dare-20190331.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="dare-20190331.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="dare-20190331.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/DocumentAndEntityInformation" xlink:href="dare-20190331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/GoingConcern" xlink:href="dare-20190331.xsd#GoingConcern" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/GoingConcernAdditionalInformationDetail" xlink:href="dare-20190331.xsd#GoingConcernAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/GrantAward" xlink:href="dare-20190331.xsd#GrantAward" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/GrantAwardAdditionalInformationDetail" xlink:href="dare-20190331.xsd#GrantAwardAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedProperties" xlink:href="dare-20190331.xsd#LeasedProperties" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesDetails" xlink:href="dare-20190331.xsd#LeasedPropertiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:href="dare-20190331.xsd#LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetailsCalc2" xlink:href="dare-20190331.xsd#LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesTables" xlink:href="dare-20190331.xsd#LeasedPropertiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerShare" xlink:href="dare-20190331.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetail" xlink:href="dare-20190331.xsd#NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerShareTables" xlink:href="dare-20190331.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/OrganizationAndDescriptionOfBusiness" xlink:href="dare-20190331.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail" xlink:href="dare-20190331.xsd#OrganizationAndDescriptionOfBusinessAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensation" xlink:href="dare-20190331.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:href="dare-20190331.xsd#StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedToEmployeesAndDirectorsDetail" xlink:href="dare-20190331.xsd#StockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedToEmployeesAndDirectorsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToStockOptionsGrantedToEmployeesAndDirectorsDetails" xlink:href="dare-20190331.xsd#StockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToStockOptionsGrantedToEmployeesAndDirectorsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryOfStockOptionActivityForAmended2014PlanAndRelatedInformationDetail" xlink:href="dare-20190331.xsd#StockBasedCompensationSummaryOfStockOptionActivityForAmended2014PlanAndRelatedInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationTables" xlink:href="dare-20190331.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquity" xlink:href="dare-20190331.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetail" xlink:href="dare-20190331.xsd#StockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityScheduleOfCommonStockWarrantsOutstandingDetails" xlink:href="dare-20190331.xsd#StockholdersEquityScheduleOfCommonStockWarrantsOutstandingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityTables" xlink:href="dare-20190331.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/SubsequentEvents" xlink:href="dare-20190331.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/SubsequentEventsDetails" xlink:href="dare-20190331.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="dare-20190331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="dare-20190331.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="dare-20190331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/Acquisitions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/AcquisitionsAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/AcquisitionsScheduleOfPurchasePriceConsiderationAllocationDetail" xlink:type="extended">
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1f2f887e-446b-cb22-5b3e-72c0b1cac8a6" xlink:type="locator" />
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ab2acb12-8353-00f8-d62d-72c0b151a74f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1f2f887e-446b-cb22-5b3e-72c0b1cac8a6" xlink:to="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ab2acb12-8353-00f8-d62d-72c0b151a74f" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherCurrentAssets" xlink:label="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherCurrentAssets_080cc50d-ea94-9bfe-ded8-72c0b19e7c7f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1f2f887e-446b-cb22-5b3e-72c0b1cac8a6" xlink:to="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherCurrentAssets_080cc50d-ea94-9bfe-ded8-72c0b19e7c7f" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_2cd73b21-3173-f15e-e8fd-72c0b168c742" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1f2f887e-446b-cb22-5b3e-72c0b1cac8a6" xlink:to="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_2cd73b21-3173-f15e-e8fd-72c0b168c742" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerConsiderationTransferred" xlink:label="loc_dare_BusinessCombinationReverseMergerConsiderationTransferred_a256e9ad-cd6f-9dff-bc03-72c0b172fb4a" xlink:type="locator" />
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_dare_BusinessCombinationReverseMergerConsiderationTransferredEquityInterestsIssuedAndIssuable_a4af10dc-ad0e-fe73-239e-72c0b1cb5f9c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dare_BusinessCombinationReverseMergerConsiderationTransferred_a256e9ad-cd6f-9dff-bc03-72c0b172fb4a" xlink:to="loc_dare_BusinessCombinationReverseMergerConsiderationTransferredEquityInterestsIssuedAndIssuable_a4af10dc-ad0e-fe73-239e-72c0b1cb5f9c" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions" xlink:label="loc_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_592850e9-2989-5c1a-8649-72c0b1b2f960" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dare_BusinessCombinationReverseMergerConsiderationTransferred_a256e9ad-cd6f-9dff-bc03-72c0b172fb4a" xlink:to="loc_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_592850e9-2989-5c1a-8649-72c0b1b2f960" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://darebioscience.com/role/AcquisitionsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_dbfa1e75-5ca7-c18e-328b-85edddaeec4f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_dbfa1e75-5ca7-c18e-328b-85edddaeec4f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_b69fa2fe-d7f6-024f-39fb-29cad0c95853" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_b69fa2fe-d7f6-024f-39fb-29cad0c95853" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ddb0d184-2205-2a10-5b0e-faf2ccd717ae" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ddb0d184-2205-2a10-5b0e-faf2ccd717ae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_47ecca60-0dc8-25b2-6295-72031a21e0cb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_47ecca60-0dc8-25b2-6295-72031a21e0cb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_bba08e5f-78e8-6c25-01a4-6720051135cc" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_bba08e5f-78e8-6c25-01a4-6720051135cc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f0c68f4f-7ec1-d447-8ba7-0f2766abbe67" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f0c68f4f-7ec1-d447-8ba7-0f2766abbe67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_ea289a9d-deba-2cde-21e4-3d0ae7a1f011" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_PreferredStockValue_ea289a9d-deba-2cde-21e4-3d0ae7a1f011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_df284507-8ac7-eed1-41db-05e81b70be6d" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_df284507-8ac7-eed1-41db-05e81b70be6d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_38b416a4-4707-fba3-1084-9b8a37fd745a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_Depreciation_38b416a4-4707-fba3-1084-9b8a37fd745a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_0d30eb77-a66f-56df-77a0-7c7ad008c84e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_0d30eb77-a66f-56df-77a0-7c7ad008c84e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_5c03a9d6-b8ac-bbf3-746c-c7ea8b29c405" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_5c03a9d6-b8ac-bbf3-746c-c7ea8b29c405" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_f2f5c0d1-023d-ee70-251c-234ad5970f07" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_f2f5c0d1-023d-ee70-251c-234ad5970f07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_30b51b02-ce1a-7a8d-83e5-0db42b6e72ce" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_30b51b02-ce1a-7a8d-83e5-0db42b6e72ce" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges" xlink:label="loc_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_92C7E166063E511EA618140790539928" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_92C7E166063E511EA618140790539928" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_91c354d1-d18f-051e-80cb-f13c01058b9d" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_91c354d1-d18f-051e-80cb-f13c01058b9d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2d76eef5-dce5-0152-632e-9bab39da698c" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2d76eef5-dce5-0152-632e-9bab39da698c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a039d388-4db8-a076-4618-28899f6ce801" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a039d388-4db8-a076-4618-28899f6ce801" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_NonCashLeaseExpense" xlink:label="loc_dare_NonCashLeaseExpense_F79D2514A01FE8144D70A2E5D457459F" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_dare_NonCashLeaseExpense_F79D2514A01FE8144D70A2E5D457459F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="loc_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_1AC12F3F591158C2BD54E93554218F98" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_1AC12F3F591158C2BD54E93554218F98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_e0089888-8677-d95e-95e6-00fe630f2dcb" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_e0089888-8677-d95e-95e6-00fe630f2dcb" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://darebioscience.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a698662c-5d68-9b87-98fe-02485cda58f8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a698662c-5d68-9b87-98fe-02485cda58f8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseFee" xlink:label="loc_dare_LicenseFee_91568da7-7f44-9303-515a-72c0b1c0b502" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_dare_LicenseFee_91568da7-7f44-9303-515a-72c0b1c0b502" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_0d30eb77-a66f-56df-77a0-7c7ad008c84e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_0d30eb77-a66f-56df-77a0-7c7ad008c84e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_41e96f8d-e499-8de8-69a8-27f1c7d4df6e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_41e96f8d-e499-8de8-69a8-27f1c7d4df6e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b087c8bb-e0f6-4c7f-883c-027f52d32745" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b087c8bb-e0f6-4c7f-883c-027f52d32745" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://darebioscience.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/GoingConcern" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/GoingConcernAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/GrantAward" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/GrantAwardAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/LeasedProperties" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_198c3642-781c-a7d4-6f7d-8400ab29b18c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_198c3642-781c-a7d4-6f7d-8400ab29b18c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e0f20176-305e-e29f-ab09-584aea596901" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e0f20176-305e-e29f-ab09-584aea596901" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8e35e675-3955-0e95-1b9c-d08dd410962e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8e35e675-3955-0e95-1b9c-d08dd410962e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetailsCalc2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_28A824392AAD084C3186A2C976AAF1D3_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_28A824392AAD084C3186A2C976AAF1D3_dba432e7-eec4-e0dc-718d-f46fe263fe47" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_28A824392AAD084C3186A2C976AAF1D3_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_28A824392AAD084C3186A2C976AAF1D3_dba432e7-eec4-e0dc-718d-f46fe263fe47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_28A824392AAD084C3186A2C976AAF1D3_41784c6f-4555-af92-3354-8f8701c77f60" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_28A824392AAD084C3186A2C976AAF1D3_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_OperatingLeaseLiability_28A824392AAD084C3186A2C976AAF1D3_41784c6f-4555-af92-3354-8f8701c77f60" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/NetLossPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/NetLossPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/OrganizationAndDescriptionOfBusiness" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedToEmployeesAndDirectorsDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToStockOptionsGrantedToEmployeesAndDirectorsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryOfStockOptionActivityForAmended2014PlanAndRelatedInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/StockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/StockholdersEquityScheduleOfCommonStockWarrantsOutstandingDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/StockholdersEquityTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/SubsequentEvents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/SubsequentEventsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>dare-20190331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://darebioscience.com/role/Acquisitions" xlink:href="dare-20190331.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/AcquisitionsAdditionalInformationDetail" xlink:href="dare-20190331.xsd#AcquisitionsAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/AcquisitionsScheduleOfPurchasePriceConsiderationAllocationDetail" xlink:href="dare-20190331.xsd#AcquisitionsScheduleOfPurchasePriceConsiderationAllocationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/AcquisitionsTables" xlink:href="dare-20190331.xsd#AcquisitionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/CommitmentsAndContingencies" xlink:href="dare-20190331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="dare-20190331.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedBalanceSheets" xlink:href="dare-20190331.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="dare-20190331.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="dare-20190331.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="dare-20190331.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="dare-20190331.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/DocumentAndEntityInformation" xlink:href="dare-20190331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/GoingConcern" xlink:href="dare-20190331.xsd#GoingConcern" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/GoingConcernAdditionalInformationDetail" xlink:href="dare-20190331.xsd#GoingConcernAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/GrantAward" xlink:href="dare-20190331.xsd#GrantAward" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/GrantAwardAdditionalInformationDetail" xlink:href="dare-20190331.xsd#GrantAwardAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedProperties" xlink:href="dare-20190331.xsd#LeasedProperties" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesDetails" xlink:href="dare-20190331.xsd#LeasedPropertiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:href="dare-20190331.xsd#LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesTables" xlink:href="dare-20190331.xsd#LeasedPropertiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerShare" xlink:href="dare-20190331.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetail" xlink:href="dare-20190331.xsd#NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerShareTables" xlink:href="dare-20190331.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/OrganizationAndDescriptionOfBusiness" xlink:href="dare-20190331.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail" xlink:href="dare-20190331.xsd#OrganizationAndDescriptionOfBusinessAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensation" xlink:href="dare-20190331.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:href="dare-20190331.xsd#StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedToEmployeesAndDirectorsDetail" xlink:href="dare-20190331.xsd#StockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedToEmployeesAndDirectorsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToStockOptionsGrantedToEmployeesAndDirectorsDetails" xlink:href="dare-20190331.xsd#StockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToStockOptionsGrantedToEmployeesAndDirectorsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryOfStockOptionActivityForAmended2014PlanAndRelatedInformationDetail" xlink:href="dare-20190331.xsd#StockBasedCompensationSummaryOfStockOptionActivityForAmended2014PlanAndRelatedInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationTables" xlink:href="dare-20190331.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquity" xlink:href="dare-20190331.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetail" xlink:href="dare-20190331.xsd#StockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityScheduleOfCommonStockWarrantsOutstandingDetails" xlink:href="dare-20190331.xsd#StockholdersEquityScheduleOfCommonStockWarrantsOutstandingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityTables" xlink:href="dare-20190331.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/SubsequentEvents" xlink:href="dare-20190331.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/SubsequentEventsDetails" xlink:href="dare-20190331.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="dare-20190331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="dare-20190331.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="dare-20190331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/Acquisitions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/AcquisitionsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerLineItems" xlink:label="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:type="locator" />
    <link:loc xlink:href="dare-20190331.xsd#dare_ScheduleOfBusinessCombinationReverseMergerTable" xlink:label="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_645B69D56C766E61C186988EB36D30AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_645B69D56C766E61C186988EB36D30AC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_AC59DB811D6437EBFD98988EB36DECD6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_645B69D56C766E61C186988EB36D30AC" xlink:to="loc_dei_LegalEntityAxis_AC59DB811D6437EBFD98988EB36DECD6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_C46089FD10A5057C047E988EB36D6441_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_AC59DB811D6437EBFD98988EB36DECD6" xlink:to="loc_dei_EntityDomain_C46089FD10A5057C047E988EB36D6441_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_C46089FD10A5057C047E988EB36D6441" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_AC59DB811D6437EBFD98988EB36DECD6" xlink:to="loc_dei_EntityDomain_C46089FD10A5057C047E988EB36D6441" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_PrivateDareMember" xlink:label="loc_dare_PrivateDareMember_DFED8E4F3B4F936FB800988EB36D3330" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_C46089FD10A5057C047E988EB36D6441" xlink:to="loc_dare_PrivateDareMember_DFED8E4F3B4F936FB800988EB36D3330" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3864F8EA69C4B78CF526988EB36E8529" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_645B69D56C766E61C186988EB36D30AC" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3864F8EA69C4B78CF526988EB36E8529" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_175D11F404BBC458915C988EB36E3CCD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3864F8EA69C4B78CF526988EB36E8529" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_175D11F404BBC458915C988EB36E3CCD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_175D11F404BBC458915C988EB36E3CCD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3864F8EA69C4B78CF526988EB36E8529" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_175D11F404BBC458915C988EB36E3CCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_04852BF7BED96F142A60988EB36E859B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_175D11F404BBC458915C988EB36E3CCD" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_04852BF7BED96F142A60988EB36E859B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_B3A2A26371D6C381760E988EB36F5580" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_175D11F404BBC458915C988EB36E3CCD" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_B3A2A26371D6C381760E988EB36F5580" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_AE5555FF93BB0183415A988EB36F51C6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_645B69D56C766E61C186988EB36D30AC" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_AE5555FF93BB0183415A988EB36F51C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4A340493B2421FB3C53B988EB3743BBC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_AE5555FF93BB0183415A988EB36F51C6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4A340493B2421FB3C53B988EB3743BBC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4A340493B2421FB3C53B988EB3743BBC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_AE5555FF93BB0183415A988EB36F51C6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4A340493B2421FB3C53B988EB3743BBC" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_PearTreePharmaceuticalsIncMember" xlink:label="loc_dare_PearTreePharmaceuticalsIncMember_1D3D3D65D5F4FE52C972988EB374605F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4A340493B2421FB3C53B988EB3743BBC" xlink:to="loc_dare_PearTreePharmaceuticalsIncMember_1D3D3D65D5F4FE52C972988EB374605F" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_StockPurchaseAndOtherTransactionsCompletionDate" xlink:label="loc_dare_StockPurchaseAndOtherTransactionsCompletionDate_2FD650BC80B451FB1BBB988EB3758703" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_dare_StockPurchaseAndOtherTransactionsCompletionDate_2FD650BC80B451FB1BBB988EB3758703" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_StockPurchaseAgreementDate" xlink:label="loc_dare_StockPurchaseAgreementDate_0D96A20D08E7DD8BF98F988EB37536D3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_dare_StockPurchaseAgreementDate_0D96A20D08E7DD8BF98F988EB37536D3" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_70CDA993FC186A61A1EA988EB3750E2A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_70CDA993FC186A61A1EA988EB3750E2A" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions" xlink:label="loc_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_57BF742C12EA903748F0988EB375FFAD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_57BF742C12EA903748F0988EB375FFAD" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_StockOptionModificationApprovalDate" xlink:label="loc_dare_StockOptionModificationApprovalDate_15925D8B9D60D12E94D1988EB3755BAF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_dare_StockOptionModificationApprovalDate_15925D8B9D60D12E94D1988EB3755BAF" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost" xlink:label="loc_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost_1990FD2D97686FFFE94F988EB376C641" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost_1990FD2D97686FFFE94F988EB376C641" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerConsiderationTransferred" xlink:label="loc_dare_BusinessCombinationReverseMergerConsiderationTransferred_D2C07F46B05223B7A920988EB3765D31" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_dare_BusinessCombinationReverseMergerConsiderationTransferred_D2C07F46B05223B7A920988EB3765D31" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentLiabilities" xlink:label="loc_dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentLiabilities_1EC8DB7C04ADF087A120988EB3769395" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentLiabilities_1EC8DB7C04ADF087A120988EB3769395" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentAssets" xlink:label="loc_dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentAssets_20457E3812FA6A570674988EB37678E7" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentAssets_20457E3812FA6A570674988EB37678E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_760A67C44A9570E3D679988EB3767213" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_760A67C44A9570E3D679988EB3767213" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_2E1B6C00ADD6CABC6FB2988EB376580F" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_2E1B6C00ADD6CABC6FB2988EB376580F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_B1CC37A32599488000DE988EB37788C7" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_B1CC37A32599488000DE988EB37788C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_2BC79DED165162B89EF9988EB37795E8" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_us-gaap_Goodwill_2BC79DED165162B89EF9988EB37795E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:label="loc_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_14BB5311EFB2A013ED8A988EB377F9F3" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_14BB5311EFB2A013ED8A988EB377F9F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:label="loc_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_51F2AE5BFE3C002655A4988EB3774FEB" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_51F2AE5BFE3C002655A4988EB3774FEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_925E927365AE22BDE1E3988EB37732CC" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_925E927365AE22BDE1E3988EB37732CC" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_PotentialCashPaymentsToAcquireBusiness" xlink:label="loc_dare_PotentialCashPaymentsToAcquireBusiness_15E4CB794ABF01F66937988EB377F1CE" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_dare_PotentialCashPaymentsToAcquireBusiness_15E4CB794ABF01F66937988EB377F1CE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://darebioscience.com/role/AcquisitionsScheduleOfPurchasePriceConsiderationAllocationDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/AcquisitionsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="dare-20190331.xsd#dare_CommitmentsAndContingenciesLineItems" xlink:label="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:type="locator" />
    <link:loc xlink:href="dare-20190331.xsd#dare_CommitmentsAndContingenciesTable" xlink:label="loc_dare_CommitmentsAndContingenciesTable_38764C78A6D822C742859A560004D15D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_CommitmentsAndContingenciesTable_38764C78A6D822C742859A560004D15D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_5226954CA22B824B3BF29A5600047536" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_CommitmentsAndContingenciesTable_38764C78A6D822C742859A560004D15D" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_5226954CA22B824B3BF29A5600047536" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_1204BFFFC315296D30709A5600044412_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_5226954CA22B824B3BF29A5600047536" xlink:to="loc_us-gaap_ProjectMember_1204BFFFC315296D30709A5600044412_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_1204BFFFC315296D30709A5600044412" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_5226954CA22B824B3BF29A5600047536" xlink:to="loc_us-gaap_ProjectMember_1204BFFFC315296D30709A5600044412" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" xlink:label="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_98769D6901002B06AA839A560004BF7F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_1204BFFFC315296D30709A5600044412" xlink:to="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_98769D6901002B06AA839A560004BF7F" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_UponReachingCertainWorldwideNetSalesMilestonesMember" xlink:label="loc_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_50C351C39922DEDE006E9A5600043689" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_1204BFFFC315296D30709A5600044412" xlink:to="loc_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_50C351C39922DEDE006E9A5600043689" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_UponAchievementOfSpecifiedCommercializationMilestonesMember" xlink:label="loc_dare_UponAchievementOfSpecifiedCommercializationMilestonesMember_39B96A41607AD303190C9A7E3F93C74B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_1204BFFFC315296D30709A5600044412" xlink:to="loc_dare_UponAchievementOfSpecifiedCommercializationMilestonesMember_39B96A41607AD303190C9A7E3F93C74B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_C411893F38F50A8F70E79A5600042D01" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_CommitmentsAndContingenciesTable_38764C78A6D822C742859A560004D15D" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_C411893F38F50A8F70E79A5600042D01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_6A27705050929DD3B4929A5600040F89_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_C411893F38F50A8F70E79A5600042D01" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_6A27705050929DD3B4929A5600040F89_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_6A27705050929DD3B4929A5600040F89" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_C411893F38F50A8F70E79A5600042D01" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_6A27705050929DD3B4929A5600040F89" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_UponAchievingCertainCommercialMilestonesMember" xlink:label="loc_dare_UponAchievingCertainCommercialMilestonesMember_758ED85E852D6BDD8A1A9A560004A56D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_6A27705050929DD3B4929A5600040F89" xlink:to="loc_dare_UponAchievingCertainCommercialMilestonesMember_758ED85E852D6BDD8A1A9A560004A56D" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_UponSigningOfDevelopmentAndOptionAgreementMember" xlink:label="loc_dare_UponSigningOfDevelopmentAndOptionAgreementMember_6BFE06515276F44C86869A5600142816" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_6A27705050929DD3B4929A5600040F89" xlink:to="loc_dare_UponSigningOfDevelopmentAndOptionAgreementMember_6BFE06515276F44C86869A5600142816" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember" xlink:label="loc_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_A7F214FB1B5EA8C8B8DF9A5600144764" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_6A27705050929DD3B4929A5600040F89" xlink:to="loc_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_A7F214FB1B5EA8C8B8DF9A5600144764" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_UponAchievingCertainDevelopmentMilestonesMember" xlink:label="loc_dare_UponAchievingCertainDevelopmentMilestonesMember_6EF4E3B29F5F1C6E17339A560014E299" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_6A27705050929DD3B4929A5600040F89" xlink:to="loc_dare_UponAchievingCertainDevelopmentMilestonesMember_6EF4E3B29F5F1C6E17339A560014E299" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" xlink:label="loc_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_47601C1304B5433057CD9A56001444BE" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_6A27705050929DD3B4929A5600040F89" xlink:to="loc_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_47601C1304B5433057CD9A56001444BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A5F48F4F6A83318C78569A560014E751" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_CommitmentsAndContingenciesTable_38764C78A6D822C742859A560004D15D" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A5F48F4F6A83318C78569A560014E751" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3280554863447EC9E2B29A560014956C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A5F48F4F6A83318C78569A560014E751" xlink:to="loc_us-gaap_RelatedPartyDomain_3280554863447EC9E2B29A560014956C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3280554863447EC9E2B29A560014956C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A5F48F4F6A83318C78569A560014E751" xlink:to="loc_us-gaap_RelatedPartyDomain_3280554863447EC9E2B29A560014956C" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" xlink:label="loc_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_2BE18553FE162BBA3E429A560014A2AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3280554863447EC9E2B29A560014956C" xlink:to="loc_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_2BE18553FE162BBA3E429A560014A2AD" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_OrbisMember" xlink:label="loc_dare_OrbisMember_CD8CA70051BF6338844D9A560014F300" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3280554863447EC9E2B29A560014956C" xlink:to="loc_dare_OrbisMember_CD8CA70051BF6338844D9A560014F300" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_MilanaPharmMember" xlink:label="loc_dare_MilanaPharmMember_62745BECE235C3F3A8979A5600145009" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3280554863447EC9E2B29A560014956C" xlink:to="loc_dare_MilanaPharmMember_62745BECE235C3F3A8979A5600145009" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_HammockPharmaceuticalsInc.Member" xlink:label="loc_dare_HammockPharmaceuticalsInc.Member_0DD342201994E71532B99A5600143869" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3280554863447EC9E2B29A560014956C" xlink:to="loc_dare_HammockPharmaceuticalsInc.Member_0DD342201994E71532B99A5600143869" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_D2219D9BB0711A3D41E39A560014E021" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_CommitmentsAndContingenciesTable_38764C78A6D822C742859A560004D15D" xlink:to="loc_us-gaap_TypeOfArrangementAxis_D2219D9BB0711A3D41E39A560014E021" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19B1C2BB56A8648E26369A560014E530_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_D2219D9BB0711A3D41E39A560014E021" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19B1C2BB56A8648E26369A560014E530_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19B1C2BB56A8648E26369A560014E530" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_D2219D9BB0711A3D41E39A560014E021" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19B1C2BB56A8648E26369A560014E530" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_1D3E842F4EFE0E3BB98B9A5600143699" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19B1C2BB56A8648E26369A560014E530" xlink:to="loc_us-gaap_LicensingAgreementsMember_1D3E842F4EFE0E3BB98B9A5600143699" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_AssignmentAgreementMember" xlink:label="loc_dare_AssignmentAgreementMember_96857C39E55F481E65BD9A5600147302" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19B1C2BB56A8648E26369A560014E530" xlink:to="loc_dare_AssignmentAgreementMember_96857C39E55F481E65BD9A5600147302" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseAndCollaborationAgreementMember" xlink:label="loc_dare_LicenseAndCollaborationAgreementMember_B3E62F718A04FE6901589A56001426A0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19B1C2BB56A8648E26369A560014E530" xlink:to="loc_dare_LicenseAndCollaborationAgreementMember_B3E62F718A04FE6901589A56001426A0" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_DevelopmentAndOptionAgreementMember" xlink:label="loc_dare_DevelopmentAndOptionAgreementMember_5AA91B1D560B61EBD8E19A5600143961" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19B1C2BB56A8648E26369A560014E530" xlink:to="loc_dare_DevelopmentAndOptionAgreementMember_5AA91B1D560B61EBD8E19A5600143961" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_JuniperPharmaceuticalsInc.Member" xlink:label="loc_dare_JuniperPharmaceuticalsInc.Member_72D9E8CEA61D402E65569A560014A18B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19B1C2BB56A8648E26369A560014E530" xlink:to="loc_dare_JuniperPharmaceuticalsInc.Member_72D9E8CEA61D402E65569A560014A18B" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_JuniperPharmaceuticalsMember" xlink:label="loc_dare_JuniperPharmaceuticalsMember_50114727EDF37823F9FA9A560014A640" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19B1C2BB56A8648E26369A560014E530" xlink:to="loc_dare_JuniperPharmaceuticalsMember_50114727EDF37823F9FA9A560014A640" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A0158D96A503FC2CC3BE9A56001481A5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_CommitmentsAndContingenciesTable_38764C78A6D822C742859A560004D15D" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A0158D96A503FC2CC3BE9A56001481A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_EA4F5017546F337CFB1D9A560014C7D2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A0158D96A503FC2CC3BE9A56001481A5" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_EA4F5017546F337CFB1D9A560014C7D2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_EA4F5017546F337CFB1D9A560014C7D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A0158D96A503FC2CC3BE9A56001481A5" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_EA4F5017546F337CFB1D9A560014C7D2" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_ADVATecAgreementMember" xlink:label="loc_dare_ADVATecAgreementMember_969471B2814694C360949A560014892D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_EA4F5017546F337CFB1D9A560014C7D2" xlink:to="loc_dare_ADVATecAgreementMember_969471B2814694C360949A560014892D" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_ClinicalAndRegulatoryMilestonesMember" xlink:label="loc_dare_ClinicalAndRegulatoryMilestonesMember_E86D6B5DF4A6F3B1ADF99A560014C1B9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_EA4F5017546F337CFB1D9A560014C7D2" xlink:to="loc_dare_ClinicalAndRegulatoryMilestonesMember_E86D6B5DF4A6F3B1ADF99A560014C1B9" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_SalesMilestonesMember" xlink:label="loc_dare_SalesMilestonesMember_B041AF0AC6FB606A58559A560014BF2E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_EA4F5017546F337CFB1D9A560014C7D2" xlink:to="loc_dare_SalesMilestonesMember_B041AF0AC6FB606A58559A560014BF2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_354CDF255C05767CA7DF9A560014205B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_CommitmentsAndContingenciesTable_38764C78A6D822C742859A560004D15D" xlink:to="loc_srt_RangeAxis_354CDF255C05767CA7DF9A560014205B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_00B86CCB992413FA89259A560014701A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_354CDF255C05767CA7DF9A560014205B" xlink:to="loc_srt_RangeMember_00B86CCB992413FA89259A560014701A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_00B86CCB992413FA89259A560014701A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_354CDF255C05767CA7DF9A560014205B" xlink:to="loc_srt_RangeMember_00B86CCB992413FA89259A560014701A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_A2D17817970D187DE9509A560014D4C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_00B86CCB992413FA89259A560014701A" xlink:to="loc_srt_MinimumMember_A2D17817970D187DE9509A560014D4C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_093995F495C3B27368769A560014D735" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_00B86CCB992413FA89259A560014701A" xlink:to="loc_srt_MaximumMember_093995F495C3B27368769A560014D735" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_59563A40B783DB2D84E29A560014A873" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_CommitmentsAndContingenciesTable_38764C78A6D822C742859A560004D15D" xlink:to="loc_srt_ProductOrServiceAxis_59563A40B783DB2D84E29A560014A873" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_DA798FDC0287133632209A5600144AED_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_59563A40B783DB2D84E29A560014A873" xlink:to="loc_srt_ProductsAndServicesDomain_DA798FDC0287133632209A5600144AED_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_DA798FDC0287133632209A5600144AED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_59563A40B783DB2D84E29A560014A873" xlink:to="loc_srt_ProductsAndServicesDomain_DA798FDC0287133632209A5600144AED" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_OvapreneMember" xlink:label="loc_dare_OvapreneMember_C20E64FE5DE4896696749A560014E0FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_DA798FDC0287133632209A5600144AED" xlink:to="loc_dare_OvapreneMember_C20E64FE5DE4896696749A560014E0FC" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_NumberOfPatentsIssued" xlink:label="loc_dare_NumberOfPatentsIssued_E80D88B0800F8FB720519A5600149998" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_NumberOfPatentsIssued_E80D88B0800F8FB720519A5600149998" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_NumberOfPendingPatents" xlink:label="loc_dare_NumberOfPendingPatents_1BC6D5630F25BABAEFBC9A560024F8DC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_NumberOfPendingPatents_1BC6D5630F25BABAEFBC9A560024F8DC" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_NumberOfPatentsGranted" xlink:label="loc_dare_NumberOfPatentsGranted_45780CDADC370C3630C69A560024A0FB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_NumberOfPatentsGranted_45780CDADC370C3630C69A560024A0FB" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_NumberOfPatentApplications" xlink:label="loc_dare_NumberOfPatentApplications_928D3B145E48D14FAF449A5600244E6C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_NumberOfPatentApplications_928D3B145E48D14FAF449A5600244E6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_F535BA93A17C5B8828289A560024ABB9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_us-gaap_ContractualObligation_F535BA93A17C5B8828289A560024ABB9" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries" xlink:label="loc_dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries_52FAD2A4EB67740EB0699A5600246699" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries_52FAD2A4EB67740EB0699A5600246699" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_NumberOfDesignatedCountries" xlink:label="loc_dare_NumberOfDesignatedCountries_BB66673F56F2430B455D9A5600240127" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_NumberOfDesignatedCountries_BB66673F56F2430B455D9A5600240127" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_PercentageOfRoyaltyRate" xlink:label="loc_dare_PercentageOfRoyaltyRate_6C247173C8CDB6CBDF8A9A560024E842" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_PercentageOfRoyaltyRate_6C247173C8CDB6CBDF8A9A560024E842" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure" xlink:label="loc_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_40A4F7505810715F6AEA9A56002444E2" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_40A4F7505810715F6AEA9A56002444E2" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease" xlink:label="loc_dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease_C9A2BF985131F6143FFD9A560024E498" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease_C9A2BF985131F6143FFD9A560024E498" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement" xlink:label="loc_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_00DFD9685A4BF88AB74D9A5600245D3A" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_00DFD9685A4BF88AB74D9A5600245D3A" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_MilestonePaymentsContingentAmount" xlink:label="loc_dare_MilestonePaymentsContingentAmount_B78283700539874CDE8F9A56002440B7" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_MilestonePaymentsContingentAmount_B78283700539874CDE8F9A56002440B7" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_SecuredInvestmentRequiredForLicenseAgreement" xlink:label="loc_dare_SecuredInvestmentRequiredForLicenseAgreement_872582390F9D53AF2AAE9A560024DD41" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_SecuredInvestmentRequiredForLicenseAgreement_872582390F9D53AF2AAE9A560024DD41" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseAgreementExpirationPeriod" xlink:label="loc_dare_LicenseAgreementExpirationPeriod_A0108DD623BAE0B6903F9A560024047E" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_LicenseAgreementExpirationPeriod_A0108DD623BAE0B6903F9A560024047E" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval" xlink:label="loc_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval_FBB837D21481090AF7219A560024FFF8" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval_FBB837D21481090AF7219A560024FFF8" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval" xlink:label="loc_dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval_76CCC3476D3257EABB9C9A56002489B5" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval_76CCC3476D3257EABB9C9A56002489B5" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries" xlink:label="loc_dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries_F124726C3421E867D1CD9A5600240049" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries_F124726C3421E867D1CD9A5600240049" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_NoticePeriodForTerminationOfAgreementForBothParties" xlink:label="loc_dare_NoticePeriodForTerminationOfAgreementForBothParties_CF6435B3AEFC7CBAB3F79A56002444A9" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_NoticePeriodForTerminationOfAgreementForBothParties_CF6435B3AEFC7CBAB3F79A56002444A9" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_ResearchAndDevelopmentMilestonePayment" xlink:label="loc_dare_ResearchAndDevelopmentMilestonePayment_EC3B4824F10C9177D2209A560024FEBE" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_ResearchAndDevelopmentMilestonePayment_EC3B4824F10C9177D2209A560024FEBE" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_CommencementPeriodForStageTwoUponAchievementOfStageOne" xlink:label="loc_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_5810BD177D60B22254289A5600246007" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_5810BD177D60B22254289A5600246007" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_UpfrontLicenseFeePaid" xlink:label="loc_dare_UpfrontLicenseFeePaid_5D7D2EC543FF757133159A5600242C6F" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_UpfrontLicenseFeePaid_5D7D2EC543FF757133159A5600242C6F" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne" xlink:label="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_56BD0638CD219DCA6E4C9A5600240E89" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_56BD0638CD219DCA6E4C9A5600240E89" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" xlink:label="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_3D2EBD3A7E3D9B6AAA1A9A5600245A33" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_3D2EBD3A7E3D9B6AAA1A9A5600245A33" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_MaximumPotentialMilestonePayments" xlink:label="loc_dare_MaximumPotentialMilestonePayments_1E20C25B4B9697F644BD9A5600242F55" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_MaximumPotentialMilestonePayments_1E20C25B4B9697F644BD9A5600242F55" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess" xlink:label="loc_dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess_F6B481148AECD100D2579A560024091F" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess_F6B481148AECD100D2579A560024091F" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation" xlink:label="loc_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation_E8FDC8D4D591972F80549A56002430AE" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation_E8FDC8D4D591972F80549A56002430AE" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_PeriodOfDismissalOfBankruptcyPetition" xlink:label="loc_dare_PeriodOfDismissalOfBankruptcyPetition_9A66142D7D6466E0B3849A5600334DD1" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_PeriodOfDismissalOfBankruptcyPetition_9A66142D7D6466E0B3849A5600334DD1" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation" xlink:label="loc_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation_3172676B13C81A8A8C329A560033F776" xlink:type="locator" />
    <link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation_3172676B13C81A8A8C329A560033F776" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseAgreementNoticePeriodOfTermination" xlink:label="loc_dare_LicenseAgreementNoticePeriodOfTermination_9DD65469CF7431C21BEE9A5600339C9B" xlink:type="locator" />
    <link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_LicenseAgreementNoticePeriodOfTermination_9DD65469CF7431C21BEE9A5600339C9B" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseFee" xlink:label="loc_dare_LicenseFee_EC70CA24DF2CC78006AD9A5600331328" xlink:type="locator" />
    <link:definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_LicenseFee_EC70CA24DF2CC78006AD9A5600331328" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseFeeToBePaidUponContingency" xlink:label="loc_dare_LicenseFeeToBePaidUponContingency_EC3867FD1715A408E3DB9A560033532E" xlink:type="locator" />
    <link:definitionArc order="31" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_LicenseFeeToBePaidUponContingency_EC3867FD1715A408E3DB9A560033532E" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_ProceedsRaisedFromEquityFinancing" xlink:label="loc_dare_ProceedsRaisedFromEquityFinancing_E39FDEFAFEF3860A55E39A5600336B8F" xlink:type="locator" />
    <link:definitionArc order="32" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_ProceedsRaisedFromEquityFinancing_E39FDEFAFEF3860A55E39A5600336B8F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://darebioscience.com/role/ConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_9A2DA989A8F8700921189A56025F903C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_0D8407D9AF6A49CC828C9A56025FDE1D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9A2DA989A8F8700921189A56025F903C" xlink:to="loc_us-gaap_StatementTable_0D8407D9AF6A49CC828C9A56025FDE1D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_C9B92ABFCFCA94D0DC759A56025FC687" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0D8407D9AF6A49CC828C9A56025FDE1D" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_C9B92ABFCFCA94D0DC759A56025FC687" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_0A1E880EE9B0B38CC5939A56025F55CD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_C9B92ABFCFCA94D0DC759A56025FC687" xlink:to="loc_us-gaap_EquityComponentDomain_0A1E880EE9B0B38CC5939A56025F55CD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_0A1E880EE9B0B38CC5939A56025F55CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_C9B92ABFCFCA94D0DC759A56025FC687" xlink:to="loc_us-gaap_EquityComponentDomain_0A1E880EE9B0B38CC5939A56025F55CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_5655E775302341B229589A56025FC4E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0A1E880EE9B0B38CC5939A56025F55CD" xlink:to="loc_us-gaap_CommonStockMember_5655E775302341B229589A56025FC4E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_A4269AD8803217CE0CD09A56025FAA1E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0A1E880EE9B0B38CC5939A56025F55CD" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_A4269AD8803217CE0CD09A56025FAA1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3C1E4AFF00DDAC8931BE9A56025F39ED" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0A1E880EE9B0B38CC5939A56025F55CD" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3C1E4AFF00DDAC8931BE9A56025F39ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_ED1DB1061AF786E377429A56025FC1F2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0A1E880EE9B0B38CC5939A56025F55CD" xlink:to="loc_us-gaap_RetainedEarningsMember_ED1DB1061AF786E377429A56025FC1F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9A2DA989A8F8700921189A56025F903C" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_B4A669E84ED4CD87D93C9A56025FB2C6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25" xlink:to="loc_us-gaap_SharesOutstanding_B4A669E84ED4CD87D93C9A56025FB2C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_7F685565E0403878AC429A56025F0EF6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25" xlink:to="loc_us-gaap_StockholdersEquity_7F685565E0403878AC429A56025F0EF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5A6FAB27765356E493E89A56025F1DDB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5A6FAB27765356E493E89A56025F1DDB" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" xlink:label="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_A57FC78530EFE2FD37759A5A97200D70" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25" xlink:to="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_A57FC78530EFE2FD37759A5A97200D70" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued" xlink:label="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued_2F693C9DFD1A02DFA3339A5A0441C9EC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25" xlink:to="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued_2F693C9DFD1A02DFA3339A5A0441C9EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2F6D6B4B0041ECC832599A5BCDACC151" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2F6D6B4B0041ECC832599A5BCDACC151" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_F9F3FF8C2B45048CCB999A5B3F34E3D9" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_F9F3FF8C2B45048CCB999A5B3F34E3D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_09D5EBDF1E1FFB0810DE9A56025F8EA4" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25" xlink:to="loc_us-gaap_NetIncomeLoss_09D5EBDF1E1FFB0810DE9A56025F8EA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_17A93AB3F7B86CAE5C9E9A56025FC352" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_17A93AB3F7B86CAE5C9E9A56025FC352" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://darebioscience.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/GoingConcern" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/GoingConcernAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_C6A9DC7E6F70E08E59849A66100563DE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_C65FCFC94C7020C17E409A661003757E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C6A9DC7E6F70E08E59849A66100563DE" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_C65FCFC94C7020C17E409A661003757E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1D0B60342F347D546F3C9A84699279BB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_C65FCFC94C7020C17E409A661003757E" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1D0B60342F347D546F3C9A84699279BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0970354C206E9163AC609A8469964378_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1D0B60342F347D546F3C9A84699279BB" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0970354C206E9163AC609A8469964378_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0970354C206E9163AC609A8469964378" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1D0B60342F347D546F3C9A84699279BB" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0970354C206E9163AC609A8469964378" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_5D743DF17E387FF9F7049A849F42EB6D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0970354C206E9163AC609A8469964378" xlink:to="loc_us-gaap_SubsequentEventMember_5D743DF17E387FF9F7049A849F42EB6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_6A7A9765388363B2681C9A661723B3F9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_C65FCFC94C7020C17E409A661003757E" xlink:to="loc_srt_ProductOrServiceAxis_6A7A9765388363B2681C9A661723B3F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_5451778105F9C033F0509A66172B02B6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6A7A9765388363B2681C9A661723B3F9" xlink:to="loc_srt_ProductsAndServicesDomain_5451778105F9C033F0509A66172B02B6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_5451778105F9C033F0509A66172B02B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6A7A9765388363B2681C9A661723B3F9" xlink:to="loc_srt_ProductsAndServicesDomain_5451778105F9C033F0509A66172B02B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_08ABC9667536FF65301A9A661D8A1F59" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5451778105F9C033F0509A66172B02B6" xlink:to="loc_us-gaap_GrantMember_08ABC9667536FF65301A9A661D8A1F59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_701EF41A3A73139ED7D89A6615ECC4C7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_C65FCFC94C7020C17E409A661003757E" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_701EF41A3A73139ED7D89A6615ECC4C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_72D8568E08EF024BCD5F9A6615F0D669_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_701EF41A3A73139ED7D89A6615ECC4C7" xlink:to="loc_us-gaap_RelatedPartyDomain_72D8568E08EF024BCD5F9A6615F0D669_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_72D8568E08EF024BCD5F9A6615F0D669" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_701EF41A3A73139ED7D89A6615ECC4C7" xlink:to="loc_us-gaap_RelatedPartyDomain_72D8568E08EF024BCD5F9A6615F0D669" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_NationalInstitutesOfHealthMember" xlink:label="loc_dare_NationalInstitutesOfHealthMember_2A3CE531656E9E3BF9449A66190FDBF1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_72D8568E08EF024BCD5F9A6615F0D669" xlink:to="loc_dare_NationalInstitutesOfHealthMember_2A3CE531656E9E3BF9449A66190FDBF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareTrustFundAxis" xlink:label="loc_us-gaap_HealthCareTrustFundAxis_0621D943414831A142E39A6615507190" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_C65FCFC94C7020C17E409A661003757E" xlink:to="loc_us-gaap_HealthCareTrustFundAxis_0621D943414831A142E39A6615507190" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareTrustFundNameDomain" xlink:label="loc_us-gaap_HealthCareTrustFundNameDomain_4A026E9C487D6AA2E51C9A661550A251_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HealthCareTrustFundAxis_0621D943414831A142E39A6615507190" xlink:to="loc_us-gaap_HealthCareTrustFundNameDomain_4A026E9C487D6AA2E51C9A661550A251_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareTrustFundNameDomain" xlink:label="loc_us-gaap_HealthCareTrustFundNameDomain_4A026E9C487D6AA2E51C9A661550A251" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HealthCareTrustFundAxis_0621D943414831A142E39A6615507190" xlink:to="loc_us-gaap_HealthCareTrustFundNameDomain_4A026E9C487D6AA2E51C9A661550A251" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember" xlink:label="loc_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_D6372A6B44BC874CA8699A661A89793F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareTrustFundNameDomain_4A026E9C487D6AA2E51C9A661550A251" xlink:to="loc_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_D6372A6B44BC874CA8699A661A89793F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B5D20EE39CE78FA0D84F9A6614AC84FE" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_C65FCFC94C7020C17E409A661003757E" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B5D20EE39CE78FA0D84F9A6614AC84FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0525603D6DAB9EBAB3859A6614B4D8C5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B5D20EE39CE78FA0D84F9A6614AC84FE" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0525603D6DAB9EBAB3859A6614B4D8C5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0525603D6DAB9EBAB3859A6614B4D8C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B5D20EE39CE78FA0D84F9A6614AC84FE" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0525603D6DAB9EBAB3859A6614B4D8C5" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember" xlink:label="loc_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_A2B9627521A2233D65669A6617D1AFBC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0525603D6DAB9EBAB3859A6614B4D8C5" xlink:to="loc_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_A2B9627521A2233D65669A6617D1AFBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1F34DFD916C3E99152E79A56024F6D47" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C6A9DC7E6F70E08E59849A66100563DE" xlink:to="loc_us-gaap_NetIncomeLoss_1F34DFD916C3E99152E79A56024F6D47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_108E27EC00EFB037FDAD9A56024F194D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C6A9DC7E6F70E08E59849A66100563DE" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_108E27EC00EFB037FDAD9A56024F194D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C843732967C5D5C961E79A56024F68CD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C6A9DC7E6F70E08E59849A66100563DE" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C843732967C5D5C961E79A56024F68CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5634AEF9A0FD6D808D4B9A56024FB6C2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C6A9DC7E6F70E08E59849A66100563DE" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5634AEF9A0FD6D808D4B9A56024FB6C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_758204A0F638657C87D49A66138723AC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C6A9DC7E6F70E08E59849A66100563DE" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_758204A0F638657C87D49A66138723AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="loc_us-gaap_GrantsReceivable_F41D57809178DD9499289A6614465A5F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C6A9DC7E6F70E08E59849A66100563DE" xlink:to="loc_us-gaap_GrantsReceivable_F41D57809178DD9499289A6614465A5F" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_ReimbursementOfGrantExpensesReceivable" xlink:label="loc_dare_ReimbursementOfGrantExpensesReceivable_86E85800438703E017EF9A696B36EA73" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C6A9DC7E6F70E08E59849A66100563DE" xlink:to="loc_dare_ReimbursementOfGrantExpensesReceivable_86E85800438703E017EF9A696B36EA73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3FDA002F9E23F13D25AB9A56024F7FAB" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C6A9DC7E6F70E08E59849A66100563DE" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3FDA002F9E23F13D25AB9A56024F7FAB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://darebioscience.com/role/GrantAward" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/GrantAwardAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4550E0A5A1BED752DA3D4B45614FBAFE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_DBA46B363FAED29C336A4B4561485874" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4550E0A5A1BED752DA3D4B45614FBAFE" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_DBA46B363FAED29C336A4B4561485874" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_23E9D3403EE0E44381D34B44EE205A3E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_DBA46B363FAED29C336A4B4561485874" xlink:to="loc_srt_ProductOrServiceAxis_23E9D3403EE0E44381D34B44EE205A3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_7FF817D75A3AA15751184B44EE205F33_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_23E9D3403EE0E44381D34B44EE205A3E" xlink:to="loc_srt_ProductsAndServicesDomain_7FF817D75A3AA15751184B44EE205F33_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_7FF817D75A3AA15751184B44EE205F33" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_23E9D3403EE0E44381D34B44EE205A3E" xlink:to="loc_srt_ProductsAndServicesDomain_7FF817D75A3AA15751184B44EE205F33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_C39998FEC7B17BD7EEFE4B44EE20A3A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7FF817D75A3AA15751184B44EE205F33" xlink:to="loc_us-gaap_GrantMember_C39998FEC7B17BD7EEFE4B44EE20A3A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareTrustFundAxis" xlink:label="loc_us-gaap_HealthCareTrustFundAxis_70847F1A29F1EA462DFF4B44EE1F1692" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_DBA46B363FAED29C336A4B4561485874" xlink:to="loc_us-gaap_HealthCareTrustFundAxis_70847F1A29F1EA462DFF4B44EE1F1692" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareTrustFundNameDomain" xlink:label="loc_us-gaap_HealthCareTrustFundNameDomain_E66BD0AB10830789F37D4B44EE1F29F1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HealthCareTrustFundAxis_70847F1A29F1EA462DFF4B44EE1F1692" xlink:to="loc_us-gaap_HealthCareTrustFundNameDomain_E66BD0AB10830789F37D4B44EE1F29F1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareTrustFundNameDomain" xlink:label="loc_us-gaap_HealthCareTrustFundNameDomain_E66BD0AB10830789F37D4B44EE1F29F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HealthCareTrustFundAxis_70847F1A29F1EA462DFF4B44EE1F1692" xlink:to="loc_us-gaap_HealthCareTrustFundNameDomain_E66BD0AB10830789F37D4B44EE1F29F1" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember" xlink:label="loc_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_D2512C37158110EFA1FC4B44EE2084B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareTrustFundNameDomain_E66BD0AB10830789F37D4B44EE1F29F1" xlink:to="loc_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_D2512C37158110EFA1FC4B44EE2084B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5C779FA6DDDEA1F81ECC4B44EE1EF86A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_DBA46B363FAED29C336A4B4561485874" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5C779FA6DDDEA1F81ECC4B44EE1EF86A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1B356045613E4AAC4DD34B44EE1E3F55_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5C779FA6DDDEA1F81ECC4B44EE1EF86A" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1B356045613E4AAC4DD34B44EE1E3F55_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1B356045613E4AAC4DD34B44EE1E3F55" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5C779FA6DDDEA1F81ECC4B44EE1EF86A" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1B356045613E4AAC4DD34B44EE1E3F55" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember" xlink:label="loc_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_9A22F295407FDC669C894B44EE1E5360" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1B356045613E4AAC4DD34B44EE1E3F55" xlink:to="loc_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_9A22F295407FDC669C894B44EE1E5360" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember" xlink:label="loc_dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember_08BD4C50CB61002D96B44B44EE1F286B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1B356045613E4AAC4DD34B44EE1E3F55" xlink:to="loc_dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember_08BD4C50CB61002D96B44B44EE1F286B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1B6FBF7545ABAE4480B94B44EE1D472A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_DBA46B363FAED29C336A4B4561485874" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1B6FBF7545ABAE4480B94B44EE1D472A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_F7EB2DD3EF8D519F85924B44EE1D3335_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1B6FBF7545ABAE4480B94B44EE1D472A" xlink:to="loc_us-gaap_RelatedPartyDomain_F7EB2DD3EF8D519F85924B44EE1D3335_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_F7EB2DD3EF8D519F85924B44EE1D3335" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1B6FBF7545ABAE4480B94B44EE1D472A" xlink:to="loc_us-gaap_RelatedPartyDomain_F7EB2DD3EF8D519F85924B44EE1D3335" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_NationalInstitutesOfHealthMember" xlink:label="loc_dare_NationalInstitutesOfHealthMember_C98F76402D2DF376E0594B44EE1D96E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_F7EB2DD3EF8D519F85924B44EE1D3335" xlink:to="loc_dare_NationalInstitutesOfHealthMember_C98F76402D2DF376E0594B44EE1D96E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EAA3DBB7DCB745D015344B44EE21580A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4550E0A5A1BED752DA3D4B45614FBAFE" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EAA3DBB7DCB745D015344B44EE21580A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="loc_us-gaap_GrantsReceivable_A700E7260F051B02470F4B44EE211D07" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4550E0A5A1BED752DA3D4B45614FBAFE" xlink:to="loc_us-gaap_GrantsReceivable_A700E7260F051B02470F4B44EE211D07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_BAB8B5647671C3BAB84D4B44EE21F949" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4550E0A5A1BED752DA3D4B45614FBAFE" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_BAB8B5647671C3BAB84D4B44EE21F949" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_ReimbursementOfGrantExpensesReceivable" xlink:label="loc_dare_ReimbursementOfGrantExpensesReceivable_47DA93AB45B5EFA55C6A4B44EE216660" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4550E0A5A1BED752DA3D4B45614FBAFE" xlink:to="loc_dare_ReimbursementOfGrantExpensesReceivable_47DA93AB45B5EFA55C6A4B44EE216660" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://darebioscience.com/role/LeasedProperties" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/LeasedPropertiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/LeasedPropertiesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/NetLossPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B0F328129B771F7D176151507F8BA25B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A5F31AE7E735460E67C551507F8ADD30" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B0F328129B771F7D176151507F8BA25B" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A5F31AE7E735460E67C551507F8ADD30" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_654A15EAD8614C64865E51507F8A5EAC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A5F31AE7E735460E67C551507F8ADD30" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_654A15EAD8614C64865E51507F8A5EAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DEC83A89638BA53C6CDD51507F8B632A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_654A15EAD8614C64865E51507F8A5EAC" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DEC83A89638BA53C6CDD51507F8B632A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DEC83A89638BA53C6CDD51507F8B632A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_654A15EAD8614C64865E51507F8A5EAC" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DEC83A89638BA53C6CDD51507F8B632A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_01255FC7C91B9183CB1351507F8B65A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DEC83A89638BA53C6CDD51507F8B632A" xlink:to="loc_us-gaap_EmployeeStockOptionMember_01255FC7C91B9183CB1351507F8B65A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_F8FF28106EE0E5A8D6EB51507F8B530F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DEC83A89638BA53C6CDD51507F8B632A" xlink:to="loc_us-gaap_WarrantMember_F8FF28106EE0E5A8D6EB51507F8B530F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_29798CE20C589852D4B951507F8C0398" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B0F328129B771F7D176151507F8BA25B" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_29798CE20C589852D4B951507F8C0398" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://darebioscience.com/role/NetLossPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/OrganizationAndDescriptionOfBusiness" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_25A683F3ED379DEBFC3E9A5601BB4B53" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_25A683F3ED379DEBFC3E9A5601BB4B53" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_48870CCDDB55825428849A5601BB2BB7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_25A683F3ED379DEBFC3E9A5601BB4B53" xlink:to="loc_us-gaap_PlanNameAxis_48870CCDDB55825428849A5601BB2BB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_593BB9E5B2A015DC9AA09A5601BB13C4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_48870CCDDB55825428849A5601BB2BB7" xlink:to="loc_us-gaap_PlanNameDomain_593BB9E5B2A015DC9AA09A5601BB13C4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_593BB9E5B2A015DC9AA09A5601BB13C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_48870CCDDB55825428849A5601BB2BB7" xlink:to="loc_us-gaap_PlanNameDomain_593BB9E5B2A015DC9AA09A5601BB13C4" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_TwoThousandAndFifteenStockIncentivePlanMember" xlink:label="loc_dare_TwoThousandAndFifteenStockIncentivePlanMember_35D3C39ECC2840F652749A5601BB6815" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_593BB9E5B2A015DC9AA09A5601BB13C4" xlink:to="loc_dare_TwoThousandAndFifteenStockIncentivePlanMember_35D3C39ECC2840F652749A5601BB6815" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:label="loc_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_459BAB6B343E1E39EC069A5601BB289D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_593BB9E5B2A015DC9AA09A5601BB13C4" xlink:to="loc_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_459BAB6B343E1E39EC069A5601BB289D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_240E2E434E2C89A4EB4B9A5601BBEDB6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_25A683F3ED379DEBFC3E9A5601BB4B53" xlink:to="loc_us-gaap_AwardTypeAxis_240E2E434E2C89A4EB4B9A5601BBEDB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_139E42EC4CA7A34D0A189A5601BBE29C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_240E2E434E2C89A4EB4B9A5601BBEDB6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_139E42EC4CA7A34D0A189A5601BBE29C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_139E42EC4CA7A34D0A189A5601BBE29C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_240E2E434E2C89A4EB4B9A5601BBEDB6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_139E42EC4CA7A34D0A189A5601BBE29C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2F6055154DFD13FA3FA19A5601BB3874" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_139E42EC4CA7A34D0A189A5601BBE29C" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2F6055154DFD13FA3FA19A5601BB3874" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_22B1F453F634535B5F6D9A5601BBEA70" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_139E42EC4CA7A34D0A189A5601BBE29C" xlink:to="loc_us-gaap_RestrictedStockMember_22B1F453F634535B5F6D9A5601BBEA70" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4217EA82834CB80D25A39A5601BBC2E6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_25A683F3ED379DEBFC3E9A5601BB4B53" xlink:to="loc_dei_LegalEntityAxis_4217EA82834CB80D25A39A5601BBC2E6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_ACE2091CE3A407297A639A5601BB1019_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_4217EA82834CB80D25A39A5601BBC2E6" xlink:to="loc_dei_EntityDomain_ACE2091CE3A407297A639A5601BB1019_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_ACE2091CE3A407297A639A5601BB1019" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_4217EA82834CB80D25A39A5601BBC2E6" xlink:to="loc_dei_EntityDomain_ACE2091CE3A407297A639A5601BB1019" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_PrivateDareMember" xlink:label="loc_dare_PrivateDareMember_078104A728AF77BAA2939A5601BB852F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_ACE2091CE3A407297A639A5601BB1019" xlink:to="loc_dare_PrivateDareMember_078104A728AF77BAA2939A5601BB852F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_45FD996FCF17AC5EB0A49A5601BB7622" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_45FD996FCF17AC5EB0A49A5601BB7622" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_CF43963E2637D82475139A5601BBFC2A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_CF43963E2637D82475139A5601BBFC2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_22E2D28E31EED35999179A5601BB8ED5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_22E2D28E31EED35999179A5601BB8ED5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_EEE994B2C10CBD6737AD9A5601BB869E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_EEE994B2C10CBD6737AD9A5601BB869E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4BD30893B58BBCD31ABB9A5601BBFE29" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4BD30893B58BBCD31ABB9A5601BBFE29" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_OfferingPeriod" xlink:label="loc_dare_OfferingPeriod_9FB0BCD7BD8A0DAE83B29A5601BBD38A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_dare_OfferingPeriod_9FB0BCD7BD8A0DAE83B29A5601BBD38A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B469C966899CB3DDAE989A5601BB87E8" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B469C966899CB3DDAE989A5601BB87E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7D5A95EECA1BBF6522DE9A5601BBB8C5" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7D5A95EECA1BBF6522DE9A5601BBB8C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4C79DB18BAFDB9C7E8D89A5601BB0868" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4C79DB18BAFDB9C7E8D89A5601BB0868" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_679E315D7AFC0ECED3319A5601BBD58B" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_679E315D7AFC0ECED3319A5601BBD58B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_9DC187901A1D38110D809A6EE7F997B6" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_9DC187901A1D38110D809A6EE7F997B6" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_PeriodOfTerminationOfStockOptionsVestedAfterTerminationDate" xlink:label="loc_dare_PeriodOfTerminationOfStockOptionsVestedAfterTerminationDate_1CE2001FEDDDC23D0DD59A5601CB739D" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_dare_PeriodOfTerminationOfStockOptionsVestedAfterTerminationDate_1CE2001FEDDDC23D0DD59A5601CB739D" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_UnamortizedFairValueExpenseInStockPurchaseTransaction" xlink:label="loc_dare_UnamortizedFairValueExpenseInStockPurchaseTransaction_DC867681B9F98682B0949A5601CB6549" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_dare_UnamortizedFairValueExpenseInStockPurchaseTransaction_DC867681B9F98682B0949A5601CB6549" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2BB48A3A6E3037F185429A5601CB6EC7" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2BB48A3A6E3037F185429A5601CB6EC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_A428667660A593200A5E9A5601CB637F" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_A428667660A593200A5E9A5601CB637F" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_WeightedAverageAmortizationPeriod" xlink:label="loc_dare_WeightedAverageAmortizationPeriod_6259CC02B14BEC3204FE9A5601CB8829" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_dare_WeightedAverageAmortizationPeriod_6259CC02B14BEC3204FE9A5601CB8829" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_2CF1273DBD2CFE613F799A5601CB5726" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_us-gaap_CommonStockSharesIssued_2CF1273DBD2CFE613F799A5601CB5726" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedToEmployeesAndDirectorsDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToStockOptionsGrantedToEmployeesAndDirectorsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_91E51F8F1EA945AC22EF51507FE271E7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8DDEB45E6CB8974EEF1751507FE06CFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_91E51F8F1EA945AC22EF51507FE271E7" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8DDEB45E6CB8974EEF1751507FE06CFD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_B7FF42C1898AA5F554D751507FE0B421" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8DDEB45E6CB8974EEF1751507FE06CFD" xlink:to="loc_us-gaap_AwardTypeAxis_B7FF42C1898AA5F554D751507FE0B421" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_987C1ED52C47C5238FD051507FE1688B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_B7FF42C1898AA5F554D751507FE0B421" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_987C1ED52C47C5238FD051507FE1688B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_987C1ED52C47C5238FD051507FE1688B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_B7FF42C1898AA5F554D751507FE0B421" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_987C1ED52C47C5238FD051507FE1688B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_EADFC24BC492ECCAA43A51507FE15C87" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_987C1ED52C47C5238FD051507FE1688B" xlink:to="loc_us-gaap_EmployeeStockOptionMember_EADFC24BC492ECCAA43A51507FE15C87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_660C9161C9051B9E94E551507FE19B01" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8DDEB45E6CB8974EEF1751507FE06CFD" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_660C9161C9051B9E94E551507FE19B01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F84B87542D228B3C61CF51507FE1D584_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_660C9161C9051B9E94E551507FE19B01" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F84B87542D228B3C61CF51507FE1D584_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F84B87542D228B3C61CF51507FE1D584" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_660C9161C9051B9E94E551507FE19B01" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F84B87542D228B3C61CF51507FE1D584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_D015CAA557C9FBEB6C0851507FE2BE04" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F84B87542D228B3C61CF51507FE1D584" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_D015CAA557C9FBEB6C0851507FE2BE04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_50AAB4692214FEBAAEF651507FE2D66B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F84B87542D228B3C61CF51507FE1D584" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_50AAB4692214FEBAAEF651507FE2D66B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5E79B67084FA56C06A0651507FE2C39D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_91E51F8F1EA945AC22EF51507FE271E7" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5E79B67084FA56C06A0651507FE2C39D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryOfStockOptionActivityForAmended2014PlanAndRelatedInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5967506064B4192D93969A56017D7955" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1351860212A78057BB199A56016DE44F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5967506064B4192D93969A56017D7955" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1351860212A78057BB199A56016DE44F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4AE7E7134C1EEBB0FF419A56016D94C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1351860212A78057BB199A56016DE44F" xlink:to="loc_dei_LegalEntityAxis_4AE7E7134C1EEBB0FF419A56016D94C3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_5559E8D22A53372A34069A56017DE2F1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_4AE7E7134C1EEBB0FF419A56016D94C3" xlink:to="loc_dei_EntityDomain_5559E8D22A53372A34069A56017DE2F1_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_5559E8D22A53372A34069A56017DE2F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_4AE7E7134C1EEBB0FF419A56016D94C3" xlink:to="loc_dei_EntityDomain_5559E8D22A53372A34069A56017DE2F1" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_PrivateDareMember" xlink:label="loc_dare_PrivateDareMember_FF5AE179D8D86A2385089A56017D2FDC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5559E8D22A53372A34069A56017DE2F1" xlink:to="loc_dare_PrivateDareMember_FF5AE179D8D86A2385089A56017D2FDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_5E2B0D8020E9EAD2EE7E9A56017D7ED2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1351860212A78057BB199A56016DE44F" xlink:to="loc_us-gaap_PlanNameAxis_5E2B0D8020E9EAD2EE7E9A56017D7ED2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_A63D6CF1F1EC078D76CF9A56017DA75E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_5E2B0D8020E9EAD2EE7E9A56017D7ED2" xlink:to="loc_us-gaap_PlanNameDomain_A63D6CF1F1EC078D76CF9A56017DA75E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_A63D6CF1F1EC078D76CF9A56017DA75E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_5E2B0D8020E9EAD2EE7E9A56017D7ED2" xlink:to="loc_us-gaap_PlanNameDomain_A63D6CF1F1EC078D76CF9A56017DA75E" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_TwoThousandAndFifteenStockIncentivePlanMember" xlink:label="loc_dare_TwoThousandAndFifteenStockIncentivePlanMember_C900E1E039880E0362609A56017D0554" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_A63D6CF1F1EC078D76CF9A56017DA75E" xlink:to="loc_dare_TwoThousandAndFifteenStockIncentivePlanMember_C900E1E039880E0362609A56017D0554" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_19C1D5EF62C1AC2991169A56017D4137" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1351860212A78057BB199A56016DE44F" xlink:to="loc_us-gaap_AwardTypeAxis_19C1D5EF62C1AC2991169A56017D4137" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6AF109E71D367B80E76B9A56017DC2E0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_19C1D5EF62C1AC2991169A56017D4137" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6AF109E71D367B80E76B9A56017DC2E0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6AF109E71D367B80E76B9A56017DC2E0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_19C1D5EF62C1AC2991169A56017D4137" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6AF109E71D367B80E76B9A56017DC2E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_D5577CB6D44DA99CD3919A56017DCD7E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6AF109E71D367B80E76B9A56017DC2E0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_D5577CB6D44DA99CD3919A56017DCD7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_84ECE9C2DC980E9E9B529A56017DAAA7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5967506064B4192D93969A56017D7955" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_84ECE9C2DC980E9E9B529A56017DAAA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9D1A3E1EA36553F6D1319A56017DE49A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_84ECE9C2DC980E9E9B529A56017DAAA7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9D1A3E1EA36553F6D1319A56017DE49A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0B6C403778928637A9589A56017DC04F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_84ECE9C2DC980E9E9B529A56017DAAA7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0B6C403778928637A9589A56017DC04F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2EC51878368BB058EFAB9A56017D988D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_84ECE9C2DC980E9E9B529A56017DAAA7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2EC51878368BB058EFAB9A56017D988D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1305F445BA73213A01B69A56017DEB5A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_84ECE9C2DC980E9E9B529A56017DAAA7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1305F445BA73213A01B69A56017DEB5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_8A7466BA7935ACD22BF29A751759F633" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_84ECE9C2DC980E9E9B529A56017DAAA7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_8A7466BA7935ACD22BF29A751759F633" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BD1F3BCA2ED4F4237EFE9A56017D9EDD" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_84ECE9C2DC980E9E9B529A56017DAAA7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BD1F3BCA2ED4F4237EFE9A56017D9EDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_D13CF58278C99867BCBA9A56017D35CC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5967506064B4192D93969A56017D7955" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_D13CF58278C99867BCBA9A56017D35CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_DE6099BA6D8920BC30949A56017DC80F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_D13CF58278C99867BCBA9A56017D35CC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_DE6099BA6D8920BC30949A56017DC80F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_202BC10C27B461A07C0C9A56017D0FBD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_D13CF58278C99867BCBA9A56017D35CC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_202BC10C27B461A07C0C9A56017D0FBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_96A98856B81E76ED13F09A56017D8501" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_D13CF58278C99867BCBA9A56017D35CC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_96A98856B81E76ED13F09A56017D8501" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_98C7ABDF36972D91169A9A56017D827D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_D13CF58278C99867BCBA9A56017D35CC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_98C7ABDF36972D91169A9A56017D827D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1A2EC86558388032F9079A72FFD1C382" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_D13CF58278C99867BCBA9A56017D35CC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1A2EC86558388032F9079A72FFD1C382" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_FC48EB33EF0AE075D1EF9A56017D5ADD" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_D13CF58278C99867BCBA9A56017D35CC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_FC48EB33EF0AE075D1EF9A56017D5ADD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockholdersEquity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="dare-20190331.xsd#dare_StockholdersEquityLineItems" xlink:label="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:type="locator" />
    <link:loc xlink:href="dare-20190331.xsd#dare_StockholdersEquityTable" xlink:label="loc_dare_StockholdersEquityTable_D5FB4A778DA18AE4ADA19A5600EFE79A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:to="loc_dare_StockholdersEquityTable_D5FB4A778DA18AE4ADA19A5600EFE79A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2D7794772D9A4AC4BA199A5600EF5B2F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_StockholdersEquityTable_D5FB4A778DA18AE4ADA19A5600EFE79A" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2D7794772D9A4AC4BA199A5600EF5B2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_B361BD59915A291B89139A5600EF53A1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2D7794772D9A4AC4BA199A5600EF5B2F" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_B361BD59915A291B89139A5600EF53A1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_B361BD59915A291B89139A5600EF53A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2D7794772D9A4AC4BA199A5600EF5B2F" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_B361BD59915A291B89139A5600EF53A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_6A1FC21ABEB14A46ACC99A5600EF5662" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_B361BD59915A291B89139A5600EF53A1" xlink:to="loc_us-gaap_OverAllotmentOptionMember_6A1FC21ABEB14A46ACC99A5600EF5662" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_628424DA475E7FB6D4AF9A5600EF44CA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_StockholdersEquityTable_D5FB4A778DA18AE4ADA19A5600EFE79A" xlink:to="loc_srt_RangeAxis_628424DA475E7FB6D4AF9A5600EF44CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_79130FE4DC635509FF319A5600EFA8EA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_628424DA475E7FB6D4AF9A5600EF44CA" xlink:to="loc_srt_RangeMember_79130FE4DC635509FF319A5600EFA8EA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_79130FE4DC635509FF319A5600EFA8EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_628424DA475E7FB6D4AF9A5600EF44CA" xlink:to="loc_srt_RangeMember_79130FE4DC635509FF319A5600EFA8EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_01346C7D7240156A82D89A5600EFE74B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_79130FE4DC635509FF319A5600EFA8EA" xlink:to="loc_srt_MaximumMember_01346C7D7240156A82D89A5600EFE74B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2A6798B8C6D46559836B9A5600EFCFCE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_79130FE4DC635509FF319A5600EFA8EA" xlink:to="loc_srt_MinimumMember_2A6798B8C6D46559836B9A5600EFCFCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_61C89BEDF2C94C851A229A5600EFB274" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_StockholdersEquityTable_D5FB4A778DA18AE4ADA19A5600EFE79A" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_61C89BEDF2C94C851A229A5600EFB274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_B89E7282D1EA02C8186E9A5600EFFD3F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_61C89BEDF2C94C851A229A5600EFB274" xlink:to="loc_us-gaap_TypeOfAdoptionMember_B89E7282D1EA02C8186E9A5600EFFD3F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_B89E7282D1EA02C8186E9A5600EFFD3F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_61C89BEDF2C94C851A229A5600EFB274" xlink:to="loc_us-gaap_TypeOfAdoptionMember_B89E7282D1EA02C8186E9A5600EFFD3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201711Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201711Member_9D760536EB8FC07DCF069A5600EF36E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_B89E7282D1EA02C8186E9A5600EFFD3F" xlink:to="loc_us-gaap_AccountingStandardsUpdate201711Member_9D760536EB8FC07DCF069A5600EF36E3" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_GrossProceedsFromIssuanceOfCommonStock" xlink:label="loc_dare_GrossProceedsFromIssuanceOfCommonStock_541328027702DD5EE6239A5600EF05CF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:to="loc_dare_GrossProceedsFromIssuanceOfCommonStock_541328027702DD5EE6239A5600EF05CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_5ADE29BA86B30E6861F49A7935E98D18" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_5ADE29BA86B30E6861F49A7935E98D18" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_PercentageOfAggregateCommission" xlink:label="loc_dare_PercentageOfAggregateCommission_BF2DD2B4C51E34B4E7369A5600EFF931" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:to="loc_dare_PercentageOfAggregateCommission_BF2DD2B4C51E34B4E7369A5600EFF931" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C0BA5D889889BF83490B9A5600EFA33A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C0BA5D889889BF83490B9A5600EFA33A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FAEC226EB9FBEC3B5BAE9A5600EFF9CF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FAEC226EB9FBEC3B5BAE9A5600EFF9CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_E7D330FD81A0192E9B0A9A5600EFEBB8" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_E7D330FD81A0192E9B0A9A5600EFEBB8" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod" xlink:label="loc_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_1A5DE60B5CFF5634058F9A5600EF6F2D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:to="loc_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_1A5DE60B5CFF5634058F9A5600EF6F2D" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_UnderwritersOptionToPurchaseAdditionalShares" xlink:label="loc_dare_UnderwritersOptionToPurchaseAdditionalShares_4D8B9CEBD2F80103B8F09A5600EF734B" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:to="loc_dare_UnderwritersOptionToPurchaseAdditionalShares_4D8B9CEBD2F80103B8F09A5600EF734B" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_GrossProceedsFromOfferingOfCommonStockAndWarrants" xlink:label="loc_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_93CE12C38F7ED0A25BE79A5600EF94AD" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:to="loc_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_93CE12C38F7ED0A25BE79A5600EF94AD" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="loc_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_449A0E02D5CFB2F9880E9A5600EFC91A" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:to="loc_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_449A0E02D5CFB2F9880E9A5600EFC91A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2F28D596560E4F3EEABB9A5600EFD71E" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2F28D596560E4F3EEABB9A5600EFD71E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_CD8B319B0A0BF83D7FC39A5600EF23B6" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_CD8B319B0A0BF83D7FC39A5600EF23B6" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_EstimatedFairValueOfWarrantsRecordedInEquity" xlink:label="loc_dare_EstimatedFairValueOfWarrantsRecordedInEquity_CAC3A74392D9D38EEAAA9A5600EF0D44" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:to="loc_dare_EstimatedFairValueOfWarrantsRecordedInEquity_CAC3A74392D9D38EEAAA9A5600EF0D44" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_NumberOfCommonStockWarrantsExercised" xlink:label="loc_dare_NumberOfCommonStockWarrantsExercised_6B4F64925C5653F79A259A5600EFC2D9" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:to="loc_dare_NumberOfCommonStockWarrantsExercised_6B4F64925C5653F79A259A5600EFC2D9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockholdersEquityScheduleOfCommonStockWarrantsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_7A4CA7CB9D4D1803D7095B1492A17A65" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_4F8ECCF68CD2965497AE5B14929F5B5C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_7A4CA7CB9D4D1803D7095B1492A17A65" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_4F8ECCF68CD2965497AE5B14929F5B5C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_684565221C9A7AC6E5C55B1492A07AB7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_4F8ECCF68CD2965497AE5B14929F5B5C" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_684565221C9A7AC6E5C55B1492A07AB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_265D5EB1364073D6B1A75B1492A0E599_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_684565221C9A7AC6E5C55B1492A07AB7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_265D5EB1364073D6B1A75B1492A0E599_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_265D5EB1364073D6B1A75B1492A0E599" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_684565221C9A7AC6E5C55B1492A07AB7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_265D5EB1364073D6B1A75B1492A0E599" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember" xlink:label="loc_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_FB22DFF1D126703A59625B1492A1F47F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_265D5EB1364073D6B1A75B1492A0E599" xlink:to="loc_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_FB22DFF1D126703A59625B1492A1F47F" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember" xlink:label="loc_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_44F2CA9C004D12A3798E5B1492A136FF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_265D5EB1364073D6B1A75B1492A0E599" xlink:to="loc_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_44F2CA9C004D12A3798E5B1492A136FF" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember" xlink:label="loc_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember_7092C3A880B79555EFDA5B1492A1E2E8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_265D5EB1364073D6B1A75B1492A0E599" xlink:to="loc_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember_7092C3A880B79555EFDA5B1492A1E2E8" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" xlink:label="loc_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_7F8BE4CE1B714C6D87DA5B1492A12BF4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_265D5EB1364073D6B1A75B1492A0E599" xlink:to="loc_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_7F8BE4CE1B714C6D87DA5B1492A12BF4" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" xlink:label="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_67C4FCF03D41BEAB80BA5B1492A133B1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_265D5EB1364073D6B1A75B1492A0E599" xlink:to="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_67C4FCF03D41BEAB80BA5B1492A133B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_64DCA049BD022DD41E325B1492A2D276" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_7A4CA7CB9D4D1803D7095B1492A17A65" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_64DCA049BD022DD41E325B1492A2D276" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_EA0B7DADBDC78AC47AA95B1492A2A395" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_7A4CA7CB9D4D1803D7095B1492A17A65" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_EA0B7DADBDC78AC47AA95B1492A2A395" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_ClassOfWarrantOrRightsWarrantsExpirationDate" xlink:label="loc_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_0DEFEC0E46C1A8E95E3A5B1492A261DE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_7A4CA7CB9D4D1803D7095B1492A17A65" xlink:to="loc_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_0DEFEC0E46C1A8E95E3A5B1492A261DE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://darebioscience.com/role/StockholdersEquityTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/SubsequentEvents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0E63A6C63F07269864219A55FF225403" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_A00D47F203A36B0C7B439A55FF1F22EC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0E63A6C63F07269864219A55FF225403" xlink:to="loc_us-gaap_SubsequentEventTable_A00D47F203A36B0C7B439A55FF1F22EC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_912266D0BFAAC4E9D2C29A55FF1F3C42" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_A00D47F203A36B0C7B439A55FF1F22EC" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_912266D0BFAAC4E9D2C29A55FF1F3C42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_F162273E6C6BA68D1B0C9A55FF21E228_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_912266D0BFAAC4E9D2C29A55FF1F3C42" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_F162273E6C6BA68D1B0C9A55FF21E228_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_F162273E6C6BA68D1B0C9A55FF21E228" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_912266D0BFAAC4E9D2C29A55FF1F3C42" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_F162273E6C6BA68D1B0C9A55FF21E228" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" xlink:label="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_C33C495C12F4D87C890B9A55FF21B487" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_F162273E6C6BA68D1B0C9A55FF21E228" xlink:to="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_C33C495C12F4D87C890B9A55FF21B487" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_645A772483AE32EF357B9A55FF2214C6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_A00D47F203A36B0C7B439A55FF1F22EC" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_645A772483AE32EF357B9A55FF2214C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F7B531EA5A357FFF29039A55FF224B4C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_645A772483AE32EF357B9A55FF2214C6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F7B531EA5A357FFF29039A55FF224B4C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F7B531EA5A357FFF29039A55FF224B4C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_645A772483AE32EF357B9A55FF2214C6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F7B531EA5A357FFF29039A55FF224B4C" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_PublicStockOfferingMember" xlink:label="loc_dare_PublicStockOfferingMember_A8FF6E2CCF7EDB2D57399A55FF22DD74" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F7B531EA5A357FFF29039A55FF224B4C" xlink:to="loc_dare_PublicStockOfferingMember_A8FF6E2CCF7EDB2D57399A55FF22DD74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_A9DDC986A197CCC6AD6B9A55FF2226E1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F7B531EA5A357FFF29039A55FF224B4C" xlink:to="loc_us-gaap_OverAllotmentOptionMember_A9DDC986A197CCC6AD6B9A55FF2226E1" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_PublicStockOfferingIncludingOverAllotmentOfSharesMember" xlink:label="loc_dare_PublicStockOfferingIncludingOverAllotmentOfSharesMember_C19133A2E23D4D3790FE9A55FF22E900" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F7B531EA5A357FFF29039A55FF224B4C" xlink:to="loc_dare_PublicStockOfferingIncludingOverAllotmentOfSharesMember_C19133A2E23D4D3790FE9A55FF22E900" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_FC2F473B823399E439F89A55FF22FD25" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_A00D47F203A36B0C7B439A55FF1F22EC" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_FC2F473B823399E439F89A55FF22FD25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8CE836CD3355C069223F9A55FF22590C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_FC2F473B823399E439F89A55FF22FD25" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8CE836CD3355C069223F9A55FF22590C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8CE836CD3355C069223F9A55FF22590C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_FC2F473B823399E439F89A55FF22FD25" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8CE836CD3355C069223F9A55FF22590C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_6236177671D2003C93649A55FF22BDD6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8CE836CD3355C069223F9A55FF22590C" xlink:to="loc_us-gaap_SubsequentEventMember_6236177671D2003C93649A55FF22BDD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_E07D90359D3B2F5BD6779A55FF229C71" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0E63A6C63F07269864219A55FF225403" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_E07D90359D3B2F5BD6779A55FF229C71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1BC98667892A513497549A55FF227BF1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0E63A6C63F07269864219A55FF225403" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1BC98667892A513497549A55FF227BF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_886995828302A43896A39A55FF225EB7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0E63A6C63F07269864219A55FF225403" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_886995828302A43896A39A55FF225EB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_36FD42EB216DB962DD6F9A55FF22C169" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0E63A6C63F07269864219A55FF225403" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_36FD42EB216DB962DD6F9A55FF22C169" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2A736DD6F9B3D560842C9A55FF26535A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0E63A6C63F07269864219A55FF225403" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2A736DD6F9B3D560842C9A55FF26535A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_C3C9FAC04200104FE9849A55FF26EE3D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0E63A6C63F07269864219A55FF225403" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_C3C9FAC04200104FE9849A55FF26EE3D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://darebioscience.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="dare-20190331.xsd#dare_SignificantAccountingPoliciesLineItems" xlink:label="loc_dare_SignificantAccountingPoliciesLineItems_D889DB9D3C168C07023B9A56022FB6F4" xlink:type="locator" />
    <link:loc xlink:href="dare-20190331.xsd#dare_SignificantAccountingPoliciesTable" xlink:label="loc_dare_SignificantAccountingPoliciesTable_93C23DDD43FA4A521FC89A56022F7A5D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_D889DB9D3C168C07023B9A56022FB6F4" xlink:to="loc_dare_SignificantAccountingPoliciesTable_93C23DDD43FA4A521FC89A56022F7A5D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5CD7E0215C0D939117539A56022FE9CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dare_SignificantAccountingPoliciesTable_93C23DDD43FA4A521FC89A56022F7A5D" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5CD7E0215C0D939117539A56022FE9CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_004EED79203865698FDB9A56022F1DC0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5CD7E0215C0D939117539A56022FE9CD" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_004EED79203865698FDB9A56022F1DC0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_004EED79203865698FDB9A56022F1DC0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5CD7E0215C0D939117539A56022FE9CD" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_004EED79203865698FDB9A56022F1DC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_E3ADFD332D5C8729B5279A56022F6093" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_004EED79203865698FDB9A56022F1DC0" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_E3ADFD332D5C8729B5279A56022F6093" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_75CC75E42D13BA9B5A639A56022FEC60" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_D889DB9D3C168C07023B9A56022FB6F4" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_75CC75E42D13BA9B5A639A56022FEC60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_E9DCD4DE6780D18E00819A56022F191E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_D889DB9D3C168C07023B9A56022FB6F4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_E9DCD4DE6780D18E00819A56022F191E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_2042DA67A159DE71733C9A56022F3AB6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_D889DB9D3C168C07023B9A56022FB6F4" xlink:to="loc_us-gaap_OperatingLeaseLiability_2042DA67A159DE71733C9A56022F3AB6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>dare-20190331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_6679D68054E11151A2B7B18BDA919557_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_6679D68054E11151A2B7B18BDA919557" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6679D68054E11151A2B7B18BDA919557" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6679D68054E11151A2B7B18BDA919557" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_6679D68054E11151A2B7B18BDA919557" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D317E1C869256790D1ACB18BDA91E9FE_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D317E1C869256790D1ACB18BDA91E9FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D317E1C869256790D1ACB18BDA91E9FE_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D317E1C869256790D1ACB18BDA91E9FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D317E1C869256790D1ACB18BDA91E9FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D317E1C869256790D1ACB18BDA91E9FE" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D317E1C869256790D1ACB18BDA91E9FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_1AAB14F900E12EA90688B18BDA9157DB_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_1AAB14F900E12EA90688B18BDA9157DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_1AAB14F900E12EA90688B18BDA9157DB_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_1AAB14F900E12EA90688B18BDA9157DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1AAB14F900E12EA90688B18BDA9157DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_1AAB14F900E12EA90688B18BDA9157DB" xlink:to="lab_us-gaap_ProfitLoss_1AAB14F900E12EA90688B18BDA9157DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C087155E60C4A4F94EADB18BDA91AD6A_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C087155E60C4A4F94EADB18BDA91AD6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash adjustments reconciling net loss to operating cash flows:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C087155E60C4A4F94EADB18BDA91AD6A_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C087155E60C4A4F94EADB18BDA91AD6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C087155E60C4A4F94EADB18BDA91AD6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C087155E60C4A4F94EADB18BDA91AD6A" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C087155E60C4A4F94EADB18BDA91AD6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_335F3165B19CE4F74A3AB18BDA918747_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_335F3165B19CE4F74A3AB18BDA918747" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_335F3165B19CE4F74A3AB18BDA918747_label_en-US" xlink:label="lab_us-gaap_Depreciation_335F3165B19CE4F74A3AB18BDA918747" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_335F3165B19CE4F74A3AB18BDA918747" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_335F3165B19CE4F74A3AB18BDA918747" xlink:to="lab_us-gaap_Depreciation_335F3165B19CE4F74A3AB18BDA918747" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_CBB2E103E47833399D44B18BDA910971_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_CBB2E103E47833399D44B18BDA910971" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_CBB2E103E47833399D44B18BDA910971_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_CBB2E103E47833399D44B18BDA910971" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_CBB2E103E47833399D44B18BDA910971" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_CBB2E103E47833399D44B18BDA910971" xlink:to="lab_us-gaap_ShareBasedCompensation_CBB2E103E47833399D44B18BDA910971" xlink:type="arc" />
    <link:label id="lab_dare_NonCashLeaseExpense_2FC6C5912A9BD23335E4B18BDA91A93A_terseLabel_en-US" xlink:label="lab_dare_NonCashLeaseExpense_2FC6C5912A9BD23335E4B18BDA91A93A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease expenses</link:label>
    <link:label id="lab_dare_NonCashLeaseExpense_2FC6C5912A9BD23335E4B18BDA91A93A_label_en-US" xlink:label="lab_dare_NonCashLeaseExpense_2FC6C5912A9BD23335E4B18BDA91A93A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Lease Expense</link:label>
    <link:label id="lab_dare_NonCashLeaseExpense_2FC6C5912A9BD23335E4B18BDA91A93A_documentation_en-US" xlink:label="lab_dare_NonCashLeaseExpense_2FC6C5912A9BD23335E4B18BDA91A93A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Lease Expense</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_NonCashLeaseExpense" xlink:label="loc_dare_NonCashLeaseExpense_2FC6C5912A9BD23335E4B18BDA91A93A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NonCashLeaseExpense_2FC6C5912A9BD23335E4B18BDA91A93A" xlink:to="lab_dare_NonCashLeaseExpense_2FC6C5912A9BD23335E4B18BDA91A93A" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_67738A0E144BA5622195B18BDA9188B5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_67738A0E144BA5622195B18BDA9188B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_67738A0E144BA5622195B18BDA9188B5_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_67738A0E144BA5622195B18BDA9188B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_67738A0E144BA5622195B18BDA9188B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss_67738A0E144BA5622195B18BDA9188B5" xlink:to="lab_us-gaap_GoodwillImpairmentLoss_67738A0E144BA5622195B18BDA9188B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7083B0ED7E6C0C375EB3B18BDA918564_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7083B0ED7E6C0C375EB3B18BDA918564" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7083B0ED7E6C0C375EB3B18BDA918564_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7083B0ED7E6C0C375EB3B18BDA918564" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7083B0ED7E6C0C375EB3B18BDA918564" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7083B0ED7E6C0C375EB3B18BDA918564" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7083B0ED7E6C0C375EB3B18BDA918564" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_48C3A7492B921BCCCA78B18BDAA1490B_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables_48C3A7492B921BCCCA78B18BDAA1490B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_48C3A7492B921BCCCA78B18BDAA1490B_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables_48C3A7492B921BCCCA78B18BDAA1490B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_48C3A7492B921BCCCA78B18BDAA1490B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables_48C3A7492B921BCCCA78B18BDAA1490B" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables_48C3A7492B921BCCCA78B18BDAA1490B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_4CAEF4A93DE580FE3F07B18BDAA15F08_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_4CAEF4A93DE580FE3F07B18BDAA15F08" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_4CAEF4A93DE580FE3F07B18BDAA15F08_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_4CAEF4A93DE580FE3F07B18BDAA15F08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_4CAEF4A93DE580FE3F07B18BDAA15F08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_4CAEF4A93DE580FE3F07B18BDAA15F08" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_4CAEF4A93DE580FE3F07B18BDAA15F08" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_F70DAC87110DB401A12DB18BDAA19B32_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_F70DAC87110DB401A12DB18BDAA19B32" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_F70DAC87110DB401A12DB18BDAA19B32_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_F70DAC87110DB401A12DB18BDAA19B32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_F70DAC87110DB401A12DB18BDAA19B32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_F70DAC87110DB401A12DB18BDAA19B32" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_F70DAC87110DB401A12DB18BDAA19B32" xlink:type="arc" />
    <link:label id="lab_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_33EADA3C1CA2E40BF73EB18BDAA1ACB7_negatedLabel_en-US" xlink:label="lab_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_33EADA3C1CA2E40BF73EB18BDAA1ACB7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets and deferred charges</link:label>
    <link:label id="lab_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_33EADA3C1CA2E40BF73EB18BDAA1ACB7_label_en-US" xlink:label="lab_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_33EADA3C1CA2E40BF73EB18BDAA1ACB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Other Non Current Assets And Deferred Charges</link:label>
    <link:label id="lab_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_33EADA3C1CA2E40BF73EB18BDAA1ACB7_documentation_en-US" xlink:label="lab_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_33EADA3C1CA2E40BF73EB18BDAA1ACB7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase decrease in other non-current assets and deferred charges.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges" xlink:label="loc_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_33EADA3C1CA2E40BF73EB18BDAA1ACB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_33EADA3C1CA2E40BF73EB18BDAA1ACB7" xlink:to="lab_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_33EADA3C1CA2E40BF73EB18BDAA1ACB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_794AA4F2C9C55F0857F1B18BDAA17509_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_794AA4F2C9C55F0857F1B18BDAA17509" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_794AA4F2C9C55F0857F1B18BDAA17509_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_794AA4F2C9C55F0857F1B18BDAA17509" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_794AA4F2C9C55F0857F1B18BDAA17509" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_794AA4F2C9C55F0857F1B18BDAA17509" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_794AA4F2C9C55F0857F1B18BDAA17509" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_07700AF16ACE440BD5ECB18BDAA18682_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_07700AF16ACE440BD5ECB18BDAA18682" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_07700AF16ACE440BD5ECB18BDAA18682_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_07700AF16ACE440BD5ECB18BDAA18682" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_07700AF16ACE440BD5ECB18BDAA18682" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_07700AF16ACE440BD5ECB18BDAA18682" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_07700AF16ACE440BD5ECB18BDAA18682" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0099BD8F996BE4BB30A7B18BDAA1B3D5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0099BD8F996BE4BB30A7B18BDAA1B3D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0099BD8F996BE4BB30A7B18BDAA1B3D5_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0099BD8F996BE4BB30A7B18BDAA1B3D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0099BD8F996BE4BB30A7B18BDAA1B3D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0099BD8F996BE4BB30A7B18BDAA1B3D5" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0099BD8F996BE4BB30A7B18BDAA1B3D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_BB43D64CDADC7FC9C139B18BDAA1C220_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_BB43D64CDADC7FC9C139B18BDAA1C220" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_BB43D64CDADC7FC9C139B18BDAA1C220_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_BB43D64CDADC7FC9C139B18BDAA1C220" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_BB43D64CDADC7FC9C139B18BDAA1C220" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_BB43D64CDADC7FC9C139B18BDAA1C220" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_BB43D64CDADC7FC9C139B18BDAA1C220" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_62384E8A2B83F98CA01EB18BDAA107DA_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_62384E8A2B83F98CA01EB18BDAA107DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_62384E8A2B83F98CA01EB18BDAA107DA_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_62384E8A2B83F98CA01EB18BDAA107DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_62384E8A2B83F98CA01EB18BDAA107DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_62384E8A2B83F98CA01EB18BDAA107DA" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_62384E8A2B83F98CA01EB18BDAA107DA" xlink:type="arc" />
    <link:label id="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_BE061AA701D4AF3EB78AB18BDAA1DE07_terseLabel_en-US" xlink:label="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_BE061AA701D4AF3EB78AB18BDAA1DE07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of common stock and warrants</link:label>
    <link:label id="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_BE061AA701D4AF3EB78AB18BDAA1DE07_label_en-US" xlink:label="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_BE061AA701D4AF3EB78AB18BDAA1DE07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Proceeds From Issuance Of Common Stock And Warrants</link:label>
    <link:label id="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_BE061AA701D4AF3EB78AB18BDAA1DE07_documentation_en-US" xlink:label="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_BE061AA701D4AF3EB78AB18BDAA1DE07" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of common stock and warrants.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="loc_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_BE061AA701D4AF3EB78AB18BDAA1DE07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_BE061AA701D4AF3EB78AB18BDAA1DE07" xlink:to="lab_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_BE061AA701D4AF3EB78AB18BDAA1DE07" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_A25A64428EC8E2745F92B18BDAA196FA_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_A25A64428EC8E2745F92B18BDAA196FA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_A25A64428EC8E2745F92B18BDAA196FA_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_A25A64428EC8E2745F92B18BDAA196FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_A25A64428EC8E2745F92B18BDAA196FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_A25A64428EC8E2745F92B18BDAA196FA" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_A25A64428EC8E2745F92B18BDAA196FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_B278DE1E015E77BC879DB18BDAA147AD_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_B278DE1E015E77BC879DB18BDAA147AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_B278DE1E015E77BC879DB18BDAA147AD_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_B278DE1E015E77BC879DB18BDAA147AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_B278DE1E015E77BC879DB18BDAA147AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_B278DE1E015E77BC879DB18BDAA147AD" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_B278DE1E015E77BC879DB18BDAA147AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0C1CF19A3F309EF9A2F2B18BDAA17F0F_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0C1CF19A3F309EF9A2F2B18BDAA17F0F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0C1CF19A3F309EF9A2F2B18BDAA17F0F_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0C1CF19A3F309EF9A2F2B18BDAA17F0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0C1CF19A3F309EF9A2F2B18BDAA17F0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0C1CF19A3F309EF9A2F2B18BDAA17F0F" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0C1CF19A3F309EF9A2F2B18BDAA17F0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_16D36CE99793425C795DB18BDAA1DAC1_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_16D36CE99793425C795DB18BDAA1DAC1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_16D36CE99793425C795DB18BDAA1DAC1_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_16D36CE99793425C795DB18BDAA1DAC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_16D36CE99793425C795DB18BDAA1DAC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_16D36CE99793425C795DB18BDAA1DAC1" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_16D36CE99793425C795DB18BDAA1DAC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4A4C0AE7361A6D5905C7B18BDAA1EEE1_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4A4C0AE7361A6D5905C7B18BDAA1EEE1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4A4C0AE7361A6D5905C7B18BDAA1EEE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4A4C0AE7361A6D5905C7B18BDAA1EEE1" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4A4C0AE7361A6D5905C7B18BDAA1EEE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_7102BCEF3C77AD1F94D7B18BDAA16B19_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_7102BCEF3C77AD1F94D7B18BDAA16B19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash operating activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_7102BCEF3C77AD1F94D7B18BDAA16B19_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_7102BCEF3C77AD1F94D7B18BDAA16B19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_7102BCEF3C77AD1F94D7B18BDAA16B19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7102BCEF3C77AD1F94D7B18BDAA16B19" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_7102BCEF3C77AD1F94D7B18BDAA16B19" xlink:type="arc" />
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7F4E3DE34F6FA67EDAADB18BDAA1E4B7_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7F4E3DE34F6FA67EDAADB18BDAA1E4B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating right-of-use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7F4E3DE34F6FA67EDAADB18BDAA1E4B7_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7F4E3DE34F6FA67EDAADB18BDAA1E4B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7F4E3DE34F6FA67EDAADB18BDAA1E4B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7F4E3DE34F6FA67EDAADB18BDAA1E4B7" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7F4E3DE34F6FA67EDAADB18BDAA1E4B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_832B0E92B39F47C125E84CA0CA912384_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_832B0E92B39F47C125E84CA0CA912384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_832B0E92B39F47C125E84CA0CA912384" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_832B0E92B39F47C125E84CA0CA912384" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_832B0E92B39F47C125E84CA0CA912384" xlink:type="arc" />
    <link:label id="lab_dare_BusinessCombinationReverseMergerConsiderationTransferredEquityInterestsIssuedAndIssuable_C9779ECA77AF11F277C34CA9612E8B7F_terseLabel_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerConsiderationTransferredEquityInterestsIssuedAndIssuable_C9779ECA77AF11F277C34CA9612E8B7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of shares issued</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerConsiderationTransferredEquityInterestsIssuedAndIssuable_C9779ECA77AF11F277C34CA9612E8B7F_label_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerConsiderationTransferredEquityInterestsIssuedAndIssuable_C9779ECA77AF11F277C34CA9612E8B7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Reverse Merger Consideration Transferred Equity Interests Issued And Issuable</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerConsiderationTransferredEquityInterestsIssuedAndIssuable_C9779ECA77AF11F277C34CA9612E8B7F_documentation_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerConsiderationTransferredEquityInterestsIssuedAndIssuable_C9779ECA77AF11F277C34CA9612E8B7F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business combination reverse merger consideration transferred equity interests issued and issuable.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_dare_BusinessCombinationReverseMergerConsiderationTransferredEquityInterestsIssuedAndIssuable_C9779ECA77AF11F277C34CA9612E8B7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_BusinessCombinationReverseMergerConsiderationTransferredEquityInterestsIssuedAndIssuable_C9779ECA77AF11F277C34CA9612E8B7F" xlink:to="lab_dare_BusinessCombinationReverseMergerConsiderationTransferredEquityInterestsIssuedAndIssuable_C9779ECA77AF11F277C34CA9612E8B7F" xlink:type="arc" />
    <link:label id="lab_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_7ABF34CE3795ACF1CD3A4CA96133B61F_verboseLabel_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_7ABF34CE3795ACF1CD3A4CA96133B61F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unamortized fair value of Cerulean options</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_7ABF34CE3795ACF1CD3A4CA96133B61F_label_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_7ABF34CE3795ACF1CD3A4CA96133B61F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Reverse Merger Unamortized Fair Value Of Stock Options</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_7ABF34CE3795ACF1CD3A4CA96133B61F_documentation_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_7ABF34CE3795ACF1CD3A4CA96133B61F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business combination reverse merger unamortized fair value of stock options.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions" xlink:label="loc_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_7ABF34CE3795ACF1CD3A4CA96133B61F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_7ABF34CE3795ACF1CD3A4CA96133B61F" xlink:to="lab_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_7ABF34CE3795ACF1CD3A4CA96133B61F" xlink:type="arc" />
    <link:label id="lab_dare_BusinessCombinationReverseMergerConsiderationTransferred_37117C0D03D5C21711A24CA9613929A8_totalLabel_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerConsiderationTransferred_37117C0D03D5C21711A24CA9613929A8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Fair value of total consideration</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerConsiderationTransferred_37117C0D03D5C21711A24CA9613929A8_label_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerConsiderationTransferred_37117C0D03D5C21711A24CA9613929A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Reverse Merger Consideration Transferred</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerConsiderationTransferred_37117C0D03D5C21711A24CA9613929A8_documentation_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerConsiderationTransferred_37117C0D03D5C21711A24CA9613929A8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business combination reverse merger consideration transferred.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerConsiderationTransferred" xlink:label="loc_dare_BusinessCombinationReverseMergerConsiderationTransferred_37117C0D03D5C21711A24CA9613929A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_BusinessCombinationReverseMergerConsiderationTransferred_37117C0D03D5C21711A24CA9613929A8" xlink:to="lab_dare_BusinessCombinationReverseMergerConsiderationTransferred_37117C0D03D5C21711A24CA9613929A8" xlink:type="arc" />
    <link:label id="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_EBF3A34AE1EF79F549C94CA96139D70F_terseLabel_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_EBF3A34AE1EF79F549C94CA96139D70F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets acquired and liabilities assumed</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_EBF3A34AE1EF79F549C94CA96139D70F_label_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_EBF3A34AE1EF79F549C94CA96139D70F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Reverse Merger Recognized Identifiable Assets Acquired And Liabilities Assumed Net [Abstract]</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_EBF3A34AE1EF79F549C94CA96139D70F_documentation_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_EBF3A34AE1EF79F549C94CA96139D70F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business combination reverse merger recognized identifiable assets acquired and liabilities assumed net.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:label="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_EBF3A34AE1EF79F549C94CA96139D70F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_EBF3A34AE1EF79F549C94CA96139D70F" xlink:to="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_EBF3A34AE1EF79F549C94CA96139D70F" xlink:type="arc" />
    <link:label id="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6D3A09C8D80CC4E9E9214CA9613970D0_terseLabel_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6D3A09C8D80CC4E9E9214CA9613970D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6D3A09C8D80CC4E9E9214CA9613970D0_label_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6D3A09C8D80CC4E9E9214CA9613970D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Reverse Merger Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6D3A09C8D80CC4E9E9214CA9613970D0_documentation_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6D3A09C8D80CC4E9E9214CA9613970D0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business combination reverse merger recognized identifiable assets acquired and liabilities assumed cash and equivalents.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6D3A09C8D80CC4E9E9214CA9613970D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6D3A09C8D80CC4E9E9214CA9613970D0" xlink:to="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6D3A09C8D80CC4E9E9214CA9613970D0" xlink:type="arc" />
    <link:label id="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherCurrentAssets_626D54B843D88A6932BF4CA9613DB058_terseLabel_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherCurrentAssets_626D54B843D88A6932BF4CA9613DB058" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expense and other current assets</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherCurrentAssets_626D54B843D88A6932BF4CA9613DB058_label_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherCurrentAssets_626D54B843D88A6932BF4CA9613DB058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Reverse Merger Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Current Assets</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherCurrentAssets_626D54B843D88A6932BF4CA9613DB058_documentation_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherCurrentAssets_626D54B843D88A6932BF4CA9613DB058" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business combination reverse merger recognized identifiable assets acquired and liabilities assumed current assets prepaid expense and other current assets.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherCurrentAssets" xlink:label="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherCurrentAssets_626D54B843D88A6932BF4CA9613DB058" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherCurrentAssets_626D54B843D88A6932BF4CA9613DB058" xlink:to="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherCurrentAssets_626D54B843D88A6932BF4CA9613DB058" xlink:type="arc" />
    <link:label id="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_B29534B1B4BEFFF022684CA9613E913C_negatedLabel_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_B29534B1B4BEFFF022684CA9613E913C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_B29534B1B4BEFFF022684CA9613E913C_label_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_B29534B1B4BEFFF022684CA9613E913C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Reverse Merger Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_B29534B1B4BEFFF022684CA9613E913C_documentation_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_B29534B1B4BEFFF022684CA9613E913C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business combination reverse merger recognized identifiable assets acquired and liabilities assumed current liabilities accounts payable.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_B29534B1B4BEFFF022684CA9613E913C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_B29534B1B4BEFFF022684CA9613E913C" xlink:to="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_B29534B1B4BEFFF022684CA9613E913C" xlink:type="arc" />
    <link:label id="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_D9C7508CDB502BEA4F114CA9613E3899_totalLabel_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_D9C7508CDB502BEA4F114CA9613E3899" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets acquired and liabilities assumed</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_D9C7508CDB502BEA4F114CA9613E3899_label_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_D9C7508CDB502BEA4F114CA9613E3899" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Reverse Merger Recognized Identifiable Assets Acquired And Liabilities Assumed Net</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_D9C7508CDB502BEA4F114CA9613E3899_documentation_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_D9C7508CDB502BEA4F114CA9613E3899" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business combination reverse merger recognized identifiable assets acquired and liabilities assumed net.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_D9C7508CDB502BEA4F114CA9613E3899" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_D9C7508CDB502BEA4F114CA9613E3899" xlink:to="lab_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_D9C7508CDB502BEA4F114CA9613E3899" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_1AD0126A8D4714DAF83C4CA96143A1D3_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_1AD0126A8D4714DAF83C4CA96143A1D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_1AD0126A8D4714DAF83C4CA96143A1D3_label_en-US" xlink:label="lab_us-gaap_Goodwill_1AD0126A8D4714DAF83C4CA96143A1D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_1AD0126A8D4714DAF83C4CA96143A1D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_1AD0126A8D4714DAF83C4CA96143A1D3" xlink:to="lab_us-gaap_Goodwill_1AD0126A8D4714DAF83C4CA96143A1D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A409150C6BEB012DED9351508016D36C_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A409150C6BEB012DED9351508016D36C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A409150C6BEB012DED9351508016D36C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A409150C6BEB012DED9351508016D36C" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A409150C6BEB012DED9351508016D36C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_EF1CBE6C5DF2AE997A2C51508016A937_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_EF1CBE6C5DF2AE997A2C51508016A937" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Stock Option Activity for Amended 2014 Plan and Related Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_EF1CBE6C5DF2AE997A2C51508016A937_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_EF1CBE6C5DF2AE997A2C51508016A937" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_EF1CBE6C5DF2AE997A2C51508016A937" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_EF1CBE6C5DF2AE997A2C51508016A937" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_EF1CBE6C5DF2AE997A2C51508016A937" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_90468317243DAE17ED18515080167C98_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_90468317243DAE17ED18515080167C98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_90468317243DAE17ED18515080167C98_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_90468317243DAE17ED18515080167C98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_90468317243DAE17ED18515080167C98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_90468317243DAE17ED18515080167C98" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_90468317243DAE17ED18515080167C98" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_B3449CFDA6F4155D3C1351508017F697_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_B3449CFDA6F4155D3C1351508017F697" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_B3449CFDA6F4155D3C1351508017F697_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_B3449CFDA6F4155D3C1351508017F697" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_B3449CFDA6F4155D3C1351508017F697" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_B3449CFDA6F4155D3C1351508017F697" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_B3449CFDA6F4155D3C1351508017F697" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F8CBD3944FD315960B804AFD877E0F86_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F8CBD3944FD315960B804AFD877E0F86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F8CBD3944FD315960B804AFD877E0F86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F8CBD3944FD315960B804AFD877E0F86" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F8CBD3944FD315960B804AFD877E0F86" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_E6F622492E86E2EF34304AFD877F6297_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_E6F622492E86E2EF34304AFD877F6297" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_E6F622492E86E2EF34304AFD877F6297_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_E6F622492E86E2EF34304AFD877F6297" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_E6F622492E86E2EF34304AFD877F6297" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_E6F622492E86E2EF34304AFD877F6297" xlink:to="lab_us-gaap_NumberOfOperatingSegments_E6F622492E86E2EF34304AFD877F6297" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8DDEB45E6CB8974EEF1751507FE06CFD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8DDEB45E6CB8974EEF1751507FE06CFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8DDEB45E6CB8974EEF1751507FE06CFD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8DDEB45E6CB8974EEF1751507FE06CFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8DDEB45E6CB8974EEF1751507FE06CFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8DDEB45E6CB8974EEF1751507FE06CFD" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8DDEB45E6CB8974EEF1751507FE06CFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_B7FF42C1898AA5F554D751507FE0B421_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_B7FF42C1898AA5F554D751507FE0B421" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_B7FF42C1898AA5F554D751507FE0B421_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_B7FF42C1898AA5F554D751507FE0B421" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_B7FF42C1898AA5F554D751507FE0B421" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_B7FF42C1898AA5F554D751507FE0B421" xlink:to="lab_us-gaap_AwardTypeAxis_B7FF42C1898AA5F554D751507FE0B421" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_987C1ED52C47C5238FD051507FE1688B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_987C1ED52C47C5238FD051507FE1688B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_987C1ED52C47C5238FD051507FE1688B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_987C1ED52C47C5238FD051507FE1688B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_987C1ED52C47C5238FD051507FE1688B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_987C1ED52C47C5238FD051507FE1688B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_987C1ED52C47C5238FD051507FE1688B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_EADFC24BC492ECCAA43A51507FE15C87_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_EADFC24BC492ECCAA43A51507FE15C87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_EADFC24BC492ECCAA43A51507FE15C87_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_EADFC24BC492ECCAA43A51507FE15C87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_EADFC24BC492ECCAA43A51507FE15C87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_EADFC24BC492ECCAA43A51507FE15C87" xlink:to="lab_us-gaap_EmployeeStockOptionMember_EADFC24BC492ECCAA43A51507FE15C87" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_660C9161C9051B9E94E551507FE19B01_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_660C9161C9051B9E94E551507FE19B01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_660C9161C9051B9E94E551507FE19B01_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_660C9161C9051B9E94E551507FE19B01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_660C9161C9051B9E94E551507FE19B01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_660C9161C9051B9E94E551507FE19B01" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_660C9161C9051B9E94E551507FE19B01" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_F84B87542D228B3C61CF51507FE1D584_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_F84B87542D228B3C61CF51507FE1D584" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_F84B87542D228B3C61CF51507FE1D584_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_F84B87542D228B3C61CF51507FE1D584" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F84B87542D228B3C61CF51507FE1D584" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F84B87542D228B3C61CF51507FE1D584" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_F84B87542D228B3C61CF51507FE1D584" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_D015CAA557C9FBEB6C0851507FE2BE04_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_D015CAA557C9FBEB6C0851507FE2BE04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development [Member]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_D015CAA557C9FBEB6C0851507FE2BE04_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_D015CAA557C9FBEB6C0851507FE2BE04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_D015CAA557C9FBEB6C0851507FE2BE04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_D015CAA557C9FBEB6C0851507FE2BE04" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_D015CAA557C9FBEB6C0851507FE2BE04" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_50AAB4692214FEBAAEF651507FE2D66B_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_50AAB4692214FEBAAEF651507FE2D66B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_50AAB4692214FEBAAEF651507FE2D66B_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_50AAB4692214FEBAAEF651507FE2D66B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_50AAB4692214FEBAAEF651507FE2D66B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_50AAB4692214FEBAAEF651507FE2D66B" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_50AAB4692214FEBAAEF651507FE2D66B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_91E51F8F1EA945AC22EF51507FE271E7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_91E51F8F1EA945AC22EF51507FE271E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_91E51F8F1EA945AC22EF51507FE271E7_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_91E51F8F1EA945AC22EF51507FE271E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_91E51F8F1EA945AC22EF51507FE271E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_91E51F8F1EA945AC22EF51507FE271E7" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_91E51F8F1EA945AC22EF51507FE271E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_5E79B67084FA56C06A0651507FE2C39D_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_5E79B67084FA56C06A0651507FE2C39D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_5E79B67084FA56C06A0651507FE2C39D_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_5E79B67084FA56C06A0651507FE2C39D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5E79B67084FA56C06A0651507FE2C39D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_5E79B67084FA56C06A0651507FE2C39D" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_5E79B67084FA56C06A0651507FE2C39D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_969A5AF60BDF21150C789A55FF1FA347_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_969A5AF60BDF21150C789A55FF1FA347" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_969A5AF60BDF21150C789A55FF1FA347" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_969A5AF60BDF21150C789A55FF1FA347" xlink:to="lab_us-gaap_SubsequentEventsAbstract_969A5AF60BDF21150C789A55FF1FA347" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_A00D47F203A36B0C7B439A55FF1F22EC_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_A00D47F203A36B0C7B439A55FF1F22EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_A00D47F203A36B0C7B439A55FF1F22EC_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_A00D47F203A36B0C7B439A55FF1F22EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_A00D47F203A36B0C7B439A55FF1F22EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_A00D47F203A36B0C7B439A55FF1F22EC" xlink:to="lab_us-gaap_SubsequentEventTable_A00D47F203A36B0C7B439A55FF1F22EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_912266D0BFAAC4E9D2C29A55FF1F3C42_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_912266D0BFAAC4E9D2C29A55FF1F3C42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_912266D0BFAAC4E9D2C29A55FF1F3C42_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_912266D0BFAAC4E9D2C29A55FF1F3C42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_912266D0BFAAC4E9D2C29A55FF1F3C42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_912266D0BFAAC4E9D2C29A55FF1F3C42" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_912266D0BFAAC4E9D2C29A55FF1F3C42" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_F162273E6C6BA68D1B0C9A55FF21E228_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_F162273E6C6BA68D1B0C9A55FF21E228" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_F162273E6C6BA68D1B0C9A55FF21E228_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_F162273E6C6BA68D1B0C9A55FF21E228" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_F162273E6C6BA68D1B0C9A55FF21E228" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_F162273E6C6BA68D1B0C9A55FF21E228" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_F162273E6C6BA68D1B0C9A55FF21E228" xlink:type="arc" />
    <link:label id="lab_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_C33C495C12F4D87C890B9A55FF21B487_terseLabel_en-US" xlink:label="lab_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_C33C495C12F4D87C890B9A55FF21B487" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring on February 15, 2023 [Member]</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_C33C495C12F4D87C890B9A55FF21B487_label_en-US" xlink:label="lab_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_C33C495C12F4D87C890B9A55FF21B487" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring On February Fifteen Two Thousand Twenty Three [Member]</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_C33C495C12F4D87C890B9A55FF21B487_documentation_en-US" xlink:label="lab_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_C33C495C12F4D87C890B9A55FF21B487" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring On February Fifteen Two Thousand Twenty Three [Member]</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" xlink:label="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_C33C495C12F4D87C890B9A55FF21B487" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_C33C495C12F4D87C890B9A55FF21B487" xlink:to="lab_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_C33C495C12F4D87C890B9A55FF21B487" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_645A772483AE32EF357B9A55FF2214C6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_645A772483AE32EF357B9A55FF2214C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_645A772483AE32EF357B9A55FF2214C6_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_645A772483AE32EF357B9A55FF2214C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_645A772483AE32EF357B9A55FF2214C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_645A772483AE32EF357B9A55FF2214C6" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_645A772483AE32EF357B9A55FF2214C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_F7B531EA5A357FFF29039A55FF224B4C_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_F7B531EA5A357FFF29039A55FF224B4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_F7B531EA5A357FFF29039A55FF224B4C_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_F7B531EA5A357FFF29039A55FF224B4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F7B531EA5A357FFF29039A55FF224B4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F7B531EA5A357FFF29039A55FF224B4C" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_F7B531EA5A357FFF29039A55FF224B4C" xlink:type="arc" />
    <link:label id="lab_dare_PublicStockOfferingMember_A8FF6E2CCF7EDB2D57399A55FF22DD74_terseLabel_en-US" xlink:label="lab_dare_PublicStockOfferingMember_A8FF6E2CCF7EDB2D57399A55FF22DD74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public Stock Offering [Member]</link:label>
    <link:label id="lab_dare_PublicStockOfferingMember_A8FF6E2CCF7EDB2D57399A55FF22DD74_label_en-US" xlink:label="lab_dare_PublicStockOfferingMember_A8FF6E2CCF7EDB2D57399A55FF22DD74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public Stock Offering [Member]</link:label>
    <link:label id="lab_dare_PublicStockOfferingMember_A8FF6E2CCF7EDB2D57399A55FF22DD74_documentation_en-US" xlink:label="lab_dare_PublicStockOfferingMember_A8FF6E2CCF7EDB2D57399A55FF22DD74" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Public Stock Offering [Member]</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_PublicStockOfferingMember" xlink:label="loc_dare_PublicStockOfferingMember_A8FF6E2CCF7EDB2D57399A55FF22DD74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PublicStockOfferingMember_A8FF6E2CCF7EDB2D57399A55FF22DD74" xlink:to="lab_dare_PublicStockOfferingMember_A8FF6E2CCF7EDB2D57399A55FF22DD74" xlink:type="arc" />
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_A9DDC986A197CCC6AD6B9A55FF2226E1_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_A9DDC986A197CCC6AD6B9A55FF2226E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwritten Offering [Member]</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_A9DDC986A197CCC6AD6B9A55FF2226E1_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_A9DDC986A197CCC6AD6B9A55FF2226E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_A9DDC986A197CCC6AD6B9A55FF2226E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember_A9DDC986A197CCC6AD6B9A55FF2226E1" xlink:to="lab_us-gaap_OverAllotmentOptionMember_A9DDC986A197CCC6AD6B9A55FF2226E1" xlink:type="arc" />
    <link:label id="lab_dare_PublicStockOfferingIncludingOverAllotmentOfSharesMember_C19133A2E23D4D3790FE9A55FF22E900_terseLabel_en-US" xlink:label="lab_dare_PublicStockOfferingIncludingOverAllotmentOfSharesMember_C19133A2E23D4D3790FE9A55FF22E900" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public Stock Offering, Including Over-Allotment Of Shares [Member]</link:label>
    <link:label id="lab_dare_PublicStockOfferingIncludingOverAllotmentOfSharesMember_C19133A2E23D4D3790FE9A55FF22E900_label_en-US" xlink:label="lab_dare_PublicStockOfferingIncludingOverAllotmentOfSharesMember_C19133A2E23D4D3790FE9A55FF22E900" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public Stock Offering, Including Over-Allotment Of Shares [Member]</link:label>
    <link:label id="lab_dare_PublicStockOfferingIncludingOverAllotmentOfSharesMember_C19133A2E23D4D3790FE9A55FF22E900_documentation_en-US" xlink:label="lab_dare_PublicStockOfferingIncludingOverAllotmentOfSharesMember_C19133A2E23D4D3790FE9A55FF22E900" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Public Stock Offering, Including Over-Allotment Of Shares [Member]</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_PublicStockOfferingIncludingOverAllotmentOfSharesMember" xlink:label="loc_dare_PublicStockOfferingIncludingOverAllotmentOfSharesMember_C19133A2E23D4D3790FE9A55FF22E900" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PublicStockOfferingIncludingOverAllotmentOfSharesMember_C19133A2E23D4D3790FE9A55FF22E900" xlink:to="lab_dare_PublicStockOfferingIncludingOverAllotmentOfSharesMember_C19133A2E23D4D3790FE9A55FF22E900" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_FC2F473B823399E439F89A55FF22FD25_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_FC2F473B823399E439F89A55FF22FD25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_FC2F473B823399E439F89A55FF22FD25_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_FC2F473B823399E439F89A55FF22FD25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_FC2F473B823399E439F89A55FF22FD25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_FC2F473B823399E439F89A55FF22FD25" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_FC2F473B823399E439F89A55FF22FD25" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_8CE836CD3355C069223F9A55FF22590C_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_8CE836CD3355C069223F9A55FF22590C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_8CE836CD3355C069223F9A55FF22590C_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_8CE836CD3355C069223F9A55FF22590C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8CE836CD3355C069223F9A55FF22590C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8CE836CD3355C069223F9A55FF22590C" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_8CE836CD3355C069223F9A55FF22590C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_6236177671D2003C93649A55FF22BDD6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_6236177671D2003C93649A55FF22BDD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_6236177671D2003C93649A55FF22BDD6_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_6236177671D2003C93649A55FF22BDD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_6236177671D2003C93649A55FF22BDD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_6236177671D2003C93649A55FF22BDD6" xlink:to="lab_us-gaap_SubsequentEventMember_6236177671D2003C93649A55FF22BDD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_0E63A6C63F07269864219A55FF225403_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_0E63A6C63F07269864219A55FF225403" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_0E63A6C63F07269864219A55FF225403_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_0E63A6C63F07269864219A55FF225403" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0E63A6C63F07269864219A55FF225403" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_0E63A6C63F07269864219A55FF225403" xlink:to="lab_us-gaap_SubsequentEventLineItems_0E63A6C63F07269864219A55FF225403" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_E07D90359D3B2F5BD6779A55FF229C71_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_E07D90359D3B2F5BD6779A55FF229C71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued in the Offering (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_E07D90359D3B2F5BD6779A55FF229C71_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_E07D90359D3B2F5BD6779A55FF229C71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_E07D90359D3B2F5BD6779A55FF229C71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_E07D90359D3B2F5BD6779A55FF229C71" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_E07D90359D3B2F5BD6779A55FF229C71" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_1BC98667892A513497549A55FF227BF1_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_1BC98667892A513497549A55FF227BF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public offering price in the Offering (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_1BC98667892A513497549A55FF227BF1_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_1BC98667892A513497549A55FF227BF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1BC98667892A513497549A55FF227BF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_1BC98667892A513497549A55FF227BF1" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_1BC98667892A513497549A55FF227BF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_886995828302A43896A39A55FF225EB7_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_886995828302A43896A39A55FF225EB7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds received in public offering</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_886995828302A43896A39A55FF225EB7_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_886995828302A43896A39A55FF225EB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_886995828302A43896A39A55FF225EB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_886995828302A43896A39A55FF225EB7" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_886995828302A43896A39A55FF225EB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_36FD42EB216DB962DD6F9A55FF22C169_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_36FD42EB216DB962DD6F9A55FF22C169" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds received in public offering, net of underwriting discounts and offering expenses</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_36FD42EB216DB962DD6F9A55FF22C169_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_36FD42EB216DB962DD6F9A55FF22C169" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_36FD42EB216DB962DD6F9A55FF22C169" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_36FD42EB216DB962DD6F9A55FF22C169" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_36FD42EB216DB962DD6F9A55FF22C169" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_2A736DD6F9B3D560842C9A55FF26535A_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_2A736DD6F9B3D560842C9A55FF26535A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outstanding warrants to purchase (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_2A736DD6F9B3D560842C9A55FF26535A_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_2A736DD6F9B3D560842C9A55FF26535A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2A736DD6F9B3D560842C9A55FF26535A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2A736DD6F9B3D560842C9A55FF26535A" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_2A736DD6F9B3D560842C9A55FF26535A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_C3C9FAC04200104FE9849A55FF26EE3D_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_C3C9FAC04200104FE9849A55FF26EE3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_C3C9FAC04200104FE9849A55FF26EE3D_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_C3C9FAC04200104FE9849A55FF26EE3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_C3C9FAC04200104FE9849A55FF26EE3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_C3C9FAC04200104FE9849A55FF26EE3D" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_C3C9FAC04200104FE9849A55FF26EE3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_9B95EB975FB076A9931D98953F31ED26_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_9B95EB975FB076A9931D98953F31ED26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_9B95EB975FB076A9931D98953F31ED26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_9B95EB975FB076A9931D98953F31ED26" xlink:to="lab_us-gaap_IncomeStatementAbstract_9B95EB975FB076A9931D98953F31ED26" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_3E2032EDAA9D158D248598953F312E1D_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_3E2032EDAA9D158D248598953F312E1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_3E2032EDAA9D158D248598953F312E1D_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_3E2032EDAA9D158D248598953F312E1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_3E2032EDAA9D158D248598953F312E1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3E2032EDAA9D158D248598953F312E1D" xlink:to="lab_us-gaap_OperatingExpensesAbstract_3E2032EDAA9D158D248598953F312E1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_1171F5538C0EA6545C4798953F314823_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_1171F5538C0EA6545C4798953F314823" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_1171F5538C0EA6545C4798953F314823_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_1171F5538C0EA6545C4798953F314823" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1171F5538C0EA6545C4798953F314823" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_1171F5538C0EA6545C4798953F314823" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_1171F5538C0EA6545C4798953F314823" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_62835F46B665ABD7E86098953F3294FA_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_62835F46B665ABD7E86098953F3294FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_62835F46B665ABD7E86098953F3294FA_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_62835F46B665ABD7E86098953F3294FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_62835F46B665ABD7E86098953F3294FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_62835F46B665ABD7E86098953F3294FA" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_62835F46B665ABD7E86098953F3294FA" xlink:type="arc" />
    <link:label id="lab_dare_LicenseFee_23CCFE06152080F3309698953F32C16B_terseLabel_en-US" xlink:label="lab_dare_LicenseFee_23CCFE06152080F3309698953F32C16B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License expenses</link:label>
    <link:label id="lab_dare_LicenseFee_23CCFE06152080F3309698953F32C16B_label_en-US" xlink:label="lab_dare_LicenseFee_23CCFE06152080F3309698953F32C16B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Fee</link:label>
    <link:label id="lab_dare_LicenseFee_23CCFE06152080F3309698953F32C16B_documentation_en-US" xlink:label="lab_dare_LicenseFee_23CCFE06152080F3309698953F32C16B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Fee</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseFee" xlink:label="loc_dare_LicenseFee_23CCFE06152080F3309698953F32C16B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseFee_23CCFE06152080F3309698953F32C16B" xlink:to="lab_dare_LicenseFee_23CCFE06152080F3309698953F32C16B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_4C0BD30350432AB1AFAC98953F32B9D6_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_4C0BD30350432AB1AFAC98953F32B9D6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_4C0BD30350432AB1AFAC98953F32B9D6_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_4C0BD30350432AB1AFAC98953F32B9D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_4C0BD30350432AB1AFAC98953F32B9D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_4C0BD30350432AB1AFAC98953F32B9D6" xlink:to="lab_us-gaap_OperatingExpenses_4C0BD30350432AB1AFAC98953F32B9D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_E0E7F18781E37DEBB68498953F32985A_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_E0E7F18781E37DEBB68498953F32985A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_E0E7F18781E37DEBB68498953F32985A_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_E0E7F18781E37DEBB68498953F32985A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_E0E7F18781E37DEBB68498953F32985A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_E0E7F18781E37DEBB68498953F32985A" xlink:to="lab_us-gaap_OperatingIncomeLoss_E0E7F18781E37DEBB68498953F32985A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_7DD19B35DC5BE04302F798953F33997A_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_7DD19B35DC5BE04302F798953F33997A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_7DD19B35DC5BE04302F798953F33997A_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_7DD19B35DC5BE04302F798953F33997A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7DD19B35DC5BE04302F798953F33997A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_7DD19B35DC5BE04302F798953F33997A" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_7DD19B35DC5BE04302F798953F33997A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_6C59008EF4D3EF03BB1198953F3388FF_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_6C59008EF4D3EF03BB1198953F3388FF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_6C59008EF4D3EF03BB1198953F3388FF_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_6C59008EF4D3EF03BB1198953F3388FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_6C59008EF4D3EF03BB1198953F3388FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_6C59008EF4D3EF03BB1198953F3388FF" xlink:to="lab_us-gaap_NetIncomeLoss_6C59008EF4D3EF03BB1198953F3388FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_E3F85B784686DE6A24A598953F33926F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_E3F85B784686DE6A24A598953F33926F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_E3F85B784686DE6A24A598953F33926F_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_E3F85B784686DE6A24A598953F33926F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_E3F85B784686DE6A24A598953F33926F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_E3F85B784686DE6A24A598953F33926F" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_E3F85B784686DE6A24A598953F33926F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_56566AB84F7C1EF7E9FF98953F332116_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_56566AB84F7C1EF7E9FF98953F332116" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_56566AB84F7C1EF7E9FF98953F332116_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_56566AB84F7C1EF7E9FF98953F332116" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_56566AB84F7C1EF7E9FF98953F332116" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_56566AB84F7C1EF7E9FF98953F332116" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_56566AB84F7C1EF7E9FF98953F332116" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_46D95E701B8A457EB3CD98953F332419_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_46D95E701B8A457EB3CD98953F332419" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss per common share - basic and diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_46D95E701B8A457EB3CD98953F332419_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_46D95E701B8A457EB3CD98953F332419" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_46D95E701B8A457EB3CD98953F332419" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_46D95E701B8A457EB3CD98953F332419" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_46D95E701B8A457EB3CD98953F332419" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_D3B9167ECF2C28DA403E98953F3307C4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_D3B9167ECF2C28DA403E98953F3307C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_D3B9167ECF2C28DA403E98953F3307C4_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_D3B9167ECF2C28DA403E98953F3307C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_D3B9167ECF2C28DA403E98953F3307C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_D3B9167ECF2C28DA403E98953F3307C4" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_D3B9167ECF2C28DA403E98953F3307C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_6765405C1D1C312512F498953F3463BF_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_6765405C1D1C312512F498953F3463BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_6765405C1D1C312512F498953F3463BF_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_6765405C1D1C312512F498953F3463BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_6765405C1D1C312512F498953F3463BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_6765405C1D1C312512F498953F3463BF" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_6765405C1D1C312512F498953F3463BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_66D586C4FD1C123940795B0CFD3B80D5_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_66D586C4FD1C123940795B0CFD3B80D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_66D586C4FD1C123940795B0CFD3B80D5_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_66D586C4FD1C123940795B0CFD3B80D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_66D586C4FD1C123940795B0CFD3B80D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_66D586C4FD1C123940795B0CFD3B80D5" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_66D586C4FD1C123940795B0CFD3B80D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9011CCD548C94268B8655B0CFC3E571D_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9011CCD548C94268B8655B0CFC3E571D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9011CCD548C94268B8655B0CFC3E571D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9011CCD548C94268B8655B0CFC3E571D" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9011CCD548C94268B8655B0CFC3E571D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsDisclosureTextBlock_EC017C87C964FC242A865B0CFC3FE23B_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock_EC017C87C964FC242A865B0CFC3FE23B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsDisclosureTextBlock_EC017C87C964FC242A865B0CFC3FE23B_label_en-US" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock_EC017C87C964FC242A865B0CFC3FE23B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_EC017C87C964FC242A865B0CFC3FE23B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsDisclosureTextBlock_EC017C87C964FC242A865B0CFC3FE23B" xlink:to="lab_us-gaap_CommitmentsDisclosureTextBlock_EC017C87C964FC242A865B0CFC3FE23B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_C495553BD32D79B05D3C51507F8AEAB7_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_C495553BD32D79B05D3C51507F8AEAB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_C495553BD32D79B05D3C51507F8AEAB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_C495553BD32D79B05D3C51507F8AEAB7" xlink:to="lab_us-gaap_EarningsPerShareAbstract_C495553BD32D79B05D3C51507F8AEAB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A5F31AE7E735460E67C551507F8ADD30_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A5F31AE7E735460E67C551507F8ADD30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A5F31AE7E735460E67C551507F8ADD30_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A5F31AE7E735460E67C551507F8ADD30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A5F31AE7E735460E67C551507F8ADD30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A5F31AE7E735460E67C551507F8ADD30" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A5F31AE7E735460E67C551507F8ADD30" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_654A15EAD8614C64865E51507F8A5EAC_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_654A15EAD8614C64865E51507F8A5EAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_654A15EAD8614C64865E51507F8A5EAC_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_654A15EAD8614C64865E51507F8A5EAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_654A15EAD8614C64865E51507F8A5EAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_654A15EAD8614C64865E51507F8A5EAC" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_654A15EAD8614C64865E51507F8A5EAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_DEC83A89638BA53C6CDD51507F8B632A_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_DEC83A89638BA53C6CDD51507F8B632A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_DEC83A89638BA53C6CDD51507F8B632A_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_DEC83A89638BA53C6CDD51507F8B632A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DEC83A89638BA53C6CDD51507F8B632A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DEC83A89638BA53C6CDD51507F8B632A" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_DEC83A89638BA53C6CDD51507F8B632A" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_F8FF28106EE0E5A8D6EB51507F8B530F_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_F8FF28106EE0E5A8D6EB51507F8B530F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants [Member]</link:label>
    <link:label id="lab_us-gaap_WarrantMember_F8FF28106EE0E5A8D6EB51507F8B530F_label_en-US" xlink:label="lab_us-gaap_WarrantMember_F8FF28106EE0E5A8D6EB51507F8B530F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_F8FF28106EE0E5A8D6EB51507F8B530F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_F8FF28106EE0E5A8D6EB51507F8B530F" xlink:to="lab_us-gaap_WarrantMember_F8FF28106EE0E5A8D6EB51507F8B530F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B0F328129B771F7D176151507F8BA25B_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B0F328129B771F7D176151507F8BA25B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B0F328129B771F7D176151507F8BA25B_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B0F328129B771F7D176151507F8BA25B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B0F328129B771F7D176151507F8BA25B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B0F328129B771F7D176151507F8BA25B" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B0F328129B771F7D176151507F8BA25B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_29798CE20C589852D4B951507F8C0398_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_29798CE20C589852D4B951507F8C0398" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_29798CE20C589852D4B951507F8C0398_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_29798CE20C589852D4B951507F8C0398" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_29798CE20C589852D4B951507F8C0398" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_29798CE20C589852D4B951507F8C0398" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_29798CE20C589852D4B951507F8C0398" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeasesAbstract_A8BAF487FA566CDE2B57558B20859328_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract_A8BAF487FA566CDE2B57558B20859328" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_A8BAF487FA566CDE2B57558B20859328" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract_A8BAF487FA566CDE2B57558B20859328" xlink:to="lab_us-gaap_LeasesAbstract_A8BAF487FA566CDE2B57558B20859328" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4FA3ED0D4EA58762368555940C2DFC09_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4FA3ED0D4EA58762368555940C2DFC09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4FA3ED0D4EA58762368555940C2DFC09_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4FA3ED0D4EA58762368555940C2DFC09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4FA3ED0D4EA58762368555940C2DFC09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4FA3ED0D4EA58762368555940C2DFC09" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4FA3ED0D4EA58762368555940C2DFC09" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_47947645EBAF5BA368994AFD87A9CB15_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_47947645EBAF5BA368994AFD87A9CB15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_47947645EBAF5BA368994AFD87A9CB15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_47947645EBAF5BA368994AFD87A9CB15" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_47947645EBAF5BA368994AFD87A9CB15" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_DE883CE1F5ACA9FB28AB4AFD87A90115_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_DE883CE1F5ACA9FB28AB4AFD87A90115" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_DE883CE1F5ACA9FB28AB4AFD87A90115_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_DE883CE1F5ACA9FB28AB4AFD87A90115" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_DE883CE1F5ACA9FB28AB4AFD87A90115" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_DE883CE1F5ACA9FB28AB4AFD87A90115" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_DE883CE1F5ACA9FB28AB4AFD87A90115" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_42774BA14B3F9AE466784AFD87A944E4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_42774BA14B3F9AE466784AFD87A944E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_42774BA14B3F9AE466784AFD87A944E4_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_42774BA14B3F9AE466784AFD87A944E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_42774BA14B3F9AE466784AFD87A944E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_42774BA14B3F9AE466784AFD87A944E4" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_42774BA14B3F9AE466784AFD87A944E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_445473AEC3E5D80A9CE84AFD87A9C16C_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_445473AEC3E5D80A9CE84AFD87A9C16C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_445473AEC3E5D80A9CE84AFD87A9C16C_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_445473AEC3E5D80A9CE84AFD87A9C16C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_445473AEC3E5D80A9CE84AFD87A9C16C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_445473AEC3E5D80A9CE84AFD87A9C16C" xlink:to="lab_us-gaap_PreferredStockSharesIssued_445473AEC3E5D80A9CE84AFD87A9C16C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_E0B9F9ACB71325C4A9524AFD87A9DC4E_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_E0B9F9ACB71325C4A9524AFD87A9DC4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_E0B9F9ACB71325C4A9524AFD87A9DC4E_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_E0B9F9ACB71325C4A9524AFD87A9DC4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_E0B9F9ACB71325C4A9524AFD87A9DC4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_E0B9F9ACB71325C4A9524AFD87A9DC4E" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_E0B9F9ACB71325C4A9524AFD87A9DC4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_4C203616CB1F8C6B2BA24AFD87AA0329_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_4C203616CB1F8C6B2BA24AFD87AA0329" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_4C203616CB1F8C6B2BA24AFD87AA0329_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_4C203616CB1F8C6B2BA24AFD87AA0329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4C203616CB1F8C6B2BA24AFD87AA0329" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_4C203616CB1F8C6B2BA24AFD87AA0329" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_4C203616CB1F8C6B2BA24AFD87AA0329" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_4D5F6671C099F82A84E94AFD87AA93B5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_4D5F6671C099F82A84E94AFD87AA93B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_4D5F6671C099F82A84E94AFD87AA93B5_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_4D5F6671C099F82A84E94AFD87AA93B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4D5F6671C099F82A84E94AFD87AA93B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_4D5F6671C099F82A84E94AFD87AA93B5" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_4D5F6671C099F82A84E94AFD87AA93B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_3BC28C6E72004E449D8A4AFD87AAA191_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_3BC28C6E72004E449D8A4AFD87AAA191" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_3BC28C6E72004E449D8A4AFD87AAA191_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_3BC28C6E72004E449D8A4AFD87AAA191" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_3BC28C6E72004E449D8A4AFD87AAA191" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_3BC28C6E72004E449D8A4AFD87AAA191" xlink:to="lab_us-gaap_CommonStockSharesIssued_3BC28C6E72004E449D8A4AFD87AAA191" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ACFFBBD10E1A526332C54AFD87AA9B8F_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_ACFFBBD10E1A526332C54AFD87AA9B8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ACFFBBD10E1A526332C54AFD87AA9B8F_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_ACFFBBD10E1A526332C54AFD87AA9B8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ACFFBBD10E1A526332C54AFD87AA9B8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_ACFFBBD10E1A526332C54AFD87AA9B8F" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_ACFFBBD10E1A526332C54AFD87AA9B8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_98C7F8F7887E1B1937D9B919C3CAF639_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0CE9F1B1F68357CD9BDD1C5305FC6BF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Description of the Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_98C7F8F7887E1B1937D9B919C3CAF639_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0CE9F1B1F68357CD9BDD1C5305FC6BF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0CE9F1B1F68357CD9BDD1C5305FC6BF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0CE9F1B1F68357CD9BDD1C5305FC6BF1" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0CE9F1B1F68357CD9BDD1C5305FC6BF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_25A683F3ED379DEBFC3E9A5601BB4B53_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_25A683F3ED379DEBFC3E9A5601BB4B53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_25A683F3ED379DEBFC3E9A5601BB4B53_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_25A683F3ED379DEBFC3E9A5601BB4B53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_25A683F3ED379DEBFC3E9A5601BB4B53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_25A683F3ED379DEBFC3E9A5601BB4B53" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_25A683F3ED379DEBFC3E9A5601BB4B53" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_48870CCDDB55825428849A5601BB2BB7_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_48870CCDDB55825428849A5601BB2BB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_48870CCDDB55825428849A5601BB2BB7_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_48870CCDDB55825428849A5601BB2BB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_48870CCDDB55825428849A5601BB2BB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_48870CCDDB55825428849A5601BB2BB7" xlink:to="lab_us-gaap_PlanNameAxis_48870CCDDB55825428849A5601BB2BB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_593BB9E5B2A015DC9AA09A5601BB13C4_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_593BB9E5B2A015DC9AA09A5601BB13C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_593BB9E5B2A015DC9AA09A5601BB13C4_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_593BB9E5B2A015DC9AA09A5601BB13C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_593BB9E5B2A015DC9AA09A5601BB13C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_593BB9E5B2A015DC9AA09A5601BB13C4" xlink:to="lab_us-gaap_PlanNameDomain_593BB9E5B2A015DC9AA09A5601BB13C4" xlink:type="arc" />
    <link:label id="lab_dare_TwoThousandAndFifteenStockIncentivePlanMember_35D3C39ECC2840F652749A5601BB6815_terseLabel_en-US" xlink:label="lab_dare_TwoThousandAndFifteenStockIncentivePlanMember_35D3C39ECC2840F652749A5601BB6815" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_dare_TwoThousandAndFifteenStockIncentivePlanMember_35D3C39ECC2840F652749A5601BB6815_label_en-US" xlink:label="lab_dare_TwoThousandAndFifteenStockIncentivePlanMember_35D3C39ECC2840F652749A5601BB6815" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Fifteen Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_dare_TwoThousandAndFifteenStockIncentivePlanMember_35D3C39ECC2840F652749A5601BB6815_documentation_en-US" xlink:label="lab_dare_TwoThousandAndFifteenStockIncentivePlanMember_35D3C39ECC2840F652749A5601BB6815" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand And Fifteen Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_TwoThousandAndFifteenStockIncentivePlanMember" xlink:label="loc_dare_TwoThousandAndFifteenStockIncentivePlanMember_35D3C39ECC2840F652749A5601BB6815" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_TwoThousandAndFifteenStockIncentivePlanMember_35D3C39ECC2840F652749A5601BB6815" xlink:to="lab_dare_TwoThousandAndFifteenStockIncentivePlanMember_35D3C39ECC2840F652749A5601BB6815" xlink:type="arc" />
    <link:label id="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_459BAB6B343E1E39EC069A5601BB289D_terseLabel_en-US" xlink:label="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_459BAB6B343E1E39EC069A5601BB289D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2014 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_459BAB6B343E1E39EC069A5601BB289D_label_en-US" xlink:label="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_459BAB6B343E1E39EC069A5601BB289D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Fourteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_459BAB6B343E1E39EC069A5601BB289D_documentation_en-US" xlink:label="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_459BAB6B343E1E39EC069A5601BB289D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand and fourteen employee stock purchase plan.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:label="loc_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_459BAB6B343E1E39EC069A5601BB289D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_459BAB6B343E1E39EC069A5601BB289D" xlink:to="lab_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_459BAB6B343E1E39EC069A5601BB289D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockMember_22B1F453F634535B5F6D9A5601BBEA70_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_22B1F453F634535B5F6D9A5601BBEA70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_22B1F453F634535B5F6D9A5601BBEA70_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_22B1F453F634535B5F6D9A5601BBEA70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_22B1F453F634535B5F6D9A5601BBEA70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember_22B1F453F634535B5F6D9A5601BBEA70" xlink:to="lab_us-gaap_RestrictedStockMember_22B1F453F634535B5F6D9A5601BBEA70" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_4217EA82834CB80D25A39A5601BBC2E6_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_4217EA82834CB80D25A39A5601BBC2E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity</link:label>
    <link:label id="lab_dei_LegalEntityAxis_4217EA82834CB80D25A39A5601BBC2E6_label_en-US" xlink:label="lab_dei_LegalEntityAxis_4217EA82834CB80D25A39A5601BBC2E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4217EA82834CB80D25A39A5601BBC2E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_4217EA82834CB80D25A39A5601BBC2E6" xlink:to="lab_dei_LegalEntityAxis_4217EA82834CB80D25A39A5601BBC2E6" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_ACE2091CE3A407297A639A5601BB1019_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_ACE2091CE3A407297A639A5601BB1019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity</link:label>
    <link:label id="lab_dei_EntityDomain_ACE2091CE3A407297A639A5601BB1019_label_en-US" xlink:label="lab_dei_EntityDomain_ACE2091CE3A407297A639A5601BB1019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_ACE2091CE3A407297A639A5601BB1019" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_ACE2091CE3A407297A639A5601BB1019" xlink:to="lab_dei_EntityDomain_ACE2091CE3A407297A639A5601BB1019" xlink:type="arc" />
    <link:label id="lab_dare_PrivateDareMember_078104A728AF77BAA2939A5601BB852F_terseLabel_en-US" xlink:label="lab_dare_PrivateDareMember_078104A728AF77BAA2939A5601BB852F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Dare [Member]</link:label>
    <link:label id="lab_dare_PrivateDareMember_078104A728AF77BAA2939A5601BB852F_label_en-US" xlink:label="lab_dare_PrivateDareMember_078104A728AF77BAA2939A5601BB852F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Dare [Member]</link:label>
    <link:label id="lab_dare_PrivateDareMember_078104A728AF77BAA2939A5601BB852F_documentation_en-US" xlink:label="lab_dare_PrivateDareMember_078104A728AF77BAA2939A5601BB852F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Private Dare.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_PrivateDareMember" xlink:label="loc_dare_PrivateDareMember_078104A728AF77BAA2939A5601BB852F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PrivateDareMember_078104A728AF77BAA2939A5601BB852F" xlink:to="lab_dare_PrivateDareMember_078104A728AF77BAA2939A5601BB852F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_45FD996FCF17AC5EB0A49A5601BB7622_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_45FD996FCF17AC5EB0A49A5601BB7622" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options grant period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_45FD996FCF17AC5EB0A49A5601BB7622_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_45FD996FCF17AC5EB0A49A5601BB7622" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_45FD996FCF17AC5EB0A49A5601BB7622" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_45FD996FCF17AC5EB0A49A5601BB7622" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_45FD996FCF17AC5EB0A49A5601BB7622" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_CF43963E2637D82475139A5601BBFC2A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_CF43963E2637D82475139A5601BBFC2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_CF43963E2637D82475139A5601BBFC2A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_CF43963E2637D82475139A5601BBFC2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_CF43963E2637D82475139A5601BBFC2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_CF43963E2637D82475139A5601BBFC2A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_CF43963E2637D82475139A5601BBFC2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_22E2D28E31EED35999179A5601BB8ED5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_22E2D28E31EED35999179A5601BB8ED5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_22E2D28E31EED35999179A5601BB8ED5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_22E2D28E31EED35999179A5601BB8ED5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_22E2D28E31EED35999179A5601BB8ED5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_22E2D28E31EED35999179A5601BB8ED5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_22E2D28E31EED35999179A5601BB8ED5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_EEE994B2C10CBD6737AD9A5601BB869E_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_EEE994B2C10CBD6737AD9A5601BB869E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued to non-employees (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_EEE994B2C10CBD6737AD9A5601BB869E_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_EEE994B2C10CBD6737AD9A5601BB869E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_EEE994B2C10CBD6737AD9A5601BB869E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_EEE994B2C10CBD6737AD9A5601BB869E" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_EEE994B2C10CBD6737AD9A5601BB869E" xlink:type="arc" />
    <link:label id="lab_dare_OfferingPeriod_9FB0BCD7BD8A0DAE83B29A5601BBD38A_terseLabel_en-US" xlink:label="lab_dare_OfferingPeriod_9FB0BCD7BD8A0DAE83B29A5601BBD38A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering period</link:label>
    <link:label id="lab_dare_OfferingPeriod_9FB0BCD7BD8A0DAE83B29A5601BBD38A_label_en-US" xlink:label="lab_dare_OfferingPeriod_9FB0BCD7BD8A0DAE83B29A5601BBD38A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offering Period</link:label>
    <link:label id="lab_dare_OfferingPeriod_9FB0BCD7BD8A0DAE83B29A5601BBD38A_documentation_en-US" xlink:label="lab_dare_OfferingPeriod_9FB0BCD7BD8A0DAE83B29A5601BBD38A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Offering period.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_OfferingPeriod" xlink:label="loc_dare_OfferingPeriod_9FB0BCD7BD8A0DAE83B29A5601BBD38A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_OfferingPeriod_9FB0BCD7BD8A0DAE83B29A5601BBD38A" xlink:to="lab_dare_OfferingPeriod_9FB0BCD7BD8A0DAE83B29A5601BBD38A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B469C966899CB3DDAE989A5601BB87E8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B469C966899CB3DDAE989A5601BB87E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price as percentage of stock price on offering period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B469C966899CB3DDAE989A5601BB87E8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B469C966899CB3DDAE989A5601BB87E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B469C966899CB3DDAE989A5601BB87E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B469C966899CB3DDAE989A5601BB87E8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B469C966899CB3DDAE989A5601BB87E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4C79DB18BAFDB9C7E8D89A5601BB0868_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4C79DB18BAFDB9C7E8D89A5601BB0868" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options to purchase number of outstanding shares of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4C79DB18BAFDB9C7E8D89A5601BB0868_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4C79DB18BAFDB9C7E8D89A5601BB0868" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4C79DB18BAFDB9C7E8D89A5601BB0868" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4C79DB18BAFDB9C7E8D89A5601BB0868" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4C79DB18BAFDB9C7E8D89A5601BB0868" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_679E315D7AFC0ECED3319A5601BBD58B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_679E315D7AFC0ECED3319A5601BBD58B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual percentage increase in outstanding number of common stock</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_679E315D7AFC0ECED3319A5601BBD58B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_679E315D7AFC0ECED3319A5601BBD58B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_679E315D7AFC0ECED3319A5601BBD58B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_679E315D7AFC0ECED3319A5601BBD58B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_679E315D7AFC0ECED3319A5601BBD58B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_9DC187901A1D38110D809A6EE7F997B6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_9DC187901A1D38110D809A6EE7F997B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_9DC187901A1D38110D809A6EE7F997B6_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_9DC187901A1D38110D809A6EE7F997B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_9DC187901A1D38110D809A6EE7F997B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_9DC187901A1D38110D809A6EE7F997B6" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_9DC187901A1D38110D809A6EE7F997B6" xlink:type="arc" />
    <link:label id="lab_dare_PeriodOfTerminationOfStockOptionsVestedAfterTerminationDate_1CE2001FEDDDC23D0DD59A5601CB739D_terseLabel_en-US" xlink:label="lab_dare_PeriodOfTerminationOfStockOptionsVestedAfterTerminationDate_1CE2001FEDDDC23D0DD59A5601CB739D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise period for stock options after termination date</link:label>
    <link:label id="lab_dare_PeriodOfTerminationOfStockOptionsVestedAfterTerminationDate_1CE2001FEDDDC23D0DD59A5601CB739D_label_en-US" xlink:label="lab_dare_PeriodOfTerminationOfStockOptionsVestedAfterTerminationDate_1CE2001FEDDDC23D0DD59A5601CB739D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Of Termination Of Stock Options Vested After Termination Date</link:label>
    <link:label id="lab_dare_PeriodOfTerminationOfStockOptionsVestedAfterTerminationDate_1CE2001FEDDDC23D0DD59A5601CB739D_documentation_en-US" xlink:label="lab_dare_PeriodOfTerminationOfStockOptionsVestedAfterTerminationDate_1CE2001FEDDDC23D0DD59A5601CB739D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period of termination of stock options vested after termination date.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_PeriodOfTerminationOfStockOptionsVestedAfterTerminationDate" xlink:label="loc_dare_PeriodOfTerminationOfStockOptionsVestedAfterTerminationDate_1CE2001FEDDDC23D0DD59A5601CB739D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PeriodOfTerminationOfStockOptionsVestedAfterTerminationDate_1CE2001FEDDDC23D0DD59A5601CB739D" xlink:to="lab_dare_PeriodOfTerminationOfStockOptionsVestedAfterTerminationDate_1CE2001FEDDDC23D0DD59A5601CB739D" xlink:type="arc" />
    <link:label id="lab_dare_UnamortizedFairValueExpenseInStockPurchaseTransaction_DC867681B9F98682B0949A5601CB6549_terseLabel_en-US" xlink:label="lab_dare_UnamortizedFairValueExpenseInStockPurchaseTransaction_DC867681B9F98682B0949A5601CB6549" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized fair value expense</link:label>
    <link:label id="lab_dare_UnamortizedFairValueExpenseInStockPurchaseTransaction_DC867681B9F98682B0949A5601CB6549_label_en-US" xlink:label="lab_dare_UnamortizedFairValueExpenseInStockPurchaseTransaction_DC867681B9F98682B0949A5601CB6549" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unamortized Fair Value Expense In Stock Purchase Transaction</link:label>
    <link:label id="lab_dare_UnamortizedFairValueExpenseInStockPurchaseTransaction_DC867681B9F98682B0949A5601CB6549_documentation_en-US" xlink:label="lab_dare_UnamortizedFairValueExpenseInStockPurchaseTransaction_DC867681B9F98682B0949A5601CB6549" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unamortized fair value expense in stock purchase transaction.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_UnamortizedFairValueExpenseInStockPurchaseTransaction" xlink:label="loc_dare_UnamortizedFairValueExpenseInStockPurchaseTransaction_DC867681B9F98682B0949A5601CB6549" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UnamortizedFairValueExpenseInStockPurchaseTransaction_DC867681B9F98682B0949A5601CB6549" xlink:to="lab_dare_UnamortizedFairValueExpenseInStockPurchaseTransaction_DC867681B9F98682B0949A5601CB6549" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2BB48A3A6E3037F185429A5601CB6EC7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2BB48A3A6E3037F185429A5601CB6EC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2BB48A3A6E3037F185429A5601CB6EC7_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2BB48A3A6E3037F185429A5601CB6EC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2BB48A3A6E3037F185429A5601CB6EC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2BB48A3A6E3037F185429A5601CB6EC7" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2BB48A3A6E3037F185429A5601CB6EC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_A428667660A593200A5E9A5601CB637F_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_A428667660A593200A5E9A5601CB637F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_A428667660A593200A5E9A5601CB637F_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_A428667660A593200A5E9A5601CB637F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_A428667660A593200A5E9A5601CB637F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_A428667660A593200A5E9A5601CB637F" xlink:to="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_A428667660A593200A5E9A5601CB637F" xlink:type="arc" />
    <link:label id="lab_dare_WeightedAverageAmortizationPeriod_6259CC02B14BEC3204FE9A5601CB8829_terseLabel_en-US" xlink:label="lab_dare_WeightedAverageAmortizationPeriod_6259CC02B14BEC3204FE9A5601CB8829" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized weighted average period</link:label>
    <link:label id="lab_dare_WeightedAverageAmortizationPeriod_6259CC02B14BEC3204FE9A5601CB8829_label_en-US" xlink:label="lab_dare_WeightedAverageAmortizationPeriod_6259CC02B14BEC3204FE9A5601CB8829" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Amortization Period</link:label>
    <link:label id="lab_dare_WeightedAverageAmortizationPeriod_6259CC02B14BEC3204FE9A5601CB8829_documentation_en-US" xlink:label="lab_dare_WeightedAverageAmortizationPeriod_6259CC02B14BEC3204FE9A5601CB8829" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Amortization Period</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_WeightedAverageAmortizationPeriod" xlink:label="loc_dare_WeightedAverageAmortizationPeriod_6259CC02B14BEC3204FE9A5601CB8829" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_WeightedAverageAmortizationPeriod_6259CC02B14BEC3204FE9A5601CB8829" xlink:to="lab_dare_WeightedAverageAmortizationPeriod_6259CC02B14BEC3204FE9A5601CB8829" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_2CF1273DBD2CFE613F799A5601CB5726_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_2CF1273DBD2CFE613F799A5601CB5726" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_2CF1273DBD2CFE613F799A5601CB5726" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_2CF1273DBD2CFE613F799A5601CB5726" xlink:to="lab_us-gaap_CommonStockSharesIssued_2CF1273DBD2CFE613F799A5601CB5726" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1E9A5BEA833D05630757A2CBCDE0C7A2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1E9A5BEA833D05630757A2CBCDE0C7A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remainder of 2019</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1E9A5BEA833D05630757A2CBCDE0C7A2_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1E9A5BEA833D05630757A2CBCDE0C7A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1E9A5BEA833D05630757A2CBCDE0C7A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1E9A5BEA833D05630757A2CBCDE0C7A2" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1E9A5BEA833D05630757A2CBCDE0C7A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_98FD05DB67D25A812E16A2CAE89DDC2E_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_98FD05DB67D25A812E16A2CAE89DDC2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_98FD05DB67D25A812E16A2CAE89DDC2E_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_98FD05DB67D25A812E16A2CAE89DDC2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_98FD05DB67D25A812E16A2CAE89DDC2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_98FD05DB67D25A812E16A2CAE89DDC2E" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_98FD05DB67D25A812E16A2CAE89DDC2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_D077CEB697C13FF63BABA2CAE89EECA1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_D077CEB697C13FF63BABA2CAE89EECA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_D077CEB697C13FF63BABA2CAE89EECA1_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_D077CEB697C13FF63BABA2CAE89EECA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_D077CEB697C13FF63BABA2CAE89EECA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_D077CEB697C13FF63BABA2CAE89EECA1" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_D077CEB697C13FF63BABA2CAE89EECA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_09EBD0CC9160696B4F95A2CAE89ED71C_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_09EBD0CC9160696B4F95A2CAE89ED71C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_09EBD0CC9160696B4F95A2CAE89ED71C_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_09EBD0CC9160696B4F95A2CAE89ED71C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_09EBD0CC9160696B4F95A2CAE89ED71C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_09EBD0CC9160696B4F95A2CAE89ED71C" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_09EBD0CC9160696B4F95A2CAE89ED71C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1ED25BCFE2168B004790A2CAE89EBBFB_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1ED25BCFE2168B004790A2CAE89EBBFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Difference between future minimum lease payments and discounted operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1ED25BCFE2168B004790A2CAE89EBBFB_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1ED25BCFE2168B004790A2CAE89EBBFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1ED25BCFE2168B004790A2CAE89EBBFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1ED25BCFE2168B004790A2CAE89EBBFB" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1ED25BCFE2168B004790A2CAE89EBBFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_CA9AC81015DDC2FC3169A2CAE89E149B_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_CA9AC81015DDC2FC3169A2CAE89E149B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_CA9AC81015DDC2FC3169A2CAE89E149B_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_CA9AC81015DDC2FC3169A2CAE89E149B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_CA9AC81015DDC2FC3169A2CAE89E149B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_CA9AC81015DDC2FC3169A2CAE89E149B" xlink:to="lab_us-gaap_OperatingLeaseLiability_CA9AC81015DDC2FC3169A2CAE89E149B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_863B1DB00957354336AF51507FDC3C5E_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_863B1DB00957354336AF51507FDC3C5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_863B1DB00957354336AF51507FDC3C5E_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_863B1DB00957354336AF51507FDC3C5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_863B1DB00957354336AF51507FDC3C5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_863B1DB00957354336AF51507FDC3C5E" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_863B1DB00957354336AF51507FDC3C5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_A315F35486D3CC7A787D51507FDCAFF8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_A315F35486D3CC7A787D51507FDCAFF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_A315F35486D3CC7A787D51507FDCAFF8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_A315F35486D3CC7A787D51507FDCAFF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_A315F35486D3CC7A787D51507FDCAFF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_A315F35486D3CC7A787D51507FDCAFF8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_A315F35486D3CC7A787D51507FDCAFF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_FCE4F1390870D2BD510B51507FDCDA55_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_FCE4F1390870D2BD510B51507FDCDA55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_FCE4F1390870D2BD510B51507FDCDA55_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_FCE4F1390870D2BD510B51507FDCDA55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_FCE4F1390870D2BD510B51507FDCDA55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_FCE4F1390870D2BD510B51507FDCDA55" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_FCE4F1390870D2BD510B51507FDCDA55" xlink:type="arc" />
    <link:label id="lab_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_FB72D966C540A0AC1FA951507FDC9B8C_terseLabel_en-US" xlink:label="lab_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_FB72D966C540A0AC1FA951507FDC9B8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeiture rate</link:label>
    <link:label id="lab_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_FB72D966C540A0AC1FA951507FDC9B8C_label_en-US" xlink:label="lab_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_FB72D966C540A0AC1FA951507FDC9B8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate</link:label>
    <link:label id="lab_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_FB72D966C540A0AC1FA951507FDC9B8C_documentation_en-US" xlink:label="lab_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_FB72D966C540A0AC1FA951507FDC9B8C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by Share-based payment award fair value assumptions forfeiture rate.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:label="loc_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_FB72D966C540A0AC1FA951507FDC9B8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_FB72D966C540A0AC1FA951507FDC9B8C" xlink:to="lab_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_FB72D966C540A0AC1FA951507FDC9B8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E97C4932FE6B27D49D8651507FDDC2E3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E97C4932FE6B27D49D8651507FDDC2E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E97C4932FE6B27D49D8651507FDDC2E3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E97C4932FE6B27D49D8651507FDDC2E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E97C4932FE6B27D49D8651507FDDC2E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E97C4932FE6B27D49D8651507FDDC2E3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E97C4932FE6B27D49D8651507FDDC2E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C0A9423F6C891813EEE251507FDD0D94_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C0A9423F6C891813EEE251507FDD0D94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average fair value of options granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C0A9423F6C891813EEE251507FDD0D94_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C0A9423F6C891813EEE251507FDD0D94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C0A9423F6C891813EEE251507FDD0D94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C0A9423F6C891813EEE251507FDD0D94" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C0A9423F6C891813EEE251507FDD0D94" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_F6AA5EB73D169996FD475B0CFCCA9A86_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_F6AA5EB73D169996FD475B0CFCCA9A86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leased Properties</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_F6AA5EB73D169996FD475B0CFCCA9A86_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_F6AA5EB73D169996FD475B0CFCCA9A86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_F6AA5EB73D169996FD475B0CFCCA9A86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_F6AA5EB73D169996FD475B0CFCCA9A86" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_F6AA5EB73D169996FD475B0CFCCA9A86" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesAbstract_F3ADC89DCC63EEF2AC485B0CFBCC2937_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract_F3ADC89DCC63EEF2AC485B0CFBCC2937" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaap_ReceivablesAbstract_F3ADC89DCC63EEF2AC485B0CFBCC2937" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract_F3ADC89DCC63EEF2AC485B0CFBCC2937" xlink:to="lab_us-gaap_ReceivablesAbstract_F3ADC89DCC63EEF2AC485B0CFBCC2937" xlink:type="arc" />
    <link:label id="lab_dare_GrantAwardTextBlock_60E5F4A97C48CE4E8EFC5B0CFBCCFC45_terseLabel_en-US" xlink:label="lab_dare_GrantAwardTextBlock_60E5F4A97C48CE4E8EFC5B0CFBCCFC45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant Award</link:label>
    <link:label id="lab_dare_GrantAwardTextBlock_60E5F4A97C48CE4E8EFC5B0CFBCCFC45_label_en-US" xlink:label="lab_dare_GrantAwardTextBlock_60E5F4A97C48CE4E8EFC5B0CFBCCFC45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant Award [Text Block]</link:label>
    <link:label id="lab_dare_GrantAwardTextBlock_60E5F4A97C48CE4E8EFC5B0CFBCCFC45_documentation_en-US" xlink:label="lab_dare_GrantAwardTextBlock_60E5F4A97C48CE4E8EFC5B0CFBCCFC45" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grant Award [Text Block]</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_GrantAwardTextBlock" xlink:label="loc_dare_GrantAwardTextBlock_60E5F4A97C48CE4E8EFC5B0CFBCCFC45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_GrantAwardTextBlock_60E5F4A97C48CE4E8EFC5B0CFBCCFC45" xlink:to="lab_dare_GrantAwardTextBlock_60E5F4A97C48CE4E8EFC5B0CFBCCFC45" xlink:type="arc" />
    <link:label id="lab_dare_CommitmentsAndContingenciesTable_38764C78A6D822C742859A560004D15D_terseLabel_en-US" xlink:label="lab_dare_CommitmentsAndContingenciesTable_38764C78A6D822C742859A560004D15D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_dare_CommitmentsAndContingenciesTable_38764C78A6D822C742859A560004D15D_label_en-US" xlink:label="lab_dare_CommitmentsAndContingenciesTable_38764C78A6D822C742859A560004D15D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_dare_CommitmentsAndContingenciesTable_38764C78A6D822C742859A560004D15D_documentation_en-US" xlink:label="lab_dare_CommitmentsAndContingenciesTable_38764C78A6D822C742859A560004D15D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_CommitmentsAndContingenciesTable" xlink:label="loc_dare_CommitmentsAndContingenciesTable_38764C78A6D822C742859A560004D15D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_CommitmentsAndContingenciesTable_38764C78A6D822C742859A560004D15D" xlink:to="lab_dare_CommitmentsAndContingenciesTable_38764C78A6D822C742859A560004D15D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_5226954CA22B824B3BF29A5600047536_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_5226954CA22B824B3BF29A5600047536" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Project</link:label>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_5226954CA22B824B3BF29A5600047536_label_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_5226954CA22B824B3BF29A5600047536" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Project [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_5226954CA22B824B3BF29A5600047536" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_5226954CA22B824B3BF29A5600047536" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_5226954CA22B824B3BF29A5600047536" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProjectMember_1204BFFFC315296D30709A5600044412_terseLabel_en-US" xlink:label="lab_us-gaap_ProjectMember_1204BFFFC315296D30709A5600044412" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Project</link:label>
    <link:label id="lab_us-gaap_ProjectMember_1204BFFFC315296D30709A5600044412_label_en-US" xlink:label="lab_us-gaap_ProjectMember_1204BFFFC315296D30709A5600044412" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Project [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_1204BFFFC315296D30709A5600044412" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember_1204BFFFC315296D30709A5600044412" xlink:to="lab_us-gaap_ProjectMember_1204BFFFC315296D30709A5600044412" xlink:type="arc" />
    <link:label id="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_98769D6901002B06AA839A560004BF7F_terseLabel_en-US" xlink:label="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_98769D6901002B06AA839A560004BF7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upon Achievement Of Specified Development And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_98769D6901002B06AA839A560004BF7F_label_en-US" xlink:label="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_98769D6901002B06AA839A560004BF7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upon Achievement Of Specified Development And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_98769D6901002B06AA839A560004BF7F_documentation_en-US" xlink:label="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_98769D6901002B06AA839A560004BF7F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upon achievement of specified development and regulatory milestones.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" xlink:label="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_98769D6901002B06AA839A560004BF7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_98769D6901002B06AA839A560004BF7F" xlink:to="lab_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_98769D6901002B06AA839A560004BF7F" xlink:type="arc" />
    <link:label id="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_50C351C39922DEDE006E9A5600043689_terseLabel_en-US" xlink:label="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_50C351C39922DEDE006E9A5600043689" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upon Reaching Certain Worldwide Net Sales Milestones [Member]</link:label>
    <link:label id="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_50C351C39922DEDE006E9A5600043689_label_en-US" xlink:label="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_50C351C39922DEDE006E9A5600043689" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upon Reaching Certain Worldwide Net Sales Milestones [Member]</link:label>
    <link:label id="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_50C351C39922DEDE006E9A5600043689_documentation_en-US" xlink:label="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_50C351C39922DEDE006E9A5600043689" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upon reaching certain worldwide net sales milestones.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_UponReachingCertainWorldwideNetSalesMilestonesMember" xlink:label="loc_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_50C351C39922DEDE006E9A5600043689" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_50C351C39922DEDE006E9A5600043689" xlink:to="lab_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_50C351C39922DEDE006E9A5600043689" xlink:type="arc" />
    <link:label id="lab_dare_UponAchievementOfSpecifiedCommercializationMilestonesMember_39B96A41607AD303190C9A7E3F93C74B_terseLabel_en-US" xlink:label="lab_dare_UponAchievementOfSpecifiedCommercializationMilestonesMember_39B96A41607AD303190C9A7E3F93C74B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upon Achievement Of Specified Commercialization Milestones [Member]</link:label>
    <link:label id="lab_dare_UponAchievementOfSpecifiedCommercializationMilestonesMember_39B96A41607AD303190C9A7E3F93C74B_label_en-US" xlink:label="lab_dare_UponAchievementOfSpecifiedCommercializationMilestonesMember_39B96A41607AD303190C9A7E3F93C74B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upon Achievement Of Specified Commercialization Milestones [Member]</link:label>
    <link:label id="lab_dare_UponAchievementOfSpecifiedCommercializationMilestonesMember_39B96A41607AD303190C9A7E3F93C74B_documentation_en-US" xlink:label="lab_dare_UponAchievementOfSpecifiedCommercializationMilestonesMember_39B96A41607AD303190C9A7E3F93C74B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upon Achievement Of Specified Commercialization Milestones [Member]</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_UponAchievementOfSpecifiedCommercializationMilestonesMember" xlink:label="loc_dare_UponAchievementOfSpecifiedCommercializationMilestonesMember_39B96A41607AD303190C9A7E3F93C74B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponAchievementOfSpecifiedCommercializationMilestonesMember_39B96A41607AD303190C9A7E3F93C74B" xlink:to="lab_dare_UponAchievementOfSpecifiedCommercializationMilestonesMember_39B96A41607AD303190C9A7E3F93C74B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_C411893F38F50A8F70E79A5600042D01_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_C411893F38F50A8F70E79A5600042D01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_C411893F38F50A8F70E79A5600042D01_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_C411893F38F50A8F70E79A5600042D01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_C411893F38F50A8F70E79A5600042D01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_C411893F38F50A8F70E79A5600042D01" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis_C411893F38F50A8F70E79A5600042D01" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_6A27705050929DD3B4929A5600040F89_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_6A27705050929DD3B4929A5600040F89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_6A27705050929DD3B4929A5600040F89_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_6A27705050929DD3B4929A5600040F89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_6A27705050929DD3B4929A5600040F89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_6A27705050929DD3B4929A5600040F89" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain_6A27705050929DD3B4929A5600040F89" xlink:type="arc" />
    <link:label id="lab_dare_UponAchievingCertainCommercialMilestonesMember_758ED85E852D6BDD8A1A9A560004A56D_terseLabel_en-US" xlink:label="lab_dare_UponAchievingCertainCommercialMilestonesMember_758ED85E852D6BDD8A1A9A560004A56D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upon Achieving Certain Commercial Milestones [Member]</link:label>
    <link:label id="lab_dare_UponAchievingCertainCommercialMilestonesMember_758ED85E852D6BDD8A1A9A560004A56D_label_en-US" xlink:label="lab_dare_UponAchievingCertainCommercialMilestonesMember_758ED85E852D6BDD8A1A9A560004A56D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upon Achieving Certain Commercial Milestones [Member]</link:label>
    <link:label id="lab_dare_UponAchievingCertainCommercialMilestonesMember_758ED85E852D6BDD8A1A9A560004A56D_documentation_en-US" xlink:label="lab_dare_UponAchievingCertainCommercialMilestonesMember_758ED85E852D6BDD8A1A9A560004A56D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upon Achieving Certain Commercial Milestones [Member]</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_UponAchievingCertainCommercialMilestonesMember" xlink:label="loc_dare_UponAchievingCertainCommercialMilestonesMember_758ED85E852D6BDD8A1A9A560004A56D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponAchievingCertainCommercialMilestonesMember_758ED85E852D6BDD8A1A9A560004A56D" xlink:to="lab_dare_UponAchievingCertainCommercialMilestonesMember_758ED85E852D6BDD8A1A9A560004A56D" xlink:type="arc" />
    <link:label id="lab_dare_UponSigningOfDevelopmentAndOptionAgreementMember_6BFE06515276F44C86869A5600142816_terseLabel_en-US" xlink:label="lab_dare_UponSigningOfDevelopmentAndOptionAgreementMember_6BFE06515276F44C86869A5600142816" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upon Signing Of Development And Option Agreement [Member]</link:label>
    <link:label id="lab_dare_UponSigningOfDevelopmentAndOptionAgreementMember_6BFE06515276F44C86869A5600142816_label_en-US" xlink:label="lab_dare_UponSigningOfDevelopmentAndOptionAgreementMember_6BFE06515276F44C86869A5600142816" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upon Signing Of Development And Option Agreement [Member]</link:label>
    <link:label id="lab_dare_UponSigningOfDevelopmentAndOptionAgreementMember_6BFE06515276F44C86869A5600142816_documentation_en-US" xlink:label="lab_dare_UponSigningOfDevelopmentAndOptionAgreementMember_6BFE06515276F44C86869A5600142816" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upon Signing Of Development And Option Agreement [Member]</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_UponSigningOfDevelopmentAndOptionAgreementMember" xlink:label="loc_dare_UponSigningOfDevelopmentAndOptionAgreementMember_6BFE06515276F44C86869A5600142816" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponSigningOfDevelopmentAndOptionAgreementMember_6BFE06515276F44C86869A5600142816" xlink:to="lab_dare_UponSigningOfDevelopmentAndOptionAgreementMember_6BFE06515276F44C86869A5600142816" xlink:type="arc" />
    <link:label id="lab_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_A7F214FB1B5EA8C8B8DF9A5600144764_terseLabel_en-US" xlink:label="lab_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_A7F214FB1B5EA8C8B8DF9A5600144764" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upon Completion Of Fifty Percent Development Not Later Than Six Months [Member]</link:label>
    <link:label id="lab_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_A7F214FB1B5EA8C8B8DF9A5600144764_label_en-US" xlink:label="lab_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_A7F214FB1B5EA8C8B8DF9A5600144764" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upon Completion Of Fifty Percent Development Not Later Than Six Months [Member]</link:label>
    <link:label id="lab_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_A7F214FB1B5EA8C8B8DF9A5600144764_documentation_en-US" xlink:label="lab_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_A7F214FB1B5EA8C8B8DF9A5600144764" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upon Completion Of Fifty Percent Development Not Later Than Six Months [Member]</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember" xlink:label="loc_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_A7F214FB1B5EA8C8B8DF9A5600144764" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_A7F214FB1B5EA8C8B8DF9A5600144764" xlink:to="lab_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_A7F214FB1B5EA8C8B8DF9A5600144764" xlink:type="arc" />
    <link:label id="lab_dare_UponAchievingCertainDevelopmentMilestonesMember_6EF4E3B29F5F1C6E17339A560014E299_terseLabel_en-US" xlink:label="lab_dare_UponAchievingCertainDevelopmentMilestonesMember_6EF4E3B29F5F1C6E17339A560014E299" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upon Achieving Certain Development Milestones [Member]</link:label>
    <link:label id="lab_dare_UponAchievingCertainDevelopmentMilestonesMember_6EF4E3B29F5F1C6E17339A560014E299_label_en-US" xlink:label="lab_dare_UponAchievingCertainDevelopmentMilestonesMember_6EF4E3B29F5F1C6E17339A560014E299" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upon Achieving Certain Development Milestones [Member]</link:label>
    <link:label id="lab_dare_UponAchievingCertainDevelopmentMilestonesMember_6EF4E3B29F5F1C6E17339A560014E299_documentation_en-US" xlink:label="lab_dare_UponAchievingCertainDevelopmentMilestonesMember_6EF4E3B29F5F1C6E17339A560014E299" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upon Achieving Certain Development Milestones [Member]</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_UponAchievingCertainDevelopmentMilestonesMember" xlink:label="loc_dare_UponAchievingCertainDevelopmentMilestonesMember_6EF4E3B29F5F1C6E17339A560014E299" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponAchievingCertainDevelopmentMilestonesMember_6EF4E3B29F5F1C6E17339A560014E299" xlink:to="lab_dare_UponAchievingCertainDevelopmentMilestonesMember_6EF4E3B29F5F1C6E17339A560014E299" xlink:type="arc" />
    <link:label id="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_47601C1304B5433057CD9A56001444BE_terseLabel_en-US" xlink:label="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_47601C1304B5433057CD9A56001444BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upon Achieving Certain Clinical And Regulatory Development Milestones [Member]</link:label>
    <link:label id="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_47601C1304B5433057CD9A56001444BE_label_en-US" xlink:label="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_47601C1304B5433057CD9A56001444BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upon Achieving Certain Clinical And Regulatory Development Milestones [Member]</link:label>
    <link:label id="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_47601C1304B5433057CD9A56001444BE_documentation_en-US" xlink:label="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_47601C1304B5433057CD9A56001444BE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upon Achieving Certain Clinical And Regulatory Development Milestones [Member]</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" xlink:label="loc_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_47601C1304B5433057CD9A56001444BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_47601C1304B5433057CD9A56001444BE" xlink:to="lab_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_47601C1304B5433057CD9A56001444BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A5F48F4F6A83318C78569A560014E751_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A5F48F4F6A83318C78569A560014E751" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A5F48F4F6A83318C78569A560014E751_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A5F48F4F6A83318C78569A560014E751" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A5F48F4F6A83318C78569A560014E751" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A5F48F4F6A83318C78569A560014E751" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A5F48F4F6A83318C78569A560014E751" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyDomain_3280554863447EC9E2B29A560014956C_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_3280554863447EC9E2B29A560014956C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_3280554863447EC9E2B29A560014956C_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_3280554863447EC9E2B29A560014956C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3280554863447EC9E2B29A560014956C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_3280554863447EC9E2B29A560014956C" xlink:to="lab_us-gaap_RelatedPartyDomain_3280554863447EC9E2B29A560014956C" xlink:type="arc" />
    <link:label id="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_2BE18553FE162BBA3E429A560014A2AD_terseLabel_en-US" xlink:label="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_2BE18553FE162BBA3E429A560014A2AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SST [Member]</link:label>
    <link:label id="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_2BE18553FE162BBA3E429A560014A2AD_label_en-US" xlink:label="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_2BE18553FE162BBA3E429A560014A2AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Science And Technologies D Limited Liability Company And Strategic Science Technologies Limited Liability Company [Member]</link:label>
    <link:label id="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_2BE18553FE162BBA3E429A560014A2AD_documentation_en-US" xlink:label="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_2BE18553FE162BBA3E429A560014A2AD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" xlink:label="loc_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_2BE18553FE162BBA3E429A560014A2AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_2BE18553FE162BBA3E429A560014A2AD" xlink:to="lab_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_2BE18553FE162BBA3E429A560014A2AD" xlink:type="arc" />
    <link:label id="lab_dare_OrbisMember_CD8CA70051BF6338844D9A560014F300_terseLabel_en-US" xlink:label="lab_dare_OrbisMember_CD8CA70051BF6338844D9A560014F300" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Orbis [Member]</link:label>
    <link:label id="lab_dare_OrbisMember_CD8CA70051BF6338844D9A560014F300_label_en-US" xlink:label="lab_dare_OrbisMember_CD8CA70051BF6338844D9A560014F300" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Orbis [Member]</link:label>
    <link:label id="lab_dare_OrbisMember_CD8CA70051BF6338844D9A560014F300_documentation_en-US" xlink:label="lab_dare_OrbisMember_CD8CA70051BF6338844D9A560014F300" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Orbis [Member]</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_OrbisMember" xlink:label="loc_dare_OrbisMember_CD8CA70051BF6338844D9A560014F300" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_OrbisMember_CD8CA70051BF6338844D9A560014F300" xlink:to="lab_dare_OrbisMember_CD8CA70051BF6338844D9A560014F300" xlink:type="arc" />
    <link:label id="lab_dare_MilanaPharmMember_62745BECE235C3F3A8979A5600145009_terseLabel_en-US" xlink:label="lab_dare_MilanaPharmMember_62745BECE235C3F3A8979A5600145009" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MilanaPharm [Member]</link:label>
    <link:label id="lab_dare_MilanaPharmMember_62745BECE235C3F3A8979A5600145009_label_en-US" xlink:label="lab_dare_MilanaPharmMember_62745BECE235C3F3A8979A5600145009" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MilanaPharm [Member]</link:label>
    <link:label id="lab_dare_MilanaPharmMember_62745BECE235C3F3A8979A5600145009_documentation_en-US" xlink:label="lab_dare_MilanaPharmMember_62745BECE235C3F3A8979A5600145009" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MilanaPharm [Member]</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_MilanaPharmMember" xlink:label="loc_dare_MilanaPharmMember_62745BECE235C3F3A8979A5600145009" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_MilanaPharmMember_62745BECE235C3F3A8979A5600145009" xlink:to="lab_dare_MilanaPharmMember_62745BECE235C3F3A8979A5600145009" xlink:type="arc" />
    <link:label id="lab_dare_HammockPharmaceuticalsInc.Member_0DD342201994E71532B99A5600143869_terseLabel_en-US" xlink:label="lab_dare_HammockPharmaceuticalsInc.Member_0DD342201994E71532B99A5600143869" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hammock Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_dare_HammockPharmaceuticalsInc.Member_0DD342201994E71532B99A5600143869_label_en-US" xlink:label="lab_dare_HammockPharmaceuticalsInc.Member_0DD342201994E71532B99A5600143869" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hammock Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_dare_HammockPharmaceuticalsInc.Member_0DD342201994E71532B99A5600143869_documentation_en-US" xlink:label="lab_dare_HammockPharmaceuticalsInc.Member_0DD342201994E71532B99A5600143869" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hammock Pharmaceuticals, Inc. [Member]</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_HammockPharmaceuticalsInc.Member" xlink:label="loc_dare_HammockPharmaceuticalsInc.Member_0DD342201994E71532B99A5600143869" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_HammockPharmaceuticalsInc.Member_0DD342201994E71532B99A5600143869" xlink:to="lab_dare_HammockPharmaceuticalsInc.Member_0DD342201994E71532B99A5600143869" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_D2219D9BB0711A3D41E39A560014E021_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_D2219D9BB0711A3D41E39A560014E021" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_D2219D9BB0711A3D41E39A560014E021_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_D2219D9BB0711A3D41E39A560014E021" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_D2219D9BB0711A3D41E39A560014E021" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_D2219D9BB0711A3D41E39A560014E021" xlink:to="lab_us-gaap_TypeOfArrangementAxis_D2219D9BB0711A3D41E39A560014E021" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19B1C2BB56A8648E26369A560014E530_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19B1C2BB56A8648E26369A560014E530" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19B1C2BB56A8648E26369A560014E530_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19B1C2BB56A8648E26369A560014E530" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19B1C2BB56A8648E26369A560014E530" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19B1C2BB56A8648E26369A560014E530" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19B1C2BB56A8648E26369A560014E530" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicensingAgreementsMember_1D3E842F4EFE0E3BB98B9A5600143699_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember_1D3E842F4EFE0E3BB98B9A5600143699" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_1D3E842F4EFE0E3BB98B9A5600143699_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember_1D3E842F4EFE0E3BB98B9A5600143699" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_1D3E842F4EFE0E3BB98B9A5600143699" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember_1D3E842F4EFE0E3BB98B9A5600143699" xlink:to="lab_us-gaap_LicensingAgreementsMember_1D3E842F4EFE0E3BB98B9A5600143699" xlink:type="arc" />
    <link:label id="lab_dare_AssignmentAgreementMember_96857C39E55F481E65BD9A5600147302_terseLabel_en-US" xlink:label="lab_dare_AssignmentAgreementMember_96857C39E55F481E65BD9A5600147302" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assignment Agreement [Member]</link:label>
    <link:label id="lab_dare_AssignmentAgreementMember_96857C39E55F481E65BD9A5600147302_label_en-US" xlink:label="lab_dare_AssignmentAgreementMember_96857C39E55F481E65BD9A5600147302" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assignment Agreement [Member]</link:label>
    <link:label id="lab_dare_AssignmentAgreementMember_96857C39E55F481E65BD9A5600147302_documentation_en-US" xlink:label="lab_dare_AssignmentAgreementMember_96857C39E55F481E65BD9A5600147302" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assignment Agreement [Member]</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_AssignmentAgreementMember" xlink:label="loc_dare_AssignmentAgreementMember_96857C39E55F481E65BD9A5600147302" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AssignmentAgreementMember_96857C39E55F481E65BD9A5600147302" xlink:to="lab_dare_AssignmentAgreementMember_96857C39E55F481E65BD9A5600147302" xlink:type="arc" />
    <link:label id="lab_dare_LicenseAndCollaborationAgreementMember_B3E62F718A04FE6901589A56001426A0_terseLabel_en-US" xlink:label="lab_dare_LicenseAndCollaborationAgreementMember_B3E62F718A04FE6901589A56001426A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreement [Member]</link:label>
    <link:label id="lab_dare_LicenseAndCollaborationAgreementMember_B3E62F718A04FE6901589A56001426A0_label_en-US" xlink:label="lab_dare_LicenseAndCollaborationAgreementMember_B3E62F718A04FE6901589A56001426A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreement [Member]</link:label>
    <link:label id="lab_dare_LicenseAndCollaborationAgreementMember_B3E62F718A04FE6901589A56001426A0_documentation_en-US" xlink:label="lab_dare_LicenseAndCollaborationAgreementMember_B3E62F718A04FE6901589A56001426A0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreement [Member]</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseAndCollaborationAgreementMember" xlink:label="loc_dare_LicenseAndCollaborationAgreementMember_B3E62F718A04FE6901589A56001426A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseAndCollaborationAgreementMember_B3E62F718A04FE6901589A56001426A0" xlink:to="lab_dare_LicenseAndCollaborationAgreementMember_B3E62F718A04FE6901589A56001426A0" xlink:type="arc" />
    <link:label id="lab_dare_DevelopmentAndOptionAgreementMember_5AA91B1D560B61EBD8E19A5600143961_terseLabel_en-US" xlink:label="lab_dare_DevelopmentAndOptionAgreementMember_5AA91B1D560B61EBD8E19A5600143961" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development And Option Agreement [Member]</link:label>
    <link:label id="lab_dare_DevelopmentAndOptionAgreementMember_5AA91B1D560B61EBD8E19A5600143961_label_en-US" xlink:label="lab_dare_DevelopmentAndOptionAgreementMember_5AA91B1D560B61EBD8E19A5600143961" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development And Option Agreement [Member]</link:label>
    <link:label id="lab_dare_DevelopmentAndOptionAgreementMember_5AA91B1D560B61EBD8E19A5600143961_documentation_en-US" xlink:label="lab_dare_DevelopmentAndOptionAgreementMember_5AA91B1D560B61EBD8E19A5600143961" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development And Option Agreement [Member]</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_DevelopmentAndOptionAgreementMember" xlink:label="loc_dare_DevelopmentAndOptionAgreementMember_5AA91B1D560B61EBD8E19A5600143961" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_DevelopmentAndOptionAgreementMember_5AA91B1D560B61EBD8E19A5600143961" xlink:to="lab_dare_DevelopmentAndOptionAgreementMember_5AA91B1D560B61EBD8E19A5600143961" xlink:type="arc" />
    <link:label id="lab_dare_JuniperPharmaceuticalsInc.Member_72D9E8CEA61D402E65569A560014A18B_terseLabel_en-US" xlink:label="lab_dare_JuniperPharmaceuticalsInc.Member_72D9E8CEA61D402E65569A560014A18B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Juniper Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_dare_JuniperPharmaceuticalsInc.Member_72D9E8CEA61D402E65569A560014A18B_label_en-US" xlink:label="lab_dare_JuniperPharmaceuticalsInc.Member_72D9E8CEA61D402E65569A560014A18B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Juniper Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_dare_JuniperPharmaceuticalsInc.Member_72D9E8CEA61D402E65569A560014A18B_documentation_en-US" xlink:label="lab_dare_JuniperPharmaceuticalsInc.Member_72D9E8CEA61D402E65569A560014A18B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Juniper Pharmaceuticals, Inc. [Member]</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_JuniperPharmaceuticalsInc.Member" xlink:label="loc_dare_JuniperPharmaceuticalsInc.Member_72D9E8CEA61D402E65569A560014A18B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_JuniperPharmaceuticalsInc.Member_72D9E8CEA61D402E65569A560014A18B" xlink:to="lab_dare_JuniperPharmaceuticalsInc.Member_72D9E8CEA61D402E65569A560014A18B" xlink:type="arc" />
    <link:label id="lab_dare_JuniperPharmaceuticalsMember_50114727EDF37823F9FA9A560014A640_terseLabel_en-US" xlink:label="lab_dare_JuniperPharmaceuticalsMember_50114727EDF37823F9FA9A560014A640" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Juniper Pharmaceuticals [Member]</link:label>
    <link:label id="lab_dare_JuniperPharmaceuticalsMember_50114727EDF37823F9FA9A560014A640_label_en-US" xlink:label="lab_dare_JuniperPharmaceuticalsMember_50114727EDF37823F9FA9A560014A640" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Juniper Pharmaceuticals [Member]</link:label>
    <link:label id="lab_dare_JuniperPharmaceuticalsMember_50114727EDF37823F9FA9A560014A640_documentation_en-US" xlink:label="lab_dare_JuniperPharmaceuticalsMember_50114727EDF37823F9FA9A560014A640" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Juniper Pharmaceuticals.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_JuniperPharmaceuticalsMember" xlink:label="loc_dare_JuniperPharmaceuticalsMember_50114727EDF37823F9FA9A560014A640" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_JuniperPharmaceuticalsMember_50114727EDF37823F9FA9A560014A640" xlink:to="lab_dare_JuniperPharmaceuticalsMember_50114727EDF37823F9FA9A560014A640" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A0158D96A503FC2CC3BE9A56001481A5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A0158D96A503FC2CC3BE9A56001481A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A0158D96A503FC2CC3BE9A56001481A5_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A0158D96A503FC2CC3BE9A56001481A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A0158D96A503FC2CC3BE9A56001481A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A0158D96A503FC2CC3BE9A56001481A5" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A0158D96A503FC2CC3BE9A56001481A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_EA4F5017546F337CFB1D9A560014C7D2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_EA4F5017546F337CFB1D9A560014C7D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_EA4F5017546F337CFB1D9A560014C7D2_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_EA4F5017546F337CFB1D9A560014C7D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_EA4F5017546F337CFB1D9A560014C7D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_EA4F5017546F337CFB1D9A560014C7D2" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_EA4F5017546F337CFB1D9A560014C7D2" xlink:type="arc" />
    <link:label id="lab_dare_ADVATecAgreementMember_969471B2814694C360949A560014892D_terseLabel_en-US" xlink:label="lab_dare_ADVATecAgreementMember_969471B2814694C360949A560014892D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ADVA Tec Agreement [Member]</link:label>
    <link:label id="lab_dare_ADVATecAgreementMember_969471B2814694C360949A560014892D_label_en-US" xlink:label="lab_dare_ADVATecAgreementMember_969471B2814694C360949A560014892D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">A D V A Tec Agreement [Member]</link:label>
    <link:label id="lab_dare_ADVATecAgreementMember_969471B2814694C360949A560014892D_documentation_en-US" xlink:label="lab_dare_ADVATecAgreementMember_969471B2814694C360949A560014892D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ADVA Tec agreement.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_ADVATecAgreementMember" xlink:label="loc_dare_ADVATecAgreementMember_969471B2814694C360949A560014892D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ADVATecAgreementMember_969471B2814694C360949A560014892D" xlink:to="lab_dare_ADVATecAgreementMember_969471B2814694C360949A560014892D" xlink:type="arc" />
    <link:label id="lab_dare_ClinicalAndRegulatoryMilestonesMember_E86D6B5DF4A6F3B1ADF99A560014C1B9_terseLabel_en-US" xlink:label="lab_dare_ClinicalAndRegulatoryMilestonesMember_E86D6B5DF4A6F3B1ADF99A560014C1B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_dare_ClinicalAndRegulatoryMilestonesMember_E86D6B5DF4A6F3B1ADF99A560014C1B9_label_en-US" xlink:label="lab_dare_ClinicalAndRegulatoryMilestonesMember_E86D6B5DF4A6F3B1ADF99A560014C1B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_dare_ClinicalAndRegulatoryMilestonesMember_E86D6B5DF4A6F3B1ADF99A560014C1B9_documentation_en-US" xlink:label="lab_dare_ClinicalAndRegulatoryMilestonesMember_E86D6B5DF4A6F3B1ADF99A560014C1B9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical And Regulatory Milestones [Member]</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_ClinicalAndRegulatoryMilestonesMember" xlink:label="loc_dare_ClinicalAndRegulatoryMilestonesMember_E86D6B5DF4A6F3B1ADF99A560014C1B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ClinicalAndRegulatoryMilestonesMember_E86D6B5DF4A6F3B1ADF99A560014C1B9" xlink:to="lab_dare_ClinicalAndRegulatoryMilestonesMember_E86D6B5DF4A6F3B1ADF99A560014C1B9" xlink:type="arc" />
    <link:label id="lab_dare_SalesMilestonesMember_B041AF0AC6FB606A58559A560014BF2E_terseLabel_en-US" xlink:label="lab_dare_SalesMilestonesMember_B041AF0AC6FB606A58559A560014BF2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Milestones [Member]</link:label>
    <link:label id="lab_dare_SalesMilestonesMember_B041AF0AC6FB606A58559A560014BF2E_label_en-US" xlink:label="lab_dare_SalesMilestonesMember_B041AF0AC6FB606A58559A560014BF2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Milestones [Member]</link:label>
    <link:label id="lab_dare_SalesMilestonesMember_B041AF0AC6FB606A58559A560014BF2E_documentation_en-US" xlink:label="lab_dare_SalesMilestonesMember_B041AF0AC6FB606A58559A560014BF2E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Milestones [Member]</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_SalesMilestonesMember" xlink:label="loc_dare_SalesMilestonesMember_B041AF0AC6FB606A58559A560014BF2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_SalesMilestonesMember_B041AF0AC6FB606A58559A560014BF2E" xlink:to="lab_dare_SalesMilestonesMember_B041AF0AC6FB606A58559A560014BF2E" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_354CDF255C05767CA7DF9A560014205B_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_354CDF255C05767CA7DF9A560014205B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeAxis_354CDF255C05767CA7DF9A560014205B_label_en-US" xlink:label="lab_srt_RangeAxis_354CDF255C05767CA7DF9A560014205B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_354CDF255C05767CA7DF9A560014205B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_354CDF255C05767CA7DF9A560014205B" xlink:to="lab_srt_RangeAxis_354CDF255C05767CA7DF9A560014205B" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_00B86CCB992413FA89259A560014701A_terseLabel_en-US" xlink:label="lab_srt_RangeMember_00B86CCB992413FA89259A560014701A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_00B86CCB992413FA89259A560014701A_label_en-US" xlink:label="lab_srt_RangeMember_00B86CCB992413FA89259A560014701A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_00B86CCB992413FA89259A560014701A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_00B86CCB992413FA89259A560014701A" xlink:to="lab_srt_RangeMember_00B86CCB992413FA89259A560014701A" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_A2D17817970D187DE9509A560014D4C9_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_A2D17817970D187DE9509A560014D4C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label id="lab_srt_MinimumMember_A2D17817970D187DE9509A560014D4C9_label_en-US" xlink:label="lab_srt_MinimumMember_A2D17817970D187DE9509A560014D4C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_A2D17817970D187DE9509A560014D4C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_A2D17817970D187DE9509A560014D4C9" xlink:to="lab_srt_MinimumMember_A2D17817970D187DE9509A560014D4C9" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_093995F495C3B27368769A560014D735_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_093995F495C3B27368769A560014D735" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label id="lab_srt_MaximumMember_093995F495C3B27368769A560014D735_label_en-US" xlink:label="lab_srt_MaximumMember_093995F495C3B27368769A560014D735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_093995F495C3B27368769A560014D735" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_093995F495C3B27368769A560014D735" xlink:to="lab_srt_MaximumMember_093995F495C3B27368769A560014D735" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_59563A40B783DB2D84E29A560014A873_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_59563A40B783DB2D84E29A560014A873" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_59563A40B783DB2D84E29A560014A873_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_59563A40B783DB2D84E29A560014A873" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_59563A40B783DB2D84E29A560014A873" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_59563A40B783DB2D84E29A560014A873" xlink:to="lab_srt_ProductOrServiceAxis_59563A40B783DB2D84E29A560014A873" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_DA798FDC0287133632209A5600144AED_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_DA798FDC0287133632209A5600144AED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_DA798FDC0287133632209A5600144AED_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_DA798FDC0287133632209A5600144AED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_DA798FDC0287133632209A5600144AED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_DA798FDC0287133632209A5600144AED" xlink:to="lab_srt_ProductsAndServicesDomain_DA798FDC0287133632209A5600144AED" xlink:type="arc" />
    <link:label id="lab_dare_OvapreneMember_C20E64FE5DE4896696749A560014E0FC_terseLabel_en-US" xlink:label="lab_dare_OvapreneMember_C20E64FE5DE4896696749A560014E0FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ovaprene [Member]</link:label>
    <link:label id="lab_dare_OvapreneMember_C20E64FE5DE4896696749A560014E0FC_label_en-US" xlink:label="lab_dare_OvapreneMember_C20E64FE5DE4896696749A560014E0FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ovaprene [Member]</link:label>
    <link:label id="lab_dare_OvapreneMember_C20E64FE5DE4896696749A560014E0FC_documentation_en-US" xlink:label="lab_dare_OvapreneMember_C20E64FE5DE4896696749A560014E0FC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ovaprene.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_OvapreneMember" xlink:label="loc_dare_OvapreneMember_C20E64FE5DE4896696749A560014E0FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_OvapreneMember_C20E64FE5DE4896696749A560014E0FC" xlink:to="lab_dare_OvapreneMember_C20E64FE5DE4896696749A560014E0FC" xlink:type="arc" />
    <link:label id="lab_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9_terseLabel_en-US" xlink:label="lab_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9_label_en-US" xlink:label="lab_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9_documentation_en-US" xlink:label="lab_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_CommitmentsAndContingenciesLineItems" xlink:label="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="lab_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:type="arc" />
    <link:label id="lab_dare_NumberOfPatentsIssued_E80D88B0800F8FB720519A5600149998_terseLabel_en-US" xlink:label="lab_dare_NumberOfPatentsIssued_E80D88B0800F8FB720519A5600149998" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patents issued</link:label>
    <link:label id="lab_dare_NumberOfPatentsIssued_E80D88B0800F8FB720519A5600149998_label_en-US" xlink:label="lab_dare_NumberOfPatentsIssued_E80D88B0800F8FB720519A5600149998" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Patents Issued</link:label>
    <link:label id="lab_dare_NumberOfPatentsIssued_E80D88B0800F8FB720519A5600149998_documentation_en-US" xlink:label="lab_dare_NumberOfPatentsIssued_E80D88B0800F8FB720519A5600149998" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of patents issued.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_NumberOfPatentsIssued" xlink:label="loc_dare_NumberOfPatentsIssued_E80D88B0800F8FB720519A5600149998" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NumberOfPatentsIssued_E80D88B0800F8FB720519A5600149998" xlink:to="lab_dare_NumberOfPatentsIssued_E80D88B0800F8FB720519A5600149998" xlink:type="arc" />
    <link:label id="lab_dare_NumberOfPendingPatents_1BC6D5630F25BABAEFBC9A560024F8DC_terseLabel_en-US" xlink:label="lab_dare_NumberOfPendingPatents_1BC6D5630F25BABAEFBC9A560024F8DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of pending US patent applications</link:label>
    <link:label id="lab_dare_NumberOfPendingPatents_1BC6D5630F25BABAEFBC9A560024F8DC_label_en-US" xlink:label="lab_dare_NumberOfPendingPatents_1BC6D5630F25BABAEFBC9A560024F8DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Pending Patents</link:label>
    <link:label id="lab_dare_NumberOfPendingPatents_1BC6D5630F25BABAEFBC9A560024F8DC_documentation_en-US" xlink:label="lab_dare_NumberOfPendingPatents_1BC6D5630F25BABAEFBC9A560024F8DC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Pending Patents</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_NumberOfPendingPatents" xlink:label="loc_dare_NumberOfPendingPatents_1BC6D5630F25BABAEFBC9A560024F8DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NumberOfPendingPatents_1BC6D5630F25BABAEFBC9A560024F8DC" xlink:to="lab_dare_NumberOfPendingPatents_1BC6D5630F25BABAEFBC9A560024F8DC" xlink:type="arc" />
    <link:label id="lab_dare_NumberOfPatentsGranted_45780CDADC370C3630C69A560024A0FB_terseLabel_en-US" xlink:label="lab_dare_NumberOfPatentsGranted_45780CDADC370C3630C69A560024A0FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patents granted</link:label>
    <link:label id="lab_dare_NumberOfPatentsGranted_45780CDADC370C3630C69A560024A0FB_label_en-US" xlink:label="lab_dare_NumberOfPatentsGranted_45780CDADC370C3630C69A560024A0FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Patents Granted</link:label>
    <link:label id="lab_dare_NumberOfPatentsGranted_45780CDADC370C3630C69A560024A0FB_documentation_en-US" xlink:label="lab_dare_NumberOfPatentsGranted_45780CDADC370C3630C69A560024A0FB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Patents Granted</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_NumberOfPatentsGranted" xlink:label="loc_dare_NumberOfPatentsGranted_45780CDADC370C3630C69A560024A0FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NumberOfPatentsGranted_45780CDADC370C3630C69A560024A0FB" xlink:to="lab_dare_NumberOfPatentsGranted_45780CDADC370C3630C69A560024A0FB" xlink:type="arc" />
    <link:label id="lab_dare_NumberOfPatentApplications_928D3B145E48D14FAF449A5600244E6C_terseLabel_en-US" xlink:label="lab_dare_NumberOfPatentApplications_928D3B145E48D14FAF449A5600244E6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patent applications in other major markets</link:label>
    <link:label id="lab_dare_NumberOfPatentApplications_928D3B145E48D14FAF449A5600244E6C_label_en-US" xlink:label="lab_dare_NumberOfPatentApplications_928D3B145E48D14FAF449A5600244E6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Patent Applications</link:label>
    <link:label id="lab_dare_NumberOfPatentApplications_928D3B145E48D14FAF449A5600244E6C_documentation_en-US" xlink:label="lab_dare_NumberOfPatentApplications_928D3B145E48D14FAF449A5600244E6C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of patent applications.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_NumberOfPatentApplications" xlink:label="loc_dare_NumberOfPatentApplications_928D3B145E48D14FAF449A5600244E6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NumberOfPatentApplications_928D3B145E48D14FAF449A5600244E6C" xlink:to="lab_dare_NumberOfPatentApplications_928D3B145E48D14FAF449A5600244E6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractualObligation_F535BA93A17C5B8828289A560024ABB9_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation_F535BA93A17C5B8828289A560024ABB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum spending amounts per year</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_F535BA93A17C5B8828289A560024ABB9_label_en-US" xlink:label="lab_us-gaap_ContractualObligation_F535BA93A17C5B8828289A560024ABB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_F535BA93A17C5B8828289A560024ABB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation_F535BA93A17C5B8828289A560024ABB9" xlink:to="lab_us-gaap_ContractualObligation_F535BA93A17C5B8828289A560024ABB9" xlink:type="arc" />
    <link:label id="lab_dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries_52FAD2A4EB67740EB0699A5600246699_terseLabel_en-US" xlink:label="lab_dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries_52FAD2A4EB67740EB0699A5600246699" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement termination period on failing to commercialize in certain designated countries</link:label>
    <link:label id="lab_dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries_52FAD2A4EB67740EB0699A5600246699_label_en-US" xlink:label="lab_dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries_52FAD2A4EB67740EB0699A5600246699" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement Termination Period On Failing To Commercialize In Certain Designated Countries</link:label>
    <link:label id="lab_dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries_52FAD2A4EB67740EB0699A5600246699_documentation_en-US" xlink:label="lab_dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries_52FAD2A4EB67740EB0699A5600246699" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement termination period on failing to commercialize in certain designated countries.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries" xlink:label="loc_dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries_52FAD2A4EB67740EB0699A5600246699" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries_52FAD2A4EB67740EB0699A5600246699" xlink:to="lab_dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries_52FAD2A4EB67740EB0699A5600246699" xlink:type="arc" />
    <link:label id="lab_dare_NumberOfDesignatedCountries_BB66673F56F2430B455D9A5600240127_terseLabel_en-US" xlink:label="lab_dare_NumberOfDesignatedCountries_BB66673F56F2430B455D9A5600240127" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of designated European countries</link:label>
    <link:label id="lab_dare_NumberOfDesignatedCountries_BB66673F56F2430B455D9A5600240127_label_en-US" xlink:label="lab_dare_NumberOfDesignatedCountries_BB66673F56F2430B455D9A5600240127" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Designated Countries</link:label>
    <link:label id="lab_dare_NumberOfDesignatedCountries_BB66673F56F2430B455D9A5600240127_documentation_en-US" xlink:label="lab_dare_NumberOfDesignatedCountries_BB66673F56F2430B455D9A5600240127" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of designated countries.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_NumberOfDesignatedCountries" xlink:label="loc_dare_NumberOfDesignatedCountries_BB66673F56F2430B455D9A5600240127" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NumberOfDesignatedCountries_BB66673F56F2430B455D9A5600240127" xlink:to="lab_dare_NumberOfDesignatedCountries_BB66673F56F2430B455D9A5600240127" xlink:type="arc" />
    <link:label id="lab_dare_PercentageOfRoyaltyRate_6C247173C8CDB6CBDF8A9A560024E842_terseLabel_en-US" xlink:label="lab_dare_PercentageOfRoyaltyRate_6C247173C8CDB6CBDF8A9A560024E842" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of royalty rate</link:label>
    <link:label id="lab_dare_PercentageOfRoyaltyRate_6C247173C8CDB6CBDF8A9A560024E842_label_en-US" xlink:label="lab_dare_PercentageOfRoyaltyRate_6C247173C8CDB6CBDF8A9A560024E842" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Royalty Rate</link:label>
    <link:label id="lab_dare_PercentageOfRoyaltyRate_6C247173C8CDB6CBDF8A9A560024E842_documentation_en-US" xlink:label="lab_dare_PercentageOfRoyaltyRate_6C247173C8CDB6CBDF8A9A560024E842" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of royalty rate.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_PercentageOfRoyaltyRate" xlink:label="loc_dare_PercentageOfRoyaltyRate_6C247173C8CDB6CBDF8A9A560024E842" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PercentageOfRoyaltyRate_6C247173C8CDB6CBDF8A9A560024E842" xlink:to="lab_dare_PercentageOfRoyaltyRate_6C247173C8CDB6CBDF8A9A560024E842" xlink:type="arc" />
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_40A4F7505810715F6AEA9A56002444E2_terseLabel_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_40A4F7505810715F6AEA9A56002444E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement, termination period due to performance failure</link:label>
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_40A4F7505810715F6AEA9A56002444E2_label_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_40A4F7505810715F6AEA9A56002444E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Termination Period Due To Performance Failure</link:label>
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_40A4F7505810715F6AEA9A56002444E2_documentation_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_40A4F7505810715F6AEA9A56002444E2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License agreement, termination period due to performance failure.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure" xlink:label="loc_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_40A4F7505810715F6AEA9A56002444E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_40A4F7505810715F6AEA9A56002444E2" xlink:to="lab_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_40A4F7505810715F6AEA9A56002444E2" xlink:type="arc" />
    <link:label id="lab_dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease_C9A2BF985131F6143FFD9A560024E498_terseLabel_en-US" xlink:label="lab_dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease_C9A2BF985131F6143FFD9A560024E498" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement termination on failing to enroll patient within months of production and release</link:label>
    <link:label id="lab_dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease_C9A2BF985131F6143FFD9A560024E498_label_en-US" xlink:label="lab_dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease_C9A2BF985131F6143FFD9A560024E498" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement Termination On Failing To Enroll Patient Within Months Of Production And Release</link:label>
    <link:label id="lab_dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease_C9A2BF985131F6143FFD9A560024E498_documentation_en-US" xlink:label="lab_dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease_C9A2BF985131F6143FFD9A560024E498" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement termination on failing to enroll patient within months of production and release.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease" xlink:label="loc_dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease_C9A2BF985131F6143FFD9A560024E498" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease_C9A2BF985131F6143FFD9A560024E498" xlink:to="lab_dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease_C9A2BF985131F6143FFD9A560024E498" xlink:type="arc" />
    <link:label id="lab_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_00DFD9685A4BF88AB74D9A5600245D3A_terseLabel_en-US" xlink:label="lab_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_00DFD9685A4BF88AB74D9A5600245D3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of rights to inventions by employees under license agreement</link:label>
    <link:label id="lab_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_00DFD9685A4BF88AB74D9A5600245D3A_label_en-US" xlink:label="lab_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_00DFD9685A4BF88AB74D9A5600245D3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Rights To Inventions By Employees Under License Agreement</link:label>
    <link:label id="lab_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_00DFD9685A4BF88AB74D9A5600245D3A_documentation_en-US" xlink:label="lab_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_00DFD9685A4BF88AB74D9A5600245D3A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of rights to inventions by employees under license agreement.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement" xlink:label="loc_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_00DFD9685A4BF88AB74D9A5600245D3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_00DFD9685A4BF88AB74D9A5600245D3A" xlink:to="lab_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_00DFD9685A4BF88AB74D9A5600245D3A" xlink:type="arc" />
    <link:label id="lab_dare_MilestonePaymentsContingentAmount_B78283700539874CDE8F9A56002440B7_terseLabel_en-US" xlink:label="lab_dare_MilestonePaymentsContingentAmount_B78283700539874CDE8F9A56002440B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments, contingent amount</link:label>
    <link:label id="lab_dare_MilestonePaymentsContingentAmount_B78283700539874CDE8F9A56002440B7_label_en-US" xlink:label="lab_dare_MilestonePaymentsContingentAmount_B78283700539874CDE8F9A56002440B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payments Contingent Amount</link:label>
    <link:label id="lab_dare_MilestonePaymentsContingentAmount_B78283700539874CDE8F9A56002440B7_documentation_en-US" xlink:label="lab_dare_MilestonePaymentsContingentAmount_B78283700539874CDE8F9A56002440B7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone payments, contingent amount.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_MilestonePaymentsContingentAmount" xlink:label="loc_dare_MilestonePaymentsContingentAmount_B78283700539874CDE8F9A56002440B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_MilestonePaymentsContingentAmount_B78283700539874CDE8F9A56002440B7" xlink:to="lab_dare_MilestonePaymentsContingentAmount_B78283700539874CDE8F9A56002440B7" xlink:type="arc" />
    <link:label id="lab_dare_SecuredInvestmentRequiredForLicenseAgreement_872582390F9D53AF2AAE9A560024DD41_terseLabel_en-US" xlink:label="lab_dare_SecuredInvestmentRequiredForLicenseAgreement_872582390F9D53AF2AAE9A560024DD41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured investment required for license agreement</link:label>
    <link:label id="lab_dare_SecuredInvestmentRequiredForLicenseAgreement_872582390F9D53AF2AAE9A560024DD41_label_en-US" xlink:label="lab_dare_SecuredInvestmentRequiredForLicenseAgreement_872582390F9D53AF2AAE9A560024DD41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Investment Required For License Agreement</link:label>
    <link:label id="lab_dare_SecuredInvestmentRequiredForLicenseAgreement_872582390F9D53AF2AAE9A560024DD41_documentation_en-US" xlink:label="lab_dare_SecuredInvestmentRequiredForLicenseAgreement_872582390F9D53AF2AAE9A560024DD41" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Secured investment required for license agreement.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_SecuredInvestmentRequiredForLicenseAgreement" xlink:label="loc_dare_SecuredInvestmentRequiredForLicenseAgreement_872582390F9D53AF2AAE9A560024DD41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_SecuredInvestmentRequiredForLicenseAgreement_872582390F9D53AF2AAE9A560024DD41" xlink:to="lab_dare_SecuredInvestmentRequiredForLicenseAgreement_872582390F9D53AF2AAE9A560024DD41" xlink:type="arc" />
    <link:label id="lab_dare_LicenseAgreementExpirationPeriod_A0108DD623BAE0B6903F9A560024047E_terseLabel_en-US" xlink:label="lab_dare_LicenseAgreementExpirationPeriod_A0108DD623BAE0B6903F9A560024047E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement, expiration period</link:label>
    <link:label id="lab_dare_LicenseAgreementExpirationPeriod_A0108DD623BAE0B6903F9A560024047E_label_en-US" xlink:label="lab_dare_LicenseAgreementExpirationPeriod_A0108DD623BAE0B6903F9A560024047E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Expiration Period</link:label>
    <link:label id="lab_dare_LicenseAgreementExpirationPeriod_A0108DD623BAE0B6903F9A560024047E_documentation_en-US" xlink:label="lab_dare_LicenseAgreementExpirationPeriod_A0108DD623BAE0B6903F9A560024047E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License agreement expiration period.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseAgreementExpirationPeriod" xlink:label="loc_dare_LicenseAgreementExpirationPeriod_A0108DD623BAE0B6903F9A560024047E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseAgreementExpirationPeriod_A0108DD623BAE0B6903F9A560024047E" xlink:to="lab_dare_LicenseAgreementExpirationPeriod_A0108DD623BAE0B6903F9A560024047E" xlink:type="arc" />
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval_FBB837D21481090AF7219A560024FFF8_terseLabel_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval_FBB837D21481090AF7219A560024FFF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement, termination period prior to receipt of approval</link:label>
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval_FBB837D21481090AF7219A560024FFF8_label_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval_FBB837D21481090AF7219A560024FFF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Termination Period Prior To Receipt Of Approval</link:label>
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval_FBB837D21481090AF7219A560024FFF8_documentation_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval_FBB837D21481090AF7219A560024FFF8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License agreement, termination period prior to receipt of approval.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval" xlink:label="loc_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval_FBB837D21481090AF7219A560024FFF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval_FBB837D21481090AF7219A560024FFF8" xlink:to="lab_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval_FBB837D21481090AF7219A560024FFF8" xlink:type="arc" />
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval_76CCC3476D3257EABB9C9A56002489B5_terseLabel_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval_76CCC3476D3257EABB9C9A56002489B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement, termination period after receipt of approval</link:label>
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval_76CCC3476D3257EABB9C9A56002489B5_label_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval_76CCC3476D3257EABB9C9A56002489B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Termination Period After Receipt Of Approval</link:label>
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval_76CCC3476D3257EABB9C9A56002489B5_documentation_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval_76CCC3476D3257EABB9C9A56002489B5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License agreement, termination period after receipt of approval.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval" xlink:label="loc_dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval_76CCC3476D3257EABB9C9A56002489B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval_76CCC3476D3257EABB9C9A56002489B5" xlink:to="lab_dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval_76CCC3476D3257EABB9C9A56002489B5" xlink:type="arc" />
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries_F124726C3421E867D1CD9A5600240049_terseLabel_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries_F124726C3421E867D1CD9A5600240049" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement, termination period for applicable license products of applicable countries</link:label>
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries_F124726C3421E867D1CD9A5600240049_label_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries_F124726C3421E867D1CD9A5600240049" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Termination Period For Applicable License Products Of Applicable Countries</link:label>
    <link:label id="lab_dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries_F124726C3421E867D1CD9A5600240049_documentation_en-US" xlink:label="lab_dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries_F124726C3421E867D1CD9A5600240049" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License agreement, termination period for applicable license products of applicable countries.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries" xlink:label="loc_dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries_F124726C3421E867D1CD9A5600240049" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries_F124726C3421E867D1CD9A5600240049" xlink:to="lab_dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries_F124726C3421E867D1CD9A5600240049" xlink:type="arc" />
    <link:label id="lab_dare_NoticePeriodForTerminationOfAgreementForBothParties_CF6435B3AEFC7CBAB3F79A56002444A9_terseLabel_en-US" xlink:label="lab_dare_NoticePeriodForTerminationOfAgreementForBothParties_CF6435B3AEFC7CBAB3F79A56002444A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior written notice period for termination of agreement for both parties</link:label>
    <link:label id="lab_dare_NoticePeriodForTerminationOfAgreementForBothParties_CF6435B3AEFC7CBAB3F79A56002444A9_label_en-US" xlink:label="lab_dare_NoticePeriodForTerminationOfAgreementForBothParties_CF6435B3AEFC7CBAB3F79A56002444A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notice Period For Termination Of Agreement For Both Parties</link:label>
    <link:label id="lab_dare_NoticePeriodForTerminationOfAgreementForBothParties_CF6435B3AEFC7CBAB3F79A56002444A9_documentation_en-US" xlink:label="lab_dare_NoticePeriodForTerminationOfAgreementForBothParties_CF6435B3AEFC7CBAB3F79A56002444A9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notice period for termination of agreement for both parties.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_NoticePeriodForTerminationOfAgreementForBothParties" xlink:label="loc_dare_NoticePeriodForTerminationOfAgreementForBothParties_CF6435B3AEFC7CBAB3F79A56002444A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NoticePeriodForTerminationOfAgreementForBothParties_CF6435B3AEFC7CBAB3F79A56002444A9" xlink:to="lab_dare_NoticePeriodForTerminationOfAgreementForBothParties_CF6435B3AEFC7CBAB3F79A56002444A9" xlink:type="arc" />
    <link:label id="lab_dare_ResearchAndDevelopmentMilestonePayment_EC3B4824F10C9177D2209A560024FEBE_terseLabel_en-US" xlink:label="lab_dare_ResearchAndDevelopmentMilestonePayment_EC3B4824F10C9177D2209A560024FEBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_dare_ResearchAndDevelopmentMilestonePayment_EC3B4824F10C9177D2209A560024FEBE_label_en-US" xlink:label="lab_dare_ResearchAndDevelopmentMilestonePayment_EC3B4824F10C9177D2209A560024FEBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Milestone Payment</link:label>
    <link:label id="lab_dare_ResearchAndDevelopmentMilestonePayment_EC3B4824F10C9177D2209A560024FEBE_documentation_en-US" xlink:label="lab_dare_ResearchAndDevelopmentMilestonePayment_EC3B4824F10C9177D2209A560024FEBE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and development milestone payment.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_ResearchAndDevelopmentMilestonePayment" xlink:label="loc_dare_ResearchAndDevelopmentMilestonePayment_EC3B4824F10C9177D2209A560024FEBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ResearchAndDevelopmentMilestonePayment_EC3B4824F10C9177D2209A560024FEBE" xlink:to="lab_dare_ResearchAndDevelopmentMilestonePayment_EC3B4824F10C9177D2209A560024FEBE" xlink:type="arc" />
    <link:label id="lab_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_5810BD177D60B22254289A5600246007_terseLabel_en-US" xlink:label="lab_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_5810BD177D60B22254289A5600246007" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commencement period for stage two upon achievement of stage one</link:label>
    <link:label id="lab_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_5810BD177D60B22254289A5600246007_label_en-US" xlink:label="lab_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_5810BD177D60B22254289A5600246007" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commencement Period For Stage Two Upon Achievement Of Stage One</link:label>
    <link:label id="lab_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_5810BD177D60B22254289A5600246007_documentation_en-US" xlink:label="lab_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_5810BD177D60B22254289A5600246007" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commencement Period For Stage Two Upon Achievement Of Stage One</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_CommencementPeriodForStageTwoUponAchievementOfStageOne" xlink:label="loc_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_5810BD177D60B22254289A5600246007" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_5810BD177D60B22254289A5600246007" xlink:to="lab_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_5810BD177D60B22254289A5600246007" xlink:type="arc" />
    <link:label id="lab_dare_UpfrontLicenseFeePaid_5D7D2EC543FF757133159A5600242C6F_terseLabel_en-US" xlink:label="lab_dare_UpfrontLicenseFeePaid_5D7D2EC543FF757133159A5600242C6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront license fee paid</link:label>
    <link:label id="lab_dare_UpfrontLicenseFeePaid_5D7D2EC543FF757133159A5600242C6F_label_en-US" xlink:label="lab_dare_UpfrontLicenseFeePaid_5D7D2EC543FF757133159A5600242C6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront License Fee Paid</link:label>
    <link:label id="lab_dare_UpfrontLicenseFeePaid_5D7D2EC543FF757133159A5600242C6F_documentation_en-US" xlink:label="lab_dare_UpfrontLicenseFeePaid_5D7D2EC543FF757133159A5600242C6F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront License Fee Paid</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_UpfrontLicenseFeePaid" xlink:label="loc_dare_UpfrontLicenseFeePaid_5D7D2EC543FF757133159A5600242C6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UpfrontLicenseFeePaid_5D7D2EC543FF757133159A5600242C6F" xlink:to="lab_dare_UpfrontLicenseFeePaid_5D7D2EC543FF757133159A5600242C6F" xlink:type="arc" />
    <link:label id="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_56BD0638CD219DCA6E4C9A5600240E89_terseLabel_en-US" xlink:label="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_56BD0638CD219DCA6E4C9A5600240E89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential annual license maintenance fee, payments in year one</link:label>
    <link:label id="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_56BD0638CD219DCA6E4C9A5600240E89_label_en-US" xlink:label="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_56BD0638CD219DCA6E4C9A5600240E89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Annual License Maintenance Fee, Payments In Year One</link:label>
    <link:label id="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_56BD0638CD219DCA6E4C9A5600240E89_documentation_en-US" xlink:label="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_56BD0638CD219DCA6E4C9A5600240E89" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential Annual License Maintenance Fee, Payments In Year One</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne" xlink:label="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_56BD0638CD219DCA6E4C9A5600240E89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_56BD0638CD219DCA6E4C9A5600240E89" xlink:to="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_56BD0638CD219DCA6E4C9A5600240E89" xlink:type="arc" />
    <link:label id="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_3D2EBD3A7E3D9B6AAA1A9A5600245A33_terseLabel_en-US" xlink:label="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_3D2EBD3A7E3D9B6AAA1A9A5600245A33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential annual license maintenance fee payments, thereafter</link:label>
    <link:label id="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_3D2EBD3A7E3D9B6AAA1A9A5600245A33_label_en-US" xlink:label="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_3D2EBD3A7E3D9B6AAA1A9A5600245A33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Annual License Maintenance Fee Payments, Thereafter</link:label>
    <link:label id="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_3D2EBD3A7E3D9B6AAA1A9A5600245A33_documentation_en-US" xlink:label="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_3D2EBD3A7E3D9B6AAA1A9A5600245A33" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential Annual License Maintenance Fee Payments, Thereafter</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" xlink:label="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_3D2EBD3A7E3D9B6AAA1A9A5600245A33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_3D2EBD3A7E3D9B6AAA1A9A5600245A33" xlink:to="lab_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_3D2EBD3A7E3D9B6AAA1A9A5600245A33" xlink:type="arc" />
    <link:label id="lab_dare_MaximumPotentialMilestonePayments_1E20C25B4B9697F644BD9A5600242F55_terseLabel_en-US" xlink:label="lab_dare_MaximumPotentialMilestonePayments_1E20C25B4B9697F644BD9A5600242F55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum potential milestone payments</link:label>
    <link:label id="lab_dare_MaximumPotentialMilestonePayments_1E20C25B4B9697F644BD9A5600242F55_label_en-US" xlink:label="lab_dare_MaximumPotentialMilestonePayments_1E20C25B4B9697F644BD9A5600242F55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Potential Milestone Payments</link:label>
    <link:label id="lab_dare_MaximumPotentialMilestonePayments_1E20C25B4B9697F644BD9A5600242F55_documentation_en-US" xlink:label="lab_dare_MaximumPotentialMilestonePayments_1E20C25B4B9697F644BD9A5600242F55" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Potential Milestone Payments</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_MaximumPotentialMilestonePayments" xlink:label="loc_dare_MaximumPotentialMilestonePayments_1E20C25B4B9697F644BD9A5600242F55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_MaximumPotentialMilestonePayments_1E20C25B4B9697F644BD9A5600242F55" xlink:to="lab_dare_MaximumPotentialMilestonePayments_1E20C25B4B9697F644BD9A5600242F55" xlink:type="arc" />
    <link:label id="lab_dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess_F6B481148AECD100D2579A560024091F_terseLabel_en-US" xlink:label="lab_dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess_F6B481148AECD100D2579A560024091F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement, period of continuation from date of first commercial sale of product or process</link:label>
    <link:label id="lab_dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess_F6B481148AECD100D2579A560024091F_label_en-US" xlink:label="lab_dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess_F6B481148AECD100D2579A560024091F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Period Of Continuation From Date Of First Commercial Sale Of Product Or Process</link:label>
    <link:label id="lab_dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess_F6B481148AECD100D2579A560024091F_documentation_en-US" xlink:label="lab_dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess_F6B481148AECD100D2579A560024091F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement Period Of Continuation From Date Of First Commercial Sale Of Product Or Process</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess" xlink:label="loc_dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess_F6B481148AECD100D2579A560024091F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess_F6B481148AECD100D2579A560024091F" xlink:to="lab_dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess_F6B481148AECD100D2579A560024091F" xlink:type="arc" />
    <link:label id="lab_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation_E8FDC8D4D591972F80549A56002430AE_terseLabel_en-US" xlink:label="lab_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation_E8FDC8D4D591972F80549A56002430AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement notice period of termination for breach of payment obligation</link:label>
    <link:label id="lab_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation_E8FDC8D4D591972F80549A56002430AE_label_en-US" xlink:label="lab_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation_E8FDC8D4D591972F80549A56002430AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Notice Period Of Termination For Breach Of Payment Obligation</link:label>
    <link:label id="lab_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation_E8FDC8D4D591972F80549A56002430AE_documentation_en-US" xlink:label="lab_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation_E8FDC8D4D591972F80549A56002430AE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement Notice Period Of Termination For Breach Of Payment Obligation</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation" xlink:label="loc_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation_E8FDC8D4D591972F80549A56002430AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation_E8FDC8D4D591972F80549A56002430AE" xlink:to="lab_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation_E8FDC8D4D591972F80549A56002430AE" xlink:type="arc" />
    <link:label id="lab_dare_PeriodOfDismissalOfBankruptcyPetition_9A66142D7D6466E0B3849A5600334DD1_terseLabel_en-US" xlink:label="lab_dare_PeriodOfDismissalOfBankruptcyPetition_9A66142D7D6466E0B3849A5600334DD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of dismissal of bankruptcy petition</link:label>
    <link:label id="lab_dare_PeriodOfDismissalOfBankruptcyPetition_9A66142D7D6466E0B3849A5600334DD1_label_en-US" xlink:label="lab_dare_PeriodOfDismissalOfBankruptcyPetition_9A66142D7D6466E0B3849A5600334DD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Of Dismissal Of Bankruptcy Petition</link:label>
    <link:label id="lab_dare_PeriodOfDismissalOfBankruptcyPetition_9A66142D7D6466E0B3849A5600334DD1_documentation_en-US" xlink:label="lab_dare_PeriodOfDismissalOfBankruptcyPetition_9A66142D7D6466E0B3849A5600334DD1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period Of Dismissal Of Bankruptcy Petition</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_PeriodOfDismissalOfBankruptcyPetition" xlink:label="loc_dare_PeriodOfDismissalOfBankruptcyPetition_9A66142D7D6466E0B3849A5600334DD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PeriodOfDismissalOfBankruptcyPetition_9A66142D7D6466E0B3849A5600334DD1" xlink:to="lab_dare_PeriodOfDismissalOfBankruptcyPetition_9A66142D7D6466E0B3849A5600334DD1" xlink:type="arc" />
    <link:label id="lab_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation_3172676B13C81A8A8C329A560033F776_terseLabel_en-US" xlink:label="lab_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation_3172676B13C81A8A8C329A560033F776" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement notice period of termination for breach of other obligation</link:label>
    <link:label id="lab_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation_3172676B13C81A8A8C329A560033F776_label_en-US" xlink:label="lab_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation_3172676B13C81A8A8C329A560033F776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Notice Period Of Termination For Breach Of Other Obligation</link:label>
    <link:label id="lab_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation_3172676B13C81A8A8C329A560033F776_documentation_en-US" xlink:label="lab_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation_3172676B13C81A8A8C329A560033F776" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement Notice Period Of Termination For Breach Of Other Obligation</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation" xlink:label="loc_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation_3172676B13C81A8A8C329A560033F776" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation_3172676B13C81A8A8C329A560033F776" xlink:to="lab_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation_3172676B13C81A8A8C329A560033F776" xlink:type="arc" />
    <link:label id="lab_dare_LicenseAgreementNoticePeriodOfTermination_9DD65469CF7431C21BEE9A5600339C9B_terseLabel_en-US" xlink:label="lab_dare_LicenseAgreementNoticePeriodOfTermination_9DD65469CF7431C21BEE9A5600339C9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement, notice period of termination</link:label>
    <link:label id="lab_dare_LicenseAgreementNoticePeriodOfTermination_9DD65469CF7431C21BEE9A5600339C9B_label_en-US" xlink:label="lab_dare_LicenseAgreementNoticePeriodOfTermination_9DD65469CF7431C21BEE9A5600339C9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Notice Period Of Termination</link:label>
    <link:label id="lab_dare_LicenseAgreementNoticePeriodOfTermination_9DD65469CF7431C21BEE9A5600339C9B_documentation_en-US" xlink:label="lab_dare_LicenseAgreementNoticePeriodOfTermination_9DD65469CF7431C21BEE9A5600339C9B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement Notice Period Of Termination</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseAgreementNoticePeriodOfTermination" xlink:label="loc_dare_LicenseAgreementNoticePeriodOfTermination_9DD65469CF7431C21BEE9A5600339C9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseAgreementNoticePeriodOfTermination_9DD65469CF7431C21BEE9A5600339C9B" xlink:to="lab_dare_LicenseAgreementNoticePeriodOfTermination_9DD65469CF7431C21BEE9A5600339C9B" xlink:type="arc" />
    <link:label id="lab_dare_LicenseFee_EC70CA24DF2CC78006AD9A5600331328_verboseLabel_en-US" xlink:label="lab_dare_LicenseFee_EC70CA24DF2CC78006AD9A5600331328" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">License fee</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseFee" xlink:label="loc_dare_LicenseFee_EC70CA24DF2CC78006AD9A5600331328" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseFee_EC70CA24DF2CC78006AD9A5600331328" xlink:to="lab_dare_LicenseFee_EC70CA24DF2CC78006AD9A5600331328" xlink:type="arc" />
    <link:label id="lab_dare_LicenseFeeToBePaidUponContingency_EC3867FD1715A408E3DB9A560033532E_terseLabel_en-US" xlink:label="lab_dare_LicenseFeeToBePaidUponContingency_EC3867FD1715A408E3DB9A560033532E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License fee to be paid upon contingency</link:label>
    <link:label id="lab_dare_LicenseFeeToBePaidUponContingency_EC3867FD1715A408E3DB9A560033532E_label_en-US" xlink:label="lab_dare_LicenseFeeToBePaidUponContingency_EC3867FD1715A408E3DB9A560033532E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Fee, To Be Paid Upon Contingency</link:label>
    <link:label id="lab_dare_LicenseFeeToBePaidUponContingency_EC3867FD1715A408E3DB9A560033532E_documentation_en-US" xlink:label="lab_dare_LicenseFeeToBePaidUponContingency_EC3867FD1715A408E3DB9A560033532E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Fee, To Be Paid Upon Contingency</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseFeeToBePaidUponContingency" xlink:label="loc_dare_LicenseFeeToBePaidUponContingency_EC3867FD1715A408E3DB9A560033532E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_LicenseFeeToBePaidUponContingency_EC3867FD1715A408E3DB9A560033532E" xlink:to="lab_dare_LicenseFeeToBePaidUponContingency_EC3867FD1715A408E3DB9A560033532E" xlink:type="arc" />
    <link:label id="lab_dare_ProceedsRaisedFromEquityFinancing_E39FDEFAFEF3860A55E39A5600336B8F_terseLabel_en-US" xlink:label="lab_dare_ProceedsRaisedFromEquityFinancing_E39FDEFAFEF3860A55E39A5600336B8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds raised from equity financing</link:label>
    <link:label id="lab_dare_ProceedsRaisedFromEquityFinancing_E39FDEFAFEF3860A55E39A5600336B8F_label_en-US" xlink:label="lab_dare_ProceedsRaisedFromEquityFinancing_E39FDEFAFEF3860A55E39A5600336B8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds Raised From Equity Financing</link:label>
    <link:label id="lab_dare_ProceedsRaisedFromEquityFinancing_E39FDEFAFEF3860A55E39A5600336B8F_documentation_en-US" xlink:label="lab_dare_ProceedsRaisedFromEquityFinancing_E39FDEFAFEF3860A55E39A5600336B8F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds Raised From Equity Financing</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_ProceedsRaisedFromEquityFinancing" xlink:label="loc_dare_ProceedsRaisedFromEquityFinancing_E39FDEFAFEF3860A55E39A5600336B8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ProceedsRaisedFromEquityFinancing_E39FDEFAFEF3860A55E39A5600336B8F" xlink:to="lab_dare_ProceedsRaisedFromEquityFinancing_E39FDEFAFEF3860A55E39A5600336B8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_DBA46B363FAED29C336A4B4561485874_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_DBA46B363FAED29C336A4B4561485874" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_DBA46B363FAED29C336A4B4561485874_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_DBA46B363FAED29C336A4B4561485874" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_DBA46B363FAED29C336A4B4561485874" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_DBA46B363FAED29C336A4B4561485874" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_DBA46B363FAED29C336A4B4561485874" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrantMember_C39998FEC7B17BD7EEFE4B44EE20A3A5_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember_C39998FEC7B17BD7EEFE4B44EE20A3A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant [Member]</link:label>
    <link:label id="lab_us-gaap_GrantMember_C39998FEC7B17BD7EEFE4B44EE20A3A5_label_en-US" xlink:label="lab_us-gaap_GrantMember_C39998FEC7B17BD7EEFE4B44EE20A3A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_C39998FEC7B17BD7EEFE4B44EE20A3A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember_C39998FEC7B17BD7EEFE4B44EE20A3A5" xlink:to="lab_us-gaap_GrantMember_C39998FEC7B17BD7EEFE4B44EE20A3A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_HealthCareTrustFundAxis_70847F1A29F1EA462DFF4B44EE1F1692_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareTrustFundAxis_70847F1A29F1EA462DFF4B44EE1F1692" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Health Care Trust Fund</link:label>
    <link:label id="lab_us-gaap_HealthCareTrustFundAxis_70847F1A29F1EA462DFF4B44EE1F1692_label_en-US" xlink:label="lab_us-gaap_HealthCareTrustFundAxis_70847F1A29F1EA462DFF4B44EE1F1692" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Health Care Trust Fund [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareTrustFundAxis" xlink:label="loc_us-gaap_HealthCareTrustFundAxis_70847F1A29F1EA462DFF4B44EE1F1692" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareTrustFundAxis_70847F1A29F1EA462DFF4B44EE1F1692" xlink:to="lab_us-gaap_HealthCareTrustFundAxis_70847F1A29F1EA462DFF4B44EE1F1692" xlink:type="arc" />
    <link:label id="lab_us-gaap_HealthCareTrustFundNameDomain_E66BD0AB10830789F37D4B44EE1F29F1_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareTrustFundNameDomain_E66BD0AB10830789F37D4B44EE1F29F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Health Care Trust Fund, Name</link:label>
    <link:label id="lab_us-gaap_HealthCareTrustFundNameDomain_E66BD0AB10830789F37D4B44EE1F29F1_label_en-US" xlink:label="lab_us-gaap_HealthCareTrustFundNameDomain_E66BD0AB10830789F37D4B44EE1F29F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Health Care Trust Fund, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareTrustFundNameDomain" xlink:label="loc_us-gaap_HealthCareTrustFundNameDomain_E66BD0AB10830789F37D4B44EE1F29F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareTrustFundNameDomain_E66BD0AB10830789F37D4B44EE1F29F1" xlink:to="lab_us-gaap_HealthCareTrustFundNameDomain_E66BD0AB10830789F37D4B44EE1F29F1" xlink:type="arc" />
    <link:label id="lab_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_D2512C37158110EFA1FC4B44EE2084B2_terseLabel_en-US" xlink:label="lab_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_D2512C37158110EFA1FC4B44EE2084B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eunice Kennedy Shriver National Institute Of Child Health And Human Development [Member]</link:label>
    <link:label id="lab_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_D2512C37158110EFA1FC4B44EE2084B2_label_en-US" xlink:label="lab_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_D2512C37158110EFA1FC4B44EE2084B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eunice Kennedy Shriver National Institute Of Child Health And Human Development [Member]</link:label>
    <link:label id="lab_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_D2512C37158110EFA1FC4B44EE2084B2_documentation_en-US" xlink:label="lab_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_D2512C37158110EFA1FC4B44EE2084B2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eunice Kennedy Shriver National Institute Of Child Health And Human Development [Member]</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember" xlink:label="loc_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_D2512C37158110EFA1FC4B44EE2084B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_D2512C37158110EFA1FC4B44EE2084B2" xlink:to="lab_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_D2512C37158110EFA1FC4B44EE2084B2" xlink:type="arc" />
    <link:label id="lab_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_9A22F295407FDC669C894B44EE1E5360_terseLabel_en-US" xlink:label="lab_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_9A22F295407FDC669C894B44EE1E5360" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Second Phase Of Research And Availability Of Funds [Member]</link:label>
    <link:label id="lab_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_9A22F295407FDC669C894B44EE1E5360_label_en-US" xlink:label="lab_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_9A22F295407FDC669C894B44EE1E5360" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Second Phase Of Research And Availability Of Funds [Member]</link:label>
    <link:label id="lab_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_9A22F295407FDC669C894B44EE1E5360_documentation_en-US" xlink:label="lab_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_9A22F295407FDC669C894B44EE1E5360" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Second Phase Of Research And Availability Of Funds [Member]</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember" xlink:label="loc_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_9A22F295407FDC669C894B44EE1E5360" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_9A22F295407FDC669C894B44EE1E5360" xlink:to="lab_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_9A22F295407FDC669C894B44EE1E5360" xlink:type="arc" />
    <link:label id="lab_dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember_08BD4C50CB61002D96B44B44EE1F286B_terseLabel_en-US" xlink:label="lab_dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember_08BD4C50CB61002D96B44B44EE1F286B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining Portion Of Research And Availability Of Funds [Member]</link:label>
    <link:label id="lab_dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember_08BD4C50CB61002D96B44B44EE1F286B_label_en-US" xlink:label="lab_dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember_08BD4C50CB61002D96B44B44EE1F286B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remaining Portion Of Research And Availability Of Funds [Member]</link:label>
    <link:label id="lab_dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember_08BD4C50CB61002D96B44B44EE1F286B_documentation_en-US" xlink:label="lab_dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember_08BD4C50CB61002D96B44B44EE1F286B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Remaining Portion Of Research And Availability Of Funds [Member]</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember" xlink:label="loc_dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember_08BD4C50CB61002D96B44B44EE1F286B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember_08BD4C50CB61002D96B44B44EE1F286B" xlink:to="lab_dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember_08BD4C50CB61002D96B44B44EE1F286B" xlink:type="arc" />
    <link:label id="lab_dare_NationalInstitutesOfHealthMember_C98F76402D2DF376E0594B44EE1D96E7_terseLabel_en-US" xlink:label="lab_dare_NationalInstitutesOfHealthMember_C98F76402D2DF376E0594B44EE1D96E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">National Institutes Of Health [Member]</link:label>
    <link:label id="lab_dare_NationalInstitutesOfHealthMember_C98F76402D2DF376E0594B44EE1D96E7_label_en-US" xlink:label="lab_dare_NationalInstitutesOfHealthMember_C98F76402D2DF376E0594B44EE1D96E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">National Institutes Of Health [Member]</link:label>
    <link:label id="lab_dare_NationalInstitutesOfHealthMember_C98F76402D2DF376E0594B44EE1D96E7_documentation_en-US" xlink:label="lab_dare_NationalInstitutesOfHealthMember_C98F76402D2DF376E0594B44EE1D96E7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">National Institutes Of Health [Member]</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_NationalInstitutesOfHealthMember" xlink:label="loc_dare_NationalInstitutesOfHealthMember_C98F76402D2DF376E0594B44EE1D96E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NationalInstitutesOfHealthMember_C98F76402D2DF376E0594B44EE1D96E7" xlink:to="lab_dare_NationalInstitutesOfHealthMember_C98F76402D2DF376E0594B44EE1D96E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_4550E0A5A1BED752DA3D4B45614FBAFE_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_4550E0A5A1BED752DA3D4B45614FBAFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_4550E0A5A1BED752DA3D4B45614FBAFE_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_4550E0A5A1BED752DA3D4B45614FBAFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4550E0A5A1BED752DA3D4B45614FBAFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4550E0A5A1BED752DA3D4B45614FBAFE" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_4550E0A5A1BED752DA3D4B45614FBAFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EAA3DBB7DCB745D015344B44EE21580A_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EAA3DBB7DCB745D015344B44EE21580A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from grant for notice of award</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EAA3DBB7DCB745D015344B44EE21580A_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EAA3DBB7DCB745D015344B44EE21580A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EAA3DBB7DCB745D015344B44EE21580A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EAA3DBB7DCB745D015344B44EE21580A" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EAA3DBB7DCB745D015344B44EE21580A" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrantsReceivable_A700E7260F051B02470F4B44EE211D07_terseLabel_en-US" xlink:label="lab_us-gaap_GrantsReceivable_A700E7260F051B02470F4B44EE211D07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grants receivable</link:label>
    <link:label id="lab_us-gaap_GrantsReceivable_A700E7260F051B02470F4B44EE211D07_label_en-US" xlink:label="lab_us-gaap_GrantsReceivable_A700E7260F051B02470F4B44EE211D07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grants Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="loc_us-gaap_GrantsReceivable_A700E7260F051B02470F4B44EE211D07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantsReceivable_A700E7260F051B02470F4B44EE211D07" xlink:to="lab_us-gaap_GrantsReceivable_A700E7260F051B02470F4B44EE211D07" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_BAB8B5647671C3BAB84D4B44EE21F949_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_BAB8B5647671C3BAB84D4B44EE21F949" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash received from federal grant</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_BAB8B5647671C3BAB84D4B44EE21F949_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_BAB8B5647671C3BAB84D4B44EE21F949" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_BAB8B5647671C3BAB84D4B44EE21F949" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_BAB8B5647671C3BAB84D4B44EE21F949" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_BAB8B5647671C3BAB84D4B44EE21F949" xlink:type="arc" />
    <link:label id="lab_dare_ReimbursementOfGrantExpensesReceivable_47DA93AB45B5EFA55C6A4B44EE216660_terseLabel_en-US" xlink:label="lab_dare_ReimbursementOfGrantExpensesReceivable_47DA93AB45B5EFA55C6A4B44EE216660" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement of grant expenses receivable</link:label>
    <link:label id="lab_dare_ReimbursementOfGrantExpensesReceivable_47DA93AB45B5EFA55C6A4B44EE216660_label_en-US" xlink:label="lab_dare_ReimbursementOfGrantExpensesReceivable_47DA93AB45B5EFA55C6A4B44EE216660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursement Of Grant Expenses Receivable</link:label>
    <link:label id="lab_dare_ReimbursementOfGrantExpensesReceivable_47DA93AB45B5EFA55C6A4B44EE216660_documentation_en-US" xlink:label="lab_dare_ReimbursementOfGrantExpensesReceivable_47DA93AB45B5EFA55C6A4B44EE216660" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reimbursement of grant expenses receivable.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_ReimbursementOfGrantExpensesReceivable" xlink:label="loc_dare_ReimbursementOfGrantExpensesReceivable_47DA93AB45B5EFA55C6A4B44EE216660" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ReimbursementOfGrantExpensesReceivable_47DA93AB45B5EFA55C6A4B44EE216660" xlink:to="lab_dare_ReimbursementOfGrantExpensesReceivable_47DA93AB45B5EFA55C6A4B44EE216660" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_8AD112719732F8A08E325B0CFD6148C9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_8AD112719732F8A08E325B0CFD6148C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_8AD112719732F8A08E325B0CFD6148C9_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_8AD112719732F8A08E325B0CFD6148C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_8AD112719732F8A08E325B0CFD6148C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_8AD112719732F8A08E325B0CFD6148C9" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_8AD112719732F8A08E325B0CFD6148C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_063C4D0132B9EB441DD29A56022F952C_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_063C4D0132B9EB441DD29A56022F952C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_063C4D0132B9EB441DD29A56022F952C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_063C4D0132B9EB441DD29A56022F952C" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_063C4D0132B9EB441DD29A56022F952C" xlink:type="arc" />
    <link:label id="lab_dare_SignificantAccountingPoliciesTable_93C23DDD43FA4A521FC89A56022F7A5D_terseLabel_en-US" xlink:label="lab_dare_SignificantAccountingPoliciesTable_93C23DDD43FA4A521FC89A56022F7A5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_dare_SignificantAccountingPoliciesTable_93C23DDD43FA4A521FC89A56022F7A5D_label_en-US" xlink:label="lab_dare_SignificantAccountingPoliciesTable_93C23DDD43FA4A521FC89A56022F7A5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_dare_SignificantAccountingPoliciesTable_93C23DDD43FA4A521FC89A56022F7A5D_documentation_en-US" xlink:label="lab_dare_SignificantAccountingPoliciesTable_93C23DDD43FA4A521FC89A56022F7A5D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Significant accounting policies.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_SignificantAccountingPoliciesTable" xlink:label="loc_dare_SignificantAccountingPoliciesTable_93C23DDD43FA4A521FC89A56022F7A5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_SignificantAccountingPoliciesTable_93C23DDD43FA4A521FC89A56022F7A5D" xlink:to="lab_dare_SignificantAccountingPoliciesTable_93C23DDD43FA4A521FC89A56022F7A5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_5CD7E0215C0D939117539A56022FE9CD_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_5CD7E0215C0D939117539A56022FE9CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_5CD7E0215C0D939117539A56022FE9CD_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_5CD7E0215C0D939117539A56022FE9CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5CD7E0215C0D939117539A56022FE9CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5CD7E0215C0D939117539A56022FE9CD" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_5CD7E0215C0D939117539A56022FE9CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_004EED79203865698FDB9A56022F1DC0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_004EED79203865698FDB9A56022F1DC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_004EED79203865698FDB9A56022F1DC0_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_004EED79203865698FDB9A56022F1DC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_004EED79203865698FDB9A56022F1DC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_004EED79203865698FDB9A56022F1DC0" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_004EED79203865698FDB9A56022F1DC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_E3ADFD332D5C8729B5279A56022F6093_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_E3ADFD332D5C8729B5279A56022F6093" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_E3ADFD332D5C8729B5279A56022F6093_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_E3ADFD332D5C8729B5279A56022F6093" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_E3ADFD332D5C8729B5279A56022F6093" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_E3ADFD332D5C8729B5279A56022F6093" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_E3ADFD332D5C8729B5279A56022F6093" xlink:type="arc" />
    <link:label id="lab_dare_SignificantAccountingPoliciesLineItems_D889DB9D3C168C07023B9A56022FB6F4_terseLabel_en-US" xlink:label="lab_dare_SignificantAccountingPoliciesLineItems_D889DB9D3C168C07023B9A56022FB6F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_dare_SignificantAccountingPoliciesLineItems_D889DB9D3C168C07023B9A56022FB6F4_label_en-US" xlink:label="lab_dare_SignificantAccountingPoliciesLineItems_D889DB9D3C168C07023B9A56022FB6F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_dare_SignificantAccountingPoliciesLineItems_D889DB9D3C168C07023B9A56022FB6F4_documentation_en-US" xlink:label="lab_dare_SignificantAccountingPoliciesLineItems_D889DB9D3C168C07023B9A56022FB6F4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_SignificantAccountingPoliciesLineItems" xlink:label="loc_dare_SignificantAccountingPoliciesLineItems_D889DB9D3C168C07023B9A56022FB6F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_D889DB9D3C168C07023B9A56022FB6F4" xlink:to="lab_dare_SignificantAccountingPoliciesLineItems_D889DB9D3C168C07023B9A56022FB6F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_75CC75E42D13BA9B5A639A56022FEC60_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_75CC75E42D13BA9B5A639A56022FEC60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_75CC75E42D13BA9B5A639A56022FEC60_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_75CC75E42D13BA9B5A639A56022FEC60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_75CC75E42D13BA9B5A639A56022FEC60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_75CC75E42D13BA9B5A639A56022FEC60" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_75CC75E42D13BA9B5A639A56022FEC60" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_E9DCD4DE6780D18E00819A56022F191E_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_E9DCD4DE6780D18E00819A56022F191E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right of use leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_E9DCD4DE6780D18E00819A56022F191E_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_E9DCD4DE6780D18E00819A56022F191E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_E9DCD4DE6780D18E00819A56022F191E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_E9DCD4DE6780D18E00819A56022F191E" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_E9DCD4DE6780D18E00819A56022F191E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_C65FCFC94C7020C17E409A661003757E_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_C65FCFC94C7020C17E409A661003757E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_C65FCFC94C7020C17E409A661003757E_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_C65FCFC94C7020C17E409A661003757E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_C65FCFC94C7020C17E409A661003757E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_C65FCFC94C7020C17E409A661003757E" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable_C65FCFC94C7020C17E409A661003757E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_C6A9DC7E6F70E08E59849A66100563DE_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_C6A9DC7E6F70E08E59849A66100563DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_C6A9DC7E6F70E08E59849A66100563DE_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_C6A9DC7E6F70E08E59849A66100563DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_C6A9DC7E6F70E08E59849A66100563DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C6A9DC7E6F70E08E59849A66100563DE" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems_C6A9DC7E6F70E08E59849A66100563DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_1F34DFD916C3E99152E79A56024F6D47_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_1F34DFD916C3E99152E79A56024F6D47" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1F34DFD916C3E99152E79A56024F6D47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_1F34DFD916C3E99152E79A56024F6D47" xlink:to="lab_us-gaap_NetIncomeLoss_1F34DFD916C3E99152E79A56024F6D47" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_108E27EC00EFB037FDAD9A56024F194D_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_108E27EC00EFB037FDAD9A56024F194D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_108E27EC00EFB037FDAD9A56024F194D_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_108E27EC00EFB037FDAD9A56024F194D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_108E27EC00EFB037FDAD9A56024F194D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_108E27EC00EFB037FDAD9A56024F194D" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_108E27EC00EFB037FDAD9A56024F194D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C843732967C5D5C961E79A56024F68CD_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C843732967C5D5C961E79A56024F68CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C843732967C5D5C961E79A56024F68CD_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C843732967C5D5C961E79A56024F68CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C843732967C5D5C961E79A56024F68CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C843732967C5D5C961E79A56024F68CD" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C843732967C5D5C961E79A56024F68CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5634AEF9A0FD6D808D4B9A56024FB6C2_negatedLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5634AEF9A0FD6D808D4B9A56024FB6C2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cash flow from operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5634AEF9A0FD6D808D4B9A56024FB6C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5634AEF9A0FD6D808D4B9A56024FB6C2" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5634AEF9A0FD6D808D4B9A56024FB6C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_3FDA002F9E23F13D25AB9A56024F7FAB_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_3FDA002F9E23F13D25AB9A56024F7FAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate net proceeds on sales of shares of common stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3FDA002F9E23F13D25AB9A56024F7FAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3FDA002F9E23F13D25AB9A56024F7FAB" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_3FDA002F9E23F13D25AB9A56024F7FAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_AD5490C1229320B2C5E9BA4E6F926D3E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0EE9B21F09735D2491486977C42C2A06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_AD5490C1229320B2C5E9BA4E6F926D3E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0EE9B21F09735D2491486977C42C2A06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0EE9B21F09735D2491486977C42C2A06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0EE9B21F09735D2491486977C42C2A06" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0EE9B21F09735D2491486977C42C2A06" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_7C16DFD5FA72C95C53905B0CFC907294_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_7C16DFD5FA72C95C53905B0CFC907294" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_7C16DFD5FA72C95C53905B0CFC907294" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_7C16DFD5FA72C95C53905B0CFC907294" xlink:to="lab_us-gaap_EquityAbstract_7C16DFD5FA72C95C53905B0CFC907294" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7FBDC5C72597ACF2265F5B0CFC90854B_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7FBDC5C72597ACF2265F5B0CFC90854B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7FBDC5C72597ACF2265F5B0CFC90854B_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7FBDC5C72597ACF2265F5B0CFC90854B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7FBDC5C72597ACF2265F5B0CFC90854B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7FBDC5C72597ACF2265F5B0CFC90854B" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7FBDC5C72597ACF2265F5B0CFC90854B" xlink:type="arc" />
    <link:label id="lab_dare_DocumentAndEntityInformationAbstract_1C11E524C8BFA45BD654BAAC5C6CD8A7_label_en-US" xlink:label="lab_dare_DocumentAndEntityInformationAbstract_08DBFF8ED9675105A70B476DBD17D689" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_dare_DocumentAndEntityInformationAbstract_1C11E524C8BFA45BD654BAAC5C6CD8A7_documentation_en-US" xlink:label="lab_dare_DocumentAndEntityInformationAbstract_08DBFF8ED9675105A70B476DBD17D689" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and entity information.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_DocumentAndEntityInformationAbstract" xlink:label="loc_dare_DocumentAndEntityInformationAbstract_08DBFF8ED9675105A70B476DBD17D689" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_08DBFF8ED9675105A70B476DBD17D689" xlink:to="lab_dare_DocumentAndEntityInformationAbstract_08DBFF8ED9675105A70B476DBD17D689" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_056555393C103DB93B57BAAC5C6CA8B3_verboseLabel_en-US" xlink:label="lab_dei_DocumentType_07305CB1EC745D48ADDDEB7EEAA5D182" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_056555393C103DB93B57BAAC5C6CA8B3_label_en-US" xlink:label="lab_dei_DocumentType_07305CB1EC745D48ADDDEB7EEAA5D182" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_07305CB1EC745D48ADDDEB7EEAA5D182" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_07305CB1EC745D48ADDDEB7EEAA5D182" xlink:to="lab_dei_DocumentType_07305CB1EC745D48ADDDEB7EEAA5D182" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_9AB554E24E9ED141BA04BAAC5C6C438B_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_280A3A115DAB58579CBBA2B59E09495A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_9AB554E24E9ED141BA04BAAC5C6C438B_label_en-US" xlink:label="lab_dei_AmendmentFlag_280A3A115DAB58579CBBA2B59E09495A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_280A3A115DAB58579CBBA2B59E09495A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_280A3A115DAB58579CBBA2B59E09495A" xlink:to="lab_dei_AmendmentFlag_280A3A115DAB58579CBBA2B59E09495A" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_7399AF85C4CB0616104FBAAC5C6D89F0_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_E4865217EE045911A68CF25D5BA6E7AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_7399AF85C4CB0616104FBAAC5C6D89F0_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_E4865217EE045911A68CF25D5BA6E7AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_E4865217EE045911A68CF25D5BA6E7AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_E4865217EE045911A68CF25D5BA6E7AB" xlink:to="lab_dei_DocumentPeriodEndDate_E4865217EE045911A68CF25D5BA6E7AB" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_241039A440CCDE4D0328BAAC5C6D4926_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_991B8F8AC33B53619ECF0784A4608DA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_241039A440CCDE4D0328BAAC5C6D4926_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_991B8F8AC33B53619ECF0784A4608DA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_991B8F8AC33B53619ECF0784A4608DA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_991B8F8AC33B53619ECF0784A4608DA1" xlink:to="lab_dei_DocumentFiscalYearFocus_991B8F8AC33B53619ECF0784A4608DA1" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_39C4A4155528EEE8B79FBAAC5C6D590A_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_9611D900CD9D514BBF4F557566D7FE1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_39C4A4155528EEE8B79FBAAC5C6D590A_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_9611D900CD9D514BBF4F557566D7FE1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9611D900CD9D514BBF4F557566D7FE1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_9611D900CD9D514BBF4F557566D7FE1C" xlink:to="lab_dei_DocumentFiscalPeriodFocus_9611D900CD9D514BBF4F557566D7FE1C" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_7620767634E74A0E906CBAAC5C6D9669_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_1EAC5AFA2A0153569396C7250CAC5142" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_7620767634E74A0E906CBAAC5C6D9669_label_en-US" xlink:label="lab_dei_TradingSymbol_1EAC5AFA2A0153569396C7250CAC5142" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_1EAC5AFA2A0153569396C7250CAC5142" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_1EAC5AFA2A0153569396C7250CAC5142" xlink:to="lab_dei_TradingSymbol_1EAC5AFA2A0153569396C7250CAC5142" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_90750B32479CE65C6C32BAAC5C6D5716_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_56E1AC418AB65A0E955D80683C4B79C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_90750B32479CE65C6C32BAAC5C6D5716_label_en-US" xlink:label="lab_dei_EntityRegistrantName_56E1AC418AB65A0E955D80683C4B79C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_56E1AC418AB65A0E955D80683C4B79C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_56E1AC418AB65A0E955D80683C4B79C1" xlink:to="lab_dei_EntityRegistrantName_56E1AC418AB65A0E955D80683C4B79C1" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_0E3F60121A4C941E2840BAAC5C6E2B76_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_6F706D3E4FD05AF89A678276963FA5AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_0E3F60121A4C941E2840BAAC5C6E2B76_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_6F706D3E4FD05AF89A678276963FA5AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_6F706D3E4FD05AF89A678276963FA5AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_6F706D3E4FD05AF89A678276963FA5AD" xlink:to="lab_dei_EntityCentralIndexKey_6F706D3E4FD05AF89A678276963FA5AD" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_5585A37C710A8304F72EBAAC5C6E0E4D_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_01424642A01355F19E1BCCCA27EBCE69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_5585A37C710A8304F72EBAAC5C6E0E4D_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_01424642A01355F19E1BCCCA27EBCE69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_01424642A01355F19E1BCCCA27EBCE69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_01424642A01355F19E1BCCCA27EBCE69" xlink:to="lab_dei_CurrentFiscalYearEndDate_01424642A01355F19E1BCCCA27EBCE69" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_10DBFA36B6DEF5DA4A55BAAC5C6E52CE_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_E70351BD91285C8D8D6C5E07405D00E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_10DBFA36B6DEF5DA4A55BAAC5C6E52CE_label_en-US" xlink:label="lab_dei_EntityFilerCategory_E70351BD91285C8D8D6C5E07405D00E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_E70351BD91285C8D8D6C5E07405D00E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_E70351BD91285C8D8D6C5E07405D00E0" xlink:to="lab_dei_EntityFilerCategory_E70351BD91285C8D8D6C5E07405D00E0" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_33F0BF8D308EE7046BDEBAAC5C6E5130_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_EB234353E7F153D6AAFCE94FAACF89B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_33F0BF8D308EE7046BDEBAAC5C6E5130_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_EB234353E7F153D6AAFCE94FAACF89B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_EB234353E7F153D6AAFCE94FAACF89B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_EB234353E7F153D6AAFCE94FAACF89B4" xlink:to="lab_dei_EntitySmallBusiness_EB234353E7F153D6AAFCE94FAACF89B4" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3B78926FC588D40B19A7BAAC5C6E48F9_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_E57237172DAF5B3092693081B0FFCD84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3B78926FC588D40B19A7BAAC5C6E48F9_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_E57237172DAF5B3092693081B0FFCD84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_E57237172DAF5B3092693081B0FFCD84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_E57237172DAF5B3092693081B0FFCD84" xlink:to="lab_dei_EntityEmergingGrowthCompany_E57237172DAF5B3092693081B0FFCD84" xlink:type="arc" />
    <link:label id="lab_dei_EntityExTransitionPeriod_9DDDFC28C5099EDD4B6ABAAC5C6E7B87_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod_C84F85B0C1DF5DBD80CCD3B8BE902118" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_9DDDFC28C5099EDD4B6ABAAC5C6E7B87_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod_C84F85B0C1DF5DBD80CCD3B8BE902118" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_C84F85B0C1DF5DBD80CCD3B8BE902118" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod_C84F85B0C1DF5DBD80CCD3B8BE902118" xlink:to="lab_dei_EntityExTransitionPeriod_C84F85B0C1DF5DBD80CCD3B8BE902118" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_27D773226F7ECBFB6409BAAC5C6FA8A9_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_2BFCE551E548530B91645A4CFA08E7D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_27D773226F7ECBFB6409BAAC5C6FA8A9_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_2BFCE551E548530B91645A4CFA08E7D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_2BFCE551E548530B91645A4CFA08E7D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_2BFCE551E548530B91645A4CFA08E7D6" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_2BFCE551E548530B91645A4CFA08E7D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_84ECE9C2DC980E9E9B529A56017DAAA7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_84ECE9C2DC980E9E9B529A56017DAAA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_84ECE9C2DC980E9E9B529A56017DAAA7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_84ECE9C2DC980E9E9B529A56017DAAA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_84ECE9C2DC980E9E9B529A56017DAAA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_84ECE9C2DC980E9E9B529A56017DAAA7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_84ECE9C2DC980E9E9B529A56017DAAA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9D1A3E1EA36553F6D1319A56017DE49A_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9D1A3E1EA36553F6D1319A56017DE49A" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding beginning balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9D1A3E1EA36553F6D1319A56017DE49A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9D1A3E1EA36553F6D1319A56017DE49A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9D1A3E1EA36553F6D1319A56017DE49A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0B6C403778928637A9589A56017DC04F_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0B6C403778928637A9589A56017DC04F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0B6C403778928637A9589A56017DC04F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0B6C403778928637A9589A56017DC04F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0B6C403778928637A9589A56017DC04F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0B6C403778928637A9589A56017DC04F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0B6C403778928637A9589A56017DC04F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2EC51878368BB058EFAB9A56017D988D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2EC51878368BB058EFAB9A56017D988D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2EC51878368BB058EFAB9A56017D988D_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2EC51878368BB058EFAB9A56017D988D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2EC51878368BB058EFAB9A56017D988D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2EC51878368BB058EFAB9A56017D988D" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2EC51878368BB058EFAB9A56017D988D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1305F445BA73213A01B69A56017DEB5A_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1305F445BA73213A01B69A56017DEB5A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Canceled/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1305F445BA73213A01B69A56017DEB5A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1305F445BA73213A01B69A56017DEB5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1305F445BA73213A01B69A56017DEB5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1305F445BA73213A01B69A56017DEB5A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1305F445BA73213A01B69A56017DEB5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_8A7466BA7935ACD22BF29A751759F633_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_8A7466BA7935ACD22BF29A751759F633" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_8A7466BA7935ACD22BF29A751759F633_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_8A7466BA7935ACD22BF29A751759F633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_8A7466BA7935ACD22BF29A751759F633" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_8A7466BA7935ACD22BF29A751759F633" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_8A7466BA7935ACD22BF29A751759F633" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_438B462FC43EF79A9D789A56017D2E8E_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_438B462FC43EF79A9D789A56017D2E8E" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_438B462FC43EF79A9D789A56017D2E8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_438B462FC43EF79A9D789A56017D2E8E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_438B462FC43EF79A9D789A56017D2E8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BD1F3BCA2ED4F4237EFE9A56017D9EDD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BD1F3BCA2ED4F4237EFE9A56017D9EDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BD1F3BCA2ED4F4237EFE9A56017D9EDD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BD1F3BCA2ED4F4237EFE9A56017D9EDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BD1F3BCA2ED4F4237EFE9A56017D9EDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BD1F3BCA2ED4F4237EFE9A56017D9EDD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BD1F3BCA2ED4F4237EFE9A56017D9EDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_D13CF58278C99867BCBA9A56017D35CC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_D13CF58278C99867BCBA9A56017D35CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_D13CF58278C99867BCBA9A56017D35CC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_D13CF58278C99867BCBA9A56017D35CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_D13CF58278C99867BCBA9A56017D35CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_D13CF58278C99867BCBA9A56017D35CC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_D13CF58278C99867BCBA9A56017D35CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_DE6099BA6D8920BC30949A56017DC80F_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_DE6099BA6D8920BC30949A56017DC80F" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_DE6099BA6D8920BC30949A56017DC80F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_DE6099BA6D8920BC30949A56017DC80F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_DE6099BA6D8920BC30949A56017DC80F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_DE6099BA6D8920BC30949A56017DC80F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_DE6099BA6D8920BC30949A56017DC80F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_202BC10C27B461A07C0C9A56017D0FBD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_202BC10C27B461A07C0C9A56017D0FBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_202BC10C27B461A07C0C9A56017D0FBD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_202BC10C27B461A07C0C9A56017D0FBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_202BC10C27B461A07C0C9A56017D0FBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_202BC10C27B461A07C0C9A56017D0FBD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_202BC10C27B461A07C0C9A56017D0FBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_96A98856B81E76ED13F09A56017D8501_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_96A98856B81E76ED13F09A56017D8501" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_96A98856B81E76ED13F09A56017D8501_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_96A98856B81E76ED13F09A56017D8501" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_96A98856B81E76ED13F09A56017D8501" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_96A98856B81E76ED13F09A56017D8501" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_96A98856B81E76ED13F09A56017D8501" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_98C7ABDF36972D91169A9A56017D827D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_98C7ABDF36972D91169A9A56017D827D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canceled/forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_98C7ABDF36972D91169A9A56017D827D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_98C7ABDF36972D91169A9A56017D827D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_98C7ABDF36972D91169A9A56017D827D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_98C7ABDF36972D91169A9A56017D827D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_98C7ABDF36972D91169A9A56017D827D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1A2EC86558388032F9079A72FFD1C382_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1A2EC86558388032F9079A72FFD1C382" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1A2EC86558388032F9079A72FFD1C382_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1A2EC86558388032F9079A72FFD1C382" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1A2EC86558388032F9079A72FFD1C382" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1A2EC86558388032F9079A72FFD1C382" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1A2EC86558388032F9079A72FFD1C382" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E1E99C706E1003004D9A9A56017D860B_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E1E99C706E1003004D9A9A56017D860B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding ending balance (in usd per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E1E99C706E1003004D9A9A56017D860B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E1E99C706E1003004D9A9A56017D860B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E1E99C706E1003004D9A9A56017D860B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_FC48EB33EF0AE075D1EF9A56017D5ADD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_FC48EB33EF0AE075D1EF9A56017D5ADD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_FC48EB33EF0AE075D1EF9A56017D5ADD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_FC48EB33EF0AE075D1EF9A56017D5ADD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_FC48EB33EF0AE075D1EF9A56017D5ADD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_FC48EB33EF0AE075D1EF9A56017D5ADD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_FC48EB33EF0AE075D1EF9A56017D5ADD" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_4FB4D6512B5C76E839AE5B0CFD7D0553_terseLabel_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_4FB4D6512B5C76E839AE5B0CFD7D0553" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Going Concern</link:label>
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_4FB4D6512B5C76E839AE5B0CFD7D0553_label_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_4FB4D6512B5C76E839AE5B0CFD7D0553" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_4FB4D6512B5C76E839AE5B0CFD7D0553" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_4FB4D6512B5C76E839AE5B0CFD7D0553" xlink:to="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_4FB4D6512B5C76E839AE5B0CFD7D0553" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_4F8ECCF68CD2965497AE5B14929F5B5C_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_4F8ECCF68CD2965497AE5B14929F5B5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_4F8ECCF68CD2965497AE5B14929F5B5C_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_4F8ECCF68CD2965497AE5B14929F5B5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_4F8ECCF68CD2965497AE5B14929F5B5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_4F8ECCF68CD2965497AE5B14929F5B5C" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable_4F8ECCF68CD2965497AE5B14929F5B5C" xlink:type="arc" />
    <link:label id="lab_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_FB22DFF1D126703A59625B1492A1F47F_terseLabel_en-US" xlink:label="lab_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_FB22DFF1D126703A59625B1492A1F47F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring on December 1, 2021 [Member]</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_FB22DFF1D126703A59625B1492A1F47F_label_en-US" xlink:label="lab_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_FB22DFF1D126703A59625B1492A1F47F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring On December One Two Thousand Twenty One [Member]</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_FB22DFF1D126703A59625B1492A1F47F_documentation_en-US" xlink:label="lab_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_FB22DFF1D126703A59625B1492A1F47F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants expiring on december one two thousand twenty one.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember" xlink:label="loc_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_FB22DFF1D126703A59625B1492A1F47F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_FB22DFF1D126703A59625B1492A1F47F" xlink:to="lab_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_FB22DFF1D126703A59625B1492A1F47F" xlink:type="arc" />
    <link:label id="lab_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_44F2CA9C004D12A3798E5B1492A136FF_terseLabel_en-US" xlink:label="lab_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_44F2CA9C004D12A3798E5B1492A136FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring on December 6, 2021 [Member]</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_44F2CA9C004D12A3798E5B1492A136FF_label_en-US" xlink:label="lab_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_44F2CA9C004D12A3798E5B1492A136FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring On December Six Two Thousand Twenty One [Member]</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_44F2CA9C004D12A3798E5B1492A136FF_documentation_en-US" xlink:label="lab_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_44F2CA9C004D12A3798E5B1492A136FF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants expiring on december six two thousand twenty one.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember" xlink:label="loc_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_44F2CA9C004D12A3798E5B1492A136FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_44F2CA9C004D12A3798E5B1492A136FF" xlink:to="lab_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_44F2CA9C004D12A3798E5B1492A136FF" xlink:type="arc" />
    <link:label id="lab_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember_7092C3A880B79555EFDA5B1492A1E2E8_terseLabel_en-US" xlink:label="lab_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember_7092C3A880B79555EFDA5B1492A1E2E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring on January 8, 2020 [Member]</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember_7092C3A880B79555EFDA5B1492A1E2E8_label_en-US" xlink:label="lab_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember_7092C3A880B79555EFDA5B1492A1E2E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring On January Eight Two Thousand Twenty [Member]</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember_7092C3A880B79555EFDA5B1492A1E2E8_documentation_en-US" xlink:label="lab_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember_7092C3A880B79555EFDA5B1492A1E2E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants expiring on january eight two thousand twenty.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember" xlink:label="loc_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember_7092C3A880B79555EFDA5B1492A1E2E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember_7092C3A880B79555EFDA5B1492A1E2E8" xlink:to="lab_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember_7092C3A880B79555EFDA5B1492A1E2E8" xlink:type="arc" />
    <link:label id="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_7F8BE4CE1B714C6D87DA5B1492A12BF4_terseLabel_en-US" xlink:label="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_7F8BE4CE1B714C6D87DA5B1492A12BF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring on April 4, 2026 [Member]</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_7F8BE4CE1B714C6D87DA5B1492A12BF4_label_en-US" xlink:label="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_7F8BE4CE1B714C6D87DA5B1492A12BF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring On April Four Two Thousand Twenty Six [Member]</link:label>
    <link:label id="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_7F8BE4CE1B714C6D87DA5B1492A12BF4_documentation_en-US" xlink:label="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_7F8BE4CE1B714C6D87DA5B1492A12BF4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants expiring on april four two thousand twenty six.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" xlink:label="loc_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_7F8BE4CE1B714C6D87DA5B1492A12BF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_7F8BE4CE1B714C6D87DA5B1492A12BF4" xlink:to="lab_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_7F8BE4CE1B714C6D87DA5B1492A12BF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_7A4CA7CB9D4D1803D7095B1492A17A65_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_7A4CA7CB9D4D1803D7095B1492A17A65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_7A4CA7CB9D4D1803D7095B1492A17A65_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_7A4CA7CB9D4D1803D7095B1492A17A65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_7A4CA7CB9D4D1803D7095B1492A17A65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_7A4CA7CB9D4D1803D7095B1492A17A65" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems_7A4CA7CB9D4D1803D7095B1492A17A65" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_64DCA049BD022DD41E325B1492A2D276_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_64DCA049BD022DD41E325B1492A2D276" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Underlying Outstanding Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_64DCA049BD022DD41E325B1492A2D276" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_64DCA049BD022DD41E325B1492A2D276" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_64DCA049BD022DD41E325B1492A2D276" xlink:type="arc" />
    <link:label id="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_0DEFEC0E46C1A8E95E3A5B1492A261DE_terseLabel_en-US" xlink:label="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_0DEFEC0E46C1A8E95E3A5B1492A261DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_0DEFEC0E46C1A8E95E3A5B1492A261DE_label_en-US" xlink:label="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_0DEFEC0E46C1A8E95E3A5B1492A261DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Rights Warrants Expiration Date</link:label>
    <link:label id="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_0DEFEC0E46C1A8E95E3A5B1492A261DE_documentation_en-US" xlink:label="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_0DEFEC0E46C1A8E95E3A5B1492A261DE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of warrant or rights warrants expiration date.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_ClassOfWarrantOrRightsWarrantsExpirationDate" xlink:label="loc_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_0DEFEC0E46C1A8E95E3A5B1492A261DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_0DEFEC0E46C1A8E95E3A5B1492A261DE" xlink:to="lab_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_0DEFEC0E46C1A8E95E3A5B1492A261DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_123DE0AC56DE9BC79B4AB2D49A8256C9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_123DE0AC56DE9BC79B4AB2D49A8256C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_123DE0AC56DE9BC79B4AB2D49A8256C9_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_123DE0AC56DE9BC79B4AB2D49A8256C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_123DE0AC56DE9BC79B4AB2D49A8256C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_123DE0AC56DE9BC79B4AB2D49A8256C9" xlink:to="lab_us-gaap_AssetsAbstract_123DE0AC56DE9BC79B4AB2D49A8256C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_3FEA17BE08F56C6526B6B2D49A8282EC_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_3FEA17BE08F56C6526B6B2D49A8282EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_3FEA17BE08F56C6526B6B2D49A8282EC_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_3FEA17BE08F56C6526B6B2D49A8282EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3FEA17BE08F56C6526B6B2D49A8282EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3FEA17BE08F56C6526B6B2D49A8282EC" xlink:to="lab_us-gaap_AssetsCurrentAbstract_3FEA17BE08F56C6526B6B2D49A8282EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_D6FCA347B3D4648DCB50B2D49A83C087_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent_D6FCA347B3D4648DCB50B2D49A83C087" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_D6FCA347B3D4648DCB50B2D49A83C087_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent_D6FCA347B3D4648DCB50B2D49A83C087" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_D6FCA347B3D4648DCB50B2D49A83C087" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent_D6FCA347B3D4648DCB50B2D49A83C087" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent_D6FCA347B3D4648DCB50B2D49A83C087" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_5DC654A67EB2185D6BEAB2D49A83FFDC_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_5DC654A67EB2185D6BEAB2D49A83FFDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_5DC654A67EB2185D6BEAB2D49A83FFDC_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_5DC654A67EB2185D6BEAB2D49A83FFDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_5DC654A67EB2185D6BEAB2D49A83FFDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_5DC654A67EB2185D6BEAB2D49A83FFDC" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_5DC654A67EB2185D6BEAB2D49A83FFDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_4B3A9F71C7A6EFF08FC8B2D49A83F169_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_4B3A9F71C7A6EFF08FC8B2D49A83F169" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_4B3A9F71C7A6EFF08FC8B2D49A83F169_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_4B3A9F71C7A6EFF08FC8B2D49A83F169" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_4B3A9F71C7A6EFF08FC8B2D49A83F169" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_4B3A9F71C7A6EFF08FC8B2D49A83F169" xlink:to="lab_us-gaap_AssetsCurrent_4B3A9F71C7A6EFF08FC8B2D49A83F169" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_E28002A7A0DB89AFF8DCB2D49A837B8C_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_E28002A7A0DB89AFF8DCB2D49A837B8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_E28002A7A0DB89AFF8DCB2D49A837B8C_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_E28002A7A0DB89AFF8DCB2D49A837B8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_E28002A7A0DB89AFF8DCB2D49A837B8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_E28002A7A0DB89AFF8DCB2D49A837B8C" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_E28002A7A0DB89AFF8DCB2D49A837B8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_A4B841C11C10D20EFDC3B2D49A835AF8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_A4B841C11C10D20EFDC3B2D49A835AF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_A4B841C11C10D20EFDC3B2D49A835AF8_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_A4B841C11C10D20EFDC3B2D49A835AF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_A4B841C11C10D20EFDC3B2D49A835AF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_A4B841C11C10D20EFDC3B2D49A835AF8" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_A4B841C11C10D20EFDC3B2D49A835AF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_C3B9FC7C5903C1A529E7B2D49A848A5E_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_C3B9FC7C5903C1A529E7B2D49A848A5E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_C3B9FC7C5903C1A529E7B2D49A848A5E_label_en-US" xlink:label="lab_us-gaap_Assets_C3B9FC7C5903C1A529E7B2D49A848A5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_C3B9FC7C5903C1A529E7B2D49A848A5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_C3B9FC7C5903C1A529E7B2D49A848A5E" xlink:to="lab_us-gaap_Assets_C3B9FC7C5903C1A529E7B2D49A848A5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_806763A8247A490451C2B2D49A84965F_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_806763A8247A490451C2B2D49A84965F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_806763A8247A490451C2B2D49A84965F_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_806763A8247A490451C2B2D49A84965F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_806763A8247A490451C2B2D49A84965F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_806763A8247A490451C2B2D49A84965F" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_806763A8247A490451C2B2D49A84965F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_E2B2F4CE9A829CE90488B2D49A84A2D6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_E2B2F4CE9A829CE90488B2D49A84A2D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_E2B2F4CE9A829CE90488B2D49A84A2D6_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_E2B2F4CE9A829CE90488B2D49A84A2D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_E2B2F4CE9A829CE90488B2D49A84A2D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_E2B2F4CE9A829CE90488B2D49A84A2D6" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_E2B2F4CE9A829CE90488B2D49A84A2D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_BE8607A134CF73B9CCE6B2D49A84B637_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_BE8607A134CF73B9CCE6B2D49A84B637" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_BE8607A134CF73B9CCE6B2D49A84B637_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_BE8607A134CF73B9CCE6B2D49A84B637" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_BE8607A134CF73B9CCE6B2D49A84B637" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_BE8607A134CF73B9CCE6B2D49A84B637" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_BE8607A134CF73B9CCE6B2D49A84B637" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_38EDE4F41CCB20C58EBAB2D49A844E7B_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_38EDE4F41CCB20C58EBAB2D49A844E7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_38EDE4F41CCB20C58EBAB2D49A844E7B_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_38EDE4F41CCB20C58EBAB2D49A844E7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_38EDE4F41CCB20C58EBAB2D49A844E7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_38EDE4F41CCB20C58EBAB2D49A844E7B" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_38EDE4F41CCB20C58EBAB2D49A844E7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_FB95DBE26ACB747CD115B2D49A859870_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_FB95DBE26ACB747CD115B2D49A859870" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_FB95DBE26ACB747CD115B2D49A859870_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_FB95DBE26ACB747CD115B2D49A859870" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_FB95DBE26ACB747CD115B2D49A859870" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_FB95DBE26ACB747CD115B2D49A859870" xlink:to="lab_us-gaap_LiabilitiesCurrent_FB95DBE26ACB747CD115B2D49A859870" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_EB6EE3B2DFE344447686B2D49A8527E0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_EB6EE3B2DFE344447686B2D49A8527E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_EB6EE3B2DFE344447686B2D49A8527E0_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_EB6EE3B2DFE344447686B2D49A8527E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_EB6EE3B2DFE344447686B2D49A8527E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_EB6EE3B2DFE344447686B2D49A8527E0" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_EB6EE3B2DFE344447686B2D49A8527E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_2AAC2C2247D518B37963B2D49A851B7F_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_2AAC2C2247D518B37963B2D49A851B7F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_2AAC2C2247D518B37963B2D49A851B7F_label_en-US" xlink:label="lab_us-gaap_Liabilities_2AAC2C2247D518B37963B2D49A851B7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_2AAC2C2247D518B37963B2D49A851B7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_2AAC2C2247D518B37963B2D49A851B7F" xlink:to="lab_us-gaap_Liabilities_2AAC2C2247D518B37963B2D49A851B7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_121DEFF3EAAD3E3CE959B2D49A859685_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_121DEFF3EAAD3E3CE959B2D49A859685" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 8)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_121DEFF3EAAD3E3CE959B2D49A859685_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_121DEFF3EAAD3E3CE959B2D49A859685" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_121DEFF3EAAD3E3CE959B2D49A859685" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_121DEFF3EAAD3E3CE959B2D49A859685" xlink:to="lab_us-gaap_CommitmentsAndContingencies_121DEFF3EAAD3E3CE959B2D49A859685" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_D5C23961379911476F6FB2D49A85E8D8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_D5C23961379911476F6FB2D49A85E8D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_D5C23961379911476F6FB2D49A85E8D8_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_D5C23961379911476F6FB2D49A85E8D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_D5C23961379911476F6FB2D49A85E8D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_D5C23961379911476F6FB2D49A85E8D8" xlink:to="lab_us-gaap_StockholdersEquityAbstract_D5C23961379911476F6FB2D49A85E8D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_68F21DF223626E4054B1B2D49A856E86_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_68F21DF223626E4054B1B2D49A856E86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_68F21DF223626E4054B1B2D49A856E86_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_68F21DF223626E4054B1B2D49A856E86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_68F21DF223626E4054B1B2D49A856E86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_68F21DF223626E4054B1B2D49A856E86" xlink:to="lab_us-gaap_PreferredStockValue_68F21DF223626E4054B1B2D49A856E86" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_4E2175BFC2B3D4348DFBB2D49A86A1E0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_4E2175BFC2B3D4348DFBB2D49A86A1E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value; 120,000,000 shares authorized; 11,422,161 shares issued and outstanding each period</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_4E2175BFC2B3D4348DFBB2D49A86A1E0_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_4E2175BFC2B3D4348DFBB2D49A86A1E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_4E2175BFC2B3D4348DFBB2D49A86A1E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_4E2175BFC2B3D4348DFBB2D49A86A1E0" xlink:to="lab_us-gaap_CommonStockValue_4E2175BFC2B3D4348DFBB2D49A86A1E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_258ECFF68924BF54A433B2D49A86F553_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_258ECFF68924BF54A433B2D49A86F553" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_258ECFF68924BF54A433B2D49A86F553_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_258ECFF68924BF54A433B2D49A86F553" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_258ECFF68924BF54A433B2D49A86F553" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_258ECFF68924BF54A433B2D49A86F553" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_258ECFF68924BF54A433B2D49A86F553" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_F4562C692B4CA60A8EB5B2D49A862726_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_F4562C692B4CA60A8EB5B2D49A862726" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_F4562C692B4CA60A8EB5B2D49A862726_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_F4562C692B4CA60A8EB5B2D49A862726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_F4562C692B4CA60A8EB5B2D49A862726" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_F4562C692B4CA60A8EB5B2D49A862726" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_F4562C692B4CA60A8EB5B2D49A862726" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0E784BF2B76ABD43E43FB2D49A86E6C9_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0E784BF2B76ABD43E43FB2D49A86E6C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0E784BF2B76ABD43E43FB2D49A86E6C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0E784BF2B76ABD43E43FB2D49A86E6C9" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0E784BF2B76ABD43E43FB2D49A86E6C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_69EA62674167734AAC32B2D49A873274_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_69EA62674167734AAC32B2D49A873274" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_69EA62674167734AAC32B2D49A873274_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_69EA62674167734AAC32B2D49A873274" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_69EA62674167734AAC32B2D49A873274" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_69EA62674167734AAC32B2D49A873274" xlink:to="lab_us-gaap_StockholdersEquity_69EA62674167734AAC32B2D49A873274" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_0AAE7F70EC2B0CE25892B2D49A87017F_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_0AAE7F70EC2B0CE25892B2D49A87017F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_0AAE7F70EC2B0CE25892B2D49A87017F_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_0AAE7F70EC2B0CE25892B2D49A87017F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_0AAE7F70EC2B0CE25892B2D49A87017F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0AAE7F70EC2B0CE25892B2D49A87017F" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_0AAE7F70EC2B0CE25892B2D49A87017F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2724CFFD36C2CCA2FD7D5B0CFD705BD2_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2724CFFD36C2CCA2FD7D5B0CFD705BD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2724CFFD36C2CCA2FD7D5B0CFD705BD2_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2724CFFD36C2CCA2FD7D5B0CFD705BD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2724CFFD36C2CCA2FD7D5B0CFD705BD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2724CFFD36C2CCA2FD7D5B0CFD705BD2" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2724CFFD36C2CCA2FD7D5B0CFD705BD2" xlink:type="arc" />
    <link:label id="lab_dare_ScheduleOfBusinessCombinationReverseMergerTextBlock_FCB4327A2F999C8F3542B919C6139692_terseLabel_en-US" xlink:label="lab_dare_ScheduleOfBusinessCombinationReverseMergerTextBlock_85ABBEED9BF65F8C88034691ABCAC79E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Purchase Price Consideration Allocation</link:label>
    <link:label id="lab_dare_ScheduleOfBusinessCombinationReverseMergerTextBlock_FCB4327A2F999C8F3542B919C6139692_label_en-US" xlink:label="lab_dare_ScheduleOfBusinessCombinationReverseMergerTextBlock_85ABBEED9BF65F8C88034691ABCAC79E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Business Combination Reverse Merger [Text Block]</link:label>
    <link:label id="lab_dare_ScheduleOfBusinessCombinationReverseMergerTextBlock_FCB4327A2F999C8F3542B919C6139692_documentation_en-US" xlink:label="lab_dare_ScheduleOfBusinessCombinationReverseMergerTextBlock_85ABBEED9BF65F8C88034691ABCAC79E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of business combination reverse merger.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_ScheduleOfBusinessCombinationReverseMergerTextBlock" xlink:label="loc_dare_ScheduleOfBusinessCombinationReverseMergerTextBlock_85ABBEED9BF65F8C88034691ABCAC79E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ScheduleOfBusinessCombinationReverseMergerTextBlock_85ABBEED9BF65F8C88034691ABCAC79E" xlink:to="lab_dare_ScheduleOfBusinessCombinationReverseMergerTextBlock_85ABBEED9BF65F8C88034691ABCAC79E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_4DF5037AFC7D0857ED5C5B0CFB81A036_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_4DF5037AFC7D0857ED5C5B0CFB81A036" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_4DF5037AFC7D0857ED5C5B0CFB81A036_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_4DF5037AFC7D0857ED5C5B0CFB81A036" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_4DF5037AFC7D0857ED5C5B0CFB81A036" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_4DF5037AFC7D0857ED5C5B0CFB81A036" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_4DF5037AFC7D0857ED5C5B0CFB81A036" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_FCE03DF4CC270DAEA778B9F088A2FB53_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_42269856E9815B36A4AC0BCA2E034E84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Common Stock Warrants Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_FCE03DF4CC270DAEA778B9F088A2FB53_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_42269856E9815B36A4AC0BCA2E034E84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_42269856E9815B36A4AC0BCA2E034E84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_42269856E9815B36A4AC0BCA2E034E84" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_42269856E9815B36A4AC0BCA2E034E84" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_7A4924DC0BD237E80F0C9A56025F80CF_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_7A4924DC0BD237E80F0C9A56025F80CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7A4924DC0BD237E80F0C9A56025F80CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7A4924DC0BD237E80F0C9A56025F80CF" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_7A4924DC0BD237E80F0C9A56025F80CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_0D8407D9AF6A49CC828C9A56025FDE1D_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_0D8407D9AF6A49CC828C9A56025FDE1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_0D8407D9AF6A49CC828C9A56025FDE1D_label_en-US" xlink:label="lab_us-gaap_StatementTable_0D8407D9AF6A49CC828C9A56025FDE1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_0D8407D9AF6A49CC828C9A56025FDE1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_0D8407D9AF6A49CC828C9A56025FDE1D" xlink:to="lab_us-gaap_StatementTable_0D8407D9AF6A49CC828C9A56025FDE1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_C9B92ABFCFCA94D0DC759A56025FC687_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_C9B92ABFCFCA94D0DC759A56025FC687" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_C9B92ABFCFCA94D0DC759A56025FC687_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_C9B92ABFCFCA94D0DC759A56025FC687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_C9B92ABFCFCA94D0DC759A56025FC687" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_C9B92ABFCFCA94D0DC759A56025FC687" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_C9B92ABFCFCA94D0DC759A56025FC687" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_0A1E880EE9B0B38CC5939A56025F55CD_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_0A1E880EE9B0B38CC5939A56025F55CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_0A1E880EE9B0B38CC5939A56025F55CD_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_0A1E880EE9B0B38CC5939A56025F55CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_0A1E880EE9B0B38CC5939A56025F55CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_0A1E880EE9B0B38CC5939A56025F55CD" xlink:to="lab_us-gaap_EquityComponentDomain_0A1E880EE9B0B38CC5939A56025F55CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_5655E775302341B229589A56025FC4E9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_5655E775302341B229589A56025FC4E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_5655E775302341B229589A56025FC4E9_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_5655E775302341B229589A56025FC4E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_5655E775302341B229589A56025FC4E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_5655E775302341B229589A56025FC4E9" xlink:to="lab_us-gaap_CommonStockMember_5655E775302341B229589A56025FC4E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_A4269AD8803217CE0CD09A56025FAA1E_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_A4269AD8803217CE0CD09A56025FAA1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital [Member]</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_A4269AD8803217CE0CD09A56025FAA1E_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_A4269AD8803217CE0CD09A56025FAA1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_A4269AD8803217CE0CD09A56025FAA1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_A4269AD8803217CE0CD09A56025FAA1E" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_A4269AD8803217CE0CD09A56025FAA1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3C1E4AFF00DDAC8931BE9A56025F39ED_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3C1E4AFF00DDAC8931BE9A56025F39ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3C1E4AFF00DDAC8931BE9A56025F39ED_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3C1E4AFF00DDAC8931BE9A56025F39ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3C1E4AFF00DDAC8931BE9A56025F39ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3C1E4AFF00DDAC8931BE9A56025F39ED" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3C1E4AFF00DDAC8931BE9A56025F39ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_ED1DB1061AF786E377429A56025FC1F2_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_ED1DB1061AF786E377429A56025FC1F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit [Member]</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_ED1DB1061AF786E377429A56025FC1F2_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_ED1DB1061AF786E377429A56025FC1F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_ED1DB1061AF786E377429A56025FC1F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_ED1DB1061AF786E377429A56025FC1F2" xlink:to="lab_us-gaap_RetainedEarningsMember_ED1DB1061AF786E377429A56025FC1F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_9A2DA989A8F8700921189A56025F903C_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_9A2DA989A8F8700921189A56025F903C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_9A2DA989A8F8700921189A56025F903C_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_9A2DA989A8F8700921189A56025F903C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_9A2DA989A8F8700921189A56025F903C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_9A2DA989A8F8700921189A56025F903C" xlink:to="lab_us-gaap_StatementLineItems_9A2DA989A8F8700921189A56025F903C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_B4A669E84ED4CD87D93C9A56025FB2C6_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_B4A669E84ED4CD87D93C9A56025FB2C6" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_B4A669E84ED4CD87D93C9A56025FB2C6_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding_B4A669E84ED4CD87D93C9A56025FB2C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_B4A669E84ED4CD87D93C9A56025FB2C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_B4A669E84ED4CD87D93C9A56025FB2C6" xlink:to="lab_us-gaap_SharesOutstanding_B4A669E84ED4CD87D93C9A56025FB2C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_7F685565E0403878AC429A56025F0EF6_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_7F685565E0403878AC429A56025F0EF6" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_7F685565E0403878AC429A56025F0EF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_7F685565E0403878AC429A56025F0EF6" xlink:to="lab_us-gaap_StockholdersEquity_7F685565E0403878AC429A56025F0EF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5A6FAB27765356E493E89A56025F1DDB_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5A6FAB27765356E493E89A56025F1DDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5A6FAB27765356E493E89A56025F1DDB_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5A6FAB27765356E493E89A56025F1DDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5A6FAB27765356E493E89A56025F1DDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5A6FAB27765356E493E89A56025F1DDB" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5A6FAB27765356E493E89A56025F1DDB" xlink:type="arc" />
    <link:label id="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_A57FC78530EFE2FD37759A5A97200D70_terseLabel_en-US" xlink:label="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_A57FC78530EFE2FD37759A5A97200D70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of common stock and warrants (in shares)</link:label>
    <link:label id="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_A57FC78530EFE2FD37759A5A97200D70_label_en-US" xlink:label="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_A57FC78530EFE2FD37759A5A97200D70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares</link:label>
    <link:label id="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_A57FC78530EFE2FD37759A5A97200D70_documentation_en-US" xlink:label="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_A57FC78530EFE2FD37759A5A97200D70" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" xlink:label="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_A57FC78530EFE2FD37759A5A97200D70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_A57FC78530EFE2FD37759A5A97200D70" xlink:to="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_A57FC78530EFE2FD37759A5A97200D70" xlink:type="arc" />
    <link:label id="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued_2F693C9DFD1A02DFA3339A5A0441C9EC_terseLabel_en-US" xlink:label="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued_2F693C9DFD1A02DFA3339A5A0441C9EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of common stock and warrants</link:label>
    <link:label id="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued_2F693C9DFD1A02DFA3339A5A0441C9EC_label_en-US" xlink:label="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued_2F693C9DFD1A02DFA3339A5A0441C9EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued</link:label>
    <link:label id="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued_2F693C9DFD1A02DFA3339A5A0441C9EC_documentation_en-US" xlink:label="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued_2F693C9DFD1A02DFA3339A5A0441C9EC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued" xlink:label="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued_2F693C9DFD1A02DFA3339A5A0441C9EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued_2F693C9DFD1A02DFA3339A5A0441C9EC" xlink:to="lab_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued_2F693C9DFD1A02DFA3339A5A0441C9EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2F6D6B4B0041ECC832599A5BCDACC151_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2F6D6B4B0041ECC832599A5BCDACC151" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock via public offering, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2F6D6B4B0041ECC832599A5BCDACC151_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2F6D6B4B0041ECC832599A5BCDACC151" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2F6D6B4B0041ECC832599A5BCDACC151" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2F6D6B4B0041ECC832599A5BCDACC151" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2F6D6B4B0041ECC832599A5BCDACC151" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_F9F3FF8C2B45048CCB999A5B3F34E3D9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_F9F3FF8C2B45048CCB999A5B3F34E3D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock via public offering, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_F9F3FF8C2B45048CCB999A5B3F34E3D9_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_F9F3FF8C2B45048CCB999A5B3F34E3D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_F9F3FF8C2B45048CCB999A5B3F34E3D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_F9F3FF8C2B45048CCB999A5B3F34E3D9" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_F9F3FF8C2B45048CCB999A5B3F34E3D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_09D5EBDF1E1FFB0810DE9A56025F8EA4_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_09D5EBDF1E1FFB0810DE9A56025F8EA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_09D5EBDF1E1FFB0810DE9A56025F8EA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_09D5EBDF1E1FFB0810DE9A56025F8EA4" xlink:to="lab_us-gaap_NetIncomeLoss_09D5EBDF1E1FFB0810DE9A56025F8EA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_17A93AB3F7B86CAE5C9E9A56025FC352_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_17A93AB3F7B86CAE5C9E9A56025FC352" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_17A93AB3F7B86CAE5C9E9A56025FC352" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_17A93AB3F7B86CAE5C9E9A56025FC352" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_17A93AB3F7B86CAE5C9E9A56025FC352" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_D617E4A4CAE2BF62AC519A56025F8245_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_D617E4A4CAE2BF62AC519A56025F8245" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_D617E4A4CAE2BF62AC519A56025F8245" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_D617E4A4CAE2BF62AC519A56025F8245" xlink:to="lab_us-gaap_SharesOutstanding_D617E4A4CAE2BF62AC519A56025F8245" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_6A4D455ED71837E37A899A56025FDE22_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_6A4D455ED71837E37A899A56025FDE22" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6A4D455ED71837E37A899A56025FDE22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_6A4D455ED71837E37A899A56025FDE22" xlink:to="lab_us-gaap_StockholdersEquity_6A4D455ED71837E37A899A56025FDE22" xlink:type="arc" />
    <link:label id="lab_dare_StockholdersEquityTable_D5FB4A778DA18AE4ADA19A5600EFE79A_terseLabel_en-US" xlink:label="lab_dare_StockholdersEquityTable_D5FB4A778DA18AE4ADA19A5600EFE79A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders Equity [Table]</link:label>
    <link:label id="lab_dare_StockholdersEquityTable_D5FB4A778DA18AE4ADA19A5600EFE79A_label_en-US" xlink:label="lab_dare_StockholdersEquityTable_D5FB4A778DA18AE4ADA19A5600EFE79A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders Equity [Table]</link:label>
    <link:label id="lab_dare_StockholdersEquityTable_D5FB4A778DA18AE4ADA19A5600EFE79A_documentation_en-US" xlink:label="lab_dare_StockholdersEquityTable_D5FB4A778DA18AE4ADA19A5600EFE79A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stockholders' equity.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_StockholdersEquityTable" xlink:label="loc_dare_StockholdersEquityTable_D5FB4A778DA18AE4ADA19A5600EFE79A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_StockholdersEquityTable_D5FB4A778DA18AE4ADA19A5600EFE79A" xlink:to="lab_dare_StockholdersEquityTable_D5FB4A778DA18AE4ADA19A5600EFE79A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_61C89BEDF2C94C851A229A5600EFB274_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_61C89BEDF2C94C851A229A5600EFB274" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_61C89BEDF2C94C851A229A5600EFB274_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_61C89BEDF2C94C851A229A5600EFB274" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_61C89BEDF2C94C851A229A5600EFB274" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_61C89BEDF2C94C851A229A5600EFB274" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_61C89BEDF2C94C851A229A5600EFB274" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_B89E7282D1EA02C8186E9A5600EFFD3F_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_B89E7282D1EA02C8186E9A5600EFFD3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_B89E7282D1EA02C8186E9A5600EFFD3F_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_B89E7282D1EA02C8186E9A5600EFFD3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_B89E7282D1EA02C8186E9A5600EFFD3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_B89E7282D1EA02C8186E9A5600EFFD3F" xlink:to="lab_us-gaap_TypeOfAdoptionMember_B89E7282D1EA02C8186E9A5600EFFD3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201711Member_9D760536EB8FC07DCF069A5600EF36E3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201711Member_9D760536EB8FC07DCF069A5600EF36E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2017-11 [Member]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201711Member_9D760536EB8FC07DCF069A5600EF36E3_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201711Member_9D760536EB8FC07DCF069A5600EF36E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2017-11 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201711Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201711Member_9D760536EB8FC07DCF069A5600EF36E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201711Member_9D760536EB8FC07DCF069A5600EF36E3" xlink:to="lab_us-gaap_AccountingStandardsUpdate201711Member_9D760536EB8FC07DCF069A5600EF36E3" xlink:type="arc" />
    <link:label id="lab_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089_terseLabel_en-US" xlink:label="lab_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders Equity [Line Items]</link:label>
    <link:label id="lab_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089_label_en-US" xlink:label="lab_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders Equity [Line Items]</link:label>
    <link:label id="lab_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089_documentation_en-US" xlink:label="lab_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stockholders' equity.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_StockholdersEquityLineItems" xlink:label="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:to="lab_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:type="arc" />
    <link:label id="lab_dare_GrossProceedsFromIssuanceOfCommonStock_541328027702DD5EE6239A5600EF05CF_verboseLabel_en-US" xlink:label="lab_dare_GrossProceedsFromIssuanceOfCommonStock_541328027702DD5EE6239A5600EF05CF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds on sale of shares of common stock</link:label>
    <link:label id="lab_dare_GrossProceedsFromIssuanceOfCommonStock_541328027702DD5EE6239A5600EF05CF_label_en-US" xlink:label="lab_dare_GrossProceedsFromIssuanceOfCommonStock_541328027702DD5EE6239A5600EF05CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Proceeds From Issuance Of Common Stock</link:label>
    <link:label id="lab_dare_GrossProceedsFromIssuanceOfCommonStock_541328027702DD5EE6239A5600EF05CF_documentation_en-US" xlink:label="lab_dare_GrossProceedsFromIssuanceOfCommonStock_541328027702DD5EE6239A5600EF05CF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gross Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_GrossProceedsFromIssuanceOfCommonStock" xlink:label="loc_dare_GrossProceedsFromIssuanceOfCommonStock_541328027702DD5EE6239A5600EF05CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_GrossProceedsFromIssuanceOfCommonStock_541328027702DD5EE6239A5600EF05CF" xlink:to="lab_dare_GrossProceedsFromIssuanceOfCommonStock_541328027702DD5EE6239A5600EF05CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_5ADE29BA86B30E6861F49A7935E98D18_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_5ADE29BA86B30E6861F49A7935E98D18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_5ADE29BA86B30E6861F49A7935E98D18_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_5ADE29BA86B30E6861F49A7935E98D18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_5ADE29BA86B30E6861F49A7935E98D18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_5ADE29BA86B30E6861F49A7935E98D18" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_5ADE29BA86B30E6861F49A7935E98D18" xlink:type="arc" />
    <link:label id="lab_dare_PercentageOfAggregateCommission_BF2DD2B4C51E34B4E7369A5600EFF931_terseLabel_en-US" xlink:label="lab_dare_PercentageOfAggregateCommission_BF2DD2B4C51E34B4E7369A5600EFF931" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate commission rate</link:label>
    <link:label id="lab_dare_PercentageOfAggregateCommission_BF2DD2B4C51E34B4E7369A5600EFF931_label_en-US" xlink:label="lab_dare_PercentageOfAggregateCommission_BF2DD2B4C51E34B4E7369A5600EFF931" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Aggregate Commission</link:label>
    <link:label id="lab_dare_PercentageOfAggregateCommission_BF2DD2B4C51E34B4E7369A5600EFF931_documentation_en-US" xlink:label="lab_dare_PercentageOfAggregateCommission_BF2DD2B4C51E34B4E7369A5600EFF931" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of aggregate commission.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_PercentageOfAggregateCommission" xlink:label="loc_dare_PercentageOfAggregateCommission_BF2DD2B4C51E34B4E7369A5600EFF931" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PercentageOfAggregateCommission_BF2DD2B4C51E34B4E7369A5600EFF931" xlink:to="lab_dare_PercentageOfAggregateCommission_BF2DD2B4C51E34B4E7369A5600EFF931" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C0BA5D889889BF83490B9A5600EFA33A_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C0BA5D889889BF83490B9A5600EFA33A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued and sold (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C0BA5D889889BF83490B9A5600EFA33A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C0BA5D889889BF83490B9A5600EFA33A" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C0BA5D889889BF83490B9A5600EFA33A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FAEC226EB9FBEC3B5BAE9A5600EFF9CF_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FAEC226EB9FBEC3B5BAE9A5600EFF9CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to purchase common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FAEC226EB9FBEC3B5BAE9A5600EFF9CF_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FAEC226EB9FBEC3B5BAE9A5600EFF9CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FAEC226EB9FBEC3B5BAE9A5600EFF9CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FAEC226EB9FBEC3B5BAE9A5600EFF9CF" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FAEC226EB9FBEC3B5BAE9A5600EFF9CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_E7D330FD81A0192E9B0A9A5600EFEBB8_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_E7D330FD81A0192E9B0A9A5600EFEBB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_E7D330FD81A0192E9B0A9A5600EFEBB8_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_E7D330FD81A0192E9B0A9A5600EFEBB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_E7D330FD81A0192E9B0A9A5600EFEBB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_E7D330FD81A0192E9B0A9A5600EFEBB8" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_E7D330FD81A0192E9B0A9A5600EFEBB8" xlink:type="arc" />
    <link:label id="lab_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_1A5DE60B5CFF5634058F9A5600EF6F2D_terseLabel_en-US" xlink:label="lab_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_1A5DE60B5CFF5634058F9A5600EF6F2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwriters overallotment option to purchase additional shares of common stock and warrants period</link:label>
    <link:label id="lab_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_1A5DE60B5CFF5634058F9A5600EF6F2D_label_en-US" xlink:label="lab_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_1A5DE60B5CFF5634058F9A5600EF6F2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underwriters Option To Purchase Additional Shares Of Common Stock Period</link:label>
    <link:label id="lab_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_1A5DE60B5CFF5634058F9A5600EF6F2D_documentation_en-US" xlink:label="lab_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_1A5DE60B5CFF5634058F9A5600EF6F2D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Underwriters option to purchase additional shares of common stock period.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod" xlink:label="loc_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_1A5DE60B5CFF5634058F9A5600EF6F2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_1A5DE60B5CFF5634058F9A5600EF6F2D" xlink:to="lab_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_1A5DE60B5CFF5634058F9A5600EF6F2D" xlink:type="arc" />
    <link:label id="lab_dare_UnderwritersOptionToPurchaseAdditionalShares_4D8B9CEBD2F80103B8F09A5600EF734B_terseLabel_en-US" xlink:label="lab_dare_UnderwritersOptionToPurchaseAdditionalShares_4D8B9CEBD2F80103B8F09A5600EF734B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwriters option to purchase additional shares (in shares)</link:label>
    <link:label id="lab_dare_UnderwritersOptionToPurchaseAdditionalShares_4D8B9CEBD2F80103B8F09A5600EF734B_label_en-US" xlink:label="lab_dare_UnderwritersOptionToPurchaseAdditionalShares_4D8B9CEBD2F80103B8F09A5600EF734B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underwriters Option To Purchase Additional Shares</link:label>
    <link:label id="lab_dare_UnderwritersOptionToPurchaseAdditionalShares_4D8B9CEBD2F80103B8F09A5600EF734B_documentation_en-US" xlink:label="lab_dare_UnderwritersOptionToPurchaseAdditionalShares_4D8B9CEBD2F80103B8F09A5600EF734B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Underwriters option to purchase additional shares.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_UnderwritersOptionToPurchaseAdditionalShares" xlink:label="loc_dare_UnderwritersOptionToPurchaseAdditionalShares_4D8B9CEBD2F80103B8F09A5600EF734B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_UnderwritersOptionToPurchaseAdditionalShares_4D8B9CEBD2F80103B8F09A5600EF734B" xlink:to="lab_dare_UnderwritersOptionToPurchaseAdditionalShares_4D8B9CEBD2F80103B8F09A5600EF734B" xlink:type="arc" />
    <link:label id="lab_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_93CE12C38F7ED0A25BE79A5600EF94AD_terseLabel_en-US" xlink:label="lab_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_93CE12C38F7ED0A25BE79A5600EF94AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds from offering of common stock and warrants</link:label>
    <link:label id="lab_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_93CE12C38F7ED0A25BE79A5600EF94AD_label_en-US" xlink:label="lab_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_93CE12C38F7ED0A25BE79A5600EF94AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Proceeds From Offering Of Common Stock And Warrants</link:label>
    <link:label id="lab_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_93CE12C38F7ED0A25BE79A5600EF94AD_documentation_en-US" xlink:label="lab_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_93CE12C38F7ED0A25BE79A5600EF94AD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gross Proceeds From Offering Of Common Stock And Warrants</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_GrossProceedsFromOfferingOfCommonStockAndWarrants" xlink:label="loc_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_93CE12C38F7ED0A25BE79A5600EF94AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_93CE12C38F7ED0A25BE79A5600EF94AD" xlink:to="lab_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_93CE12C38F7ED0A25BE79A5600EF94AD" xlink:type="arc" />
    <link:label id="lab_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_449A0E02D5CFB2F9880E9A5600EFC91A_terseLabel_en-US" xlink:label="lab_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_449A0E02D5CFB2F9880E9A5600EFC91A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from offering of common stock and warrants, net of costs</link:label>
    <link:label id="lab_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_449A0E02D5CFB2F9880E9A5600EFC91A_label_en-US" xlink:label="lab_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_449A0E02D5CFB2F9880E9A5600EFC91A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance Of Common Stock And Warrants</link:label>
    <link:label id="lab_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_449A0E02D5CFB2F9880E9A5600EFC91A_documentation_en-US" xlink:label="lab_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_449A0E02D5CFB2F9880E9A5600EFC91A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock and warrants.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="loc_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_449A0E02D5CFB2F9880E9A5600EFC91A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_449A0E02D5CFB2F9880E9A5600EFC91A" xlink:to="lab_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_449A0E02D5CFB2F9880E9A5600EFC91A" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_CD8B319B0A0BF83D7FC39A5600EF23B6_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm_CD8B319B0A0BF83D7FC39A5600EF23B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right exercisable period</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_CD8B319B0A0BF83D7FC39A5600EF23B6_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm_CD8B319B0A0BF83D7FC39A5600EF23B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_CD8B319B0A0BF83D7FC39A5600EF23B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm_CD8B319B0A0BF83D7FC39A5600EF23B6" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm_CD8B319B0A0BF83D7FC39A5600EF23B6" xlink:type="arc" />
    <link:label id="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity_CAC3A74392D9D38EEAAA9A5600EF0D44_terseLabel_en-US" xlink:label="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity_CAC3A74392D9D38EEAAA9A5600EF0D44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value of warrants, recorded in equity</link:label>
    <link:label id="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity_CAC3A74392D9D38EEAAA9A5600EF0D44_label_en-US" xlink:label="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity_CAC3A74392D9D38EEAAA9A5600EF0D44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Fair Value Of Warrants Recorded In Equity</link:label>
    <link:label id="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity_CAC3A74392D9D38EEAAA9A5600EF0D44_documentation_en-US" xlink:label="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity_CAC3A74392D9D38EEAAA9A5600EF0D44" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated Fair Value Of Warrants Recorded In Equity</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_EstimatedFairValueOfWarrantsRecordedInEquity" xlink:label="loc_dare_EstimatedFairValueOfWarrantsRecordedInEquity_CAC3A74392D9D38EEAAA9A5600EF0D44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_EstimatedFairValueOfWarrantsRecordedInEquity_CAC3A74392D9D38EEAAA9A5600EF0D44" xlink:to="lab_dare_EstimatedFairValueOfWarrantsRecordedInEquity_CAC3A74392D9D38EEAAA9A5600EF0D44" xlink:type="arc" />
    <link:label id="lab_dare_NumberOfCommonStockWarrantsExercised_6B4F64925C5653F79A259A5600EFC2D9_terseLabel_en-US" xlink:label="lab_dare_NumberOfCommonStockWarrantsExercised_6B4F64925C5653F79A259A5600EFC2D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_dare_NumberOfCommonStockWarrantsExercised_6B4F64925C5653F79A259A5600EFC2D9_label_en-US" xlink:label="lab_dare_NumberOfCommonStockWarrantsExercised_6B4F64925C5653F79A259A5600EFC2D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Common Stock Warrants Exercised</link:label>
    <link:label id="lab_dare_NumberOfCommonStockWarrantsExercised_6B4F64925C5653F79A259A5600EFC2D9_documentation_en-US" xlink:label="lab_dare_NumberOfCommonStockWarrantsExercised_6B4F64925C5653F79A259A5600EFC2D9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of common stock warrants exercised.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_NumberOfCommonStockWarrantsExercised" xlink:label="loc_dare_NumberOfCommonStockWarrantsExercised_6B4F64925C5653F79A259A5600EFC2D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_NumberOfCommonStockWarrantsExercised_6B4F64925C5653F79A259A5600EFC2D9" xlink:to="lab_dare_NumberOfCommonStockWarrantsExercised_6B4F64925C5653F79A259A5600EFC2D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_0B0438353097CFA219695B0CFBA33C24_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_0B0438353097CFA219695B0CFBA33C24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_0B0438353097CFA219695B0CFBA33C24_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_0B0438353097CFA219695B0CFBA33C24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_0B0438353097CFA219695B0CFBA33C24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_0B0438353097CFA219695B0CFBA33C24" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_0B0438353097CFA219695B0CFBA33C24" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetRentableArea_6B5CB2931E6369BCC9EC9A5600814A87_terseLabel_en-US" xlink:label="lab_us-gaap_NetRentableArea_6B5CB2931E6369BCC9EC9A5600814A87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Square footage of office space</link:label>
    <link:label id="lab_us-gaap_NetRentableArea_6B5CB2931E6369BCC9EC9A5600814A87_label_en-US" xlink:label="lab_us-gaap_NetRentableArea_6B5CB2931E6369BCC9EC9A5600814A87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Rentable Area</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetRentableArea" xlink:label="loc_us-gaap_NetRentableArea_6B5CB2931E6369BCC9EC9A5600814A87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetRentableArea_6B5CB2931E6369BCC9EC9A5600814A87" xlink:to="lab_us-gaap_NetRentableArea_6B5CB2931E6369BCC9EC9A5600814A87" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_9C76FD35CFA1573E12829A5600811DAE_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_9C76FD35CFA1573E12829A5600811DAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of operating lease</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_9C76FD35CFA1573E12829A5600811DAE_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_9C76FD35CFA1573E12829A5600811DAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9C76FD35CFA1573E12829A5600811DAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9C76FD35CFA1573E12829A5600811DAE" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract_9C76FD35CFA1573E12829A5600811DAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_09289270C44F42B3986E9A56008183A0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_09289270C44F42B3986E9A56008183A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renewal term of operating lease</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_09289270C44F42B3986E9A56008183A0_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_09289270C44F42B3986E9A56008183A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_09289270C44F42B3986E9A56008183A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_09289270C44F42B3986E9A56008183A0" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_09289270C44F42B3986E9A56008183A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseMinimumRentals_E2C07D8136918033A7EA9A560081C4AB_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseMinimumRentals_E2C07D8136918033A7EA9A560081C4AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross monthly base rent</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseMinimumRentals_E2C07D8136918033A7EA9A560081C4AB_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseMinimumRentals_E2C07D8136918033A7EA9A560081C4AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Minimum Rentals</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_E2C07D8136918033A7EA9A560081C4AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_E2C07D8136918033A7EA9A560081C4AB" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseMinimumRentals_E2C07D8136918033A7EA9A560081C4AB" xlink:type="arc" />
    <link:label id="lab_dare_PercentageOfIncreaseInAnnualBaseRent_1D6C6620D15B2CCB26A09A56008108DD_terseLabel_en-US" xlink:label="lab_dare_PercentageOfIncreaseInAnnualBaseRent_1D6C6620D15B2CCB26A09A56008108DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of increase in annual base rent, each year</link:label>
    <link:label id="lab_dare_PercentageOfIncreaseInAnnualBaseRent_1D6C6620D15B2CCB26A09A56008108DD_label_en-US" xlink:label="lab_dare_PercentageOfIncreaseInAnnualBaseRent_1D6C6620D15B2CCB26A09A56008108DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Increase In Annual Base Rent</link:label>
    <link:label id="lab_dare_PercentageOfIncreaseInAnnualBaseRent_1D6C6620D15B2CCB26A09A56008108DD_documentation_en-US" xlink:label="lab_dare_PercentageOfIncreaseInAnnualBaseRent_1D6C6620D15B2CCB26A09A56008108DD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Increase In Annual Base Rent</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_PercentageOfIncreaseInAnnualBaseRent" xlink:label="loc_dare_PercentageOfIncreaseInAnnualBaseRent_1D6C6620D15B2CCB26A09A56008108DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PercentageOfIncreaseInAnnualBaseRent_1D6C6620D15B2CCB26A09A56008108DD" xlink:to="lab_dare_PercentageOfIncreaseInAnnualBaseRent_1D6C6620D15B2CCB26A09A56008108DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_BE13FF9F56D61460AA199A5600815355_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_BE13FF9F56D61460AA199A5600815355" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Right of use asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_BE13FF9F56D61460AA199A5600815355" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_BE13FF9F56D61460AA199A5600815355" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_BE13FF9F56D61460AA199A5600815355" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_30F7E801439B894CE4E99A560081B7EF_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_30F7E801439B894CE4E99A560081B7EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability, short term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_30F7E801439B894CE4E99A560081B7EF_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_30F7E801439B894CE4E99A560081B7EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_30F7E801439B894CE4E99A560081B7EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_30F7E801439B894CE4E99A560081B7EF" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_30F7E801439B894CE4E99A560081B7EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_A10CF1591D363F9CFE689A56008173C9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_A10CF1591D363F9CFE689A56008173C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability, long term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_A10CF1591D363F9CFE689A56008173C9_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_A10CF1591D363F9CFE689A56008173C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_A10CF1591D363F9CFE689A56008173C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_A10CF1591D363F9CFE689A56008173C9" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_A10CF1591D363F9CFE689A56008173C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseCost_3288700E132D697C454A9A5600813EB0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_3288700E132D697C454A9A5600813EB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease expenses</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_3288700E132D697C454A9A5600813EB0_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_3288700E132D697C454A9A5600813EB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_3288700E132D697C454A9A5600813EB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost_3288700E132D697C454A9A5600813EB0" xlink:to="lab_us-gaap_OperatingLeaseCost_3288700E132D697C454A9A5600813EB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasePayments_2214E395661607D006449A56008183DB_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_2214E395661607D006449A56008183DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for measurement of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_2214E395661607D006449A56008183DB_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_2214E395661607D006449A56008183DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_2214E395661607D006449A56008183DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_2214E395661607D006449A56008183DB" xlink:to="lab_us-gaap_OperatingLeasePayments_2214E395661607D006449A56008183DB" xlink:type="arc" />
    <link:label id="lab_dare_ScheduleOfBusinessCombinationReverseMergerTable_645B69D56C766E61C186988EB36D30AC_terseLabel_en-US" xlink:label="lab_dare_ScheduleOfBusinessCombinationReverseMergerTable_645B69D56C766E61C186988EB36D30AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Business Combination Reverse Merger [Table]</link:label>
    <link:label id="lab_dare_ScheduleOfBusinessCombinationReverseMergerTable_645B69D56C766E61C186988EB36D30AC_label_en-US" xlink:label="lab_dare_ScheduleOfBusinessCombinationReverseMergerTable_645B69D56C766E61C186988EB36D30AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Business Combination Reverse Merger [Table]</link:label>
    <link:label id="lab_dare_ScheduleOfBusinessCombinationReverseMergerTable_645B69D56C766E61C186988EB36D30AC_documentation_en-US" xlink:label="lab_dare_ScheduleOfBusinessCombinationReverseMergerTable_645B69D56C766E61C186988EB36D30AC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of business combination reverse merger.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_ScheduleOfBusinessCombinationReverseMergerTable" xlink:label="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_645B69D56C766E61C186988EB36D30AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_645B69D56C766E61C186988EB36D30AC" xlink:to="lab_dare_ScheduleOfBusinessCombinationReverseMergerTable_645B69D56C766E61C186988EB36D30AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_B3A2A26371D6C381760E988EB36F5580_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_B3A2A26371D6C381760E988EB36F5580" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_B3A2A26371D6C381760E988EB36F5580" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_B3A2A26371D6C381760E988EB36F5580" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_B3A2A26371D6C381760E988EB36F5580" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_AE5555FF93BB0183415A988EB36F51C6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_AE5555FF93BB0183415A988EB36F51C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_AE5555FF93BB0183415A988EB36F51C6_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_AE5555FF93BB0183415A988EB36F51C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_AE5555FF93BB0183415A988EB36F51C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_AE5555FF93BB0183415A988EB36F51C6" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_AE5555FF93BB0183415A988EB36F51C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_4A340493B2421FB3C53B988EB3743BBC_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_4A340493B2421FB3C53B988EB3743BBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_4A340493B2421FB3C53B988EB3743BBC_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_4A340493B2421FB3C53B988EB3743BBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4A340493B2421FB3C53B988EB3743BBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4A340493B2421FB3C53B988EB3743BBC" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_4A340493B2421FB3C53B988EB3743BBC" xlink:type="arc" />
    <link:label id="lab_dare_PearTreePharmaceuticalsIncMember_1D3D3D65D5F4FE52C972988EB374605F_terseLabel_en-US" xlink:label="lab_dare_PearTreePharmaceuticalsIncMember_1D3D3D65D5F4FE52C972988EB374605F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pear Tree Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_dare_PearTreePharmaceuticalsIncMember_1D3D3D65D5F4FE52C972988EB374605F_label_en-US" xlink:label="lab_dare_PearTreePharmaceuticalsIncMember_1D3D3D65D5F4FE52C972988EB374605F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pear Tree Pharmaceuticals Inc [Member]</link:label>
    <link:label id="lab_dare_PearTreePharmaceuticalsIncMember_1D3D3D65D5F4FE52C972988EB374605F_documentation_en-US" xlink:label="lab_dare_PearTreePharmaceuticalsIncMember_1D3D3D65D5F4FE52C972988EB374605F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pear Tree Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_PearTreePharmaceuticalsIncMember" xlink:label="loc_dare_PearTreePharmaceuticalsIncMember_1D3D3D65D5F4FE52C972988EB374605F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PearTreePharmaceuticalsIncMember_1D3D3D65D5F4FE52C972988EB374605F" xlink:to="lab_dare_PearTreePharmaceuticalsIncMember_1D3D3D65D5F4FE52C972988EB374605F" xlink:type="arc" />
    <link:label id="lab_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799_terseLabel_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination Reverse Merger [Line Items]</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799_label_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Reverse Merger [Line Items]</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799_documentation_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business combination reverse merger.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerLineItems" xlink:label="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="lab_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:type="arc" />
    <link:label id="lab_dare_StockPurchaseAndOtherTransactionsCompletionDate_2FD650BC80B451FB1BBB988EB3758703_terseLabel_en-US" xlink:label="lab_dare_StockPurchaseAndOtherTransactionsCompletionDate_2FD650BC80B451FB1BBB988EB3758703" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock purchase transaction completion date</link:label>
    <link:label id="lab_dare_StockPurchaseAndOtherTransactionsCompletionDate_2FD650BC80B451FB1BBB988EB3758703_label_en-US" xlink:label="lab_dare_StockPurchaseAndOtherTransactionsCompletionDate_2FD650BC80B451FB1BBB988EB3758703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Purchase And Other Transactions Completion Date</link:label>
    <link:label id="lab_dare_StockPurchaseAndOtherTransactionsCompletionDate_2FD650BC80B451FB1BBB988EB3758703_documentation_en-US" xlink:label="lab_dare_StockPurchaseAndOtherTransactionsCompletionDate_2FD650BC80B451FB1BBB988EB3758703" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock purchase and other transactions completion date.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_StockPurchaseAndOtherTransactionsCompletionDate" xlink:label="loc_dare_StockPurchaseAndOtherTransactionsCompletionDate_2FD650BC80B451FB1BBB988EB3758703" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_StockPurchaseAndOtherTransactionsCompletionDate_2FD650BC80B451FB1BBB988EB3758703" xlink:to="lab_dare_StockPurchaseAndOtherTransactionsCompletionDate_2FD650BC80B451FB1BBB988EB3758703" xlink:type="arc" />
    <link:label id="lab_dare_StockPurchaseAgreementDate_0D96A20D08E7DD8BF98F988EB37536D3_terseLabel_en-US" xlink:label="lab_dare_StockPurchaseAgreementDate_0D96A20D08E7DD8BF98F988EB37536D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock purchase agreement date</link:label>
    <link:label id="lab_dare_StockPurchaseAgreementDate_0D96A20D08E7DD8BF98F988EB37536D3_label_en-US" xlink:label="lab_dare_StockPurchaseAgreementDate_0D96A20D08E7DD8BF98F988EB37536D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Purchase Agreement Date</link:label>
    <link:label id="lab_dare_StockPurchaseAgreementDate_0D96A20D08E7DD8BF98F988EB37536D3_documentation_en-US" xlink:label="lab_dare_StockPurchaseAgreementDate_0D96A20D08E7DD8BF98F988EB37536D3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock purchase agreement date.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_StockPurchaseAgreementDate" xlink:label="loc_dare_StockPurchaseAgreementDate_0D96A20D08E7DD8BF98F988EB37536D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_StockPurchaseAgreementDate_0D96A20D08E7DD8BF98F988EB37536D3" xlink:to="lab_dare_StockPurchaseAgreementDate_0D96A20D08E7DD8BF98F988EB37536D3" xlink:type="arc" />
    <link:label id="lab_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_57BF742C12EA903748F0988EB375FFAD_terseLabel_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_57BF742C12EA903748F0988EB375FFAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized fair value of stock options</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions" xlink:label="loc_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_57BF742C12EA903748F0988EB375FFAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_57BF742C12EA903748F0988EB375FFAD" xlink:to="lab_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_57BF742C12EA903748F0988EB375FFAD" xlink:type="arc" />
    <link:label id="lab_dare_StockOptionModificationApprovalDate_15925D8B9D60D12E94D1988EB3755BAF_terseLabel_en-US" xlink:label="lab_dare_StockOptionModificationApprovalDate_15925D8B9D60D12E94D1988EB3755BAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option modification approval date</link:label>
    <link:label id="lab_dare_StockOptionModificationApprovalDate_15925D8B9D60D12E94D1988EB3755BAF_label_en-US" xlink:label="lab_dare_StockOptionModificationApprovalDate_15925D8B9D60D12E94D1988EB3755BAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Option Modification Approval Date</link:label>
    <link:label id="lab_dare_StockOptionModificationApprovalDate_15925D8B9D60D12E94D1988EB3755BAF_documentation_en-US" xlink:label="lab_dare_StockOptionModificationApprovalDate_15925D8B9D60D12E94D1988EB3755BAF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock option modification approval date.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_StockOptionModificationApprovalDate" xlink:label="loc_dare_StockOptionModificationApprovalDate_15925D8B9D60D12E94D1988EB3755BAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_StockOptionModificationApprovalDate_15925D8B9D60D12E94D1988EB3755BAF" xlink:to="lab_dare_StockOptionModificationApprovalDate_15925D8B9D60D12E94D1988EB3755BAF" xlink:type="arc" />
    <link:label id="lab_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost_1990FD2D97686FFFE94F988EB376C641_terseLabel_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost_1990FD2D97686FFFE94F988EB376C641" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost_1990FD2D97686FFFE94F988EB376C641_label_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost_1990FD2D97686FFFE94F988EB376C641" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Reverse Merger Stock Purchase Transaction Cost</link:label>
    <link:label id="lab_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost_1990FD2D97686FFFE94F988EB376C641_documentation_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost_1990FD2D97686FFFE94F988EB376C641" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business combination reverses merger stock purchase transaction cost.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost" xlink:label="loc_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost_1990FD2D97686FFFE94F988EB376C641" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost_1990FD2D97686FFFE94F988EB376C641" xlink:to="lab_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost_1990FD2D97686FFFE94F988EB376C641" xlink:type="arc" />
    <link:label id="lab_dare_BusinessCombinationReverseMergerConsiderationTransferred_D2C07F46B05223B7A920988EB3765D31_terseLabel_en-US" xlink:label="lab_dare_BusinessCombinationReverseMergerConsiderationTransferred_D2C07F46B05223B7A920988EB3765D31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total purchase price consideration</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerConsiderationTransferred" xlink:label="loc_dare_BusinessCombinationReverseMergerConsiderationTransferred_D2C07F46B05223B7A920988EB3765D31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_BusinessCombinationReverseMergerConsiderationTransferred_D2C07F46B05223B7A920988EB3765D31" xlink:to="lab_dare_BusinessCombinationReverseMergerConsiderationTransferred_D2C07F46B05223B7A920988EB3765D31" xlink:type="arc" />
    <link:label id="lab_dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentLiabilities_1EC8DB7C04ADF087A120988EB3769395_terseLabel_en-US" xlink:label="lab_dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentLiabilities_1EC8DB7C04ADF087A120988EB3769395" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price adjustments increase in current liabilities</link:label>
    <link:label id="lab_dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentLiabilities_1EC8DB7C04ADF087A120988EB3769395_label_en-US" xlink:label="lab_dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentLiabilities_1EC8DB7C04ADF087A120988EB3769395" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Purchase Price Adjustment Increase In Current Liabilities</link:label>
    <link:label id="lab_dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentLiabilities_1EC8DB7C04ADF087A120988EB3769395_documentation_en-US" xlink:label="lab_dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentLiabilities_1EC8DB7C04ADF087A120988EB3769395" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business combination purchase price adjustment increase in current liabilities.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentLiabilities" xlink:label="loc_dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentLiabilities_1EC8DB7C04ADF087A120988EB3769395" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentLiabilities_1EC8DB7C04ADF087A120988EB3769395" xlink:to="lab_dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentLiabilities_1EC8DB7C04ADF087A120988EB3769395" xlink:type="arc" />
    <link:label id="lab_dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentAssets_20457E3812FA6A570674988EB37678E7_terseLabel_en-US" xlink:label="lab_dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentAssets_20457E3812FA6A570674988EB37678E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price adjustments increase in current assets</link:label>
    <link:label id="lab_dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentAssets_20457E3812FA6A570674988EB37678E7_label_en-US" xlink:label="lab_dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentAssets_20457E3812FA6A570674988EB37678E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Purchase Price Adjustment Increase In Current Assets</link:label>
    <link:label id="lab_dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentAssets_20457E3812FA6A570674988EB37678E7_documentation_en-US" xlink:label="lab_dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentAssets_20457E3812FA6A570674988EB37678E7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business combination purchase price adjustment increase in current assets.</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentAssets" xlink:label="loc_dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentAssets_20457E3812FA6A570674988EB37678E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentAssets_20457E3812FA6A570674988EB37678E7" xlink:to="lab_dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentAssets_20457E3812FA6A570674988EB37678E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_760A67C44A9570E3D679988EB3767213_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_760A67C44A9570E3D679988EB3767213" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Original goodwill amount acquired</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_760A67C44A9570E3D679988EB3767213_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_760A67C44A9570E3D679988EB3767213" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_760A67C44A9570E3D679988EB3767213" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod_760A67C44A9570E3D679988EB3767213" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod_760A67C44A9570E3D679988EB3767213" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_2E1B6C00ADD6CABC6FB2988EB376580F_negatedLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_2E1B6C00ADD6CABC6FB2988EB376580F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Reduced original goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_2E1B6C00ADD6CABC6FB2988EB376580F_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_2E1B6C00ADD6CABC6FB2988EB376580F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_2E1B6C00ADD6CABC6FB2988EB376580F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_2E1B6C00ADD6CABC6FB2988EB376580F" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_2E1B6C00ADD6CABC6FB2988EB376580F" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_B1CC37A32599488000DE988EB37788C7_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_B1CC37A32599488000DE988EB37788C7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill impairment charge</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_B1CC37A32599488000DE988EB37788C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss_B1CC37A32599488000DE988EB37788C7" xlink:to="lab_us-gaap_GoodwillImpairmentLoss_B1CC37A32599488000DE988EB37788C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_14BB5311EFB2A013ED8A988EB377F9F3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_14BB5311EFB2A013ED8A988EB377F9F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Merger Agreement entered date</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_14BB5311EFB2A013ED8A988EB377F9F3_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_14BB5311EFB2A013ED8A988EB377F9F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Date of Acquisition Agreement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:label="loc_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_14BB5311EFB2A013ED8A988EB377F9F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_14BB5311EFB2A013ED8A988EB377F9F3" xlink:to="lab_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_14BB5311EFB2A013ED8A988EB377F9F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_51F2AE5BFE3C002655A4988EB3774FEB_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_51F2AE5BFE3C002655A4988EB3774FEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business combination completed date</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_51F2AE5BFE3C002655A4988EB3774FEB_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_51F2AE5BFE3C002655A4988EB3774FEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Effective Date of Acquisition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:label="loc_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_51F2AE5BFE3C002655A4988EB3774FEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_51F2AE5BFE3C002655A4988EB3774FEB" xlink:to="lab_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_51F2AE5BFE3C002655A4988EB3774FEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_925E927365AE22BDE1E3988EB37732CC_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_925E927365AE22BDE1E3988EB37732CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration amount</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_925E927365AE22BDE1E3988EB37732CC_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_925E927365AE22BDE1E3988EB37732CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_925E927365AE22BDE1E3988EB37732CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_925E927365AE22BDE1E3988EB37732CC" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1_925E927365AE22BDE1E3988EB37732CC" xlink:type="arc" />
    <link:label id="lab_dare_PotentialCashPaymentsToAcquireBusiness_15E4CB794ABF01F66937988EB377F1CE_terseLabel_en-US" xlink:label="lab_dare_PotentialCashPaymentsToAcquireBusiness_15E4CB794ABF01F66937988EB377F1CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential cash payments to acquire business</link:label>
    <link:label id="lab_dare_PotentialCashPaymentsToAcquireBusiness_15E4CB794ABF01F66937988EB377F1CE_label_en-US" xlink:label="lab_dare_PotentialCashPaymentsToAcquireBusiness_15E4CB794ABF01F66937988EB377F1CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Cash Payments To Acquire Business</link:label>
    <link:label id="lab_dare_PotentialCashPaymentsToAcquireBusiness_15E4CB794ABF01F66937988EB377F1CE_documentation_en-US" xlink:label="lab_dare_PotentialCashPaymentsToAcquireBusiness_15E4CB794ABF01F66937988EB377F1CE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential Cash Payments To Acquire Business</link:label>
    <link:loc xlink:href="dare-20190331.xsd#dare_PotentialCashPaymentsToAcquireBusiness" xlink:label="loc_dare_PotentialCashPaymentsToAcquireBusiness_15E4CB794ABF01F66937988EB377F1CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dare_PotentialCashPaymentsToAcquireBusiness_15E4CB794ABF01F66937988EB377F1CE" xlink:to="lab_dare_PotentialCashPaymentsToAcquireBusiness_15E4CB794ABF01F66937988EB377F1CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_A29C5FF6D290992C9BE09A56023E9ED8_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_A29C5FF6D290992C9BE09A56023E9ED8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_A29C5FF6D290992C9BE09A56023E9ED8_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_A29C5FF6D290992C9BE09A56023E9ED8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_A29C5FF6D290992C9BE09A56023E9ED8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_A29C5FF6D290992C9BE09A56023E9ED8" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_A29C5FF6D290992C9BE09A56023E9ED8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_5AF23F50A920E8FC9DB19A56023E8B07_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_5AF23F50A920E8FC9DB19A56023E8B07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_5AF23F50A920E8FC9DB19A56023E8B07_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_5AF23F50A920E8FC9DB19A56023E8B07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_5AF23F50A920E8FC9DB19A56023E8B07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_5AF23F50A920E8FC9DB19A56023E8B07" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_5AF23F50A920E8FC9DB19A56023E8B07" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6327697B7B3E9F63FCFD9A56023E6BA9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6327697B7B3E9F63FCFD9A56023E6BA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6327697B7B3E9F63FCFD9A56023E6BA9_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6327697B7B3E9F63FCFD9A56023E6BA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6327697B7B3E9F63FCFD9A56023E6BA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6327697B7B3E9F63FCFD9A56023E6BA9" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6327697B7B3E9F63FCFD9A56023E6BA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_82A3B5CC4C999B4214329A56023EFD36_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_82A3B5CC4C999B4214329A56023EFD36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Adopted Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_82A3B5CC4C999B4214329A56023EFD36_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_82A3B5CC4C999B4214329A56023EFD36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_82A3B5CC4C999B4214329A56023EFD36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_82A3B5CC4C999B4214329A56023EFD36" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_82A3B5CC4C999B4214329A56023EFD36" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>dare-20190331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://darebioscience.com/role/Acquisitions" xlink:href="dare-20190331.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/AcquisitionsAdditionalInformationDetail" xlink:href="dare-20190331.xsd#AcquisitionsAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/AcquisitionsScheduleOfPurchasePriceConsiderationAllocationDetail" xlink:href="dare-20190331.xsd#AcquisitionsScheduleOfPurchasePriceConsiderationAllocationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/AcquisitionsTables" xlink:href="dare-20190331.xsd#AcquisitionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/CommitmentsAndContingencies" xlink:href="dare-20190331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="dare-20190331.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedBalanceSheets" xlink:href="dare-20190331.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="dare-20190331.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="dare-20190331.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="dare-20190331.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="dare-20190331.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/DocumentAndEntityInformation" xlink:href="dare-20190331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/GoingConcern" xlink:href="dare-20190331.xsd#GoingConcern" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/GoingConcernAdditionalInformationDetail" xlink:href="dare-20190331.xsd#GoingConcernAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/GrantAward" xlink:href="dare-20190331.xsd#GrantAward" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/GrantAwardAdditionalInformationDetail" xlink:href="dare-20190331.xsd#GrantAwardAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedProperties" xlink:href="dare-20190331.xsd#LeasedProperties" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesDetails" xlink:href="dare-20190331.xsd#LeasedPropertiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:href="dare-20190331.xsd#LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/LeasedPropertiesTables" xlink:href="dare-20190331.xsd#LeasedPropertiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerShare" xlink:href="dare-20190331.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetail" xlink:href="dare-20190331.xsd#NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/NetLossPerShareTables" xlink:href="dare-20190331.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/OrganizationAndDescriptionOfBusiness" xlink:href="dare-20190331.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail" xlink:href="dare-20190331.xsd#OrganizationAndDescriptionOfBusinessAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensation" xlink:href="dare-20190331.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:href="dare-20190331.xsd#StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedToEmployeesAndDirectorsDetail" xlink:href="dare-20190331.xsd#StockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedToEmployeesAndDirectorsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToStockOptionsGrantedToEmployeesAndDirectorsDetails" xlink:href="dare-20190331.xsd#StockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToStockOptionsGrantedToEmployeesAndDirectorsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationSummaryOfStockOptionActivityForAmended2014PlanAndRelatedInformationDetail" xlink:href="dare-20190331.xsd#StockBasedCompensationSummaryOfStockOptionActivityForAmended2014PlanAndRelatedInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockBasedCompensationTables" xlink:href="dare-20190331.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquity" xlink:href="dare-20190331.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetail" xlink:href="dare-20190331.xsd#StockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityScheduleOfCommonStockWarrantsOutstandingDetails" xlink:href="dare-20190331.xsd#StockholdersEquityScheduleOfCommonStockWarrantsOutstandingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/StockholdersEquityTables" xlink:href="dare-20190331.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/SubsequentEvents" xlink:href="dare-20190331.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/SubsequentEventsDetails" xlink:href="dare-20190331.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="dare-20190331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="dare-20190331.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="dare-20190331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://darebioscience.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_3DBB3FEB7B3AADB7790A5B0CFD617E81" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_8AD112719732F8A08E325B0CFD6148C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3DBB3FEB7B3AADB7790A5B0CFD617E81" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_8AD112719732F8A08E325B0CFD6148C9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/AcquisitionsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_40DA05A766B89B649EC7988EB36C9A7E" xlink:type="locator" />
    <link:loc xlink:href="dare-20190331.xsd#dare_ScheduleOfBusinessCombinationReverseMergerTable" xlink:label="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_645B69D56C766E61C186988EB36D30AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_40DA05A766B89B649EC7988EB36C9A7E" xlink:to="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_645B69D56C766E61C186988EB36D30AC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_AC59DB811D6437EBFD98988EB36DECD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_645B69D56C766E61C186988EB36D30AC" xlink:to="loc_dei_LegalEntityAxis_AC59DB811D6437EBFD98988EB36DECD6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_C46089FD10A5057C047E988EB36D6441" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_AC59DB811D6437EBFD98988EB36DECD6" xlink:to="loc_dei_EntityDomain_C46089FD10A5057C047E988EB36D6441" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_PrivateDareMember" xlink:label="loc_dare_PrivateDareMember_DFED8E4F3B4F936FB800988EB36D3330" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_C46089FD10A5057C047E988EB36D6441" xlink:to="loc_dare_PrivateDareMember_DFED8E4F3B4F936FB800988EB36D3330" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3864F8EA69C4B78CF526988EB36E8529" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_645B69D56C766E61C186988EB36D30AC" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3864F8EA69C4B78CF526988EB36E8529" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_175D11F404BBC458915C988EB36E3CCD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3864F8EA69C4B78CF526988EB36E8529" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_175D11F404BBC458915C988EB36E3CCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_04852BF7BED96F142A60988EB36E859B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_175D11F404BBC458915C988EB36E3CCD" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_04852BF7BED96F142A60988EB36E859B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_B3A2A26371D6C381760E988EB36F5580" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_175D11F404BBC458915C988EB36E3CCD" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_B3A2A26371D6C381760E988EB36F5580" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_AE5555FF93BB0183415A988EB36F51C6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_645B69D56C766E61C186988EB36D30AC" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_AE5555FF93BB0183415A988EB36F51C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4A340493B2421FB3C53B988EB3743BBC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_AE5555FF93BB0183415A988EB36F51C6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4A340493B2421FB3C53B988EB3743BBC" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_PearTreePharmaceuticalsIncMember" xlink:label="loc_dare_PearTreePharmaceuticalsIncMember_1D3D3D65D5F4FE52C972988EB374605F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4A340493B2421FB3C53B988EB3743BBC" xlink:to="loc_dare_PearTreePharmaceuticalsIncMember_1D3D3D65D5F4FE52C972988EB374605F" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerLineItems" xlink:label="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_ScheduleOfBusinessCombinationReverseMergerTable_645B69D56C766E61C186988EB36D30AC" xlink:to="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_StockPurchaseAndOtherTransactionsCompletionDate" xlink:label="loc_dare_StockPurchaseAndOtherTransactionsCompletionDate_2FD650BC80B451FB1BBB988EB3758703" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_dare_StockPurchaseAndOtherTransactionsCompletionDate_2FD650BC80B451FB1BBB988EB3758703" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_StockPurchaseAgreementDate" xlink:label="loc_dare_StockPurchaseAgreementDate_0D96A20D08E7DD8BF98F988EB37536D3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_dare_StockPurchaseAgreementDate_0D96A20D08E7DD8BF98F988EB37536D3" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_70CDA993FC186A61A1EA988EB3750E2A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_70CDA993FC186A61A1EA988EB3750E2A" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions" xlink:label="loc_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_57BF742C12EA903748F0988EB375FFAD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_57BF742C12EA903748F0988EB375FFAD" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_StockOptionModificationApprovalDate" xlink:label="loc_dare_StockOptionModificationApprovalDate_15925D8B9D60D12E94D1988EB3755BAF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_dare_StockOptionModificationApprovalDate_15925D8B9D60D12E94D1988EB3755BAF" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost" xlink:label="loc_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost_1990FD2D97686FFFE94F988EB376C641" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost_1990FD2D97686FFFE94F988EB376C641" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerConsiderationTransferred" xlink:label="loc_dare_BusinessCombinationReverseMergerConsiderationTransferred_D2C07F46B05223B7A920988EB3765D31" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_dare_BusinessCombinationReverseMergerConsiderationTransferred_D2C07F46B05223B7A920988EB3765D31" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentLiabilities" xlink:label="loc_dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentLiabilities_1EC8DB7C04ADF087A120988EB3769395" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentLiabilities_1EC8DB7C04ADF087A120988EB3769395" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentAssets" xlink:label="loc_dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentAssets_20457E3812FA6A570674988EB37678E7" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentAssets_20457E3812FA6A570674988EB37678E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_760A67C44A9570E3D679988EB3767213" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_760A67C44A9570E3D679988EB3767213" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_2E1B6C00ADD6CABC6FB2988EB376580F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_2E1B6C00ADD6CABC6FB2988EB376580F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_B1CC37A32599488000DE988EB37788C7" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_B1CC37A32599488000DE988EB37788C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_2BC79DED165162B89EF9988EB37795E8" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_us-gaap_Goodwill_2BC79DED165162B89EF9988EB37795E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:label="loc_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_14BB5311EFB2A013ED8A988EB377F9F3" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_14BB5311EFB2A013ED8A988EB377F9F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:label="loc_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_51F2AE5BFE3C002655A4988EB3774FEB" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_51F2AE5BFE3C002655A4988EB3774FEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_925E927365AE22BDE1E3988EB37732CC" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_925E927365AE22BDE1E3988EB37732CC" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_PotentialCashPaymentsToAcquireBusiness" xlink:label="loc_dare_PotentialCashPaymentsToAcquireBusiness_15E4CB794ABF01F66937988EB377F1CE" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerLineItems_53441F71767888759CB1988EB374A799" xlink:to="loc_dare_PotentialCashPaymentsToAcquireBusiness_15E4CB794ABF01F66937988EB377F1CE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/AcquisitionsScheduleOfPurchasePriceConsiderationAllocationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_832B0E92B39F47C125E84CA0CA912384" xlink:type="locator" />
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_dare_BusinessCombinationReverseMergerConsiderationTransferredEquityInterestsIssuedAndIssuable_F6C1A44F0E95FCB3CE534CA0CA93F12A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_832B0E92B39F47C125E84CA0CA912384" xlink:to="loc_dare_BusinessCombinationReverseMergerConsiderationTransferredEquityInterestsIssuedAndIssuable_F6C1A44F0E95FCB3CE534CA0CA93F12A" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions" xlink:label="loc_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_7A713BB679738C5EDAD04CA0CA9351C5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_832B0E92B39F47C125E84CA0CA912384" xlink:to="loc_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions_7A713BB679738C5EDAD04CA0CA9351C5" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerConsiderationTransferred" xlink:label="loc_dare_BusinessCombinationReverseMergerConsiderationTransferred_A249E51068BCE37F7AC44CA0CA931488" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_832B0E92B39F47C125E84CA0CA912384" xlink:to="loc_dare_BusinessCombinationReverseMergerConsiderationTransferred_A249E51068BCE37F7AC44CA0CA931488" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:label="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_6D906CE24AFEFB5E1A494CA0CA939C08" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_832B0E92B39F47C125E84CA0CA912384" xlink:to="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_6D906CE24AFEFB5E1A494CA0CA939C08" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3E2EF568CBFD42B5C9FE4CA0CA93B22F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_6D906CE24AFEFB5E1A494CA0CA939C08" xlink:to="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3E2EF568CBFD42B5C9FE4CA0CA93B22F" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherCurrentAssets" xlink:label="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherCurrentAssets_34BE1B890D38B6DDDC334CA0CA9366C4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_6D906CE24AFEFB5E1A494CA0CA939C08" xlink:to="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherCurrentAssets_34BE1B890D38B6DDDC334CA0CA9366C4" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_1786FD489517C7F6BB314CA0CA933E75" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_6D906CE24AFEFB5E1A494CA0CA939C08" xlink:to="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_1786FD489517C7F6BB314CA0CA933E75" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_A54107390898A43D61DB4CA0CA932042" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_6D906CE24AFEFB5E1A494CA0CA939C08" xlink:to="loc_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_A54107390898A43D61DB4CA0CA932042" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_9C782FC5C8FB0DF644784CA0CA93294C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_832B0E92B39F47C125E84CA0CA912384" xlink:to="loc_us-gaap_Goodwill_9C782FC5C8FB0DF644784CA0CA93294C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/AcquisitionsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_33696D0C965B5DAD8A7D80CF74F39006" xlink:type="locator" />
    <link:loc xlink:href="dare-20190331.xsd#dare_ScheduleOfBusinessCombinationReverseMergerTextBlock" xlink:label="loc_dare_ScheduleOfBusinessCombinationReverseMergerTextBlock_85ABBEED9BF65F8C88034691ABCAC79E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_33696D0C965B5DAD8A7D80CF74F39006" xlink:to="loc_dare_ScheduleOfBusinessCombinationReverseMergerTextBlock_85ABBEED9BF65F8C88034691ABCAC79E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9011CCD548C94268B8655B0CFC3E571D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_EC017C87C964FC242A865B0CFC3FE23B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9011CCD548C94268B8655B0CFC3E571D" xlink:to="loc_us-gaap_CommitmentsDisclosureTextBlock_EC017C87C964FC242A865B0CFC3FE23B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_07D484341FC79EBC7FC89A56000418AB" xlink:type="locator" />
    <link:loc xlink:href="dare-20190331.xsd#dare_CommitmentsAndContingenciesTable" xlink:label="loc_dare_CommitmentsAndContingenciesTable_38764C78A6D822C742859A560004D15D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_07D484341FC79EBC7FC89A56000418AB" xlink:to="loc_dare_CommitmentsAndContingenciesTable_38764C78A6D822C742859A560004D15D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_5226954CA22B824B3BF29A5600047536" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesTable_38764C78A6D822C742859A560004D15D" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_5226954CA22B824B3BF29A5600047536" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_1204BFFFC315296D30709A5600044412" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_5226954CA22B824B3BF29A5600047536" xlink:to="loc_us-gaap_ProjectMember_1204BFFFC315296D30709A5600044412" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember" xlink:label="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_98769D6901002B06AA839A560004BF7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_1204BFFFC315296D30709A5600044412" xlink:to="loc_dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember_98769D6901002B06AA839A560004BF7F" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_UponReachingCertainWorldwideNetSalesMilestonesMember" xlink:label="loc_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_50C351C39922DEDE006E9A5600043689" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_1204BFFFC315296D30709A5600044412" xlink:to="loc_dare_UponReachingCertainWorldwideNetSalesMilestonesMember_50C351C39922DEDE006E9A5600043689" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_UponAchievementOfSpecifiedCommercializationMilestonesMember" xlink:label="loc_dare_UponAchievementOfSpecifiedCommercializationMilestonesMember_39B96A41607AD303190C9A7E3F93C74B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_1204BFFFC315296D30709A5600044412" xlink:to="loc_dare_UponAchievementOfSpecifiedCommercializationMilestonesMember_39B96A41607AD303190C9A7E3F93C74B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_C411893F38F50A8F70E79A5600042D01" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesTable_38764C78A6D822C742859A560004D15D" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_C411893F38F50A8F70E79A5600042D01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_6A27705050929DD3B4929A5600040F89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_C411893F38F50A8F70E79A5600042D01" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_6A27705050929DD3B4929A5600040F89" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_UponAchievingCertainCommercialMilestonesMember" xlink:label="loc_dare_UponAchievingCertainCommercialMilestonesMember_758ED85E852D6BDD8A1A9A560004A56D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_6A27705050929DD3B4929A5600040F89" xlink:to="loc_dare_UponAchievingCertainCommercialMilestonesMember_758ED85E852D6BDD8A1A9A560004A56D" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_UponSigningOfDevelopmentAndOptionAgreementMember" xlink:label="loc_dare_UponSigningOfDevelopmentAndOptionAgreementMember_6BFE06515276F44C86869A5600142816" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_6A27705050929DD3B4929A5600040F89" xlink:to="loc_dare_UponSigningOfDevelopmentAndOptionAgreementMember_6BFE06515276F44C86869A5600142816" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember" xlink:label="loc_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_A7F214FB1B5EA8C8B8DF9A5600144764" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_6A27705050929DD3B4929A5600040F89" xlink:to="loc_dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember_A7F214FB1B5EA8C8B8DF9A5600144764" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_UponAchievingCertainDevelopmentMilestonesMember" xlink:label="loc_dare_UponAchievingCertainDevelopmentMilestonesMember_6EF4E3B29F5F1C6E17339A560014E299" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_6A27705050929DD3B4929A5600040F89" xlink:to="loc_dare_UponAchievingCertainDevelopmentMilestonesMember_6EF4E3B29F5F1C6E17339A560014E299" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember" xlink:label="loc_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_47601C1304B5433057CD9A56001444BE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_6A27705050929DD3B4929A5600040F89" xlink:to="loc_dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember_47601C1304B5433057CD9A56001444BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A5F48F4F6A83318C78569A560014E751" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesTable_38764C78A6D822C742859A560004D15D" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A5F48F4F6A83318C78569A560014E751" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3280554863447EC9E2B29A560014956C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A5F48F4F6A83318C78569A560014E751" xlink:to="loc_us-gaap_RelatedPartyDomain_3280554863447EC9E2B29A560014956C" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember" xlink:label="loc_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_2BE18553FE162BBA3E429A560014A2AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3280554863447EC9E2B29A560014956C" xlink:to="loc_dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember_2BE18553FE162BBA3E429A560014A2AD" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_OrbisMember" xlink:label="loc_dare_OrbisMember_CD8CA70051BF6338844D9A560014F300" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3280554863447EC9E2B29A560014956C" xlink:to="loc_dare_OrbisMember_CD8CA70051BF6338844D9A560014F300" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_MilanaPharmMember" xlink:label="loc_dare_MilanaPharmMember_62745BECE235C3F3A8979A5600145009" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3280554863447EC9E2B29A560014956C" xlink:to="loc_dare_MilanaPharmMember_62745BECE235C3F3A8979A5600145009" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_HammockPharmaceuticalsInc.Member" xlink:label="loc_dare_HammockPharmaceuticalsInc.Member_0DD342201994E71532B99A5600143869" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3280554863447EC9E2B29A560014956C" xlink:to="loc_dare_HammockPharmaceuticalsInc.Member_0DD342201994E71532B99A5600143869" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_D2219D9BB0711A3D41E39A560014E021" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesTable_38764C78A6D822C742859A560004D15D" xlink:to="loc_us-gaap_TypeOfArrangementAxis_D2219D9BB0711A3D41E39A560014E021" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19B1C2BB56A8648E26369A560014E530" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_D2219D9BB0711A3D41E39A560014E021" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19B1C2BB56A8648E26369A560014E530" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_1D3E842F4EFE0E3BB98B9A5600143699" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19B1C2BB56A8648E26369A560014E530" xlink:to="loc_us-gaap_LicensingAgreementsMember_1D3E842F4EFE0E3BB98B9A5600143699" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_AssignmentAgreementMember" xlink:label="loc_dare_AssignmentAgreementMember_96857C39E55F481E65BD9A5600147302" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19B1C2BB56A8648E26369A560014E530" xlink:to="loc_dare_AssignmentAgreementMember_96857C39E55F481E65BD9A5600147302" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseAndCollaborationAgreementMember" xlink:label="loc_dare_LicenseAndCollaborationAgreementMember_B3E62F718A04FE6901589A56001426A0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19B1C2BB56A8648E26369A560014E530" xlink:to="loc_dare_LicenseAndCollaborationAgreementMember_B3E62F718A04FE6901589A56001426A0" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_DevelopmentAndOptionAgreementMember" xlink:label="loc_dare_DevelopmentAndOptionAgreementMember_5AA91B1D560B61EBD8E19A5600143961" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19B1C2BB56A8648E26369A560014E530" xlink:to="loc_dare_DevelopmentAndOptionAgreementMember_5AA91B1D560B61EBD8E19A5600143961" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_JuniperPharmaceuticalsInc.Member" xlink:label="loc_dare_JuniperPharmaceuticalsInc.Member_72D9E8CEA61D402E65569A560014A18B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19B1C2BB56A8648E26369A560014E530" xlink:to="loc_dare_JuniperPharmaceuticalsInc.Member_72D9E8CEA61D402E65569A560014A18B" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_JuniperPharmaceuticalsMember" xlink:label="loc_dare_JuniperPharmaceuticalsMember_50114727EDF37823F9FA9A560014A640" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19B1C2BB56A8648E26369A560014E530" xlink:to="loc_dare_JuniperPharmaceuticalsMember_50114727EDF37823F9FA9A560014A640" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A0158D96A503FC2CC3BE9A56001481A5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesTable_38764C78A6D822C742859A560004D15D" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A0158D96A503FC2CC3BE9A56001481A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_EA4F5017546F337CFB1D9A560014C7D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A0158D96A503FC2CC3BE9A56001481A5" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_EA4F5017546F337CFB1D9A560014C7D2" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_ADVATecAgreementMember" xlink:label="loc_dare_ADVATecAgreementMember_969471B2814694C360949A560014892D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_EA4F5017546F337CFB1D9A560014C7D2" xlink:to="loc_dare_ADVATecAgreementMember_969471B2814694C360949A560014892D" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_ClinicalAndRegulatoryMilestonesMember" xlink:label="loc_dare_ClinicalAndRegulatoryMilestonesMember_E86D6B5DF4A6F3B1ADF99A560014C1B9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_EA4F5017546F337CFB1D9A560014C7D2" xlink:to="loc_dare_ClinicalAndRegulatoryMilestonesMember_E86D6B5DF4A6F3B1ADF99A560014C1B9" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_SalesMilestonesMember" xlink:label="loc_dare_SalesMilestonesMember_B041AF0AC6FB606A58559A560014BF2E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_EA4F5017546F337CFB1D9A560014C7D2" xlink:to="loc_dare_SalesMilestonesMember_B041AF0AC6FB606A58559A560014BF2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_354CDF255C05767CA7DF9A560014205B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesTable_38764C78A6D822C742859A560004D15D" xlink:to="loc_srt_RangeAxis_354CDF255C05767CA7DF9A560014205B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_00B86CCB992413FA89259A560014701A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_354CDF255C05767CA7DF9A560014205B" xlink:to="loc_srt_RangeMember_00B86CCB992413FA89259A560014701A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_A2D17817970D187DE9509A560014D4C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_00B86CCB992413FA89259A560014701A" xlink:to="loc_srt_MinimumMember_A2D17817970D187DE9509A560014D4C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_093995F495C3B27368769A560014D735" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_00B86CCB992413FA89259A560014701A" xlink:to="loc_srt_MaximumMember_093995F495C3B27368769A560014D735" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_59563A40B783DB2D84E29A560014A873" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesTable_38764C78A6D822C742859A560004D15D" xlink:to="loc_srt_ProductOrServiceAxis_59563A40B783DB2D84E29A560014A873" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_DA798FDC0287133632209A5600144AED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_59563A40B783DB2D84E29A560014A873" xlink:to="loc_srt_ProductsAndServicesDomain_DA798FDC0287133632209A5600144AED" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_OvapreneMember" xlink:label="loc_dare_OvapreneMember_C20E64FE5DE4896696749A560014E0FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_DA798FDC0287133632209A5600144AED" xlink:to="loc_dare_OvapreneMember_C20E64FE5DE4896696749A560014E0FC" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_CommitmentsAndContingenciesLineItems" xlink:label="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesTable_38764C78A6D822C742859A560004D15D" xlink:to="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_NumberOfPatentsIssued" xlink:label="loc_dare_NumberOfPatentsIssued_E80D88B0800F8FB720519A5600149998" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_NumberOfPatentsIssued_E80D88B0800F8FB720519A5600149998" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_NumberOfPendingPatents" xlink:label="loc_dare_NumberOfPendingPatents_1BC6D5630F25BABAEFBC9A560024F8DC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_NumberOfPendingPatents_1BC6D5630F25BABAEFBC9A560024F8DC" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_NumberOfPatentsGranted" xlink:label="loc_dare_NumberOfPatentsGranted_45780CDADC370C3630C69A560024A0FB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_NumberOfPatentsGranted_45780CDADC370C3630C69A560024A0FB" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_NumberOfPatentApplications" xlink:label="loc_dare_NumberOfPatentApplications_928D3B145E48D14FAF449A5600244E6C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_NumberOfPatentApplications_928D3B145E48D14FAF449A5600244E6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_F535BA93A17C5B8828289A560024ABB9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_us-gaap_ContractualObligation_F535BA93A17C5B8828289A560024ABB9" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries" xlink:label="loc_dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries_52FAD2A4EB67740EB0699A5600246699" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries_52FAD2A4EB67740EB0699A5600246699" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_NumberOfDesignatedCountries" xlink:label="loc_dare_NumberOfDesignatedCountries_BB66673F56F2430B455D9A5600240127" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_NumberOfDesignatedCountries_BB66673F56F2430B455D9A5600240127" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_PercentageOfRoyaltyRate" xlink:label="loc_dare_PercentageOfRoyaltyRate_6C247173C8CDB6CBDF8A9A560024E842" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_PercentageOfRoyaltyRate_6C247173C8CDB6CBDF8A9A560024E842" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure" xlink:label="loc_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_40A4F7505810715F6AEA9A56002444E2" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure_40A4F7505810715F6AEA9A56002444E2" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease" xlink:label="loc_dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease_C9A2BF985131F6143FFD9A560024E498" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease_C9A2BF985131F6143FFD9A560024E498" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement" xlink:label="loc_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_00DFD9685A4BF88AB74D9A5600245D3A" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement_00DFD9685A4BF88AB74D9A5600245D3A" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_MilestonePaymentsContingentAmount" xlink:label="loc_dare_MilestonePaymentsContingentAmount_B78283700539874CDE8F9A56002440B7" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_MilestonePaymentsContingentAmount_B78283700539874CDE8F9A56002440B7" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_SecuredInvestmentRequiredForLicenseAgreement" xlink:label="loc_dare_SecuredInvestmentRequiredForLicenseAgreement_872582390F9D53AF2AAE9A560024DD41" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_SecuredInvestmentRequiredForLicenseAgreement_872582390F9D53AF2AAE9A560024DD41" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseAgreementExpirationPeriod" xlink:label="loc_dare_LicenseAgreementExpirationPeriod_A0108DD623BAE0B6903F9A560024047E" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_LicenseAgreementExpirationPeriod_A0108DD623BAE0B6903F9A560024047E" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval" xlink:label="loc_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval_FBB837D21481090AF7219A560024FFF8" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval_FBB837D21481090AF7219A560024FFF8" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval" xlink:label="loc_dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval_76CCC3476D3257EABB9C9A56002489B5" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval_76CCC3476D3257EABB9C9A56002489B5" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries" xlink:label="loc_dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries_F124726C3421E867D1CD9A5600240049" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries_F124726C3421E867D1CD9A5600240049" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_NoticePeriodForTerminationOfAgreementForBothParties" xlink:label="loc_dare_NoticePeriodForTerminationOfAgreementForBothParties_CF6435B3AEFC7CBAB3F79A56002444A9" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_NoticePeriodForTerminationOfAgreementForBothParties_CF6435B3AEFC7CBAB3F79A56002444A9" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_ResearchAndDevelopmentMilestonePayment" xlink:label="loc_dare_ResearchAndDevelopmentMilestonePayment_EC3B4824F10C9177D2209A560024FEBE" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_ResearchAndDevelopmentMilestonePayment_EC3B4824F10C9177D2209A560024FEBE" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_CommencementPeriodForStageTwoUponAchievementOfStageOne" xlink:label="loc_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_5810BD177D60B22254289A5600246007" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne_5810BD177D60B22254289A5600246007" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_UpfrontLicenseFeePaid" xlink:label="loc_dare_UpfrontLicenseFeePaid_5D7D2EC543FF757133159A5600242C6F" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_UpfrontLicenseFeePaid_5D7D2EC543FF757133159A5600242C6F" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne" xlink:label="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_56BD0638CD219DCA6E4C9A5600240E89" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne_56BD0638CD219DCA6E4C9A5600240E89" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter" xlink:label="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_3D2EBD3A7E3D9B6AAA1A9A5600245A33" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter_3D2EBD3A7E3D9B6AAA1A9A5600245A33" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_MaximumPotentialMilestonePayments" xlink:label="loc_dare_MaximumPotentialMilestonePayments_1E20C25B4B9697F644BD9A5600242F55" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_MaximumPotentialMilestonePayments_1E20C25B4B9697F644BD9A5600242F55" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess" xlink:label="loc_dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess_F6B481148AECD100D2579A560024091F" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess_F6B481148AECD100D2579A560024091F" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation" xlink:label="loc_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation_E8FDC8D4D591972F80549A56002430AE" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation_E8FDC8D4D591972F80549A56002430AE" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_PeriodOfDismissalOfBankruptcyPetition" xlink:label="loc_dare_PeriodOfDismissalOfBankruptcyPetition_9A66142D7D6466E0B3849A5600334DD1" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_PeriodOfDismissalOfBankruptcyPetition_9A66142D7D6466E0B3849A5600334DD1" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation" xlink:label="loc_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation_3172676B13C81A8A8C329A560033F776" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation_3172676B13C81A8A8C329A560033F776" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseAgreementNoticePeriodOfTermination" xlink:label="loc_dare_LicenseAgreementNoticePeriodOfTermination_9DD65469CF7431C21BEE9A5600339C9B" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_LicenseAgreementNoticePeriodOfTermination_9DD65469CF7431C21BEE9A5600339C9B" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseFee" xlink:label="loc_dare_LicenseFee_EC70CA24DF2CC78006AD9A5600331328" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_LicenseFee_EC70CA24DF2CC78006AD9A5600331328" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseFeeToBePaidUponContingency" xlink:label="loc_dare_LicenseFeeToBePaidUponContingency_EC3867FD1715A408E3DB9A560033532E" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_LicenseFeeToBePaidUponContingency_EC3867FD1715A408E3DB9A560033532E" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_ProceedsRaisedFromEquityFinancing" xlink:label="loc_dare_ProceedsRaisedFromEquityFinancing_E39FDEFAFEF3860A55E39A5600336B8F" xlink:type="locator" />
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_CommitmentsAndContingenciesLineItems_0083987B86416E941F839A56001435E9" xlink:to="loc_dare_ProceedsRaisedFromEquityFinancing_E39FDEFAFEF3860A55E39A5600336B8F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_AB21A797C075135B8E6AB2D49A813330" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_123DE0AC56DE9BC79B4AB2D49A8256C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_AB21A797C075135B8E6AB2D49A813330" xlink:to="loc_us-gaap_AssetsAbstract_123DE0AC56DE9BC79B4AB2D49A8256C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3FEA17BE08F56C6526B6B2D49A8282EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_123DE0AC56DE9BC79B4AB2D49A8256C9" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3FEA17BE08F56C6526B6B2D49A8282EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ABE0931011721201B5FAB2D49A8214D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3FEA17BE08F56C6526B6B2D49A8282EC" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ABE0931011721201B5FAB2D49A8214D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_D6FCA347B3D4648DCB50B2D49A83C087" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3FEA17BE08F56C6526B6B2D49A8282EC" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_D6FCA347B3D4648DCB50B2D49A83C087" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_5DC654A67EB2185D6BEAB2D49A83FFDC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3FEA17BE08F56C6526B6B2D49A8282EC" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_5DC654A67EB2185D6BEAB2D49A83FFDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_4B3A9F71C7A6EFF08FC8B2D49A83F169" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3FEA17BE08F56C6526B6B2D49A8282EC" xlink:to="loc_us-gaap_AssetsCurrent_4B3A9F71C7A6EFF08FC8B2D49A83F169" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_E28002A7A0DB89AFF8DCB2D49A837B8C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_123DE0AC56DE9BC79B4AB2D49A8256C9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_E28002A7A0DB89AFF8DCB2D49A837B8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_A4B841C11C10D20EFDC3B2D49A835AF8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_123DE0AC56DE9BC79B4AB2D49A8256C9" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_A4B841C11C10D20EFDC3B2D49A835AF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_C3B9FC7C5903C1A529E7B2D49A848A5E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_123DE0AC56DE9BC79B4AB2D49A8256C9" xlink:to="loc_us-gaap_Assets_C3B9FC7C5903C1A529E7B2D49A848A5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_806763A8247A490451C2B2D49A84965F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_AB21A797C075135B8E6AB2D49A813330" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_806763A8247A490451C2B2D49A84965F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_E2B2F4CE9A829CE90488B2D49A84A2D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_806763A8247A490451C2B2D49A84965F" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_E2B2F4CE9A829CE90488B2D49A84A2D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_BE8607A134CF73B9CCE6B2D49A84B637" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_E2B2F4CE9A829CE90488B2D49A84A2D6" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_BE8607A134CF73B9CCE6B2D49A84B637" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_38EDE4F41CCB20C58EBAB2D49A844E7B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_E2B2F4CE9A829CE90488B2D49A84A2D6" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_38EDE4F41CCB20C58EBAB2D49A844E7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_FB95DBE26ACB747CD115B2D49A859870" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_E2B2F4CE9A829CE90488B2D49A84A2D6" xlink:to="loc_us-gaap_LiabilitiesCurrent_FB95DBE26ACB747CD115B2D49A859870" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_EB6EE3B2DFE344447686B2D49A8527E0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_806763A8247A490451C2B2D49A84965F" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_EB6EE3B2DFE344447686B2D49A8527E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_2AAC2C2247D518B37963B2D49A851B7F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_806763A8247A490451C2B2D49A84965F" xlink:to="loc_us-gaap_Liabilities_2AAC2C2247D518B37963B2D49A851B7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_121DEFF3EAAD3E3CE959B2D49A859685" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_806763A8247A490451C2B2D49A84965F" xlink:to="loc_us-gaap_CommitmentsAndContingencies_121DEFF3EAAD3E3CE959B2D49A859685" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_D5C23961379911476F6FB2D49A85E8D8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_806763A8247A490451C2B2D49A84965F" xlink:to="loc_us-gaap_StockholdersEquityAbstract_D5C23961379911476F6FB2D49A85E8D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_68F21DF223626E4054B1B2D49A856E86" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_D5C23961379911476F6FB2D49A85E8D8" xlink:to="loc_us-gaap_PreferredStockValue_68F21DF223626E4054B1B2D49A856E86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_4E2175BFC2B3D4348DFBB2D49A86A1E0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_D5C23961379911476F6FB2D49A85E8D8" xlink:to="loc_us-gaap_CommonStockValue_4E2175BFC2B3D4348DFBB2D49A86A1E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_258ECFF68924BF54A433B2D49A86F553" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_D5C23961379911476F6FB2D49A85E8D8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_258ECFF68924BF54A433B2D49A86F553" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_F4562C692B4CA60A8EB5B2D49A862726" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_D5C23961379911476F6FB2D49A85E8D8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_F4562C692B4CA60A8EB5B2D49A862726" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0E784BF2B76ABD43E43FB2D49A86E6C9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_D5C23961379911476F6FB2D49A85E8D8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0E784BF2B76ABD43E43FB2D49A86E6C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_69EA62674167734AAC32B2D49A873274" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_D5C23961379911476F6FB2D49A85E8D8" xlink:to="loc_us-gaap_StockholdersEquity_69EA62674167734AAC32B2D49A873274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_0AAE7F70EC2B0CE25892B2D49A87017F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_806763A8247A490451C2B2D49A84965F" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_0AAE7F70EC2B0CE25892B2D49A87017F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_47947645EBAF5BA368994AFD87A9CB15" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_DE883CE1F5ACA9FB28AB4AFD87A90115" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_47947645EBAF5BA368994AFD87A9CB15" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_DE883CE1F5ACA9FB28AB4AFD87A90115" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_42774BA14B3F9AE466784AFD87A944E4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_47947645EBAF5BA368994AFD87A9CB15" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_42774BA14B3F9AE466784AFD87A944E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_445473AEC3E5D80A9CE84AFD87A9C16C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_47947645EBAF5BA368994AFD87A9CB15" xlink:to="loc_us-gaap_PreferredStockSharesIssued_445473AEC3E5D80A9CE84AFD87A9C16C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_E0B9F9ACB71325C4A9524AFD87A9DC4E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_47947645EBAF5BA368994AFD87A9CB15" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_E0B9F9ACB71325C4A9524AFD87A9DC4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4C203616CB1F8C6B2BA24AFD87AA0329" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_47947645EBAF5BA368994AFD87A9CB15" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4C203616CB1F8C6B2BA24AFD87AA0329" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4D5F6671C099F82A84E94AFD87AA93B5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_47947645EBAF5BA368994AFD87A9CB15" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_4D5F6671C099F82A84E94AFD87AA93B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_3BC28C6E72004E449D8A4AFD87AAA191" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_47947645EBAF5BA368994AFD87A9CB15" xlink:to="loc_us-gaap_CommonStockSharesIssued_3BC28C6E72004E449D8A4AFD87AAA191" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ACFFBBD10E1A526332C54AFD87AA9B8F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_47947645EBAF5BA368994AFD87A9CB15" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ACFFBBD10E1A526332C54AFD87AA9B8F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6679D68054E11151A2B7B18BDA919557" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D317E1C869256790D1ACB18BDA91E9FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6679D68054E11151A2B7B18BDA919557" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D317E1C869256790D1ACB18BDA91E9FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1AAB14F900E12EA90688B18BDA9157DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D317E1C869256790D1ACB18BDA91E9FE" xlink:to="loc_us-gaap_ProfitLoss_1AAB14F900E12EA90688B18BDA9157DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C087155E60C4A4F94EADB18BDA91AD6A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D317E1C869256790D1ACB18BDA91E9FE" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C087155E60C4A4F94EADB18BDA91AD6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_335F3165B19CE4F74A3AB18BDA918747" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C087155E60C4A4F94EADB18BDA91AD6A" xlink:to="loc_us-gaap_Depreciation_335F3165B19CE4F74A3AB18BDA918747" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_CBB2E103E47833399D44B18BDA910971" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C087155E60C4A4F94EADB18BDA91AD6A" xlink:to="loc_us-gaap_ShareBasedCompensation_CBB2E103E47833399D44B18BDA910971" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_NonCashLeaseExpense" xlink:label="loc_dare_NonCashLeaseExpense_2FC6C5912A9BD23335E4B18BDA91A93A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C087155E60C4A4F94EADB18BDA91AD6A" xlink:to="loc_dare_NonCashLeaseExpense_2FC6C5912A9BD23335E4B18BDA91A93A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_67738A0E144BA5622195B18BDA9188B5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C087155E60C4A4F94EADB18BDA91AD6A" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_67738A0E144BA5622195B18BDA9188B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7083B0ED7E6C0C375EB3B18BDA918564" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C087155E60C4A4F94EADB18BDA91AD6A" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7083B0ED7E6C0C375EB3B18BDA918564" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_48C3A7492B921BCCCA78B18BDAA1490B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7083B0ED7E6C0C375EB3B18BDA918564" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_48C3A7492B921BCCCA78B18BDAA1490B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_4CAEF4A93DE580FE3F07B18BDAA15F08" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7083B0ED7E6C0C375EB3B18BDA918564" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_4CAEF4A93DE580FE3F07B18BDAA15F08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_F70DAC87110DB401A12DB18BDAA19B32" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7083B0ED7E6C0C375EB3B18BDA918564" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_F70DAC87110DB401A12DB18BDAA19B32" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges" xlink:label="loc_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_33EADA3C1CA2E40BF73EB18BDAA1ACB7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7083B0ED7E6C0C375EB3B18BDA918564" xlink:to="loc_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges_33EADA3C1CA2E40BF73EB18BDAA1ACB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_794AA4F2C9C55F0857F1B18BDAA17509" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7083B0ED7E6C0C375EB3B18BDA918564" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_794AA4F2C9C55F0857F1B18BDAA17509" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_07700AF16ACE440BD5ECB18BDAA18682" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7083B0ED7E6C0C375EB3B18BDA918564" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_07700AF16ACE440BD5ECB18BDAA18682" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0099BD8F996BE4BB30A7B18BDAA1B3D5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7083B0ED7E6C0C375EB3B18BDA918564" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0099BD8F996BE4BB30A7B18BDAA1B3D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_BB43D64CDADC7FC9C139B18BDAA1C220" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D317E1C869256790D1ACB18BDA91E9FE" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_BB43D64CDADC7FC9C139B18BDAA1C220" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_62384E8A2B83F98CA01EB18BDAA107DA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6679D68054E11151A2B7B18BDA919557" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_62384E8A2B83F98CA01EB18BDAA107DA" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_NetProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="loc_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_BE061AA701D4AF3EB78AB18BDAA1DE07" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_62384E8A2B83F98CA01EB18BDAA107DA" xlink:to="loc_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants_BE061AA701D4AF3EB78AB18BDAA1DE07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_A25A64428EC8E2745F92B18BDAA196FA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_62384E8A2B83F98CA01EB18BDAA107DA" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_A25A64428EC8E2745F92B18BDAA196FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_B278DE1E015E77BC879DB18BDAA147AD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6679D68054E11151A2B7B18BDA919557" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_B278DE1E015E77BC879DB18BDAA147AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0C1CF19A3F309EF9A2F2B18BDAA17F0F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6679D68054E11151A2B7B18BDA919557" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0C1CF19A3F309EF9A2F2B18BDAA17F0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_16D36CE99793425C795DB18BDAA1DAC1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6679D68054E11151A2B7B18BDA919557" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_16D36CE99793425C795DB18BDAA1DAC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4A4C0AE7361A6D5905C7B18BDAA1EEE1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6679D68054E11151A2B7B18BDA919557" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4A4C0AE7361A6D5905C7B18BDAA1EEE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_7102BCEF3C77AD1F94D7B18BDAA16B19" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6679D68054E11151A2B7B18BDA919557" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_7102BCEF3C77AD1F94D7B18BDAA16B19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7F4E3DE34F6FA67EDAADB18BDAA1E4B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7102BCEF3C77AD1F94D7B18BDAA16B19" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7F4E3DE34F6FA67EDAADB18BDAA1E4B7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_9B95EB975FB076A9931D98953F31ED26" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_3E2032EDAA9D158D248598953F312E1D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9B95EB975FB076A9931D98953F31ED26" xlink:to="loc_us-gaap_OperatingExpensesAbstract_3E2032EDAA9D158D248598953F312E1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1171F5538C0EA6545C4798953F314823" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3E2032EDAA9D158D248598953F312E1D" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1171F5538C0EA6545C4798953F314823" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_62835F46B665ABD7E86098953F3294FA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3E2032EDAA9D158D248598953F312E1D" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_62835F46B665ABD7E86098953F3294FA" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_LicenseFee" xlink:label="loc_dare_LicenseFee_23CCFE06152080F3309698953F32C16B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3E2032EDAA9D158D248598953F312E1D" xlink:to="loc_dare_LicenseFee_23CCFE06152080F3309698953F32C16B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_E13152499468E59FF9B698953F3267F5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3E2032EDAA9D158D248598953F312E1D" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_E13152499468E59FF9B698953F3267F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_4C0BD30350432AB1AFAC98953F32B9D6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3E2032EDAA9D158D248598953F312E1D" xlink:to="loc_us-gaap_OperatingExpenses_4C0BD30350432AB1AFAC98953F32B9D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_E0E7F18781E37DEBB68498953F32985A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9B95EB975FB076A9931D98953F31ED26" xlink:to="loc_us-gaap_OperatingIncomeLoss_E0E7F18781E37DEBB68498953F32985A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7DD19B35DC5BE04302F798953F33997A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9B95EB975FB076A9931D98953F31ED26" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7DD19B35DC5BE04302F798953F33997A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_6C59008EF4D3EF03BB1198953F3388FF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9B95EB975FB076A9931D98953F31ED26" xlink:to="loc_us-gaap_NetIncomeLoss_6C59008EF4D3EF03BB1198953F3388FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_E3F85B784686DE6A24A598953F33926F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9B95EB975FB076A9931D98953F31ED26" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_E3F85B784686DE6A24A598953F33926F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_56566AB84F7C1EF7E9FF98953F332116" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9B95EB975FB076A9931D98953F31ED26" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_56566AB84F7C1EF7E9FF98953F332116" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_46D95E701B8A457EB3CD98953F332419" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9B95EB975FB076A9931D98953F31ED26" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_46D95E701B8A457EB3CD98953F332419" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_D3B9167ECF2C28DA403E98953F3307C4" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9B95EB975FB076A9931D98953F31ED26" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_D3B9167ECF2C28DA403E98953F3307C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_6765405C1D1C312512F498953F3463BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_D3B9167ECF2C28DA403E98953F3307C4" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_6765405C1D1C312512F498953F3463BF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7A4924DC0BD237E80F0C9A56025F80CF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_0D8407D9AF6A49CC828C9A56025FDE1D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7A4924DC0BD237E80F0C9A56025F80CF" xlink:to="loc_us-gaap_StatementTable_0D8407D9AF6A49CC828C9A56025FDE1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_C9B92ABFCFCA94D0DC759A56025FC687" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0D8407D9AF6A49CC828C9A56025FDE1D" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_C9B92ABFCFCA94D0DC759A56025FC687" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_0A1E880EE9B0B38CC5939A56025F55CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_C9B92ABFCFCA94D0DC759A56025FC687" xlink:to="loc_us-gaap_EquityComponentDomain_0A1E880EE9B0B38CC5939A56025F55CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_5655E775302341B229589A56025FC4E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0A1E880EE9B0B38CC5939A56025F55CD" xlink:to="loc_us-gaap_CommonStockMember_5655E775302341B229589A56025FC4E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_A4269AD8803217CE0CD09A56025FAA1E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0A1E880EE9B0B38CC5939A56025F55CD" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_A4269AD8803217CE0CD09A56025FAA1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3C1E4AFF00DDAC8931BE9A56025F39ED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0A1E880EE9B0B38CC5939A56025F55CD" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3C1E4AFF00DDAC8931BE9A56025F39ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_ED1DB1061AF786E377429A56025FC1F2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0A1E880EE9B0B38CC5939A56025F55CD" xlink:to="loc_us-gaap_RetainedEarningsMember_ED1DB1061AF786E377429A56025FC1F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_9A2DA989A8F8700921189A56025F903C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0D8407D9AF6A49CC828C9A56025FDE1D" xlink:to="loc_us-gaap_StatementLineItems_9A2DA989A8F8700921189A56025F903C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9A2DA989A8F8700921189A56025F903C" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_B4A669E84ED4CD87D93C9A56025FB2C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25" xlink:to="loc_us-gaap_SharesOutstanding_B4A669E84ED4CD87D93C9A56025FB2C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_7F685565E0403878AC429A56025F0EF6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25" xlink:to="loc_us-gaap_StockholdersEquity_7F685565E0403878AC429A56025F0EF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5A6FAB27765356E493E89A56025F1DDB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5A6FAB27765356E493E89A56025F1DDB" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares" xlink:label="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_A57FC78530EFE2FD37759A5A97200D70" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25" xlink:to="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares_A57FC78530EFE2FD37759A5A97200D70" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued" xlink:label="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued_2F693C9DFD1A02DFA3339A5A0441C9EC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25" xlink:to="loc_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued_2F693C9DFD1A02DFA3339A5A0441C9EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2F6D6B4B0041ECC832599A5BCDACC151" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2F6D6B4B0041ECC832599A5BCDACC151" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_F9F3FF8C2B45048CCB999A5B3F34E3D9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_F9F3FF8C2B45048CCB999A5B3F34E3D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_09D5EBDF1E1FFB0810DE9A56025F8EA4" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25" xlink:to="loc_us-gaap_NetIncomeLoss_09D5EBDF1E1FFB0810DE9A56025F8EA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_17A93AB3F7B86CAE5C9E9A56025FC352" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_17A93AB3F7B86CAE5C9E9A56025FC352" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_D617E4A4CAE2BF62AC519A56025F8245" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25" xlink:to="loc_us-gaap_SharesOutstanding_D617E4A4CAE2BF62AC519A56025F8245" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6A4D455ED71837E37A899A56025FDE22" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80636016A33DCF6BF88A9A56025FAA25" xlink:to="loc_us-gaap_StockholdersEquity_6A4D455ED71837E37A899A56025FDE22" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="dare-20190331.xsd#dare_DocumentAndEntityInformationAbstract" xlink:label="loc_dare_DocumentAndEntityInformationAbstract_08DBFF8ED9675105A70B476DBD17D689" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_07305CB1EC745D48ADDDEB7EEAA5D182" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_08DBFF8ED9675105A70B476DBD17D689" xlink:to="loc_dei_DocumentType_07305CB1EC745D48ADDDEB7EEAA5D182" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_280A3A115DAB58579CBBA2B59E09495A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_08DBFF8ED9675105A70B476DBD17D689" xlink:to="loc_dei_AmendmentFlag_280A3A115DAB58579CBBA2B59E09495A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_E4865217EE045911A68CF25D5BA6E7AB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_08DBFF8ED9675105A70B476DBD17D689" xlink:to="loc_dei_DocumentPeriodEndDate_E4865217EE045911A68CF25D5BA6E7AB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_991B8F8AC33B53619ECF0784A4608DA1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_08DBFF8ED9675105A70B476DBD17D689" xlink:to="loc_dei_DocumentFiscalYearFocus_991B8F8AC33B53619ECF0784A4608DA1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9611D900CD9D514BBF4F557566D7FE1C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_08DBFF8ED9675105A70B476DBD17D689" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9611D900CD9D514BBF4F557566D7FE1C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_1EAC5AFA2A0153569396C7250CAC5142" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_08DBFF8ED9675105A70B476DBD17D689" xlink:to="loc_dei_TradingSymbol_1EAC5AFA2A0153569396C7250CAC5142" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_56E1AC418AB65A0E955D80683C4B79C1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_08DBFF8ED9675105A70B476DBD17D689" xlink:to="loc_dei_EntityRegistrantName_56E1AC418AB65A0E955D80683C4B79C1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_6F706D3E4FD05AF89A678276963FA5AD" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_08DBFF8ED9675105A70B476DBD17D689" xlink:to="loc_dei_EntityCentralIndexKey_6F706D3E4FD05AF89A678276963FA5AD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_01424642A01355F19E1BCCCA27EBCE69" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_08DBFF8ED9675105A70B476DBD17D689" xlink:to="loc_dei_CurrentFiscalYearEndDate_01424642A01355F19E1BCCCA27EBCE69" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_E70351BD91285C8D8D6C5E07405D00E0" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_08DBFF8ED9675105A70B476DBD17D689" xlink:to="loc_dei_EntityFilerCategory_E70351BD91285C8D8D6C5E07405D00E0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_EB234353E7F153D6AAFCE94FAACF89B4" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_08DBFF8ED9675105A70B476DBD17D689" xlink:to="loc_dei_EntitySmallBusiness_EB234353E7F153D6AAFCE94FAACF89B4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_E57237172DAF5B3092693081B0FFCD84" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_08DBFF8ED9675105A70B476DBD17D689" xlink:to="loc_dei_EntityEmergingGrowthCompany_E57237172DAF5B3092693081B0FFCD84" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_C84F85B0C1DF5DBD80CCD3B8BE902118" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_08DBFF8ED9675105A70B476DBD17D689" xlink:to="loc_dei_EntityExTransitionPeriod_C84F85B0C1DF5DBD80CCD3B8BE902118" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_2BFCE551E548530B91645A4CFA08E7D6" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_DocumentAndEntityInformationAbstract_08DBFF8ED9675105A70B476DBD17D689" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_2BFCE551E548530B91645A4CFA08E7D6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/GoingConcern" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EC1AE1EC025EA317C59A5B0CFD7D3670" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_4FB4D6512B5C76E839AE5B0CFD7D0553" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EC1AE1EC025EA317C59A5B0CFD7D3670" xlink:to="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_4FB4D6512B5C76E839AE5B0CFD7D0553" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/GoingConcernAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BEB3F88D40C7F3B807499A56024F3A99" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_C65FCFC94C7020C17E409A661003757E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BEB3F88D40C7F3B807499A56024F3A99" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_C65FCFC94C7020C17E409A661003757E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1D0B60342F347D546F3C9A84699279BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_C65FCFC94C7020C17E409A661003757E" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1D0B60342F347D546F3C9A84699279BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0970354C206E9163AC609A8469964378" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1D0B60342F347D546F3C9A84699279BB" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0970354C206E9163AC609A8469964378" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_5D743DF17E387FF9F7049A849F42EB6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0970354C206E9163AC609A8469964378" xlink:to="loc_us-gaap_SubsequentEventMember_5D743DF17E387FF9F7049A849F42EB6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_6A7A9765388363B2681C9A661723B3F9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_C65FCFC94C7020C17E409A661003757E" xlink:to="loc_srt_ProductOrServiceAxis_6A7A9765388363B2681C9A661723B3F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_5451778105F9C033F0509A66172B02B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6A7A9765388363B2681C9A661723B3F9" xlink:to="loc_srt_ProductsAndServicesDomain_5451778105F9C033F0509A66172B02B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_08ABC9667536FF65301A9A661D8A1F59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5451778105F9C033F0509A66172B02B6" xlink:to="loc_us-gaap_GrantMember_08ABC9667536FF65301A9A661D8A1F59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_701EF41A3A73139ED7D89A6615ECC4C7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_C65FCFC94C7020C17E409A661003757E" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_701EF41A3A73139ED7D89A6615ECC4C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_72D8568E08EF024BCD5F9A6615F0D669" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_701EF41A3A73139ED7D89A6615ECC4C7" xlink:to="loc_us-gaap_RelatedPartyDomain_72D8568E08EF024BCD5F9A6615F0D669" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_NationalInstitutesOfHealthMember" xlink:label="loc_dare_NationalInstitutesOfHealthMember_2A3CE531656E9E3BF9449A66190FDBF1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_72D8568E08EF024BCD5F9A6615F0D669" xlink:to="loc_dare_NationalInstitutesOfHealthMember_2A3CE531656E9E3BF9449A66190FDBF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareTrustFundAxis" xlink:label="loc_us-gaap_HealthCareTrustFundAxis_0621D943414831A142E39A6615507190" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_C65FCFC94C7020C17E409A661003757E" xlink:to="loc_us-gaap_HealthCareTrustFundAxis_0621D943414831A142E39A6615507190" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareTrustFundNameDomain" xlink:label="loc_us-gaap_HealthCareTrustFundNameDomain_4A026E9C487D6AA2E51C9A661550A251" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareTrustFundAxis_0621D943414831A142E39A6615507190" xlink:to="loc_us-gaap_HealthCareTrustFundNameDomain_4A026E9C487D6AA2E51C9A661550A251" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember" xlink:label="loc_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_D6372A6B44BC874CA8699A661A89793F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareTrustFundNameDomain_4A026E9C487D6AA2E51C9A661550A251" xlink:to="loc_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_D6372A6B44BC874CA8699A661A89793F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B5D20EE39CE78FA0D84F9A6614AC84FE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_C65FCFC94C7020C17E409A661003757E" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B5D20EE39CE78FA0D84F9A6614AC84FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0525603D6DAB9EBAB3859A6614B4D8C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_B5D20EE39CE78FA0D84F9A6614AC84FE" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0525603D6DAB9EBAB3859A6614B4D8C5" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember" xlink:label="loc_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_A2B9627521A2233D65669A6617D1AFBC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0525603D6DAB9EBAB3859A6614B4D8C5" xlink:to="loc_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_A2B9627521A2233D65669A6617D1AFBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_C6A9DC7E6F70E08E59849A66100563DE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_C65FCFC94C7020C17E409A661003757E" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_C6A9DC7E6F70E08E59849A66100563DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1F34DFD916C3E99152E79A56024F6D47" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C6A9DC7E6F70E08E59849A66100563DE" xlink:to="loc_us-gaap_NetIncomeLoss_1F34DFD916C3E99152E79A56024F6D47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_108E27EC00EFB037FDAD9A56024F194D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C6A9DC7E6F70E08E59849A66100563DE" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_108E27EC00EFB037FDAD9A56024F194D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C843732967C5D5C961E79A56024F68CD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C6A9DC7E6F70E08E59849A66100563DE" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C843732967C5D5C961E79A56024F68CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5634AEF9A0FD6D808D4B9A56024FB6C2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C6A9DC7E6F70E08E59849A66100563DE" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5634AEF9A0FD6D808D4B9A56024FB6C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_758204A0F638657C87D49A66138723AC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C6A9DC7E6F70E08E59849A66100563DE" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_758204A0F638657C87D49A66138723AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="loc_us-gaap_GrantsReceivable_F41D57809178DD9499289A6614465A5F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C6A9DC7E6F70E08E59849A66100563DE" xlink:to="loc_us-gaap_GrantsReceivable_F41D57809178DD9499289A6614465A5F" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_ReimbursementOfGrantExpensesReceivable" xlink:label="loc_dare_ReimbursementOfGrantExpensesReceivable_86E85800438703E017EF9A696B36EA73" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C6A9DC7E6F70E08E59849A66100563DE" xlink:to="loc_dare_ReimbursementOfGrantExpensesReceivable_86E85800438703E017EF9A696B36EA73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3FDA002F9E23F13D25AB9A56024F7FAB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C6A9DC7E6F70E08E59849A66100563DE" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3FDA002F9E23F13D25AB9A56024F7FAB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/GrantAward" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaap_ReceivablesAbstract_F3ADC89DCC63EEF2AC485B0CFBCC2937" xlink:type="locator" />
    <link:loc xlink:href="dare-20190331.xsd#dare_GrantAwardTextBlock" xlink:label="loc_dare_GrantAwardTextBlock_60E5F4A97C48CE4E8EFC5B0CFBCCFC45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_F3ADC89DCC63EEF2AC485B0CFBCC2937" xlink:to="loc_dare_GrantAwardTextBlock_60E5F4A97C48CE4E8EFC5B0CFBCCFC45" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/GrantAwardAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaap_ReceivablesAbstract_08C4442328E5C9312FF34B44EE18ADE7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_DBA46B363FAED29C336A4B4561485874" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_08C4442328E5C9312FF34B44EE18ADE7" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_DBA46B363FAED29C336A4B4561485874" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_23E9D3403EE0E44381D34B44EE205A3E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_DBA46B363FAED29C336A4B4561485874" xlink:to="loc_srt_ProductOrServiceAxis_23E9D3403EE0E44381D34B44EE205A3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_3D00AD7B1B42CD93BD694AFD86AB108F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_23E9D3403EE0E44381D34B44EE205A3E" xlink:to="loc_srt_ProductsAndServicesDomain_3D00AD7B1B42CD93BD694AFD86AB108F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_5288ADBCBB79C797AFE54AFD86AB27D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3D00AD7B1B42CD93BD694AFD86AB108F" xlink:to="loc_us-gaap_GrantMember_5288ADBCBB79C797AFE54AFD86AB27D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareTrustFundAxis" xlink:label="loc_us-gaap_HealthCareTrustFundAxis_70847F1A29F1EA462DFF4B44EE1F1692" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_DBA46B363FAED29C336A4B4561485874" xlink:to="loc_us-gaap_HealthCareTrustFundAxis_70847F1A29F1EA462DFF4B44EE1F1692" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HealthCareTrustFundNameDomain" xlink:label="loc_us-gaap_HealthCareTrustFundNameDomain_97CCA2C445E6505A076B4AFD86AAA61F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareTrustFundAxis_70847F1A29F1EA462DFF4B44EE1F1692" xlink:to="loc_us-gaap_HealthCareTrustFundNameDomain_97CCA2C445E6505A076B4AFD86AAA61F" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember" xlink:label="loc_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_351A433D9E50199380194B426FD37627" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareTrustFundNameDomain_97CCA2C445E6505A076B4AFD86AAA61F" xlink:to="loc_dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember_351A433D9E50199380194B426FD37627" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5C779FA6DDDEA1F81ECC4B44EE1EF86A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_DBA46B363FAED29C336A4B4561485874" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5C779FA6DDDEA1F81ECC4B44EE1EF86A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9D13C508777DE43B11994AFD86AAA62E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5C779FA6DDDEA1F81ECC4B44EE1EF86A" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9D13C508777DE43B11994AFD86AAA62E" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember" xlink:label="loc_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_1D0C11650F066CE3E1A84B4271339683" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9D13C508777DE43B11994AFD86AAA62E" xlink:to="loc_dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember_1D0C11650F066CE3E1A84B4271339683" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember" xlink:label="loc_dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember_5F68CA79C01D1A29D7034B4271EC177A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9D13C508777DE43B11994AFD86AAA62E" xlink:to="loc_dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember_5F68CA79C01D1A29D7034B4271EC177A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1B6FBF7545ABAE4480B94B44EE1D472A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_DBA46B363FAED29C336A4B4561485874" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1B6FBF7545ABAE4480B94B44EE1D472A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_0A29BF089F0F05A4009D4AFD86A91A6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1B6FBF7545ABAE4480B94B44EE1D472A" xlink:to="loc_us-gaap_RelatedPartyDomain_0A29BF089F0F05A4009D4AFD86A91A6E" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_NationalInstitutesOfHealthMember" xlink:label="loc_dare_NationalInstitutesOfHealthMember_C8092FB0F7B7B382122D4B4270CD8E95" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_0A29BF089F0F05A4009D4AFD86A91A6E" xlink:to="loc_dare_NationalInstitutesOfHealthMember_C8092FB0F7B7B382122D4B4270CD8E95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4550E0A5A1BED752DA3D4B45614FBAFE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_DBA46B363FAED29C336A4B4561485874" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4550E0A5A1BED752DA3D4B45614FBAFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EAA3DBB7DCB745D015344B44EE21580A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4550E0A5A1BED752DA3D4B45614FBAFE" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EAA3DBB7DCB745D015344B44EE21580A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="loc_us-gaap_GrantsReceivable_A700E7260F051B02470F4B44EE211D07" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4550E0A5A1BED752DA3D4B45614FBAFE" xlink:to="loc_us-gaap_GrantsReceivable_A700E7260F051B02470F4B44EE211D07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_BAB8B5647671C3BAB84D4B44EE21F949" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4550E0A5A1BED752DA3D4B45614FBAFE" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_BAB8B5647671C3BAB84D4B44EE21F949" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_ReimbursementOfGrantExpensesReceivable" xlink:label="loc_dare_ReimbursementOfGrantExpensesReceivable_47DA93AB45B5EFA55C6A4B44EE216660" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4550E0A5A1BED752DA3D4B45614FBAFE" xlink:to="loc_dare_ReimbursementOfGrantExpensesReceivable_47DA93AB45B5EFA55C6A4B44EE216660" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/LeasedProperties" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_DB7FB49972D33242032D5B0CFCC91C8A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_F6AA5EB73D169996FD475B0CFCCA9A86" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_DB7FB49972D33242032D5B0CFCC91C8A" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_F6AA5EB73D169996FD475B0CFCCA9A86" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_9D6F261031A6C89368DA9A5600819461" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetRentableArea" xlink:label="loc_us-gaap_NetRentableArea_6B5CB2931E6369BCC9EC9A5600814A87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9D6F261031A6C89368DA9A5600819461" xlink:to="loc_us-gaap_NetRentableArea_6B5CB2931E6369BCC9EC9A5600814A87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9C76FD35CFA1573E12829A5600811DAE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9D6F261031A6C89368DA9A5600819461" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9C76FD35CFA1573E12829A5600811DAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_09289270C44F42B3986E9A56008183A0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9D6F261031A6C89368DA9A5600819461" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_09289270C44F42B3986E9A56008183A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_E2C07D8136918033A7EA9A560081C4AB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9D6F261031A6C89368DA9A5600819461" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_E2C07D8136918033A7EA9A560081C4AB" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_PercentageOfIncreaseInAnnualBaseRent" xlink:label="loc_dare_PercentageOfIncreaseInAnnualBaseRent_1D6C6620D15B2CCB26A09A56008108DD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9D6F261031A6C89368DA9A5600819461" xlink:to="loc_dare_PercentageOfIncreaseInAnnualBaseRent_1D6C6620D15B2CCB26A09A56008108DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_BE13FF9F56D61460AA199A5600815355" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9D6F261031A6C89368DA9A5600819461" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_BE13FF9F56D61460AA199A5600815355" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_30F7E801439B894CE4E99A560081B7EF" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9D6F261031A6C89368DA9A5600819461" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_30F7E801439B894CE4E99A560081B7EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_A10CF1591D363F9CFE689A56008173C9" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9D6F261031A6C89368DA9A5600819461" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_A10CF1591D363F9CFE689A56008173C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_3288700E132D697C454A9A5600813EB0" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9D6F261031A6C89368DA9A5600819461" xlink:to="loc_us-gaap_OperatingLeaseCost_3288700E132D697C454A9A5600813EB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_2214E395661607D006449A56008183DB" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9D6F261031A6C89368DA9A5600819461" xlink:to="loc_us-gaap_OperatingLeasePayments_2214E395661607D006449A56008183DB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_55FB50A9CEAF28AF60C8A2CAE899C09B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1E9A5BEA833D05630757A2CBCDE0C7A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_55FB50A9CEAF28AF60C8A2CAE899C09B" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1E9A5BEA833D05630757A2CBCDE0C7A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_98FD05DB67D25A812E16A2CAE89DDC2E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_55FB50A9CEAF28AF60C8A2CAE899C09B" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_98FD05DB67D25A812E16A2CAE89DDC2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_D077CEB697C13FF63BABA2CAE89EECA1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_55FB50A9CEAF28AF60C8A2CAE899C09B" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_D077CEB697C13FF63BABA2CAE89EECA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_09EBD0CC9160696B4F95A2CAE89ED71C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_55FB50A9CEAF28AF60C8A2CAE899C09B" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_09EBD0CC9160696B4F95A2CAE89ED71C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1ED25BCFE2168B004790A2CAE89EBBFB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_55FB50A9CEAF28AF60C8A2CAE899C09B" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1ED25BCFE2168B004790A2CAE89EBBFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_CA9AC81015DDC2FC3169A2CAE89E149B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_55FB50A9CEAF28AF60C8A2CAE899C09B" xlink:to="loc_us-gaap_OperatingLeaseLiability_CA9AC81015DDC2FC3169A2CAE89E149B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/LeasedPropertiesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_A8BAF487FA566CDE2B57558B20859328" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4FA3ED0D4EA58762368555940C2DFC09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_A8BAF487FA566CDE2B57558B20859328" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4FA3ED0D4EA58762368555940C2DFC09" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0E011D3F507DB1F30D305B0CFBA3F16F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_0B0438353097CFA219695B0CFBA33C24" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0E011D3F507DB1F30D305B0CFBA3F16F" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_0B0438353097CFA219695B0CFBA33C24" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_C495553BD32D79B05D3C51507F8AEAB7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A5F31AE7E735460E67C551507F8ADD30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_C495553BD32D79B05D3C51507F8AEAB7" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A5F31AE7E735460E67C551507F8ADD30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_654A15EAD8614C64865E51507F8A5EAC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A5F31AE7E735460E67C551507F8ADD30" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_654A15EAD8614C64865E51507F8A5EAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DEC83A89638BA53C6CDD51507F8B632A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_654A15EAD8614C64865E51507F8A5EAC" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DEC83A89638BA53C6CDD51507F8B632A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_01255FC7C91B9183CB1351507F8B65A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DEC83A89638BA53C6CDD51507F8B632A" xlink:to="loc_us-gaap_EmployeeStockOptionMember_01255FC7C91B9183CB1351507F8B65A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_F8FF28106EE0E5A8D6EB51507F8B530F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DEC83A89638BA53C6CDD51507F8B632A" xlink:to="loc_us-gaap_WarrantMember_F8FF28106EE0E5A8D6EB51507F8B530F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B0F328129B771F7D176151507F8BA25B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A5F31AE7E735460E67C551507F8ADD30" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B0F328129B771F7D176151507F8BA25B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_29798CE20C589852D4B951507F8C0398" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B0F328129B771F7D176151507F8BA25B" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_29798CE20C589852D4B951507F8C0398" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_EE1117346B0D5EA3801B34AA4BF1FBF2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0EE9B21F09735D2491486977C42C2A06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_EE1117346B0D5EA3801B34AA4BF1FBF2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0EE9B21F09735D2491486977C42C2A06" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/OrganizationAndDescriptionOfBusiness" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7ABF70D8D0A85B6B9FE9427A5B2F6BD0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0CE9F1B1F68357CD9BDD1C5305FC6BF1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7ABF70D8D0A85B6B9FE9427A5B2F6BD0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0CE9F1B1F68357CD9BDD1C5305FC6BF1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F8CBD3944FD315960B804AFD877E0F86" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_E6F622492E86E2EF34304AFD877F6297" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F8CBD3944FD315960B804AFD877E0F86" xlink:to="loc_us-gaap_NumberOfOperatingSegments_E6F622492E86E2EF34304AFD877F6297" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_18E02A0E3A0390C91AFF5B0CFD3BB012" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_66D586C4FD1C123940795B0CFD3B80D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_18E02A0E3A0390C91AFF5B0CFD3BB012" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_66D586C4FD1C123940795B0CFD3B80D5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F4478DFDFC47D5AD25009A5601BBDB4C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_25A683F3ED379DEBFC3E9A5601BB4B53" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F4478DFDFC47D5AD25009A5601BBDB4C" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_25A683F3ED379DEBFC3E9A5601BB4B53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_48870CCDDB55825428849A5601BB2BB7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_25A683F3ED379DEBFC3E9A5601BB4B53" xlink:to="loc_us-gaap_PlanNameAxis_48870CCDDB55825428849A5601BB2BB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_593BB9E5B2A015DC9AA09A5601BB13C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_48870CCDDB55825428849A5601BB2BB7" xlink:to="loc_us-gaap_PlanNameDomain_593BB9E5B2A015DC9AA09A5601BB13C4" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_TwoThousandAndFifteenStockIncentivePlanMember" xlink:label="loc_dare_TwoThousandAndFifteenStockIncentivePlanMember_35D3C39ECC2840F652749A5601BB6815" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_593BB9E5B2A015DC9AA09A5601BB13C4" xlink:to="loc_dare_TwoThousandAndFifteenStockIncentivePlanMember_35D3C39ECC2840F652749A5601BB6815" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:label="loc_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_459BAB6B343E1E39EC069A5601BB289D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_593BB9E5B2A015DC9AA09A5601BB13C4" xlink:to="loc_dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_459BAB6B343E1E39EC069A5601BB289D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_240E2E434E2C89A4EB4B9A5601BBEDB6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_25A683F3ED379DEBFC3E9A5601BB4B53" xlink:to="loc_us-gaap_AwardTypeAxis_240E2E434E2C89A4EB4B9A5601BBEDB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_139E42EC4CA7A34D0A189A5601BBE29C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_240E2E434E2C89A4EB4B9A5601BBEDB6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_139E42EC4CA7A34D0A189A5601BBE29C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2F6055154DFD13FA3FA19A5601BB3874" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_139E42EC4CA7A34D0A189A5601BBE29C" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2F6055154DFD13FA3FA19A5601BB3874" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_22B1F453F634535B5F6D9A5601BBEA70" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_139E42EC4CA7A34D0A189A5601BBE29C" xlink:to="loc_us-gaap_RestrictedStockMember_22B1F453F634535B5F6D9A5601BBEA70" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4217EA82834CB80D25A39A5601BBC2E6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_25A683F3ED379DEBFC3E9A5601BB4B53" xlink:to="loc_dei_LegalEntityAxis_4217EA82834CB80D25A39A5601BBC2E6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_ACE2091CE3A407297A639A5601BB1019" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4217EA82834CB80D25A39A5601BBC2E6" xlink:to="loc_dei_EntityDomain_ACE2091CE3A407297A639A5601BB1019" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_PrivateDareMember" xlink:label="loc_dare_PrivateDareMember_078104A728AF77BAA2939A5601BB852F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_ACE2091CE3A407297A639A5601BB1019" xlink:to="loc_dare_PrivateDareMember_078104A728AF77BAA2939A5601BB852F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_25A683F3ED379DEBFC3E9A5601BB4B53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_45FD996FCF17AC5EB0A49A5601BB7622" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_45FD996FCF17AC5EB0A49A5601BB7622" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_CF43963E2637D82475139A5601BBFC2A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_CF43963E2637D82475139A5601BBFC2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_22E2D28E31EED35999179A5601BB8ED5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_22E2D28E31EED35999179A5601BB8ED5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_EEE994B2C10CBD6737AD9A5601BB869E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_EEE994B2C10CBD6737AD9A5601BB869E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4BD30893B58BBCD31ABB9A5601BBFE29" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4BD30893B58BBCD31ABB9A5601BBFE29" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_OfferingPeriod" xlink:label="loc_dare_OfferingPeriod_9FB0BCD7BD8A0DAE83B29A5601BBD38A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_dare_OfferingPeriod_9FB0BCD7BD8A0DAE83B29A5601BBD38A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B469C966899CB3DDAE989A5601BB87E8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B469C966899CB3DDAE989A5601BB87E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7D5A95EECA1BBF6522DE9A5601BBB8C5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7D5A95EECA1BBF6522DE9A5601BBB8C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4C79DB18BAFDB9C7E8D89A5601BB0868" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4C79DB18BAFDB9C7E8D89A5601BB0868" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_679E315D7AFC0ECED3319A5601BBD58B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_679E315D7AFC0ECED3319A5601BBD58B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_9DC187901A1D38110D809A6EE7F997B6" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_9DC187901A1D38110D809A6EE7F997B6" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_PeriodOfTerminationOfStockOptionsVestedAfterTerminationDate" xlink:label="loc_dare_PeriodOfTerminationOfStockOptionsVestedAfterTerminationDate_1CE2001FEDDDC23D0DD59A5601CB739D" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_dare_PeriodOfTerminationOfStockOptionsVestedAfterTerminationDate_1CE2001FEDDDC23D0DD59A5601CB739D" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_UnamortizedFairValueExpenseInStockPurchaseTransaction" xlink:label="loc_dare_UnamortizedFairValueExpenseInStockPurchaseTransaction_DC867681B9F98682B0949A5601CB6549" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_dare_UnamortizedFairValueExpenseInStockPurchaseTransaction_DC867681B9F98682B0949A5601CB6549" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2BB48A3A6E3037F185429A5601CB6EC7" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2BB48A3A6E3037F185429A5601CB6EC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_A428667660A593200A5E9A5601CB637F" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_A428667660A593200A5E9A5601CB637F" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_WeightedAverageAmortizationPeriod" xlink:label="loc_dare_WeightedAverageAmortizationPeriod_6259CC02B14BEC3204FE9A5601CB8829" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_dare_WeightedAverageAmortizationPeriod_6259CC02B14BEC3204FE9A5601CB8829" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_2CF1273DBD2CFE613F799A5601CB5726" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2E110B6DDE167FB722A29A5601BB9806" xlink:to="loc_us-gaap_CommonStockSharesIssued_2CF1273DBD2CFE613F799A5601CB5726" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedToEmployeesAndDirectorsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BA9C81597991DD2F92ED51507FDB67E5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_863B1DB00957354336AF51507FDC3C5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BA9C81597991DD2F92ED51507FDB67E5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_863B1DB00957354336AF51507FDC3C5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_A315F35486D3CC7A787D51507FDCAFF8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BA9C81597991DD2F92ED51507FDB67E5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_A315F35486D3CC7A787D51507FDCAFF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_FCE4F1390870D2BD510B51507FDCDA55" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BA9C81597991DD2F92ED51507FDB67E5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_FCE4F1390870D2BD510B51507FDCDA55" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:label="loc_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_FB72D966C540A0AC1FA951507FDC9B8C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BA9C81597991DD2F92ED51507FDB67E5" xlink:to="loc_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_FB72D966C540A0AC1FA951507FDC9B8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E97C4932FE6B27D49D8651507FDDC2E3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BA9C81597991DD2F92ED51507FDB67E5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E97C4932FE6B27D49D8651507FDDC2E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C0A9423F6C891813EEE251507FDD0D94" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BA9C81597991DD2F92ED51507FDB67E5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C0A9423F6C891813EEE251507FDD0D94" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToStockOptionsGrantedToEmployeesAndDirectorsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_23403BA85CD99550464551507FE0FC28" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8DDEB45E6CB8974EEF1751507FE06CFD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_23403BA85CD99550464551507FE0FC28" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8DDEB45E6CB8974EEF1751507FE06CFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_B7FF42C1898AA5F554D751507FE0B421" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8DDEB45E6CB8974EEF1751507FE06CFD" xlink:to="loc_us-gaap_AwardTypeAxis_B7FF42C1898AA5F554D751507FE0B421" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_987C1ED52C47C5238FD051507FE1688B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_B7FF42C1898AA5F554D751507FE0B421" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_987C1ED52C47C5238FD051507FE1688B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_EADFC24BC492ECCAA43A51507FE15C87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_987C1ED52C47C5238FD051507FE1688B" xlink:to="loc_us-gaap_EmployeeStockOptionMember_EADFC24BC492ECCAA43A51507FE15C87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_660C9161C9051B9E94E551507FE19B01" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8DDEB45E6CB8974EEF1751507FE06CFD" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_660C9161C9051B9E94E551507FE19B01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F84B87542D228B3C61CF51507FE1D584" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_660C9161C9051B9E94E551507FE19B01" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F84B87542D228B3C61CF51507FE1D584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_D015CAA557C9FBEB6C0851507FE2BE04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F84B87542D228B3C61CF51507FE1D584" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_D015CAA557C9FBEB6C0851507FE2BE04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_50AAB4692214FEBAAEF651507FE2D66B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F84B87542D228B3C61CF51507FE1D584" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_50AAB4692214FEBAAEF651507FE2D66B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_91E51F8F1EA945AC22EF51507FE271E7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8DDEB45E6CB8974EEF1751507FE06CFD" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_91E51F8F1EA945AC22EF51507FE271E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5E79B67084FA56C06A0651507FE2C39D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_91E51F8F1EA945AC22EF51507FE271E7" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5E79B67084FA56C06A0651507FE2C39D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationSummaryOfStockOptionActivityForAmended2014PlanAndRelatedInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D6DCB906B53BBE37001D9A56016DA0C4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1351860212A78057BB199A56016DE44F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D6DCB906B53BBE37001D9A56016DA0C4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1351860212A78057BB199A56016DE44F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4AE7E7134C1EEBB0FF419A56016D94C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1351860212A78057BB199A56016DE44F" xlink:to="loc_dei_LegalEntityAxis_4AE7E7134C1EEBB0FF419A56016D94C3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_5559E8D22A53372A34069A56017DE2F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4AE7E7134C1EEBB0FF419A56016D94C3" xlink:to="loc_dei_EntityDomain_5559E8D22A53372A34069A56017DE2F1" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_PrivateDareMember" xlink:label="loc_dare_PrivateDareMember_FF5AE179D8D86A2385089A56017D2FDC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_5559E8D22A53372A34069A56017DE2F1" xlink:to="loc_dare_PrivateDareMember_FF5AE179D8D86A2385089A56017D2FDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_5E2B0D8020E9EAD2EE7E9A56017D7ED2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1351860212A78057BB199A56016DE44F" xlink:to="loc_us-gaap_PlanNameAxis_5E2B0D8020E9EAD2EE7E9A56017D7ED2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_A63D6CF1F1EC078D76CF9A56017DA75E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_5E2B0D8020E9EAD2EE7E9A56017D7ED2" xlink:to="loc_us-gaap_PlanNameDomain_A63D6CF1F1EC078D76CF9A56017DA75E" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_TwoThousandAndFifteenStockIncentivePlanMember" xlink:label="loc_dare_TwoThousandAndFifteenStockIncentivePlanMember_C900E1E039880E0362609A56017D0554" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_A63D6CF1F1EC078D76CF9A56017DA75E" xlink:to="loc_dare_TwoThousandAndFifteenStockIncentivePlanMember_C900E1E039880E0362609A56017D0554" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_19C1D5EF62C1AC2991169A56017D4137" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1351860212A78057BB199A56016DE44F" xlink:to="loc_us-gaap_AwardTypeAxis_19C1D5EF62C1AC2991169A56017D4137" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6AF109E71D367B80E76B9A56017DC2E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_19C1D5EF62C1AC2991169A56017D4137" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6AF109E71D367B80E76B9A56017DC2E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_D5577CB6D44DA99CD3919A56017DCD7E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6AF109E71D367B80E76B9A56017DC2E0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_D5577CB6D44DA99CD3919A56017DCD7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5967506064B4192D93969A56017D7955" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1351860212A78057BB199A56016DE44F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5967506064B4192D93969A56017D7955" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_84ECE9C2DC980E9E9B529A56017DAAA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5967506064B4192D93969A56017D7955" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_84ECE9C2DC980E9E9B529A56017DAAA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9D1A3E1EA36553F6D1319A56017DE49A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_84ECE9C2DC980E9E9B529A56017DAAA7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9D1A3E1EA36553F6D1319A56017DE49A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0B6C403778928637A9589A56017DC04F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_84ECE9C2DC980E9E9B529A56017DAAA7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0B6C403778928637A9589A56017DC04F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2EC51878368BB058EFAB9A56017D988D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_84ECE9C2DC980E9E9B529A56017DAAA7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2EC51878368BB058EFAB9A56017D988D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1305F445BA73213A01B69A56017DEB5A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_84ECE9C2DC980E9E9B529A56017DAAA7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1305F445BA73213A01B69A56017DEB5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_8A7466BA7935ACD22BF29A751759F633" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_84ECE9C2DC980E9E9B529A56017DAAA7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_8A7466BA7935ACD22BF29A751759F633" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_438B462FC43EF79A9D789A56017D2E8E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_84ECE9C2DC980E9E9B529A56017DAAA7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_438B462FC43EF79A9D789A56017D2E8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BD1F3BCA2ED4F4237EFE9A56017D9EDD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_84ECE9C2DC980E9E9B529A56017DAAA7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BD1F3BCA2ED4F4237EFE9A56017D9EDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_D13CF58278C99867BCBA9A56017D35CC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5967506064B4192D93969A56017D7955" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_D13CF58278C99867BCBA9A56017D35CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_DE6099BA6D8920BC30949A56017DC80F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_D13CF58278C99867BCBA9A56017D35CC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_DE6099BA6D8920BC30949A56017DC80F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_202BC10C27B461A07C0C9A56017D0FBD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_D13CF58278C99867BCBA9A56017D35CC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_202BC10C27B461A07C0C9A56017D0FBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_96A98856B81E76ED13F09A56017D8501" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_D13CF58278C99867BCBA9A56017D35CC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_96A98856B81E76ED13F09A56017D8501" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_98C7ABDF36972D91169A9A56017D827D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_D13CF58278C99867BCBA9A56017D35CC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_98C7ABDF36972D91169A9A56017D827D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1A2EC86558388032F9079A72FFD1C382" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_D13CF58278C99867BCBA9A56017D35CC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1A2EC86558388032F9079A72FFD1C382" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E1E99C706E1003004D9A9A56017D860B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_D13CF58278C99867BCBA9A56017D35CC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E1E99C706E1003004D9A9A56017D860B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_FC48EB33EF0AE075D1EF9A56017D5ADD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_D13CF58278C99867BCBA9A56017D35CC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_FC48EB33EF0AE075D1EF9A56017D5ADD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A409150C6BEB012DED9351508016D36C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_EF1CBE6C5DF2AE997A2C51508016A937" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A409150C6BEB012DED9351508016D36C" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_EF1CBE6C5DF2AE997A2C51508016A937" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_90468317243DAE17ED18515080167C98" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A409150C6BEB012DED9351508016D36C" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_90468317243DAE17ED18515080167C98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_B3449CFDA6F4155D3C1351508017F697" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A409150C6BEB012DED9351508016D36C" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_B3449CFDA6F4155D3C1351508017F697" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_7C16DFD5FA72C95C53905B0CFC907294" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7FBDC5C72597ACF2265F5B0CFC90854B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7C16DFD5FA72C95C53905B0CFC907294" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7FBDC5C72597ACF2265F5B0CFC90854B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_2141024454A235A5A77B9A5600EF98CE" xlink:type="locator" />
    <link:loc xlink:href="dare-20190331.xsd#dare_StockholdersEquityTable" xlink:label="loc_dare_StockholdersEquityTable_D5FB4A778DA18AE4ADA19A5600EFE79A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2141024454A235A5A77B9A5600EF98CE" xlink:to="loc_dare_StockholdersEquityTable_D5FB4A778DA18AE4ADA19A5600EFE79A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2D7794772D9A4AC4BA199A5600EF5B2F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityTable_D5FB4A778DA18AE4ADA19A5600EFE79A" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2D7794772D9A4AC4BA199A5600EF5B2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_B361BD59915A291B89139A5600EF53A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2D7794772D9A4AC4BA199A5600EF5B2F" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_B361BD59915A291B89139A5600EF53A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_6A1FC21ABEB14A46ACC99A5600EF5662" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_B361BD59915A291B89139A5600EF53A1" xlink:to="loc_us-gaap_OverAllotmentOptionMember_6A1FC21ABEB14A46ACC99A5600EF5662" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_628424DA475E7FB6D4AF9A5600EF44CA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityTable_D5FB4A778DA18AE4ADA19A5600EFE79A" xlink:to="loc_srt_RangeAxis_628424DA475E7FB6D4AF9A5600EF44CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_79130FE4DC635509FF319A5600EFA8EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_628424DA475E7FB6D4AF9A5600EF44CA" xlink:to="loc_srt_RangeMember_79130FE4DC635509FF319A5600EFA8EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_01346C7D7240156A82D89A5600EFE74B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_79130FE4DC635509FF319A5600EFA8EA" xlink:to="loc_srt_MaximumMember_01346C7D7240156A82D89A5600EFE74B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2A6798B8C6D46559836B9A5600EFCFCE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_79130FE4DC635509FF319A5600EFA8EA" xlink:to="loc_srt_MinimumMember_2A6798B8C6D46559836B9A5600EFCFCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_61C89BEDF2C94C851A229A5600EFB274" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityTable_D5FB4A778DA18AE4ADA19A5600EFE79A" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_61C89BEDF2C94C851A229A5600EFB274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_B89E7282D1EA02C8186E9A5600EFFD3F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_61C89BEDF2C94C851A229A5600EFB274" xlink:to="loc_us-gaap_TypeOfAdoptionMember_B89E7282D1EA02C8186E9A5600EFFD3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201711Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201711Member_9D760536EB8FC07DCF069A5600EF36E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_B89E7282D1EA02C8186E9A5600EFFD3F" xlink:to="loc_us-gaap_AccountingStandardsUpdate201711Member_9D760536EB8FC07DCF069A5600EF36E3" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_StockholdersEquityLineItems" xlink:label="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityTable_D5FB4A778DA18AE4ADA19A5600EFE79A" xlink:to="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_GrossProceedsFromIssuanceOfCommonStock" xlink:label="loc_dare_GrossProceedsFromIssuanceOfCommonStock_541328027702DD5EE6239A5600EF05CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:to="loc_dare_GrossProceedsFromIssuanceOfCommonStock_541328027702DD5EE6239A5600EF05CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_5ADE29BA86B30E6861F49A7935E98D18" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_5ADE29BA86B30E6861F49A7935E98D18" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_PercentageOfAggregateCommission" xlink:label="loc_dare_PercentageOfAggregateCommission_BF2DD2B4C51E34B4E7369A5600EFF931" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:to="loc_dare_PercentageOfAggregateCommission_BF2DD2B4C51E34B4E7369A5600EFF931" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C0BA5D889889BF83490B9A5600EFA33A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C0BA5D889889BF83490B9A5600EFA33A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FAEC226EB9FBEC3B5BAE9A5600EFF9CF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_FAEC226EB9FBEC3B5BAE9A5600EFF9CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_E7D330FD81A0192E9B0A9A5600EFEBB8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_E7D330FD81A0192E9B0A9A5600EFEBB8" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod" xlink:label="loc_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_1A5DE60B5CFF5634058F9A5600EF6F2D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:to="loc_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod_1A5DE60B5CFF5634058F9A5600EF6F2D" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_UnderwritersOptionToPurchaseAdditionalShares" xlink:label="loc_dare_UnderwritersOptionToPurchaseAdditionalShares_4D8B9CEBD2F80103B8F09A5600EF734B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:to="loc_dare_UnderwritersOptionToPurchaseAdditionalShares_4D8B9CEBD2F80103B8F09A5600EF734B" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_GrossProceedsFromOfferingOfCommonStockAndWarrants" xlink:label="loc_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_93CE12C38F7ED0A25BE79A5600EF94AD" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:to="loc_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants_93CE12C38F7ED0A25BE79A5600EF94AD" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="loc_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_449A0E02D5CFB2F9880E9A5600EFC91A" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:to="loc_dare_ProceedsFromIssuanceOfCommonStockAndWarrants_449A0E02D5CFB2F9880E9A5600EFC91A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2F28D596560E4F3EEABB9A5600EFD71E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2F28D596560E4F3EEABB9A5600EFD71E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_CD8B319B0A0BF83D7FC39A5600EF23B6" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_CD8B319B0A0BF83D7FC39A5600EF23B6" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_EstimatedFairValueOfWarrantsRecordedInEquity" xlink:label="loc_dare_EstimatedFairValueOfWarrantsRecordedInEquity_CAC3A74392D9D38EEAAA9A5600EF0D44" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:to="loc_dare_EstimatedFairValueOfWarrantsRecordedInEquity_CAC3A74392D9D38EEAAA9A5600EF0D44" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_NumberOfCommonStockWarrantsExercised" xlink:label="loc_dare_NumberOfCommonStockWarrantsExercised_6B4F64925C5653F79A259A5600EFC2D9" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_StockholdersEquityLineItems_4A2E34BE6DA14109EAF89A5600EF5089" xlink:to="loc_dare_NumberOfCommonStockWarrantsExercised_6B4F64925C5653F79A259A5600EFC2D9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockholdersEquityScheduleOfCommonStockWarrantsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_8F483D9ACCEF1FDB17925B1492982187" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_A4B2FE50196CD8364B815B0CFC4F801F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8F483D9ACCEF1FDB17925B1492982187" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_A4B2FE50196CD8364B815B0CFC4F801F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_638A0C5380FFC0218DBE5B0CFC4FF847" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_A4B2FE50196CD8364B815B0CFC4F801F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_638A0C5380FFC0218DBE5B0CFC4FF847" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_DA81431AFF8D0F1206675B0CFC5070FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_638A0C5380FFC0218DBE5B0CFC4FF847" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_DA81431AFF8D0F1206675B0CFC5070FF" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember" xlink:label="loc_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_CCEF31083C2F69CD80D65B0CFC502B44" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_DA81431AFF8D0F1206675B0CFC5070FF" xlink:to="loc_dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember_CCEF31083C2F69CD80D65B0CFC502B44" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember" xlink:label="loc_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_FB5C9D1CB208D7EC847F5B0CFC506F08" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_DA81431AFF8D0F1206675B0CFC5070FF" xlink:to="loc_dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember_FB5C9D1CB208D7EC847F5B0CFC506F08" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember" xlink:label="loc_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember_5175FB11C7D510EA66C45B0CFC50D82D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_DA81431AFF8D0F1206675B0CFC5070FF" xlink:to="loc_dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember_5175FB11C7D510EA66C45B0CFC50D82D" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember" xlink:label="loc_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_EFE3C74B9A0EF3B9932F5B0CFC50F5D3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_DA81431AFF8D0F1206675B0CFC5070FF" xlink:to="loc_dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember_EFE3C74B9A0EF3B9932F5B0CFC50F5D3" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" xlink:label="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_8972636AA0D30E75F5FF5B0CFC51CC3E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_DA81431AFF8D0F1206675B0CFC5070FF" xlink:to="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_8972636AA0D30E75F5FF5B0CFC51CC3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_16C8F8FA3E48EF49B6505B0CFC51A569" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_A4B2FE50196CD8364B815B0CFC4F801F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_16C8F8FA3E48EF49B6505B0CFC51A569" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_B2CD4683BC7C48017C725B0CFC51F957" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_16C8F8FA3E48EF49B6505B0CFC51A569" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_B2CD4683BC7C48017C725B0CFC51F957" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6B942092455202FD598E5B0CFC580EC2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_16C8F8FA3E48EF49B6505B0CFC51A569" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6B942092455202FD598E5B0CFC580EC2" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_ClassOfWarrantOrRightsWarrantsExpirationDate" xlink:label="loc_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_3741FE6E1A020B4CBB8D5B0CFC58658D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_16C8F8FA3E48EF49B6505B0CFC51A569" xlink:to="loc_dare_ClassOfWarrantOrRightsWarrantsExpirationDate_3741FE6E1A020B4CBB8D5B0CFC58658D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_58DCA4E773A95E7B9227ED870E76824C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_42269856E9815B36A4AC0BCA2E034E84" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_58DCA4E773A95E7B9227ED870E76824C" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_42269856E9815B36A4AC0BCA2E034E84" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_A65A67242BF622CC15CF5B0CFB812436" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_4DF5037AFC7D0857ED5C5B0CFB81A036" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_A65A67242BF622CC15CF5B0CFB812436" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_4DF5037AFC7D0857ED5C5B0CFB81A036" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_969A5AF60BDF21150C789A55FF1FA347" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_A00D47F203A36B0C7B439A55FF1F22EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_969A5AF60BDF21150C789A55FF1FA347" xlink:to="loc_us-gaap_SubsequentEventTable_A00D47F203A36B0C7B439A55FF1F22EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_912266D0BFAAC4E9D2C29A55FF1F3C42" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_A00D47F203A36B0C7B439A55FF1F22EC" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_912266D0BFAAC4E9D2C29A55FF1F3C42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_F162273E6C6BA68D1B0C9A55FF21E228" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_912266D0BFAAC4E9D2C29A55FF1F3C42" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_F162273E6C6BA68D1B0C9A55FF21E228" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember" xlink:label="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_C33C495C12F4D87C890B9A55FF21B487" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_F162273E6C6BA68D1B0C9A55FF21E228" xlink:to="loc_dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember_C33C495C12F4D87C890B9A55FF21B487" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_645A772483AE32EF357B9A55FF2214C6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_A00D47F203A36B0C7B439A55FF1F22EC" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_645A772483AE32EF357B9A55FF2214C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F7B531EA5A357FFF29039A55FF224B4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_645A772483AE32EF357B9A55FF2214C6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F7B531EA5A357FFF29039A55FF224B4C" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_PublicStockOfferingMember" xlink:label="loc_dare_PublicStockOfferingMember_A8FF6E2CCF7EDB2D57399A55FF22DD74" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F7B531EA5A357FFF29039A55FF224B4C" xlink:to="loc_dare_PublicStockOfferingMember_A8FF6E2CCF7EDB2D57399A55FF22DD74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_A9DDC986A197CCC6AD6B9A55FF2226E1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F7B531EA5A357FFF29039A55FF224B4C" xlink:to="loc_us-gaap_OverAllotmentOptionMember_A9DDC986A197CCC6AD6B9A55FF2226E1" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_PublicStockOfferingIncludingOverAllotmentOfSharesMember" xlink:label="loc_dare_PublicStockOfferingIncludingOverAllotmentOfSharesMember_C19133A2E23D4D3790FE9A55FF22E900" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F7B531EA5A357FFF29039A55FF224B4C" xlink:to="loc_dare_PublicStockOfferingIncludingOverAllotmentOfSharesMember_C19133A2E23D4D3790FE9A55FF22E900" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_FC2F473B823399E439F89A55FF22FD25" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_A00D47F203A36B0C7B439A55FF1F22EC" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_FC2F473B823399E439F89A55FF22FD25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8CE836CD3355C069223F9A55FF22590C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_FC2F473B823399E439F89A55FF22FD25" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8CE836CD3355C069223F9A55FF22590C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_6236177671D2003C93649A55FF22BDD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8CE836CD3355C069223F9A55FF22590C" xlink:to="loc_us-gaap_SubsequentEventMember_6236177671D2003C93649A55FF22BDD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0E63A6C63F07269864219A55FF225403" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_A00D47F203A36B0C7B439A55FF1F22EC" xlink:to="loc_us-gaap_SubsequentEventLineItems_0E63A6C63F07269864219A55FF225403" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_E07D90359D3B2F5BD6779A55FF229C71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0E63A6C63F07269864219A55FF225403" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_E07D90359D3B2F5BD6779A55FF229C71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1BC98667892A513497549A55FF227BF1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0E63A6C63F07269864219A55FF225403" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1BC98667892A513497549A55FF227BF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_886995828302A43896A39A55FF225EB7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0E63A6C63F07269864219A55FF225403" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_886995828302A43896A39A55FF225EB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_36FD42EB216DB962DD6F9A55FF22C169" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0E63A6C63F07269864219A55FF225403" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_36FD42EB216DB962DD6F9A55FF22C169" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2A736DD6F9B3D560842C9A55FF26535A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0E63A6C63F07269864219A55FF225403" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2A736DD6F9B3D560842C9A55FF26535A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_C3C9FAC04200104FE9849A55FF26EE3D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0E63A6C63F07269864219A55FF225403" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_C3C9FAC04200104FE9849A55FF26EE3D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4FEEF8232E1E22EC210C5B0CFD70C1B8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2724CFFD36C2CCA2FD7D5B0CFD705BD2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4FEEF8232E1E22EC210C5B0CFD70C1B8" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2724CFFD36C2CCA2FD7D5B0CFD705BD2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_063C4D0132B9EB441DD29A56022F952C" xlink:type="locator" />
    <link:loc xlink:href="dare-20190331.xsd#dare_SignificantAccountingPoliciesTable" xlink:label="loc_dare_SignificantAccountingPoliciesTable_93C23DDD43FA4A521FC89A56022F7A5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_063C4D0132B9EB441DD29A56022F952C" xlink:to="loc_dare_SignificantAccountingPoliciesTable_93C23DDD43FA4A521FC89A56022F7A5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5CD7E0215C0D939117539A56022FE9CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesTable_93C23DDD43FA4A521FC89A56022F7A5D" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5CD7E0215C0D939117539A56022FE9CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_004EED79203865698FDB9A56022F1DC0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5CD7E0215C0D939117539A56022FE9CD" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_004EED79203865698FDB9A56022F1DC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_E3ADFD332D5C8729B5279A56022F6093" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_004EED79203865698FDB9A56022F1DC0" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_E3ADFD332D5C8729B5279A56022F6093" xlink:type="arc" />
    <link:loc xlink:href="dare-20190331.xsd#dare_SignificantAccountingPoliciesLineItems" xlink:label="loc_dare_SignificantAccountingPoliciesLineItems_D889DB9D3C168C07023B9A56022FB6F4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesTable_93C23DDD43FA4A521FC89A56022F7A5D" xlink:to="loc_dare_SignificantAccountingPoliciesLineItems_D889DB9D3C168C07023B9A56022FB6F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_75CC75E42D13BA9B5A639A56022FEC60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_D889DB9D3C168C07023B9A56022FB6F4" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_75CC75E42D13BA9B5A639A56022FEC60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_E9DCD4DE6780D18E00819A56022F191E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_D889DB9D3C168C07023B9A56022FB6F4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_E9DCD4DE6780D18E00819A56022F191E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_2042DA67A159DE71733C9A56022F3AB6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dare_SignificantAccountingPoliciesLineItems_D889DB9D3C168C07023B9A56022FB6F4" xlink:to="loc_us-gaap_OperatingLeaseLiability_2042DA67A159DE71733C9A56022F3AB6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8D7834F378CB645A75F19A56023ECE7C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_A29C5FF6D290992C9BE09A56023E9ED8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8D7834F378CB645A75F19A56023ECE7C" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_A29C5FF6D290992C9BE09A56023E9ED8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_5AF23F50A920E8FC9DB19A56023E8B07" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8D7834F378CB645A75F19A56023ECE7C" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_5AF23F50A920E8FC9DB19A56023E8B07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6327697B7B3E9F63FCFD9A56023E6BA9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8D7834F378CB645A75F19A56023ECE7C" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6327697B7B3E9F63FCFD9A56023E6BA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_82A3B5CC4C999B4214329A56023EFD36" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8D7834F378CB645A75F19A56023ECE7C" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_82A3B5CC4C999B4214329A56023EFD36" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>darecovera03.jpg
<TEXT>
begin 644 darecovera03.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[@ .061O8F4 9      !_^$,;D5X:68
M $U- "H    (  P!   #     04Z   ! 0 #     0:)   ! @ #     P
M )X!!@ #     0 "   !$@ #     0 !   !%0 #     0 #   !&@ %
M 0   *0!&P %     0   *P!*  #     0 "   !,0 "    )    +0!,@ "
M    %    -B':0 $     0   .P   $D  @ "  ( 2P    !   !+     $
M $%D;V)E(%!H;W1O<VAO<"!#0R R,#$U("A-86-I;G1O<V@I #(P,3<Z,#DZ
M,#8@,30Z,#0Z,S(   20   '    !# R,C&@ 0 #     ?__  "@ @ $
M 0  !3J@ P $     0   <H         !@$#  ,    !  8   $:  4    !
M   !<@$;  4    !   !>@$H  ,    !  (   (!  0    !   !@@("  0
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
M @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@ , P$  A$#$0 _ /54DDDE*22224I))))2DDDDE*6;UW^BT_\ ABG_ *I6
M\O+HPZ'7WF&C0 <DGAC!^\L7)R\_,H;=?2*<9UU/H#\XDO'NG]W;_(8I<,"9
M"70$;_L:O-Y8C'/'O*4":&O#']Z7[K;^K'_)+?\ C;?_ #XY:RY7#ZAU7 Q?
MM%5-65TT.>7&EIK+8<[U"6[6;?=_P6S^HNCPLW'SL=N1CNW,=V.A!'TF/'[S
M50Y3+ XX8]1.,1I(5Q1_?C^]%U><PS&2>30PE.6L3?#+]R?[DTZ222M-1222
M22E))))*4DDDDI__T/54DDDE*22224I))))2DDDDE.-U!@R^N8N)9K36PVN;
MV)]W/^8Q'Z[_ $6G_P ,4_\ 5(/6!9B9N-U1C2YE?Z.X#]TS'_GQ_P#USTU/
MJU].1@T6TO#V.R*8</ZP_P U6!9.$CY=O\._4T,A AS43\YN7]['P^A;ZL?\
MDM_XVW_JWJMT=@PNO9_3JOY@M%S&]F_0T;_V]L_ZVQ$Z%E48G0_7R'BNMMEN
MI[G>_P!K1^<Y1^KS+<O+R^LVMV#(/IT-/[C?_.*V?UV6+(@01RD8_. )'^KB
M]OUW_>]+OY 1+G)2_FR3 ?ULON>CA_N^IW4DDE?<]22222E))))*4DDDDI__
MT?54E1_:%UCG.Q<5U]+'%IM#FMW%IVO]!K_YS:[][TT+#SVLPWY#R^WU,BQM
M+-2]Q+W>G4UMFW;M;^]_-I_MRJ_$"O-B]^%U?0RXJJ-1_=_?_P !TTE39G6M
MM97EXYQ_6.VI^X/:7<^F]S?H6?N_F?RTUW42S)=B4TONR&AK@T$!NUT^]UCO
MH-;'_D$."5U72]]/\9/O0J[._#52XN+MP?,W4E1RLJZUUN-AUO>]GMMN:YK
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MJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?K_Q  ? 0
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M8?\ I47'_:)+UUW^X/\ \D3EO_I=Q_\ :7#UKI>_G-Z^H#KWOW7NMGW^7?\
M]D=]/_Z_8'_OT,W[[%_=6_Z<+L7_ %&_]W&[ZXT?>N_Z?[O_ /U _P#=NL^C
MJ^\A.L=^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__TM_CW[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]UJJ>^B/7"?KWOW7NKAOCG_V0AV7_P"&UW-_
M[H*CW@C]ZK_</F'_ *5%Q_VB2]==_N#_ /)$Y;_Z7<?_ &EP]:Z7OYS>OJ Z
M][]U[K9]_EW_ /9'?3_^OV!_[]#-^^Q?W5O^G"[%_P!1O_=QN^N-'WKO^G^[
M_P#]0/\ W;K/HZOO(3K'?KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__]/?
MX]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:JGOHCUPGZ][]U[JX;XY_
M]D(=E_\ AM=S?^Z"H]X(_>J_W#YA_P"E1<?]HDO77?[@_P#R1.6_^EW'_P!I
M</6NE[^<WKZ@.O>_=>ZV??Y=_P#V1WT__K]@?^_0S?OL7]U;_IPNQ?\ 4;_W
M<;OKC1]Z[_I_N_\ _4#_ -VZSZ.K[R$ZQWZ][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO__4W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6JI[Z(]<
M)^O>_=>ZN&^.?_9"'9?_ (;7<W_N@J/>"/WJO]P^8?\ I47'_:)+UUW^X/\
M\D3EO_I=Q_\ :7#UKI>_G-Z^H#KWOW7NMGW^7?\ ]D=]/_Z_8'_OT,W[[%_=
M6_Z<+L7_ %&_]W&[ZXT?>N_Z?[O_ /U _P#=NL^CJ^\A.L=^O>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[K__U=_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]UJJ>^B/7"?KWOW7NKAOCG_V0AV7_P"&UW-_[H*CW@C]ZK_</F'_ *5%
MQ_VB2]==_N#_ /)$Y;_Z7<?_ &EP]:Z7OYS>OJ Z][]U[K9]_EW_ /9'?3_^
MOV!_[]#-^^Q?W5O^G"[%_P!1O_=QN^N-'WKO^G^[_P#]0/\ W;K/HZOO(3K'
M?KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__];?X]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=:JGOHCUPGZ][]U[JX;XY_]D(=E_\ AM=S?^Z"H]X(
M_>J_W#YA_P"E1<?]HDO77?[@_P#R1.6_^EW'_P!I</6NE[^<WKZ@.O>_=>ZV
M??Y=_P#V1WT__K]@?^_0S?OL7]U;_IPNQ?\ 4;_W<;OKC1]Z[_I_N_\ _4#_
M -VZSZ.K[R$ZQWZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO__7W^/?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6JI[Z(]<)^O>_=>ZN&^.?_9"'9?_
M (;7<W_N@J/>"/WJO]P^8?\ I47'_:)+UUW^X/\ \D3EO_I=Q_\ :7#UKI>_
MG-Z^H#KWOW7NMGW^7?\ ]D=]/_Z_8'_OT,W[[%_=6_Z<+L7_ %&_]W&[ZXT?
M>N_Z?[O_ /U _P#=NL^CJ^\A.L=^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[K__T-_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJJ>^B/7"?KWOW7
MNKC?C32U5=\'.PJ*@IIZRLK,!W!2TE)2PR5%55551@9XJ>FIJ>$,SR2.P5$4
M$L2  2?>"GWI89KF/?K>W0R22;5.JJH+,S-;2A5514EB2   22:#KKE]P^>&
MVY?Y>N;EQ'''O2,S,0JJJW<)9F8T 4 $DD@ "IZH0K.HNUL>(S7]8=B4*REA
M$U9LK<=,)"EBPC,U,-5@1JM]+^_GRN.1>=K4 W6S7T8;AJM+A:TXTK&*]?2]
M;\^<C79(M=YL)=/'1=V[4KPK20TZ1%905V.E$&0H:JAG*ZQ#64\U+*4+% X2
M<*UM2L+VM<$?CV')[:YM7\*ZC:-N-'4J:<*T(!I4$?ET)+>ZMKM/%M9%E2M*
MHP85P:5!(K0@_F.MF_\ EW_]D=]/_P"OV!_[]#-^^PWW5O\ IPNQ?]1O_=QN
M^N-?WKO^G^[_ /\ 4#_W;K/HZOO(3K'?KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z__T=_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4#(9+'8BDER&5R-%C*"G4-
M/6Y&K@HJ2%3QJFJ:EE1?]<L/;L$$]S((+5&D<\%4%F/V 5)Z37E[9[?;M=W\
MR01)\3R,J(OVLQ 'YGIAVKOC9^^8<A4[.W-A=T4N*KCC:^LP5?3Y.B@KA E2
M:;[RD+1.=$B-Z'(L?K[5[CM&Z;.Z1[I;O;M(NI5D4HQ6I%=)H1D$9 Z*]BYG
MY=YHCFGY=O8;Z.!_#=X)%D17TAM.M"5)TL#@D9ZU@??0'KB)U[W[KW5UWP\W
M)_<[XC9W=XHOXE_=9NQMR?P[[C[/[_\ @=&V4^R^[\<OB\OBT>3Q/IOJTM:Q
MPJ^\1N_[@W7<M^\/Q?HK$W&C5IU^#"\FC51M.K335I:E:T/#KJ[]RS:/ZP<A
M[5L/B>#]=N;6_B:=>CQIXX]>G4NK3JKIU+6E-0X]%:@_F^P-.BU7Q]FA@)(D
MD@[2CJ9D !L4IY-NQ!KFPL9%XY_P]\O8OOWPEP)N5BJ^97<0Q'V V*@_[T.N
MQ,OW")1&3#S4&;R#;:5!^TB_8C_>3TL:/^:STKGH!1;YZ?WM%12#]ZGI/[J;
MMIM3Q/$]X,M/CU86(0D@$JS\<6806_WV/;W<X_I^8MANQ&>*K]-<KD,#VRO
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M8-LMX[=/2-%6OVT J?F:GK&G?.9>8>9KKZOF"^GO9:_%-*\A'R742%'D H
MP!3JVO\ EO?\RLWU_P"'^W_O-T/O&[WU_P"5@LO^>;_K+)UG]]S/_E1-T_Y[
MS_VCP]4S^\H>N=/7O?NO=7#?'/\ [(0[+_\ #:[F_P#=!4>\$?O5?[A\P_\
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MKIID-TDCD571P;@@$>\&?O07=U8#?+ZS<Q30[7-)&ZFC(Z6TK*RD9#*P!!'
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M_P#2HN/^T27KKO\ <'_Y(G+?_2[C_P"TN'K72]_.;U]0'7O?NO=;/O\ +O\
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M H+G^Z=4VE02=*3QNS6'X !)/]/8S]O"!SMMM?\ ?P_P'J)_?0$^T6_@"O\
MBK?R92?Y=:Z?O-[KC_U[W[KW2^ZOGCI>R^O*F<E8:??.TII6 +%(X<_3R2$*
MO)X!X')]E',"-)L%]&G%K>8#[3&PZ$W(\J0<Z[/-)A4O;1C]@GC)_EULV^\!
M>NV77O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:JGOHCUPGZ][]U[J
MX;XY_P#9"'9?_AM=S?\ N@J/>"/WJO\ </F'_I47'_:)+UUW^X/_ ,D3EO\
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M#UKI>_G-Z^H#KWOW7NMGW^7?_P!D=]/_ .OV!_[]#-^^Q?W5O^G"[%_U&_\
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M6!!_,=%VW3\0/CONQI):GKG&X:JD+D5&UJK(;:6(L?48\?B98Z,CC@-3$#\
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M?[U0Y67<&-WMCH-Q_P '>@CIQNW'24$,\N+^YF),!DU,HJ/5:P8?7W!?NSN
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M:%R. ^% :+4ZF;J;[,^R6R>U.V?42$76[W" 3W%,*,$PV]0"L0-*D]\K ,]
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M^Z]U[W[KW7O?NO=>]^Z]U[W[KW6K/\4O^RRNL/\ Q)]7_P!#57OC#[*?]/\
M-F_Z6+?X9.NU7O=_XC_O7_2N7_!'UM,>^SW7%7KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__U=_CW[KW7O?NO=)W
M<VZMM[-P]3G]V9S&;>PM(!]QD<M60T=,KL"8XD>8C7(]B(XD!=SPJD\>UEAM
MVX;K=+9;="\\K<%12Q^W' #S)H!Q)'13O>^[-RWMS[MO]U'9VT?Q22N$4'R
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M*4"PY&MIZJOL QL#5GFQ^H!&-.]_>I][MZ=A'NBV2,?[.VMX4 \L.Z23>?\
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M(-,@)4ZHV9<@<*U'GT)WL8= _KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z)#WO\
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M;BQ()E][^4(WTI%=2#U6..G_ !J93\^'\^I;MON?>Z,\8DEN=NA8_A>>X+#
M/^AVKK\L,<@^5"4EN7X)_(;;T,D])@,'NJ*+49/[L[@I))-"FVN.ES0HIGO;
MA8XV;G]/UL9V'O#R3>L(Y)I+8G_?L9 _,Q^(H^TD#Y]!_>ONM>[VT1&6WM(+
M\+Q^FN$)IZA9A"[?8JEOEQZ*IN';6X=J9*;#;GP>5V]EJ>WFQN:Q]9C*U$?E
M'--6*CZ6^JM;2?J"1[D:RO[+<8!=;?,D\3<&C8.I_-217U'EU ^[;-N^PWS;
M9OEK+9W"<8YHWC<>ATN :'R-*$9&.IFT=X[GV'G:/<VSLYD-OYR@)^WR&.E,
M4FAF#/3SQL&CFADL!)!,C1N.'5AQ[;W+;-OW>S:PW2%9X7XJPJ/D0>*L/)E(
M8<01T_R_S%OG*VZ1[UR[=26=U%\,D9H:>:L,JZ-^)'#(PPRD=77_ !<^66*[
MLI4VKNE:+!=ET-,7--$_BQV[*:"/5/D<*DGZ)XP"U31:F(4&6(M'K6'$_P!P
M_;:YY3D.X;=JFL'/$Y:$DX62G%3P5\5/:U&H6Z8>QGO]M_N9"-AWX):[U$M=
M(-([I5'=)"#\+J,R0U) [T)34(SH^XLZR2Z][]U[KWOW7NO>_=>Z*K\VO^R8
MNS/_ "2__?@XGW(GM1_RO]A_S?\ ^T:;J"/O,?\ 3D=[_P"H/_M/M>M?[WF;
MUR>ZV!.N.QMK=5?%?K7>>\:_[+$8WKW;(5(U$E;D:Z7&+]KB\93,09:B=@0B
MW  #.[)&CNN%^^['N/,7N)?[5M::Y9+F7CA54,=3N?)5\SQX  L0#UEY.YRV
M+D/V)V7F7F*7PK>&PM@ ,O(YB&B*-:C5(Y% *@ 59BJ*S"HSOOY,;\[VRDB9
M"HDP.RZ>HU8C9=!52/01*CWAJ\O,H0UM5P#Y9$"(;^*.,%M63')O(6S\GVP,
M*B:Z([YV U&O%4&?#3Y U/XBV*<^O=?WIYJ]T[]ENW:UVU#6*SC8^&*'#RF@
M\:7^DP"K_H:)4U+B 6( #$EK*HY))^@ ]C?J' "30<>AMVU\<>]-W4Z5F"ZO
MW;-1RHLD-978\X2EJ(R#IDI*C-M3+*IM^J,D7]A7<.>>3]LD,-YN$(88(5O$
M(/H1'J(/VTZDS9?9SW1Y@A%SM>QW;1L*J[Q^"K#U5IC&&'S4D=79_%GK[.=8
M]'[/VGNC&_PG<M/)G*[-T0J*.K,-3DL_55=*KU%!)+$Q%*U.ITR-]+&Q! Q.
M]Q-\L^8.;;K<MO?Q+<^&L;485"QH#A@"._5Q _R]=,O8KE'=.2/;#;M@WR'Z
M>]0SO,FI'HTD\CK5HV9"?",8-&-*4P10&(]@KJ7>O>_=>Z(]\I?EUC>FXYME
M[+%%F^RJJ"]0TI^XQFS8)T#0U>3B3B:L=6#T]&2  1+/Z"D<\L^W7MI/S21N
MNZZHK!3BF'G(.50_A0'#/YFJIFK)C'[Z_>#L_;E&Y;Y9T76].O<3W1V:L,-(
M!\<Q!K'"2 !227MTI+2SNC=.X]ZYNMW)NS-9#/YS(R>2KR62J'J)Y+<)"NKT
MQQH/3%#&%C10%154 >\K-OVZQVJT2QVR)884% JB@^WYD\2QJ2<DD]<UM[W[
M>>9=SEWG?[F2[NIC5Y)&+,?0#R55X*B@*HHJ@  =<ML[1W1O3)1X7:6W\QN3
M*R#6M!A<?4Y"=8]01IY4IE;QQJ2-4CV47Y(]ZO\ <=OVJW-UN4Z01#\3L%%?
M05(J?0#)\AUO9-@WSF2^&V\OVDM[.V=$,;2-3A4A0=*BN6-%'F1T:O;WP,^0
MF=ABFK<1MW:JRE2$W#N.F\P1F $DL. 2O9+ ZBK . ""NJP,<WWO#R39N5BE
MEN*?[ZB-/L!D,8/V\/G3/4\;/]U3W=W6-9+FWM[ -3%Q<+4 TR1 )R/4@C5@
MXKCI2UO\NSO6EA,L.:ZWR+J&_P GHL_GXYFTH6 #9#%01\D:1>0<D7L+D((O
M>_E!VTO%=1CU:..G_&9F/\NCNY^Y_P"Z4$>N*YVZ8_PI/.#P_P"&6J+GA\7'
MC09Z+_O_ .-W=G6=-/7[JV!EX,33AWFS.+-+G\3!$JZC/5UN$DG6G2P_54>/
M^GU]C79N>^4]_<0[=>H96X(]8W)] L@74?\ 2ZNHDYL]F?<SDJ%KO?MIE6W3
M)FBTSQ*/XG>%I!&/G)HZ GV+>HSZ.E\<?F#N[IZJH=M[LFK]V=:EUA;'2/\
M<YC;4)X$^VZBI9;Q*>6H97$9 /C,+%F:+.>O;';>9XWO]M"VU_2NH"B2GTE
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MR_ZZK?<:_P"G2;E_TMY_^T.PZM9^!W_9)/3'_:ES?_O7Y'WFM]VC_IQW+_\
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M5%/$RR1L R,K $$N_P#+NQ<T[7)LW,=I%>VLHHT<J!E/H17*L.*NI#*:%2"
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M CI:Y8WTJ3]U-(50X3>ZOW,KFRAEWGVMG:X5:L;"X9?%IQ(MY^U7I^&.8*U
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M'0T-%"9ZNKJZF8A8XXHU9W=C8 $GVEN[JUL+62^OY%AAA1GD=R%1$4%F9F-
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M.S-)*HD"*3>HGB+IKQ_]JO9#GOWJW.3<8F,-D7)N-PN-;AG8U<)4Z[F<DEF
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MB*\C7 $E.V51Y1S*"RC@K!XP3HJ3(>P/U,?7O?NO=>]^Z]T57YM?]DQ=F?\
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M@??.YC/BMH4DJK**>54'\0S]1$]U:*B1U958$/,\2,I1G*C[VZY.;F[>Q'<
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MQ.LJ/9_QX3?+TZKF^TL_DLM45)4"H&#V]73;<P= QL#XUDAK*J,$F_W!-[$
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M-R]OD@4R8[D57&2HQY=;5OOM7UQ%Z][]U[KWOW7NO>_=>ZU[/YLG_91>R_\
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M(EEV/G*% '<36<K4R0M)H!7Y5N./Y==%ON(\T2-%OO)<SDJAAO(5K@%JPW!
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M[M?//_G0?+K_ ,]7<G_7OW[]S_>6_P"47F;_ )Q[K_T#U[][_=C_ .4OE?\
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MT'RZ_P#/5W)_U[]^_<_WEO\ E%YF_P"<>Z_] ]>_>_W8_P#E+Y7_ .<FT?\
M072#RW0ORAS^1JLQG.E^^LUEJYD>MRF6ZY[#R61JWC00H]56UE&\DA"*J NQ
ML !] /87OO;+WDW.[>_W+E_>;B>0@O)+8WTDC$  %G>(LQ   J3@ >70FL/<
M_P!E]KM$L-LYBV2V@C!"1Q7]C'&H))(5$E"J"22: 9)/GT??^_ORB_Y\?W?_
M -D<?Z!_^97[^_X_#_GI/^+?_P "O]K_ $_X>\FOZS>\W_3.;O\ \JM^YO\
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M#_$+HK??3^P-W;DVSD:S.Y[ 0U^3J8MRY^DCFJ7G=6=*:FJ%C2X4<*H]XO\
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M?)/[XG_3Z9O^>2U_XXW77C[FW_3D8/\ GKN_^/IU>%\3/^R9NBO_ !&&T?\
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MS5^_-_RMNP_\\DW_ %>'73/[B7_*H[]_SV0_]63T=3^6+_V2QB?_  ]=X_\
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M $L;K_JZW1A?<I=15U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:W'\SK_LJ?+?\
MAD[._P#<23WR3^^)_P!/IF_YY+7_ (XW77C[FW_3D8/^>N[_ ./IU=1\+O\
MLECI'_PRJ7_W,F]]"/N^?].7Y=_YY%_X^_7.[[P__3[.8_\ GK;_ (XG1G_<
MR=0QU[W[KW7O?NO=:S7\R#;<N ^6&^:UHQ'3[JP^SMR4:JI4-$=M4^!JG!/U
M+U5!4,3_ %)'X]\@/O:;0^V>]^Y7!%%OHK6X3[/ITA8_G)"Y/SZ[%_=%W=-T
M]C-MMPU6L9;NW?[?J'G4?E',@'RZO\^.NZZ?>W0_4&YZ=U?^)]>;4^ZTE2L6
M3H<1%C\Q3@H #XJJ*:.X47TWL/H.GWM1O47,7MGL.\1&OC6-MJ^4B1*DJXI\
M,BNO <. X=<MO=K8Y>7/<[?]FE%/!O[G3\XWE:2)LD_%$R-Q/'B>/0T^Y!ZC
MWKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>ZUW?YJ6W9L5\B\-FRLAI-S];8"JCF)'C^\Q>5K\354R?3E(XJ>1OQ^X.?
MJ!RK^^EM4ME[K6^XT.B\L(6!\M<<DT3*/L548_Z<?EU@^Y+NT5[[2W&VU'B6
M5_.I'GHDBAE5C]K,ZC_2''F;>OA/NR'>/Q:Z9R,4PD?&;3@VG4*6)>"?9M5+
MM;PR!B2/12(R VNC*0 "/>=?W>-\CW_V8Y?NHVU&&V%LWJ#:LUO0\:8C!']$
M@C!'6!7WC-CDY?\ >OF&S=:":Y-ROH1=JMS48%<RD'^D""20>C4>YIZA3KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__4V'/G/UU+
MLGO+*9R&G*87L*DAW/0RJMHADE04.X:4O^9!4(*IQ^%J$]Y@>T.^+N_*,=FY
MK+9$Q,//3\49^S2= ^:'KEE]Z+DZ3EGW0GW2-:6V[H+E#3'B4"7"U\V\0>*?
M02KT$'QZ[4EZ;[7VSO21I6PT<[XK<T$(=GGVWD[4^2*Q)R[0>BKBC^C2PH#[
M$W.W+B\T\N7&U+3Q2-<1/E*F5SY!LH3Y*QZCSVBY\D]N.?;+F5JFW#&*Y45J
MUO+VR8'Q%,2JOF\:CK8MH*ZCRE#19/'54%;C\C24]?05M-(L]-54=7"*BEJJ
M>5+ADD1E=6!L001[P<FAEMIF@F4HZ$JRD4*L#0@CR((H1UV)M;JVOK6.]LW$
MD4R*Z.IJKHX#*RD8*LI!!'$&O4[W3I_KWOW7NO>_=>Z][]U[KWOW7ND]NC<N
M'V;MW,[JW!6)087 8ZIRF2JY/I'34L9D=8TX+R-PD<:\NY55!) ]J]OL+G=+
MZ+;K)2\LS!%'J2:9] .)/  $G Z*M\WK;>7-GN=]W>016UI&TDC'R517 \V/
M!5&68A1DCK6Y[2W]D>T.PMU[]RBO'4;BRTU9%3,YD^QQT2K28G':S^H4]+%#
M #^=%_>=O+VS0\O;+;;-;Y6! I/#4QR[?[9RS?GUQDYZYLO.>>;K_FN^%'O)
M2X4FNB, )%'7S\.)42OGIKT<G^7CUW-G>S,WV-50$XW8F'FHJ"9E(#;BW+"]
M$HA<\-XZ$5@E"W*^6.]@PO%OO;O:V>P1;'&>^\<,P_X5$0V?MDT4]=+>G61_
MW0>3I-TYVN><)U_0VN(I&WK<7(*"A\],'C:J<-:5IJ%;GO>+/72'KWOW7NJY
M/YBO74N;V)M;L>@@\D^R\I-B<TR*-8P6Y&CCIJJ9[_H@K8H8E4 F]03] ?<Y
M>Q^^BUWBXV*9J+=H'C_YJ15) ^;(6)_YI@=8<_?#Y/DW+E:PYRM4JVVRF*8@
M9\"XTA6)]$F5% ]9B>%>J>J6IJ*.I@K*2:6GJJ6>*JIJB%BDD%1!()89HG7D
M,K ,I'((]Y.21)*K1. RL""#P(."#\B.N=T4TMM,EQ Q22,AE8&A5E-00?(@
MBH/KUL;=!=LX_N?K#;V\:>2/^*&!<7NFB30KX_<M!&L>3A:-.%24E:FG'YBE
MCN ;@8-<Y\MS<J\P3[6X/AUUPM_%$Q)0U/$CX&_I*?+/78[VGY_M/<CD>SYC
MA8?4:1%<IBL=S& )!08"OB2/_A;I6AJ -7L+=23U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=4<?.KN*F[&[-@VC@ZQ:K;?7$=9BS/$Y:"NW/52+_ !^HC((#K 8H
MJ-#:VJ*5D8I("<M_:#E=]CY>.YWBZ;B^*O0\5B /ACY%JES\F4$5'7,'[TGN
M-#SCSNO+^UR![+9M<6H'M>Y8CQV'D0FE80:?$CE25<=$;]RUUC+UL+_#_P#[
M)NZN_P"U7E__ 'IJ[WA5[G?\KUN'^G3_ *M1]=;_ +N__3F=B_YI2_\ :3-T
M93V ^IIZ][]U[HJOS:_[)B[,_P#)+_\ ?@XGW(GM1_RO]A_S?_[1INH(^\Q_
MTY'>_P#J#_[3[7K7^]YF]<GNMD'XX_\ ,A>H?_$?[9_]UD?O!GGG_E<=S_YZ
M)?\ CQZ[&^S7_3J>7O\ G@MO^K:]#5["G4E]>]^Z]U[W[KW7O?NO=1:NEIZZ
MEJJ&KB2>EK()J6J@DYCFIZB,PSQ. ?HRL0?]?W:.1X)%FB.EE((/H0:@_D>F
M;B"&Z@>UN%#QR*593P96!# _(@D=:T':&Q:_K3L+=VQ<BL@FVYFZJA@FD0J:
MO'%_/B<@@(!TU-*\,ZFWT<>\]N7MWBW_ &2VW>"E)T5B!^%N#K]JN&4_9UQ4
MYXY7NN2N;MPY7O =5G,Z*3^..NJ*3RQ)$4<8X-T;CX$]QT^Q.PJ[8&=JUI<!
MV-]G!CYIG*P4>[J)F3%ISP@K8Y'I6-KM**<$V'$;>\G*[[QLB;S9KJGL=18#
MBT+4U_;X9 <>BZ^L@ONH^XL/*W-TO*>Z2:+7>-"QECVI=I41#T'C*S1D^;B$
M' ZNQ]XH==+^O>_=>Z][]U[KWOW7NO>_=>Z][]U[H(^X^Y]F=';6CW7O)Z^:
MFJ<A3XS'XK#0T=5FLI5SW=UH:6NGIHRL,8:69WF5546N79%81\K<J[KS=N1V
M[:PH*J79W+!$ _B*JQJQH% 4DD^@) !]Q?<CEOVPV(;]S&9&1Y%CCBA"--*[
M9.A7>-2$4%W)=0%'$L55BM_\..](?\\KVM_YX]H__7SW(?\ K&\V?\I%I_SD
MF_[9^H+_ .#']L?^4'<_^<-I_P!MO1N^K>Q\5VSLK%;\P>)S^'Q&::M_A]-N
M6EH:+)304E6]&U9]O05-5'XI'C?Q-Y;LHU6L03&7,.Q7/+>[R;/=R1RRQ:=1
MB+,H+*&TU94-0"*XP<<:]9"<C<Y6//W+5OS5M=O/;VUR7\-;E420JCE->F.2
M5=+%3I.JI&:4(J(OLFZ%W7O?NO=>]^Z]UKF_S..J)]D=_P#]^Z:F9,#VOAJ;
M+PS(A%/'N/ 4\.$W%1);^UXUHJR0_DU!_I[Y0??$Y)FY<]T/ZRPH1;;W$LH/
MD)X56&=!\Z"*4^IFZZU_<UYYBYD]K?ZLS.#=;'*T1%>XV\[-- Y^53-$OH(>
MKD/A[W13]Y]"[+W3)5"HW'AZ./:.](VD#3Q[HV_31T]54SA?H:V$P9!0. LX
M7ZJ0,^O87W!B]R/;/;]Z9]5W HM;L5[A<0*JLS?\UD*3CT$@'$'KGW[_ 'MW
M-[:^Y^X[*B:;.X<W5H:=IMIV9E5?^:+AX#ZF(G@1T:+W,O4,=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO= 9\CNX:#HKIK>W8U5)$*_%XJ2DVU22Z&.1W7E
M :+;]'XF_6OW#+-.%!*PI*]B$/N./=CGNU]MN0-QYKG*^+#&4MU-/U+F3L@2
MGF-9#/0&D:NU**>I(]H^0+KW,]P-NY2@!\*:0/<,*_IVT??.]?(Z 52I%9&1
M:U8=4+_R\>LJWM+Y-X+<62CGK<3UTM9V%FZZ77()<O _@VVCU3W'G?(S1585
MO4Z02D?I)',[[JW)]QSG[OVV[7@,D&TAKZ9S4UE!I "QKWF=EEH<LL3D<"1T
M]^]?SE;\E>S=SM%H1'/NQ6QA04%(B*W!"BG8+=6BJ,*TJ \0#LM^^O'7'KKW
MOW7NO>_=>Z][]U[K7L_FR?\ 91>R_P#Q"NW/_>YW'[Y:_?=_Z>MM_P#TJ8/^
MTR_ZZK?<:_Z=)N7_ $MY_P#M#L.K6?@=_P!DD],?]J7-_P#O7Y'WFM]VC_IQ
MW+__ #2F_P"TJ?K"#[S7_3].8?\ FM#_ -HL'1NO<Z=01U[W[KW7O?NO=$K^
M?G5<W:GQHWE#CJ9ZO/;'>E["PL4<?DED;;J2+FX8U +EFQ<]=XT3EY @Y]X]
M_>>Y*DYT]H-PBM4+W.VE;Z( 5)\ ,)@.))-N\VD#+-I'60_W7.=X^2O>';Y+
MMQ':[D&L9B30#QRIA)R  +A(=1.%4L>JR?Y6_<U/LSMC/]59FI6'%=IX^GFP
MLDS$)'O';22U%'2KKLB?>4<M4A:]WEBIXP"6'O#[[F7N!%R_SQ=<E;@X6'>D
M4Q$G NK<,RJ/(>+$T@KQ9TB05)'69/WU/;V7F'D:UYWVY"T^R2,)@!DVEP55
MV/F?"E6(TX*CRN2 #UL%>^HO7*_KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NM97Y^]QCNOY$Y3'[<EDR6W=@I'U[MQ*/74+E,E25SMGJ^DAB+!VGR
M$DE/$\=Q+## P^H]\?OO/\_#W#]UIK7:B9;7:P+& +5O$D1V,SJ!6I>9C&I6
MNM(XR./78[[KGM^?;KVF@N]U'@W>Z$WUP6HOAQNBB!&)II"0*LC!J:))) >'
M5_?QPZQ_T.='=:]=21K'7X';=,^<52&7^\F7D?-;ET2#]2"NJ:A8R>= 4?CW
MT\]IN3OZA>W.T<J,*2VT"F;S_P 8E)FN*'S'C2.%/\('7+CW>YS_ -<#W*WC
MFU"3%=7#"'_GGB AMZCR/@QH6'\1/0W^Y%ZCCKWOW7NO>_=>ZK^B_F.]&R=I
M1]2MMKM.'/OO].NFR4N"VJ<#%F&W%_=HUSSPYIZHT:S'R%TI#+X^1"7]'O&!
M?O8^W+<YCD=K/<5NC>BQ\0PVW@B7Q_I]9879D\(/W$B(OHR(RW;UE(WW1_<I
M>2CSVMYMK6HLC?\ AB:Y\<Q>!]1H"FT$?BE.T RA->#(%[NK ?>3_6+?7O?N
MO=>]^Z]U[W[KW46IIJ>LIZBBK:>&KHZN&6FJJ6IBCGIJFFGC,513U%/*"KQN
MI*NC A@2"+>VIH8IXF@G4.C@JRL RLK"A5@:@@@T(.",'J\,TUO,EQ;N4="&
M5E)5E934,I%""" 00:@Y'6IY\B=A-T-\BM_;/VW/-0Q;-W=3Y;:LRRK)58['
M9""GW7M<"8WU2T]-4TZZV%RRW(O<>^(ONKRR?;7W5W38=I8Q+M]RLEL:U:.-
MPES;Y\V1)$%3Q(J1UW,]IN9Q[G>TVU\P;NHE;<+5HKD4HLDD;/;7./)7DCD-
M!P!H#UM-==[I7?'7^QM[(JHN\-G[9W2J("L:+N#"P9<1H&N0!YK"Y)M[[/<J
M;T.8^5]MYA4 "_M;>YH. \>%):"O^FZXH<V;*>6N:MSY<8DG;[NXMB3Q/@3/
M%4TQ7MZ6?L0]!_KWOW7NHE;1TN1HZK'UT$=515U-/1UE-,-4512U41@J()%_
M*NI96']#[8N+>&[@>UN5UQR*493D,K JP/R()!Z>M[B:TN([JV8I)$RNC#!5
ME(*L/F" 1UJA9FAW/\3_ )+5$,"2MF>H^P8JS'^<^$9S!TE8M;CGE8 VARF,
MD0O87"3$6!]\2K^WWGV1]W72$$W&Q7P9*X\:%6#QDXPMQ;L*XKID/GUW&V^X
MV;WR]GDDE(%OOUB5>F?!F92D@&<O;7"FF?BC'EUM0[/W9@]][5V[O+;-8N0P
M&Z,/09S$UBV4RT61IEJ81,@)T2J&T2QDW1PR-9E(]]I=AWO;>9MEM>8-HD$M
MK>1)-$WJDBAA4>3"M&4Y5@5.0>N)6_['N7+.]W?+V\QF*ZLI7AE7T>-BIH<5
M4TJK##*0PP1TI_9OT4=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%8^1GR[
MZL^,D^V*+?E-NK,9/=4.0JJ#$[/H<-D<A2T..>.*3(9*/,U] L44DDGC@(=B
M[)( MHV(ACW7]].2_9Z2SM^9DN;B:]#LD=JD4CJD94%Y!+-"%5F;2AJ2Q5J#
MM)$U>TOL-SM[RQWMSRP]M;PV)17ENGEC1GD#$)&8H)BS*JZG% %#)4]P!7/0
MO>>V_D-L8]A;1V_O# [>?,5^'H?[XT6(Q]9E),8L8JZ['Q8:NKT:F65WI];R
M*QECD73902(_;/W(VGW4Y;_K3L5K=6MJ97B3ZI(D:0QZ=3H(II@8PQ*5+ ZT
M<::"I#/N?[:;M[4<R_U4WVZM;J[$22O](\KI&)-6E',L,!$A4!Z!2-#H=530
M#=[D3J.^O>_=>Z][]U[JB+^;E_S,7J+_ ,,K.?\ N\'OFK]^;_E;=A_YY)O^
MKPZZ9_<2_P"51W[_ )[(?^K)Z.I_+%_[)8Q/_AZ[Q_\ <R/WD)]SS_IR\/\
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M2N&+-P_W(0#@>B7[[GMW+M?-5I[CV4?^+[FBV]PP_#=0K2,M_P U;=0J\?\
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MEIQ^FNM",QIDZ)DAH#\(=VJ,US5^Y+SQ%L?/E[R9>OICWF$-%7A]3:ZW517
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M!Q/N1/:C_E?[#_F__P!HTW4$?>8_Z<CO?_4'_P!I]KUK_>\S>N3W6R#\<?\
MF0O4/_B/]L_^ZR/W@SSS_P KCN?_ #T2_P#'CUV-]FO^G4\O?\\%M_U;7H:O
M84ZDOKWOW7NO>_=>Z][]U[KWOW7NJSOY@'14V<Q='W/MFA,V0P%*F,WO3TT9
M::IP2-?'9YE3DFB8M#4-I)\+HQ*QP,?<]>S'."6MRW*M^]$F.J DX$GXH_\
M;X91@:@1EG'6%7WL_:V7=+&/W)V2+5+:(([U5'<T _LYZ#CX))20T)\-E8T2
M(]5&1R/$Z2Q.\<D;HZ.CE'B=#J1T=;$$$7!'(/O)<C556 ((R.N?4<C1,&4E
M2IJ",$$<"#Y$=73?$[Y>8OL7'XWK[L?)18_L2DC6CQN7K7B@H=ZPQVCIM,SD
M!,F1Z98"!YR/)$2S/&F*GN3[97&QSR;WL49>Q8ZF1:EH#Q./.+T;\'PM0 ,>
ME/L%]X2QYPM(.4><IA#O$8"1S.0J7@&%HQ-!<TPR&GBGOCJ2R*?[W#/66/7O
M?NO=>]^Z]U[W[KW2"[$['V?U9MFLW9O;,08G%TBLL2,RO79.L\9DAQN)HKAI
MZB6QT1K] "SE45F!MLFQ;IS%?IMNTQ&21N/\*+YN[<%4>9/V"I(!"W.'.?+O
M(>QR<P<S7"V\$8-!Q>5Z$B.).+R-3"C@*LQ50S"@SY =[[B[ZWFVX,FCXW!8
MU)J+:NW$F:6#$XZ1]3RS-])*NHTHU5,%&HA44!(T S,Y+Y/L>3MI^BMSXDTE
M&FEI0NU. ]$7(1?*I)R2>N4'NU[J;Q[J\R'=;X&&TA!2UMP25BC)J2?)I9*
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M.#V#]VKWV7YYEM-]5TVV[<6]_"5.N%XV*K.$IJ\2W8NLB4JT;2+I+A*=*OO
M^T-G[V<BQ7FPLC[E:(;BPF##1.DBAF@+UT^'<*$:-ZT618VU!"]=F+$9?%;A
MQ6.SF#R-%EL-EJ*FR.+RF.J8JNAR%#5Q":FJZ2IA)5XW4AE938CWU]L+^RW.
MRBW+;94GMYT5XY$8,CHPJK*PJ"I!J".N.E_87VTWTNV[E$\%Q [1R1R*5='4
MT964T(8$4(/3G[6=).O>_=>Z][]U[KWOW7NO>_=>ZC5%13TM//554\--2TT,
ML]34SRI#3T]/"ADFGGFD(5$1069F(  ))M[9EEB@B::9@B("S,Q 55 J22<
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M &23TQ_VI<W_ .]?D?>:WW:/^G'<O_\ -*;_ +2I^L(/O-?]/TYA_P":T/\
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M4;"IHRD>77'3G3E>^Y*YLW#E3<@1-83R0DD4U*K'1(,#MD33(AH*JP/GTO\
MV)^@SU[W[KW7O?NO=>]^Z]UK#?S#LU0YKY:]G&@E2>+%Q[2PLTT;ZD:NQ^T*
M%,A$.+@PS%X'!^CQM[XZ?>IW"WW#WRWCZ9M2P_31$CAK2UA#C[5>J'^DIZ[,
M?=0VZYV[V*V872Z3,;J8 \=$EU,4/V.@#C^BPZV"OC50U>.^/'1E#722O5P=
M2]?"99D*20,^UJ61:-E))_8!$(Y^B?0?0=1?:*WGM?:KENWN22Z[98UK@K6V
MC.CB?@!T?[7@.'7*WWBN8+SW8YEN;8 (VZ7U*9#4N9!KX#XR-?\ MN)X]#?[
MD;J.>O>_=>Z][]U[JHC^9_\ &ZIW/@J#Y ;2H6GRNT:"+#=@4E+$&FJMK+.S
MXW<>B/U,V/DE>*J:Q/V[J[%8J9C[P5^^1[2S;QML7NAL<1::Q017JJ,M;U)C
MGH,DP,Q60T)\)@Q(2$]9X_<O]W8=FW27VLWV33!?N9;%F.%N=($D%3@"=5#1
MBH'BJ5 +S#H&_P"6[\MZ'9M0G0/8^52CV[E\@]1USG*^<1T>%S>1F,E9M:KF
ME.F*GKIF,U(Y("5+2(U_N%* #[I7OE;<ORCVPYLF$=K<.6L)G-%BFD-6MF)P
MJ3,2\1P!,S*:^*-,@_>\]B;KF&(^Z7*,!DN[= M_"BU>:&,42Y4#+20H DHR
M3"J,*>$=5[?OI3US-Z][]U[KWOW7NO>_=>Z][]U[KWOW7ND!V;V7M#J'9&=[
M WQDTQ>WL!2F:>2VNIK*F0^*BQ>.IAS-4U,I6*&,?4F[%5#, OS?S?L7(O+M
MSS1S%,(;6U6K'BSL<)'&O%I)&HJ*.)-20 2!1R9R?OW/O,EMRMRW"9KJZ:BC
M@J*,O)(W!8XUJSL> % "Q .LWN',=E_.7Y)P_:4I7,;URD.*PU#=Y\=LG9>-
M9I$-0ZA;4]!3>6JJI% ::4R,J^254/(+=K_F_P"\?[N*;=#X^XR".),M':6D
M=2-1QV0QZI)& !D<N0-;A3V*VJPY/^[5[/L)WK;[=&9)GPLEY=R4!T@U_4GD
MTQQJ21&@0,=$98;-?6^PL#U=L/:G7NV83#A-I8:CP]%J $M3]NEZJOJ=/!FJ
M9FDJ)V'UD=C^??8+E+EG;.3>6K+E;9UTV]C$L25XMI'<[?TY'+.Y\V8GKCAS
M=S1N?.G,U]S5O+:KF_F>5Z<%U'M1?Z$:!40>2J!TN/8CZ#G7O?NO=>]^Z]U1
M%_-R_P"9B]1?^&5G/_=X/?-7[\W_ "MNP_\ /)-_U>'73/[B7_*H[]_SV0_]
M63T=3^6+_P!DL8G_ ,/7>/\ [F1^\A/N>?\ 3EX?^>NZ_P"/+UCQ]\O_ *?9
M/_SQVG_'&ZL)]Y3=8I]>]^Z]U[W[KW4>>""I@GIZB"*HIZB*2"HIYXTEAJ(9
M4,<L,T4@*NCJ2K*P((-C[;DCCFC:*50ZN"&4@$$$4((."",$'!'5HY)(9%FA
M8HZ$%6!(((-001D$'((R#UJ\_+CH;/?%[O"9MO\ WV-VIE<G_?+JS<%(\T+T
M,-/7+6+BX*U22E9AZC1%?69#&*>H.GS*!QK]\_;3<_9OW&8[7KAL9I/JMNG4
MD%%5P_AA^(EM9*+QU:?"E-/$ Z[2>Q/N=MGO1[:J-UT37T$?TFY0, 0[,A3Q
M"G Q74=6X:=7BQ"OAD]7G_#WY1X3Y)]>03U4]+1]E;8I:.CW[@8P(-52P,4.
MY,5 3S15I1G"J28)-4+<"-Y.D/L+[S;=[M\K++,RQ[O9JJWL(Q5J4%Q&/]\R
MD$@"OAO6-N"L_-/W_P#97<O9_FMHH%:39KUF>RG.:+6IMY3Y30@@5-/$2DBY
M+*AO_<[]0+U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5]?/+Y9T70^QZG9.TLDA[
M=WMC9(<6E.^J?:. J]=)4[LJ=-]$QTR0XY&()F!FLR0,K8N_>6][[?VUY;;E
MW9)A^_=QC(C"G-K U5:Y;T;#+ #Q>KY6,@Y3?=B]C+CW.YE3F3?83^X=MD!D
M+#%U.M&6U7U3*O<$5I'2/#2 K7?_ "U_CA5=C]DKW/N:B8[*ZTR"RX5JF,-%
MG]_K&)\?'$6'J3%JZ5\K@@K.:51J#2:<5/NC>TTW-G-H]P-XC/[NV=ZQ:AB>
M] #(!7B+<$3,?*3P1D%J99?? ]W8.4>43[>[/(/WCO*4ETG,%B25<FG W)!A
M4><?C'!"5V%??4WKE/U[W[KW7O?NO=>]^Z]UK<?S.O\ LJ?+?^&3L[_W$D]\
MD_OB?]/IF_YY+7_CC==>/N;?].1@_P">N[_X^G5X7Q,_[)FZ*_\ $8;1_P#=
M3'[Z->R/_3H.6O\ I76O_5I>N;GOE_T^+F;_ *6-U_U=;HPON4NHJZ][]U[K
MWOW7NO>_=>Z][]U[KWOW7NM;C^9U_P!E3Y;_ ,,G9W_N))[Y)_?$_P"GTS?\
M\EK_ ,<;KKQ]S;_IR,'_ #UW?_'TZNH^%W_9+'2/_AE4O_N9-[Z$?=\_Z<OR
M[_SR+_Q]^N=WWA_^GV<Q_P#/6W_'$Z,_[F3J&.O>_=>Z][]U[I ]G=>X#M?K
M_=O7.YXC)A=W86JQ-4Z*CS4<T@$U#DZ0277STE0D553E@0)(U)! M[#'./*V
MV<[<KWW*F[BMO?1-$Q !*$Y21:XUQ.%D2N ZJ3T)>3>:]TY'YIL.;=F:EQ82
MK*H-0' P\;4SHEC+1O3)1V ZU?:*I[/^&'R&$CQ"EW?USG7BJ*=_/'B-U[?J
MDTR)<A6DQ^4HGU1O;4@=7&B:,:>.%O/SC]W_ -T];+HOMIF(93J$5S PH1Y%
MH;B(U4TJNH,-,B"G:&XAY+^\+[4Z VNPW>$%6&DRVTZFH/F%GMIA1A72Q4J=
M4;FNS7TUV_L[O/8&$[#V17"IQ>4B\=90R21_Q+ 9>%5_B&"S$$9/CJ(&(N#P
MZ%)8RT4B,W8'D#GS8/<CE>WYJY=D#PS"CH2/$AE%-<,H'PNA/V,I5U)1E8\;
MO<'D'F#VUYIN>5.8XRDT!JC@'PYXB3HFB8_%&X'VJP9& =&4"K[&O0*Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NJ5/YE'RTHJFEJ_CIUWE$JB:F)NTLWCZA7AB:
MCF$U/L>GJ(B=3K*JS9321H*1TQ))J8UYZ?>Y]\;>:%_:CE68.=0.XS(U0-)J
MMFK#B0P#7%/A*K"229D'1/[G_L5<P3Q^[7-D)0:2-MA=:$ZQ1KQE(P"A*VU?
MB#-,  (7*_\ Y87QOJMH;;R/?6[:!J?-;WQPQ6PZ6JB*5%%LYYEJ*S.^.505
M;)RQQ"F8 '[:+6K-'4^Q1]SGVFFV+:)?<S?(BEQN,?AV:L*%+4D,\U",&X95
M\,\?"34"5FZ"WWS?=V#?MXB]L-AE#V^W/XMZRFJO=@%4AJ#D6ZLWB#AXSZ2
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MHX9*FLJZRID$-/34U/""TCR,0J(H))( %_8IEEB@B:>=@B("S,Q "@"I))P
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M_F15.S*'%=;]_/D,QMNBC@H,)V/3I-D<WA:2,"*GI-TT40::NIHUX6KA#5*
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MS.O^RI\M_P"&3L[_ -Q)/?)/[XG_ $^F;_GDM?\ CC==>/N;?].1@_YZ[O\
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M&\AIEE7AT_[,_F*_*K9,:457O'&[SIJ6T:4N^-O460G3Q^AEGRF-^SKY&O\
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MPR5:(B4],& *TE*D<7I5G#R R'HQ[8>S?)'M/MYMN6H"US( )KN6CW$OG0L
M D=:4CC"I@%@SC4>;GNE[S\\^[FX"YYFN MM$28;2&J6\/E4*22\E*@RR%GR
M0I5#I!B_<K=11U[W[KW7O?NO=>]^Z]U[W[KW58OSQ^(G:WR0W;L+-]>U&TH:
M+;6W<GBLBNX\Q78Z9JFLR8JXS3K2TE3J72.26!!_'O#O[RWL5SM[M[[MFX\J
MO;+':021OX\KQG4TFH:0L4E13B21GRZS*^[%[\\D>T.Q;IMW-:7+27D\<D?@
M1)(-*QZ3J+2QT->  .//HQ7PRZ7WAT)TE0]>[XEPTN>IMQ;@RLCX*MGK\?\
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MF20I;1TXE(Z$YHI/4A7?,?L3[#6#6HDL-G(&8(%5KN3TU1QA[F2O /)4#%6
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MZO3H#\]_\DG_ )9OX_\ DJ?[C\/]6KY=5S;D_P"!]+_V[3_XNLG_  !_S_\
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M?7_K5_QU]Q#[N_\ )&_Y8'P/_P E_P#W'_Z)_BZF#V@_Y+'_ #L'QI_R0/\
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CIO[7XV_MO[7_ )N?T_7IV]K>D?7O?NO=>]^Z]U[W[KW7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6821523872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>May 13, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DARE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Dare Bioscience, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001401914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,683,411<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and entity information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6821780592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,505,026<span></span>
</td>
<td class="nump">$ 6,805,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">166,713<span></span>
</td>
<td class="nump">31,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">588,524<span></span>
</td>
<td class="nump">403,097<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">4,260,263<span></span>
</td>
<td class="nump">7,240,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">8,245<span></span>
</td>
<td class="nump">9,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">751,347<span></span>
</td>
<td class="nump">577,968<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">5,019,855<span></span>
</td>
<td class="nump">7,827,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable</a></td>
<td class="nump">325,618<span></span>
</td>
<td class="nump">459,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">690,829<span></span>
</td>
<td class="nump">631,351<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,016,447<span></span>
</td>
<td class="nump">1,091,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">223,039<span></span>
</td>
<td class="nump">9,711<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,239,486<span></span>
</td>
<td class="nump">1,100,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 120,000,000 shares authorized; 11,422,161 shares issued and outstanding each period</a></td>
<td class="nump">1,143<span></span>
</td>
<td class="nump">1,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(89,107)<span></span>
</td>
<td class="num">(96,728)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">35,889,940<span></span>
</td>
<td class="nump">35,791,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(32,021,607)<span></span>
</td>
<td class="num">(28,969,767)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">3,780,369<span></span>
</td>
<td class="nump">6,726,620<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 5,019,855<span></span>
</td>
<td class="nump">$ 7,827,387<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6821629920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">11,422,161<span></span>
</td>
<td class="nump">11,422,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">11,422,161<span></span>
</td>
<td class="nump">11,422,161<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6809121584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 1,277,180<span></span>
</td>
<td class="nump">$ 1,303,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">1,693,391<span></span>
</td>
<td class="nump">1,086,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseFee', window );">License expenses</a></td>
<td class="nump">112,500<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,187,519<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">3,083,071<span></span>
</td>
<td class="nump">7,677,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(3,083,071)<span></span>
</td>
<td class="num">(7,677,361)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">31,231<span></span>
</td>
<td class="nump">11,744<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,051,840)<span></span>
</td>
<td class="num">(7,665,617)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">7,621<span></span>
</td>
<td class="num">(13,746)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (3,044,219)<span></span>
</td>
<td class="num">$ (7,679,363)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per common share - basic and diluted (in usd per share)</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.88)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted (in shares)</a></td>
<td class="nump">11,422,161<span></span>
</td>
<td class="nump">8,684,550<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109240241&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6821474800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock [Member]</div></th>
<th class="th"><div>Additional paid-in capital [Member]</div></th>
<th class="th"><div>Accumulated other comprehensive loss [Member]</div></th>
<th class="th"><div>Accumulated deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,047,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="nump">$ 13,292,783<span></span>
</td>
<td class="nump">$ 605<span></span>
</td>
<td class="nump">$ 25,541,210<span></span>
</td>
<td class="num">$ (18,080)<span></span>
</td>
<td class="num">$ (12,230,952)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">9,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares', window );">Net proceeds from issuance of common stock and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued', window );">Net proceeds from issuance of common stock and warrants</a></td>
<td class="nump">$ 1,037,764<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">1,037,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock via public offering, net (in shares)</a></td>
<td class="nump">375,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock via public offering, net</a></td>
<td class="nump">$ 9,160,048<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">9,159,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(7,665,617)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,665,617)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(13,746)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,746)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,422,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2018</a></td>
<td class="nump">15,820,356<span></span>
</td>
<td class="nump">$ 1,142<span></span>
</td>
<td class="nump">35,747,609<span></span>
</td>
<td class="num">(31,826)<span></span>
</td>
<td class="num">(19,896,569)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,422,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">6,726,620<span></span>
</td>
<td class="nump">$ 1,143<span></span>
</td>
<td class="nump">35,791,972<span></span>
</td>
<td class="num">(96,728)<span></span>
</td>
<td class="num">(28,969,767)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 97,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock via public offering, net (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,051,840)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,051,840)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">7,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,422,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="nump">$ 3,780,369<span></span>
</td>
<td class="nump">$ 1,143<span></span>
</td>
<td class="nump">$ 35,889,940<span></span>
</td>
<td class="num">$ (89,107)<span></span>
</td>
<td class="num">$ (32,021,607)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109240241&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6822500208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (3,051,840)<span></span>
</td>
<td class="num">$ (7,665,617)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Non-cash adjustments reconciling net loss to operating cash flows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,150<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">97,968<span></span>
</td>
<td class="nump">9,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_NonCashLeaseExpense', window );">Non-cash lease expenses</a></td>
<td class="nump">10,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,187,519<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="num">(135,676)<span></span>
</td>
<td class="nump">255,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(201,129)<span></span>
</td>
<td class="nump">20,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">193,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges', window );">Other non-current assets and deferred charges</a></td>
<td class="nump">55,233<span></span>
</td>
<td class="nump">37,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable</a></td>
<td class="num">(134,087)<span></span>
</td>
<td class="num">(40,340)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">59,478<span></span>
</td>
<td class="num">(118,707)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(9,711)<span></span>
</td>
<td class="nump">2,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(3,308,484)<span></span>
</td>
<td class="num">(2,118,887)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants', window );">Net proceeds from issuance of common stock and warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,197,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,197,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">7,621<span></span>
</td>
<td class="num">(13,746)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(3,300,863)<span></span>
</td>
<td class="nump">8,065,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">6,805,889<span></span>
</td>
<td class="nump">7,559,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">3,505,026<span></span>
</td>
<td class="nump">$ 15,625,026<span></span>
</td>
<td class="nump">$ 7,559,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 231,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in other non-current assets and deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_NetProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_NetProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6812716816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of the Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of the Business</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ORGANIZATION AND DESCRIPTION OF THE BUSINESS</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dar&#233; Bioscience, Inc. is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women&#8217;s health. Dar&#233; Bioscience, Inc. and its wholly owned subsidiaries operate in </font><font style="font-family:Arial;font-size:10pt;">one</font><font style="font-family:Arial;font-size:10pt;"> segment. In this report, the &#8220;Company&#8221; refers collectively to Dar&#233; Bioscience, Inc. and its wholly owned subsidiaries, unless otherwise stated or the context otherwise requires.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company is driven by a mission to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health and fertility. The Company's business strategy is to license or otherwise acquire the rights to differentiated product candidates in women's health, some of which have existing clinical proof-of-concept data, and to advance those candidates through clinical development and regulatory approval alone or in collaboration with strategic partners.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has assembled a portfolio of clinical-stage and pre-clinical-stage candidates addressing unmet needs in women&#8217;s health. The Company&#8217;s portfolio includes these four clinical-stage candidates:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis, or BV; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ovaprene, a non-hormonal monthly contraceptive intravaginal ring; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder, or FSAD; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy following menopause. </font></div></td></tr></table><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company's portfolio also includes these pre-clinical stage product candidates:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy, or VVA, in patients with hormone-receptor positive breast cancer;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-RH1, a novel approach to non-hormonal contraception for both men and women by targeting the CatSper ion channel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ORB-204 and ORB-214, 6-month and 12-month formulations of injectable etonogestrel for contraception;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and for fertility support as part of an </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">in vitro</font><font style="font-family:Arial;font-size:10pt;"> fertilization, or IVF, treatment plan;  and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DARE-OAB1, an intravaginal ring containing oxybutynin for the treatment of overactive bladder.</font></div></td></tr></table><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s primary operations have consisted of, and are expected to continue to consist of, product research and development and advancing its portfolio of product candidates through clinical development and regulatory approval.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">To date, the Company has not obtained any regulatory approvals for any of its product candidates, commercialized any of its product candidates or generated any product revenue. The Company is subject to several risks common to clinical-stage biopharmaceutical companies, including dependence on key individuals, competition from other companies, the need to develop commercially viable products in a timely and cost-effective manner, and the need to obtain adequate additional capital to fund the development of product candidates. The Company is also subject to several risks common to other companies in the industry, including rapid technology change, regulatory approval of products, uncertainty of market acceptance of products, competition from substitute products and larger companies, compliance with government regulations, protection of proprietary technology, dependence on third parties, and product liability.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6636174416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Going Concern</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">GOING CONCERN</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, as of </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">, the Company had an accumulated deficit of approximately </font><font style="font-family:Arial;font-size:10pt;">$32.0 million</font><font style="font-family:Arial;font-size:10pt;"> and had cash and cash equivalents of approximately </font><font style="font-family:Arial;font-size:10pt;">$3.5 million</font><font style="font-family:Arial;font-size:10pt;">. The Company also had negative cash flow from operations of approximately </font><font style="font-family:Arial;font-size:10pt;">$3.3 million</font><font style="font-family:Arial;font-size:10pt;"> during the three months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"> In March of 2019, the Company announced that it received a Notice of Award for an additional </font><font style="font-family:Arial;font-size:10pt;">$982,851</font><font style="font-family:Arial;font-size:10pt;"> of the anticipated </font><font style="font-family:Arial;font-size:10pt;">$1.9 million</font><font style="font-family:Arial;font-size:10pt;"> from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, or the NIH Grant, which will be applied to the clinical development efforts supporting Ovaprene. As of March 31, 2019, the Company recorded a receivable in the amount of </font><font style="font-family:Arial;font-size:10pt;">$161,007</font><font style="font-family:Arial;font-size:10pt;"> for expenses eligible for reimbursement under the NIH Grant that were incurred through March 31, 2019. See Note 9, "Grant Award," herein. In April of 2019, the Company completed a sale of common stock raising net proceeds of approximately </font><font style="font-family:Arial;font-size:10pt;">$5.2 million</font><font style="font-family:Arial;font-size:10pt;">. See Note 11, "Subsequent Events," herein. The Company still needs to raise additional capital to continue to fund its operations and to successfully execute its current operating plan, including the development of its current product candidates. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has a history of losses from operations, expects negative cash flows from its operations will continue for the foreseeable future, and expects that its net losses will continue for at least the next several years as it develops its existing product candidates and seeks to acquire, license or develop additional product candidates. These circumstances raise substantial doubt about the Company's ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty of the Company's ability to continue as a going concern.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company is focused primarily on the development and commercialization of innovative products in women&#8217;s health. The Company will continue to incur significant research and development and other expenses related to these activities. If the clinical trials for any of the Company&#8217;s product candidates fail to produce successful results such that those product candidates do not advance in clinical development, then the Company&#8217;s business and prospects may suffer. Even if the product candidates advance in clinical development, they may fail to gain regulatory approval. Even if the product candidates are approved, they may fail to achieve market acceptance, and the Company may never become profitable. Even if the Company becomes profitable, it may not sustain profitability.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company believes that its current available current cash resources will be sufficient to fund planned operations into the first quarter of 2020. For the foreseeable future, the Company's ability to continue its operations will depend on its ability to obtain additional capital.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company is currently evaluating a variety of capital raising options, including financings, government or other grant funding, collaborations and strategic alliances or other similar types of arrangements to cover its operating expenses, including the development of its product candidates and any future product candidates it may license or otherwise acquire. The amount and timing of the Company's capital needs have been and will continue to depend highly on many factors, including the product development programs the Company chooses to pursue and the pace and results of its clinical development efforts. If the Company raises capital through collaborations, strategic alliances or other similar types of arrangements, it may have to relinquish, on terms that are not favorable to the Company, rights to some of its technologies or product candidates it would otherwise seek to develop or commercialize. There can be no assurance that capital will be available when needed or that, if available, it will be obtained on terms favorable to the Company and its stockholders. Additionally, equity or debt financings may have a dilutive effect on the holdings of the Company's existing stockholders. If the Company cannot raise capital when needed, on favorable terms or at all, the Company will not be able to continue development of its product candidates, will need to reevaluate its planned operations and may need to delay, scale back or eliminate some or all of its development programs, reduce expenses, file for bankruptcy, reorganize, merge with another entity, or cease operations. If the Company becomes unable to continue as a going concern, the Company may have to liquidate its assets, and might realize significantly less than the values at which they are carried on its consolidated financial statements, and stockholders may lose all or part of their investment in the Company's common stock. The interim consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6812769552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s significant accounting policies are described in Note 1 to the interim consolidated financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, filed with the Securities and Exchange Commission, or SEC on April 1, 2019. Since the date of those consolidated financial statements, there have been no material changes to the Company&#8217;s significant accounting policies, except as described below.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The accompanying interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as defined by the Financial Accounting Standards Board, or FASB, for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X.&#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management&#8217;s opinion, the accompanying interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results of the interim periods presented.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Interim financial results are not necessarily indicative of results anticipated for any other interim period or for the full year. The accompanying interim consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use, or ROU, lease assets, current portion of lease obligations, and long-term lease obligations on the Company's balance sheets.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ROU lease assets represent the Company's right to use an underlying asset for the lease term and lease obligations represent the Company's obligation to make lease payments arising from the lease. Operating ROU lease assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term. If the lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The ROU lease asset also includes any lease payments made and excludes lease incentives. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. (See Note 7, Leased Properties.)</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The three-level hierarchy of valuation techniques established to measure fair value is defined as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level 1: inputs are unadjusted quoted prices in active markets for identical assets or liabilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level 2: inputs other than level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of assets or liabilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash and cash equivalents of </font><font style="font-family:Arial;font-size:10pt;">$3.5 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$6.8 million</font><font style="font-family:Arial;font-size:10pt;"> measured at fair value as of </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, respectively, are classified within Level 1 of the fair value hierarchy. Other receivables are financial assets with carrying values that approximate fair value due to the short-term nature of these assets. Accounts payable and accrued expenses and other liabilities are financial liabilities with carrying values that approximate fair value due to the short-term nature of these liabilities.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Standards</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In May 2014, FASB issued Accounting Standards Update, or ASU, 2014-09, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Arial;font-size:10pt;">, which impacts the way in which some entities recognize revenue for certain types of transactions. The new standard became effective beginning in 2018 for public companies. Because the Company does not currently have any contracts with customers, the Company&#8217;s adoption of this accounting standard did not impact the Company&#8217;s interim consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In February 2016, FASB issued ASU 2016-02, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:Arial;font-size:10pt;">, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. The new standard is effective for public companies for fiscal years beginning after December&#160;15, 2018, with early adoption permitted. ASU 2016-02 became effective for the Company on January 1, 2019 and was adopted using a modified retrospective approach and the effective date is as of the initial application. Consequently, financial information was not updated, and the disclosures required under ASU 2016-02 are not provided for dates and periods prior to January 1, 2019. ASU 2016-02 provides a number of optional practical expedients and accounting policy elections. The Company elected the package of practical expedients requiring no reassessment of whether any expired or existing contracts are or contain leases, the lease classification of any expired or existing leases, or initial direct costs for any existing leases. The Company recorded approximately </font><font style="font-family:Arial;font-size:10pt;">$232,000</font><font style="font-family:Arial;font-size:10pt;"> right-of-use assets and </font><font style="font-family:Arial;font-size:10pt;">$241,000</font><font style="font-family:Arial;font-size:10pt;"> lease liabilities related to its lease of office space as of the adoption date in the consolidated balance sheets. There are no changes to the statement of operations or cash flows as a result of the adoption.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In January 2017, FASB issued ASU 2017-01, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Business Combinations (Topic 805): Clarifying the Definition of a Business</font><font style="font-family:Arial;font-size:10pt;">, which intended to clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The standard became effective for the Company on January 1, 2018. The Company&#8217;s early adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In July 2017, FASB issued ASU 2017-11, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815): (I) Accounting for Certain Financial Instruments with Down Round Features, (II) Replacement for the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception.</font><font style="font-family:Arial;font-size:10pt;"> This update was issued to provide additional clarity related to accounting for certain financial instruments that have characteristics of both liabilities and equity. In particular, this update addresses freestanding and embedded financial instruments with down round features and whether they should be treated as a liability or equity instrument. Part II simply replaces the indefinite deferral for certain mandatorily redeemable non-controlling interests and mandatorily redeemable financial instruments of nonpublic entities contained within the Accounting Standards Committee Topic 480 with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. For public business entities, the amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company has early adopted ASU 2017-11. As a result, the Company has not recognized the fair value of the warrants containing down round features that were issued in the underwritten offering in February 2018 (see Note 6) as liabilities.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Disclosure Update and Simplification,</font><font style="font-family:Arial;font-size:10pt;"> amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements relating to the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of income is required to be filed. This final rule was effective November 5, 2018. In accordance with the new rule, the Company added a Consolidated Statement of Stockholders' Equity in this report and elected to present a reconciliation in a single statement that shows the changes in stockholders' equity for each interim period, as well as each comparable period.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6630174720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ACQUISITIONS</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Cerulean/Private Dar&#233; Stock Purchase Transaction</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On </font><font style="font-family:Arial;font-size:10pt;">July&#160;19, 2017</font><font style="font-family:Arial;font-size:10pt;">, the Company completed its business combination with Dar&#233; Bioscience Operations, Inc., a privately held Delaware corporation, or Private Dar&#233;, in accordance with the terms of the Stock Purchase Agreement dated as of </font><font style="font-family:Arial;font-size:10pt;">March&#160;19, 2017</font><font style="font-family:Arial;font-size:10pt;">, or the Dar&#233; Stock Purchase Agreement, by and among the Company, Private Dar&#233; and the holders of capital stock and securities convertible into capital stock of Private Dar&#233; named therein, or the Private Dar&#233; Stockholders. Pursuant to the Dar&#233; Stock Purchase Agreement, each Private Dar&#233; Stockholder sold their shares of capital stock in Private Dar&#233; to the Company in exchange for newly issued shares of the Company&#8217;s common stock, and as a result, Private Dar&#233; became a wholly owned subsidiary of the Company and the Private Dar&#233; Stockholders became majority stockholders of the Company. In connection with the closing of that transaction, the Company changed its name from &#8220;Cerulean Pharma Inc.&#8221; to &#8220;Dar&#233; Bioscience, Inc.&#8221; In this report, that transaction is referred to as the Cerulean/Private Dar&#233; stock purchase transaction and &#8220;Cerulean&#8221; refers to Cerulean Pharma Inc. before that transaction closed. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Cerulean/Private Dar&#233; stock purchase transaction was accounted for as a reverse merger under the acquisition method of accounting whereby Private Dar&#233; was considered to have acquired Cerulean for financial reporting purposes because immediately upon completion of the transaction, Private Dar&#233; stockholders held a majority of the voting interest of the combined company. Pursuant to business combination accounting, the Company applied the acquisition method, which requires the assets acquired and liabilities assumed be recorded at fair value with limited exceptions. The excess of the purchase price over the assets acquired and liabilities assumed represents goodwill. The goodwill is primarily attributable to the cash and cash equivalents at closing of the transaction of approximately </font><font style="font-family:Arial;font-size:10pt;">$9.9 million</font><font style="font-family:Arial;font-size:10pt;"> and the impact of the unamortized fair value of stock options granted by Cerulean that were outstanding immediately before the transaction closed of approximately </font><font style="font-family:Arial;font-size:10pt;">$3.7 million</font><font style="font-family:Arial;font-size:10pt;">. The unamortized fair value of such stock options relates to an option modification approved on </font><font style="font-family:Arial;font-size:10pt;">March&#160;19, 2017</font><font style="font-family:Arial;font-size:10pt;"> that provided for an acceleration of vesting of such options upon a change in control event. Such modification became effective upon the closing of the Cerulean/Private Dar&#233; stock purchase transaction. Hence, the unamortized fair value of such stock options is deemed to be part of total purchase consideration and goodwill. Transaction costs associated with the Cerulean/Private Dar&#233; stock purchase transaction of </font><font style="font-family:Arial;font-size:10pt;">$0.96 million</font><font style="font-family:Arial;font-size:10pt;"> are included in general and administrative expense. The total purchase price consideration of approximately </font><font style="font-family:Arial;font-size:10pt;">$24.3 million</font><font style="font-family:Arial;font-size:10pt;"> represents the fair value of the shares of Cerulean stock issued in connection with the Cerulean/Private Dar&#233; stock purchase transaction and the unamortized fair value of the stock options described above, which was allocated as follows:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Purchase Consideration</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fair value of shares issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">20,625</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unamortized fair value of Cerulean options</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,654</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Fair value of total consideration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">24,279</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Assets acquired and liabilities assumed</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,918</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prepaid expense and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,915</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(233</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total assets acquired and liabilities assumed</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,600</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Goodwill</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12,679</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The final allocation of the purchase price depended on finalizing the valuation of the fair value of assets acquired and liabilities assumed. The Company retrospectively recorded purchase price adjustments at the acquisition date to increase current liabilities and current assets by </font><font style="font-family:Arial;font-size:10pt;">$23,609</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$225,778</font><font style="font-family:Arial;font-size:10pt;">, respectively, which reduced the original goodwill amount of </font><font style="font-family:Arial;font-size:10pt;">$12.9 million</font><font style="font-family:Arial;font-size:10pt;"> by </font><font style="font-family:Arial;font-size:10pt;">$202,169</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company tests its goodwill for impairment at least annually as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31</font><font style="font-family:Arial;font-size:10pt;"> and between annual tests if it becomes aware of an event or change in circumstance that would indicate the carrying value may be impaired. The Company tests goodwill for impairment at the entity level because it operates on the basis of a single reporting unit. A goodwill impairment is the amount by which a reporting unit&#8217;s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. When impaired, the carrying value of goodwill is written down to fair value. Any excess of the reporting unit goodwill carrying value over the fair value is recognized as impairment loss.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company assessed goodwill at December&#160;31, 2017. The Company determined there was an impairment and recognized an impairment charge of approximately </font><font style="font-family:Arial;font-size:10pt;">$7.5 million</font><font style="font-family:Arial;font-size:10pt;"> in the consolidated statement of operations and comprehensive loss for the year ended December&#160;31, 2017 and reduced the goodwill carrying value from approximately </font><font style="font-family:Arial;font-size:10pt;">$12.7 million</font><font style="font-family:Arial;font-size:10pt;"> to </font><font style="font-family:Arial;font-size:10pt;">$5.2 million</font><font style="font-family:Arial;font-size:10pt;"> on its consolidated balance sheet as of December&#160;31, 2017. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company assessed goodwill at March 31, 2018, determined there was an impairment and recognized an impairment charge of approximately </font><font style="font-family:Arial;font-size:10pt;">$5.2 million</font><font style="font-family:Arial;font-size:10pt;"> in the interim consolidated statement of operations and comprehensive loss for the three months ended March 31, 2018. As of March 31, 2018, the goodwill carrying value on the Company&#8217;s consolidated balance sheet was written off in its entirety.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Pear Tree Merger</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On </font><font style="font-family:Arial;font-size:10pt;">April&#160;30, 2018</font><font style="font-family:Arial;font-size:10pt;">, the Company entered into an Agreement and Plan of Merger, the Merger Agreement, with Pear Tree Pharmaceuticals, Inc., or Pear Tree, Dar&#233; Merger Sub, Inc., a wholly-owned subsidiary of the Company, or Merger Sub, and two individuals in their respective capacities as Pear Tree stockholders&#8217; representatives. The transactions contemplated by the Merger Agreement closed on </font><font style="font-family:Arial;font-size:10pt;">May&#160;16, 2018</font><font style="font-family:Arial;font-size:10pt;">, and as a result, Pear Tree became the Company&#8217;s wholly owned subsidiary. The Company acquired Pear Tree to secure the rights to develop DARE-VVA1, a proprietary vaginal formulation of tamoxifen, as a potential treatment for vulvar and vaginal atrophy.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company determined that the acquisition of Pear Tree should be accounted for as an asset acquisition instead of a business combination because substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, and therefore, the asset is not considered a business. Transaction costs of approximately </font><font style="font-family:Arial;font-size:10pt;">$452,000</font><font style="font-family:Arial;font-size:10pt;"> associated with the merger are included in the Company&#8217;s research and development expense.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In accordance with the terms of the Merger Agreement, because the Negative Consideration Amount (as defined below) exceeded the Positive Consideration Amount (as defined below), at the time of the closing of the merger, the excess amount (approximately </font><font style="font-family:Arial;font-size:10pt;">$132,000</font><font style="font-family:Arial;font-size:10pt;">) will be offset against future payments otherwise due under the Merger Agreement to certain former and continuing Pear Tree service providers and former holders of Pear Tree&#8217;s capital stock, or the Holders, including the potential </font><font style="font-family:Arial;font-size:10pt;">$75,000</font><font style="font-family:Arial;font-size:10pt;"> payment due on the </font><font style="font-family:Arial;font-size:10pt;">one</font><font style="font-family:Arial;font-size:10pt;">-year anniversary of the closing of the merger. Positive Consideration Amount means the sum of </font><font style="font-family:Arial;font-size:10pt;">$75,000</font><font style="font-family:Arial;font-size:10pt;">, and the cash and cash equivalents held by Pear Tree at closing, and Negative Consideration Amount means the sum of (i) certain Pear Tree indebtedness and transaction expenses, (ii) transaction expenses of the stockholders&#8217; representatives, and (iii) amounts payable under Pear Tree&#8217;s management incentive plan. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Under the Merger Agreement, the Holders will be eligible to receive, subject to certain offsets, tiered royalties, including customary provisions permitting royalty reductions and offset, based on percentages of annual net sales of certain products subject to license agreements the Company assumed and a percentage of sublicense revenue. The Company must also make contingent payments to the Holders that are based on achieving certain clinical, regulatory and commercial milestones, which may be paid, in the Company&#8217;s sole discretion, in cash or shares of the Company&#8217;s common stock.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6812713232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">STOCK-BASED COMPENSATION</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">The 2015 Employee, Director and Consultant Equity Incentive Plan</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prior to the Cerulean/Private Dar&#233; stock purchase transaction, the 2015 Employee, Director and Consultant Equity Incentive Plan of Private Dar&#233;, or the 2015 Private Dar&#233; Plan, governed the issuance of equity awards to Private Dar&#233; employees, officers, non-employee directors and consultants. Options granted under the 2015 Private Dar&#233; Plan have terms of </font><font style="font-family:Arial;font-size:10pt;">ten years</font><font style="font-family:Arial;font-size:10pt;"> from the date of grant unless earlier terminated and generally vest over a </font><font style="font-family:Arial;font-size:10pt;">three</font><font style="font-family:Arial;font-size:10pt;">-year period. Upon closing of the Cerulean/Private Dar&#233; stock purchase transaction, the Company assumed the 2015 Private Dar&#233; Plan and each outstanding option to acquire Private Dar&#233; stock that was not exercised prior to the closing. Options to purchase </font><font style="font-family:Arial;font-size:10pt;">50,000</font><font style="font-family:Arial;font-size:10pt;"> shares of Private Dar&#233; stock were assumed. Such options were assumed on the same terms as were applicable to them under the 2015 Private Dar&#233; Plan and became an option to purchase such number of shares of the Company&#8217;s common stock equal to the number of Private Dar&#233; shares subject to such option multiplied by the exchange ratio specified in the Dar&#233; Stock Purchase Agreement, at a correspondingly adjusted exercise price. Based on the exchange ratio and after giving effect to the reverse stock split effected in connection with the closing of the Cerulean/Private Dar&#233; stock purchase transaction, such options were replaced with options to purchase </font><font style="font-family:Arial;font-size:10pt;">10,149</font><font style="font-family:Arial;font-size:10pt;"> shares of the Company&#8217;s common stock, all of which were outstanding as of </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Private Dar&#233; issued </font><font style="font-family:Arial;font-size:10pt;">900,000</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">200,000</font><font style="font-family:Arial;font-size:10pt;"> shares of fully vested restricted stock to non-employees under the 2015 Private Dar&#233; Plan during 2015 and 2016, respectively. In connection with the closing of the Cerulean/Private Dar&#233; stock purchase transaction, the Company assumed these shares and replaced them with </font><font style="font-family:Arial;font-size:10pt;">223,295</font><font style="font-family:Arial;font-size:10pt;"> restricted shares of the Company&#8217;s common stock (after giving effect to the reverse stock split effected in connection with the closing of the Cerulean/Private Dar&#233; stock purchase transaction).</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">No further awards may be granted under the 2015 Private Dar&#233; Plan following the closing of the Cerulean/Private Dar&#233; stock purchase transaction.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">2014 Employee Stock Purchase Plan</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In March 2014, the Company&#8217;s board of directors adopted, and its stockholders approved the 2014 Employee Stock Purchase Plan, or the ESPP, which became effective in April 2014. The ESPP permits eligible employees to enroll in a </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;">-month offering period whereby participants may purchase shares of the Company&#8217;s common stock, through payroll deductions, at a price equal to </font><font style="font-family:Arial;font-size:10pt;">85%</font><font style="font-family:Arial;font-size:10pt;"> of the closing price of the common stock on the first day of the offering period or on the last day of the offering period, whichever is lower. Purchase dates under the ESPP occur on or about June 30 and December 31 each year. The Company&#8217;s board of directors decided not to initiate a new offering period beginning January 1, 2017 and no offering period has been initiated since then. There was </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;"> stock-based compensation related to the ESPP for the </font><font style="font-family:Arial;font-size:10pt;">three</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;"> or </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Amended and Restated 2014 Stock Incentive Plan</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company maintains the Amended and Restated 2014 Plan, or the Amended 2014 Plan, which was approved by the Company&#8217;s stockholders on July 10, 2018. The Amended 2014 Plan was an amendment and restatement of the Company&#8217;s 2014 Stock Incentive Plan, or the 2014 Plan.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">When adopted, there were </font><font style="font-family:Arial;font-size:10pt;">2,046,885</font><font style="font-family:Arial;font-size:10pt;"> shares of common stock authorized for issuance under the Amended 2014 Plan. The number of authorized shares increases annually on the first day of each fiscal year until, and including, the fiscal year ending December 31, 2024 by the least of (i) </font><font style="font-family:Arial;font-size:10pt;">2,000,000</font><font style="font-family:Arial;font-size:10pt;">, (ii) </font><font style="font-family:Arial;font-size:10pt;">4%</font><font style="font-family:Arial;font-size:10pt;"> of the number of outstanding shares of common stock on such date, or (iii) an amount determined by the Company&#8217;s board of directors. On January 1, 2019, the number of authorized shares increased by </font><font style="font-family:Arial;font-size:10pt;">456,886</font><font style="font-family:Arial;font-size:10pt;"> to </font><font style="font-family:Arial;font-size:10pt;">2,503,771</font><font style="font-family:Arial;font-size:10pt;">, which increase represented </font><font style="font-family:Arial;font-size:10pt;">4%</font><font style="font-family:Arial;font-size:10pt;"> of the number of outstanding shares of common stock on such date.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In March 2017, the Company&#8217;s board of directors approved two modifications to outstanding stock options granted under the 2014 Plan to participants providing services to the Company as of that date. One modification extended the exercise period of such stock options to </font><font style="font-family:Arial;font-size:10pt;">two years</font><font style="font-family:Arial;font-size:10pt;"> after such participant&#8217;s termination date, unless the exercise period absent such modification would be longer. The other modification provided for accelerated vesting of such stock options upon a change in control event. These modifications resulted in unamortized fair value expense of approximately </font><font style="font-family:Arial;font-size:10pt;">$3.7 million</font><font style="font-family:Arial;font-size:10pt;"> and was recorded as part of the total consideration in the Cerulean/Private Dar&#233; stock purchase transaction (see Note 4). The two modifications resulted in certain options remaining outstanding that would have otherwise expired.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">At </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">323,560</font><font style="font-family:Arial;font-size:10pt;"> shares of common stock were reserved for future issuance under the Amended 2014 Plan, and options to purchase </font><font style="font-family:Arial;font-size:10pt;">2,190,360</font><font style="font-family:Arial;font-size:10pt;"> shares of the Company&#8217;s common stock granted under the Amended 2014 Plan were outstanding.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Summary of Stock Option Activity</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The table below summarizes stock option activity under the Amended 2014 Plan, and related information for the </font><font style="font-family:Arial;font-size:10pt;">three</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">. The exercise price of all options granted during the </font><font style="font-family:Arial;font-size:10pt;">three</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;"> was equal to the market value of the Company&#8217;s common stock on the date of the grant. As of </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">, unamortized stock-based compensation expense of </font><font style="font-family:Arial;font-size:10pt;">$1,343,624</font><font style="font-family:Arial;font-size:10pt;"> will be amortized over a weighted average period of </font><font style="font-family:Arial;font-size:10pt;">3.3 years</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Number of Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Outstanding at December 31, 2018 (1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,635,790</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">563,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.76</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Canceled/forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(8,360</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17.81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(70</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">59.48</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Outstanding at March 31, 2019 (unaudited) (1)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,190,360</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8.40</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Exercisable at March&#160;31, 2019 (unaudited)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">650,151</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">25.97</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:0px;padding-top:8px;text-indent:0px;"><font style="padding-top:8px;font-family:Arial;font-size:10pt;padding-right:48px;">(1)</font><font style="font-family:Arial;font-size:10pt;">Includes </font><font style="font-family:Arial;font-size:10pt;">10,149</font><font style="font-family:Arial;font-size:10pt;"> shares subject to options granted under the 2015 Private Dar&#233; Plan assumed in connection with the Cerulean/Private Dar&#233; stock purchase transaction.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Compensation Expense</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total stock-based compensation expense related to stock options granted to employees and directors recognized in the consolidated statement of operations is as follows:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">24,703</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">73,265</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,124</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">97,968</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,124</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The assumptions used in the Black-Scholes option-pricing model for stock options granted to employees and to directors in respect of board services during the </font><font style="font-family:Arial;font-size:10pt;">three</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Expected life in years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10.0</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.70%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">120%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Forfeiture rate</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.0%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.0%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Weighted-average fair value of options granted</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$0.72</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock After the Cerulean/Private Dar&#233; Stock Purchase Transaction</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The </font><font style="font-family:Arial;font-size:10pt;">3.14 million</font><font style="font-family:Arial;font-size:10pt;"> shares of common stock issued in connection with the Cerulean/Private Dar&#233; stock purchase transaction to the Private Dar&#233; stockholders were not registered with the SEC and may only be sold if registered under the Securities Act of 1933, as amended, or pursuant to an exemption from the registration requirements thereunder. The shares held by non-affiliates became eligible for sale </font><font style="font-family:Arial;font-size:10pt;color:#222222;">under&#160;Rule 144 beginning</font><font style="font-family:Arial;font-size:10pt;"> six months after the closing of the Cerulean/Private Dar&#233; stock purchase transaction</font><font style="font-family:Arial;font-size:10pt;color:#222222;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6633911616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">STOCKHOLDERS&#8217; EQUITY</font></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">ATM Sales Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In January 2018, the Company entered into a common stock sales agreement under which the Company may sell up to an aggregate of </font><font style="font-family:Arial;font-size:10pt;">$10 million</font><font style="font-family:Arial;font-size:10pt;"> in gross proceeds through the sale of shares of common stock from time to time in &#8220;at-the-market&#8221; equity offerings (as defined in Rule 415 promulgated under the Securities Act of 1933, as amended), including in sales made directly on the Nasdaq Capital Market, or Nasdaq, to or through a market maker or, subject to the Company's prior approval, in negotiated transactions. The Company agreed to pay a commission of up to </font><font style="font-family:Arial;font-size:10pt;">3%</font><font style="font-family:Arial;font-size:10pt;"> of the gross proceeds of any common stock sold under this agreement plus certain legal expenses. The common stock sales agreement was amended in August 2018 to refer to the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-227019) that was filed to replace the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-206396) that expired on August 28, 2018.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">During the three months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">, the Company issued and sold </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;"> shares under the common stock sales agreement. During the three months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, the Company generated gross proceeds of approximately </font><font style="font-family:Arial;font-size:10pt;">$1.1 million</font><font style="font-family:Arial;font-size:10pt;"> and incurred issuance costs of </font><font style="font-family:Arial;font-size:10pt;">$237,403</font><font style="font-family:Arial;font-size:10pt;"> under this agreement on sales of an aggregate of </font><font style="font-family:Arial;font-size:10pt;">375,000</font><font style="font-family:Arial;font-size:10pt;"> shares of the Company's common stock.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Underwritten Public Offering</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In February 2018, the Company closed an underwritten public offering of </font><font style="font-family:Arial;font-size:10pt;">5.0 million</font><font style="font-family:Arial;font-size:10pt;"> shares of its common stock and warrants to purchase up to </font><font style="font-family:Arial;font-size:10pt;">3.5 million</font><font style="font-family:Arial;font-size:10pt;"> shares of its common stock. Each share of common stock was sold with a warrant to purchase up to </font><font style="font-family:Arial;font-size:10pt;">0.70</font><font style="font-family:Arial;font-size:10pt;"> of a share of the Company&#8217;s common stock. The Company granted the underwriter a </font><font style="font-family:Arial;font-size:10pt;">30</font><font style="font-family:Arial;font-size:10pt;">-day over-allotment option to purchase up to an additional </font><font style="font-family:Arial;font-size:10pt;">750,000</font><font style="font-family:Arial;font-size:10pt;"> shares of common stock and/or warrants to purchase up to </font><font style="font-family:Arial;font-size:10pt;">525,000</font><font style="font-family:Arial;font-size:10pt;"> shares of common stock.&#160; The underwriter exercised the option with respect to warrants to purchase </font><font style="font-family:Arial;font-size:10pt;">220,500</font><font style="font-family:Arial;font-size:10pt;"> shares of common stock. The Company received gross proceeds of </font><font style="font-family:Arial;font-size:10pt;">$10.3 million</font><font style="font-family:Arial;font-size:10pt;">, including the proceeds from the sale of the warrants upon exercise of the underwriter&#8217;s over-allotment option, and net proceeds of approximately </font><font style="font-family:Arial;font-size:10pt;">$9.4 million</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock Warrants</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The warrants issued in the February 2018 underwritten offering have an exercise price of </font><font style="font-family:Arial;font-size:10pt;">$3.00</font><font style="font-family:Arial;font-size:10pt;"> per share and</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"> </font><font style="font-family:Arial;font-size:10pt;">are exercisable immediately and for </font><font style="font-family:Arial;font-size:10pt;">five</font><font style="font-family:Arial;font-size:10pt;"> years from issuance.</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;"> </font><font style="font-family:Arial;font-size:10pt;">The warrants include a price-based anti-dilution provision, which provides that, subject to certain limited exceptions, the exercise price of the warrants will be adjusted downward if the Company issues or sells (or is deemed to issue or sell) securities at a price that is less than the exercise price in effect immediately prior to such issuance or sale (or deemed issuance or sale). In that case, the exercise price of the warrants will be adjusted to equal the price at which the new securities are issued or sold (or are deemed to have been issued or sold). In addition, subject to certain exceptions, if the Company issues, sells or enters into any agreement to issue or sell securities at a price which varies or may vary with the market price of the shares of the Company&#8217;s common stock, the warrant holders have the right to substitute such variable price for the exercise price of the warrant then in effect. The warrants are exercisable only for cash, unless a registration statement covering the shares issued upon exercise of the warrants is not effective, in which case the warrants may be exercised on a cashless basis. A registration statement covering the shares issued upon exercise of the warrants is currently effective.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The exercise price of these warrants was automatically reduced to </font><font style="font-family:Arial;font-size:10pt;">$0.98</font><font style="font-family:Arial;font-size:10pt;"> per share in connection with the initial closing of the Company's underwritten public offering in April 2019. See Note 11, "Subsequent Events," herein.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company estimated the fair value of the warrants as of February 15, 2018 to be approximately </font><font style="font-family:Arial;font-size:10pt;">$3.0 million</font><font style="font-family:Arial;font-size:10pt;"> which has been recorded in equity as of the grant date. The Company early adopted ASU 2017-11 and as a result has recorded the fair value of the warrants as equity (see Note 3).</font></div><div style="line-height:120%;padding-top:8px;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">No</font><font style="font-family:Arial;font-size:10pt;"> warrants were exercised during the three months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;"> or </font><font style="font-family:Arial;font-size:10pt;">2018</font><font style="font-family:Arial;font-size:10pt;">. As of </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">, the Company had these warrants outstanding:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:32%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Shares Underlying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Outstanding Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Expiration Date</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,906</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">120.40</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December&#160;1, 2021</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,737</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">120.40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December&#160;6, 2021</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17,190</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">60.50</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">January&#160;8, 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6,500</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">April&#160;4, 2026</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,720,500</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3.00</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">February&#160;15, 2023</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,750,833</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6812686496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leased Properties<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leased Properties</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">LEASED PROPERTIES</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Effective January 1, 2019, the Company adopted ASC 842, which requires recognition of a right-of-use asset and lease liability for all leases at the commencement date based on the present value of lease payments over the lease term. Additional qualitative and quantitative disclosures regarding the Company's leasing arrangements are also required. The Company adopted ASC 842 prospectively and elected the package of transition practical expedients that does not require reassessment of: (1) whether any existing or expired contracts are or contain leases, (2) lease classification and (3) initial direct costs. In addition, the Company has elected other available practical expedients to not separate lease and nonlease components, which consist principally of common area maintenance charges, for all classes of underlying assets and to exclude leases with an initial term of 12 months or less.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has one lease for its corporate headquarters that commenced on July 1, 2018 for </font><font style="font-family:Arial;font-size:10pt;">3,169</font><font style="font-family:Arial;font-size:10pt;"> square feet of office space. The term of the lease is </font><font style="font-family:Arial;font-size:10pt;">37 months</font><font style="font-family:Arial;font-size:10pt;"> and terminates on July 31, 2021. The Company has the option to extend the term of the lease for </font><font style="font-family:Arial;font-size:10pt;">one year</font><font style="font-family:Arial;font-size:10pt;"> at the Company's discretion. The gross monthly base rent is </font><font style="font-family:Arial;font-size:10pt;">$8,873</font><font style="font-family:Arial;font-size:10pt;">, which will increase approximately </font><font style="font-family:Arial;font-size:10pt;">4%</font><font style="font-family:Arial;font-size:10pt;"> per year, subject to certain future adjustments. The base rent was abated during the second month of the lease. The Company evaluates renewal options at lease inception and on an ongoing basis, and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. The lease does not require material variable lease payments, a residual value guarantee or restrictive covenants.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The lease does not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment. The Company used an incremental borrowing rate of 7% as of January 1, 2019 for the operating lease that commenced prior to that date. The depreciable lives of operating lease assets and leasehold improvements are limited by the expected lease term.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of March 31, 2019, the Company recorded a right of use asset of </font><font style="font-family:Arial;font-size:10pt;">$212,909</font><font style="font-family:Arial;font-size:10pt;"> within its other non-current  assets and </font><font style="font-family:Arial;font-size:10pt;">$83,751</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$139,288</font><font style="font-family:Arial;font-size:10pt;">, respectively within current and non-current other liabilities on its consolidated balance sheet.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of March 31, 2019, future minimum lease payments for the Company's corporate headquarters are:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Years ending December 31:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Remainder of 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">81,950</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">112,943</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">67,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total future minimum lease payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">262,488</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Less: Difference between future minimum lease payments and discounted operating lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">39,449</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total operating lease liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">223,039</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Operating lease costs were&#160;</font><font style="font-family:Arial;font-size:10pt;">$27,038</font><font style="font-family:Arial;font-size:10pt;">&#160;for the three months ended&#160;March&#160;31, 2019. Operating lease costs are included in general and administrative expenses in the condensed consolidated statement of operations. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash paid for amounts included in the measurement of operating lease liabilities were&#160;</font><font style="font-family:Arial;font-size:10pt;">$26,620</font><font style="font-family:Arial;font-size:10pt;">&#160;for the three months ended&#160;March&#160;31, 2019, and this amount is included in operating activities in the condensed consolidated statements of cash flows.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6812723424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">COMMITMENTS AND CONTINGENCIES</font></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">License and Research Agreements</font></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">ADVA-Tec License Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In March 2017, the Company entered into a license agreement, or the ADVA-Tec License Agreement, with ADVA-Tec, Inc., or ADVA-Tec, under which the Company was granted the exclusive right to develop and commercialize Ovaprene for human contraceptive use worldwide. ADVA-Tec and its affiliates own issued patents or patent applications covering Ovaprene and control proprietary trade secrets covering the manufacture of Ovaprene. As of the date of this report, this patent portfolio includes </font><font style="font-family:Arial;font-size:10pt;">nine</font><font style="font-family:Arial;font-size:10pt;"> issued U.S. patents and </font><font style="font-family:Arial;font-size:10pt;">one</font><font style="font-family:Arial;font-size:10pt;"> pending U.S. patent application, and </font><font style="font-family:Arial;font-size:10pt;">59</font><font style="font-family:Arial;font-size:10pt;"> granted patents and </font><font style="font-family:Arial;font-size:10pt;">four</font><font style="font-family:Arial;font-size:10pt;"> pending patent applications in other major markets, all of which are exclusively licensed to the Company for the human contraceptive use of Ovaprene as a human contraceptive device. The license continues on a country-by-country basis until the later of the life of the licensed patents or the Company&#8217;s last commercial sale of Ovaprene. Under the terms of the ADVA-Tec Agreement, the Company has a right of first refusal to license these patents and patent applications for additional indications.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following is a summary of other terms of the ADVA-Tec License Agreement:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Research and Development.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">ADVA-Tec will conduct certain research and development work as necessary to allow the Company to seek a Premarket Approval, or PMA, from the United States Food and Drug Administration, or the FDA, and will supply the Company with its requirements of Ovaprene for clinical and commercial use on commercially reasonable terms. The Company must use commercially reasonable efforts to develop and commercialize Ovaprene, and must meet certain minimum spending amounts per year, such amounts totaling </font><font style="font-family:Arial;font-size:10pt;">$5.0 million</font><font style="font-family:Arial;font-size:10pt;"> in the aggregate over the first </font><font style="font-family:Arial;font-size:10pt;">three years</font><font style="font-family:Arial;font-size:10pt;">, to cover such activities until a final PMA is filed, or until the first commercial sale of Ovaprene, whichever occurs first.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Milestone Payments.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">The Company will pay ADVA-Tec: (1) up to </font><font style="font-family:Arial;font-size:10pt;">$14.6 million</font><font style="font-family:Arial;font-size:10pt;"> in the aggregate based on the achievement of specified development and regulatory milestones; and (2) up to </font><font style="font-family:Arial;font-size:10pt;">$20 million</font><font style="font-family:Arial;font-size:10pt;"> in the aggregate based on the achievement of certain worldwide net sales milestones. The development and regulatory milestones  include: the completion of a successful postcoital clinical study, which is required before the Company can commence a Phase 3 pivotal human clinical trial; approval by the FDA to commence such Phase 3 pivotal human clinical trial; successful completion of such Phase 3 pivotal human clinical trial; the FDA&#8217;s acceptance of a PMA filing for Ovaprene; the FDA&#8217;s approval of the PMA for Ovaprene; obtaining Conformit&#233; Europ&#233;enne Marking of Ovaprene in at least </font><font style="font-family:Arial;font-size:10pt;">three</font><font style="font-family:Arial;font-size:10pt;"> designated European countries; obtaining regulatory approval in at least three designated European countries; and obtaining regulatory approval in Japan. Because these milestone payments depend upon the successful progress of the Company&#8217;s product development programs, the Company cannot estimate with certainty when these payments will occur, if ever.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Royalty Payments.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">After the commercial launch of Ovaprene, the Company will pay to ADVA-Tec royalties based on aggregate annual net sales of Ovaprene in specified regions, at a royalty rate that will vary between </font><font style="font-family:Arial;font-size:10pt;">1%</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">10%</font><font style="font-family:Arial;font-size:10pt;"> and will increase based on various net sales thresholds.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Termination Rights.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">Unless earlier terminated, the license the Company received under the ADVA-Tec License Agreement continues on a country-by-country basis until the later of the life of the licensed patents or the Company's last commercial sale of Ovaprene. In addition to customary termination rights for both parties: (A) the Company may terminate the agreement with or without cause in whole or on a country-by-country basis upon </font><font style="font-family:Arial;font-size:10pt;">60</font><font style="font-family:Arial;font-size:10pt;"> days prior written notice; and (B) ADVA-Tec may terminate the agreement if the Company develops or commercializes any non-hormonal ring-based vaginal contraceptive device competitive to Ovaprene or if the Company fails to: (1) in certain limited circumstances, commercialize Ovaprene in certain designated countries within three years of the first commercial sale of Ovaprene, (2) satisfy the annual spending obligation described above, (3) use commercially reasonable efforts to complete all necessary pre-clinical and clinical studies required to support and submit a PMA, (4) conduct clinical trials as set forth in the development plan that is agreed by the Company and ADVA-Tec, and as may be modified by a joint research committee, unless such failure is caused by events outside of the Company&#8217;s reasonable control, or (5) enroll a patient in the first non-significant risk medical device study or clinical trial as allowed by an institutional review board within </font><font style="font-family:Arial;font-size:10pt;">six months</font><font style="font-family:Arial;font-size:10pt;"> of the production and release of Ovaprene, unless such failure is caused by events outside of its reasonable control.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For products currently in development, future potential milestone payments based on product development are approximately </font><font style="font-family:Arial;font-size:10pt;">$14.6 million</font><font style="font-family:Arial;font-size:10pt;"> as of </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">. Future potential milestone payments related to commercialization totaled </font><font style="font-family:Arial;font-size:10pt;">$20 million</font><font style="font-family:Arial;font-size:10pt;"> at </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">. There are </font><font style="font-family:Arial;font-size:10pt;">1</font><font style="font-family:Arial;font-size:10pt;">-</font><font style="font-family:Arial;font-size:10pt;">10%</font><font style="font-family:Arial;font-size:10pt;"> royalties required under the license agreement. The Company is unable to estimate with certainty the timing on when these milestone payments will occur as these payments are dependent upon the Company's product development programs.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">SST License and Collaboration Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In February 2018, the Company entered into a license and collaboration agreement, or the SST License Agreement, with Strategic Science &amp;&#160;Technologies-D,&#160;LLC and Strategic Science &amp; Technologies, LLC, referred to collectively as SST. The SST License Agreement provides the Company with an exclusive, royalty-bearing, sublicensable license to develop and commercialize, in all countries and geographic territories of the world, for all indications for women related to female sexual dysfunction and/or female reproductive health, including treatment of female sexual arousal disorder, or the Field of Use, SST&#8217;s topical formulation of Sildenafil Cream, 3.6% as it exists as of the effective date of the SST License Agreement, or any other topically applied pharmaceutical product containing sildenafil or a salt thereof as a pharmaceutically active ingredient, alone or with other active ingredients, but specifically excluding any product containing ibuprofen or any salt derivative of ibuprofen, or the Licensed Products.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following is a summary of other terms of the SST License Agreement:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Invention </font><font style="font-family:Arial;font-size:10pt;">Ownership</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">The Company retains rights to inventions made by its employees, SST retains rights to inventions made by its employees, and each party shall own a </font><font style="font-family:Arial;font-size:10pt;">50%</font><font style="font-family:Arial;font-size:10pt;"> undivided interest in all joint inventions.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Joint </font><font style="font-family:Arial;font-size:10pt;">Development</font><font style="font-family:Arial;font-size:10pt;font-style:italic;"> Committee</font><font style="font-family:Arial;font-size:10pt;">. The parties will collaborate through a joint development committee that will determine the strategic objectives for, and generally oversee, the development efforts of both parties under the SST License Agreement.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Development</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">The Company must use commercially reasonable efforts to develop the Licensed Products in the Field of Use in accordance with a development plan in the SST License Agreement, and to commercialize the Licensed Products in the Field of Use. The Company is responsible for all reasonable internal and external costs and expenses incurred by SST in its performance of the development activities it must perform under the SST License Agreement.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Royalty </font><font style="font-family:Arial;font-size:10pt;">Payments.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">SST will be eligible to receive tiered royalties based on percentages of annual net sales of Licensed Products in the single digits to the mid double digits, subject to customary royalty reductions and offsets, and a percentage of sublicense revenue.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Milestone Payments.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">SST will be eligible to receive payments (1) ranging from </font><font style="font-family:Arial;font-size:10pt;">$0.5 million</font><font style="font-family:Arial;font-size:10pt;"> to </font><font style="font-family:Arial;font-size:10pt;">$18.0 million</font><font style="font-family:Arial;font-size:10pt;"> in the aggregate on achieving certain clinical and regulatory milestones in the U.S. and worldwide, and (2) between </font><font style="font-family:Arial;font-size:10pt;">$10.0 million</font><font style="font-family:Arial;font-size:10pt;"> to </font><font style="font-family:Arial;font-size:10pt;">$100 million</font><font style="font-family:Arial;font-size:10pt;"> in the aggregate upon achieving certain commercial sales milestones. If the Company enters into strategic development or distribution partnerships related to the Licensed Products, additional milestone payments would be due to SST.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">License Term.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s license received under the SST License Agreement continues on a country-by-country basis until the later of </font><font style="font-family:Arial;font-size:10pt;">10 years</font><font style="font-family:Arial;font-size:10pt;"> from the date of the first commercial sale of such Licensed Product or the expiration of the last valid claim of patent rights covering the Licensed Product in the Field of Use. Upon expiration (but not termination) of the SST License Agreement in a particular country, the Company will have a fully paid-up license under the licensed intellectual property to develop and commercialize the applicable Licensed Products in the applicable country on a non-exclusive basis.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Termination.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">In addition to customary termination rights for both parties: (1) prior to receipt of approval by a regulatory authority necessary for commercialization of a Licensed Product in the corresponding jurisdiction, including New Drug Application Approval, or NDA Approval, the Company may terminate the SST License Agreement without cause upon </font><font style="font-family:Arial;font-size:10pt;">90</font><font style="font-family:Arial;font-size:10pt;"> days prior written notice to SST; (2)&#160;following receipt of approval by a regulatory authority necessary for commercialization of a Licensed Product in the corresponding jurisdiction, including NDA Approval, the Company may terminate the SST License Agreement without cause upon </font><font style="font-family:Arial;font-size:10pt;">180</font><font style="font-family:Arial;font-size:10pt;">&#160;days prior written notice; and (3) SST may terminate the SST License Agreement with respect to the applicable Licensed Product(s) in the applicable country(ies) upon </font><font style="font-family:Arial;font-size:10pt;">30</font><font style="font-family:Arial;font-size:10pt;">&#160;days&#8217; notice to the Company if the Company fails to use commercially reasonable efforts to perform development activities in substantial accordance with the development plan and does not cure such failure within </font><font style="font-family:Arial;font-size:10pt;">60</font><font style="font-family:Arial;font-size:10pt;">&#160;days of receipt of SST&#8217;s notice thereof.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Orbis Development and Option Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In March 2018, the Company entered into an exclusive development and option agreement, or the Orbis Agreement, with Orbis Biosciences, or Orbis, for the development of long-acting injectable etonogestrel contraceptive with 6- and 12-month durations (ORB-204 and ORB-214, respectively). Under the Orbis Agreement, the  Company paid Orbis </font><font style="font-family:Arial;font-size:10pt;">$300,000</font><font style="font-family:Arial;font-size:10pt;"> to conduct the first stage of development work, Stage 1, as follows: </font><font style="font-family:Arial;font-size:10pt;">$150,000</font><font style="font-family:Arial;font-size:10pt;"> upon signing the Orbis Agreement, </font><font style="font-family:Arial;font-size:10pt;">$75,000</font><font style="font-family:Arial;font-size:10pt;"> at the </font><font style="font-family:Arial;font-size:10pt;">50%</font><font style="font-family:Arial;font-size:10pt;"> completion point, not later than 6 months following the date the Orbis Agreement was signed (which the Company paid in September 2018), and </font><font style="font-family:Arial;font-size:10pt;">$75,000</font><font style="font-family:Arial;font-size:10pt;"> upon delivery by Orbis of the 6-month batch, not later than 11 months following the date the Orbis Agreement was signed (which the Company paid in January 2019). Upon Orbis successfully completing Stage 1 of the development program and achieving the predetermined target milestones for Stage 1, the Company will have </font><font style="font-family:Arial;font-size:10pt;">90</font><font style="font-family:Arial;font-size:10pt;"> days to instruct Orbis whether to commence the second stage of development work, Stage 2. Should the Company execute its option to proceed to Stage 2, it will have to provide additional funding to Orbis for such activities. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pre-clinical studies for the 6- and 12-month formulations have been completed, including establishing pharmacokinetics and pharmacodynamics profiles. The collaboration with Orbis will continue to advance the program through formulation optimization with the goal of achieving sustained release over the target time period.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Orbis Agreement provides the Company with an option to enter into a license agreement for ORB-204 and ORB-214 should development efforts be successful.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Juniper Pharmaceuticals - License Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In April 2018,&#160;the Company entered into an Exclusive License Agreement, or the Juniper License Agreement, with Juniper Pharmaceuticals, Inc., or Juniper, under which Juniper granted the Company (a) an exclusive, royalty-bearing worldwide license under certain patent rights, either owned by or exclusively licensed to Juniper, to make, have made, use, have used, sell, have sold, import and have imported products and processes; and (b) a non-exclusive, royalty-bearing worldwide license to use certain technological information owned by Juniper to make, have made, use, have used, sell, have sold, import and have imported products and processes. The Company is entitled to sublicense the rights granted to it under the Juniper License Agreement.</font></div><div style="line-height:120%;padding-top:8px;text-indent:94px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following is a summary of certain terms of the Juniper License Agreement:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Upfront Fee.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">The Company paid a </font><font style="font-family:Arial;font-size:10pt;">$250,000</font><font style="font-family:Arial;font-size:10pt;"> non-creditable upfront license fee to Juniper in connection with the execution of the Juniper License Agreement.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Annual Maintenance Fee</font><font style="font-family:Arial;font-size:10pt;">. The Company will pay an annual license maintenance fee to Juniper on each anniversary of the date of the Juniper License Agreement, the amount of which will be </font><font style="font-family:Arial;font-size:10pt;">$50,000</font><font style="font-family:Arial;font-size:10pt;"> for the first two years and </font><font style="font-family:Arial;font-size:10pt;">$100,000</font><font style="font-family:Arial;font-size:10pt;"> thereafter, and which will be creditable against royalties and other payments due to Juniper in the same calendar year but may not be carried forward to any other year.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Milestone </font><font style="font-family:Arial;font-size:10pt;">Payments.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">The Company must make potential future development and sales milestone payments of (1) up to </font><font style="font-family:Arial;font-size:10pt;">$13.5 million</font><font style="font-family:Arial;font-size:10pt;"> in the aggregate upon achieving certain clinical and regulatory milestones, and (2) up to </font><font style="font-family:Arial;font-size:10pt;">$30.3 million</font><font style="font-family:Arial;font-size:10pt;"> in the aggregate upon achieving certain commercial sales milestones for each product or process covered by the licenses granted under the Juniper License Agreement.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Royalty Payments</font><font style="font-family:Arial;font-size:10pt;">. During the royalty term, the Company will pay Juniper mid-single-digit to low double-digit royalties based on worldwide net sales of products and processes covered by the licenses granted under the Juniper</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">License</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">Agreement. In lieu of such royalty payments, the Company will pay Juniper a low double-digit percentage of all sublicense income the Company receives for the sublicense of rights under the Juniper License Agreement to a third party. The royalty term, which is determined on a country-by-country basis and product-by-product basis (or process-by-process basis), begins with the first commercial sale of a product or process in a country and terminates on the latest of (1) the expiration date of the last valid claim within the licensed patent rights with respect to such product or process in such country, (2) </font><font style="font-family:Arial;font-size:10pt;">10 years</font><font style="font-family:Arial;font-size:10pt;"> following the first commercial sale of such product or process in such country, and (3) when one or more generic products for such product or process are commercially available in such country, except that if there is no such generic product by the 10th year following the first commercial sale in such country, then the royalty term will terminate on the 10-year anniversary of the first commercial sale in such country.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Efforts</font><font style="font-family:Arial;font-size:10pt;">. The Company must use commercially reasonable efforts to develop and make at least one product or process available to the public, which efforts include achieving specific diligence requirements by specific dates specified in the Juniper License Agreement.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">T</font><font style="font-family:Arial;font-size:10pt;">erm. Unless earlier terminated, the term of the Juniper License Agreement will continue on a country-by-country basis until the later of (1) the expiration date of the last valid claim within such country, or (2) 10 years from the date of first commercial sale of a product or process in such country. Upon expiration (but not early termination) of the Juniper License Agreement, the licenses granted thereunder will convert automatically to fully-paid irrevocable licenses. Juniper may terminate the Juniper License Agreement (1) upon </font><font style="font-family:Arial;font-size:10pt;">30</font><font style="font-family:Arial;font-size:10pt;"> days&#8217; notice for the Company&#8217;s uncured breach of any payment obligation under the Juniper License Agreement, (2) if the Company fails to maintain required insurance, (3) immediately upon the Company&#8217;s insolvency or the making of an assignment for the benefit of the Company&#8217;s creditors or if a bankruptcy petition is filed for or against the Company, which petition is not dismissed within </font><font style="font-family:Arial;font-size:10pt;">90 days</font><font style="font-family:Arial;font-size:10pt;">, or (4) upon </font><font style="font-family:Arial;font-size:10pt;">60</font><font style="font-family:Arial;font-size:10pt;"> days&#8217; notice for any uncured material breach by the Company of any of its other obligations under the Juniper License Agreement. The Company may terminate the Juniper License Agreement on a country-by-country basis for any reason by giving </font><font style="font-family:Arial;font-size:10pt;">180</font><font style="font-family:Arial;font-size:10pt;"> days&#8217; notice (or </font><font style="font-family:Arial;font-size:10pt;">90 days</font><font style="font-family:Arial;font-size:10pt;">&#8217; notice if such termination occurs prior to receipt of marketing approval in the United States). If Juniper terminates the Juniper License Agreement for the reason described in clause (4) above or if the Company terminates the Juniper License Agreement, Juniper will have full access including the right to use and reference all product data generated during the term of the Juniper License Agreement that is owned by the Company.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Pear Tree Acquisition</font></div><div style="line-height:120%;padding-top:8px;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company may be required to make certain royalty and milestone payments under the Merger Agreement (see Note 4).</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Hammock/MilanaPharm Assignment and License Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On December 5, 2018, the Company entered into (a) an Assignment Agreement with Hammock Pharmaceuticals, Inc., or the Assignment Agreement, and (b) a First Amendment to License Agreement with TriLogic Pharma, LLC and MilanaPharm LLC, or the License Amendment. Both agreements relate to the Exclusive License Agreement among Hammock, TriLogic and MilanaPharm dated as of January 9, 2017, or the MilanaPharm License Agreement. Under the Assignment Agreement and the MilanaPharm License Agreement, as amended by the License Amendment, the Company acquired an exclusive, worldwide license under certain intellectual property to, among other things, develop and commercialize products for the diagnosis, treatment and prevention of human diseases or conditions in or through any intravaginal or urological applications. The licensed intellectual property relates to the hydrogel drug delivery platform of TriLogic and MilanaPharm known as TRI-726. In DARE-BV1, this proprietary technology is formulated with clindamycin, an antibiotic used to treat certain bacterial infections, including BV, and has been engineered to produce a dual release pattern after vaginal application, providing maximum duration of exposure to clindamycin at the site of infection.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following is a summary of other terms of the License Amendment:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">License Fees.</font><font style="font-family:Arial;font-size:10pt;"> The Company paid </font><font style="font-family:Arial;font-size:10pt;">$25,000</font><font style="font-family:Arial;font-size:10pt;"> to MilanaPharm in connection with the execution of the License Amendment and must pay </font><font style="font-family:Arial;font-size:10pt;">$200,000</font><font style="font-family:Arial;font-size:10pt;"> to MilanaPharm (in the Company's discretion, either in cash or with shares of the Company's common stock) within 15 days of the first to occur of December 5, 2019 or the closing of an equity financing in which the Company raises aggregate proceeds of at least </font><font style="font-family:Arial;font-size:10pt;">$10.0 million</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Milestone Payments.</font><font style="font-family:Arial;font-size:10pt;"> The Company will pay to MilanaPharm (1) up to </font><font style="font-family:Arial;font-size:10pt;">$300,000</font><font style="font-family:Arial;font-size:10pt;"> in the aggregate upon achievement of certain development milestones; and (2) up to </font><font style="font-family:Arial;font-size:10pt;">$1.75 million</font><font style="font-family:Arial;font-size:10pt;"> in the aggregate upon achieving certain commercial sales milestones. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Foreign Sublicense Income.</font><font style="font-family:Arial;font-size:10pt;"> The Company will pay MilanaPharm a low double-digit percentage of all income received by the Company or its affiliates in connection with any sublicense granted to a third party for use outside of the United States, subject to certain exclusions.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Royalty Payments.</font><font style="font-family:Arial;font-size:10pt;"> During the royalty term, the Company will pay MilanaPharm high single-digit to low double-digit royalties based on annual worldwide net sales of licensed products and processes. The royalty term, which is determined on a country-by-country basis and licensed product-by-product basis (or process-by-process basis), begins with the first commercial sale of a licensed product or process in a country and terminates on the latest of (a) the expiration date of the last valid claim of the licensed patent rights that cover the method of use of such product or process in such country, or (b) 10 years following the first commercial sale of such product or process in such country. Royalty payments are subject to reduction in certain circumstances, including as a result of generic competition, patent prosecution expenses incurred by the Company, or payments to third parties for rights or know-how that are required for the Company to exercise the licenses granted to it under the MilanaPharm License Agreement or that are strategically important or could add value to a licensed product or process in a manner expected to materially generate or increase sales.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Efforts</font><font style="font-family:Arial;font-size:10pt;">. The Company must use commercially reasonable efforts and resources to (1) develop and commercialize at least one licensed product or process in the United States and at least one licensed product or process in at least one of Canada, the United Kingdom, France, Germany, Italy or Spain, and (2) continue to commercialize that product or process following the first commercial sale of a licensed product or process in the applicable jurisdiction.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Term</font><font style="font-family:Arial;font-size:10pt;">. Unless earlier terminated, the term of the MilanaPharm License Agreement will continue until (1) on a licensed product-by-product (or process-by-process basis) and country-by-country basis, the date of expiration of the royalty term with respect to such licensed product in such country, and (2) the expiration of all applicable royalty terms under the MilanaPharm License Agreement with respect to all licensed products and processes in all countries. Upon expiration of the term with respect to any licensed product or process in a country (but not upon earlier termination of the MilanaPharm License Agreement), the licenses granted to the Company under the MilanaPharm License Agreement will convert automatically to an exclusive, fully paid-up, royalty-free, perpetual, non-terminable and irrevocable right and license under the licensed intellectual property. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition to customary termination rights for all parties, MilanaPharm may terminate the license granted to the Company solely with respect to a licensed product or process in a country if, after having launched such product or process in such country, (1) the Company, or its affiliates or sublicensees, discontinue the sale of such product or process in such country and MilanaPharm notifies the Company of such termination within 60 days of having first been notified by the Company of such discontinuation, or (2) the Company, or its affiliates or sublicensees, (A) discontinues all commercially reasonable marketing efforts to sell, and discontinues all sales of, such product or process in such country for nine months or more, (B) fails to resume such commercially reasonable marketing efforts within 120 days of having been notified of such failure by MilanaPharm, (C) fails to reasonably demonstrate a strategic justification for the discontinuation and failure to resume to MilanaPharm, and (D) MilanaPharm gives 90 days&#8217; notice to the Company.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following is a summary of other terms of the Assignment Agreement with Hammock:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Assignment; Technology Transfer</font><font style="font-family:Arial;font-size:10pt;">. Hammock assigned and transferred to the Company all of its right, title and interest in and to the MilanaPharm License Agreement and agreed to cooperate to transfer to the Company all of the data, materials and the licensed technology in its possession pursuant to a technology transfer plan to be agreed upon by the parties, with a goal for the Company to independently practice the licensed intellectual property as soon as commercially practical in order to develop and commercialize the licensed products and processes. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Fees</font><font style="font-family:Arial;font-size:10pt;">. The Company paid </font><font style="font-family:Arial;font-size:10pt;">$250,000</font><font style="font-family:Arial;font-size:10pt;"> to Hammock in connection with the execution of the Assignment Agreement and must pay </font><font style="font-family:Arial;font-size:10pt;">$250,000</font><font style="font-family:Arial;font-size:10pt;"> to Hammock (in the Company's discretion either in cash or with shares of the Company's common stock) within 15 days of the first to occur of December 5, 2019 or the closing of an equity financing in which the Company raises aggregate proceeds of at least </font><font style="font-family:Arial;font-size:10pt;">$10.0 million</font><font style="font-family:Arial;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Milestone Payments</font><font style="font-family:Arial;font-size:10pt;">. The Company will pay Hammock up to </font><font style="font-family:Arial;font-size:10pt;">$1.1 million</font><font style="font-family:Arial;font-size:10pt;"> in the aggregate upon achievement of certain clinical and regulatory development milestones.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Term</font><font style="font-family:Arial;font-size:10pt;">. The Assignment Agreement will terminate upon the later of (1) completion of the parties&#8217; technology transfer plan, and (2) payment to Hammock of the last of the payments described above, including the milestone payments.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6629101808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Award<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_GrantAwardTextBlock', window );">Grant Award</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">GRANT AWARD</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In April 2018, the Company received a Notice of Award for the first </font><font style="font-family:Arial;font-size:10pt;">$224,665</font><font style="font-family:Arial;font-size:10pt;"> of the anticipated </font><font style="font-family:Arial;font-size:10pt;">$1.9 million</font><font style="font-family:Arial;font-size:10pt;"> in grant funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, a division of the National Institutes of Health, or the NIH.&#160;The Company must incur and track expenses eligible for reimbursement under the award and submit a detailed accounting of such expenses to receive payment. The Company subsequently received award payments totaling </font><font style="font-family:Arial;font-size:10pt;">$224,665</font><font style="font-family:Arial;font-size:10pt;">. The award payments were applied to clinical development efforts supporting Ovaprene and were recognized in the statement of operations as a reduction to research and development activities as the related costs were incurred to meet those obligations over the period. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On March 11, 2019, the Company received a Notice of Award for an additional </font><font style="font-family:Arial;font-size:10pt;">$982,851</font><font style="font-family:Arial;font-size:10pt;"> of the anticipated </font><font style="font-family:Arial;font-size:10pt;">$1.9 million</font><font style="font-family:Arial;font-size:10pt;"> in grant funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The second award followed the NIH's review of an interim data analysis and other results of the first phase of the research supporting Ovaprene. The award will be applied to clinical development efforts supporting Ovaprene. The remaining portion of the award under the grant, </font><font style="font-family:Arial;font-size:10pt;">$730,722</font><font style="font-family:Arial;font-size:10pt;">, is contingent upon, among other matters, assessment that the results of the ongoing Ovaprene study satisfy specified requirements set out in the award notice, and the availability of funds. At </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">, the Company recorded a receivable of approximately </font><font style="font-family:Arial;font-size:10pt;">$161,007</font><font style="font-family:Arial;font-size:10pt;"> for expenses eligible for reimbursement incurred through </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_GrantAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Award [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_GrantAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6812710112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">NET LOSS PER SHARE</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company computes basic net loss per share using the weighted average number of common shares outstanding during the period. Diluted net income per share is based upon the weighted average number of common shares and potentially dilutive securities (common share equivalents) outstanding during the period. Common share equivalents outstanding, determined using the treasury stock method, are comprised of shares that may be issued under outstanding options and warrants to purchase shares of the Company&#8217;s common stock. Common share equivalents are excluded from the diluted net loss per share calculation if their effect is anti-dilutive.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following potentially dilutive outstanding securities were excluded from diluted net loss per common share for the period indicated because of their anti-dilutive effect:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Potentially dilutive securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Three months ended<br clear="none"/>March&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,190,360</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">543,396</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,750,833</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,751,002</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,941,193</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,294,398</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6628952288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">SUBSEQUENT EVENTS</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Capital Raising</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On April 11, 2019, the Company closed an underwritten public offering of </font><font style="font-family:Arial;font-size:10pt;">4,575,000</font><font style="font-family:Arial;font-size:10pt;"> shares of its common stock at a public offering price of </font><font style="font-family:Arial;font-size:10pt;">$1.10</font><font style="font-family:Arial;font-size:10pt;"> per share. The Company granted the underwriters a 30-day over-allotment option to purchase up to an additional </font><font style="font-family:Arial;font-size:10pt;">686,250</font><font style="font-family:Arial;font-size:10pt;"> shares which was exercised in full on April 12, 2019. Including the over-allotment shares, the Company issued a total of </font><font style="font-family:Arial;font-size:10pt;">5,261,250</font><font style="font-family:Arial;font-size:10pt;"> shares in the underwritten public offering, and received gross proceeds of approximately </font><font style="font-family:Arial;font-size:10pt;">$5.8 million</font><font style="font-family:Arial;font-size:10pt;"> and net proceeds of approximately </font><font style="font-family:Arial;font-size:10pt;">$5.2 million</font><font style="font-family:Arial;font-size:10pt;"> after deducting underwriting discounts and offering expenses.</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">February 2018 Warrant Exercise Price Reduced </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As discussed in Note 6 above, the outstanding warrants to purchase up to an aggregate of </font><font style="font-family:Arial;font-size:10pt;">3,720,500</font><font style="font-family:Arial;font-size:10pt;"> shares of the Company's common that were issued and sold in February 2018 include price-based anti-dilution provisions. Under the terms of those warrants, subject to certain limited exceptions, their exercise price will be reduced each time the Company issues or sells any securities for a consideration per share less than a price equal to the exercise price of those warrants in effect immediately prior to such issuance or sale. If the Company issues shares of common stock for cash, the consideration received therefor will be deemed to be the net amount of consideration the Company received therefor. As of immediately prior to the initial closing of the April 2019 underwritten public offering, the exercise price of the warrants was </font><font style="font-family:Arial;font-size:10pt;">$3.00</font><font style="font-family:Arial;font-size:10pt;"> per share. The net amount of consideration the Company received for shares issued and sold at the initial closing was </font><font style="font-family:Arial;font-size:10pt;">$0.98</font><font style="font-family:Arial;font-size:10pt;"> per share. On April 11, 2019, in accordance with the anti-dilution provision of the warrants and as a result of the sale of such shares, the exercise price of the warrants was automatically reduced to </font><font style="font-family:Arial;font-size:10pt;">$0.98</font><font style="font-family:Arial;font-size:10pt;"> per share.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6760513824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The accompanying interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as defined by the Financial Accounting Standards Board, or FASB, for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X.&#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management&#8217;s opinion, the accompanying interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results of the interim periods presented.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Interim financial results are not necessarily indicative of results anticipated for any other interim period or for the full year. The accompanying interim consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use, or ROU, lease assets, current portion of lease obligations, and long-term lease obligations on the Company's balance sheets.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ROU lease assets represent the Company's right to use an underlying asset for the lease term and lease obligations represent the Company's obligation to make lease payments arising from the lease. Operating ROU lease assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term. If the lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The ROU lease asset also includes any lease payments made and excludes lease incentives. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The three-level hierarchy of valuation techniques established to measure fair value is defined as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level 1: inputs are unadjusted quoted prices in active markets for identical assets or liabilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level 2: inputs other than level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of assets or liabilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash and cash equivalents of </font><font style="font-family:Arial;font-size:10pt;">$3.5 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$6.8 million</font><font style="font-family:Arial;font-size:10pt;"> measured at fair value as of </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, respectively, are classified within Level 1 of the fair value hierarchy. Other receivables are financial assets with carrying values that approximate fair value due to the short-term nature of these assets. Accounts payable and accrued expenses and other liabilities are financial liabilities with carrying values that approximate fair value due to the short-term nature of these liabilities.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standards</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Standards</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In May 2014, FASB issued Accounting Standards Update, or ASU, 2014-09, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Arial;font-size:10pt;">, which impacts the way in which some entities recognize revenue for certain types of transactions. The new standard became effective beginning in 2018 for public companies. Because the Company does not currently have any contracts with customers, the Company&#8217;s adoption of this accounting standard did not impact the Company&#8217;s interim consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In February 2016, FASB issued ASU 2016-02, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:Arial;font-size:10pt;">, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. The new standard is effective for public companies for fiscal years beginning after December&#160;15, 2018, with early adoption permitted. ASU 2016-02 became effective for the Company on January 1, 2019 and was adopted using a modified retrospective approach and the effective date is as of the initial application. Consequently, financial information was not updated, and the disclosures required under ASU 2016-02 are not provided for dates and periods prior to January 1, 2019. ASU 2016-02 provides a number of optional practical expedients and accounting policy elections. The Company elected the package of practical expedients requiring no reassessment of whether any expired or existing contracts are or contain leases, the lease classification of any expired or existing leases, or initial direct costs for any existing leases. The Company recorded approximately </font><font style="font-family:Arial;font-size:10pt;">$232,000</font><font style="font-family:Arial;font-size:10pt;"> right-of-use assets and </font><font style="font-family:Arial;font-size:10pt;">$241,000</font><font style="font-family:Arial;font-size:10pt;"> lease liabilities related to its lease of office space as of the adoption date in the consolidated balance sheets. There are no changes to the statement of operations or cash flows as a result of the adoption.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In January 2017, FASB issued ASU 2017-01, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Business Combinations (Topic 805): Clarifying the Definition of a Business</font><font style="font-family:Arial;font-size:10pt;">, which intended to clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The standard became effective for the Company on January 1, 2018. The Company&#8217;s early adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In July 2017, FASB issued ASU 2017-11, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815): (I) Accounting for Certain Financial Instruments with Down Round Features, (II) Replacement for the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception.</font><font style="font-family:Arial;font-size:10pt;"> This update was issued to provide additional clarity related to accounting for certain financial instruments that have characteristics of both liabilities and equity. In particular, this update addresses freestanding and embedded financial instruments with down round features and whether they should be treated as a liability or equity instrument. Part II simply replaces the indefinite deferral for certain mandatorily redeemable non-controlling interests and mandatorily redeemable financial instruments of nonpublic entities contained within the Accounting Standards Committee Topic 480 with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. For public business entities, the amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company has early adopted ASU 2017-11. As a result, the Company has not recognized the fair value of the warrants containing down round features that were issued in the underwritten offering in February 2018 (see Note 6) as liabilities.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Disclosure Update and Simplification,</font><font style="font-family:Arial;font-size:10pt;"> amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements relating to the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of income is required to be filed. This final rule was effective November 5, 2018. In accordance with the new rule, the Company added a Consolidated Statement of Stockholders' Equity in this report and elected to present a reconciliation in a single statement that shows the changes in stockholders' equity for each interim period, as well as each comparable period.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6821544160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ScheduleOfBusinessCombinationReverseMergerTextBlock', window );">Schedule of Purchase Price Consideration Allocation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The total purchase price consideration of approximately </font><font style="font-family:Arial;font-size:10pt;">$24.3 million</font><font style="font-family:Arial;font-size:10pt;"> represents the fair value of the shares of Cerulean stock issued in connection with the Cerulean/Private Dar&#233; stock purchase transaction and the unamortized fair value of the stock options described above, which was allocated as follows:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Purchase Consideration</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fair value of shares issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">20,625</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Unamortized fair value of Cerulean options</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,654</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Fair value of total consideration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">24,279</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Assets acquired and liabilities assumed</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,918</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prepaid expense and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,915</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(233</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total assets acquired and liabilities assumed</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,600</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Goodwill</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">12,679</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ScheduleOfBusinessCombinationReverseMergerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of business combination reverse merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ScheduleOfBusinessCombinationReverseMergerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6786929952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity for Amended 2014 Plan and Related Information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The table below summarizes stock option activity under the Amended 2014 Plan, and related information for the </font><font style="font-family:Arial;font-size:10pt;">three</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">. The exercise price of all options granted during the </font><font style="font-family:Arial;font-size:10pt;">three</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;"> was equal to the market value of the Company&#8217;s common stock on the date of the grant. As of </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">, unamortized stock-based compensation expense of </font><font style="font-family:Arial;font-size:10pt;">$1,343,624</font><font style="font-family:Arial;font-size:10pt;"> will be amortized over a weighted average period of </font><font style="font-family:Arial;font-size:10pt;">3.3 years</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Number of Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Outstanding at December 31, 2018 (1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,635,790</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">563,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.76</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Canceled/forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(8,360</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17.81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(70</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">59.48</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Outstanding at March 31, 2019 (unaudited) (1)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,190,360</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8.40</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Exercisable at March&#160;31, 2019 (unaudited)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">650,151</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">25.97</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:0px;padding-top:8px;text-indent:0px;"><font style="padding-top:8px;font-family:Arial;font-size:10pt;padding-right:48px;">(1)</font><font style="font-family:Arial;font-size:10pt;">Includes </font><font style="font-family:Arial;font-size:10pt;">10,149</font><font style="font-family:Arial;font-size:10pt;"> shares subject to options granted under the 2015 Private Dar&#233; Plan assumed in connection with the Cerulean/Private Dar&#233; stock purchase transaction.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total stock-based compensation expense related to stock options granted to employees and directors recognized in the consolidated statement of operations is as follows:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">24,703</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">73,265</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,124</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">97,968</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,124</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The assumptions used in the Black-Scholes option-pricing model for stock options granted to employees and to directors in respect of board services during the </font><font style="font-family:Arial;font-size:10pt;">three</font><font style="font-family:Arial;font-size:10pt;"> months ended </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Expected life in years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10.0</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.70%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">120%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Forfeiture rate</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.0%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0.0%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Weighted-average fair value of options granted</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:20px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$0.72</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6812729696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Common Stock Warrants Outstanding</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">March&#160;31, 2019</font><font style="font-family:Arial;font-size:10pt;">, the Company had these warrants outstanding:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:32%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Shares Underlying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Outstanding Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Expiration Date</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,906</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">120.40</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December&#160;1, 2021</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,737</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">120.40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December&#160;6, 2021</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17,190</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">60.50</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">January&#160;8, 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6,500</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">April&#160;4, 2026</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,720,500</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3.00</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">February&#160;15, 2023</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,750,833</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6630288032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leased Properties (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future Minimum Lease Payments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"></font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Years ending December 31:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Remainder of 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">81,950</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">112,943</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">67,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total future minimum lease payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">262,488</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Less: Difference between future minimum lease payments and discounted operating lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">39,449</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total operating lease liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">223,039</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6812710112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following potentially dilutive outstanding securities were excluded from diluted net loss per common share for the period indicated because of their anti-dilutive effect:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Potentially dilutive securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Three months ended<br clear="none"/>March&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,190,360</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">543,396</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,750,833</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,751,002</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,941,193</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,294,398</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6630927664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of the Business - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2019 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6821989824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 11, 2019</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,051,840<span></span>
</td>
<td class="nump">$ 7,665,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,021,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,021,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,969,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,505,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,505,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,805,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash flow from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,308,484<span></span>
</td>
<td class="nump">$ 2,118,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ReimbursementOfGrantExpensesReceivable', window );">Reimbursement of grant expenses receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from grant for notice of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant [Member] | National Institutes Of Health [Member] | Eunice Kennedy Shriver National Institute Of Child Health And Human Development [Member] | Second Phase Of Research And Availability Of Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from grant for notice of award</a></td>
<td class="nump">$ 982,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 982,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate net proceeds on sales of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ReimbursementOfGrantExpensesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of grant expenses receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ReimbursementOfGrantExpensesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_NationalInstitutesOfHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_NationalInstitutesOfHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareTrustFundAxis=dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareTrustFundAxis=dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6809099648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use leases</a></td>
<td class="nump">$ 212,909<span></span>
</td>
<td class="nump">$ 232,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">223,039<span></span>
</td>
<td class="nump">$ 241,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6822823136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 16, 2018</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Jul. 19, 2017</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationReverseMergerLineItems', window );"><strong>Business Combination Reverse Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,918,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions', window );">Unamortized fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,654,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_StockOptionModificationApprovalDate', window );">Stock option modification approval date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 19,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationReverseMergerConsiderationTransferred', window );">Total purchase price consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,279,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentLiabilities', window );">Purchase price adjustments increase in current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentAssets', window );">Purchase price adjustments increase in current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Original goodwill amount acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Reduced original goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,187,519<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,679,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dare_PearTreePharmaceuticalsIncMember', window );">Pear Tree Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationReverseMergerLineItems', window );"><strong>Business Combination Reverse Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1', window );">Merger Agreement entered date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 30,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1', window );">Business combination completed date</a></td>
<td class="text">May 16,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration amount</a></td>
<td class="nump">$ 132,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PotentialCashPaymentsToAcquireBusiness', window );">Potential cash payments to acquire business</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationReverseMergerLineItems', window );"><strong>Business Combination Reverse Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Pear Tree Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationReverseMergerLineItems', window );"><strong>Business Combination Reverse Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost', window );">Transaction costs</a></td>
<td class="nump">$ 452,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=dare_PrivateDareMember', window );">Private Dare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationReverseMergerLineItems', window );"><strong>Business Combination Reverse Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_StockPurchaseAndOtherTransactionsCompletionDate', window );">Stock purchase transaction completion date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 19,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_StockPurchaseAgreementDate', window );">Stock purchase agreement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 19,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1', window );">Business combination completed date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 19,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination purchase price adjustment increase in current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination purchase price adjustment increase in current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_BusinessCombinationPurchasePriceAdjustmentIncreaseInCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_BusinessCombinationReverseMergerConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination reverse merger consideration transferred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_BusinessCombinationReverseMergerConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_BusinessCombinationReverseMergerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination reverse merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_BusinessCombinationReverseMergerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination reverse merger recognized identifiable assets acquired and liabilities assumed cash and equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination reverses merger stock purchase transaction cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_BusinessCombinationReverseMergerStockPurchaseTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination reverse merger unamortized fair value of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PotentialCashPaymentsToAcquireBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Cash Payments To Acquire Business</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PotentialCashPaymentsToAcquireBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_StockOptionModificationApprovalDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock option modification approval date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_StockOptionModificationApprovalDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_StockPurchaseAgreementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock purchase agreement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_StockPurchaseAgreementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_StockPurchaseAndOtherTransactionsCompletionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock purchase and other transactions completion date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_StockPurchaseAndOtherTransactionsCompletionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the business acquisition agreement was executed, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the acquirer obtains control of the acquiree, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=84229725&amp;loc=d3e848-128460<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84229725&amp;loc=d3e845-128460<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=84229725&amp;loc=d3e961-128460<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dare_PearTreePharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dare_PearTreePharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=dare_PrivateDareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=dare_PrivateDareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6823178048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Schedule of Purchase Price Consideration Allocation (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 19, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationReverseMergerConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of shares issued</a></td>
<td class="nump">$ 20,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions', window );">Unamortized fair value of Cerulean options</a></td>
<td class="nump">3,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationReverseMergerConsiderationTransferred', window );">Fair value of total consideration</a></td>
<td class="nump">24,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Assets acquired and liabilities assumed</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">9,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherCurrentAssets', window );">Prepaid expense and other current assets</a></td>
<td class="nump">1,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total assets acquired and liabilities assumed</a></td>
<td class="nump">11,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 12,679<span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_BusinessCombinationReverseMergerConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination reverse merger consideration transferred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_BusinessCombinationReverseMergerConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_BusinessCombinationReverseMergerConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination reverse merger consideration transferred equity interests issued and issuable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_BusinessCombinationReverseMergerConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination reverse merger recognized identifiable assets acquired and liabilities assumed cash and equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination reverse merger recognized identifiable assets acquired and liabilities assumed current assets prepaid expense and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination reverse merger recognized identifiable assets acquired and liabilities assumed current liabilities accounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination reverse merger recognized identifiable assets acquired and liabilities assumed net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination reverse merger recognized identifiable assets acquired and liabilities assumed net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination reverse merger unamortized fair value of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6824044304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based compensation - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Jul. 10, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2014</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,190,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,635,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,422,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,422,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Unamortized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,343,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_WeightedAverageAmortizationPeriod', window );">Amortized weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,422,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,422,161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=dare_PrivateDareMember', window );">Private Dare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,968<span></span>
</td>
<td class="nump">$ 9,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Options to purchase number of outstanding shares of common stock (in shares)</a></td>
<td class="nump">2,503,771<span></span>
</td>
<td class="nump">2,046,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,190,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Annual percentage increase in outstanding number of common stock</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease', window );">Increase in number of shares authorized (in shares)</a></td>
<td class="nump">456,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PeriodOfTerminationOfStockOptionsVestedAfterTerminationDate', window );">Exercise period for stock options after termination date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_UnamortizedFairValueExpenseInStockPurchaseTransaction', window );">Unamortized fair value expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">323,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dare_TwoThousandAndFifteenStockIncentivePlanMember', window );">2015 Stock Incentive Plan [Member] | Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dare_TwoThousandAndFifteenStockIncentivePlanMember', window );">2015 Stock Incentive Plan [Member] | Employee Stock Option [Member] | Private Dare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Stock options grant period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dare_TwoThousandAndFifteenStockIncentivePlanMember', window );">2015 Stock Incentive Plan [Member] | Restricted Stock [Member] | Private Dare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued to non-employees (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_OfferingPeriod', window );">Offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate', window );">Purchase price as percentage of stock price on offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_OfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_OfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PeriodOfTerminationOfStockOptionsVestedAfterTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of termination of stock options vested after termination date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PeriodOfTerminationOfStockOptionsVestedAfterTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_UnamortizedFairValueExpenseInStockPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unamortized fair value expense in stock purchase transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_UnamortizedFairValueExpenseInStockPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_WeightedAverageAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Amortization Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_WeightedAverageAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on offering date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of increase (decrease) of non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=dare_PrivateDareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=dare_PrivateDareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dare_TwoThousandAndFifteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dare_TwoThousandAndFifteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dare_TwoThousandAndFourteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6822926624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity for Amended 2014 Plan and Related Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding beginning balance (in shares)</a></td>
<td class="nump">1,635,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">563,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled/forfeited (in shares)</a></td>
<td class="num">(8,360)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding ending balance (in shares)</a></td>
<td class="nump">2,190,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">650,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 11.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">0.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled/forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">17.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in usd per share) | $ / shares</a></td>
<td class="nump">59.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">8.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in usd per share) | $ / shares</a></td>
<td class="nump">$ 25.97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dare_TwoThousandAndFifteenStockIncentivePlanMember', window );">2015 Stock Incentive Plan [Member] | Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding ending balance (in shares)</a></td>
<td class="nump">10,149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=dare_PrivateDareMember', window );">Private Dare [Member] | 2015 Stock Incentive Plan [Member] | Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding beginning balance (in shares)</a></td>
<td class="nump">10,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding ending balance (in shares)</a></td>
<td class="nump">50,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dare_TwoThousandAndFifteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dare_TwoThousandAndFifteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=dare_PrivateDareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=dare_PrivateDareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6823128416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors (Details) - Employee Stock Option [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 97,968<span></span>
</td>
<td class="nump">$ 9,124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">24,703<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 73,265<span></span>
</td>
<td class="nump">$ 9,124<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6784362064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2019 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">120.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate', window );">Forfeiture rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of options granted (in usd per share)</a></td>
<td class="nump">$ 0.72<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by Share-based payment award fair value assumptions forfeiture rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6823013056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Feb. 15, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds on sale of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 237,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares issued and sold (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share (in usd per share)</a></td>
<td class="nump">$ 0.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Class of warrant or right exercisable period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_NumberOfCommonStockWarrantsExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201711Member', window );">Accounting Standards Update 2017-11 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_EstimatedFairValueOfWarrantsRecordedInEquity', window );">Estimated fair value of warrants, recorded in equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds on sale of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PercentageOfAggregateCommission', window );">Aggregate commission rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="nump">3,500,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwritten Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod', window );">Underwriters overallotment option to purchase additional shares of common stock and warrants period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants', window );">Gross proceeds from offering of common stock and warrants</a></td>
<td class="nump">$ 10,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ProceedsFromIssuanceOfCommonStockAndWarrants', window );">Proceeds from offering of common stock and warrants, net of costs</a></td>
<td class="nump">$ 9,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share)</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwritten Offering [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares issued and sold (in shares)</a></td>
<td class="nump">220,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="nump">525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_UnderwritersOptionToPurchaseAdditionalShares', window );">Underwriters option to purchase additional shares (in shares)</a></td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_EstimatedFairValueOfWarrantsRecordedInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated Fair Value Of Warrants Recorded In Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_EstimatedFairValueOfWarrantsRecordedInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds From Issuance Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_GrossProceedsFromOfferingOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds From Offering Of Common Stock And Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_GrossProceedsFromOfferingOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_NumberOfCommonStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_NumberOfCommonStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PercentageOfAggregateCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of aggregate commission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PercentageOfAggregateCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_StockholdersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_StockholdersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_UnderwritersOptionToPurchaseAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriters option to purchase additional shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_UnderwritersOptionToPurchaseAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriters option to purchase additional shares of common stock period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStockPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201711Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201711Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6824771728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Common Stock Warrants Outstanding (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares Underlying Outstanding Warrants</a></td>
<td class="nump">3,750,833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember', window );">Warrants Expiring on December 1, 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares Underlying Outstanding Warrants</a></td>
<td class="nump">2,906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 120.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ClassOfWarrantOrRightsWarrantsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Dec.  01,  2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember', window );">Warrants Expiring on December 6, 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares Underlying Outstanding Warrants</a></td>
<td class="nump">3,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 120.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ClassOfWarrantOrRightsWarrantsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Dec.  06,  2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember', window );">Warrants Expiring on January 8, 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares Underlying Outstanding Warrants</a></td>
<td class="nump">17,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 60.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ClassOfWarrantOrRightsWarrantsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Jan.  08,  2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember', window );">Warrants Expiring on April 4, 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares Underlying Outstanding Warrants</a></td>
<td class="nump">6,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ClassOfWarrantOrRightsWarrantsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Apr.  04,  2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember', window );">Warrants Expiring on February 15, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares Underlying Outstanding Warrants</a></td>
<td class="nump">3,720,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ClassOfWarrantOrRightsWarrantsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Feb. 15,  2023<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ClassOfWarrantOrRightsWarrantsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or rights warrants expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ClassOfWarrantOrRightsWarrantsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnDecemberOneTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnDecemberSixTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnJanuaryEightTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnAprilFourTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6811625728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leased Properties (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 01, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Square footage of office space | ft&#178;</a></td>
<td class="nump">3,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of operating lease</a></td>
<td class="text">37 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term of operating lease</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals', window );">Gross monthly base rent</a></td>
<td class="nump">$ 8,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PercentageOfIncreaseInAnnualBaseRent', window );">Percentage of increase in annual base rent, each year</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 212,909<span></span>
</td>
<td class="nump">$ 232,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, short term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, long term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Non-cash lease expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for measurement of operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PercentageOfIncreaseInAnnualBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Increase In Annual Base Rent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PercentageOfIncreaseInAnnualBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77910348&amp;loc=d3e34039-112682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseMinimumRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6806391920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leased Properties Leased Properties - Future Minimum Lease Payments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Remainder of 2019</a></td>
<td class="nump">$ 81,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2020</a></td>
<td class="nump">112,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2021</a></td>
<td class="nump">67,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">262,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Difference between future minimum lease payments and discounted operating lease liabilities</a></td>
<td class="nump">39,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 223,039<span></span>
</td>
<td class="nump">$ 241,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6828061728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 05, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($) </div>
<div>Country</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($) </div>
<div>Patent</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseFee', window );">License fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,500<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ADVATecAgreementMember', window );">ADVA Tec Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_NumberOfPatentsIssued', window );">Number of patents issued | Patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_NumberOfPendingPatents', window );">Number of pending US patent applications | Patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_NumberOfPatentsGranted', window );">Number of patents granted | Patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_NumberOfPatentApplications', window );">Number of patent applications in other major markets | Patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements [Member] | ADVA Tec Agreement [Member] | Ovaprene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries', window );">Agreement termination period on failing to commercialize in certain designated countries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease', window );">Agreement termination on failing to enroll patient within months of production and release</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_NoticePeriodForTerminationOfAgreementForBothParties', window );">Prior written notice period for termination of agreement for both parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements [Member] | ADVA Tec Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_NumberOfDesignatedCountries', window );">Number of designated European countries | Country</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PercentageOfRoyaltyRate', window );">Percentage of royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements [Member] | ADVA Tec Agreement [Member] | Minimum [Member] | Ovaprene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Minimum spending amounts per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements [Member] | ADVA Tec Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PercentageOfRoyaltyRate', window );">Percentage of royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member', window );">Juniper Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne', window );">Potential annual license maintenance fee, payments in year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter', window );">Potential annual license maintenance fee payments, thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess', window );">License agreement, period of continuation from date of first commercial sale of product or process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation', window );">License agreement notice period of termination for breach of payment obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PeriodOfDismissalOfBankruptcyPetition', window );">Period of dismissal of bankruptcy petition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation', window );">License agreement notice period of termination for breach of other obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseAgreementNoticePeriodOfTermination', window );">License agreement, notice period of termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member', window );">Juniper Pharmaceuticals, Inc. [Member] | Clinical And Regulatory Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MaximumPotentialMilestonePayments', window );">Maximum potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member', window );">Juniper Pharmaceuticals, Inc. [Member] | Sales Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MaximumPotentialMilestonePayments', window );">Maximum potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsMember', window );">Juniper Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval', window );">License agreement, termination period prior to receipt of approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_UpfrontLicenseFeePaid', window );">Upfront license fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember', window );">SST [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure', window );">License agreement, termination period due to performance failure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement', window );">Percentage of rights to inventions by employees under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseAgreementExpirationPeriod', window );">License agreement, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval', window );">License agreement, termination period prior to receipt of approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval', window );">License agreement, termination period after receipt of approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries', window );">License agreement, termination period for applicable license products of applicable countries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember', window );">SST [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_SecuredInvestmentRequiredForLicenseAgreement', window );">Secured investment required for license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember', window );">SST [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember', window );">SST [Member] | License And Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement', window );">Percentage of rights to inventions by employees under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_OrbisMember', window );">Orbis [Member] | Development And Option Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne', window );">Commencement period for stage two upon achievement of stage one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_MilanaPharmMember', window );">MilanaPharm [Member] | Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseFee', window );">License fee</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseFeeToBePaidUponContingency', window );">License fee to be paid upon contingency</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ProceedsRaisedFromEquityFinancing', window );">Proceeds raised from equity financing</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_HammockPharmaceuticalsInc.Member', window );">Hammock Pharmaceuticals, Inc. [Member] | Assignment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseFee', window );">License fee</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_LicenseFeeToBePaidUponContingency', window );">License fee to be paid upon contingency</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ProceedsRaisedFromEquityFinancing', window );">Proceeds raised from equity financing</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainCommercialMilestonesMember', window );">Upon Achieving Certain Commercial Milestones [Member] | SST [Member] | License And Collaboration Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainCommercialMilestonesMember', window );">Upon Achieving Certain Commercial Milestones [Member] | MilanaPharm [Member] | Licensing Agreements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="nump">1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=dare_UponSigningOfDevelopmentAndOptionAgreementMember', window );">Upon Signing Of Development And Option Agreement [Member] | Orbis [Member] | Development And Option Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember', window );">Upon Completion Of Fifty Percent Development Not Later Than Six Months [Member] | Orbis [Member] | Development And Option Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainDevelopmentMilestonesMember', window );">Upon Achieving Certain Development Milestones [Member] | MilanaPharm [Member] | Licensing Agreements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember', window );">Upon Achieving Certain Clinical And Regulatory Development Milestones [Member] | Hammock Pharmaceuticals, Inc. [Member] | Assignment Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_MilestonePaymentsContingentAmount', window );">Milestone payments, contingent amount</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember', window );">Upon Achievement Of Specified Development And Regulatory Milestones [Member] | ADVA Tec Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember', window );">Upon Achievement Of Specified Development And Regulatory Milestones [Member] | Licensing Agreements [Member] | ADVA Tec Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponReachingCertainWorldwideNetSalesMilestonesMember', window );">Upon Reaching Certain Worldwide Net Sales Milestones [Member] | Licensing Agreements [Member] | ADVA Tec Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponAchievementOfSpecifiedCommercializationMilestonesMember', window );">Upon Achievement Of Specified Commercialization Milestones [Member] | ADVA Tec Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ResearchAndDevelopmentMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement termination on failing to enroll patient within months of production and release.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_AgreementTerminationOnFailingToEnrollPatientWithinMonthsOfProductionAndRelease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement termination period on failing to commercialize in certain designated countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_AgreementTerminationPeriodOnFailingToCommercializeInCertainDesignatedCountries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_CommencementPeriodForStageTwoUponAchievementOfStageOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commencement Period For Stage Two Upon Achievement Of Stage One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_CommencementPeriodForStageTwoUponAchievementOfStageOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseAgreementExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement expiration period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseAgreementExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseAgreementNoticePeriodOfTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement Notice Period Of Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseAgreementNoticePeriodOfTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement Notice Period Of Termination For Breach Of Other Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfOtherObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement Notice Period Of Termination For Breach Of Payment Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseAgreementNoticePeriodOfTerminationForBreachOfPaymentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement Period Of Continuation From Date Of First Commercial Sale Of Product Or Process</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseAgreementPeriodOfContinuationFromDateOfFirstCommercialSaleOfProductOrProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement, termination period after receipt of approval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseAgreementTerminationPeriodAfterReceiptOfApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement, termination period due to performance failure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement, termination period for applicable license products of applicable countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseAgreementTerminationPeriodForApplicableLicenseProductsOfApplicableCountries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement, termination period prior to receipt of approval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseAgreementTerminationPeriodPriorToReceiptOfApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_LicenseFeeToBePaidUponContingency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Fee, To Be Paid Upon Contingency</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_LicenseFeeToBePaidUponContingency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_MaximumPotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Potential Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_MaximumPotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_MilestonePaymentsContingentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments, contingent amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_MilestonePaymentsContingentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_NoticePeriodForTerminationOfAgreementForBothParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Notice period for termination of agreement for both parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_NoticePeriodForTerminationOfAgreementForBothParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_NumberOfDesignatedCountries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of designated countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_NumberOfDesignatedCountries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_NumberOfPatentApplications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of patent applications.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_NumberOfPatentApplications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_NumberOfPatentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Patents Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_NumberOfPatentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_NumberOfPatentsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of patents issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_NumberOfPatentsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_NumberOfPendingPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Pending Patents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_NumberOfPendingPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of rights to inventions by employees under license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PercentageOfRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PercentageOfRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PeriodOfDismissalOfBankruptcyPetition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period Of Dismissal Of Bankruptcy Petition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PeriodOfDismissalOfBankruptcyPetition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Annual License Maintenance Fee, Payments In Year One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Annual License Maintenance Fee Payments, Thereafter</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ProceedsRaisedFromEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds Raised From Equity Financing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ProceedsRaisedFromEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ResearchAndDevelopmentMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ResearchAndDevelopmentMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_SecuredInvestmentRequiredForLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Secured investment required for license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_SecuredInvestmentRequiredForLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_UpfrontLicenseFeePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront License Fee Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_UpfrontLicenseFeePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ADVATecAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ADVATecAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dare_OvapreneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dare_OvapreneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ClinicalAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ClinicalAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_SalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_SalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dare_LicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dare_LicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_OrbisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_OrbisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dare_DevelopmentAndOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dare_DevelopmentAndOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_MilanaPharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_MilanaPharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_HammockPharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_HammockPharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dare_AssignmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dare_AssignmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dare_UponSigningOfDevelopmentAndOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dare_UponSigningOfDevelopmentAndOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponReachingCertainWorldwideNetSalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponReachingCertainWorldwideNetSalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponAchievementOfSpecifiedCommercializationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponAchievementOfSpecifiedCommercializationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6811386544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Award - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 11, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred', window );">Cash received from federal grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dare_ReimbursementOfGrantExpensesReceivable', window );">Reimbursement of grant expenses receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,007<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from grant for notice of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant [Member] | Eunice Kennedy Shriver National Institute Of Child Health And Human Development [Member] | Second Phase Of Research And Availability Of Funds [Member] | National Institutes Of Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from grant for notice of award</a></td>
<td class="nump">$ 982,851<span></span>
</td>
<td class="nump">$ 982,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant [Member] | Eunice Kennedy Shriver National Institute Of Child Health And Human Development [Member] | Remaining Portion Of Research And Availability Of Funds [Member] | National Institutes Of Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from grant for notice of award</a></td>
<td class="nump">$ 730,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dare_ReimbursementOfGrantExpensesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of grant expenses receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dare_ReimbursementOfGrantExpensesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dare_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of customer funding recorded as an offset to costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareTrustFundAxis=dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareTrustFundAxis=dare_EuniceKennedyShriverNationalInstituteOfChildHealthAndHumanDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_SecondPhaseOfResearchAndAvailabilityOfFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_NationalInstitutesOfHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_NationalInstitutesOfHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_RemainingPortionOfResearchAndAvailabilityOfFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6763267680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">5,941,193<span></span>
</td>
<td class="nump">4,294,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">2,190,360<span></span>
</td>
<td class="nump">543,396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">3,750,833<span></span>
</td>
<td class="nump">3,751,002<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6822891952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 11, 2019</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding warrants to purchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,750,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price in the Offering (in usd per share)</a></td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds received in public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dare_PublicStockOfferingMember', window );">Public Stock Offering [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in the Offering (in shares)</a></td>
<td class="nump">4,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwritten Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwritten Offering [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in the Offering (in shares)</a></td>
<td class="nump">686,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dare_PublicStockOfferingIncludingOverAllotmentOfSharesMember', window );">Public Stock Offering, Including Over-Allotment Of Shares [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in the Offering (in shares)</a></td>
<td class="nump">5,261,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds received in public offering</a></td>
<td class="nump">$ 5.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds received in public offering, net of underwriting discounts and offering expenses</a></td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember', window );">Warrants Expiring on February 15, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding warrants to purchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,720,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember', window );">Warrants Expiring on February 15, 2023 [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price in the Offering (in usd per share)</a></td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share)</a></td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dare_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dare_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dare_PublicStockOfferingIncludingOverAllotmentOfSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dare_PublicStockOfferingIncludingOverAllotmentOfSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dare_WarrantsExpiringOnFebruaryFifteenTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>53
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M^L/O(NP[ZW;N'QN?!>L*?MU%_0502P,$%     @ =H&N3IE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M<7Z-0+ (:Q*8D_\#;$(%XW@$BN9 G3V=V@O</D/M,V>?3>T+KP:#A#E).]2
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M\($MCH(F1/,-VFY:L\D)MI]?$%N><?D+4$L#!!0    ( ':!KD[?UYD!KP$
M -(#   8    >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL?5-A;YPP#/TK47Y
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M!1@'\#K]^P)V'">U^@+,,.?,F6%(!S3/M@%PY%5);3/:.-<=&+-% TK8*^Q
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M=OYE8_];K1WX5+(;/T*]_V"+(:!UX?C)G\T\9K/A])!^$%F^<?4'4$L#!!0
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M_C?6!D INQL<H0X_V&(H:$(\OL>SF\9L,H+MYQ_$EF]<_@902P,$%     @
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M;#$4-"$>7^/936,V&<'V\P]BRS<N?P)02P,$%     @ =H&N3F5,*>/@ 0
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M\V<SC=ED.-W//X@LW[C\"U!+ P04    " !V@:Y.SWG4K<X!  "<!   &0
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MN:/N)E5":#"E!'>FX<8\%4O H-)V>S![.0W,%&C1SV\!61ZD_"]02P,$%
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MLK'_#:(#G\KNQH]0YS_88DAH7#@>_-E,8S89#OOY!['E&Y=_ %!+ P04
M" !V@:Y.A-73 K8!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6QM4^UNVR 4?17$ Q2'N$T4V9::3E4G;5+4:MMO8E_;J'RX@./N[0O8<;W.
M?X![.>?<#R[9H,VK;0$<>I="V1RWSG4'0FS9@F3V1G>@_$VMC63.FZ8AMC/
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M_UIK!SZ5Y,:/4.L_V&P(J%TX[OS9C&,V&DYWTP\B\S<N/@!02P,$%     @
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M-"T*B*)BW$,\GPN=\J&"QO[<&(LY+UAPR=H_(A8EGAQ9QICP0="?7\%_3@@
MGZ$ =QR1 ,8N%$UPFT_)#8JY'983*L5AK"-7IQ$8I^C&"69SA-K*&?%;"QI5
MKY@(0^ZV"0$RJ:/(%3 ,Z$CJ.'U"+CBB!0K<]#&0<%._#!IG0\@*G^H**.EF
M,Q4,J=H6:2(6H1<<$0SEM/D>!5&!"%GA,>(C= /%DUD4X05^ "% ,!4@4,[@
MKP%1(!"*FAT@! @0 5*$  &U_[A"@( 0()BS!0%D;\$XI9= R \@\D.VC5 ,
M4%>43- 6$+*Y#]8U"@(B$,%(0!BIA1L( U$5$70$A&G318PFBZA&'!EV% CL
MTEH3O 6$MV<;R?'>F*"C8%?LKPF:"81FVMD\/EC0]/GJO%0@N/B"S B"M@+^
MO,>VF%%*(""F6DB]7R#L/GN?&OL@:"OD%<M T%8@#WIW2_$1!1%S)PAN"X2V
M(7,#82!BPRP(;@OL:>ONI2SH_,'D0#Y=A R9!&>?!+J/7W\GU4M:U-YSV31E
MWG\"V)5E8UIW[$/;P[U)MJ>+S.R:[C1LSZOAH]-PT90'^T$M.'W56_T/4$L#
M!!0    ( ':!KDZ4S0*N\0(  *\+   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;)6646^;,!#'OPKB?6 ;#*9*(C6=IDW:I&K3MF<W<1)4P P[2??M
M9PQEQ)RG[B5@<W>_.Y,_=ZNK[)[520@=O-15H];A2>OV+H[5[B1JKB+9BL8\
M.<BNYMHLNV.LVD[PO76JJY@@E,4U+YMPL[)[C]UF)<^Z*AOQV 7J7->\^[T5
ME;RN0QR^;GPMCR?=;\2;5<N/XIO0W]O'SJSB*<J^K$6C2MD$G3BLPWM\MR6T
M=[ 6/TIQ5;/[H"_E2<KG?O%IOPY1GY&HQ$[W(;BY7,2#J*H^DLGCUQ@TG)B]
MX_S^-?H'6[PIYHDK\2"KG^5>G]8A"X.]./!SI;_*ZT<Q%D3#8*S^L[B(RICW
MF1C&3E;*_@:[L]*R'J.85&K^,ES+QEZO8_Q7-]B!C YD<DBL0SR ;.;ON>:;
M52>O03<<?LO[=XSOB#F;7;]IC\(^,\DKLWO9D)RLXDL?:+39#C9D9H,GB]A$
MGQ $0FS)PIWD"1P@ 7-,;(#D)D *!TC! *D-D-X$H$Z1@PVU-LU09);0O$ P
MB((@"H R!T07()HE"'DX&<C) $[N<+(%QX/(040.()B#R!>(=RS)/!@&8AB
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MC]RS1PI2NO+%Z2,^^)%[_O+XP?$R(CA_Q = 3)2"XP.!$P@(@:EC]P$G$#Y
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M2M657?+C]+K9-Z_'UOZY&6X@V@;BTD#PW@:R;2"'-E!M S6T@6X;Z*$-3-O
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MQOWOG!L-)^?8#R-%.>_D>LXNQ(B/;?<-KN])<[W%%6=3AF4M_PZRPX.RZ/C
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M:)_R%$^YHE.>R2FS2J)\ (.Z_OY3!B[[(*VW%P424Z?_P"#YB/"5JRM44-'
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M5/AJ_RI?R&^:1"SZ[]@^C=R=T$>JALVE,D7FVH:N FY!GQ#7ZNZ.D,ML,<6
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MJ]F%>:=24*9K4([3T=DP/0B^N]4TZ=[,B 1L69KH-_'U\&D8]LDDYUI_CPZ
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M%TE-RMP?P^+BG^X[38.5+[F6%D[-#YEWREH,E6,0!G\'U(N^(N)("LVGP@S
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MM90-SG*4[)-H]>+=72XOY#H.P=#.(1FFU?KZE!AR:P"+0_:QM"I-9(U>N9&
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M\'@$.M ))R'LP-K\19.@?[MR85OBO(=%_H)MZ3["GE*#TO83EUF%)VB>V"#
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M"$(.[7-\OU5F<\I9+Q=6M[JQT[L)#N)290LSLBIW/7R<[5;V[R"=A_2&]GM
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MC?'OA!_(EU@5 C<-:S5IS0(MH3;3SL8*::WRJ(#Z2#6I5,\6+*.)VP7?GQD
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MPH32;D27K%42OA%ML-L:?JCKYH__#U!+ P04    " !V@:Y.K6:[\4H"  "
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M70T%YZ9[@:DOV]5]18C8$RSSQQH.^,NV3N#E($^A[8QN8?:6?15&6*E8#GE
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M4$L! A0#%     @ =H&N3A\CSP/     $P(   L              ( !
M %]R96QS+RYR96QS4$L! A0#%     @ =H&N3B?HAPZ"    L0   !
M         ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !V@:Y.
MQ3R"2N\    K @  $0              @ &9 0  9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " !V@:Y.F5R<(Q &  "<)P  $P              @ &W
M @  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ':!KDX=60N3> (
M $ )   8              "  ?@(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    " !V@:Y.F4?:S),#   1#P  &               @ &F
M"P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ =H&N3F]^
M]/4^ @  L@<  !@              ( !;P\  'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    ( ':!KDY]-&G=_@(  .4*   8
M  "  >,1  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !V
M@:Y.\;$3^MP#  "-$   &               @ $7%0  >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ =H&N3L%79M3Q P  KQ   !@
M         ( !*1D  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   ( ':!KDZ]9?[8KP$  -(#   8              "  5 =  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !V@:Y.W]>9 :\!  #2 P
M&               @ $U'P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ =H&N3J OWSNT 0  T@,  !@              ( !&B$  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( ':!KDY9MA:)M $
M -(#   9              "  00C  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ =H&N3EG_D=VV 0  T@,  !D              ( !
M[R0  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !V@:Y.
M5<:!'K0!  #2 P  &0              @ '<)@  >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    ( ':!KDZNP5<[LP$  -(#   9
M      "  <<H  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ =H&N3H?>L].T 0  T@,  !D              ( !L2H  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !V@:Y.Z$L-V+0!  #2 P
M&0              @ &<+   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    ( ':!KDY :4'NM $  -(#   9              "  8<N  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ =H&N3NK)IY2T
M 0  T@,  !D              ( !<C   'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    " !V@:Y.94PIX^ !   !!0  &0
M@ %=,@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( ':!
MKDX7\X'/M@$  -(#   9              "  70T  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ =H&N3L]YU*W. 0  G 0  !D
M         ( !838  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    " !V@:Y.2_E_8+<!  #2 P  &0              @ %F.   >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( ':!KDZ$U=,"M@$  -(#
M   9              "  50Z  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @ =H&N3N^GU%>R 0  T@,  !D              ( !03P
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !V@:Y.297/
M';8!  #2 P  &0              @ $J/@  >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    ( ':!KDZ)N_AHXP(  '0+   9
M  "  1=   !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
M=H&N3LS/4. ' @  S 4  !D              ( !,4,  'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    " !V@:Y.M[TL/U4#  #Y#@  &0
M            @ %O10  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    ( ':!KDZJ1KL5. (  .H&   9              "  ?M(  !X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ =H&N3G)@I@C] P
MX1,  !D              ( !:DL  'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    " !V@:Y.E,T"KO$"  "O"P  &0              @ &>
M3P  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( ':!KDZ;
MI#G8+0(  (,&   9              "  <92  !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @ =H&N3@!,G.P# @  S@4  !D
M     ( !*E4  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ':!KDZ#F/P&. 8  #<H   9              "
M <IB  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ =H&N
M3I,:B%96 @  0P@  !D              ( !.6D  'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6Q02P$"% ,4    " !V@:Y.G&R,Q#@"  "4!@  &0
M        @ '&:P  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0
M   ( ':!KDY;79LU  ,  .@,   9              "  35N  !X;"]W;W)K
M<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ =H&N3M*N^#>&<   C[ !
M !0              ( !;'$  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#
M%     @ =H&N3JUFN_%* @  @ L   T              ( !).(  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " !V@:Y.\)"*[<4#   &&P  #P
M    @ &9Y   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ =H&N3O[W3D.D
M 0  W1@  !H              ( !B^@  'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ =H&N3G'*SM&H 0  +AD  !,
M ( !9^H  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #$ ,0!)#0  0.P
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>131</ContextCount>
  <ElementCount>225</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>54</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0002000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Consolidated Statements of Stockholders Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Organization and Description of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/OrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and Description of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/GoingConcern</Role>
      <ShortName>Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Leased Properties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/LeasedProperties</Role>
      <ShortName>Leased Properties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Grant Award</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/GrantAward</Role>
      <ShortName>Grant Award</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://darebioscience.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/AcquisitionsTables</Role>
      <ShortName>Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://darebioscience.com/role/Acquisitions</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://darebioscience.com/role/StockBasedCompensation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://darebioscience.com/role/StockholdersEquity</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Leased Properties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/LeasedPropertiesTables</Role>
      <ShortName>Leased Properties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://darebioscience.com/role/LeasedProperties</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://darebioscience.com/role/NetLossPerShare</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - Organization and Description of the Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail</Role>
      <ShortName>Organization and Description of the Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Going Concern - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/GoingConcernAdditionalInformationDetail</Role>
      <ShortName>Going Concern - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Acquisitions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/AcquisitionsAdditionalInformationDetail</Role>
      <ShortName>Acquisitions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Acquisitions - Schedule of Purchase Price Consideration Allocation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/AcquisitionsScheduleOfPurchasePriceConsiderationAllocationDetail</Role>
      <ShortName>Acquisitions - Schedule of Purchase Price Consideration Allocation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Stock Based compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock Based compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity for Amended 2014 Plan and Related Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockBasedCompensationSummaryOfStockOptionActivityForAmended2014PlanAndRelatedInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity for Amended 2014 Plan and Related Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2406404 - Disclosure - Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseRelatedToStockOptionsGrantedToEmployeesAndDirectorsDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2406405 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockBasedCompensationSummaryOfAssumptionsUsedInBlackScholesOptionPricingModelForStockOptionsGrantedToEmployeesAndDirectorsDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Stockholders' Equity - Schedule of Common Stock Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/StockholdersEquityScheduleOfCommonStockWarrantsOutstandingDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Common Stock Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Leased Properties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/LeasedPropertiesDetails</Role>
      <ShortName>Leased Properties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://darebioscience.com/role/LeasedPropertiesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Leased Properties Leased Properties - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/LeasedPropertiesLeasedPropertiesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leased Properties Leased Properties - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2409401 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/CommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2410401 - Disclosure - Grant Award - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/GrantAwardAdditionalInformationDetail</Role>
      <ShortName>Grant Award - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Net Loss Per Share - Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/NetLossPerSharePotentialDilutiveOutstandingSecuritiesExcludedFromDilutedNetLossPerCommonShareDetail</Role>
      <ShortName>Net Loss Per Share - Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="dare-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2412401 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://darebioscience.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://darebioscience.com/role/SubsequentEvents</ParentRole>
      <Position>40</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>dare-20190331.xml</File>
    <File>dare-20190331.xsd</File>
    <File>dare-20190331_cal.xml</File>
    <File>dare-20190331_def.xml</File>
    <File>dare-20190331_lab.xml</File>
    <File>dare-20190331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>58
<FILENAME>0001401914-19-000048-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001401914-19-000048-xbrl.zip
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M<_:DLM),[G]FDY(@DSP:_U9\=MWN: :(#3^\'H^&\&MW7M]XO2//XJ&WL&5
ME_8F?]ST #J,Z5'Z/!CS+N"T#PE6NO-LI\'3"?#[TH>'U--G?^R4]>M9O7SC
MZN6(7%;+F][;'8U%M\3S<EC4_"CXV_-@KX>[DCNA_SR/L!_-&GNXV2^700X4
M:SA=-FG((=N;4_[6&2*-$CY7H]!+YY =D'\BU^54LLO.?/3L^.BD%9&[&?<'
M>&A;(\O;_I>7SA8[(/\\V>(0BN=LHIR*B7)2BN@0K'5VC+ZF8_1BV0F$]K?,
M3AO1_T;8Z6 QFS,OO;28S2$DS=E:_EK6\BE)F4I]O],_X->'K+X43QOS>A70
MO0Z;JX\?*@?PU\ZX<H]BUX;K<_ES.7[?GZP=9&%ZU.55I1GZ_>/59NG#WOS\
MQ7T _P3_\KR$T]ZMZ2ND.M!Y5R.A%U_;@=)/EU&Q3UF!@S>N6+>WFJN!5Z@8
M8/885O/=Z'4QOAJ-K_-H?#G]6(QA;>]R+TMV=O'O[EW1?;8<? !"+-BMF1+/
MT@IK*,N)A_:OQZ/>K M6R-MB_*G?K7#!Y:?.S;@8KF?M'IW/M@C<Y>@O "RL
M_/##W?3)\^!33!-HHOI2GJZ0_4 B]>ONB<?+_N5PZZ(_D=#_RB55[]N7'F,[
M8G;)Y-<^_)B.AL4>YL_?9L,^(%)O#/G#\]B1Q]@EC<1\ @-IVUH\G74D]K..
M#MK#M479K>6K]8<-^6IG_7:$K+@JI<\J[:S2UE6:B$57[IQ2VN*CWF^\/V[@
M7]V/_>(3T#44XVFG/ZPP2:N.VS=, "_J##NEK/UV]_81,EXW+/!BQ^ZYPL>%
MJSTX4F.0;T.FE"7AB-Q=^Z\\_H0!P%61\;;_88CQ]JL=HDSGT.*A0HMKNWJ?
M1?A:V_H<\_PJ,<_[?;VTZI_#4<@)4&S+M= 6/V@_N?86^ZL6'_K=M]U^,>P6
MP*I@4G\<C@:C#_UB$G_I7_=AUB_]SOO^ &@81M<WG>$M/+8^LSJM9=;S$'Q/
MY@GM*;Z^PE(]G8#Z^E5E5N)SWT#8[!R.VE$,/YPI7CI#?(/,\)!2#0\*?( <
MOB[&W7YG<+"XQU=0(+OLG;G;B]"$T6#0>3\:=YZANW32,99V9CH;,X<4D[NQ
M\C=K51WPD"8,P"0''02O>E-\F &/C<:WYU/0PQRL[$3<\ZGH$UD>9<Z8_GW/
MQ)_SP>D+3 PZ']*>^H%*)150'R$5L*4X\C/P!$Y]&[\42_:E&9"']+C/^^&Y
M^+/G[?95MIMN[I1YWDYG]?+B4MBJ]UMWU2NA<].?=@;]_U?TPF@RG5Q>_3&\
M&8\^P;*-1_#Y*9 V?>D.9KVBE\>C:W<]@K_]OS((Y&\7S]Q>CN&W_RFZTZ8(
M<&FF7EZ]O2FZR'.]^]#=XCT;PL'?^%6B)U)91V""6NAV;RYX$9[? 87+5[[Q
M_-!<-I3#@P+_?GF%)71N@<K8/*JR&+^-IK_ B\;O/G:&>(\<OOKQL2=#Y^RV
MS><ICUN6<[[;-YCO-L^-/Z>H'YO)S[G:N_'XX7.UM]_4.A4;>E4T[7!>>#X4
M.9OBCV6F%V&1OQR!>4(7YAYJ%/RU<WV-S4';CL-W,=W=9-+_,"S_]J(,]G8#
M81O5GL T;B7ZV5C8>I!S5L3/01&?M=2+T%+/)"9^>O;\60R<[?%SA/S;R6;Z
M=NXUO)2#ZW.&_U,E:)UK$[[D%.33T(,OQ^(_B3W\!(6<CG"?\9L[)#O?,3P?
M#9Y\M&]SL^%ST9)ST9)GF[YZQ.;)&[*OCQI@>U-T0([?"?%_C(!RGX$C?RNF
MFPL+GXWV0_65.6K,;-_U/7L')Z7+3^C4^KC>0=.-\V/4?OVFS]!/VW_8DP6^
MED5SSB?XVA[&XI 2K"2ZH2C"<B/_!2BX;E+\M>@,IA\#T/+=>#:9YMFP=[^]
MTPSXL/BO8C@L>K=O/X[[GXKQ;Z6Z[0Q>@9W7G\ZFL#3A8W_0F[\(6/:OL^O.
M2BGCQXFIVO? +)A_ZWAFV)OB&K8A;,C7:&!@JGOEY>Y3![SIN;5]>84$>R9F
M5GML=+G3*@QRH+W;PEZ+W7M _OI:,G ;>YZ@%?DP[GZZLUA^0?<[BZ6'-?/.
M O7@ O5M 43N@:$P*<ZR]"Q+7XXLW9NQOQTQ:C;5Z6J0H-_,EC_LD>E7K<>V
M6.??*XVQ':#0ZP_ &?Q4P.Z8C?OK83L,4<^FG;GID3IC-$4FL-/>@A]9^-OF
M%ZQPS:+!]//@FR5W')$P]RRX0IFG8\)]TN<.WDCV*S%ANKX9C&Z+XNUTU/WW
M_)+OF2%K#-E*I6^(.>V9.<_,>8*)QU^+.<_J^Y34]PEDO]NR.#:]/^A_.WL_
M*?XS U32)_AQ%TQH&5\+7. HD+HSOL6#W<NK<GO?!R->S]X#.>=[_NH*@!U^
M>#7$9<2N7> UN\%@-%U<K<"E>R8AB24/M=#NGLD:B7<@W[J5] M_^8&T?[JM
M(/;SFL4AO>97!]L*WRZO'BRM:6UQ#Y+6]&1R;OG$ZI9ZAF;@J0JSY2.M!/XV
M)-9)*.\S1Q]3/;]T=IX-^W->_J-DL#":#:?CVRHW71>=R6Q<+!J"S,>7KUN.
MW7\ W]?P]DEIS32]=H%J.;[_:_]S-6UZZ6PZ+C[\A*-[OW(VZ36]L3\9"4;U
M3W^\C7N_<D[:U[ VPT9HY[Q7#C\$W*6/57UUK_\)MFV5;W#&;[/K8HSI5)6-
MLR.*_VL%D-475;X0B^'HNC]L_<;FU5[]R-J[ED-WJ&VAS'"V+A=7@;B!7Q^X
ME&_G6[UU+1?CV]\^3^+J_<]L4FK0R;N1Z_7Z\V/ UYU^[]5PD12,=VI&P[F\
M&O86?O+DU60R*WK?+3;UF^)J)1S\_7>]HMN_[@PF?_Z>?#\/>72ZTXLLI&!9
MJ^"#XEE0X;VS3CHBK(Q<N.^_0_#*MY6;@1*NM0)U<!!HCXOV/RNQG+=3V%+X
M_O2?V>)JP&B(GUM1QRU?7FC5%A)JF:G,*4CBK!4YY C2N"2AI\KKT$A"IE\H
M"2N?V$RV$#FE6J;$B>!<)"EEF)/-42(R72<;/SF*S;WRIZ#;J]]RA7)$<1E5
M#B0!Y42*0$*/E+/:12,9KU!NJ6JYEF#+'8B <[SOR;C,-GU7C$L1C4&_8>[T
M!V RO1NEX7@T@)=/^_#(/_K3C_WAO SNY=7B"!FS@#&]=P"BL5@A9TN-J!=X
ME_Q^=85A,HJ4,E5! C\9+3W71G'*.4F1??_S:_7K<B4/2OJ-*_JZM!XK+Z\6
M'R^ ;^;YVK' )&3,:)E;A_VU#?)-KF@V+@OK!>4@X[0QTLK,"%$,%('@N*+\
MGQM6].&DOUM1/P,8B\D$9KY?OG4&Y(-5?SU&>M^)A%?#[AB9 5X[&X\1W<FD
MF*XNXKSU'/_;;$!MFW@W2C@'DBH(*V0PRHB@J'?$>,.2YC7QSIC4VBRH\&AP
M#X'X\A[A.@OOA+W4(8<@F+)*>F8L\SKZ&'60W&2G:MAS1>SCD:^ O(D";V#'
MC">PI<8?BC%L%/"#BWG%DC(W#9S=\9H]$.]Q-A<US"]D!?7$/!>9ZY@9(\HD
M0[,7P:E,J 0Q%FNH"T[(O7)Z*+A/BB^OX$NI"3$R3X"OI0$;4.HD8'/#=B>$
M)5+'EVE[ OC.K9%7@#,H\Z5J!W&*OW3>#YH4\4[TD%0[IS@S)$0I2;9<NP!Z
MRTDP68*IKS_(0?EX>FQ#9V=ZO2FZHP]#O'CY:A'KPNESL>*Z\)5Q^=[*5H,Q
M<(%[H3-!=82 ?.H,4!/L)#96B,=HS#1)8@FH_6RU]S)*DSS/3N@4_3KQK*5F
M=]H=$+73)6=5%CFOA >>0^DCF4DN>P*_$.:5-D&S.CGW$47/BYQ5]?AZ7-R
MM9^^W"S*5I66T?X*?X5WD\[:Y R"CQOI'?C 5G*O79+64,EJO$LMW6/?/QGB
M3[84U8%N%TVVR>O.;4WT[D1[:;GG(:;@M93*,Z=I(BY1'D%JT,#K]@9_.M*W
M(WI\6O]63/>GIE::!^FU(CE) 18KM8'G9$(B.0A5$QN4JB>1&X#,SA0K7?>E
MW5BY<H#5!+:H]COG!NS+T75Q%[_X9=3MW%W:OLM:!]]L7-[/=3UP6/H3+-#1
M_U0LME@]EG$AJGQKE'8F@U &,>'12 @V&^4R <;-N<:W5NU!YTTD. X=S>_L
MU\XME1?X4]W1:/F-<G$G_=6+[Z_!CWT'3E_]ZO":([K+:C2[Q>UK4>5Z2U)F
M5%!&#'@IF9K(5%19RIBC%<JNKX4 1?JT:_''L#,O<U'TP!<>_[TSF"T/[N;G
MS4VQAIV,5IV4 !L^")JLM)K8X+Q(6D8AN8LTUX*12HK=D=\.]U<B0=568EE1
M&;T@3E@IG7(A,P%J)7D&ACRM+3_7^\B\/4@0!IW)Y/)J$7.\'+_I?_@XG2Q#
MD,#+_;GQC^>;]>"K70V^-K[L?O.MO!7SKH;N9MP?Y-%L_.[SZ-W'T6S2&?;>
M?89-=(O]N]9#.P9TJ^+2PG^IE&#V9.E"B,[&F#W+%-T;ILJ;*<LSDWW0.Q&:
MQ*);(GXY+&I4N1P6-:ID"@:V H6IJ 'C#V,^T3+&.,AX[I4KJ4++^__T^5,%
M^&(WJB2%43]N/0T2&,8G)ICW"0A$-.55JJCG2Y5<O!_/.N-;;(A7%,,:9=Y]
M!%U7HTW(.CL=*<D^R,2-D9%E#U(V1&-BE"5M.%;7HO+YTN9OG2&2)N%S-<+4
M98L2/"0!:MB#=''1.*.DTD E;IWROJ0)*3.6S:-H@M'D8;<T*N:AYCP"?=WY
M@)N]7F$=!X"]&VR?71I;/F6SR8J9Z5/6B7IOJ3(>O%2;N)0T:V\,N*GI^Y]?
M6Q*71'P0/>[(F2934*_3%3VW7 &T_,<]L/N'\W!5S369ETBDLG(B?7=6!U#\
M5GQ>>%!8LF \&L*O<T#7SK'O'@+PA@!6;_+'30^ 0G. T@9#L&H)9,-BM#J)
MX(*DD5D>P<%A8)I+3T00-4N 5"V!??"_(]I?QJ,)..>C;E'T)GB!H S; 6Z7
M5Y63R":>@ST%.P!^;N\?TWZBFERT5@HP@+27&726"L0*SZR+1&53LWTH64%Y
M-^@?@VQ+)L?*LGFP7#T/R@=&E$@&E@T$A3:*1>!Q5O.E*#TD#LL<N97'*T?'
M36O75.;_,8F\;92A'$0FV/8@ Q2LL+$@53$T%3-GANN:=4\)WTB:;;C>46EY
M0 .FPN*@IHPW_39:/:TJO;5Y&#N %_BA):E@0QJ/85IFHH4Q#!,!)*@*3XPF
MCFIC<C3K&%YPL#B6MM>#H3P&GG,=VYHTDA6/A&>G4@:_U#J2A8XB1@(65:K[
MJ!=2,LX/AN>RSO]2T=QKU+FBV)7)GT-IVTJ^2<83"$*)3E':J$&H^&AX,BQ8
M$[@![4G)\@![&XE::?G;: I_69QU7U6.OYNB+."E[6(E_ VXX:88MU9E6SG&
MHSYJ*8&YLC84]@<%-Y@Q00RH!D4127-G(^P,_/[H@IKW8ZS/>7E5LN?E^T'_
MPU,20A"MO$"O),%:&QE40D)0*Y@50F/^R?YT:,?J411ZW;DMM< 3TT@D'IA1
MT7-&P:VUT62P)QF-(F>BM,2,CD?1J(97*Y66[\%\ESZX%^6+0$>AB8]MR<>3
MZ7VZR%REWB7;E#IMTJ2:CT S&:.0$A@K YU"MDKF@#3SF@HC6-PH10Z 92L%
M:YDV#CQ7#-(7_1LP\-T-UMWM#%ZF;+<:ST03(>AL@[F LL[9*)( !@9C<K/8
MVY%TNY,^SHJ[A"TT/C'E:3;>FA3X/&FOE+*!Q00^EI9:8_!0^^1%CLJRR,Q&
M2;LKZ7:G/8@?6+ ![.#W@V+Q]&(33<JU7 RU)_:]C!W!%+&12F9EEL8;PQV#
MW1"82@E,3;I1MC^>J+NOUVOX,7XW^D8$E:.9\" \U[!9E--.Q.!2(H:XS"Q1
M*R&<!]/N.-1_N":MD2$*$CB(#"^BE5HIPZV@0AH3G ++-1Z'#+EHBO>=<M_J
MMH,^XIQRW!$1+$]:!_ <K071Z[VV('A3+5%"5@(!]]1X"@(=OI%1:]99!G7#
M@L(=Y5(PU%-I-3<T<Q:%JF7N5//U=J?)+F$,H83)ALC B(:583YP < (:@&X
M6$L:7HE@[0G)ED"#BT8G:HQB8.N;3),@<TB,4U'*>C -B;(+).]&OL"K%AA)
MGINS'T FWKZ0_>5 .J?L+*A(34G"XPJ)^RLF4*!,UM.^F_=7"Y&^(CF?;C=F
M<"TE#YHS8L'FB'C\#B0TD=H(^[&>R]6\";:1<!$:?SW"JZ;5_EP+WW.K6WC
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MY\]R#39$S;RBWAE*%=Z*RU$8%8Q2+ ?C@]"*-PEHB\4RCTJ)L@'U7H</C,K
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M)6T\B::10,!:SV1G[6FEKXF<'!+SCFBJB+2&V2RU5EIG:0@'EZ>IJ(>&G?=
MRF!/P_GMJ[)AVJ)A>W>]8?!]V/G>0-:"RFP\N&1:>J)-YIZ6MTDY 5VY?AOB
MNR^3_D_#_N#/WV,%A^^_^_'!8)3:K))H(7/(4H#BHE(R[@03%N"27@A.U/H)
MX%8P%A=WJS?/,!17C#^5M1WS#.L4+IN/;&:<1]R]6.4)A;EJWH/JD>"3Y S&
MGO(J4A>IH=$WM8_&'C/5!,*]46NAR^O.^')<IO'WRH.MI:&]]9!BK72-( 3/
M(7D"_:$Y]<S8P%16U@G@_0W6/);=:42K#;)'([+9>N+8A,Y*KUR2>&%71*W
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MMS9R*Z++9>)W3 JTD+ ,?K7U5CVT)A;6 *@"5T_DWJ7D];X;4&=-HK'*RRC
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MB!;%DBJ1Y\!UWA2>821-?*&QL!^8,6',,U:8_@EX;34^+)C!U8S75BOME:O
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M)L*H%P]V:?Z''ZQE\@D4$R&,PG=G0%T/*<[/=<2!%/8@F-L\L-"'SSMSPFG
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MMA,(- &!I4#J&OGRN[/DX/,::/]CX[*CLV"4YD':N*TI]B 0/BA^TZ3UU8?
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M[BR!N/0:4>SJ3Q# E,H^'6\51Z$)C\#*6OO!=ES\/6][(3Q2,"\/S%7>!@_
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M@$=*#RQP(32&IYF8<N:^&B:S8A"Y$*1^5H)_I\@T!.XV=[LS.93L.LA.42S
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M:M[P/F]F![/0N,)9 _2 <?_NRB2E(3>7[L?QYMB93XUA-+R ]%@8!?&48[2
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ME\97$"N;5!_]E8NLRKP4U%[X\XLX9&22;K_^9LI'A2$CI0B:$M^"?"ST'K_
MGP E2!?"52@DKH^T@G46+T !4"3ESZ$QL5TRQN&"P6M.53L"O3+D C4C-'YN
MNT1I--HQ7NOQ.5L$P,'O3)0"?QI1D6A:H.2F-Z37X&N6]A_R62N.;(5?WPGQ
MA?/ 7Z;O4MFDL!U<@OIR9" PGCXXV_\&%K+Y(D UPQNFG!O)\Y\@I);\Z'*]
M"<Y<;EV81,KM'=R%N?*KF0_,B[9F%?@()HD4=,#; *O"\=*S8$PQ\KK#X[F
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M@JPROR"@Z.>8D_$D-8;&*@#0;>.)<RLSN>.=&AX8 XQD6A$9)6!&5"R@NH7
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M-_R"+)@F;F*]T^=.N.JX4<K#PJL!BYOC:2(,_PE@!0<DEZO2&/LW[,\ZMJ1
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M>ML_9&/MI.P5KX:%GL"[MCAF9<A8F+<\*^V53,W"L?;M3^M+6SYH,O[2V1#
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MDB+8P)T(+HPZ'<#5-S&V;K'M8<)'JA_:KZY4/D$.:F8 4-8RH[1A7J/M/"Y
M@QV(2W,]=XE;WYQY>W<_FN;K0(]%%9(\+9!H: SF"B,J)1$" & W,1L\@&GJ
M3SWPTMS3K0+5-PTJ*#Y!VG!IG86,0H:TD,Z7@Q^7U(GZJKXT5W!#:,X8>!!]
M05?7NUNRY18*/$"!TRI*(-&:8@A=&.D4@-A943JNN9>^@5%Q:5[;7@ \(YW<
M]74:TP.EWTAS(IT.5)10Z)%R5'N'PS2*&*6JM,8Y\:Y!H.VE>7M[ ;!O.NW
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MP:DOG>_S@\<F!_G3Z<W<K/(\QJY^"I/G8E2FPBW^FA4KAL>9.$A\=?UI]/4
M>;IY80)YO%,BYI.)-VDJ1\,,OO7=8CJ@1-I]LW 0@/<0VFJS\2JV,+3<S9<!
MO+?S(E?X[A&43B(I_Y&%8=YDX;.\OQ<]&KP[8MJXK[$OCK;[L<1.%Z.;FSR]
MV62!^I!^2>>K]%V%Z,UC11/#E+2&.^8Y<$ X*N-!.<8@ )1A6VESNU>ICT5V
M'BH6I*4QS$42PP$"!G)'P$9:S&F3[*KMQGFVI[:L,W2&'0.Z^KQ(_[6*(4\Q
M;_BGT.)CT9\OETB@!9H!3% P(;FEA/FX_R (DQ)QJ>N[0CN.^VQ'T\^M\%9
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M[#&^Z?R+^LYP.P=[CB[FOGTXX<@*RD3THWF B#8V=+!"*@\L8W*8DWZ7ZCO
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M6]%B-68TPNMU<V209L[PJ'$>2KQ\8_S&^UHE"]:QTHD%87X-QB/E1GKM-#-
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M")58:,3KIQ+K*+54)\Z2+B'KBSXQ0\?5M9IDU98Z+SV>A!6 XR@,8] I@(R
M@KE2,F^Q'Z8=U;$6L\Z >TW4&)1Y=@&,.-,<LY7_8]P,'>63Q:_WD]$R#<]S
M"(]2HU+Y1%K. ,7,:>$-X-;X33[F('OXM,^,_16=)<U4^'PVZ0"DXP39L_56
M)"@(9!^GZ63A@^#Q//DH\/[JVF1W=]DZ@>:^G;AJI1-*($8"(,X!LI8ZQ]#6
MD02H&=#QAVZVZ#J!J:\Q81.!L-@X"\NF%U<R'1@*#A5+J+(.2:T$TQ@X)ACT
M1!9'5YT4%HKAK"Y:)T0'^-3N_.^#/1W:,+J)@]O-39[>A%$H,G*ZV+6NO[D<
MX'"Q1/M 7Z2)H3!"0QS'VZ'+2SR@2/)NNGN[^ PB'4RPC8JO#NZX5ZH@,4 K
M:H60X?_:"TPDV*ZN%<8#2I716=_O!*F^>&)FHT48M7X;Q8"UY57^(8:@K4]G
MA[$L'0>!EM-T84:S63K1#YOG%IL'#Q&H8<V)5\X@%"RF>'VHP9IJ]6B0R09F
M1NLQP)TQJU\(>PV\7:P[3!';&/I+\=FQ4-F7RB2.6XR!MP*J,",B)S506R^0
MUO6-#W8Q-&D+G-J6QZ_S(,X?@8Q!J/4.\:?L_2H?WXX6Z6.PY+J93XSDO0EO
MVJ@V@6&\=0SH8&Q[RC !5&QW:EB8M6M3H_6XYVXLEW[QZX4];5 E(59H:9RV
MR L  0YK<E#*Q7&#72SQ^GAQ(ECM>2ZNKJ_3:$P](:::3\I)KK(3XUA%B<3&
M062P\-Q9H!#5<?=@+:$DJOXP(2^##ETC5G]!>\S'4H$.I]21D+ L!PX@&T8\
MC7QQE\QVJU#"!E$)X#*HT"%:9UW0/#E*L_UR:RC# Y9GK?H2Y)&P5+* AB,>
M.Z?T=K%G.6QP9<#PG:1](M<7J\IVQGO7BX;NG##[E.9W!PATK&ABP@R+833-
M0?0+6.[-UE&,L&;UN7(Y_M.60:H]Y;C%<GHW6J83/YKF_QS-5CL<_9".(["3
MM_.GI\Z>3SFGU)$89;#B!,>,8Q:+0'>U7:$!2QI<[G8A[M4.T:K-@M+%LC/Q
ME4TZE#V[<MF$:>(9D8@:RBCVP7A"=#MU!MGJ:WWX;M.N4.KKR.L3&![OO'M!
MDITQ;'TZ=-^YV#-91>\.'"BM5C#ABAC%C9:66"A &)>!I!H&I2G(%:-5B-RC
MQ/L.HAXOE! OG#&>"6-1L$Z(Y,JM)96>:MKGC=DO'D=M6V%5C+DZR SZ:.J+
M4AZ)P-Q;)F&"A($+(6BDXLHP%P:R#=: *]WG!4PG7>39AJZKT*<&2&==11X]
M:'B@5((8M=1IB!D!'%NFH>*EG(Y*.>QHRQ;T5X41C;!ZO=P89+CEL"C1DN7_
M:(3>3PL7Z-RFX\(ROIJG.U=2?_HC3$D/X;/#%WW7K"[Q&B'K/;00,0ZPHI*A
M<I;VA \HQ*Y5W66]0]<!43Y.O[9)E(/5)81X9)0T  1S#BG,I7"EM)CY 5X0
MUB-1VH2N1:+\YVB^&N4/KK"JGK?O5)I4J"P))CXR6 D!=,QD3YVWJI34(5<_
M1**S7+ ]D*1]X%JDB+K/IS.?K?)O6A8X?2I%*E26<"^T(\9!S2$QS K^*"G2
MOKX;LK.$ICU0I'W@6J2(3S_GD<!^>KU,T_DW3?P4ZCMYTCFATH1Q0[SQ %L"
MM5-:Q/C&<OS$NGY<<&<Y.GN@3'< GG5UL^/)/'6)LU,T8<0:!8C4%@0C+8CM
M<&F;(8MX@YVN7BG3D3>M/E)_KKUUI\)T;)75UG"A#.%*E: ',TY6\CD/P.;M
MB$4MPU=[QGJQ<8LG(^8Z;^9HN3<UY"EU), Z[PQPA!FHA)/4X7(X10S:^B$7
M_5JY]6G1-61GV6#K(Y_LZO,B_=<J3,_N2[H32M;+R\Z],?BL/>\J; GN*Y(
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M1 C[[6:!!!>PF&BDN>-,:(33Z^3$8-<+PZ#"("APU)1\\?F$(<P@YXQ#BP#
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MI1-J+'< 06J E5A"R"DNP7+2]$FH$R[:;)$$6=>8]66E;%O^4KN/.M,KE$X
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M*A9&.EQW! >?%O+0PJ9QBACAUZZ/Q;I\R, _42C_?$7_NCO051?PN:SH@@B
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M2?GLFZ*E DS*5M.5$<81-A *3<_P0B]RDM#MF\>^B5;[<I_NY(KHFXUR:>>
MCWF0W]!_TI]U>L@+>CD8[)K;?8\=2C72^C;;<A55*M&*A51/]90@FLQ.>%]:
MR6Z6H$1R\B9%&7\M-ET]N&P3_UB3C\('^K>5&9-<-T));)E>$!F&XX=&CR6*
M$JZZ-&H0*,XW*>B_ )S3NG@9/1IZF^V_9UEQ64:;0RU'@T YJ$'[N5UG=I[)
M5%QQ+TJ0WUD<*%^+Q[!!BQNTP#42YG/<BJKT9%^] \F>;B./?DMBE%7,SZ!8
M(1A"%)B&Z=(5B039IA?VK9E.R"77HFTH%N0VB94FJ,),LDGF'"3RB>)Y,9Q7
M\,XP<T'2IG*IAVA-MJ*4V\-F*OHTW)6"=7UX:&\%TVM3]/D1>B787 6>'9F8
M2&3H^K;KV+8'$]=T#3_!R$8NWT-,R\%4+'\]&*)XV^8*XE.65IR:MZ03V63S
MG?B/3WDEU&L:71,>&7@%AEY!;7PG]9G>=-6%4*!!_] CFNA A*P*3+)]H[RP
M[VN O^3U[TF591_)3(!HP?X+K7$!;=--".# PS9"/O0#'_>X89+,4Z!>&EK5
M1]4(I@]; HI$MQ85J)AK .G#DNKRO8NX4YN 1RT%U%30VPJ^O)\W65A]]U8$
MU*+?:!0(]>!#5FE?19Y:)"SV<?QOY8Y\#9V@-L@3%#N):8=&X!O8B@AJ(^J1
M8^C.\^:[1+QS3?Z^#; 6#(NB/ET@,,[@3FU"X]!)CL:^]]CXNOOFBHX3.\\?
M,#Y.941EA)3B+::;W%)A)V6US7*ZI=S"C7P+AYZ'7,> !D1F L,>;A@%B/D.
M^)(@%4?#(QJ.">+BI+#<,G\O3A.(>2"Z'/.B+N9UGSN)>6="'AAUA(N!3K..
MP'$[_KUT"+%[]>,DYZ3&3WH^&>I.VH"TZ1BCZHSIJ&-L3Q5B:DU&A5YX)9?1
MQO$:% 30@H92LP&IP70>Y]_R359L&MQQZ",GM*TD]B++QTZ( Z_#3:_'V(M/
MYKG0*DY>>BS@*<]V<STP+L^5"\[AE7E1OQG\T$G^(//WL>OFGKT+=9L_\-Q=
MC(\Y9NX3/*4\&';O&?R5?'!??^S*!CVK*]3\DKYM,!BY0@8,'<M./!2$9F#:
M<1Q;O14&#IU90J,B[(H#90_P0U\9;I3KTP?,NU3_C@+OB@H=Z@VM']<6%YKK
MT7)5/4-QI-6@4\P>=X=7[UJKZ2FZUNXK\*+$6_.1YA&B4;A^)Z%8S+<J K/B
M7O;.P[1J=F0%[5F\..4^6WV3_=A'Q">_KQ(/0C>.?!N;7AB&7H(=WXT,E"!Z
M,#K@JJTWL2GE-]1:C:OHG0@Y-\IX>&2+3S-2R!=.SMP1J\%O%!UHX/W'\E?!
MCEQQWOD2(%D/-95E#,,M+F&.6+7J2[;.\F_I[2ZKX6V]K]+U?I78$!-!Q AY
M1!$3"R(G:%J*$+)"F_7=#Y&O5C>:1FC ;SV>F8?/*XQ<&#-3^--CH$RRH)37
MFSAVSILDH4DICB//,V(W<2"=[@<H=N(@3E#?3((<IJ-@PE^N.$2WDX@&$\?F
MI!!+#+O+J@GBDXP1-VPQ5Q)1'+NOJ@D3VS7E)HYMD_,58\]M3D[A18--Q4GP
M2TG]@T,U:;GE?-_4EX %F;L5-(')BC5)^6^H9*_LP/<<Y ?0PX%E(=^Q@O8I
M5<-PL.FROP,^N27%>CK"!PA <(*0# :*D4= IC/+(+NSDLJGP?KQR:'.L_(J
M)M5C?FEEF/48Y-13*6_9?TZ]I?&F@93+LZ54T;,XGXMHG[6C[^*@LM[7U]M?
MB\>J_)9MCFL\\8_U[K#)-@GA8?R.1?34?>;INB)_^L]LO8<_\GKE6I87N@Z"
MEA4%EA/946+U2'W7YGMJ8@%\B@-*!X7SK<\E_,2V*J"[B_C"4X<"_$9QS+R:
MH(#)"ZL12_I-C]6,11EX_K[)XMY@#1E="S]G#[=9M3(MPXF2A-9\<:W0P[;A
M&WT;CF-R/7C"]\TZRC0G-VP"JXX606G$)7W@969Q/&'A@JR)L:6'( EB+V7T
M%X[%@5\?RP*N[_/L6[.%>[W]^IBM\VV>;3#YT:Y\;'9QB\V7[.ZPHX0^_9SO
MLGI?%EG=H0I)-AMB+S1,P[ BPX,PL'M44<+V$O%<6!0+#;4 C$P UULP& %&
M5C33Y:,=X&@(^*TUA6?>/(<3&58J-/,?GR+^@5W'L2BBF0O%EDT:5Z8C5Y9;
M4 ^NW(Q<21=5JJ,K'P9;IBZN3.?QW/++C![28(%F3FO+9<8!9[#^DM&>7=PA
M,D<@F=O?RVJW^9YOLE^R_=>40'B!PS60[9K(#D/+PC&.#<.+>QRV%[ _"ZVD
M]3D"<@\:=*C! !L0W* !+D'&Y7N&,>8NZA2!*/MN_<$92!?URX306?7^67?^
M^3[XIR#^J1O_R(V5O%1=BH[*:-<D'JJS[WD$5,SDQ DJW6;)JG5.5]J:7OX"
MCAU&H0<=TS-\2";+-NEY*(1^;">AC7R'J:RY<A"+3DE?P%<VG9'@K4E3T'D=
M)7/N^:Y\)&6N.:^O)D1*13Z;.L=\DS_^R:4\EV@2196;R3:=E,TK^]%R,FVE
MUW2J_=--E19UNFYN\]"])N289A#:B1TDK@&#Q#=BOX_B%C:X'@J=TH[BR-A!
M PTV, +'MT\TB4FV7:.Y2.2+6F?Y6V3#_0)'%W:89#"KQWZ3%$M>'.N7Q<Y$
M66IW*5<>M'S?<,G_A5:(L1TYX; );B1L2UER6GK7TL3*YB1Q4D"D-'E:9-/[
M(D_\$L7)K]8BQ6L+FTP),<2Y)G%<'#DF<B\R.-\-8ARX<>!:V(LP#J )>P3D
M?]C/UTMN=[Z5A_%B[Q&PM'FL'"]P+2_,[@#A%85WP;W0LL'L/IB\4B#!%[QK
M RPDO;T<()5JK58 Y%KV^J1? 7O,<>IK?E>0]J^WIQO7;4T.>%=ES8I$A\&+
MDMB@=;(LWTL<!P5>X+483,<*3*;C_FI:GB-6=8#I2M[S\SXM:#"@%M5,N=Y@
MC%B+.4(@9KT['W!&KL5\,2%V2?4)>_SBH>I2!%-"N28Q3(UMSZ.80@:9XQBM
M.;7+:(/7VR3?[I\^DSA*6AU!^J7<?R(3P>KF/B60?_Q<%OO[/KI"/[%,)XG,
MR(UA@((HP$F/RO$]IDJ*<V&9(]8=3:##NC$"=%:<#')B!V@, =02(@4_0&N+
MJ/JJ]B-C3-3(A0)1\@_K/<YHJI$7)\37&;S)'G6G47HI#L_D+$TB\US6/H_5
ML[(LO%HZ0O-B(NS%B1/;D14F;F(B+S9]V^XAQ%;(=V!99L/+K)>.%4#^HMTD
M1PBNF,[E RE+IAK3/W'1="XW2%TU%76'^++I!9IXUDUEL*U):%-BVELKI_+X
M$]_B(Q_.U^GNY-[/)5PD8!HF,FW#B>BK\X;K(SP$4R>*IVW\R4:ST'9@9\;S
M:Y5J=5>^*T5W#Y?THIP]Q3^( Z=N02[I2+D;DY(=.F''DI-3KGU,5?[2-$BK
ML_?-/4^U3$\\6EA'3^/?-&<;H9LX0>(D'@Q('PV0'[C#$G;LNS(.0(LT.^>A
M0RD'#86XO1Q(%Z:5+V*>'D'4Z%3T*S3QGT"<PK76QQ$G&<9V-G$Z=R*RUYV(
MM*W <%TG\&S'\6,4QE9D]0V%KL?T2/B$KW\?,L;*%;]<*:!IDBPM?AJ:ZP@T
M)WOZ"0VO 1<$18@+IN6/KWOZ\/5=OOZZSC-B(LG=;K+U?5'NRKL\J_&G_"$G
M*#[EZ6V^R_=/=-<A+9[(QY[_R_$_._.ONK3/BF(S<%T[B4W/BB)HQ\Y@!K0@
M^S%I'<$K%KVO7V]$9M8Z,L6RDJ(C;G5Z/6 &'>AF9CY&#C#HP(,!/>C@-Q]^
M^14G__S\/_ZC="J.U1T=\:M?#'K90])GG>P#O@*?/J'FYY?[4_.YJ65A%G##
MN?4CG7N$!LM-6M-3OI.1S9&<75>W>;]6AG" H&\8KADEGFT'@>,,:V6);1C,
M21//ERI.9AHH(I&'BQB&-$,5)WSA?QXZ. *D*EK$ A<C/6Q!9V3:N6 @8KT&
M(BT$NYSH=0Y1^SDG7DT_WZ?50[^K;_F.&\4HMFP7V8D-@]#O&W$-@_T<&/]7
M*Q:X$2"1<2U %8/8J66)3_+F)XA#_M02)2:"7(2Q2>$+,\\)HC@?&LCB!/"E
ME#[!(9'_GCX\E.O?FU;2=7;8TUW5^F.Q_G/7IH&Q[5C4E:$3^Z9K6U'8MVD'
M'KMB3FY)L8!V^, S@%> 0A11C.G4,BCLK*SR":Z&A'(H\JS$B@GT1(+9)/LM
M'LXIN#3^-!!T>;:4*GH8W^;M#?GT]196%>E*S1W+9J,86Y89XC"*#-\TH8T=
M,SX>=S4LKN,I8BTHEG<*BC[:,(+5K#K^4A8?TM'/QAOJ?#N]@L2R;?:JYY1/
MW$7H7.2TRJO$7=@7GD:T'EO#$VTH978]/G$:M4+?.26]:=29QGVIDT@SC$QD
M19'KP<!S@MCR[./Y%M=F6JI4U;9B01O#E:QDTKW IG%+.H!/_;BX7^@T#">;
M%R11E5_T$$MEUI7S]&X^@?V4K[.BSHN[H<3&T!ZVX\"Q$B=.8B.VHR@,HB';
M]-BNR$YO1;%H#L".Y65XMT$D,,DFA_.0R"=\8OPIT;>S]%Q0LNF4ZJ%9$NPH
M97<VCD5'6-?Y7=&DDL\*_81>X/K(#F.7'EPV8\^-ADT@WS:8G@N>V(3JM&T
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M0*'I^]BRC&%Q/([83_-(:F_V"P4<ZBB+4H;@M ";?/&H!]C<=Q]!!"\N&"Q
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M?[]"9:"\Y#)-5],3#^Q.0X3\-.55LN*-'ZOUF$8+?U<M;^60I3E)8QZK?X"
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M:I<W?RQWI?K9KVRS%,KFNGI\.#D84^KKI[,\89!!G&1ZKS-1\WP,9&NY0(@
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M'Z4.Q;E9%C$BW8X+@<_*V6FL^CK*:0G. ]S12]M=8?**^@5RR314,53CWJZ
MYX_#'BHJ[^[*Q7[UK7R%)IZAN(!,HKR0B<J#($:(=8M365I(JR=S/)L.K*)G
MEX?;N_N^M+07\\Y:.A3I/K3T@/6<JHZNI5>8M--2'RZ9K)9Z:=S;6NJ/0ULM
M/5G[OW2(+IY1B"2%68(1DQ#F0L8RZ2 DD#L53O9B.+"./@/6KK^[":<?FNUD
M<W"&^^]$ZR<13RD_@3J.8)IP:""77ETQ+;'TV[0+4AF /[,:S-5>Y;.K^5H_
M3MB]N/:Y:C<9.G2S&,F4YQE-65Z N,"8)MDAW8VY-*_$[,=>Z%,^'<IHT;S9
MV.",]E6W.7EX_<FF@K GK@T.\(Q LYTV'AFN7\7L($:?JVX/\_#>V0@,VU1J
M'IYIQWK-'A@WK-UL1,FE<S&>"9W X1??+:K"=3_+%'N^6^UT,M]MSWRHUJO%
MS^:_G\L?^UQQ\.\S!BE'18$%I(!2R&DN0?U^)TPDE8)8)==^3(9>GM H]7SX
M@_JA;J1:YM6>N#7,J(>GU3*7[A@]0KR)&GC1'^VO&F=4 QWZC1(C]JYET7[I
MGTC^[+E1+S/G$)R9*M][):IE63]3O'MI$;$")@4"^B:>) 6G(H\[BR0'1H?E
M?=@)K'$-*#M1ZT6;F9(-Q9B=?#6H;IHWRG?C*]85EJ[(E ]NIZ%-7EI2^>]Y
M=BITJ(WV-V7T:5MO39U709S #-,LSW*E>@5."EZ(SC[.F=&S&OZM!E8H#32J
MD48G4"TERR/'9@(V#KUV<G:>V>DD9,8<7A$[_WZ8AO0%:%<5N@?;R>+OY?>3
MK'!;;=27BV;LGX=!($MRQ'G**:5Y"N,T@1V,0B16K_5Z-QY8)#^6"X5M_3-B
MR^I1[YV?'+G]M)]OEO/MTE(R_?-OIIRC4F\GH KJ*='/P4Y'1VT9O2*GP9PS
M#54-U[QJH$[^4F-/>]I[]=7_^"_==]1_OJ@D]W_\E_\+4$L#!!0    ( ':!
MKDXK\<5ZH5\  !.J!  5    9&%R92TR,#$Y,#,S,5]P<F4N>&UL[+UK=R,W
MDB;\?7^%7^]GMW&_S)G>/;AZ:K=LZ525NW<^Y6&1*8ECBJGF1:Z:7_\")).Z
MDDP2>1/EZ3FN*@E (B(> !&!0,2__^]OMY,?[O/9?%Q,__XC_!OX\8=\.BQ&
MX^GUWW_\_?-/ZK/Y\.''__V__L>__W\__?3_]*>//]ABN+S-IXL?S"P?+/+1
M#W^.%S<__'.4S__XX6I6W/[PSV+VQ_A^\--/ZTX_K/XR&4__^+?XGZ^#>?[#
MM_GXW^;#F_QV\+$8#A:K;]\L%G?_]O//?_[YY]^^?9U-_E;,KG]& ."?M[UV
MMHC_^JEL]E/\T4\0_83AW[[-1S_^$"B<SE??KO"1LOFW%^W_Q*O64$KY\^JW
MVZ;S\6L-P[#PY__WZ\?/*SI_&D_GB\%TF/_XO_['#S^LV3$K)OFG_.J'^.?O
MGSYL!QD-9OG7<3$?CH,H\K\-B]N?8Y.?U?!?R_%\'-DU#Q]?C7$SRZ_^_F/L
M$>B&$N UU?_SM;:+[W?YWW^<CV_O)H'.G^N9B!J-5G\93#Y,KXK9[4J:-E\,
MQI-CYEAAF$:F'Z4S6D[RBZO+Y6QX$Q!P.1L/<Q-^-1[EL]4TU&2R0>GQ=*6,
MWPC!7P9?)_E1\'G:H[9)F>+V=KR(.\E<34>!(8NPYX0FX\.SJ]"UC6DF0#]M
MU!J)F\Z+R7@4]W$]F,3]Z?--GB\J2.! Q^:G>!DZ3!<W^6(\'%3@]S&C-#+Y
MSXOPWY7$+Z[,8'[C)\6?1_%Y[P"-3_GB;K-;K0%[>S?+;_*PB=WG'XOYR714
M&[5QXCXOBN$?-\4D[,AS%W:^Q?=3"=H]4FU$E I8X)@+^\;B^Z-]XM"TJ_2M
M;:*_%&%3"XP:YK.#$WNM;2,32=BTCQRFONG/!D%B?PYFHX,S?-&R@4FD</"8
M06J;^L<\J%VCRUD1-IM%!?5B5_O&)K2F^^AY/>O6V/2>_]LO%\M9_NMX.KY=
MWJY^>3GXOMK_3B3DY \T1G(U+7E_K]HF]UN^B*?A93[[?!.:')K5CN9-3>>R
M6 3)C <3.YXL%^'DOE@NHJD;70B?\^%R-HZL<=^&D^4H'_E9<;MJF(\>QHG:
M<#%=C59M'VEQ"DVQK1K"]G:J;6H7L^O!=/S?:V-T.K+Y?#@;W\5_75SIY7P\
MS0]K>,>,T>K$$XZKFH:OC=R5<JGCGA-5Y: G5]+Y]O=J>'()W#]YP(9)^KR\
MO1W,OE]<J?E\>;N"P_SWT.;#5$\&PS\^#X/ZG\\O5K^(SIZP"?U:C/*)+V:K
M =>_F:]TH7STI7!AGL7W/(\FD!W/\N&BF,U36-3!!-MB^:=\6%R')1F-KM<:
MNF_QK^&+D\%JZL?2<W";Z\O\VF+XHPFJ83A:@\D88**",A9.TL 9<CD9Q+UQ
M0U%-B[SVSS?,KFJ'>96^]4[T*)=&"ZZ+EY](/1^.':Q!4AY<_1ME,K;XYV 6
ME_7\D49ZS$Y3QP<:)/D(W._I5]\$EU_G^;^6P19P]]%:/#BQ'>T;FU!5T>_O
M5N/TRFUV' ZMJ_$P>F>&PV*YNHZX+";C*K<QQXW2\N13]I>Z/M RR?7*+5E^
MS^_:Y9J6:7X=3^R/@Z_Y,TF\UF\RFSWI%B_Y9;SDAVQ%RVNCU3S3:(K7.MGG
M ]8\W\M\-BY&;EHSBU\?MI&Y?UX,9C7S?-? -<__2SCI\GIG_G+(NN=<+ :3
MFN?\8LCZYGP",!8OIUD1!7>S?!X.XM7>_C'\8-,^CGM2U,[Z0_FWQ<J.684$
ME9^:%,/7:%K1<S68?UT1M9S_=#T8W 6&0/%S/EG,RY_$'5[\!. F^.E_;GZ<
ME=ZJH#A^'4\W-ZY?YXO98+@H)S6)K/C[CV$"695N&;9:8^\TUU@IJSF70%$-
MC+<,<B?@4V)7(2[%;,/6UJFUX_EP4LR7L_Q+8+L.W_WC.+I?&2 3RD*(.)0<
M(R\4$ ZCD@-$&%F% X^AI6;#'XI94)/__F/@7OC-53Z;;4ZU/;%K*Y@M'NT/
M=V&3FP4U^^\_HG(*@]GP"5I?CK)I\?/=*B+BI^'->+*]18QQ?4T@HVB![8&N
M<BW__.IBKG^95]8)W_@.0(!5@"K.F!92,R*=X5((IS$S4G%WR@[P4D^-/\D>
M;-]79O0ICQ&L^:_Y[#J?K6S+5R@Z99B,$:J9M)290*1CT$#!-A1:#)1YKRN\
MLN2+UIC_L,[W+:1YN9+F^?!OU\7]SZ-\O%Y$X2_/UT[X4?8QJ#*3=:R,^C:>
MOP:LEZTR9:BT6D!H&<'<:6^E**?NC&5GB)MF15S4Q>N&8+*>CRUN!^/I#HP\
M;I(9PH"0WL)P,@+*#2#<E9-FA%12GMX:0%)D5]3"Q\/"WW'\7,[&]\&BL>'O
MO^:W7_/9K@/F1</,>F>%(QYKXB5F7HM@A)00QQB<J:1/DU)1(RNKK?1TS>K#
M-"B!^38(M'S1LN.TJ- KPX(1+YQBTA#-A?$4E;NB$Q2EV!6HKY!IX_2HG_<=
M8VSG>5.I7P8Y#9:4)X!H;0@5$E)3THJ-L6>X-=4*@6JP.HG9;0'KEWR:SP83
M-1VIT>UX.H[Z?8R@VP0J[#SLCNJ? 1+XICW7SDKF(4&*@0>.2OW^@'8L*(KF
MV=X6Y#X%.89OW:PBZN[S27$7&5,5<!5Z9QHKI!##/*B5!@O(&2C5#4^I2%&Y
MCCX_PZ'UM7C[@*N?[6W!;1NH^>"@.Z":[>B1*4?#__F@>FH=OH4)I&I+'S0I
M1CWNZ2[6JEI6#]^[Q%7\ZRS/#ZIE!_MF1.&P1@/%B"#H-384ZS7-G 0VO ?'
MX\DPJ "K%&:?[D0(.^B7\-7+F\'L=C#,EZM'I_.P81_P*1SHET&+P_\8M=03
M[R@RDJ-R_@Q0_\[ <J)PB^98?C)D#FVX'\-O/X2#_E6_]%$#9!03 CT/IS87
M0G JC88E18K+%*<#Z2F(VG%9-RF&DX&UBLDL4U($I>YB<1,(G VF\\%P==43
M0Y0G^4IS#)KDSONTXX;)D ]K!F@C@"8TK$:H=;D8J>  G^%.U93\B];$4!/(
MKL-^&HV&ZGAZW",#P895"%@@'+=6:"^%+^<<E]ZY.D5;A4X"QQL[XQ[>U'P8
MQ6>>5^.X#ZOY/%_,-V?]*&#^8_CQ>+)ZZ;EZ]Y2/8I*,F.@@-+D?3!X'>!][
M2M8XA8P#8Y64V,>#0S&HH%,E5X%#ZERMR(9QW%\1-K8P?I\.;HO9(M+D!^/9
M/P:39?[DR=3)>#\\<D:Y]IP@ U&@'03)" ]*'GBO4NX.>JTN=@SCVB63=KBO
MO_EK,5J]'UC)\>YN5H2%<O"4W]\U@U0B&@X=:1FP@11);,D]2K5*L6GI.\97
M_:QO;'M[HID\4F9-,7\M8C%YS Q*";Q%5G(FF/<^$%[J.\RPI)@<]HXAUZ),
M&L/BDWR-JSFN97DJ#G>-EUED />$:4 1PIHKB<K-FU&+4S#(_\)@T_*H$W]/
M\H6JT7\MYZM\D1^FPUE,._1A:I:SR-9'&NL1:#QA] PZ(ZR.T5O*>B"X@@^\
MD%C2!&R*O[#9KG2Z0.K:V&H I.N!,P0(Y0X+B+QBBG+ ."DYP(7C"?B4?^&S
M-<&T%OI4%*,_QY-):?W;Y2R^>UZ]$-T7\;2G6\894(P;0I0,9#IL6>!J22F"
M2?YM\#XQV #?VT;8UKVZ?5W_L&;V!:)4ZI\A!S4S "AKF5':,*_15D41(.GV
MM_JERJO/^L\'=76*H&WX?;B]&XQGZV"P>16\/>V0:6@,Y@HC*B41 @!@-W%=
M/##3I)RKL+_Q="T#+(GG;2.J H8RI V7UEG(*&1("^E\N25S29U(0<T[O>A(
MY'&'D7'1KWAQ]3A(I[QIA'NP=-Q &21:4PRA"[NO A [*\IK&>ZE3U*^WNF=
M1"N2Z!"7[NHJCWD%\Q?4'(G+/0-E%'JD'-7>X: C($:I*LT?3KQ+>OWP3N\R
M6I%$V[A\Q*9=_L@JJ*PR3"81=1)QS*AR"&GKH,,E)S R2?'%[_2RHP4YG!YZ
M7&9(C]$,93+]+\7&EGZ>G_M% '*EWAFDCAC-)5': ^@9DYAO=WUH*J4#V86I
MI,N+-P6CYCC>02:<]/)G;SQ%CL!(@[#"-9:>< /#<A?$*&"4A @+4F5--'R'
MN4[)^F$:5DP^7\P_S.?+52A4_,N^7#I-?2_SS$!%B ]\H]YH;%Q80VN>80^3
M(N3Z&B1<+Y;JN/FL64KG&03'%8=8:\8EQ\)09Y4%)0\H-"DWHOUUC'6'U=HE
M\O;C110BTE$(F-#&8>ZY,J2D%Q*1XF4[WLGV*-WG6>*O)BGT+U+^MWRQ1]%I
M[=L9LQ(PXQ!1WGE-73A@9,E':4 *FOOJP.L.S1U(K'_([^<;$>R0\Y0)H[TE
M2%,CO2NYJA$ZQP>]/81L5\]+CI-^#]?4X^"?RUE^-QB/-IE"RK>)IT:$=3/!
M#!/MH!826"PTL]8:O+5U&#.5K/AS?'MXCNNQ66ST=K4^_L4ZQF5^.?B>XO]I
M;D89Y(*%O5%("KGAGFD=U.P-S['C*79W=:NGEQ%/Y[LB:X-#_Y9@X'T79E>F
M*(& 8PF$%(I@RZ#5)=\0(*A5<ZL=Y\%[743'B[N/,672<(&\H49X#:QGA'"Q
MI2!P-P&P?0VD:,0_D,C8#BX27ZL8^,:O!C%FDEE@)*.:6F6%XE8 XSGQ88V"
M2ND$J[[5KI[C:$]UG%.'R@156CMGI?:,>F&$ )@P"94VRG"9%!CPEI=M902<
M6$7C1 &TM+QC$=/Q.H ^'%FF6$75AR8OB@VVN,[WS.FA$E&%A7_4.)D$$!IC
M:2Q>1! 36C"Z*FADL*,<5LJET3@_CJN@M;]CY@P(JKK@ ?K$&T20"B2O*?8.
MX7-."-T0-(H&^=_]AM#'BEK=[!6 !T.78 )]W+AU,'>-D(HR  "!0E5:.16U
MACT3VUMDZU"_# O.2- X%;,"(<,)$K2DP4)ZSG4'&A)VT1S[V[(#S>!NO!A,
MHFT;,W_,+ZY^G\:D-/GH<E;<Y;-HS+IOP\DRK&X?^*K6H2 K .COFS;?+V;A
M;_^5#Q<'<GPW\+6,(L0D#6830EH@HK'VJ.1KS)C7%:P;\*#4A['GYU;G<FD+
M[YL9'BQX\*1=!A$@VOMP3D.*9,PXRT%)"R$PQ677(XSU @U%?7(XV>7\^UW,
M9WTS#F9=7&P75Y_O\N'X:IP_KL(05N"G_'HYB:+^_NMXDL\71; +]R<53Q\Y
MDV&-2\N"B@H TH I)7#) ^UY9U$*S6#Q1/D77?(\"7>?\D&8Z_3:A#4T&$__
M6<PFHS_'H_RW?/%Y$*9U#-*.'2NCP,1X32PE0M99!P!S)9V8B<Y*H/4:6PUS
MN8%=+.H1^6PXCGO\2D[IV]?!(3,LM62*0 :X"LS%8;JKHK782QPTE13G0]+#
M]%YCJQUFMZ5\?<HG\=+^<A#4@T<I!P\8#7MZ989 *"3V6'@*E/ <.%XR%EF0
MDKBO1QM6L\I_??SM&$<'"P#M[9<QA3@'-/Q/(FDMUD1N553@DPZ_'BI6M4B]
M&I).XF\-Q][#F?RP81Y_TE49)>-4."MH+%1IF;96**A*VL(?G?G66L7.L7)^
M_;!K@-])6/H\OIZ&.5U</;46UD^?MMDW#J/IF'$RIKT#C 9M@3-/B!%,L#5]
M,&SK,,6IU:-SK6$\-<CQ)$0]E(6YN/+CJ\7WRX#R,)-'T_RM6'P,+)E]N1D$
M,K[]&D[[FPH[5MK(F>(>01(+TU"GA!%:6%_R@ 3EXKQ4](90UZH,:CTE'\TP
MY9C<,TS&G"<.:R0]]= P!SG&)74.=5?N[$TAK#F&UZMTA6ZQ?M\3UUI-&#MV
M["PL'0 -Q,$.IP1C0+FQVV5%=$HP5%(,XYL&7L-2Z-B<G.OOCW]SFI?BE4$R
M13T1GGBF1%A$(ICL=*MJ.$Y3G!8].F8[<5JDL[L+T!WEN-@L8HP$H)0(AH-:
MX(QT2*.2*DE99Z6*6]W0DL2]!U$G\?CDP_/S8A:^?#T>?E['9H65\B4?WDR+
M27$=(U0^CL,:RK?/"[Y'#7,P_1Z:/>_YN-N.7OO/V@ZFDB'MH* 4>Q>SJ6J%
M'=ER6:&DFF8]1_*Q,"O>E*1.7@\7LZ_C SKAHR:9L<(H#@"%VC.,A2!DJU1X
M#,#Y^DI2\',Z!T^6:U '!]/!JKCW?NF^:)@QQ G5SCB$J<$>*R%Y.4,*0(K=
MV".5J6X9I_+Q9$G_Q^#V-I87>U''_6_[!7^H7P:"N4)0_* ,ASFD&&E9SA\+
M=L;^@Q0<U,S6ME3D+^%K%U=J%O2]ZY6K]H )]FK[S"($I95: PZAPI;$7*^E
M/@A0BK75(\@T:VW5P=FV4/-HEI$+OQ73P<-/'ML.!V- CQPI@U)#$_0B&DP/
M1H1###]8'A2G*"(]5&03,5&TR>NVL/=Q/,RG\UBFIKQ=.HRRG7TR:+$3!'GB
MO ,.:RV%WN[*+,E9WD,\-8: HAE^GZP<J?E\?#U=K9AJM\<[.V22"<H-EHY&
MIP=TC.JMXLXQ2(E+[Z'ITS1":F7VR?!8XS-?'>"3 (5BDZ^[&E:J]<XT=@QY
M#H4"Q+L8V$S%]K:;J92CJH?V5"O :83S)Z,H(5BE2K0$54I"#6V8MV;0:2L<
MW&Z5DIV)4MTJ?NIG^\G@^3_+Z?@NGQUMOA_JEW%DI1/&*08M 2ALH0^^>05%
M2@QX#V]A6X%-S3RO&3.GX&7[2@*&<Q5Q9SWF F$OO=K.FY&4(RJI5,[98>4D
M?K=W33K/P[=BLM;'&^0#;Z*7([[:_E)<YK.8I, 7LU6^R+G^'DW4@]?V-8R?
MJ7B*6\D4!=@;9 S6KN2=@"HE,V)?,V0U?;W?OEC> *0C916"!6H8/W.*^+ E
M<$J8QY@;']2.DG>&V\Z>/+>0+:)E\-4'_9/%=[HOP_Y#?<F'51T9K[8.AK4D
M'&HD( E_,Y@!2;:<DNB<$Y.T+.RB;F&<#)Q70P>K1H16ZIPYP2S3U/J@OGBL
MH;)^>ZEEH#ZSQ\P=(JD)<9P>3'7,(_G7WV=K0*#R0,6"\@R$#5Q06LY4>Y02
M*]Q#YUB'P*F#_2=J;?/9XI'&%O[U7%L+/\H^11;L,"">_#[#E!CK$:4&4,ZX
M4?SAU08"-,6QT>NZKK4; "EL;1P*.S>39RTR +1@QF@I$8'8JW!P;B', 3S'
M6HHG"NZYV$]B8)."_S6<;;?+W0%K+]ID"EG(!>22 PL%MTY24,[=$M/9M6T;
MPC]6?$4]3&P4 (-OAP'PN$T&)):2>B)IL/EBE>F8/:B<.\>MUJ=\2P!(8&*3
M +B<%:/E<'$Q^YS/[L?#?0K!:TTS*BG#B@#-!;8:61$?WI6.5<%Q AR2ZG._
M2=V@!@ZW@)5(\&:"\YW^NKWM,ZNX%-X:@ 2'&#.,T'8#),J=HU,D7;XO@9+,
MV=-?,=P/ I>GNY7&5UIE!@''B'?4.B(D8Y+QK??% =_9JZYVI)XBK*(NII[N
MTMJ]WWT<3_,/B_QV9]&]*GW#H2JP%#R<K 0R)PGT8AM;B:E+42Q%3\'1S$'2
M%,M/ALYORPC4BZO+P2+.9UWV?1=67FV<.0&L$!H( +SPF@<K:QL:(J5,*>+;
MUYVC 3$6-?,Y'1'Y=!0(VLSA("2>M,Z@-LR&HQ,$2UPKK9S79CU71+RP*:=)
MCSS@;<$@A;=U[0R_S ;31>6M8=,Z(Y0+8*RR!G-@PB$*#"OGJH _D]2;[6X'
MI_&V)ARHN[O)>+BN:U0-"X][9!()BS4D-.A#%A*O/"'EG(E+RAW0UX+OK8(C
M@=EM!:&4ESK+P>3BZV1\O9KLGJ"25]MGGN*P^4FL(#=4"X'"_[;@UTE7K&\U
M[NET(-7)ZM,#.LIP@"_Y['93WNPR#^P<74S]8!P&N/Y2/,X_G'^8;M-0Q9<3
M\<&JB75B9X\JBKT(!*GU*QE%7EFDB-.,<P*<!DR6O&%I#Z5Z%"K:\!;6J4R2
MS\4CP+>G2Z8U8XQC3YE'! --*+7EK %$_!WZ:FLZ&=.Y?3)&-@D8!]?YQ=6G
MXOM@LOC^*4QD%SYV-,^8081#CHTP5C.CK1>JG&U\-_@.W2^)V*B'T\DO[79N
M?':9;X->!M-A'K?!Y6PG<$X=+R- $<\IH ("#JEGRFWI#3IB"K+DNSF_6N)^
MK9K5HY/530,+)\%^&(<F_QPO;L;3=5[88%2LO>-1L#'";I(/YCLQ6.]7,B,5
MTEX*"C'T+'#?^^T.[4B:5Q&\STVO4PG5<X:.KV\6\R_%A^E]^-$Z#9^[O9L4
MW_-\_OLT2/?Y6JQTU!X]:N"_#<0R01717@BE.=G23BU."K/J48:$-D_AIH5P
M,@"W8:*7@^\K+FQ9L%"W4:/<A;&#'3/-@RV-8_ZSR#QBK!-^>P  G:+TP_?C
M)Z^;SZ='@.?#<*R/(H3G*TH_Y?]:CL-/?%%Y8SIFC$QP1 7"$GAI*58>*>5*
MNJPE*8_AX?OQKS?(\MHL!/?M;CQ[I%)6M02>]XN/PX"PEB&LE0.:A>]NEP(@
M/.6) >Q1 H665?Y$-C=G2%Y&;?5+\2D?YN.[Q<65NHOU5 >3JOBI/&#FM0Y;
MK$7QC2&00'F.X/9:TOLDA;U'*1:ZMB5KXG]SB%-7@?GUX>WUX3+.C#&8<&8Q
MHMS%>XCM);B0.B72&;X?SWL[W&\.:^& WMQX?IWDF]9E1-]JNIM?'?3,U_^E
MS$-$.&*!30@ZP;B%YL'%#$C28XPDC_YY(;1IP9Q^/U0LPFRVDWSL<[G:DA-^
MH8O%3<RSN^_>Z/BA,N-9X*K&RGG#C58:>_[@6U1)\'NGEP;-B^%DL+W^E/:Y
M8;P+7]5Z9\Y@3430)B P$O*@:Y01T>%G+JF2$4RZ+7B[D&J$\TEQY+$N0_SF
M%N:?HW_NRY_%RZ+0*\?==.>%P&FC9?$R1-M() ,:(43)0[A)^$^*3PPE.?[?
M%+!:8?[)0/O]+C!BNM@<USX/0!_O=&F\VCBC-JP"9VB\=N TOM" M)PI,LRG
MP.3]>.#KX.WI-SM%#%D<Q_0=T^5@LIG$KX/Q-/Q\=4^:;UVZ'Z;_&3;*/;O-
M28-EE&D+&!;&QN3A1C%'MH8,<$F5M]'[<<"WP?M64/;E)I_E@VCSU@&SA]$R
M'-:3MEAQAZW43*EMU6A$J,(I+W'1^W'4M\+\T^\)UZ_(MY-\<2VU\Y[P4,<,
M.@0,HIIHR20/)@716Y,5>9KTKO_]..WKYG-M?JU-L.O5FMCE2D0^<,4.%GDL
MY3R;+Q["7V/JHFU$QL4L_&68SRL[MFKX5.99,$8@)$(Y8R$ %M&M30LD3%*]
MWJ^GOWW)U(;?QXZ1BZM'?I'H# F[\/ FOD]9K;&]3S[J&SQS\>FVL,12"25'
M7@"Z??N"@4KQ5:#W>S_0ABQ2 L56T[+C^>UX/A],+J[T8/K';'FW&'Z_S!?C
M?:BKU#F3BC%(4#"/&&', 8W%AA*,B;4I\1;H_?CTF^!UJWO9*@=A,SO9LZ$S
M##EBG&F(C8!**&$P*KG@.6<IB$MRX[\IQ+4OB>;QF(RZ3%K+*&'2>$XP- AJ
MYTJ*I)$IC[/1^XW^KXO?J0@*MO !B(06F3,<&(6(]<@8+@!@RI9S@ABE1.W@
MH[WM]_GL:_&F47 \2VL0\Y="K_RVT:W_0-/WP]+?T3%>-PG&O84<4D6 <-CJ
MD@**T](0OQ_?>MU\/ETQCM9A/II_&HSG^2C:E.Y?R_'BNQ]'IUF8S$ZE^%#'
MS&'IK?/*.Q]( 8K2LN@FQDR+%%< ?D?^\YKY_("4?__Y!8O#7/]8_>K5WVS&
M><*U.,>OXV(>*)T.\[\-B]LUOP,+YL5D/(I/:_5@$AVPGV_R_,'1N9Y-_FV1
M3T?YZ,?F<TM\#H1LKC0WO!M,+HOYRJ!07^>KY :O@/V8[IG2""HNN0&<0DRU
M<"S\R ;;1$",J]7:;89Z-9\'YE>@\VG##")L'5"&,NND-EQJ4E*$*#O+M,'-
M2/QY9>$4-K>5CF4]2;.<1795QLZS]AGV3D&N'1 ^D,(H8IJ5M GDSC%[9*J4
M7P5+&E];2^$SF,>(I?A'/*CN!Y/5H;@P@]GL>SBN_C&8+%\S/H[J'Y:= Q)#
M (/A#<-,-/5;3L94W&>/J9/!\#RM3P/L;@MJ*R_,*@#]/D;QSG_+%QNV[,'7
M[DZ99=XH3+C&EC BK-$4;*C$!HBDZ+)W!:K:>-P6DBYG^5VPP=RWNVB5'0;1
MJ^TS:@./B&+<!:5 4,NT*U=)?/^><M EQ7&\.?S4P=Y.=*2JNE%&-%;2<VBX
M8L[[P" CMK1 EJ)6'Q^S42P&D[<*E12VMK>[%'?Y;/'],IC!L8IV/&A7L=QA
M7]R[R>SNECDD $"**V"UD,K'Y*XEI5R+SI+HOAVEND;VMJKPK,G_K9@.J^DZ
MS]MGBFA!H('A_X%%P(6M$Y>T497T&/=M'%/)T*F#K^V>3P</IBS,5<9G2%0"
M;*"B2#J^F3T1BJ;X]=_&B523E7XD(]N"P<?QX.MX,H[OSF(YBT4Q_..FF 3Q
MS-?NY K>G:I#9 (PSG#@%N&*2$!HK F_X8!D-"D&L.<;3*,^PX8$T $$J[L4
M=W<*9[1&GA@7UZ4,?P B2F6/*&13PE_Z[@.J'PF[H9;&]M:.N>$P/N*>7PZ^
M1Y=#X$KXR6P9Q/>"DGUG8?51,NT$ UQ!3(SG8<\WQI46"]$,)^7G>COP.QD=
MSP_/QCC?(@)/P=L.&K%PUA$?],E@=P!#A=/E&4%(4"BZ.D/?$J!J86UWI^-1
MIV+FM:16.\24T9QP8R&D&ZJH%+S2U7-M5EV[^GL#Z$EF<*LN@4>SK>X7>+53
MYC1S+IJMWF$2_H\S4>ZM%'&7 J.^Z^Z-*U6UL;V#/:G:9I0AI0PR*'#&4B@T
MYI*5/A *-4^*^7H[NU#C.OF1?&[M[G]W%-R^&__=O3*(H'7>8Z>4Q0Z''9S*
M[:;+1,KCUK[6A&H-3_7QO2U\G>2VVL,Y2PW"DL&P?"2$8=/US)=4.F%3/.%]
M+135&KIJ8WN+,0!K<:UF?BA,Z976&1,^+!N/$&:(.0(HT;"DBP6;]8P] G5(
M^V400"*'VSSVBFDEV#QOFA&'(*?:AT6%+<%$6*\W%#$%SUK?;@ SB>QMT56T
MO%U.8FS\RB8(TPZ2NLFG\_%]_F$Z+&[SC\4\ADU=7'T9?-OO0#IFI Q1X8SW
M3$A$M*=$$5SJC<Q3FI)KIN]WOPW K5GNMX;&T6AU/S68Q'=('Z9F<#<.EM.C
MM;0/@ <[9YY0A@R32!.C&%#"Z=)QPA!'*<=BWW7X)C!7-\/;@MFG/!9ES$=N
M,)L&0V/^:/'8_&H\'.]3X@]WSH#C(JPJI#E3.NSUCN"2H<REO53INS+? ,QJ
M9WAW-N)1MF'&I%-!N>0$,LXQ4<K@TM[A&/&4EP7'YX9IUX/5 (R2&=R7^)B$
MN)@,*.6XY\ %+108%[0 N:48P"2G:-\AU:93M [F=_TZ]G+%U9M\,1X^U,4X
MRZ>RA,NPC1#JM/)4*QR48DF4MX(K:32LY-EMPQ$4)'(Q6U$T6IF4E_GL\\W@
MU7*KQPV062<$-@YZJHR283L52I<< + :!]ZLNZA.A.QU'-7$_FZ\D*N9SM5R
M<1,D\M_Y:VFPJW7,".*<: 6)CK6F'&$L*&\;:@EQ*6I-__U,K8$MD>U=@NS#
M?+X\&F#K3ADAE'"LG,&.6@$"Q]R62@/9.3]\:QU<)[&\2V!=+!?SQ6 Z>CV7
M3,6>F0-:AA5D-(<844.4I*BDUQK2[O.$,X?8Z7SOX,;E!/VL0N^,& 0P"PM)
M0R\,TTBKDFX%,#IO;U*#>*N?]QU@[@BU;$^OC%CJ@T( #9#2"Q0L75?R4$F<
M5*<P*0WQ&6$LD>>=8>N@-K:C1X:U06'-.!Z$$O1+(JU0)7T*RI0LQ$<G(7Z:
MLO'L4'42QSM#5#4U;%^W3!GOM;80N/BLD6&,#-VNG;2$?GVM&M@-LDYG>@?^
MRRUKYA=7,8V0GQ1_]B++WW8RQ[DL7W3+PGDA+8N9Z1V$D$*%--=0:*LDE)16
M>NG5#+4QL4Z8[N6LN!\'_NKOO\]CK?J+NSP6')]>J^%B?+]VCA_FP?&#919#
M[J 13"(:F 0L#);"AC-.^J2JCV]G1TA 3-&R"%I,>7(U7L3@E[TV?]DH@TII
M2+P$89M#3DG A"BIH-RF/'?K.Y":E/G+E">G,;R]4*3_6L[7(>FK,O9%.&@G
M>>#00S#5EZ*^':^)SV4QBQFDU#%@B H<)D[9DK/*,G7&GO86H=P#T;6U*&P>
MA!X4SAV%'5YKEF%,/8:,:BB-(YX3A55)B>#DG!^G=XN,HC:AM!8P%4T./0@L
MB.&K^71^"&BO=\B,ULA!@!WA F,LI26DI Y(GE3_Z"_(58=<+>(Y#+X=]01^
M*Z:1T(]YF, F?^,K4-K5-$/>,$,E1,&VM2C,D[KM+)7$*8=GCTJA]@HW-<FB
MK>WJEZ(8_3F>3#[<W@W&L\B[ U;&ZQVR&'PH5-!^PS)0E"$4#+/M9BR2G.]]
MOU#L!>QJ%4];X L,FL4E8O/UGX]8LHG#KV!U5!\DXT!@#9SECAE@,*=.XRT7
M*$N)VNG[+62O0-J8R#H$[K,<W<<!]EGGC B#%2<2:8F@-L8HOG$G*$@D:,=_
M(]= G>;7T2_='E2;0,=A *:)H#O@/4WN?13LGG;-B%'.DZ"*6$<%\ Y[P$N*
MJ0<IS_>K6QSO"G1) NAXKRM30QW*AUNE>^8YL,J$PP0"JPF "B);4BXU1JW8
M*>\*>LE".-FDW3&7:#(]GHZ:QI=Q*[&98()?OWJDI@V881P4%H4-- HY K3G
MV)44QQB]5HR6,X1=JV+I;A^LDF3SJ)VQRH 9ET0%91L9:6@\%2CWL.0.I^"<
M0RD[V2D;$$JGD$T$Z'/* >< * ^9,HZ$Q6JI,R7E@HF4HSLIZO*\$)C&]8Y5
MQ2V+3H7=SE&R<'Q*;867DFE'M,9 ;55FC6V*V_'H^,SWL!G6)8FV$%G]"KV6
M2*Y,:X(M(\8J:[@/IP'$LN2"0>B<TP:W&*W0F$ ZAN6V"'4=@89[!LL8PH(X
MH9 6V$MA%(!;#1MP>\Y!-6T&&M8G@M,OD/-%6?(\%CN/0?8Q/4(@_B%*.JBT
M_QS,9H/IJXZ<4X;)M ,,*L4!M$3Y8+YQH4KJK /G'##3)!:*UD32OYVPEATP
M4X@J1@@2S@B'.*%>HJV3B_EV=[Y>'-!U K-Q@;0%2W=UE0_#$>&^#6\&T^O\
M4S@T+J:O5W?> \QCALDTXL(ZZ "DCG-M1#B+MC=.7-FN@G7>ZJ'<(/-;>W86
M9OELII_RP);Q<)&/-I0\_<&CEI=Y$-SHI0TWG"SC4ZC';%FS:@^0VYU(!@PT
M'DJ%/0;2>:F0WVX*W(.4IW%]KY[8R%+HM?C>Q&)J:FUDD%G,C).22TP0-3R6
MQ2G5,F52XGR/=N??K20=$#A;O&? 'RF3]XU?HH@!RG$<C MFJ02!726OG',I
M^#W:_[_&KYN.&KT#Z"%@CQ-":T\AEG=WDQ6G!I.24Q^F5\7L=E U]6&U$3(.
M =+&>6QXT-6@E\1NZ6<:IMR))ET#O"$ -L/JMJ#V:7Q]$]@1S,Q55,'%UW6Z
MY0_34COQQ:-KBZB_E'<7^U+1)HR:<4\<M@X3'XQ8QEW@S_8,<20IMB3) ]80
M).M&S_/\V:U)HN.4#QLBPF]71:0>%4!X_"ZC]3P0ZRCQ[42KA>6_UB.36E*G
M):=> \Z4E!A:*20-M@)TMEKY@F9HW.)G$X]9Y>YE9Y\,.P0PBF"3%E)A$8EU
M+==T(@=3O#E]]X GB_YYH<>:F-S:FZI\&B8\B9%"H]OQ=!PGNP@K^'",]H&>
M&80<QLHFP@"G&"74$%[22P1*J3?3=U#5 (+G3Z5J979KFDZ07OC6S2IN\CZ?
M%'=QC1V&UMY^&4,"4T^89HPJ;7DL";ZA%4G2\K7(6P=6G:P^^>+WXW@8/^?S
MG0^&'UID"!OCX_T@14  CS&0K)R3"8K9&5\]U"?^-*:^M0>_#N) &)&2,.&H
M]%[J+76,^W-^\-O 450'C]M"T ORC]&/,V* MAA@"@A&2D/EE2EITM*FE"\[
M/GR]W:N=^G&3RM[6(?/PVK@*:!Y:9PXX[J'@ CK,K=.:";(]-04]9P6E,7/J
M9/:V!IO-@Z'BZ8P/*[O[.V;<VOBBC5I#M0L+!2!?:O982MY96I2W"*8Z.=UB
MT%FEC>A)NRQF;P% .$\L=AY@K2$L:1'"GW-00MVH26%LJYO/CA*TOICEX^O-
M0\;A]R^SP70>^!&%.AVM_C59BWB;=:-"\>%F/I@Y[ 757 0=DEG'8NY_NEV"
MB*7 ]@V\%ZQ_L^M:0JV%&[RDLP*(]_3***.,*2V(YP8ZSUVT:#9T(@A35/^^
M%VZL&XGUL;FUB-I-Y=NR+(D>S,?#Z"$;3Y:+O;49#O3,"+.!B1Q +12AW&EL
M[)9>TMWE_QN$5;VL;@M:_\SC[7 ^4O=!![W.?UO>?LUG%U<ODO]7N,\[=JC,
M8BTAX\YX9)"PB@#L2HX ;E)2BO6]B$/=X&N8]WU XR,JJN]_IPV8,<XH =1
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MW@:;*OJHE>0!(9:GY*[NH97:-(2[DTQG*&T*GQGR+&I!UENH +)>Q8J[@7Y
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M7GM."55:.4($T')S&%G"40I*^UK3HSO5M2&I=('-4S)Y@;#*M ="^K#_4T4
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M=]=4/]3"3CHF3O]0IC$ATGBKF">04HL-+.7+/9/GG+^_\Y71@0#;U'=OBDG
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M/'66$\:0"H%44FOI+]$@;CEQ;Z>]%8!#3OQ/L[\7=P]W!Z?^U3<184*Y%4X
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MX/2/0ZD1.KV_44RH^R"!@,^!1]X"1KMH=2>0Q?6*(PUDY1S"O];;AUH=1!!
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M+3(P,3DP,S,Q+GAM;%!+ 0(4 Q0    ( ':!KD[@O@>^*A,  !C*   1
M          "  4?@  !D87)E+3(P,3DP,S,Q+GAS9%!+ 0(4 Q0    ( ':!
MKDY &973TQ(  ':X   5              "  :#S  !D87)E+3(P,3DP,S,Q
M7V-A;"YX;6Q02P$"% ,4    " !V@:Y.([DF=>U   !A#0, %0
M    @ &F!@$ 9&%R92TR,#$Y,#,S,5]D968N>&UL4$L! A0#%     @ =H&N
M3JH:#AVXG@  \6@( !4              ( !QD<! &1A<F4M,C Q.3 S,S%?
M;&%B+GAM;%!+ 0(4 Q0    ( ':!KDXK\<5ZH5\  !.J!  5
M  "  ;'F 0!D87)E+3(P,3DP,S,Q7W!R92YX;6Q02P4&      8 !@"* 0
&A48"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
